Substituted pyrazoles as p38 kinase inhibitors

FIELD OF THE INVENTION

This invention relates to a novel group of pyrazole compounds, compositions and methods for treating p38 kinase mediated disorders.

BACKGROUND OF THE INVENTION

Mitogen-activated protein kinases (MAP) is a family of proline-directed serine/threonine kinases that activate their substrates by dual phosphorylation. The kinases are activated by a variety of signals including nutritional and osmotic stress, UV light, growth factors, endotoxin and inflammatory cytokines. The p38 MAP kinase group is a MAP family of various isoforms, including p38α, p38β and p38γ, and is responsible for phosphorylating and activating transcription factors (e.g. ATF2, CHOP and MEF2C) as well as other kinases (e.g. MAPKAP-2 and MAPKAP-3). The p38 isoforms are activated by bacterial lipopolysaccharide, physical and chemical stress and by pro-inflammatory cytokines, including tumor necrosis factor (TNF-α) and interleukin-1 (IL-1). The products of the p38 phosphorylation mediate the production of inflammatory cytokines, including TNF and IL-1, and cyclooxygenase-2.

TNF-α is a cytokine produced primarily by activated monocytes and macrophages. Excessive or unregulated TNF production has been implicated in mediating a number of diseases. Recent studies indicate that TNF has a causative role in the pathogenesis of rheumatoid arthritis. Additional studies demonstrate that inhibition of TNF has broad application in the treatment of inflammation, inflammatory bowel disease, multiple sclerosis and asthma.

TNF has also been implicated in viral infections, such as HIV, influenza virus, and herpes virus including herpes simplex virus type-1 (HSV-1), herpes simplex virus type-2 (HSV-2), cytomegalovirus (CMV), varicella-zoster virus (VZV), Epstein-Barr virus, human herpesvirus-6 (HHV-6), human herpesvirus-7 (HHV-7), human herpesvirus-8 (HHV-8), pseudorabies and rhinotracheitis, among others.

IL-8 is another pro-inflammatory cytokine, which is produced by mononuclear cells, fibroblasts, endothelial cells, and keratinocytes, and is associated with conditions including inflammation.

IL-1 is produced by activated monocytes and macrophages and is involved in the inflammatory response. IL-1 plays a role in many pathophysiological responses including rheumatoid arthritis, fever and reduction of bone resorption.

TNF, IL-1 and IL-8 affect a wide variety of cells and tissues and are important inflammatory mediators of a wide variety of disease states and conditions. The inhibition of these cytokines by inhibition of the p38 kinase is of benefit in controlling, reducing and alleviating many of these disease states.

Various pyrazoles have previously been described. U.S. Pat. No. 4,000,281, to Beiler and Binon, describes 4,5-aryl/heteroaryl substituted pyrazoles with antiviral activity against both RNA and DNA viruses such as myxoviruses, adenoviruses, rhinoviruses, and various viruses of the herpes group. WO 92/19615, published Nov. 12, 1992, describes pyrazoles as novel fungicides. U.S. Pat. No. 3,984,431, to Cueremy and Renault, describes derivatives of pyrazole-5-acetic acid as having anti-inflammatory activity. Specifically, [1-isobutyl-3,4-diphenyl-1H-pyrazol-5-yl]acetic acid is described. U.S. Pat. No. 3,245,093 to Hinsgen et al, describes a process for preparing pyrazoles. WO 83/00330, published Feb. 3, 1983, describes a new process for the preparation of diphenyl-3,4-methyl-5-pyrazole derivatives. WO 95/06036, published Mar. 2, 1995, describes a process for preparing pyrazole derivatives. U.S. Pat. No. 5,589,439, to T. Goto, et al., describes tetrazole derivatives and their use as herbicides. EP 515,041 describes pyrimidyl substituted pyrazole derivatives as novel agricultural fungicides. Japanese Patent 4,145,081 describes pyrazolecarboxylic acid derivatives as herbicides. Japanese Patent 5,345,772 describes novel pyrazole derivatives as inhibiting acetylcholinesterase.

Pyrazoles have been described for use in the treatment of inflammation. Japanese Patent 5,017,470 describes synthesis of pyrazole derivatives as anti-inflammatory, anti-rheumatic, anti-bacterial and anti-viral drugs. EP 115640, published Dec. 30, 1983, describes 4-imidazolyl-pyrazole derivatives as inhibitors of thromboxane synthesis. 3-(4-Isopropyl-1-methylcyclohex-1-yl)-4-(imidazol-1-yl)-1H-pyrazole is specifically described. WO 97/01551, published Jan. 16, 1997, describes pyrazole compounds as adenosine antagonists. 4-(3-Oxo-2,3-dihydropyridazin-6-yl)-3-phenylpyrazole is specifically described. U.S. Pat. No. 5,134,142, to Matsuo et al. describes 1,5-diaryl pyrazoles as having anti-inflammatory activity.

U.S. Pat. No. 5,559,137 to Adams et al, describes novel pyrazoles (1,3,4,-substituted) as inhibitors of cytokines used in the treatment of cytokine diseases. Specifically, 3-(4-fluorophenyl)l-1(4-methylsulfinylphenyl)-4-(4-pyridyl)-5H-pyrazole is described. WO 96/03385, published Feb. 8, 1996, describes 3,4-substituted pyrazoles, as having anti-inflammatory activity. Specifically, 3-methylsulfonylphenyl-4-aryl-pyrazoles and 3-aminosulfonylphenyl-4-aryl-pyrazoles are described.

Laszlo et al., Bioorg. Med. Chem. Letters, 8 (1998) 2689-2694, describes certain furans, pyrroles and pyrazolones, particularly 3-pyridyl-2,5-diaryl-pyrroles, as inhibitors of p38 kinase.

The invention's pyrazolyl compounds are found to show usefulness as p38 kinase inhibitors.

DESCRIPTION OF THE INVENTION

A class of substituted pyrazolyl compounds useful in treating p38 mediated disorders is defined by Formula IA:
embedded image

wherein

R¹is selected from hydrido, hydroxy, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclyl, cycloalkylalkylene, cycloalkenylalkylene, heterocyclylalkylene, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aralkyl, aralkenyl, aralkynyl, arylheterocyclyl, carboxy, carboxyalkyl, alkoxyalkyl, alkenoxyalkyl, alkynoxyalkyl, aryloxyalkyl, alkoxyaryl, heterocyclyloxyalkyl, alkoxyalkoxy, mercaptoalkyl, alkylthioalkylene, alkenylthioalkylene, alkylthioalkenylene, amino, aminoalkyl, alkylamino, alkenylamino, alkynylamino, arylamino, heterocyclylamino, alkylsulfinyl, alkenylsulfinyl, alkynylsulfinyl, arylsulfinyl, heterocyclylsulfinyl, alkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, arylsulfonyl, heterocyclylsulfonyl, alkylaminoalkylene, alkylsulfonylalkylene, acyl, acyloxycarbonyl, alkoxycarbonylalkylene, aryloxycarbonylalkylene, heterocyclyloxycarbonylalkylene, alkoxycarbonylarylene, aryloxycarbonylarylene, heterocyclyloxycarbonylarylene, alkylcarbonylalkylene, arylcarbonylalkylene, heterocyclylcarbonylalkylene, alkylcarbonylarylene, arylcarbonylarylene, heterocyclylcarbonylarylene, alkylcarbonyloxyalkylene, arylcarbonyloxyalkylene, heterocyclylcarbonyloxyalkylene, alkylcarbonyloxyarylene, arylcarbonyloxyarylene, and heterocyclylcarbonyloxyarylene; or

R¹has the formula
embedded image

wherein:

i is an integer from 0 to 9;

R²⁵is selected from hydrogen, alkyl, aralkyl, heterocyclylalkyl, alkoxyalkylene, aryloxyalkylene, aminoalkyl, alkylaminoalkyl, arylaminoalkyl, alkylcarbonylalkylene, arylcarbonylalkylene, and heterocyclylcarbonylaminoalkylene; and

R²⁶is selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkylalkylene, aralkyl, alkoxycarbonylalkylene, and alkylaminoalkyl; and

R²⁷is selected from alkyl, cycloalkyl, alkynyl, aryl, heterocyclyl, aralkyl, cycloalkylalkylene, cycloalkenylalkylene, cycloalkylarylene, cycloalkylcycloalkyl, heterocyclylalkylene, alkylarylene, alkylaralkyl, aralkylarylene, alkylheterocyclyl, alkylheterocyclylalkylene, alkylheterocyclylarylene, aralkylheterocyclyl, alkoxyalkylene, alkoxyarylene, alkoxyaralkyl, alkoxyheterocyclyl, alkoxyalkoxyarylene, aryloxyarylene, aralkoxyarylene, alkoxyheterocyclylalkylene, aryloxyalkoxyarylene, alkoxycarbonylalkylene, alkoxycarbonylheterocyclyl, alkoxycarbonylheterocyclylcarbonylalkylene, aminoalkyl, alkylaminoalkylene, arylaminocarbonylalkylene, alkoxyarylaminocarbonylalkylene, aminocarbonylalkylene, arylaminocarbonylalkylene, alkylaminocarbonylalkylene, arylcarbonylalkylene, alkoxycarbonylarylene, aryloxycarbonylarylene, alkylaryloxycarbonylarylene, arylcarbonylarylene, alkylarylcarbonylarylene, alkoxycarbonylheterocyclylarylene, alkoxycarbonylalkoxylarylene, heterocyclylcarbonylalkylarylene, alkylthioalkylene, cycloalkylthioalkylene, alkylthioarylene, aralkylthioarylene, heterocyclylthioarylene, arylthioalklylarylene, arylsulfonylaminoalkylene, alkylsulfonylarylene, alkylaminosulfonylarylene; wherein said alkyl, cycloalkyl, aryl, heterocyclyl, aralkyl, heterocyclylalkylene, alkylheterocyclylarylene, alkoxyarylene, aryloxyarylene, arylaminocarbonylalkylene, aryloxycarbonylarylene, arylcarbonylarylene, alkylthioarylene, heterocyclylthioarylene, arylthioalklylarylene, and alkylsulfonylarylene groups are optionally substituted with one or more radicals independently selected from alkyl, halo, haloalkyl, alkoxy, keto, amino, nitro, and cyano; or

R²⁷is —CHR²⁸R²⁹wherein R²⁸is alkoxycarbonyl, and R²⁹is selected from aralkyl, aralkoxyalkylene, heterocyclylalkylene, alkylheterocyclylalkylene, alkoxycarbonylalkylene, alkylthioalkylene, and aralkylthioalkylene; wherein said aralkyl and heterocylcyl groups are optionally substituted with one or more radicals independently selected from alkyl and nitro; or

R²⁶and R²⁷together with the nitrogen atom to which they are attached form a heterocycle, wherein said heterocycle is optionally substituted with one or more radicals independently selected from alkyl, aryl, heterocyclyl, heterocyclylalkylene, alkylheterocyclylalkylene, aryloxyalkylene, alkoxyarylene, alkylaryloxyalkylene, alkylcarbonyl, alkoxycarbonyl, aralkoxycarbonyl, alkylamino and alkoxycarbonylamino; wherein said aryl, heterocyclylalkylene and aryloxyalkylene radicals are optionally substituted with one or more radicals independently selected from halogen, alkyl and alkoxy; and

R²is selected from hydrido, halogen, mercapto, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, haloalkyl, hydroxyalkyl, aralkyl, alkylheterocyclyl, heterocyclylalkyl, heterocyclylheterocyclyl, heterocyclylalkylheterocyclyl, alkylamino, alkenylamino, alkynylamino, arylamino, aryl(hydroxyalkyl)amino, heterocyclylamino, heterocyclylalkylamino, aralkylamino, N-alkyl-N-alkynyl-amino, aminoalkyl, aminoaryl, aminoalkylamino, aminocarbonylalkylene, arylaminoalkylene, alkylaminoalkylene, arylaminoarylene, alkylaminoarylene, alkylaminoalkylamino, alkylcarbonylaminoalkylene, aminoalkylcarbonylaminoalkylene, alkylaminoalkylcarbonylamino, cycloalkyl, cycloalkenyl, aminoalkylthio, alkylaminocarbonylalkylthio, alkylaminoalkylaminocarbonylalkylthio, alkoxy, heterocyclyloxy, alkylthio, cyanoalkylthio, alkenylthio, alkynylthio, carboxyalkylthio, arylthio, heterocyclylthio, alkoxycarbonylalkylthio, alkylsulfinyl, alkylsulfonyl, carboxy, carboxyalkyl, alkoxyalkyl, alkoxyalkylthio, carboxycycloalkyl, carboxycycloalkenyl, carboxyalkylamino, alkoxycarbonyl, heterocyclylcarbonyl, alkoxycarbonylalkyl, alkoxycarbonylalkylamino, alkoxycarbonylheterocyclyl, alkoxycarbonylheterocyclylcarbonyl, alkoxyalkylamino, alkoxycarbonylaminoalkylene, alkoxycarbonylaminoalkoxy, alkoxycarbonylaminoalkylamino, heterocyclylsulfonyl, aralkythio, heterocyclylalkylthio, aminoalkoxy, cyanoalkoxy, carboxyalkoxy, aryloxy, aralkoxy, alkenyloxy, alkynyloxy, and heterocyclylalkyloxy; wherein the aryl, heterocyclyl, heterocyclylalkyl, cycloalkyl and cycloalkenyl groups are optionally substituted with one or more radicals independently selected from halo, keto, amino, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, aralkyl, heterocyclylalkyl, epoxyalkyl, amino(hydroxyalkyl)carboxy, alkoxy, aryloxy, aralkoxy, haloalkyl, alkylamino, alkynylamino, alkylaminoalkylamino, heterocyclylalkylamino, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl, arylsulfonyl, and aralkylsulfonyl; or

R²is R²⁰⁰-heterocyclyl-R²⁰¹, R²⁰⁰-aryl-R²⁰¹or R²⁰⁰-cycloalkyl-R²⁰¹wherein:

R²⁰⁰is selected from:

—(CR²⁰²R²⁰³)_y—;
—C(O)—;
—C(O)—(CH₂)_y—;
—C(O)—O—(CH₂)_y—;
—(CH₂)_y—C(O)—;
—O—(CH₂)_y—C(O)—;
—NR²⁰²—;
—NR²⁰²—(CH₂)_y—;
—(CH₂)_y—NR²⁰²—;
—(CH₂)_y—NR²⁰²—(CH₂)_z—;
—(CH₂)_y—C(O)—NR²⁰²—(CH₂)_z—;
—(CH₂)_y—NR²⁰²—C(O)—(CH₂)_z—;
—(CH₂)_y—NR²⁰²—C(O)—NR²⁰³—(CH₂)_z—;
—S(O)_x—(CR²⁰²R²⁰³)_y—;
—(CR²⁰²R²⁰³)_y—S(O)_x—;
—S(O)_x—(CR²⁰²R²⁰³)^y—O—;
—S(O)_x—(CR²⁰²R²⁰³)_y—C(O)—;
—O—(CH₂)_y—;
—(CH₂)_y—O—;
—S—;
—O—;

or R²⁰⁰represents a bond;

R²⁰¹represents one or more radicals selected from the group consisting of hydrido, halogen, hydroxy, carboxy, keto, alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heterocyclyl, aralkyl, heterocyclylalkylene, alkylcarbonyl, hydroxyalkylcarbonyl, cycloalkylcarbonyl, arylcarbonyl, haloarylcarbonyl, alkoxy, alkoxyalkylene, alkoxyarylene, alkoxycarbonyl, carboxyalkylcarbonyl, alkoxyalkylcarbonyl, heterocyclylalkylcarbonyl, alkylsulfonyl, alkylsulfonylalkylene, amino, aminoalkyl, alkylamino, aralkylamino, alkylaminoalkylene, aminocarbonyl, alkylcarbonylamino, alkylcarbonylaminoalkylene, alkylaminoalkylcarbonyl, alkylaminoalkylcarbonylamino, aminoalkylcarbonylaminoalkyl, alkoxycarbonylamino, alkoxyalkylcarbonylamino, alkoxycarbonylaminoalkylene, alkylimidocarbonyl, amidino, alkylamidino, aralkylamidino, guanidino, guanidinoalkylene, or alkylsulfonylamino; and

R²⁰²and R²⁰³are independently selected from hydrido, alkyl, aryl and aralkyl; and

y and z are independently 0, 1, 2, 3, 4, 5 or 6 wherein y+z is less than or equal to 6; and

z is 0, 1 or 2; or

R²is —NHCR²⁰⁴R²⁰⁵wherein R²⁰⁴is alkylaminoalkylene, and R²⁰⁵is aryl; or

R²is —C(NR²⁰⁶)R²⁰⁷wherein R²⁰⁶is selected from hydrogen and hydroxy, and R²⁰⁷is selected from alkyl, aryl and aralkyl; or

R²has the formula:
embedded image

wherein:

j is an integer from 0 to 8; and

m is 0 or 1; and

R³⁰and R³¹are independently selected from hydrogen, alkyl, aryl, heterocyclyl, aralkyl, heterocyclylalkylene, aminoalkyl, alkylaminoalkyl, aminocarbonylalkyl, alkoxyalkyl, and alkylcarbonyloxyalkyl; and

R³²is selected from hydrogen, alkyl, aralkyl, heterocyclylalkyl, alkoxyalkylene, aryloxyalkylene, aminoalkyl, alkylaminoalkyl, arylaminoalkyl, alkylcarbonylalkylene, arylcarbonylalkylene, and heterocyclylcarbonylaminoalkylene;

R³³is selected from hydrogen, alkyl, —C(O)R³⁵, —C(O)OR³⁵, —SO₂R³⁶, —C(O)NR³⁷R³⁸, and —SO₂NR³⁹R⁴⁰, wherein R³⁵, R³⁶, R³⁷, R³⁸, R³⁹and R⁴⁰are independently selected from hydrocarbon, heterosubstituted hydrocarbon and heterocyclyl; and

R³⁴is selected from hydrogen, alkyl, aminocarbonyl, alkylaminocarbonyl, and arylaminocarbonyl; or

R²is —CR⁴¹R⁴²wherein R⁴¹is aryl, and R⁴²is hydroxy; and

R³is selected from pyridinyl, pyrimidinyl, quinolinyl, purinyl, maleimidyl, pyridonyl, thiazolyl, thiazolylalkyl, thiazolylamino,
embedded image

wherein the R³pyridinyl, pyrimidinyl, quinolinyl, purinyl, maleimidyl, pyridonyl, thiazolyl, thiazolylalkyl, thiazolylamino,
embedded image

groups are optionally substituted with one or more radicals independently selected from halo, keto, alkyl, aralkyl, aralkenyl, arylheterocyclyl, carboxy, carboxyalkyl, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfinyl, arylsulfinyl, alkylsulfonyl, arylsulfonyl, aralkoxy, heterocyclylalkoxy, amino, alkylamino, alkenylamino, alkynylamino, cycloalkylamino, cycloalkenylamino, arylamino, haloarylamino, heterocyclylamino, aminocarbonyl, cyano, hydroxy, hydroxyalkyl, alkoxyalkylene, alkenoxyalkylene, aryloxyalkyl, alkoxyalkylamino, alkylaminoalkoxy, alkoxycarbonyl, aryloxycarbonyl, heterocyclyloxycarbonyl, alkoxycarbonylamino, alkoxyarylamino, alkoxyaralkylamino, aminosulfinyl, aminosulfonyl, alkylsulfonylamino, alkylaminoalkylamino, hydroxyalkylamino, aralkylamino, aryl(hydroxyalkyl)amino, alkylaminoalkylaminoalkylamino, alkylheterocyclylamino, heterocyclylalkylamino, alkylheterocyclylalkylamino, aralkylheterocyclylamino, heterocyclylheterocyclylalkylamino, alkoxycarbonylheterocyclylamino, nitro, alkylaminocarbonyl, alkylcarbonylamino, haloalkylsulfonyl, aminoalkyl, haloalkyl, alkylcarbonyl, hydrazinyl, alkylhydrazinyl, arylhydrazinyl, or —NR⁴⁴R⁴⁵wherein R⁴⁴is alkylcarbonyl or amino, and R⁴⁵is alkyl or aralkyl; and

R⁴is selected from hydrido, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, and heterocyclyl, wherein R⁴is optionally substituted with one or more radicals independently selected from halo, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, alkylthio, arylthio, alkylthioalkylene, arylthioalkylene, alkylsulfinyl, alkylsulfinylalkylene, arylsulfinylalkylene, alkylsulfonyl, alkylsulfonylalkylene, arylsulfonylalkylene, alkoxy, aryloxy, aralkoxy, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl, aryloxycarbonyl, haloalkyl, amino, cyano, nitro, alkylamino, arylamino, alkylaminoalkylene, arylaminoalkylene, aminoalkylamino, and hydroxy;

provided R³is not 2-pyridinyl when R⁴is a phenyl ring containing a 2-hydroxy substituent and when R¹is hydrido; and

further provided R²is selected from aryl, heterocyclyl, unsubstituted cycloalkyl and cycloalkenyl when R⁴is hydrido; and

further provided that R⁴is not methylsulfonylphenyl or aminosulfonylphenyl; and

further provided that R¹is not methylsulfonylphenyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

In a subclass of interest, R²is as defined above, and

R¹is selected from hydrido, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkylalkylene, cycloalkenylalkylene, heterocyclylalkylene, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aralkyl, aralkenyl, aralkynyl, arylheterocyclyl, carboxy, carboxyalkyl, alkoxyalkyl, alkenoxyalkyl, alkynoxyalkyl, aryloxyalkyl, heterocyclyloxyalkyl, alkoxyalkoxy, mercaptoalkyl, alkylthioalkylene, alkenylthioalkylene, alkylthioalkenylene, amino, aminoalkyl, alkylamino, alkenylamino, alkynylamino, arylamino, heterocyclylamino, alkylsulfinyl, alkenylsulfinyl, alkynylsulfinyl, arylsulfinyl, heterocyclylsulfinyl, alkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, arylsulfonyl, heterocyclylsulfonyl, alkylaminoalkylene, alkylsulfonylalkylene, acyl, acyloxycarbonyl, alkoxycarbonylalkylene, aryloxycarbonylalkylene, heterocyclyloxycarbonylalkylene, alkylcarbonylalkylene, arylcarbonylalkylene, heterocyclylcarbonylalkylene, alkylcarbonyloxyalkylene, arylcarbonyloxyalkylene, heterocyclylcarbonyloxyalkylene, alkylcarbonyloxyarylene, arylcarbonyloxyarylene, and heterocyclylcarbonyloxyarylene; or

R¹has the formula
embedded image

wherein:

i is an integer from 0 to 9;

R²⁶is selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkylalkylene, aralkyl, allcoxycarbonylalkylene, and alkylaminoalkyl; and

R³is selected from pyridinyl, pyrimidinyl, quinolinyl, purinyl, maleimidyl, pyridonyl, thiazolyl, thiazolylalkyl, thiazolylamino,
embedded image

wherein the R³pyridinyl, pyrimidinyl, quinolinyl, purinyl, maleimidyl, pyridonyl, thiazolyl, thiazolylalkyl, thiazolylamino,
embedded image

groups are optionally substituted with one or more radicals independently selected from halo, keto, alkyl, aralkyl, aralkenyl, arylheterocyclyl, carboxy, carboxyalkyl, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfinyl, arylsulfinyl, arylsulfonyl, aralkoxy, heterocyclylalkoxy, amino, alkylamino, alkenylamino, alkynylamino, cycloalkylamino, cycloalkenylamino, arylamino, haloarylamino, heterocyclylamino, aminocarbonyl, cyano, hydroxy, hydroxyalkyl, alkoxyalkylene, alkenoxyalkylene, aryloxyalkyl, alkoxyalkylamino, alkylaminoalkoxy, alkoxycarbonyl, aryloxycarbonyl, heterocyclyloxycarbonyl, alkoxycarbonylamino, alkoxyarylamino, alkoxyaralkylamino, aminosulfinyl, alkylsulfonylamino, alkylaminoalkylamino, hydroxyalkylamino, aralkylamino, aryl(hydroxyalkyl)amino, alkylaminoalkylaminoalkylamino, alkylheterocyclylamino, heterocyclylalkylamino, alkylheterocyclylalkylamino, aralkylheterocyclylamino, heterocyclylheterocyclylalkylamino, alkoxycarbonylheterocyclylamino, nitro, alkylaminocarbonyl, alkylcarbonylamino, aminoalkyl, haloalkyl, alkylcarbonyl, hydrazinyl, alkylhydrazinyl, arylhydrazinyl, or —NR⁴⁴R⁴⁵wherein R⁴⁴is alkylcarbonyl or amino, and R⁴⁵is alkyl or aralkyl; and

R⁴is selected from hydrido, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, and heterocyclyl, wherein R⁴is optionally substituted with one or more radicals independently selected from halo, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, alkylthio, arylthio, alkylthioalkylene, arylthioalkylene, alkylsulfinyl, alkylsulfinylalkylene, arylsulfinylalkylene, alkylsulfonylalkylene, arylsulfonylalkylene, alkoxy, aryloxy, aralkoxy, aminocarbonyl, alkylaminocarbonyl, arylaminocarboiiyl, alkoxycarbonyl, aryloxycarbonyl, haloalkyl, amino, cyano, nitro, alkylamino, arylamino, alkylaminoalkylene, arylaminoalkylene, aminoalkylamino, and hydroxy; or

a pharmaceutically-acceptable salt or tautomer thereof.

In the various embodiments of the present invention, the novel compounds generically disclosed herein preferably do not include those substituted pyrazoles disclosed in WO98/52940 published on Nov. 26, 1998.

A subclass of compounds useful in treating p38 mediated disorders is defined by Formula I:
embedded image

wherein

R¹is selected from hydrido, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclyl, cycloalkylalkylene, cycloalkenylalkylene, heterocyclylalkylene, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aralkyl, aralkenyl, aralkynyl, arylheterocyclyl, carboxy, carboxyalkyl, alkoxyalkyl, alkenoxyalkyl, alkynoxyalkyl, aryloxyalkyl, heterocyclyloxyalkyl, alkoxyalkoxy, mercaptoalkyl, alkylthioalkylene, alkenylthioalkylene, alkylthioalkenylene, amino, aminoalkyl, alkylamino, alkenylamino, alkynylamino, arylamino, heterocyclylamino, alkylsulfinyl, alkenylsulfinyl, alkynylsulfinyl, arylsulfinyl, heterocyclylsulfinyl, alkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, arylsulfonyl, heterocyclylsulfonyl, alkylaminoalkylene, alkylsulfonylalkylene, acyl, acyloxycarbonyl, alkoxycarbonylalkylene, aryloxycarbonylalkylene, heterocyclyloxycarbonylalkylene, alkoxycarbonylarylene, aryloxycarbonylarylene, heterocyclyloxycarbonylarylene, alkylcarbonylalkylene, arylcarbonylalkylene, heterocyclylcarbonylalkylene, alkylcarbonylarylene, arylcarbonylarylene, heterocyclylcarbonylarylene, alkylcarbonyloxyalkylene, arylcarbonyloxyalkylene, heterocyclylcarbonyloxyalkylene, alkylcarbonyloxyarylene, arylcarbonyloxyarylene, and heterocyclylcarbonyloxyarylene; or

- R¹has the formula

wherein:

- i is an integer from 0 to 9;

R²⁶is selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkylalkylene, aralkyl, alkoxycarbonylalkylene, and alkylaminoalkyl; and

R²6 and R²⁷together with the nitrogen atom to which they are attached form a heterocycle, wherein said heterocycle is optionally substituted with one or more radicals independently selected from alkyl, aryl, heterocyclyl, heterocyclylalkylene, alkylheterocyclylalkylene, aryloxyalkylene, alkoxyarylene, alkylaryloxyalkylene, alkylcarbonyl, alkoxycarbonyl, aralkoxycarbonyl, alkylamino and alkoxycarbonylamino; wherein said aryl, heterocyclylalkylene and aryloxyalkylene radicals are optionally substituted with one or more radicals independently selected from halogen, alkyl and alkoxy; and

R²is selected from hydrido, halogen, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, haloalkyl, hydroxyalkyl, aralkyl, alkylheterocyclyl, heterocyclylalkyl, alkylamino, alkenylamino, alkynylamino, arylamino, heterocyclylamino, heterocyclylalkylamino, aralkylamino, aminoalkyl, aminoaryl, aminoalkylamino, arylaminoalkylene, alkylaminoalkylene, arylaminoarylene, alkylaminoarylene, alkylaminoalkylamino, cycloalkyl, cycloalkenyl, alkoxy, heterocyclyloxy, alkylthio, arylthio, heterocyclylthio, carboxy, carboxyalkyl, carboxycycloalkyl, carboxycycloalkenyl, carboxyalkylamino, alkoxycarbonyl, heterocyclylcarbonyl, alkoxycarbonylalkyl, alkoxycarbonylheterocyclyl, alkoxycarbonylheterocyclylcarbonyl, alkoxyalkylamino, alkoxycarbonylaminoalkylamino, and heterocyclylsulfonyl; wherein the aryl, heterocyclyl, heterocyclylalkyl, cycloalkyl and cycloalkenyl groups are optionally substituted with one or more radicals independently selected from halo, keto, amino, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, aralkyl, heterocyclylalkyl, epoxyalkyl, amino(hydroxyalkyl)carboxy, alkoxy, aryloxy, aralkoxy, haloalkyl, alkylamino, alkynylamino, alkylaminoalkylamino, heterocyclylalkylamino, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl, arylsulfonyl, and aralkylsulfonyl; or

R²has the formula:
embedded image

wherein:

j is an integer from 0 to 8; and

m is 0 or 1; and

R³⁴is selected from hydrogen, alkyl, aminocarbonyl, alkylaminocarbonyl, and arylaminocarbonyl; or

R²is —CR⁴¹R⁴²wherein R⁴¹is aryl, and R⁴²is hydroxy; and

R³is selected from pyridinyl, pyrimidinyl, quinolinyl, purinyl,
embedded image

wherein R⁴³is selected from hydrogen, alkyl, aminoalkyl, alkoxyalkyl, alkenoxyalkyl, and aryloxyalkyl; and

wherein the R³pyridinyl, pyrimidinyl, quinolinyl and purinyl groups are optionally substituted with one or more radicals independently selected from halo, alkyl, aralkyl, aralkenyl, arylheterocyclyl, carboxy, carboxyalkyl, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfinyl, arylsulfinyl, alkylsulfonyl, arylsulfonyl, aralkoxy, heterocyclylalkoxy, amino, alkylamino, alkenylamino, alkynylamino, cycloalkylamino, cycloalkenylamino, arylamino, heterocyclylamino, aminocarbonyl, cyano, hydroxy, hydroxyalkyl, alkoxycarbonyl, aryloxycarbonyl, heterocyclyloxycarbonyl, alkoxycarbonylamino, alkoxyaralkylamino, aminosulfinyl, aminosulfonyl, alkylaminoalkylamino, hydroxyalkylamino, aralkylamino, heterocyclylalkylamino, aralkylheterocyclylamino, nitro, alkylaminocarbonyl, alkylcarbonylamino, halosulfonyl, aminoalkyl, haloalkyl, alkylcarbonyl, hydrazinyl, alkylhydrazinyl, arylhydrazinyl, or —NR⁴⁴R⁴⁵wherein R⁴⁴is alkylcarbonyl or amino, and R⁴⁵is alkyl or aralkyl; and

provided R³is not 2-pyridinyl when R⁴is a phenyl ring containing a 2-hydroxy substituent and when R¹is hydrido; further provided R²is selected from aryl, heterocyclyl, unsubstituted cycloalkyl and cycloalkenyl when R⁴is hydrido; and further provided R⁴is not methylsulfonylphenyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

Compounds of Formula I and/or IA would be useful for, but not limited to, the treatment of any disorder or disease state in a human, or other mammal, which is excacerbated or caused by excessive or unregulated TNF or p38 kinase production by such mammal. Accordingly, the present invention provides a method of treating a cytokine-mediated disease which comprises administering an effective cytokine-interfering amount of a compound of Formula I and/or 1A or a pharmaceutically acceptable salt thereof.

Compounds of Formula I and/or IA would be useful for, but not limited to, the treatment of inflammation in a subject, as an analgesic in the treatment of pain including but not limited to neuropathic pain, and for use as antipyretics for the treatment of fever. Compounds of the invention would be useful to treat arthritis, including but not limited to, rheumatoid arthritis, spondyloarthropathies, gouty arthritis, osteoarthritis, systemic lupus erythematosus and juvenile arthritis, osteoarthritis, gouty arthritis and other arthritic conditions. Such compounds would be useful for the treatment of pulmonary disorders or lung inflammation, including adult respiratory distress syndrome, pulmonary sarcoisosis, asthma, silicosis, and chronic pulmonary inflammatory disease. The compounds are also useful for the treatment of viral and bacterial infections, including sepsis, septic shock, gram negative sepsis, malaria, meningitis, cachexia secondary to infection or malignancy, cachexia secondary to acquired immune deficiency syndrome (AIDS), AIDS, ARC (AIDS related complex), pneumonia, and herpesvirus. The compounds are also useful for the treatment of bone resorption diseases, such as osteoporosis, endotoxic shock, toxic shock syndrome, reperfusion injury, autoimmune disease including graft vs. host reaction and allograft rejections, cardiovascular diseases including atherosclerosis, myocardial infarction, thrombosis, congestive heart failure, and cardiac reperfusion injury, renal reperfusion injury, liver disease and nephritis, and myalgias due to infection.

The compounds are also useful for the treatment of influenza, multiple sclerosis, leukemia, lymphoma, diabetes, systemic lupus erthrematosis (SLE), neuroinflammation, ischemia including stroke and brain ischemia, brain trauma, brain edema, skin-related conditions such as psoriasis, eczema, burns, dermatitis, keloid formation, scar tissue formation, and angiogenic disorders. Compounds of the invention also would be useful to treat gastrointestinal conditions such as inflammatory bowel disease, Crohn's disease, gastritis, irritable bowel syndrome and ulcerative colitis. The compounds would also be useful in the treatment of ophthalmic diseases, such as retinitis, retinopathies, uveitis, ocular photophobia, and of acute injury to the eye tissue. Compounds of the invention also would be useful for treatment of angiogenesis, including neoplasia; metastasis; ophthalmological conditions such as corneal graft rejection, ocular neovascularization, retinal neovascularization including neovascularization following injury or infection, diabetic retinopathy, retrolental fibroplasia and neovascular glaucoma; ulcerative diseases such as gastric ulcer; pathological, but non-malignant, conditions such as hemaginomas, including invantile hemaginomas, angiofibroma of the nasopharynx and avascular necrosis of bone; diabetic nephropathy and cardiomyopathy; and disorders of the female reproductive system such as endometriosis. The compounds of the invention may also be useful for preventing the production of cyclooxygenase-2.

Compounds of the invention would be useful for the prevention or treatment of benign and malignant tumors/neoplasia including cancer, such as colorectal cancer, brain cancer, bone cancer, epithelial cell-derived neoplasia (epithelial carcinoma) such as basal cell carcinoma, adenocarcinoma, gastrointestinal cancer such as lip cancer, mouth cancer, esophageal cancer, small bowel cancer and stomach cancer, colon cancer, liver cancer, bladder cancer, pancreas cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer and skin cancer, such as squamus cell and basal cell cancers, prostate cancer, renal cell carcimoma, and other known cancers that affect epithelial cells throughout the body.

The compounds of the invention also would be useful for the treatment of certain central nervous system disorders such as Alzheimer's disease and Parkinson's disease.

Besides being useful for human treatment, these compounds are also useful for veterinary treatment of companion animals, exotic animals and farm animals, including mammals, rodents, and the like. More preferred animals include horses, dogs, and cats.

The present compounds may also be used in co-therapies, partially or completely, in place of other conventional anti-inflammatories, such as together with steroids, cyclooxygenase-2 inhibitors, DMARD's, immunosuppressive agents, NSAIDs, 5-lipoxygenase inhibitors, LTB₄antagonists and LTA₄hydrolase inhibitors.

As used herein, the term “TNF mediated disorder” refers to any and all disorders and disease states in which TNF plays a role, either by control of TNF itself, or by TNF causing another monokine to be released, such as but not limited to IL-1, IL-6 or IL-8. A disease state in which, for instance, IL-1 is a major component, and whose production or action, is exacerbated or secreted in response to TNF, would therefore be considered a disorder mediated by TNF.

As used herein, the term “p38 mediated disorder” refers to any and all disorders and disease states in which p38 plays a role, either by control of p38 itself, or by p38 causing another factor to be released, such as but not limited to IL-1, IL-6 or IL-8. A disease state in which, for instance, IL-1 is a major component, and whose production or action, is exacerbated or secreted in response to p38, would therefore be considered a disorder mediated by p38.

As TNF-β has close structural homology with TNF-α (also known as cachectin) and since each induces similar biologic responses and binds to the same cellular receptor, the synthesis of both TNF-α and TNF-β are inhibited by the compounds of the present invention and thus are herein referred to collectively as “TNF” unless specifically delineated otherwise.

A preferred class of compounds consists of those compounds of Formula I wherein

R¹is selected from hydrido, lower alkyl, lower cycloalkyl, lower alkenyl, lower alkynyl, lower heterocyclyl, lower cycloalkylalkylene, lower haloalkyl, lower hydroxyalkyl, lower aralkyl, lower alkoxyalkyl, lower mercaptoalkyl, lower alkylthioalkylene, amino, lower alkylamino, lower arylamino, lower alkylaminoalkylene, and lower heterocyclylalkylene; or

R¹has the formula
embedded image

wherein:

i is 0, 1 or 2; and

R²⁵is selected from hydrogen, lower alkyl, lower phenylalkyl, lower heterocyclylalkyl, lower alkoxyalkylene, lower phenoxyalkylene, lower aminoalkyl, lower alkylaminoalkyl, lower phenoxyaminoalkyl, lower alkylcarbonylalkylene, lower phenoxycarbonylalkylene, and lower heterocyclylcarbonylaminoalkylene; and

R²⁶is selected from hydrogen, lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkylalkylene, lower phenylalkyl, lower alkoxycarbonylalkylene, and lower alkylaminoalkyl; and

R²⁷is selected from lower alkyl, lower cycloalkyl, lower alkynyl, aryl selected from phenyl, biphenyl and naphthyl, lower heterocyclyl, lower phenylalkyl, lower cycloalkylalkylene, lower cycloalkenylalkylene, lower cycloalkylarylene, lower cycloalkylcycloalkyl, lower heterocyclylalkylene, lower alkylphenylene, lower alkylphenylalkyl, lower phenylalkylphenylene, lower alkylheterocyclyl, lower alkylheterocyclylalkylene, lower alkylheterocyclylphenylene, lower phenylalkylheterocyclyl, lower alkoxyalkylene, lower alkoxyphenylene, lower alkoxyphenylalkyl, lower alkoxyheterocyclyl, lower alkoxyalkoxyphenylene, lower phenoxyphenylene, lower phenylalkoxyphenylene, lower alkoxyheterocyclylalkylene, lower phenoxyalkoxyphenylene, lower alkoxycarbonylalkylene, lower alkoxycarbonylheterocyclyl, lower alkoxycarbonylheterocyclylcarbonylalkylene, lower aminoalkyl, lower alkylaminoalkylene, lower phenylaminocarbonylalkylene, lower alkoxyphenylaminocarbonylalkylene, lower aminocarbonylalkylene, arylaminocarbonylalkylene, lower alkylaminocarbonylalkylene, lower phenylcarbonylalkylene, lower alkoxycarbonylphenylene, lower phenoxycarbonylphenylene, lower alkylphenoxycarbonylphenylene, lower phenylcarbonylphenylene, lower alkylphenylcarbonylphenylene, lower alkoxycarbonylheterocyclylphenylene, lower alkoxycarbonylalkoxylphenylene, lower heterocyclylcarbonylalkylphenylene, lower alkylthioalkylene, cycloalkylthioalkylene, lower alkylthiophenylene, lower phenylalkylthiophenylene, lower heterocyclylthiophenylene, lower phenylthioalklylphenylene, lower phenylsulfonylaminoalkylene, lower alkylsulfonylphenylene, lower alkylaminosulfonylphenylene; wherein said lower alkyl, lower cycloalkyl, aryl selected from phenyl, biphenyl and naphthyl, lower heterocyclyl, lower phenylalkyl, lower heterocyclylalkylene, lower alkylheterocyclylphenylene, lower alkoxyphenylene, lower phenoxyphenylene, lower phenylaminocarbonylalkylene, lower phenoxycarbonylphenylene, lower phenylcarbonylphenylene, lower alkylthiophenylene, lower heterocyclylthiophenylene, lower phenylthioalklylphenylene, and lower alkylsulfonylphenylene groups are optionally substituted with one or more radicals independently selected from lower alkyl, halo, lower haloalkyl, lower alkoxy, keto, amino, nitro, and cyano; or

R²⁷is —CHR⁴⁶R⁴⁷wherein R⁴⁶is lower alkoxycarbonyl, and R⁴⁷is selected from lower phenylalkyl, lower phenylalkoxyalkylene, lower heterocyclylalkylene, lower alkylheterocyclylalkylene, lower alkoxycarbonylalkylene, lower alkylthioalkylene, and lower phenylalkylthioalkylene; wherein said phenylalkyl and heterocylcyl groups are optionally substituted with one or more radicals independently selected from lower alkyl and nitro; or

R²⁶and R²⁷together with the nitrogen atom to which they are attached form a 4-8 membered ring heterocycle, wherein said heterocycle is optionally substituted with one or more radicals independently selected from lower alkyl, aryl selected from phenyl, biphenyl and naphthyl, heterocyclyl, heterocyclylalkylene, lower alkylheterocyclylalkylene, lower phenoxyalkylene, lower alkoxyphenylene, lower alkylphenoxyalkylene, lower alkylcarbonyl, lower alkoxycarbonyl, lower phenylalkoxycarbonyl, lower alkylamino and lower alkoxycarbonylamino; wherein said aryl selected from phenyl, biphenyl and naphthyl, lower heterocyclylalkylene and lower phenoxyalkylene radicals are optionally substituted with one or more radicals independently selected from halogen, lower alkyl and lower alkoxy; and

R²is selected from hydrido, halogen, lower alkyl, aryl selected from phenyl, biphenyl, and naphthyl, lower haloalkyl, lower hydroxyalkyl, 5- or 6-membered heterocyclyl, lower alkylheterocyclyl, lower heterocyclylalkyl, lower alkylamino, lower alkynylamino, phenylamino, lower heterocyclylamino, lower heterocyclylalkylamino, lower phenylalkylamino, lower aminoalkyl, lower aminoalkylamino, lower alkylaminoalkylamino, lower cycloalkyl, lower alkenyl, lower alkoxycarbonylalkyl, lower cycloalkenyl, lower carboxyalkylamino, lower alkoxycarbonyl, lower heterocyclylcarbonyl, lower alkoxycarbonylheterocyclyl, lower alkoxycarbonylheterocyclylcarbonyl, alkoxycarbonylalkyl, lower alkoxyalkylamino, lower alkoxycarbonylaminoalkylamino, lower heterocyclylsulfonyl, lower heterocyclyloxy, and lower heterocyclylthio; wherein the aryl, heterocylyl, heterocyclylalkyl, cycloalkyl, and cycloalkenyl groups are optionally substituted with one or more radicals independently selected from halo, keto, lower alkyl, lower alkynyl, phenyl, 5- or 6-membered heterocyclyl, lower phenylalkyl, lower heterocyclylalkyl, lower epoxyalkyl, carboxy, lower alkoxy, lower aryloxy, lower phenylalkoxy, lower haloalkyl, lower alkylamino, lower alkylaminoalkylamino, lower alkynylamino, lower amino(hydroxyalkyl), lower heterocyclylalkylamino, lower alkylcarbonyl, lower alkoxycarbonyl, lower alkylsulfonyl, lower phenylalkylsulfonyl, and phenylsulfonyl; or

R²has the formula:
embedded image

wherein:

j is 0, 1 or 2; and

m is 0;

R³³is selected from hydrogen, alkyl, —C(O)R³⁵, —C(O)OR³⁵, —SO₂R³⁶, —C(O)NR³⁷R³⁸, and —SO₂NR³⁹R⁴⁰;

wherein R³⁵is selected from alkyl, cycloalkyl, haloalkyl, alkenyl, aryl, heterocyclyl, aralkyl, arylcycloalkyl, cycloalkenylalkylene., heterocyclylalkylene, alkylarylene, alkylheterocyclyli, arylarylene, arylheterocyclyl, alkoxy, alkenoxy, alkoxyalkylene, alkoxyaralkyl, alkoxyarylene, aryloxyalkylene, aralkoxyalkylene, cycloalkyloxyalkylene, alkoxycarbonyl, heterocyclylcarbonyl, alkylcarbonyloxyalkylene, alkylcarbonyloxyarylene, alkoxycarbonylalkylene, alkoxycarbonylarylene, aralkoxycarbonylheterocyclyl, alkylcarbonylheterocyclyl, arylcarbonyloxyalkylarylene, and alkylthioalkylene; wherein said aryl, heterocyclyl, aralkyl, alkylarylene, arylheterocyclyl, alkoxyarylene, aryloxyalkylene, cycloalkoxyalkylene, alkoxycarbonylalkylene, and alkylcarbonylheterocyclyl groups are optionally substituted with one or more radicals independently selected from alkyl, halo, haloalkyl, alkoxy, haloalkoxy, keto, amino, nitro, and cyano; or

R³⁵is CHR⁴⁵R⁴⁹wherein R⁴⁸is arylsulfonylamino or alkylarylsulfonylamino, and R⁴⁹is selected from aralkyl, amino, alkylamino, and aralkylamino; or

R³⁵is —NR⁵⁰R⁵¹wherein R⁵¹is alkyl, and R⁵¹is aryl; and

wherein R³⁶is selected from alkyl, haloalkyl, aryl, heterocyclyl, cycloalkylalkylene, alkylarylene, alkenylarylene, arylarylene, aralkyl, aralkenyl, heterocyclylheterocyclyl, carboxyarylene, alkoxyarylene, alkoxycarbonylarylene, alkylcarbonylaminoarylene, alkylcarbonylaminoheterocyclyl, arylcarbonylaminoalkylheterocyclyl, alkylaminoarylene, alkylamino, alkylaminoarylene, alkylsulfonylarylene, alkylsulfonylaralkyl, and arylsulfonylheterocyclyl; wherein said aryl, heterocyclyl, cycloalkylalkylene, aralkyl, alkylcarbonylaminoheterocyclyl, and alkylsulfonylarylene groups are optionally substituted with one or more radicals independently selected from alkyl, halo, hydroxy, haloalkyl, alkoxy, haloalkoxy, keto, amino, nitro, and cyano; and

wherein R³⁷is selected from hydrogen and alkyl; and

wherein R³⁸is selected from hydrogen, alkyl, alkenyl, aryl, heterocyclyl, aralkyl, alkylarylene, arylcycloalkyl, arylarylene, cycloalkylalkylene, heterocyclylalkylene, alkylheterocyclylalkylene, aralkylheterocyclyl, alkoxyalkylene, alkoxyarylene, aryloxyarylene, arylcarbonyl, alkoxycarbonyl, alkoxycarbonylalkylene, alkoxycarbonylarylene, alkylcarbonylcarbonylalkylene, alkylaminoalkylene, alkylaminoaralkyl, alkylcarbonylaminoalkylene, alkylthioarylene, alkylsulfonylaralkyl, and aminosulfonylaralkyl; wherein said aryl, heterocyclyl, aralkyl, and heterocyclylalkylene groups are optionally substituted with one or more radicals independently selected from alkyl, halo, hydroxy, haloalkyl, alkoxy, haloalkoxy, keto, amino, nitro, and cyano; or

R³⁸is —CR⁵²R⁵³wherein R⁵²is alkoxycarbonyl, and R⁵³is alkylthioalkylene; or

R³⁷and R³⁸together with the nitrogen atom to which they are attached form a heterocycle; and

R³⁹and R⁴⁰have the same definition as R²⁶and R²⁷in claim 1; or

R²is —CR⁵⁴R⁵⁵wherein R⁵⁴is phenyl and R⁵⁵is hydroxy; or

R²is selected from the group consisting of
embedded image

wherein

k is an integer from 0 to 3; and

R⁵⁶is hydrogen or lower alkyl; and

R⁵⁷is hydrogen or lower alkyl; or

R⁵⁶and R⁵⁷form a lower alkylene bridge; and

R⁵⁸is selected from hydrogen, alkyl, aralkyl, aryl, heterocyclyl, heterocyclylalkyl, alkoxycarbonyl, alkylsulfonyl, aralkylsulfonyl, arylsulfonyl, —C(O)R⁵⁹, —SO₂R⁶⁰, and —C(O)NHR⁶¹;

wherein R⁵⁹is selected from alkyl, haloalkyl, cycloalkyl, aryl, heterocyclyl, alkylarylene, aralkyl, alkylheterocyclyl, alkoxy, alkenoxy, aralkoxy, alkoxyalkylene, alkoxyarylene, alkoxyaralkyl; wherein said aryl, heterocyclyl, and aralkyl groups are optionally substituted with one or more radicals independently selected from alkyl, halo, hydroxy, haloalkyl, alkoxy, haloalkoxy, keto, amino, nitro, and cyano; and

wherein R⁶⁰is selected from alkyl, aryl, heterocyclyl, alkylarylene, alkylheterocyclyl, aralkyl, heterocyclylheterocyclyl, alkoxyarylene, alkylamino, alkylaminoarylene, alkylsulfonylarylene, and arylsulfonylheterocyclyl; wherein said aryl, heterocyclyl, and aralkyl groups are optionally substituted with one or more radicals independently selected from alkyl, halo, hydroxy, haloalkyl, alkoxy, haloalkoxy, keto, amino, nitro, and cyano; and

wherein R⁶¹is selected from alkyl, aryl, alkylarylene, and alkoxyarylene; wherein said aryl group is optionally substituted with one or more radicals independently selected from alkyl, halo, hydroxy, haloalkyl, alkoxy, haloalkoxy, keto, amino, nitro, and cyano; and

R³is selected from pyridinyl, pyrimidinyl, quinolinyl, purinyl, and
embedded image

wherein R⁴³is selected from hydrogen, lower alkyl, lower aminoalkyl, lower alkoxyalkyl, lower alkenoxyalkyl and lower aryloxyalkyl; and

wherein the R³pyridinyl, pyrimidinyl, quinolinyl and purinyl groups are optionally substituted with one or more radicals independently selected from lower alkylthio, lower alkylsulfonyl, aminosulfonyl, halo, lower alkyl, lower aralkyl, lower phenylalkenyl, lower phenylheterocyclyl, carboxy, lower alkylsulfinyl, cyano, lower alkoxycarbonyl, aminocarbonyl, lower alkylcarbonylamino, lower haloalkyl, hydroxy, lower alkoxy, amino, lower cycloalkylamino, lower alkylamino, lower alkenylamino, lower alkynylamino, lower aminoalkyl, arylamino, lower aralkylamino, nitro, halosulfonyl, lower alkylcarbonyl, lower alkoxycarbonylamino, lower alkoxyphenylalkylamino, lower alkylaminoalkylamino, lower hydroxyalkylamino, lower heterocyclylamino, lower heterocyclylalkylamino, lower phenylalkylheterocyclylamino, lower alkylaminocarbonyl, lower alkoxyphenylalkylamino, hydrazinyl, lower alkylhydrazinyl, or —NR⁶²R⁶³wherein R⁶²is lower alkylcarbonyl or amino, and R⁶³is lower alkyl or lower phenylalkyl; and

R⁴is selected from hydrido, lower cycloalkyl, lower cycloalkenyl, aryl selected from phenyl, biphenyl, and naphthyl, and 5- or 6-membered heterocyclyl; wherein the lower cycloalkyl, lower cycloalkenyl, aryl and 5-10 membered heterocyclyl groups of R⁴are optionally substituted with one or more radicals independently selected from lower alkylthio, lower alkylsulfonyl, lower alkylsulfinyl, halo, lower alkyl, lower alkynyl, lower alkoxy, lower aryloxy, lower aralkoxy, lower heterocyclyl, lower haloalkyl, amino, cyano, nitro, lower alkylamino, and hydroxy; or

a pharmaceutically-acceptable salt or tautomer thereof.

A class of compounds of particular interest consists of these compounds of Formula I wherein

R¹is selected from hydrido, methyl, ethyl, propyl, isopropyl, tert-butyl, isobutyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloroethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, ethenyl, propenyl, ethynyl, propargyl, 1-propynyl, 2-propynyl, piperidinyl, piperazinyl, morpholinyl, benzyl, phenylethyl, morpholinylmethyl, morpholinylethyl, pyrrolidinylmethyl, piperazinylmethyl, piperidinylmethyl, pyridinylmethyl, thienylmethyl, methoxymethyl, ethoxymethyl, amino, methylamino, dimethylamino, phenylamino, methylaminomethyl, dimethylaminomethyl, methylaminoethyl, dimethylaminoethyl, ethylaminoethyl, diethylaminoethyl, cyclopropyl, cyclopentyl, cyclohexyl, cyclohexylmethyl, hydroxymethyl, hydroxyethyl, mercaptomethyl, and methylthiomethyl; and

R²is selected from hydrido, chloro, fluoro, bromo, methyl, ethyl, propyl, isopropyl, tert-butyl, isobutyl, phenyl, biphenyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, liydroxymethyl, hydroxyethyl, pyridinyl, isothiazolyl, isoxazolyl, thienyl, thiazolyl, oxazolyl, pyrimidinyl, quinolyl, isoquinolinyl, imidazolyl, benzimidazolyl, furyl, pyrazinyl, piperidinyl, piperazinyl, morpholinyl, N-methylpiperazinyl, methoxycarbonylethyl, ethoxycarbonylethyl, N-methylamino, N,N-dimethylamino, N-ethylamino, N,N-diethylamino, N-n-propylamino, N,N-dimethylamino, N-methyl-N-phenylamino, N-phenylamino, piperadinylamino, N-benzylamino, N-propargylamino, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, aminomethyl, aminoethyl, aminoethylamino, aminopropylamino, N,N-dimethylaminoethylamino, N,N-dimethylaminopropylamino, morpholinylethylamino, morpholinylpropylamino, carboxymethylamino, methoxyethylamino, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, 1,1-dimethylethoxycarbonyl, 1,1-dimethylethoxycarbonylaminoethylamino, 1,1-dimethylethoxycarbonylaminopropylamino, piperazinylcarbonyl, and 1,1-dimethylethoxycarbonylpiperazinylcarbonyl; wherein the aryl, heteroaryl, cycloalkyl and cycloalkenyl groups are optionally substituted with one or more radicals independently selected from fluoro, chloro, bromo, keto, methyl, ethyl, isopropyl, tert-butyl, isobutyl, benzyl, carboxy, methoxy, ethoxy, phenoxy, benzyloxy, trifluoromethyl, fluoromethyl, difluoromethyl, dimethylamino, methoxycarbonyl, ethoxycarbonyl, and 1,1-dimethylethylcarbonyl; or

R²is —CR⁵⁴R⁵⁵wherein R⁵⁴is phenyl and R⁵⁵is hydroxy; and

R³is selected from pyridinyl, pyrimidinyl, and purinyl; wherein R³is optionally substituted with one or more radicals independently selected from methylthio, methylsulfinyl, methylsulfonyl, fluoro, chloro, bromo, aminosulfonyl, methyl, ethyl, isopropyl, tert-butyl, isobutyl, cyano, methoxycarbonyl, ethoxycarbonyl, aminocarbonyl, methylcarbonylamino, trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl, dichloromethyl, chloromethyl, hydroxy, fluorophenylmethyl, fluorophenylethyl, chlorophenylmethyl, chlorophenylethyl, fluorophenylethenyl, chlorophenylethenyl, fluorophenylpyrazolyl, chlorophenylpyrazolyl, carboxy, methoxy, ethoxy, propyloxy, n-butoxy, methylamino, ethylamino, dimethylamino, diethylamino, 2-methylbutylamino, propargylamino, aminomethyl, aminoethyl, N-methyl-N-phenylamino, phenylamino, diphenylamino, benzylamino, phenethylamino, cyclopropylamino, nitro, chlorosulfonyl, amino, methylcarbonyl, methoxycarbonylamino, ethoxycarbonylamino, methoxyphenylmethylamino, N,N-dimethylaminoethylamino, hydroxypropylamino, hydroxyethylamino, imidazolylethylamino, morpholinylethylamino, (1-ethyl-2-hydroxy)ethylamino, piperidinylamino, pyridinylmethylamino, phenylmethylpiperidinylamino, phenylmethylamino, fluorophenylmethylamino, fluorophenylethylamino, methylaminocarbonyl, ethylaminocarbonyl, methylcarbonyl, methoxyphenylmethylamino, hydrazinyl, 1-methylhydrazinyl, or —NR⁶²R⁶³wherein R⁶²is methylcarbonyl or amino, and R⁶³is methyl, ethyl or phenylmethyl; and

R⁴is selected from hydrido, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, phenyl, biphenyl, morpholinyl, pyrrolidinyl, piperazinyl, piperidinyl, pyridinyl, thienyl, isothiazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, quinolyl, isoquinolinyl, imidazolyl, benzimidazolyl, furyl, pyrazinyl, dihydropyranyl, dihydropyridinyl, dihydrofuryl, tetrahydropyranyl, tetrahydrofuryl, benzofuryl, dihydrobeiizofuryl, and benzodioxolyl; wherein the cycloalkyl, cycloalkenyl, aryl and heterocyclyl groups of R⁴are optionally substituted with one or more radicals independently selected from methylthio, methylsulfinyl, methylsulfonyl, fluoro, chloro, bromo, methyl, ethyl, isopropyl, tert-butyl, isobutyl, ethynyl, methoxy, ethoxy, phenoxy, benzyloxy, trifluoromethyl, fluoromethyl, difluoromethyl, amino, cyano, nitro, dimethylamino, and hydroxy; or

a pharmaceutically-acceptable salt or tautomer thereof.

Another class of compounds of particular interest consists of these compounds of Formula I wherein

R¹is hydrido, methyl, ethyl, propargyl, hydroxyethyl, dimethylaminoethyl, diethylaminoethyl or morpholinylethyl;

R²is selected from hydrido, methyl, ethyl, propyl, phenyl, trifluoromethyl, methoxycarbonylethyl, N,N-dimethylamino, N-phenylamino, piperidinyl, piperazinyl, pyridinyl, N-methylpiperazinyl, and piperazinylamino; wherein the phenyl, piperidinyl, and pyridinyl groups are optionally substituted with one or more radicals independently selected from fluoro, chloro, bromo, methyl, ethyl, and trifluoromethyl;

R³is selected from pyridinyl, pyrimidinyl or quinolinyl; wherein R³is optionally substituted with one or-more radicals independently selected from fluoro, bromo, methyl, cyano, methoxycarbonyl, aminocarbonyl, benzyl, phenethyl, acetyl, hydroxyl, methoxy, dimethylamino, benzylamino, phenethylamino, aminomethyl, amino, hydroxy, and methylcarbonyl;

R⁴is selected from phenyl, quinolyl, biphenyl, pyridinyl, thienyl, furyl, dihydropyranyl, benzofuryl, dihydrobenzofuryl, and benzodioxolyl; wherein the cycloalkyl, cycloalkenyl, aryl and heterocyclyl groups of R⁴are optionally substituted with one or more radicals independently selected from methylthio, fluoro, chloro, bromo, methyl, ethyl, methoxy, ethoxy, phenoxy, benzyloxy, trifluoromethyl, nitro, dimethylamino, and hydroxy; or

a pharmaceutically-acceptable salt or tautomer thereof.

A class of compounds of specific interest consists of those compounds of Formula I wherein

R¹is hydrido or methyl;

R²is selected from hydrido, methyl or ethyl;

R³is selected from pyridinyl, pyrimidinyl or quinolinyl; wherein R³is optionally substituted with one or more radicals independently selected from fluoro, bromo, methyl, cyano, methoxycarbonyl, aminocarbonyl, benzyl, phenethyl, acetyl, hydroxyl, methoxy, dimethylamino, benzylamino, phenethylamino, aminomethyl, amino, hydroxy, and methylcarbonyl;

R⁴is selected from phenyl which is optionally substituted with one or more radicals independently selected from methylthio, fluoro, chloro, bromo, methyl, ethyl, methoxy, ethoxy, phenoxy, benzyloxy, trifluoromethyl, nitro, dimethylamino, and hydroxy; or

a pharmaceutically-acceptable salt or tautomer thereof.

Still another class of compounds of particular interest consists of those compounds of Formula I wherein

R²has the formula:
embedded image

wherein:

j is 0, 1 or 2; and

m is 0; and

R³⁰and R³¹are independently selected from hydrogen and lower alkyl;

R³²is selected from hydrogen, lower alkyl, lower phenylalkyl, lower heterocyclylalkyl, lower alkoxyalkylene, aryloxyalkylene, aminoalkyl, lower alkylaminoalkyl, lower phenylaminoalkyl, lower alkylcarbonylalkylene, lower phenylcarbonylalkylene, and lower heterocyclylcarbonylaminoalkylene;

R³³is selected from hydrogen, lower alkyl, —C(O)R³⁵, —C(O)OR³⁵, —SO₂R³⁶, —C(O)NR³⁷R³⁸, and —SO₂NR³⁹R⁴⁰;

wherein R³⁵is selected from lower alkyl, lower cycloalkyl, lower haloalkyl, lower alkenyl, aryl selected from phenyl, biphenyl and naphthyl, lower heterocyclyl, lower phenylalkyl, lower phenylcycloalkyl, lower cycloalkenylalkylene, lower heterocyclylalkylene, lower alkylphenylene, lower alkylheterocyclyl, phenylphenylene, lower phenylheterocyclyl, lower alkoxy, lower alkenoxy, lower alkoxyalkylene, lower alkoxyphenylalkyl, lower alkoxyphenylene, lower phenoxyalkylene, lower phenylalkoxyalkylene, lower cycloalkyloxyalkylene, lower alkoxycarbonyl, lower heterocyclylcarbonyl, lower alkylcarbonyloxyalkylene, lower alkylcarbonyloxyphenylene, lower alkoxycarbonylalkylene, lower alkoxycarbonylphenylene, lower phenylalkoxycarbonylheterocyclyl, lower alkylcarbonylheterocyclyl, lower phenylcarbonyloxyalkylphenylene, and lower alkylthioalkylene; wherein said aryl selected from phenyl, biphenyl and naphthyl, lower heterocyclyl, lower phenylalkyl, lower alkylphenylene, lower phenylheterocyclyl, lower alkoxyphenylene, lower phenoxyalkylene, lower cycloalkoxyalkylene, lower alkoxycarbonylalkylene, and lower alkylcarbonylheterocyclyl groups are optionally substituted with one or more radicals independently selected from lower alkyl, halo, lower haloalkyl, lower alkoxy, lower haloalkoxy, keto, amino, nitro, and cyano; or

R³⁵is CHR⁴⁸R⁴⁹wherein R⁴⁸is phenylsulfonylamino or lower alkylphenylsulfonylamino, and R⁴⁹is selected from lower phenylalkyl, amino, lower alkylamino, and lower phenylalkylamino; or

R³⁵is —NR⁵⁰R⁵¹wherein R⁵⁰is lower alkyl, and R⁵¹is aryl selected from phenyl, biphenyl and naphthyl; and

wherein R³⁶is selected from lower alkyl, lower haloalkyl, aryl selected from phenyl, biphenyl and naphthyl, lower heterocyclyl, lower cycloalkylalkylene, lower alkylphenylene, lower alkenylphenylene, phenylphenylene, lower phenylalkyl, lower phenylalkenyl, lower heterocyclylheterocyclyl, carboxyphenylene, lower alkoxyphenylene, lower alkoxycarbonylphenylene, lower alkylcarbonylaminophenylene, lower alkylcarbonylaminoheterocyclyl, lower phenylcarbonylaminoalkylheterocyclyl, lower alkylaminophenylene, lower alkylamino, lower alkylaminophenylene, lower alkylsulfonylphenylene, lower alkylsulfonylphenylalkyl, and lower phenylsulfonylheterocyclyl; wherein said aryl selected from phenyl, biphenyl and naphthyl, lower heterocyclyl, lower cycloalkylalkylene, lower phenylalkyl, lower alkylcarbonylaminoheterocyclyl, and lower alkylsulfonylphenylene groups are optionally substituted with one or more radicals independently selected from lower alkyl, halo, hydroxy, lower haloalkyl, lower alkoxy, lower haloalkoxy, keto, amino, nitro, and cyano; and

wherein R³⁷is selected from hydrogen and lower alkyl; and

wherein R³⁸is selected from hydrogen, lower alkyl, lower alkenyl, aryl selected from phenyl, biphenyl and naphthyl, lower heterocyclyl, lower phenylalkyl, lower alkylphenylene, lower phenylcycloalkyl, phenylphenylene, lower cycloalkylalkylene, lower heterocyclylalkylene, lower alkylheterocyclylalkylene, lower phenylalkylheterocyclyl, lower alkoxyalkylene, lower alkoxyphenylene, lower phenoxyphenylene, phenylcarbonyl, lower alkoxycarbonyl, lower alkoxycarbonylalkylene, lower alkoxycarbonylphenylene, lower alkylcarbonylcarbonylalkylene, lower alkylaminoalkylene, lower alkylaminophenylalkyl, lower alkylcarbonylaminoalkylene, lower alkylthiophenylene, lower alkylsulfonylphenylalkyl, and lower aminosulfonylphenylalkyl; wherein said aryl selected from phenyl, biphenyl and naphthyl, lower heterocyclyl, lower phenylalkyl, and lower heterocyclylalkylene groups are optionally substituted with one or more radicals independently selected from lower alkyl, halo, hydroxy, lower haloalkyl, lower alkoxy, lower haloalkoxy, keto, amino, nitro, and cyano; or

R³⁸is —CR⁵²R⁵³wherein R₅₂is lower alkoxycarbonyl, and R₅₃is lower alkylthioalkylene; or

R³⁷and R³⁸together with the nitrogen atom to which they are attached form a 4-8 membered ring heterocycle;

R³⁹and R⁴⁰have the same definition as R²⁶and R²⁷in claim 2; or

- R²is selected from the group consisting of

wherein

k is an integer from 0 to 2; and

R⁵⁶is hydrogen or lower alkyl; and

R⁵⁷is hydrogen or lower alkyl; and

R⁵⁸is selected from hydrogen, lower alkyl, lower phenylalkyl, aryl selected from phenyl, biphenyl and naphthyl, lower heterocyclyl, lower heterocyclylalkyl, lower alkoxycarbonyl, lower alkylsulfonyl, lower phenylalkylsulfonyl, lower phenylsulfonyl, —C(O)R⁵⁹, —SO₂R⁶⁰, and —C(O)NHR⁶¹;

wherein R⁵⁹is selected from lower alkyl, lower haloalkyl, lower cycloalkyl, aryl selected from phenyl, biphenyl and naphthyl, lower heterocyclyl, lower alkylphenylene, lower phenylalkyl, lower alkylheterocyclyl, lower alkoxy, lower alkenoxy, loewr phenylalkoxy, lower alkoxyalkylene, lower alkoxyphenylene, lower alkoxyphenylalkyl; wherein said aryl selected from phenyl, biphenyl and naphthyl, lower heterocyclyl, and lower phenylalkyl groups are optionally substituted with one or more radicals independently selected from lower alkyl, halo, hydroxy, lower haloalkyl, lower alkoxy, lower haloalkoxy, keto, amino, nitro, and cyano; and

wherein R⁶⁰is selected from lower alkyl, aryl selected from phenyl, biphenyl and naphthyl, lower heterocyclyl, lower alkylphenylene, lower alkylheterocyclyl, lower phenylalkyl, lower heterocyclylheterocyclyl, lower alkoxyphenylene, lower alkylamino, lower alkylaminophenylene, lower alkylsulfonylphenylene, and lower phenylsulfonylheterocyclyl; wherein said aryl selected from phenyl, biphenyl and naphthyl, lower heterocyclyl, and lower phenylalkyl groups are optionally substituted with one or more radicals independently selected from lower alkyl, halo, hydroxy, lower haloalkyl, lower alkoxy, lower haloalkoxy, keto, amino, nitro, and cyano; and

wherein R⁶¹is selected from lower alkyl, aryl selected from phenyl, biphenyl and napthyl, lower alkylphenylene, and lower alkoxyphenylene; wherein said aryl group is optionally substituted with one or more radicals independently selected from lower alkyl, halo, hydroxy, lower haloalkyl, lower alkoxy, lower haloalkoxy, keto, amino, nitro, and cyano; and

R⁴is selected from hydrido, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, phenyl, biphenyl, morpholinyl, pyrrolidinyl, piperazinyl, piperidinyl, pyridinyl, thienyl, isothiazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, quinolyl, isoquinolinyl, imidazolyl, benzimidazolyl, furyl, pyrazinyl, dihydropyranyl, dihydropyridinyl, dihydrofuryl, tetrahydropyranyl, tetrahydrofuryl, benzofuryl, dihydrobenzofuryl, and benzodioxolyl; wherein the cycloalkyl, cycloalkenyl, aryl and heterocyclyl groups of R⁴are optionally substituted with one or more radicals independently selected from methylthio, methylsulfinyl, methylsulfonyl, fluoro, chloro, bromo, methyl, ethyl, isopropyl, tert-butyl, isobutyl, ethynyl, methoxy, ethoxy, phenoxy, benzyloxy, trifluoromethyl, fluoromethyl, difluoromethyl, amino, cyano, nitro, dimethylamino, and hydroxy; or

a pharmaceutically-acceptable salt or tautomer thereof.

Still another class of compounds of particular interest consists of those compounds of Formula I wherein

R¹is hydrido, methyl, ethyl, propargyl, hydroxyethyl, dimethylaminoethyl, diethylaminoethyl or morpholinylethyl;

R²has the formula:
embedded image

wherein:

j is 0, 1 or 2; and

m is 0; and

R³⁰is hydrogen; and

R³¹is selected from hydrogen and lower alkyl; and

R³²is selected from hydrogen and lower alkyl; and

R³³is selected from lower alkyl, —C(O)R³⁵, —C(O)OR³⁵, —SO₂R³⁶, —C(O)NR³⁷R³⁸, and —SO₂NR³⁹R⁴⁰;

wherein R³⁵is selected from lower alkyl, lower cycloalkyl, phenyl, lower heterocyclyl, lower alkylphenylene, lower alkoxy, lower alkenoxy, lower alkoxyalkylene, lower phenoxyalkylene, and lower phenylalkoxyalkylene; wherein said phenyl and lower phenoxyalkylene groups are optionally substituted with one or more radicals independently selected from lower alkyl, halo, and lower haloalkyl; and

wherein R³⁶is selected from lower alkyl, phenyl, lower heterocyclyl, lower alkylphenylene, phenylphenylene, lower phenylalkyl, lower alkylheterocyclyl, lower heterocyclylheterocyclyl, lower alkoxyphenylene, and lower alkylamino; wherein said phenyl and lower heterocyclyl groups are optionally substituted with one or more radicals independently selected from lower alkyl, halo, hydroxy, lower haloalkyl, lower alkoxy, lower haloalkoxy, keto, amino, nitro, and cyano; and

wherein R³⁷is hydrogen; and

wherein R³⁸is selected from lower alkyl, phenyl, and lower alkylphenylene;

wherein R³⁹and R⁴⁰have the same definition as R²⁶and R²⁷in claim 2; or

- R²is selected from the group consisting of

wherein

k is an integer from 0 or 1; and

R⁵⁶is hydrogen; and

R⁵⁷is hydrogen; and

R⁵⁸is selected from —C(O)R⁵⁹and —SO₂R⁶⁰;

wherein R⁵⁹is selected from lower alkyl, lower cycloalkyl, phenyl, lower alkylphenylene, and lower alkoxyalkylene; wherein said phenyl group is optionally substituted with one or more radicals independently selected from lower alkyl, halo, hydroxy, lower haloalkyl, lower alkoxy, lower haloalkoxy, keto, amino, nitro, and cyano; and

wherein R⁶⁰is selected from lower alkyl; and

a pharmaceutically-acceptable salt or tautomer thereof.

Still another class of compounds of specific interest consists of those compounds of Formula I wherein

R¹is hydrido or methyl; and

a pharmaceutically-acceptable salt or tautomer thereof.

In one embodiment of the present invention, the compounds of Formula I and/or 1A satisfy one or more of the following conditions:

R¹is hydrido or lower alkyl; more preferably, R¹is hydrido or methyl; and still more preferably, R¹is hydrido;

R²is hydrido or lower alkyl; more preferably, R²is hydrido or methyl; and still more preferably, R²is hydrido;

R²comprises a piperidinyl, piperazinyl or cyclohexyl moiety;

R³is substituted or unsubstituted pyridinyl; and preferably, the pyridinyl is a 4-pyridinyl; or

R⁴is substituted or unsubstituted phenyl; and preferably, R⁴is phenyl substituted with halo.

In addition, where R³is substituted pyrimidinyl, preferably at least one R³substitutent is attached to the carbon atom positioned between two nitrogen atoms of the pyrimidinyl ring.

A family of specific compounds of particular interest within Formula I and/or 1A consists of compounds, tautomers and pharmaceutically-acceptable salts thereof as follows:

4-[5-(3-fluoro-4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
4-(3-methyl-5-phenyl-1H-pyrazol-4-y]pyridine;
4-[5-methyl-3-(2-methylphenyl)-1H-pyrazol-4-yl]pyridine;
4-[3-(4-fluorophenyl)-5-methyl-1H-pyrazol-4-yl]pyridine;
4-[5-methyl-3-(4-methylphenyl)-1H-pyrazol-4-yl]pyridine;
4-[5-methyl-3-[4-(methylthio)phenyl]-1H-pyrazol-4-yl]pyridine;
4-[3-(4-chlorohpenyl)-5-methyl-1H-pyrazol-4-yl]pyridine;
4-[3-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine;
4-[5-(2,5-dimethylphenyl)-3-methyl-1H-pyrazol-4yl]pyridine;
4-[5-(1,3-benzodioxol-5-yl)-3-methyl-1H-pyrazol-4-yl]pyridine;
4-[3-methyl-5-(4-phenoxyphenyl)-1H-pyrazol-4-yl]pyridine;
4-[5-[(1,1′-biphenyl)-4-yl]-3-methyl-1H-pyrazol-4-yl]pyridine;
4-[3-methyl-5-[3-(phenoxyphenyl)-1H-pyrazol-4-yl]pyridine;
4-[3-methyl-5-[3-(phenylmethoxy)phenyl]-1H-pyrazol-4-yl]pyridine;
4-[3-methyl-5-[2-(phenylmethoxy)phenyl]-1H-pyrazol-4-yl]pyridine;
2-[3-methyl-4-(4-pyridinyl)-1H-pyrazol-4-yl]phenol;
3-[3-methyl-4-(4-pyridinyl)-1H-pyrazol-4-yl]phenol;
1-hydroxy-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl]pyridinium;
5-(4-fluorophenyl)-N,N-dimethyl-4-(4-pyridinyl)-1H-pyrazol-3-amine;
5-(4-fluorophenyl)-N-phenyl-4-(4-pyridinyl)-1H-pyrazol-3-amine; 4-[5-(4-fluorophenyl)-3-phenyl-1H-pyrazol-4-yl]pyridine;
4-[5-(3-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-4-yl]pyridine;
4-[3-(4-fluordphenyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]pyridine;
4-(5-cyclohexyl)-3-methyl-1H-pyrazol-4-yl)pyridine;
4-[5-(3-fluoro-5-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
4-[5-(3-methylphenyl)-3-propyl-1H-pyrazol-4-yl]pyridine;
4-[(3-methyl-5-phenyl-1H-pyrazol-4-yl)methyl]pyridine;
4-[3,5-bis(3-methylphenyl)-1H-pyrazol-4-yl]pyridine;
4-[4-methyl-2-(2-trifluorophenyl)-1H-pyrazol-4-yl]pyridine;
4-[3-(2-chlorophenyl)-5-methyl-1H-pyrazol-4-yl]pyridine;
4-[5-methyl-3-(2,4-dimethylphenyl)-1H-pyrazol-4-yl]pyridine;
4-[5-(4-chlorophenyl)-1,3-dimethyl-1H-pyrazol-4-yl]pyridine;
4-[3-(3-fluoro-2-methylphenyl)-5-methyl-1H-pyrazol-4-yl]pyridine;
4-[3-(3,5-dimethylphenyl)-5-methyl-1H-pyrazol-4-yl]pyridine;
4-[3-(3,5-dimethoxyphenyl)-5-methyl-1H-pyrazol-4-yl]pyridine;
4-[5-methyl-3-(3-nitrophenyl)-1H-pyrazol-4-yl]pyridine;
N,N-dimethyl-4-[5-methyl-4-(4-pyridinyl)-1H-pyrazol-3yl]benzenamine;
4-[3-(2,3-dihydrobenzofuran-5-yl)-5-methyl-1H-pyrazol-4-yl]pyridine;
4-[3-(4-bromophenyl)-5-methyl-1H-pyrazol-4-yl]pyridine;
4-[3-(2-fluorophenyl)-5-methyl-1H-pyrazol-4-yl]pyridine;
4-[3-(3-fluorophenyl)-5-methyl-1H-pyrazol-4-yl]pyridine;
4-[3-methyl-5-[3-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]pyridine;
4-(3-ethyl-4-phenyl-1H-pyrazol-4-yl)pyridine;
4-[5-(3-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl}pyridine;
4-[3-ethyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine;
4-[5-(3,4-difluorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
4-[5-(3-ethoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
4-[3-methyl-5-[4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]pyridine;
4-[3-methyl-5-(3-thienyl)-1H-pyrazol-4-yl]pyridine;
4-[5-(2,4-dichlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
4-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
4-[5-(3-chloro-4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
ethyl 3-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazole-5-propanoate;
4-[3-(4-fluorophenyl)-1-methyl-pyrazol-4-yl]pyridine;
5-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyrimidin-2-amine;
5-[3-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyrimidin-2-amine;
5-[3-methyl-5-(2-methylphenyl)-1H-pyrazol-4-yl]pyrimidin-2-amine;
5-[5-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyrimidin-2-amine;
5-[5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]pyrimidin-2-amine;
5-[5-(4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyrimidin-2-amine;
5-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-amine;
4-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-amine;
4-[5-(3-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-amine;
4-[5-(2-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-amine;
4-[5-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-amine;
4-[5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-amine;
4-[5-(4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-amine;
5-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]-2-methoxypyridine;
2-methoxy-5-[3-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine;
2-methoxy-5-[5-(4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
4-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]-2-methoxypyridine;
2-methoxy-4-[3-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine;
2-methoxy-4-[3-methyl-5-(2-methylphenyl)-1H-pyrazol-4-yl]pyridine;
4-[5-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]-2-methoxypyridine;
4-[5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]-2-methoxypyridine;
2-methoxy-4-[3-methyl-5-(4-methylphenyl)-1H-pyrazol-4-yl]pyridine;
5-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-ol;
4-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-ol;
4-[5-(3-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-ol;
4-[5-(2-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-ol;
4-[5-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-ol;
4-[5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-ol;
4-[5-(4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-ol;
5-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine;
4-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine;
4-[5-(3-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine;
4-[5-(2-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine;
4-[5-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine;
4-[5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine;
4-[5-(4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine;
5-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-carboxamide;
4-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-carboxamide;
4-[5-(3-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-carboxamide;
4-[5-(2-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-carboxamide;
4-[5-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-carboxamide;
4-[5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-carboxamide;
4-[5-(4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-carboxamide;
4-[5-(3-fluoro-4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
4-[5-(4-fluoro-3-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
4-[5-(4-chloro-3-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
4-[5-(2,3-dihydrobenzofuran-6-yl)-3-methyl-1H-pyrazol-4-yl]pyridine;
4-[5-(benzofuran-6-yl)-3-methyl-1H-pyrazol-4-yl]pyridine;
4-[5-(3-fluoro-5-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
4-[5-(3-chloro-5-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
4-[5-(1-cyclohexyen-1-yl)-3-methyl-1H-pyrazol-4-yl]pyridine;
4-[5-(1,3-cyclohexadien-1-yl)-3-methyl-1H-pyrazol-4-yl]pyridine;
4-[5-(5,6-dihydro-2H-pyran-4-yl)-3-methyl-1H-pyrazol-4-yl]pyridine;
4-(5-cyclohexyl-3-methyl-1H-pyrazol-4-yl)pyridine;
4-[5-(4-methoxy-3-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
4-[5-(3-methoxy-4-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
4-[5-(3-methoxy-5-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
4-[5-(3-furyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
2-methyl-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine;
2-methoxy-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine;
methyl 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyri-dine-2-carboxylate;
4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine-2-carboxamide;
1-[4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridin-2-yl]ethanone;
N,N-dimethyl-4-(3-methyl-5-phenyl-1H-pyrazol-2-yl)pyridin-2-amine;
3-methyl-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine;
3-methoxy-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine;
methyl 4-(3-methyl-5-phenyl-1H-pyrazol-4yl)pyridine-3-carboxylate;
4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine-3-carboxamide;
1-[4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridin-3-yl]ethanone;
3-bromo-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine;
N,N-dimethyl-4-(3-methyl-5-phenyl-1H-pyrazol-2-yl)pyridin-3-amine;
2-methyl-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyrimidine;
4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyrimidine;
2-methoxy-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyrimidine;
4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyrimidin-2-amine;
N,N-dimethyl-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyrimidin-2-amine;
4-(5,6-dihydro-2H-pyran-4-yl)-3-methyl-5-phenyl-1H-pyrazole;
3-methyl-5-phenyl-4-(3-thienyl)-1H-pyrazole;
4-(3-furyl)-3-methyl-5-phenyl-1H-pyrazole;
3-methyl-5-phenyl-4-(2-thienyl)-1H-pyrazole;
4-(2-furyl)-3-methyl-5-phenyl-1H-pyrazole;
4-(3-isothiazolyl)-3-methyl-5-phenyl-1H-pyrazole
4-(3-isoxazolyl)-3-methyl-5-phenyl-1H-pyrazole;
4-(5-isothiazolyl)-3-methyl-5-phenyl-1H-pyrazole;
4-(5-isoxazolyl)-3-methyl-5-phenyl-1H-pyrazole;
3-methyl-5-phenyl-4-(5-thiazolyl)-1H-pyrazole;
3-methyl-4-(5-oxazolyl)-5-phenyl-1H-pyrazole;
4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine;
2-methyl-4-[3-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine;
4-(1-methyl-3-phenyl-1H-pyrazol-4-yl)pyridine;
4-(3-phenyl-1H-pyrazol-4-yl)pyridine;
2-methyl-4-(3-phenyl-1H-pyrazol-4-yl)pyridine;
4-[3-(3-chlorophenyl)-1-methyl-pyrazol-4-yl]pyridine;
4-[3-(4-chlorophenyl)-1-methyl-pyrazol-4-yl]pyridine;
4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]pyridine;
4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]pyridine;
4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-2-methylpyridine;
4-[3-(3-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine;
4-[3-(3-fluorophenyl)-1H-pyrazol-4-yl]pyridine;
4-[3-(3-chlorophenyl)-1-methyl-pyrazol-4-yl]-2-methylpyridine;
5-(4-chlorophenyl)-N-phenyl-4-(4-pyridinyl)-1H-pyrazol-3-amine;
5-(4-chlorophenyl)-N-methyl-4-(4-pyridinyl)-1H-pyrazol-3-amine;
5-(4-chlorophenyl)-N,N-dimethyl-4-(4-pyridinyl)-1H-pyrazol-3-amine dihydrate;
5-(3-fluorophenyl)-N,N-dimethyl-4-(4-pyridinyl)-1H-pyrazol-3-amine;
N,N-dimethyl-5-(3-methylphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-amine;
N-methyl-5-(3-methylphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-amine;
N-ethyl-5-(3-methylphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-amine;
N,N-diethyl-5-(3-methylphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-amine;
5-(4-chlorophenyl)-N,N-diethyl-4-(4-pyridinyl)-1H-pyrazol-3-amine;
4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]morpholine;
5-(4-chlorophenyl)-N-propyl-4-(4-pyridinyl)-1H-pyrazol-3-amine;
5-(4-chlorophenyl)-N-(phenylmethyl)-4-(4-pyridinyl)-1H-pyrazol-3-amine hydrate (2:1);
5-(4-chlorophenyl)-N-(2-methoxyethyl)-4-(4-pyridinyl)-1H-pyrazol-3-amine monohydrate;
1,1-dimethylethyl 4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazinecarboxylate;
1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]piperazine trihydrochloride;
1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine;
1,1-dimethylethyl 4-(5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazinecarboxylate;
1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]piperazine trihydrochloride;
1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]piperazine;
N-[5-(4-chlorophenyl)-4-[2-(phenylmethyl)amino]-4-pyridinyl]-1H-pyrazol-3-yl]-1,3-propanediamine, trihydrochloride;
1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-(phenylmethyl)piperazine;
4-[3-(4-fluorophenyl)-5-(1-piperazinyl)-1H-pyrazol-4-yl]pyrimidine, dihydrochloride;
1,1-dimethylethyl [3-[[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]amino]propyl]carbamate;
N-[5-[4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,3-propanediamine, trihydrochloride monohydrate;
1,1-dimethylethyl [2-[[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]amino]ethyl]carbamate;
1,1-dimethylethyl 4-[5-(4-chlorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazinecarboxylate;
1,1-dimethylethyl 4-[5-(4-fluorophenyl)-4-(4-pyrimidinyl)-1H-pyrazol-3-yl]-1-piperazinecarboxylate;
1,1-dimethylethyl [3-[[5-(4-chlorophenyl)-4-(2-fluoro-4-pyridinyl)-1H-pyrazol-3-yl]amino]propyl]carbamate;
1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-ethylpiperazine;
N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,2-ethanediamine;
4-[3-(2,6-difluorophenyl)-5-methyl-1H-pyrazol-4-yl]pyridine;
4-[3-(3-ethylphenyl)-5-methyl-1H-pyrazol-4-yl]pyridine;
4-[3-(3-chlorophenyl)-5-ethyl-1H-pyrazol-4-yl]pyridine;
4-[3-ethyl-5-(3-ethylphenyl)-1H-pyrazol-4-yl]pyridine;
4-[3-(4-chlorophenyl)-5-(1-methylethyl)-1H-pyrazol-4-yl]pyridine;
4-[3-cyclopropyl-5-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine;
4-[3-(4-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]pyridine;
4-[5-(cyclopropyl-3-(4-(fluorophenyl)-1-methyl-1H-pyrazol-4-yl)pyridine;
5-cyclopropyl-3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol;
3-(4-fluorophenyl)-5-(2-methoxy-4-pyridinyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol;
4-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]-2(1H)-pyridinone;
1-acetyl-4-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]-2(1H)-pyridinone;
Ethyl 2-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]cyclopropanecarboxylate;
2-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]cyclopropanecarboxylic acid;
3-(4-fluorophenyl)-5-(4-imidazolyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol;
4-[3-(4-chloro-3-methylphenyl)-1H-pyrazol-4-yl]pyridine
5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-3-carboxylic acid;
5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-3-methanol;
1-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]piperazine;
1,1-dimethylethyl 4-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]-1-piperazinecarboxylate;
4-(1,5-dimethyl-3-phenyl-1H-pyrazol-4-yl)pyridine;
4-(1,3-dimethyl-5-phenyl-1H-pyrazol-4-yl]pyridine;
4-[3-(4-chlorophenyl)-1,5-dimethyl-1H-pyrazol-4-yl]pyridine;
4-[5-(4-chlorophenyl)-1,3-dimethyl-1H-pyrazol-4-yl]pyridine;
4-[5-ethyl-1-methyl-3-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine;
4-[3-ethyl-1-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine;
4-[3-(4-chlorophenyl)-1-ethyl-5-methyl-1H-pyrazol-4-yl]pyridine;
4-[3-(4-chlorophenyl)-2-ethyl-5-methyl-1H-pyrazol-4-yl]pyridine;
4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine;
4-[3-(2-chlorophenyl)-1H-pyrazol-4-yl]pyridine;
3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol;
3-(4-fluorophenyl)-4-(4-pyrimidinyl)-1H-pyrazole-1-ethanol;
4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine;
2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-1-butanol;
4-[5-bromo-3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine;
4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarbonitrile;
4-[2-[3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-1-yl]ethyl]morpholine;
3-(4-fluorophenyl)-1-methyl-α-phenyl-4-(4-pyridinyl)-1H-pyrazole-5-methanol;
N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-morpholineethanamine;
4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-2(1H)-pyridinone hydrazone;
4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-(phenylmethyl)-2-pyridinamine;
4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-(phenylethyl)-2-pyridinamine;
4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-ethyl-2-pyridinamine;
4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarboxamide;
Methyl 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarboxylate;
4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-methyl-2-pyridinecarboxamide;
4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarboxylic acid;
4-[3-(3-fluorophenyl)-1H-pyrazol-4-yl]pyridine;
4-[3-(1,3-benzodioxol-5-yl)-1H-pyrazol-4-yl]pyridine4-[3-(3-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine;
4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]pyridine;
4-[3-(1,3-benzodioxol-5-y)-1-methyl-1H-pyrazol-4-yl]pyridine;
4-[3-(4-chlorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine;
4-[3-(3-chlorophenyl)-1-methyl-1H-pyrazol-4-yl]-2-methylpyridine;
4-[5-(3-chlorophenyl)-1-methyl-1H-pyrazol-4-yl]-2-methylpyridine;
4-[3-(3-chlorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine;
4-[5-(3-chlorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine;
2-methyl-4-[1-methyl-3-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine;
2-methyl-4-[1-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine;
4-(3-phenyl-1H-pyrazol-4-yl)pyridine;
4-[3-[3-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]pyridine;
4-[1-methyl-3-[3-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]pyridine;
4-[3-(3,4-difluorophenyl)-1H-pyrazol-4-yl]pyridine;
4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-2-fluoropyridine;
4-[3-(4-bromophenyl)-1H-pyrazol-4yl]pyridine;
4-[3-(3,4-difluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine;
4-[3-(4-bromophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine;
(E)-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-(2-phenylethenyl)pyridine;
(S)-4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-N-(2-methylbutyl)-2-pyridinamine;
4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-N-[(4-methoxyphenyl)methyl]-2-pyridinamine;
N-[4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-2-pyridinemethanamine;
N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-2-pyridinemethanamine;
2-fluoro-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine;
4-[3-(4-iodophenyl)-1H-pyrazol-4-yl]pyridine;
4-[3-(4-iodophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine;
4-[1-methyl-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]pyridine;
N-[1-(4-fluorophenyl)ethyl]-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinamine;
N-[(3-fluorophenyl)methyl]-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinamine;
4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-2-(1-methylhydrazino)pyridine;
2-fluoro-4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine;
4-[3-(3,4-difluorophenyl)-1H-pyrazol-4-yl]-2-fluoropyridine;
4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-3-methylpyridine;
4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-3-methylpyridine;
4-[3-(3,4-difluorophenyl)-1-methyl-1H-pyrazol-4-yl]-2-fluoropyridine;
3-(4-fluorophenyl)-N,N-dimethyl-4-(4-pyridinyl)-1H-pyrazole-1-ethanamine;
2-[2-(4-fluorophenyl)ethyl]-4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine;
4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[1-(phenylmethyl)-4-piperidinyl]-2-pyridinamine;
N′-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-N,N-dimethyl-1,2-ethanediamine;
2,4-bis[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine;
N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-4-morpholineethanamine;
3-(4-fluorophenyl)-4-(2-fluoro-4-pyridinyl)-1H-pyrazole-1-ethanol;
4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[2-(1H-imidazol-1-yl)ethyl]-2-pyridinamine;
4-[2-[3-(4-fluorophenyl)-4-(2-fluoro-4-pyridinyl)-1H-pyrazol-1-yl]ethyl]morpholine;
(E)-3-(4-fluorophenyl)-4-[2-[2-(4-fluorophenyl)ethenyl]-4-pyridinyl]-1H-pyrazole-1-ethanol;
3-(4-fluorophenyl)-4-(2-fluoro-4-pyridinyl)-N,N-dimethyl-1H-pyrazole-1-ethanamine;
3-(4-fluorophenyl)-4-[2-[2-(4-fluorophenyl)ethyl]-4-pyridinyl]-1H-pyrazole-1-ethanol;
4-[1-[2-(dimethylamino)ethyl]-3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N,N-dimethyl-2-pyridinamine;
4-[1-[2-(dimethylamino)ethyl]-3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[(4-fluorophenyl)methyl]-2-pyridinamine;
3-(4-fluorophenyl)-4-[2-[2-(4-fluorophenyl)ethyl]-4-pyridinyl]-N,N-dimethyl-1H-pyrazole-1-ethanamine;
N-[(4-fluorophenyl)methyl]-4-[3(or 5)-(4-fluorophenyl)-1-[[2-(4-morpholinyl)ethyl]-1H-pyrazol-4-yl]-2-pyridinamine;
4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-4-piperadinyl-2-pyridinamine;
N,N-diethyl-3-(4-fluorophenyl)-4-(2-fluoro-4-pyridinyl)-1H-pyrazole-1-ethanamine;
4-[1-[2-(diethylamino)ethyl]-3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[(4-fluorophenyl)methyl]-2-pyridinamine;
2-[[4-[3-(4-(fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]ethanol;
2-[[4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-2-pyridinyl]amino]ethanol;
3-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-1-propanol;
3-(4-fluorophenyl)-4-[2-[[(4-fluorophenyl)methyl]amino]-4-pyridinyl]-1H-pyrazole-1-ethanol;
5-(4-fluorophenyl)-4-[2-[[(4-fluorophenyl)methyl]amino]-4-pyridinyl]-1H-pyrazole-1-ethanol;
N,N-diethyl-3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanamine;
N-[(4-fluorophenyl)methyl]-4-[3-(4-fluorophenyl)-1-[2-(4-morpholinyl)ethyl]-1H-pyrazol-4-yl]-2-pyridinamine;
N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-morpholinepropanamine;
N′-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-N,N-dimethyl-1,3-propanediamine;
5-(4-fluorophenyl)-N-2-propynyl-4-(4-pyridinyl)-1H-pyrazol-3-amine;
3-(4-fluorophenyl)-4-[2-[[(4-fluorophenyl)methyl]amino]-4-pyridinyl]-1H-pyrazole-1-ethanol;
5-(4-fluorophenyl)-4-[2-[[(4-fluorophenyl)methyl]amino]-4-pyridinyl]-1H-pyrazole-1-ethanol;
4-[3-[(4-fluorophenyl)-1H-pyrazol-4-yl]quinoline;
N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]glycine methyl ester;
N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]glycine;
4-[3-(4-fluorophenyl)-1-(2-propynyl)-1H-pyrazol-4-yl]pyridine;
4-[5-(4-fluorophenyl)-1-(2-propynyl)-1H-pyrazol-4-yl]pyridine;
4,4′-(1H-pyrazole-3,4-diyl)bis[pyridine];
4-[3-(3,4-dichlorophenyl)-1H-pyrazol-4-yl]pyridine;
N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-piperidinamine;
2-Chloro-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine;
4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2(1H)-pyrimidinone hydrazone;
4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N,N-dimethyl-2-pyrimidinamine;
4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-methyl-2-pyrimidinamine;
4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-(phenylmethyl)-2-pyrimidinamine;
N-cyclopropyl-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinamine;
4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[(4-methoxyphenyl)methyl]-2-pyrimidinamine;
4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinamine;
N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]-N-(phenylmethyl)acetamide;
Ethyl [4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]carbamate;
4-[3-(3-methylphenyl)-1H-pyrazol-4-yl]pyrimidine;
4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]pyrimidine;
4-[3-(3-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine;
4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine;
1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl)-4-cyclopropylpiperazine;
1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine, dihydrate;
methyl 4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazinecarboxylate, monohydrate;
4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-γ-oxo-1-piperazinebutanoic acid, dihydrate;
4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-γ-oxo-1-piperazinebutanoic acid, monosodium salt dihydrate;
1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-(methylsulfonyl)piperazine, monohydrate;
1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1-(2-propynyl)-1H-pyrazol-3-yl]piperazine, trihydrochloride monohydrate;
4-[3-(4-fluorophenyl)-5-(1H-imidazol-4-yl)-1-(4-methoxyphenyl)-1H-pyrazol-4-yl]pyridine;
4-[3-(4-fluorophenyl)-1H-pyazol-4-yl]-N-2-propynyl-2-pyrimidinamine;
N-(2-fluorophenyl)-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinamine;
4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-(2-methoxyphenyl)-2-pyrimidinamine;
1-[5-(3-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine;
N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-piperidinamine, trihydrochloride;
N-[5-(4-fluorophenyl)-4-(pyridinyl)-1H-pyrazol-3-yl]-1-methyl-4-piperidinamine;
ethyl 4-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]amino]-1-piperidinecarboxylate, monohydrate;
1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-(2-methoxyphenyl)piperazine;
1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-phenylpiperazine;
N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-4-piperidinamine;
1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-(2-propynyl)piperazine;
1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]piperazine;
1,1-dimethylethyl [3-[[5-(4-chlorophenyl)-4-(2-[(phenylmethyl)amino]-4-pyridinyl-1H-pyrazol-3-yl]amino]propyl]carbamate;
1,1-dimethylethyl 4-[5-(4-chlorophenyl)-4-(2-fluoro-4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazinecarboxylate;
ethyl 4-[[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]amino]-1-piperidinecarboxylate; 1-(4-chlorophenyl)-2-(1,3-dithietan-2-ylidene)-2-(4-pyridinyl)ethanone;
4-[3-(4-fluorophenyl)-5-[(1-methyl-4-piperidinyl)methyl]-1H-pyrazol-4-yl]pyridine;
1,1-dimethylethyl 4-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]-1-piperazinecarboxylate;
1-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]methyl]-4-methylpiperazine;
1-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]methyl]-4-piperazine;
4-[3-(4-fluorophenyl)-5-(4-piperidinylmethyl)-1H-pyrazol-4-yl]pyridine;
N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-3H-pyrazol-3-yl]-4-piperidineamine, trihydrochloride, monohydrate;
N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-N,1-dimethyl-4-piperidinamine, dihydrate
1-[2-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]ethyl]piperazine;
1-[2-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]ethyl]-4-methylpiperazine;
1-[2-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]ethyl]piperazine;
1-[2-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]ethyl]-4-methylpiperazine;
1-[[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]methylpiperazine;
1-[[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]methyl]-4-methylpiperazine;
4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazineethanol;
4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazineethanamine;
4-[5-[4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazineethanol;
4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazineethanamine;
1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-3,5-dimethylpiperazine;
4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,2,6-trimethylpiperazine;
1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-3,5-dimethylpiperazine;
4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,2,6-trimethylpiperazine;
1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-3-methylpiperazine;
4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,2-dimethylpiperazine;
1-[5-(4-fluorophneyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-3-methylpiperazine;
4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,2-dimethylpiperazine;
5-(4-chlorophenyl)-4-(4-pyridinyl)-N-3-pyrrolidinyl-1H-pyrazol-3-amine;
5-(4-chlorophenyl)-N-(1-methyl-3-pyrrolidinyl)-4-(4-pyridinyl)-1H-pyrazol-3-amine;
5-(4-fluorophenyl)-4-(4-pyridinyl)-N-3-pyrrolidinyl-1H-pyrazol-3-amine;
5-(4-fluorophenyl)-N-(1-methyl-3-pyrrolidinyl)-4-(4-pyridinyl)-1H-pyrazol-3-amine;
1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-3-pyrrolidinamine;
1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-N,N-dimethyl-3-pyrrolidinamine;
1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-3-pyrrolidinamine;
1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-N,N-dimethyl-3-pyrrolidinamine;
5-(4-chlorophenyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-4-(4-pyridinyl)-1H-pyrazol-3-amine;
5-(4-fluorophenyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-4-(4-pyridinyl)-1H-pyrazol-3-amine;
N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-3-piperidinamine;
N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-3-piperidinamine;
N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-3-piperidinamine;
N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-3-piperidinamine;
4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-2-piperazinemethanol;
4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-2-piperazinemethanamine;
4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-2-piperazinemethanol;
4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-2-piperazinemethanamine;
4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-2-piperazinemethanol;
4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-2-piperazinemethanamine;
4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-2-piperazinemethanol;
4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-2-piperazinemethanamine;
4-[3-(4-chlorophenyl)-5-(4-methyl-1-piperazinyl)-1H-pyrazol-4-yl]-N-methyl-2-pyrimidinamine;
4-[3-(4-fluorophenyl)-5-(4-methyl-1-piperazinyl)-1H-pyrazol-4-yl]-N-methyl-2-pyrimidinamine;
1-[[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]methyl]-4-piperidinol;
1-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]methyl-4-piperidinol;
4-[3-(4-chlorophenyl)-5-(4-methyl-1-piperazinyl)-1H-pyrazol-4-yl]pyrimidine;
4-[3-(4-fluorophenyl)-5-(4-methyl-1-piperazinyl)-1H-pyrazol-4-yl]pyrimidine;
N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(methylethyl)-4-piperidinamine;
N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-propyl-4-piperidinamine;
ethyl 4-[[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]amino]-1-piperidinecarboxylate;
5-(4-fluorophenyl)-N-methyl-N-2-propynyl-4-(4-pyridinyl)-1H-pyrazol-3-amine;
(βR)-β-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]benzene ethanol;
(βS)-β-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]benzene propanol;
(βS)-β-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]benzene ethanol;
(βR)-β-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]benzene propanol;
N-[2-(1-ethyl-2-piperidinyl)ethyl]-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinamine;
N2, N2-diethyl-N1-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-1-phenyl-1,2-ethanediamine;
N-(1-ethyl-4-piperidinyl)-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinamine;
4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-(4-piperidinylmethyl)-2-pyridinamine;
2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-3-methyl-1-butanol;
(2S)-2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-4-methyl-1-pentanol;
N1,N1-diethyl-N4-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]-1,4-pentanediamine;
(2R)-1-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-2-propanol;
N4-[4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-N1,N1-diethyl-1,4-pentanediamine;
(2S)-1-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-2-propanol;
1-[5-(3,4-dichlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine;
4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl)-N-[2-(1-piperidinyl)ethyl]-2-pyridinamine;
N,N-diethyl-N′-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-1,2-ethanediamine;
4-[3-(4-fluorophenyl)-1-(2-propenyl)-1H-pyrazol-4-yl)pyridine, monohydrochloride;
8-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,4-dioxa-8-azaspiro[4.5]decane;
1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl)-4-piperidinone;
1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-piperidinol;
1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,2,3,6-hexahydropyridine;
1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-N,N-dimethyl-4-piperidinamine, trihydrochloride;
1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-piperidinamine, trihydrochloride;
4-[3-(4-fluorophenyl)-5-(4-(1-pyrrolidinyl)-1-piperidinyl]-1H-pyrazol-4-yl]pyridine, trihydrochloride;
ethyl 4-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-1-piperidinecarboxylate;
1-methyl-4-[5-phenyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]piperazine;
1-[5-(3,4-difluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine;
4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]morpholine;
N1,N1-diethyl-N4-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-1,4-pentanediamine;
4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[3-(2-methyl-1-piperidinyl)propyl]-2-pyridinamine;
ethyl 4-[5-phenyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazinecarboxylate;
N,N-diethyl-N′-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,3-propanediamine;
N1,N1,-diethyl-N4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,4-pentanediamine;
N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-4-methyl-1-piperazinepropanamine(2E)-2-butenedioate (1:1);
N-(2-[1,4′-bipiperidin]-1′-ylethyl)-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinamine;
N-[2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]ethyl]-N,N′,N′-trimethyl-1,3-propanediamine;
N,N,N″-triethyl-N′-[2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]ethyl]-1,3-propanediamine;
3-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-1,2-propanediol;
trans-4-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]cyclohexanol;
4-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]cyclohexanone; and
1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-N,N-diethyl-4-piperidinamine, trihydrochloride.

Within Formula I there is another subclass of compounds of high interest represented by Formula IX:
embedded image

wherein

Z represents a carbon atom or a nitrogen atom; and

R¹is selected from hydrido, lower alkyl, lower hydroxyalkyl, lower alkynyl, lower heterocycyl, lower aralkyl, lower aminoalkyl and lower alkylaminoalkyl; and

R²is selected from hydrido, lower alkyl, aryl selected from phenyl, biphenyl, and naphthyl, 5- or 6-membered heterocyclyl selected from piperidinyl, piperazinyl, imidazolyl, pyridinyl and morpholinyl, lower haloalkyl, lower hydroxyalkyl, lower alkoxycarbonyl, lower alkylamino, lower alkylaminoalkyl, phenylamino, lower aralkyl, lower aralkylamino, lower alkylaminoalkylamino, lower aminoalkyl, lower aminoalkylamino, lower alkynylamino, lower heterocyclylamino, lower heterocyclylalkyl, lower heterocyclylalkylamino, lower alkylheterocyclyl, lower carboxycycloalkyl, lower carboxyalkylamino, lower alkoxyalkylamino, lower alkoxycarbonylaminoalkylamino, lower heterocyclylcarbonyl, lower alkoxycarbonylheterocyclyl, and lower alkoxycarbonylheterocyclylcarbonyl; wherein the aryl and heteroaryl groups are optionally substituted with one or more radicals independently selected from halo, lower alkyl, keto, aralkyl, carboxy, lower alkylaminoalkylamino, lower alkynylamino, lower heterocyclylalkylamino, lower alkylcarbonyl and lower alkoxycarbonyl; or

R²is —CR⁵⁴R⁵⁵wherein R⁵⁴is phenyl and R⁵⁵is hydroxy; and

R⁴is selected from hydrido, lower cycloalkyl, lower cycloalkenyl, lower cycloalkyldienyl, 5- or 6-membered heterocyclyl, and aryl selected from phenyl, biphenyl, naphthyl; wherein R⁴is optionally substituted at a substitutable position with one or more radicals independently selected from halo, lower alkyl, lower alkoxy, aryloxy, lower aralkoxy, lower haloalkyl, lower alkylthio, lower alkylamino, nitro, hydroxy; and

R⁵is selected from halo, amino, cyano, aminocarbonyl, lower alkyl, lower alkoxy, hydroxy, lower aminoalkyl, lower aralkyl, lower aralkyloxy, lower aralkylamino, lower alkoxycarbonyl, lower alkylamino, lower alkylcarbonyl, lower aralkenyl, lower arylheterocyclyl, carboxy, lower cycloalkylamino, lower alkoxycarbonylamino, lower alkoxyaralkylamino, lower alkylaminoalkylamino, lower heterocyclylamino, lower heterocyclylalkylamino, lower aralkylheterocyclylamino, lower alkylaminocarbonyl, lower alkylcarbonyl, lower alkoxyaralkylamino, hydrazinyl, and lower alkylhydrazinyl, or —NR⁶²R⁶³wherein R⁶²is lower alkylcarbonyl or amino, and R⁶³is lower alkyl or lower phenylalkyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

A preferred class of compounds consists of those compounds of Formula IX

R¹is selected from hydrido, methyl, ethyl, hydroxyethyl and propargyl; and

R²is selected from hydrido, methyl, ethyl, propyl, phenyl, trifluoromethyl, hydroxyethyl, methoxycarbonylethyl, ethoxycarbonylethyl, N-methylamino, N,N-dimethylamino, N-ethylamino, N,N-diethylamino, N-propylamino, N-phenylamino, aminomethyl, aminoethyl, aminoethylamino, aminopropylamino, propargylamino, benzylamino, dimethylaminopropylamino, morpholinylpropylamino, morpholinylethylamino, piperidinyl, piperazinyl, imidazolyl, morpholinyl, pyridinyl, carboxymethylamino, methoxyethylamino, (1,1-dimethyl)ethylcarbonyl, (1,1-dimethyl)ethylcarbonylaminopropylamino, (1,1-dimethyl)ethylcarbonylaminoethylamino, piperazinylcarbonyl, 1,1-dimethylethylpiperazinylcarbonyl; wherein the phenyl, piperidinyl, piperazinyl, imidazolyl, morpholinyl, and pyridinyl groups are optionally substituted with one or more radicals independently selected from fluoro, chloro, bromo, keto, methyl, ethyl, trifluoromethyl, benzyl, methoxy, methoxycarbonyl, ethoxycarbonyl and (1,1-dimethyl)ethoxycarbonyl; and

R⁴is selected from cyclohexyl, cyclohexenyl, cyclohexadienyl, phenyl, quinolyl, biphenyl, pyridinyl, thienyl, furyl, dihydropyranyl, benzofuryl, dihydrobenzofuryl, and benzodioxolyl; wherein R⁴is optionally substituted with one or more radicals independently selected from methylthio, fluoro, chloro, bromo, methyl, ethyl, methoxy, ethoxy, phenoxy, benzyloxy, trifluoromethyl, nitro, dimethylamino, and hydroxy; and

R⁵is selected from fluoro, chloro, bromo, methyl, fluorophenylethyl, fluorophenylethenyl, fluorophenylpyrazolyl, cyano, methoxycarbonyl, aminocarbonyl, acetyl, hydroxy, carboxy, methoxy, methylamino, dimethylamino, 2-methylbutylamino, ethylamino, dimethylaminoethylamino, hydroxypropylamino, hydroxyethylamino, imidazolylamino, morpholinylethylamino, (1-ethyl-2-hydroxy)ethylamino, piperidinylamino, pyridinylmethylamino, phenylmethylpiperidinylamino, aminomethyl, cyclopropylamino, amino, hydroxy, methylcarbonyl, ethoxycarbonylamino, methoxyphenylmethylamino, phenylmethylamino, fluorophenylmethylamino, fluorophenylethylamino, methylaminocarbonyl, methylcarbonyl, hydrazinyl, and 1-methylhydrazinyl, or —NR⁶²R⁶³wherein R⁶²is methylcarbonyl or amino, and R⁶³is methyl or benzyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

Within Formula I there is another subclass of compounds of high interest represented by Formula X:
embedded image

wherein

Z represents a carbon atom or a nitrogen atom; and

R¹is selected from lower alkyl, lower hydroxyalkyl, lower alkynyl, lower aminoalkyl and lower alkylaminoalkyl; and

R²is —CR⁵⁴R⁵⁵wherein R⁵⁴is phenyl and R⁵⁵is hydroxy; and

R⁴is selected from 5- or 6-membered heteroaryl, and aryl selected from phenyl, biphenyl, and naphthyl; wherein R⁴is optionally substituted with one or more radicals independently selected from halo, lower alkyl, lower alkoxy, aryloxy, lower aralkoxy, lower haloalkyl, lower alkylthio, lower alkylamino, nitro, hydroxy; and

a pharmaceutically-acceptable salt or tautomer thereof.

A preferred class of compounds consists of those compounds of Formula X

R¹is selected from methyl, ethyl, hydroxyethyl and propargyl; and

R²is selected from methyl, ethyl, propyl, phenyl, trifluoromethyl, hydroxyethyl, methoxycarbonylethyl, ethoxycarbonylethyl, N-methylamino, N,N-dimethylamino, N-ethylamino, N,N-diethylamino, N-propylamino, N-phenylamino, aminomethyl, aminoethyl, aminoethylamino, aminopropylamino, propargylamino, benzylamino, piperadinylamino, dimethylaminoethylamino, dimethylaminopropylamino, morpholinylpropylamino, morpholinylethylamino, piperidinyl, piperazinyl, imidazolyl, morpholinyl, pyridinyl, N-methylpiperazinyl, carboxymethylamino, methoxyethylamino, (1,1-dimethyl)ethylcarbonyl, (1,1-dimethyl)ethylcarbonylaminopropylamino, (1,1-dimethyl)ethylcarbonylaminoethylamino, piperazinylcarbonyl, and 1,1-dimethylethylpiperazinylcarbonyl; wherein the phenyl, piperidinyl, piperazinyl, imidazolyl, morpholinyl, and pyridinyl groups are optionally substituted with one or more radicals independently selected from fluoro, chloro, bromo, keto, methyl, ethyl, trifluoromethyl, benzyl, methoxy, methoxycarbonyl, ethoxycarbonyl and (1,1-dimethyl)ethoxycarbonyl; and

R⁴is selected from phenyl, quinolyl, biphenyl, pyridinyl, thienyl, furyl, dihydropyranyl, benzofuryl, dihydrobenzofuryl, and benzodioxolyl; wherein R⁴is optionally substituted with one or more radicals independently selected from methylthio, fluoro, chloro, bromo, methyl, ethyl, methoxy, ethoxy, phenoxy, benzyloxy, trifluoromethyl, nitro, dimethylamino, and hydroxy; and

R⁵is selected from fluoro, chloro, bromo, methyl, fluorophenylethyl, fluorophenylethenyl, fluorophenylpyrazolyl, cyano, methoxycarbonyl, aminocarbonyl, acetyl, hydroxy, carboxy, methoxy, methylamino, dimethylamino, 2-methylbutylamino, ethylamino, dimethylaminoethylamino, hydroxypropylamino, hydroxyethylamino, propargylamino, imidazolylamino, morpholinylethylamino, (1-ethyl-2-hydroxy)ethylamino, piperidinylamino, pyridinylmethylamino, phenylmethylpiperidinylamino, aminomethyl, cyclopropylamino, amino, hydroxy, methylcarbonyl, ethoxycarbonylamino, methoxyphenylmethylamino, phenylmethylamino, fluorophenylmethylamino, fluorophenylethylamino, methylaminocarbonyl, methylcarbonyl, hydrazinyl, and l-methylhydrazinyl, or —NR⁶²R⁶³wherein R⁶²is methylcarbonyl or amino, and R⁶³is methyl or benzyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

Within Formula I there is another subclass of compounds of high interest represented by Formula XI:
embedded image

wherein

Z represents a carbon atom or a nitrogen atom; and

R¹is selected from lower alkyl, lower hydroxyalkyl, lower alkynyl, lower aminoalkyl and lower alkylaminoalkyl; and

R²is —CR⁵⁴R⁵⁵wherein R⁵⁴is phenyl and R⁵⁵is hydroxy; and

a pharmaceutically-acceptable salt or tautomer thereof.

A preferred class of compounds consists of those compounds of Formula XI

R¹is selected from methyl, ethyl, hydroxyethyl and propargyl; and

R²is selected from methyl, ethyl, propyl, phenyl, trifluoromethyl, hydroxyethyl, methoxycarbonylethyl, ethoxycarbonylethyl, N-methylamino, N,N-dimethylamino, N-ethylamino, N,N-diethylamino, N-propylamino, N-phenylamino, aminomethyl, aminoethyl, aminoethylamino, aminopropylamino, propargylamino, benzylamino, dimethylaminopropylamino, morpholinylpropylamino, morpholinylethylamino, piperidinyl, piperazinyl, imidazolyl, morpholinyl, pyridinyl, carboxymethylamino, methoxyethylamino, (1,1-dimethyl)ethylcarbonyl, (1,1-dimethyl)ethylcarbonylaminopropylamino, (1,1-dimethyl)ethylcarbonylaminoethylamino, piperazinylcarbonyl, 1,1-dimethylethylpiperazinylcarbonyl; wherein the phenyl, piperidinyl, piperazinyl, imidazolyl, morpholinyl, and pyridinyl groups are optionally substituted with one or more radicals independently selected from fluoro, chloro, bromo, keto, methyl, ethyl, trifluoromethyl, benzyl, methoxy, methoxycarbonyl, ethoxycarbonyl and (1,1-dimethyl)ethoxycarbonyl;

a pharmaceutically-acceptable salt or tautomer thereof.

A preferred class of compounds consists of those compounds of Formula IX wherein

Z represents a carbon atom or a nitrogen atom; and

R¹is selected from hydrido, lower alkyl, lower hydroxyalkyl, lower alkynyl, lower aminoalkyl and lower alkylaminoalkyl; and

R²is —CR⁵⁴R⁵⁵wherein R⁵⁴is phenyl and R⁵⁵is hydroxy; and

R⁴is phenyl that is optionally substituted with one or more radicals independently selected from halo, lower alkyl, lower alkoxy, aryloxy, lower aralkoxy, lower haloalkyl, lower alkylthio, lower alkylamino, nitro, hydroxy; and

a pharmaceutically-acceptable salt or tautomer thereof.

A class of compounds of specific interest consists of those compounds of Formula IX wherein

R¹is selected from hydrido, methyl, ethyl, hydroxyethyl and propargyl;

R²is selected from methyl, ethyl, propyl, phenyl, trifluoromethyl, hydroxyethyl, methoxycarbonylethyl, ethoxycarbonylethyl, N-methylamino, N,N-dimethylamino, N-ethylamino, N,N-diethylamino, N-propylamino, N-phenylamino, aminomethyl, aminoethyl, aminoethylamino, aminopropylamino, propargylamino, benzylamino, dimethylaminopropylamino, morpholinylpropylamino, morpholinylethylamino, piperidinyl, piperazinyl, imidazolyl, morpholinyl, pyridinyl, carboxymethylamino, methoxyethylamino, (1,1-dimethyl)ethylcarbonyl, (1,1-dimethyl)ethylcarbonylaminopropylamino, (1,1-dimethyl)ethylcarbonylaminoethylamino, piperazinylcarbonyl, 1,1-dimethylethylpiperazinylcarbonyl; wherein the phenyl, piperidinyl, piperazinyl, imidazolyl, morpholinyl, and pyridinyl groups are optionally substituted with one or more radicals independently selected from fluoro, chloro, bromo, keto, methyl, ethyl, trifluoromethyl, benzyl, methoxy, methoxycarbonyl, ethoxycarbonyl and (1,1-dimethyl)ethoxycarbonyl;

R⁴is phenyl that is optionally substituted with one or more radicals independently selected from methylthio, fluoro, chloro, bromo, methyl, ethyl, methoxy, ethoxy, phenoxy, benzyloxy, trifluoromethyl, nitro, dimethylamino, and hydroxy; and

a pharmaceutically-acceptable salt or tautomer thereof.

Another class of compounds of specific interest consists of those compounds of Formula IX wherein

- Z represents a carbon atom or a nitrogen atom; and

R¹is selected from hydrido, lower alkyl, lower hydroxyalkyl and lower alkynyl; and

R²is selected from hydrido and lower alkyl; and

R⁴is selected from phenyl and benzodioxolyl; wherein phenyl is optionally substituted with one or more halo radicals; and

R⁵is selected from hydrido, halo and alkylhydrazinyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

Still another class of compounds of specific interest consists of those compounds of Formula IX wherein;

Z represents a carbon atom; and

R¹is selected from hydrido, methyl, hydroxyethyl, propargyl; and

R²is hydrido; and

R⁴is selected from phenyl and benzodioxolyl; wherein phenyl is optionally substituted with one or more radicals independently selected from chloro, fluoro and bromo; and

R⁵is selected from hydrido, fluoro, and 1-methylhydrazinyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

A preferred class of compounds of specific interest consists of those compounds of Formula IX wherein

Z represents a carbon atom; and

R¹is selected from hydrido and methyl; and

R²is hydrido; and

R⁴is selected from phenyl that is optionally substituted with one or more radicals independently selected from chloro, fluoro and bromo; and

R⁵is selected from hydrido and fluoro; or

a pharmaceutically-acceptable salt or tautomer thereof.

Within Formula IA there is another subclass of compounds of interest represented by Formula IXA:
embedded image

wherein

Z represents a carbon atom or a nitrogen atom; and

R¹is selected from hydrido, lower alkyl, lower hydroxyalkyl, lower alkynyl, lower aralkyl, lower aminoalkyl and lower alkylaminoalkyl; and

R²is selected from hydrido, lower alkylamino, lower alkynylamino, arylamino, lower aralkylamino, lower heterocyclylalkylamino, lower aminoalkylamino, lower alkylaminoalkylamino, lower hydroxyalkylamino, lower carboxyalkylamino, and lower alkoxyalkylamino, lower alkoxycarbonylaminoalkylamino, wherein the aryl group is optionally substituted with one or more radicals independently selected from halo, keto, lower alkyl, aralkyl, carboxy, lower alkoxy, lower alkylaminoalkylamino, lower alkynylamino, lower heterocyclylalkylamino, lower alkylcarbonyl and lower alkoxycarbonyl; or

R²is R²⁰⁰-heterocyclyl-R²⁰¹or R²⁰⁰-cycloalkyl-R²⁰¹wherein:

R²⁰⁰is selected from:

—(CR²⁰²R²⁰³)_y—;

—NR²⁰²—;

—NR²⁰²—(CH₂)_y—;

—(CH₂)_y—NR²⁰²—;

—O—(CH₂)_y—;

—(CH₂)_y—O—;

—S—;

—O—;

or R²⁰⁰represents a bond;

R²⁰¹represents one or more radicals selected from the group consisting of hydrido, halogen, hydroxy, carboxy, keto, lower alkyl, lower hydroxyalkyl, lower haloalkyl, lower cycloalkyl, lower alkenyl, lower alkynyl, aryl, heterocyclyl, lower aralkyl, lower heterocyclylalkylene, lower alkylcarbonyl, lower hydroxyalkylcarbonyl, lower cycloalkylcarbonyl, arylcarbonyl, haloarylcarbonyl, lower alkoxy, lower alkoxyalkylene, lower alkoxyarylene, lower alkoxycarbonyl, lower carboxyalkylcarbonyl, lower alkoxyalkylcarbonyl, lower heterocyclylalkylcarbonyl, lower alkylsulfonyl, lower alkylsulfonylalkylene, amino, lower aminoalkyl, lower alkylamino, lower aralkylamino, lower alkylaminoalkylene, aminocarbonyl, lower alkylcarbonylamino, lower alkylcarbonylaminoalkylene, lower alkylaminoalkylcarbonyl, lower alkylaminoalkylcarbonylamino, lower aminoalkylcarbonylaminoalkyl, lower alkoxycarbonylamino, lower alkoxyalkylcarbonylamino, lower alkoxycarbonylaminoalkylene, lower alkylimidocarbonyl, amidino, lower alkylamidino, lower aralkylamidino, guanidino, lower guanidinoalkylene, and lower alkylsulfonylamino; and

R²⁰²and R²⁰³are independently selected from hydrido, lower alkyl, aryl and lower aralkyl; and

y is 0, 1, 2 or 3; and

R⁴is selected from aryl selected from phenyl, biphenyl, naphthyl, wherein said aryl is optionally substituted at a substitutable position with one or more radicals independently selected from halo, lower alkyl, lower alkoxy, aryloxy, lower aralkoxy, lower haloalkyl, lower alkylthio, lower alkylamino, nitro, and hydroxy; and

R⁵is selected from hydrido, halo, amino, cyano, aminocarbonyl, lower alkyl, lower alkoxy, hydroxy, lower aminoalkyl, lower aralkyl, lower aralkyloxy, lower aralkylamino, lower alkoxycarbonyl, lower alkylamino, lower hydroxyalkylamino, lower alkylcarbonyl, lower aralkenyl, lower arylheterocyclyl, carboxy, lower cycloalkylamino, lower hydroxycycloalkylamino, lower alkoxycarbonylamino, lower alkoxyaralkylamino, lower alkylaminoalkylamino, lower heterocyclylamino, lower heterocyclylalkylamino, lower aralkylheterocyclylamino, lower alkylaminocarbonyl, lower alkylcarbonyl, lower alkoxyaralkylamino, hydrazinyl, and lower alkylhydrazinyl, or —NR⁶²R⁶³wherein R⁶²is lower alkylcarbonyl or amino, and R⁶³is lower alkyl or lower phenylalkyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

When the substituent at the 4-position of the pyrazole ring is a substituted pyridinyl, at least one of the substituents preferably is attached to a ring carbon atom adjacent the nitrogen heteroatom of the pyridine ring. When the substituent at the 4-position of the pyrazole ring is a substituted pyrimidinyl, at least one of the substituents preferably is attached to the carbon ring atom between the nitrogen heteroatoms of the pyrimidine ring. When R²comprises a substituted piperidinyl or piperazinyl moiety, at least one of the substituents preferably is attached to the distal nitrogen heteroatom or to a carbon ring atom adjacent to the distal nitrogen heteroatom of the piperidine or piperazine ring.

A subclass of compounds of specific interest consists of those compounds of Formula IXA wherein;

R¹is selected from hydrido, methyl, ethyl, hydroxyethyl and propargyl; and

R²is selected from hydrido, N-methylamino, N,N-dimethylamino, N-ethylamino, N,N-diethylamino, N-propylamino, N,N-dipropylamino, N-butylamino, N-propargylamino, N-phenylamino, N-benzylamino, aminoethylamino, aminopropylamino, aminobutylamino, methylaminoethylamino, dimethylaminoethylamino, ethylaminoethylamino, diethylaminoethylamino, methylaminopropylamino, dimethylaminopropylamino, ethylaminopropylamino, diethylaminopropylamino, morpholinylmethylamino, morpholinylethylamino, morpholinylpropylamino, piperidinylmethylamino, piperidinylethylamino, piperidinylpropylamino, piperazinylmethylamino, piperazinylethylamino, piperazinylpropylamino, carboxymethylamino, carboxyethylamino, methoxyethylamino, ethoxyethylamino, ethoxymethylamino, (1,1-dimethyl)ethylcarbonylaminopropylamino, and (1,1-dimethyl)ethylcarbonylaminoethylamino, wherein the phenyl, morpholinyl, piperidinyl, and piperazinyl groups are optionally substituted with one or more radicals independently selected from fluoro, chloro, bromo, keto, methyl, ethyl, trifluoromethyl, benzyl, methoxy, ethyoxy, methoxycarbonyl, ethoxycarbonyl and (1,1-dimethyl)ethoxycarbonyl; and

R²is R²⁰⁰-piperidinyl-R²⁰¹, R²⁰⁰-piperazinyl-R²⁰¹, or R²⁰⁰-cyclohexyl-R²⁰¹wherein:

R²⁰⁰is selected from:

—(CR²⁰²R²⁰³)_y—;

—NR²⁰²—;

—S—;

—O—;

or R²⁰⁰represents a bond;

R²⁰¹represents one or more radicals selected from the group consisting of hydrido, chloro, fluoro, bromo, iodo, hydroxy, carboxy, keto, methyl, ethyl, propyl, butyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, (1-hydroxy-1,1-dimethyl)ethyl, chloromethyl, chloroethyl, chloropropyl, chlorobutyl, fluoromethyl, fluoroethyl, fluoropropyl, fluorobutyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, ethenyl, propenyl, butenyl, ethynyl, propynyl, propargyl, butynyl, phenyl, benzyl, piperidinyl, piperazinyl, morpholinyl, piperidinylmethylene, piperazinylmethylene, morpholinylmethylene, methoxy, ethoxy, propoxy, butoxy, methoxymethylene, methoxyethylene, methoxypropylene, ethoxyethylene, ethoxypropylene, propoxyethylene, propoxypropylene, methoxyphenylene, ethoxyphenylene, propoxyphenylene, methylcarbonyl, ethylcarbonyl, propylcarbonyl, cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl, benzoyl, chlorobenzoyl, fluorobenzoyl, hydroxymethylcarbonyl, hydroxyethylcarbonyl, hydroxypropylcarbonyl, carboxymethylcarbonyl, carboxyethylcarbonyl, carboxypropylcarbonyl, methoxymethylcarbonyl, methoxyethylcarbonyl, methoxypropylcarbonyl, ethoxymethylcarbonyl, ethoxyethylcarbonyl, ethoxypropylcarbonyl, propoxymethylcarbonyl, propoxyethylcarbonyl, propoxypropylcarbonyl, methoxyphenylcarbonyl, ethoxyphenylcarbonyl, propoxyphenylcarbonyl, piperidinylmethylcarbonyl, piperazinylmethylcarbonyl, morpholinylcarbonyl, methylsulfonyl, ethylsulfonyl, methylsulfonylmethylene, amino, aminomethyl, aminoethyl, aminopropyl, N-methylamino, N,N-dimethylamino, N-ethylamino, N,N-diethylamino, N-propylamino, N,N-dipropylamino, phenylamino, benzylamino, methylaminomethylene, ethylaminomethylene, methylaminoethylene, ethylaminoethylene, aminocarbonyl, methylcarbonylamino, ethylcarbonylamino, methylaminomethylcarbonyl, ethylaminomethylcarbonyl, methylcarbonylaminomethylene, ethylcarbonylaminomethylene, aminomethylcarbonylaminocarbonylmethylene, methoxycarbonylamino, ethoxycarbonylamino, methoxymethylcarbonylamino, methoxyethylcarbonylamino, ethoxymethylcarbonylamino, ethoxyethylcarbonylamino, methoxycarbonylaminomethylene, ethoxycarbonylaminomethylene, methylimidocarbonyl, ethylimidocarbonyl, amidino, methylamidino, methylamidino, benzylamidino, guanidino, guanidinomethylene, guanidinoethylene, and methylsulfonylamino; and

R²⁰²and R²⁰³are independently selected from hydrido, methyl, ethyl, propyl, butyl, phenyl and benzyl; and

y is 0, 1 or 2; and

R⁴is phenyl, wherein said phenyl is optionally substituted with one or more radicals independently selected from methylthio, fluoro, chloro, bromo, iodo, methyl, ethyl, methoxy, ethoxy, phenoxy, benzyloxy, trifluoromethyl, nitro, dimethylamino, and hydroxy; and

R⁵is selected from hydrido, fluoro, chloro, bromo, iodo, hydroxy, methyl, ethyl, propyl, benzyl, fluorophenylethyl, fluorophenylethenyl, fluorophenylpyrazolyl, cyano, carboxy, methoxy, methoxycarbonyl, aminocarbonyl, acetyl, methylamino, dimethylamino, 2-methylbutylamino, ethylamino, dimethylaminoethylamino, hydroxyethylamino, hydroxypropylamino, hydroxybutylamino, hydroxycyclopropylamino, hydroxycyclobutylamino, hydroxycyclopentylamino, hydroxycyclohexylamino, imidazolylamino, morpholinylethylamino, (1-ethyl-2-hydroxy)ethylamino, piperidinylamino, pyridinylmethylamino, phenylmethylpiperidinylamino, aminomethyl, cyclopropylamino, amino, hydroxy, ethoxycarbonylamino, methoxyphenylmethylamino, phenylmethylamino, fluorophenylmethylamino, fluorophenylethylamino, methylaminoethylamino, dimethylaminoethylamino, methylaminopropylamino, dimethylaminopropylamino, methylaminobutylamino, dimethylaminobutylamino, methylaminopentylamino, dimethylaminopentylamino, ethylaminoethylamino, diethylaminoethylamino, ethylaminopropylamino, diethylaminopropylamino, ethylaminobutylamino, diethylaminobutylamino, ethylaminopentylamino, methylaminocarbonyl, methylcarbonyl, ethylcarbonyl, hydrazinyl, and 1-methylhydrazinyl, or —NR⁶²R⁶³wherein R⁶²is methylcarbonyl or amino, and R⁶³is methyl or benzyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

Within Formula IXA there is another subclass of compounds of interest represented by Formula XA:
embedded image

wherein:

R¹is selected from hydrido, methyl, ethyl, hydroxyethyl and propargyl; and

R²is selected from hydrido, N-methylamino, N,N-dimethylamino, N-ethylamino, N,N-diethylamino, N-propylamino, N,N-dipropylamino, N-butylamino, N-propargylamino, N-phenylamino, N-benzylamino, aminoethylamino, aminopropylamino, aminobutylamino, methylaminoethylamino, dimethylaminoethylamino, ethylaminoethylamino, diethylaminoethylamino, methylaminopropylamino, dimethylaminopropylamino, ethylaminopropylamino, diethylaminopropylamino, morpholinylmethylamino, morpholinylethylamino, morpholinylpropylamino, piperidinylmethylamino, piperidinylethylamino, piperidinylpropylamino, piperazinylmethylamino, piperazinylethylamino, and piperazinylpropylamino, wherein the phenyl, morpholinyl, piperidinyl, and piperazinyl groups are optionally substituted with one or more radicals independently selected from fluoro, chloro, bromo, keto, methyl, ethyl, trifluoromethyl, benzyl, and methoxy; and

R⁴is phenyl, wherein said phenyl is optionally substituted with one or more radicals independently selected from fluoro, chloro, methyl, ethyl, methoxy and ethoxy; and

R⁵is selected from hydrido, fluoro, chloro, bromo, hydroxy, methyl, ethyl, propyl, benzyl, cyano, carboxy, methoxy, methoxycarbonyl, aminocarbonyl, acetyl, methylamino, dimethylamino, 2-methylbutylamino, ethylamino, dimethylaminoethylamino, hydroxyethylamino, hydroxypropylamino, hydroxybutylamino, hydroxycyclopropylamino, hydroxycyclobutylamino, hydroxycyclopentylamino, hydroxycyclohexylamino, imidazolylamino, morpholinylethylamino, (1-ethyl-2-hydroxy)ethylamino, piperidinylamino, pyridinylmethylamino, phenylmethylpiperidinylamino, aminomethyl, cyclopropylamino, amino, hydroxy, ethoxycarbonylamino, methoxyphenylmethylamino, phenylmethylamino, fluorophenylmethylamino, fluorophenylethylamino, methylaminoethylamino, dimethylaminoethylamino, methylaminopropylamino, dimethylaminopropylamino, methylaminobutylamino, dimethylaminobutylamino, methylaminopentylamino, dimethylaminopentylamino, ethylaminoethylamino, diethylaminoethylamino, ethylaminopropylamino, diethylaminopropylamino, ethylaminobutylamino, diethylaminobutylamino, ethylaminopentylamino, methylaminocarbonyl, methylcarbonyl, and ethylcarbonyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

A subclass of compounds of particular interest consists of those compounds of Formula XA wherein:

R¹is selected from hydrido, methyl, ethyl, hydroxyethyl and propargyl; and

R²is selected from hydrido, methylaminopropylamino, dimethylaminopropylamino, ethylaminopropylamino, diethylaminopropylamino, morpholinylmethylamino, morpholinylethylamino, morpholinylpropylamino, wherein the phenyl and morpholinyl groups are optionally substituted with one or more radicals independently selected from fluoro, chloro, bromo, methyl, ethyl, and methoxy; and

R⁴is phenyl, wherein said phenyl is optionally substituted with one or more radicals independently selected from fluoro, chloro, methyl, ethyl, methoxy and ethoxy; and

R⁵is selected from hydrido, fluoro, chloro, bromo, hydroxy, methyl, ethyl, cyano, carboxy, methoxy, methoxycarbonyl, aminocarbonyl, acetyl, methylamino, dimethylamino, ethylamino, dimethylaminoethylamino, hydroxyethylamino, hydroxypropylamino, hydroxybutylamino, hydroxycyclopropylamino, hydroxycyclobutylamino, hydroxycyclopentylamino, hydroxycyclohexylamino, (1-ethyl-2-hydroxy)ethylamino, aminomethyl, cyclopropylamino, amino, ethoxycarbonylamino, methoxyphenylmethylamino, phenylmethylamino, fluorophenylmethylamino, fluorophenylethylamino, methylaminoethylamino, dimethylaminoethylamino, methylaminopropylamino, dimethylaminopropylamino, methylaminobutylamino, dimethylaminobutylamino, methylaminopentylamino, dimethylaminopentylamino, ethylaminoethylamino, diethylaminoethylamino, ethylaminopropylamino, diethylaminopropylamino, ethylaminobutylamino, diethylaminobutylamino, ethylaminopentylamino, methylaminocarbonyl, methylcarbonyl, and ethylcarbonyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

A subclass of compounds of specific interest consists of those compounds of Formula XA wherein:

R¹is hydrido; and

R⁴is phenyl, wherein said phenyl is optionally substituted with one or more radicals independently selected from fluoro, chloro, methyl, and methoxy; and

R⁵is selected from hydrido, methylamino, dimethylamino, ethylamino, dimethylaminoethylamino, hydroxypropylamino, hydroxyethylamino, hydroxypropylamino, hydroxybutylamino, hydroxycyclopropylamino, hydroxycyclobutylamino, hydroxycyclopentylamino, hydroxycyclohexylamino, (1-ethyl-2-hydroxy)ethylamino, aminomethyl, cyclopropylamino, amino, dimethylaminoethylamino, dimethylaminopropylamino, dimethylaminobutylamino, dimethylaminopentylamino, diethylaminoethylamino, diethylaminopropylamino, diethylaminobutylamino, and diethylaminopentylamino; or

a pharmaceutically-acceptable salt or tautomer thereof.

A subclass of compounds of high interest consists of those compounds of Formula XA wherein:

R¹is selected hydrido; and

R²is selected from hydrido, dimethylaminopropylamino, diethylaminopropylamino, morpholinylethylamino, and morpholinylpropylamino; and

R⁴is phenyl, wherein said phenyl is optionally substituted with one or more radicals independently selected from fluoro, chloro, methyl, and methoxy; and

R⁵is selected from hydrido, hydroxypropylamino, hydroxycyclohexylamino, diethylaminoethylamino; or

a pharmaceutically-acceptable salt or tautomer thereof.

Within Formula IA there is another subclass of compounds of interest represented by Formula XA:
embedded image

R¹is selected from hydrido, methyl, ethyl, hydroxyethyl and propargyl; and

R²is R²⁰⁰-piperidinyl-R²⁰¹wherein:

R²⁰⁰is selected from:

—(CR²⁰²R²⁰³)_y—;

—NR²⁰²—;

—S—;

—O—;

or R²⁰⁰represents a bond;

- R²⁰²and R²⁰³are independently selected from hydrido, methyl, ethyl, propyl, butyl, phenyl and benzyl; and
- y is 0, 1 or 2; and

R⁴is phenyl, wherein said phenyl is optionally substituted with one or more radicals independently selected from fluoro, chloro, methyl, ethyl, methoxy and ethoxy; and

a pharmaceutically-acceptable salt or tautomer thereof.

A subclass of compounds of particular interest consists of those compounds of Formula XA wherein:

R¹is selected from hydrido, methyl, ethyl, hydroxyethyl and propargyl; and

R²is R²⁰⁰-piperidinyl-R²⁰¹wherein:

R²⁰⁰is selected from:

methylene;

—NR²⁰²—;

—S—;

—O—;

or R²⁰⁰represents a bond;

R²⁰¹represents one or more radicals selected from the group consisting of hydrido, chloro, fluoro, hydroxy, carboxy, keto, methyl, ethyl, propyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, (1-hydroxy-1,1-dimethyl)ethyl, chloromethyl, chloroethyl, chloropropyl, fluoromethyl, fluororoethyl, fluoropropyl, phenyl, benzyl, piperidinyl, piperazinyl, morpholinyl, piperidinylmethylene, piperazinylmethylene, morpholinylmethylene, methoxy, ethoxy, propoxy, methoxymethyl, methoxyethyl, methoxypropyl, ethoxyethyl, ethoxypropyl, propoxyethyl, propoxypropyl, methoxyphenyl, ethoxyphenyl, propoxyphenyl, methylcarbonyl, ethylcarbonyl, propylcarbonyl, hydroxymethylcarbonyl, hydroxyethylcarbonyl, carboxymethylcarbonyl, carboxyethylcarbonyl, methoxymethylcarbonyl, methoxyethylcarbonyl, methoxypropylcarbonyl, ethoxymethylcarbonyl, ethoxyethylcarbonyl, ethoxypropylcarbonyl, propoxymethylcarbonyl, propoxyethylcarbonyl, propoxypropylcarbonyl, methoxyphenylcarbonyl, ethoxyphenylcarbonyl, propoxyphenylcarbonyl, methylsulfonyl, ethylsulfonyl, methylsulfonylmethylene, amino, aminomethyl, aminoethyl, aminopropyl, N-methylamino, N,N-dimethylamino, N-ethylamino, N,N-diethylamino, N-propylamino, N,N-dipropylamino, N-benzylamino, methylaminomethylene, aminocarbonyl, methoxycarbonylamino, ethoxycarbonylamino, or methylsulfonylamino; and

R²⁰²is selected from hydrido, methyl, ethyl, phenyl and benzyl; and

R⁴is phenyl, wherein said phenyl is optionally substituted with one or more radicals independently selected from fluoro, chloro, methyl, ethyl, methoxy and ethoxy; and

a pharmaceutically-acceptable salt or tautomer thereof.

A subclass of compounds of specific interest consists of those compounds of Formula XA wherein:

R¹is hydrido; and

R²is R²⁰⁰-piperidinyl-R²⁰¹wherein:

R²⁰⁰is selected from:

methylene;

—NR²⁰²—;

—S—;

—O—;

or R²⁰⁰represents a bond;

R²⁰¹represents one or more radicals selected from the group consisting of hydrido, hydroxy, methyl, ethyl, propyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, methoxymethyl, methoxyethyl, methoxypropyl, ethoxyethyl, ethoxypropyl, propoxyethyl, propoxypropyl, methoxyphenyl, ethoxyphenyl, propoxyphenyl, methylcarbonyl, ethylcarbonyl, propylcarbonyl, hydroxymethylcarbonyl, hydroxyethylcarbonyl, carboxymethylcarbonyl, carboxyethylcarbonyl, methoxymethylcarbonyl, methoxyethylcarbonyl, ethoxymethylcarbonyl, ethoxyethylcarbonyl, methoxyphenylcarbonyl, ethoxyphenylcarbonyl, methylsulfonyl, ethylsulfonyl, amino, aminomethyl, aminoethyl, aminopropyl, N-methylamino, N,N-dimethylamino, N-ethylamino, N,N-diethylamino, N-propylamino, N,N-dipropylamino, N-benzylamino, methylaminomethylene, aminocarbonyl, methoxycarbonylamino, and ethoxycarbonylamino; and

R²⁰²is selected from hydrido, methyl phenyl and benzyl; and

R⁴is phenyl, wherein said phenyl is optionally substituted with one or more radicals independently selected from fluoro, chloro, methyl, and methoxy; and

R⁵is selected from hydrido, methylamino, dimethylamino, 2-methylbutylamino, ethylamino, dimethylaminoethylamino, hydroxypropylamino, hydroxyethylamino, hydroxypropylamino, hydroxybutylamino, hydroxycyclopropylamino, hydroxycyclobutylamino, hydroxycyclopentylamino, hydroxycyclohexylamino, (1-ethyl-2-hydroxy)ethylamino, aminomethyl, cyclopropylamino, amino, dimethylaminoethylamino, dimethylaminopropylamino, dimethylaminobutylamino, dimethylaminopentylamino, diethylaminoethylamino, diethylaminopropylamino, diethylaminobutylamino, and diethylaminopentylamino; or

a pharmaceutically-acceptable salt or tautomer thereof.

A subclass of compounds of high interest consists of those compounds of Formula XA wherein:

R¹is hydrido; and

R²is R²⁰⁰-piperidinyl-R²⁰¹wherein:

R²⁰⁰is selected from:

methylene;

—NR²⁰²—;

—S—;

—O—;

or R²⁰⁰represents a bond;

R²⁰¹represents one or more radicals selected from the group consisting of hydrido, methyl, methoxyethyl, methylcarbonyl, hydroxymethylcarbonyl, methoxymethylcarbonyl, methylsulfonyl, amino, N,N-dimethylamino, and N,N-diethylamino; and

R²⁰²is selected from hydrido and methyl; and

R⁴is phenyl, wherein said phenyl is optionally substituted with one or more radicals independently selected from fluoro, chloro, methyl, and methoxy; and

R⁵is selected from hydrido, hydroxypropylamino, hydroxycyclohexylamino, diethylaminoethylamino; or

a pharmaceutically-acceptable salt or tautomer thereof.

Within Formula IXA there is another subclass of compounds of interest represented by Formula XA:
embedded image

R¹is selected from hydrido, methyl, ethyl, hydroxyethyl and propargyl; and

R²is R²⁰⁰-piperazinyl-R²⁰¹wherein:

R²⁰⁰is selected from:

—(CR²⁰²R²⁰³)_y—;

—NR²⁰²—;

—S—;

—O—;

or R²⁰⁰represents a bond;

R²⁰²and R²⁰³are independently selected from hydrido, methyl, ethyl, propyl, butyl, phenyl and benzyl; and

- y is 0, 1 or 2; and

R⁴is phenyl, wherein said phenyl is optionally substituted with one or more radicals independently selected from fluoro, chloro, methyl, ethyl, methoxy and ethoxy; and

a pharmaceutically-acceptable salt or tautomer thereof.

A subclass of compounds of particular interest consists of those compounds of Formula XA wherein:

R¹is selected from hydrido, methyl, ethyl, hydroxyethyl and propargyl; and

R²is R²⁰⁰piperazinyl-R²⁰¹wherein:

R²⁰⁰is selected from:

—(CR²⁰²R²⁰³)—;

—NR²⁰²—;

—S—;

—O—;

or R²⁰⁰represents a bond;

R²⁰¹represents one or more radicals selected from the group consisting of hydrido, chloro, fluoro, bromo, hydroxy, carboxy, keto, methyl, ethyl, propyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, (1-hydroxy-1,1-dimethyl)ethyl, chloromethyl, chloroethyl, chloropropyl, fluoromethyl, fluoroethyl, fluoropropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, ethenyl, propenyl, butenyl, ethynyl, propynyl, propargyl, phenyl, benzyl, piperidinyl, piperazinyl, morpholinyl, piperidinylmethylene, piperazinylmethylene, morpholinylmethylene, methoxy, ethoxy, propoxy, methoxymethylene, methoxyethylene, ethoxyethylene, methoxyphenylene, ethoxyphenylene, methylcarbonyl, ethylcarbonyl, propylcarbonyl, cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl, benzoyl, chlorobenzoyl, fluorobenzoyl, hydroxymethylcarbonyl, hydroxyethylcarbonyl, hydroxypropylcarbonyl, carboxymethylcarbonyl, carboxyethylcarbonyl, carboxypropylcarbonyl, methoxymethylcarbonyl, methoxyethlylcarbonyl, methoxypropylcarbonyl, ethoxymethylcarbonyl, ethoxyethylcarbonyl, ethoxypropylcarbonyl, propoxymethylcarbonyl, propoxyethylcarbonyl, propoxypropylcarbonyl, methoxyphenylcarbonyl, ethoxyphenylcarbonyl, propoxyphenylcarbonyl, piperidinylmethylcarbonyl, piperazinylmethylcarbonyl, morpholinylcarbonyl, methylsulfonyl, ethylsulfonyl, methylsulfonylmethylene, amino, aminomethyl, aminoethyl, aminopropyl, N-methylamino,
embedded image
N,N-dimethylamino, N-ethylamino, N,N-diethylamino, N-propylamino, N,N-dipropylamino, phenylamino, benzylamino, methylaminomethylene, ethylaminomethylene, methylaminoethylene, ethylaminoethylene, aminocarbonyl, methylcarbonylamino, ethylcarbonylamino, methylaminomethylcarbonyl, ethylaminomethylcarbonyl, methylcarbonylaminomethylene, ethylcarbonylaminomethylene, aminomethylcarbonylaminocarbonylmethylene, methoxycarbonylamino, ethoxycarbonylamino, methoxymethylcarbonylamino, methoxyethylcarbonylamino, ethoxymethylcarbonylamino, ethoxyethylcarbonylamino, methoxycarbonylaminomethylene, ethoxycarbonylaminomethylene, and methylsulfonylamino; and

R²⁰²and R²⁰³are independently selected from hydrido, methyl, ethyl, phenyl and benzyl; and

y is 0, 1 or 2; and

R⁴is phenyl, wherein said phenyl is optionally substituted with one or more radicals independently selected from fluoro, chloro, methyl, ethyl, methoxy and ethoxy; and

a pharmaceutically-acceptable salt or tautomer thereof.

A subclass of compounds of specific interest consists of those compounds of Formula XA wherein:

R¹is hydrido; and

R²is R²⁰⁰-piperazinyl-R²⁰¹wherein:

R²⁰⁰is selected from:

methylene;

—NR²⁰²—;

—S—;

—O—;

or R²⁰⁰represents a bond;

R²⁰¹represents one or more radicals selected from the group consisting of hydrido, methyl, ethyl, propyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, ethynyl, propynyl, propargyl, phenyl, benzyl, piperidinyl, piperazinyl, and morpholinyl; and

R²⁰²is selected from hydrido, methyl, ethyl, phenyl and benzyl; and

y is 0, 1 or 2; and

R⁴is phenyl, wherein said phenyl is optionally substituted with one or more radicals independently selected from fluoro, chloro, methyl, and methoxy; and

a pharmaceutically-acceptable salt or tautomer thereof.

A subclass of compounds of high interest consists of those compounds of Formula XA wherein:

R¹is hydrido; and

R²is R²⁰⁰-piperazinyl-R²⁰¹wherein:

R²⁰⁰is selected from:

methylene;

—NR²⁰²—;

—S—;

—O—;

or R²⁰⁰represents a bond;

R²⁰¹represents one or more radicals selected from the group consisting of hydrido, methyl, cyclopropyl, propargyl, and benzyl; and

R²⁰²is selected from hydrido and methyl; and

R⁴is phenyl, wherein said phenyl is optionally substituted with one or more radicals independently selected from fluoro, chloro, methyl, and methoxy; and

R⁵is selected from hydrido, hydroxypropylamino, hydroxycyclohexylamino, and diethylaminoethylamino; or

a pharmaceutically-acceptable salt or tautomer thereof.

Within Formula IA there is another subclass of compounds of interest represented by Formula XA:
embedded image

R¹is selected from hydrido, methyl, ethyl, hydroxyethyl and propargyl; and

R²is R²⁰⁰-cyclohexyl-R²⁰¹wherein:

R²⁰⁰is selected from:

—(CR²⁰²R²⁰³)—;

—NR²⁰²—;

—S—;

—O—;

or R²⁰⁰represents a bond;

R²⁰²and R²⁰³are independently selected from hydrido, methyl, ethyl, propyl, butyl, phenyl and benzyl; and

y is 0, 1 or 2; and

R⁴is phenyl, wherein said phenyl is optionally substituted with one or more radicals independently selected from fluoro, chloro, methyl, ethyl, methoxy and ethoxy; and

a pharmaceutically-acceptable salt or tautomer thereof.

A subclass of compounds of particular interest consists of those compounds of Formula XA wherein:

R¹is selected from hydrido, methyl, ethyl, hydroxyethyl and propargyl; and

R²is R²⁰⁰-cyclohexyl-R²⁰¹wherein:

R²⁰⁰is selected from:

—(CR²⁰²R²⁰³)_y—;

—NR²⁰²—;

—S—;

—O—;

or R²⁰⁰represents a bond;

R²⁰¹represents one or more radicals selected from the group consisting of hydrido, chloro, fluoro, bromo, hydroxy, carboxy, keto, methyl, ethyl, propyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, (1-hydroxy-1,1-dimethyl)ethyl, chloromethyl, chloroethyl, chloropropyl, fluoromethyl, fluoroethyl, fluoropropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, benzyl, piperidinyl, piperazinyl, morpholinyl, piperidinylmethylene, piperazinylmethylene, morpholinylmethylene, methoxy, ethoxy, propoxy, methoxymethylene, methoxyethylene, methoxypropylene, ethoxyethylene, ethoxypropylene, propoxyethylene, propoxypropylene, methoxyphenylene, ethoxyphenylene, propoxyphenylene, methylcarbonyl, ethylcarbonyl, propylcarbonyl, cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl, benzoyl, chlorobenzoyl, fluorobenzoyl, hydroxymethylcarbonyl, hydroxyethylcarbonyl, hydroxypropylcarbonyl, carboxymethylcarbonyl, carboxyethylcarbonyl, carboxypropylcarbonyl, methoxymethylcarbonyl, methoxyethylcarbonyl, methoxypropylcarbonyl, ethoxymethylcarbonyl, ethoxyethylcarbonyl, ethoxypropylcarbonyl, propoxymethylcarbonyl, propoxyethylcarbonyl, propoxypropylcarbonyl, methoxyphenylcarbonyl, ethoxyphenylcarbonyl, propoxyphenylcarbonyl, piperidinylmethylcarbonyl, piperazinylmethylcarbonyl, morpholinylcarbonyl, methylsulfonyl, ethylsulfonyl, methylsulfonylmethylene, amino, aminomethyl, aminoethyl, aminopropyl, N-methylamino, N,N-dimethylamino, N-ethylamino, N,N-diethylamino, N-propylamino, N,N-dipropylamino, phenylamino, benzylamino, methylaminomethylene, ethylaminomethylene, methylaminoethylene, ethylaminoethylene, aminocarbonyl, methylcarbonylamino, ethylcarbonylamino, methylaminomethylcarbonyl, ethylaminomethylcarbonyl, methylcarbonylaminomethylene, ethylcarbonylaminomethylene, aminomethylcarbonylamino-carbonylmethylene, methoxycarbonylamino, ethoxycarbonylamino, methoxymethylcarbonylamino, methoxyethylcarbonylamino, ethoxymethylcarbonylamino, ethoxyethylcarbonylamino, methoxycarbonylaminomethylene, and ethoxycarbonylaminomethylene; and

R²⁰²and R²⁰³are independently selected from hydrido, methyl, ethyl, phenyl and benzyl; and

- y is 0, 1 or 2; and

R⁴is phenyl, wherein said phenyl is optionally substituted with one or more radicals independently selected from fluoro, chloro, methyl, ethyl, methoxy and ethoxy; and

a pharmaceutically-acceptable salt or tautomer thereof.

A subclass of compounds of specific interest consists of those compounds of Formula XA wherein:

R¹is hydrido; and

R²is R²⁰⁰-cyclohexyl-R²⁰¹wherein:

R²⁰⁰is selected from:

methylene;

—NR²⁰²—;

—S—;

—O—;

or R²⁰⁰represents a bond;

R²⁰¹represents one or more radicals selected from the group consisting of hydrido, amino, aminomethyl, aminoethyl, aminopropyl, N-methylamino, N,N-dimethylamino, N-ethylamino, N,N-diethylamino, N-propylamino, N,N-dipropylamino, phenylamino, benzylamino, methylaminomethylene, ethylaminomethylene, methylaminoethylene, ethylaminoethylene, aminocarbonyl, methylcarbonylamino, ethylcarbonylamino, methylaminomethylcarbonyl, ethylaminomethylcarbonyl, methylcarbonylaminomethylene, ethylcarbonylaminomethylene, aminomethylcarbonylaminocarbonylmethylene, methoxycarbonylamino, ethoxycarbonylamino, methoxymethylcarbonylamino, methoxyethylcarbonylamino, ethoxymethylcarbonylamino, ethoxyethylcarbonylamino, methoxycarbonylaminomethylene, and ethoxycarbonylaminomethylene; and

R²⁰²is selected from hydrido, methyl, phenyl and benzyl; and

R⁴is phenyl, wherein said phenyl is optionally substituted with one or more radicals independently selected from fluoro, chloro, methyl, and methoxy; and

a pharmaceutically-acceptable salt or tautomer thereof.

A subclass of compounds of high interest consists of those compounds of Formula XA wherein:

R¹is hydrido; and

R²is R²⁰⁰-cyclohexyl-R²⁰¹wherein:

R²⁰⁰is selected from:

methylene;

NR²⁰²—;

—S—;

—O—;

or R²⁰⁰represents a bond;

R²⁰¹represents one or more radicals selected from the group consisting of amino, aminomethyl, N,N-dimethylamino, and N-isopropylamino; and

R²⁰²is selected from hydrido and methyl; and

R⁴is phenyl, wherein said phenyl is optionally substituted with one or more radicals independently selected from fluoro, chloro, methyl, and methoxy; and

R⁵is selected from hydrido, hydroxypropylamino, hydroxycyclohexylamino, and diethylaminoethylamino; or

a pharmaceutically-acceptable salt or tautomer thereof.

Within Formula IA is another subclass of compounds of interest wherein:

R¹has the formula
embedded image

wherein:

- i is an integer from 0 to 9;

R²⁶is selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkylalkylene, aralkyl, alkoxycarbonylalkylene, and alkylaminoalkyl; and

R²is selected from mercapto, heterocyclylheterocyclyl, heterocyclylalkylheterocyclyl, N-alkyl-N-alkynyl-amino, aminocarbonylalkylene, alkylcarbonylaminoalkylene, aminoalkylcarbonylaminoalkylene, alkylaminoalkylcarbonylamino, aminoalkylthio, alkylaminocarbonylalkylthio, alkylaminoalkylaminocarbonylalkylthio, cyanoalkylthio, alkenylthio, alkynylthio, carboxyalkylthio, alkoxycarbonylalkylthio, alkylsulfinyl, alkylsulfonyl, alkoxycarbonylalkylamino, alkoxycarbonylaminoalkylene, alkoxycarbonylaminoalkoxy, aralkythio, heterocyclylalkylthio, aminoalkoxy, cyanoalkoxy, carboxyalkoxy, aryloxy, aralkoxy, alkenyloxy, alkynyloxy, and heterocyclylalkyloxy; wherein the aryl, heterocyclyl, heterocyclylalkyl, cycloalkyl and cycloalkenyl groups are optionally substituted with one or more radicals independently selected from halo, keto, amino, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, aralkyl, heterocyclylalkyl, epoxyalkyl, amino(hydroxyalkyl) carboxy, alkoxy, aryloxy, aralkoxy, haloalkyl, alkylamino, alkynylamino, alkylaminoalkylamino, heterocyclylalkylamino, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl, arylsulfonyl, and aralkylsulfonyl; or

R²is R²⁰⁰-heterocyclyl-R²⁰¹, R²⁰⁰-aryl-R²⁰¹, or R²⁰⁰-cycloalkyl-R²⁰¹wherein:

R²⁰⁰is selected from:

—(CR²⁰²R²⁰³)_y—;

—C(O)—;

—C(O)—(CH₂)_y—;

—C(O)—O—(CH₂)_y—;

—(CH₂)_y—C(O)—;

—O—(CH₂)_y—C(O)—;

—NR²⁰²—;

—NR²⁰²—(CH₂)_y—;

—(CH₂)_y—NR²⁰²—;

—(CH₂)_y—NR²⁰²—(CH₂)_z—;

—(CH₂)_y—C(O)—NR²⁰²—(CH₂)_z—;

—(CH₂)_y—NR²⁰²—C(O)—(CH₂)_z—;

—(CH₂)_y—NR²⁰²—C(O)—NR²⁰³—(CH₂)_z—;

—S(O)_x—(CR²⁰²R²⁰³)_y—;

—(CR²⁰²R²⁰³)_y—S(O)_y—;

—S(O)_x—(CR²⁰²R²⁰³)_y—O—;

—S(O)_x—(CR²⁰²R²⁰³)_y—C(O)—;

—O—(CH₂)_y—;

—(CH₂)_y—O—;

—S—;

—O—;

or R²⁰⁰represents a bond;

R²⁰²and R²⁰³are independently selected from hydrido, alkyl, aryl and aralkyl; and

y and z are independently 0, 1, 2, 3, 4, 5 or 6 wherein y+z is less than or equal to 6; and

z is 0, 1 or 2; or

R²is —NHCR²⁰⁴R²⁰⁵wherein R²⁰⁴is alkylaminoalkylene, and R²⁰⁵is aryl; or

R²is —C(NR²⁰⁶)R²⁰¹wherein R²⁰⁶is selected from hydrogen and hydroxy, and R²⁰⁷is selected from alkyl, aryl and aralkyl; and

R³is selected from pyridinyl, pyrimidinyl, quinolinyl, purinyl, maleimidyl, pyridonyl, thiazolyl, thiazolylalkyl, thiazolylamino,
embedded image

wherein the R³pyridinyl, pyrimidinyl, quinolinyl, purinyl, maleimidyl, pyridonyl, thiazolyl, thiazolylalkyl, thiazolylamino,

groups are optionally substituted with one or more radicals independently selected from halo, keto, alkyl, aralkyl, aralkenyl, arylheterocyclyl, carboxy, carboxyalkyl, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfinyl, arylsulfinyl, alkylsulfonyl, arylsulfonyl, aralkoxy, heterocyclylalkoxy, amino, alkylamino, alkenylamino, alkynylamino, cycloalkylamino, cycloalkenylamino, arylamino, haloarylamino, heterocyclylamino, aminocarbonyl, cyano, hydroxy, hydroxyalkyl, alkoxyalkylene, alkenoxyalkylene, aryloxyalkyl, alkoxyalkylamino, alkylaminoalkoxy, alkoxycarbonyl, aryloxycarbonyl, heterocyclyloxycarbonyl, alkoxycarbonylamino, alkoxyarylamino, alkoxyaralkylamino, aminosulfinyl, aminosulfonyl, alkylsulfonylamino, alkylaminoalkylamino, hydroxyalkylamino, aralkylamino, aryl(hydroxyalkyl)amino, alkylaminoalkylaminoalkylamino, alkylheterocyclylamino, heterocyclylalkylamino, alkylheterocyclylalkylamino, aralkylheterocyclylamino, heterocyclylheterocyclylalkylamino, alkoxycarbonylheterocyclylamino, nitro, alkylaminocarbonyl, alkylcarbonylamino, halosulfonyl, aminoalkyl, haloalkyl, alkylcarbonyl, hydrazinyl, alkylhydrazinyl, arylhydrazinyl, or —NR⁴⁴R⁴⁵wherein R⁴⁴is alkylcarbonyl or amino, and R⁴⁵is alkyl or aralkyl; and

a pharmaceutically-acceptable salt or tautomer thereof.

Within Formula IA is another subclass of compounds of interest wherein:

R¹has the formula
embedded image

wherein:

i is an integer from 0 to 9;

R²⁶is selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkylalkylene, aralkyl, alkoxycarbonylalkylene, and alkylaminoalkyl; and

R²is selected from hydrido, halogen, mercapto, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, haloalkyl, hydroxyalkyl, aralkyl, alkylheterocyclyl, heterocyclylalkyl, heterocyclylheterocyclyl, heterocyclylalkylheterocyclyl, alkylamino, alkenylamino, alkynylamino, arylamino, aryl (hydroxyalkyl) amino, heterocyclylamino, heterocyclylalkylamino, aralkylamino, N-alkyl-N-alkynyl-amino, aminoalkyl, aminoaryl, aminoalkylamino, aminocarbonylalkylene, arylaminoalkylene, alkylaminoalkylene, arylaminoarylene, alkylaminoarylene, alkylaminoalkylamino, alkylcarbonylaminoalkylene, aminoalkylcarbonylaminoalkylene, alkylaminoalkylcarbonylamino, cycloalkyl, cycloalkenyl, aminoalkylthio, alkylaminocarbonylalkylthio, alkylaminoalkylaminocarbonylalkylthio, alkoxy, heterocyclyloxy, alkylthio, cyanoalkylthio, alkenylthio, alkynylthio, carboxyalkylthio, arylthio, heterocyclylthio, alkoxycarbonylalkylthio, alkylsulfinyl, alkylsulfonyl, carboxy, carboxyalkyl, alkoxyalkyl, alkoxyalkylthio, carboxycycloalkyl, carboxycycloalkenyl, carboxyalkylamino, alkoxycarbonyl, heterocyclylcarbonyl, alkoxycarbonylalkyl, alkoxycarbonylalkylamino, alkoxycarbonylheterocyclyl, alkoxycarbonylheterocyclylcarbonyl, alkoxyalkylamino, alkoxycarbonylaminoalkylene, alkoxycarbonylaminoalkoxy, alkoxycarbonylaminoalkylamino, heterocyclylsulfonyl, aralkythio, heterocyclylalkylthio, aminoalkoxy, cyanoalkoxy, carboxyalkoxy, aryloxy, aralkoxy, alkenyloxy, alkynyloxy, and heterocyclylalkyloxy; wherein the aryl, heterocyclyl, heterocyclylalkyl, cycloalkyl and cycloalkenyl groups are optionally substituted with one or more radicals independently selected from halo, keto, amino, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, aralkyl, heterocyclylalkyl, epoxyalkyl, amino(hydroxyalkyl) carboxy, alkoxy, aryloxy, aralkoxy, haloalkyl, alkylamino, alkynylamino, alkylaminoalkylamino, heterocyclylalkylamino, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl, arylsulfonyl, and aralkylsulfonyl; or

R²is R²⁰⁰-heterocyclyl-R²⁰¹, R²⁰⁰-aryl-R²⁰¹, or R²⁰⁰-cycloalkyl-R²⁰¹wherein:

R²⁰⁰is selected from:

—(CR²⁰²R²⁰³)_y—;

—C(O)—;

—C(O)—(CH₂)_y—;

—C(O)—O—(CH₂)_y—;

—(CH₂)_y—C(O)—;

—O—(CH₂)_y—C(O)—;

—NR²⁰²—;

—NR²⁰²—(CH₂)_y—;

—(CH₂)_y—NR²⁰²—;

—(CH₂)_y—NR²⁰²—(CH₂)_z—;

—(CH₂)_y—C(O)—NR²⁰²—(CH₂)_z—;

—(CH₂)_y—NR²⁰²—C(O)—(CH₂)_z—;

—(CH₂)_y—NR²⁰²—C(O)—NR²⁰³—(CH₂)_z—;

—S(O)_x—(CR²⁰²R²⁰³)_y—;

—(CR²⁰²R²⁰³)—S(O)_x—;

—S(O)_x—(CR²⁰²R²⁰³)_y—O—;

—S(O)_x—(CR²⁰²R²⁰³)_y—C(O)—;

—O—(CH₂)_y—;

—(CH₂)_y—O—;

—S—;

—O—;

or R²⁰⁰represents a bond;

R²⁰²and R²⁰³are independently selected from hydrido, alkyl, aryl and aralkyl; and

y and z are independently 0, 1, 2, 3, 4, 5 or 6 wherein y+z is less than or equal to 6; and

z is 0, 1 or 2; or

R²is —NHCR²⁰⁴R²⁰⁵wherein R²⁰⁴is alkylaminoalkylene, and R²⁰⁵is aryl; or R²is —C(NR²⁰⁶)R²⁰⁷wherein R²⁰⁶is selected from hydrogen and hydroxy, and R²⁰⁷is selected from alkyl, aryl and aralkyl; or

R²has the formula:
embedded image

wherein:

j is an integer from 0 to 8; and

m is 0 or 1; and

R³³is selected from hydrogen, alkyl, —C(O)R³⁵,

—C(O)OR³⁵, —SO₂R³⁶, —C(O)NR³⁷R³⁸, and —SO₂NR³⁹R⁴⁰, wherein

R³⁵, R³⁶, R³⁷, R³⁸, R³⁹and R⁴⁰are independently selected from hydrocarbon, heterosubstituted hydrocarbon and heterocyclyl; and

R³⁴is selected from hydrogen, alkyl, aminocarbonyl, alkylaminocarbonyl, and arylaminocarbonyl; or

R²is —CR⁴¹R⁴²wherein R⁴¹is aryl, and R⁴²is hydroxy; and

a pharmaceutically-acceptable salt or tautomer thereof.

Within Formula IA is another subclass of compounds of interest wherein:

R¹has the formula
embedded image

wherein:

i is an integer from 0 to 9;

R²⁶is selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkylalkylene, aralkyl, alkoxycarbonylalkylene, and alkylaminoalkyl; and

R²is selected from hydrido, halogen, mercapto, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, haloalkyl, hydroxyalkyl, aralkyl, alkylheterocyclyl, heterocyclylalkyl, heterocyclylheterocyclyl, heterocyclylalkylheterocyclyl, alkylamino, alkenylamino, alkynylamino, arylamino, aryl(hydroxyalkyl)amino, heterocyclylamino, heterocyclylalkylamino, aralkylamino, N-alkyl-N-alkynyl-amino, aminoalkyl, aminoaryl, aminoalkylamino, aminocarbonylalkylene, arylaminoalkylene, alkylaminoalkylene, arylaminoarylene, alkylaminoarylene, alkylaminoalkylamino, alkylcarbonylaminoalkylene, aminoalkylcarbonylaminoalkylene, alkylaminoalkylcarbonylamino, cycloalkyl, cycloalkenyl, aminoalkylthio, alkylaminocarbonylalkylthio, alkylaminoalkylaminocarbonylalkylthio, alkoxy, heterocyclyloxy, alkylthio, cyanoalkylthio, alkenylthio, alkynylthio, carboxyalkylthio, arylthio, heterocyclylthio, alkoxycarbonylalkylthio, alkylsulfinyl, alkylsulfonyl, carboxy, carboxyalkyl, alkoxyalkyl, alkoxyalkylthio, carboxycycloalkyl, carboxycycloalkenyl, carboxyalkylamino, alkoxycarbonyl, heterocyclylcarbonyl, alkoxycarbonylalkyl, alkoxycarbonylalkylamino, alkoxycarbonylheterocyclyl, alkoxycarbonylheterocyclylcarbonyl, alkoxyalkylamino, alkoxycarbonylaminoalkylene, alkoxycarbonylaminoalkoxy, alkoxycarbonylaminoalkylamino, heterocyclylsulfonyl, aralkythio, heterocyclylalkylthio, aminoalkoxy, cyanoalkoxy, carboxyalkoxy, aryloxy, aralkoxy, alkenyloxy, alkynyloxy, and heterocyclylalkyloxy; wherein the aryl, heterocyclyl, heterocyclylalkyl, cycloalkyl and cycloalkenyl groups are optionally substituted with one or more radicals independently selected from halo, keto, amino, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, aralkyl, heterocyclylalkyl, epoxyalkyl, amino(hydroxyalkyl) carboxy, alkoxy, aryloxy, aralkoxy, haloalkyl, alkylamino, alkynylamino, alkylaminoalkylamino, heterocyclylalkylamino, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl, arylsulfonyl, and aralkylsulfonyl; or

R²is R²⁰⁰-heterocyclyl-R²⁰¹, R²⁰⁰-aryl-R²⁰¹, or R²⁰⁰-cycloalkyl-R²⁰¹wherein:

R²⁰⁰is selected from:

—(CR²⁰²R²⁰³)_y—;

—C(O)—;

—C(O)—(CH₂)_y—;

—C(O)—O—(CH₂)_y—;

—(CH₂)_y—C(O)—;

—O—(CH₂)_y—C(O)—;

—NR²⁰²—;

—NR²⁰²—(CH₂)_y—;

—(CH₂)_y—NR²⁰²—;

—(CH₂)_y—NR²⁰²—(CH₂)_z—;

—(CH₂)_y—C(O)—NR²⁰²—(CH₂)_z—;

—(CH₂)_y—NR²⁰²—C(O)—(CH₂)_z—;

—(CH₂)_y—NR²⁰²—C(O)—NR²⁰³—(CH₂)_Z—;

—S(O)_x—(CR²⁰²R²⁰³)_y—;

—(CR²⁰²R²⁰³)_Y—S(O)_x—;

—S(O)_x—(CR²⁰²R²⁰³)_y—O—;

—S(O)_x—(CR²⁰²R²⁰³)_y—C(O)—;

—O—(CH₂)_y—;

—(CH₂)_y—O—;

—S—;

—O—;

or R²⁰⁰represents a bond;

R²⁰²and R²⁰³are independently selected from hydrido, alkyl, aryl and aralkyl; and

y and z are independently 0, 1, 2, 3, 4, 5 or 6 wherein y+z is less than or equal to 6; and

z is 0, 1 or 2; or

R²is —NHCR²⁰⁴R²⁰⁵wherein R²⁰⁴is alkylaminoalkylene, and R²⁰⁵is aryl; or

R²is —C(NR²⁰⁶)R²⁰⁷wherein R²⁰⁶is selected from hydrogen and hydroxy, and R²⁰⁷is selected from alkyl, aryl and aralkyl; or

R²has the formula:
embedded image

wherein:

j is an integer from 0 to 8; and

m is 0 or 1; and

R³⁰and R³¹are independently selected from hydrogen, Alkyl, aryl, heterocyclyl, aralkyl, heterocyclylalkylene, aminoalkyl, alkylaminoalkyl, aminocarbonylalkyl, alkoxyalkyl, and alkylcarbonyloxyalkyl; and

R³⁴is selected from hydrogen, alkyl, aminocarbonyl, alkylaminocarbonyl, and arylaminocarbonyl; or

R²is —CR⁴¹R⁴²wherein R⁴¹is aryl, and R⁴²is hydroxy; and

R³is selected from maleimidyl, pyridonyl, thiazolyl, thiazolylalkyl, thiazolylamino,
embedded image

wherein the R³maleimidyl, pyridonyl, thiazolyl, thiazolylalkyl, thiazolylamino,

groups are optionally substituted with one or more radicals independently selected from halo, keto, alkyl, aralkyl, aralkenyl, arylheterocyclyl, carboxy, carboxyalkyl, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfinyl, arylsulfinyl, alkylsulfonyl, arylsulfonyl, aralkoxy, heterocyclylalkoxy, amino, alkylamino, alkenylamino, alkynylamino, cycloalkylamino, cycloalkenylamino, arylamino, haloarylamino, heterocyclylamino, aminocarbonyl, cyano, hydroxy, hydroxyalkyl, alkoxyalkylene, alkenoxyalkylene, aryloxyalkyl, alkoxyalkylamino, alkylaminoalkoxy, alkoxycarbonyl, aryloxycarbonyl, heterocyclyloxycarbonyl, alkoxycarbonylamino, alkoxyarylamino, alkoxyaralkylamino, aminosulfinyl, aminosulfonyl, alkylsulfonylamino, alkylaminoalkylamino, hydroxyalkylamino, aralkylamino, aryl(hydroxyalkyl)amino, alkylaminoalkylaminoalkylamino, alkylheterocyclylamino, heterocyclylalkylamino, alkylheterocyclylalkylamino, aralkylheterocyclylamino, heterocyclylheterocyclylalkylamino, alkoxycarbonylheterocyclylamino, nitro, alkylaminocarbonyl, alkylcarbonylamino, halosulfonyl, aminoalkyl, haloalkyl, alkylcarbonyl, hydrazinyl, alkylhydrazinyl, arylhydrazinyl, or —NR⁴⁴R⁴⁵wherein R⁴⁴is alkylcarbonyl or amino, and R⁴⁵is alkyl or aralkyl; and

provided that R³is other than maleimidyl or pyridonyl having the structures:
embedded image

respectively, wherein R⁴³is selected from hydrogen, alkyl, aminoalkyl, alkoxyalkyl, alkenoxyalkyl, and aryloxyalkyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

Another group of compounds of interest consists of compounds of Formula IB:
embedded image

wherein:

- R¹has the same definition as previously set forth in the description of compounds of Formula IA. In anther embodiment, R¹is selected from hydrido, alkyl, hydroxyalkyl and alkynyl. In still another embodiment, R¹is hydrido;
- R²is selected from at least one of the following four categories:
- (1) piperidinyl substituted with one or more substituents selected from hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, alkoxyalkylene, alkoxyalkenylene, alkoxyalkynylene, and hydroxyacyl, wherein said hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, alkoxyalkylene, alkoxyalkenylene, alkoxyalkynylene, and hydroxyacyl substitutents may be optionally substituted with one or more substituents selected from cycloalkyl, alkyl, aryl, arylalkyl, haloalkyl, and heteroarylalkyl, wherein said cycloalkyl, alkyl, aryl, arylalkyl, haloalkyl, and heteroarylalkyl substituents may be optionally substituted with one or more substituents selected from alkylene, alkynylene, hydroxy, halo, haloalkyl, alkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, aryloxy, heterocyclyl, and heteroaralkoxy; or one or more substituents selected from hydroxycycloalkyl, alkoxycycloalkyl, and hydroxycycloalkylcarbonyl, wherein said hydroxycycloalkyl, alkoxycycloalkyl, and hydroxycycloalkylcarbonyl substitutents may be optionally substituted with one or more substituents selected from cycloalkyl, alkyl, aryl, arylalkyl, haloalkyl, and heteroarylalkyl, wherein said cycloalkyl, alkyl, aryl, arylalkyl, haloalkyl, and heteroarylalkyl substituents may be optionally substituted with one or more substituents selected from alkylene, alkynylene, hydroxy, halo, haloalkyl, alkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, aryloxy, heterocyclyl, and heteroaralkoxy. In another embodiment, R²is piperidinyl substituted with one or more substituents selected from optionally substituted hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, alkoxyalkylene, alkoxyalkenylene, alkoxyalkynylene, hydroxyalkylcarbonyl, hydroxyalkenylcarbonyl, and hydroxyalkynylcarbonyl; or one or more substituents selected from optionally substituted hydroxycycloalkyl and hydroxycycloalkylcarbonyl. In still another embodiment, R²is piperidinyl substituted with one or more substituents selected from optionally substituted hydroxyalkyl, hydroxyalkenyl, alkoxyalkylene, alkoxyalkenylene, hydroxyalkylcarbonyl, and hydroxyalkenylcarbonyl, and hydroxycycloalkylcarbonyl. In still another embodiment, R²is piperidinyl substituted with at least one substituent selected from optionally substituted lower hydroxyalkyl, lower hydroxyalkylcarbonyl and hydroxycycloalkylcarbonyl. In still another embodiment, R²is piperidinyl substituted with 2-hydroxyacetyl, 2-hydroxy-proprionyl, 2-hydroxy-2-methylpropionyl, 2-hydroxy-2-phenylacetyl, 3-hydroxyproprionyl, 2-hydroxy-3-methylbutyryl, 2-hydroxyisocapropyl, 2-hydroxy-3-phenylproprionyl, 2-hydroxy-3-imidazolylproprionyl, 1-hydroxy-1-cyclohexylacetyl, 2-hydroxy-1-cyclohexylacetyl, 3-hydroxy-1-cyclohexylacetyl, 4-hydroxy-1-cyclohexylacetyl, 1-hydroxy-1-cyclopentylacetyl, 2-hydroxy-1-cyclopentylacetyl, 3-hydroxy-1-cyclopentylacetyl, 2-hydroxy-2-cyclohexylacetyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxyisopropyl, methoxymethylene, methoxyethylene, methoxypropylene, methoxyisopropylene, ethoxymethylene, ethoxyethylene, ethoxypropylene, and ethoxyisopropylene. In each of the above embodiments, when R²is piperidinyl, the piperidinyl ring may be substituted with at least one substituent attached to the distal nitrogen heteroatom or to a carbon ring atom adjacent to the distal nitrogen heteroatom of the piperidine ring. In each of the above embodiments, the piperidinyl ring may be monosubstituted at the distal nitrogen; and
- (2) cyclohexyl substituted with one or more substituents selected from optionally substituted hydroxyalkyl, alkylaminoalkylene and cycloalkylamino. In another embodiment, R²is cyclohexyl substituted with one or more substituents selected from optionally substituted lower hydroxyalkyl, lower alkylaminoalkylene and cycloalkylamino. In still another embodiment, R²is cyclohexyl substituted with one or more substituents selected from optionally substituted lower hydroxyalkyl, lower dialkylaminoalkylene and cycloalkylamino. In still another embodiment, R²is cyclohexyl substituted with one or more substituents selected from hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, methylaminomethylene, methylaminoethylene, methylaminopropylene, ethylaminomethylene, ethylaminoethylene, ethylaminopropylene, propylaminomethylene, propylaminoethylene, propylaminopropylene, dimethylaminomethylene, dimethylaminoethylene, dimethylaminopropylene, diethylaminomethylene, and di-isobutylamino. In each of the above embodiments, when R²is cyclohexyl, the cyclohexyl ring may be substituted with at least one substituent attached to the 4-position carbon atom of the cyclohexyl ring heteroatom of the piperidine ring. In each of the above embodiments, the cyclohexyl ring may be monosubstituted at the 4-position carbon atom; and
- (4) piperidinylamino substituted with one or more alkynyl substituents. In another embodiment, R²is piperidinylamino substituted with optionally substituted lower alkynyl. In still another embodiment, R²is piperidinylamino substituted with optionally substituted ethynyl, propynyl and butynyl. In still another embodiment, R²is piperidinylamino substituted with optionally substituted propargyl. In still another embodiment, R²is 4-propargylpiperidinylamino. In each of the above embodiments, when R²is piperidinylamino, the piperidinyl ring may be substituted with at least one substituent attached to the distal nitrogen heteroatom or to a carbon ring atom adjacent to the distal nitrogen heteroatom of the piperidine ring. In each of the above embodiments, the piperidinyl ring may be monosubstituted at the distal nitrogen; and
- R³is selected from pyridinyl, pyrimidinyl, quinolinyl, purinyl, maleimidyl, pyridonyl, thiazolyl, thiazolylalkyl, thiazolylamino,

wherein the R³pyridinyl, pyrimidinyl, quinolinyl, purinyl, maleimidyl, pyridonyl, thiazolyl, thiazolylalkyl, thiazolylamino,
embedded image

groups may be optionally substituted with one or more substituents independently selected from hydrogen, aryl, alkylamino, alkylthio, alkyloxy, aryloxy, arylamino, arylthio, aralkoxy, wherein said aryl, alkylamino, alkylthio, alkyloxy, aryloxy, arylamino, arylthio, aralkoxy substituents may be optionally substituted with one or more alkylene, alkenylene, hydroxy, halo, haloalkyl, alkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, aryloxy, heterocyclyl, and heteroaralkoxy. In another embodiment, R³is optionally substituted pyridinyl or pyrimidinyl. In still another embodiment, R³is unsubstituted pyridinyl or pyrimidinyl; and

- R⁴is selected from hydrido, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, and heterocyclyl, wherein R⁴is optionally substituted with one or more substituents independently selected from halo, haloalkyl, haloalkoxy, alkoxy, cyano, hydroxy, alkyl, alkenyl, and alkynyl, wherein said haloalkyl, haloalkoxy, alkoxy, cyano, hydroxy, alkyl, alkenyl, and alkynyl substituents may be optionally substituted with one or more alkylene, alkenylene, alkynylene, hydroxy, halo, haloalkyl, alkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, aryloxy, heterocyclyl, and heteroaralkoxy. In another embodiment, R⁴is selected from optionally substitutend cycloalkyl, cycloalkenyl, aryl, and heterocyclyl. In still another embodiment, R⁴is optionally substituted phenyl. In still another embodiment, R⁴is phenyl optionally substituted at a substitutable position with one or more radicals independently selected from chloro, fluoro, bromo and iodo. In still another embodiment, R⁴is phenyl optionally substituted at the meta or para position with one or more chloro radicals; or
- a pharmaceutically-acceptable salt or tautomer thereof. Within each of the above embodiments, R²may be located at the 3-position of the pyrazole ring with R⁴located at the 5-position of the pyrazole ring. Alternatively, R²may be located at the 5-position of the pyrazole ring with R⁴located at the 3-position of the pyrazole ring.

Still another group of compounds of interest consists of the compounds, their tautomers and their pharmaceutically acceptable salts, of the group consisting of:
embedded image

The term “hydrido” denotes a single hydrogen atom (H). This hydrido radical may be attached, for example, to an oxygen atom to form a hydroxyl radical or two hydrido radicals may be attached to a carbon atom to form a methylene (—CH₂—) radical. Where used, either alone or within other terms such as “haloalkyl”, “alkylsulfonyl”, “alkoxyalkyl” and “hydroxyalkyl”, “cyanoalkyl” and “mercaptoalkyl”, the term “alkyll” embraces linear or branched radicals having one to about twenty carbon atoms or, preferably, one to about twelve carbon atoms. More preferred alkyl radicals are “lower alkyl” radicals having one to about ten carbon atoms. Most preferred are lower alkyl radicals having one to about six carbon atoms. Examples of such radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-amyl, hexyl and the like. The term “alkenyl” embraces linear or branched radicals having at least one carbon-carbon double bond of two to about twenty carbon atoms or, preferably, two to about twelve carbon atoms. More preferred alkenyl radicals are “lower alkenyl” radicals having two to about six carbon atoms. Examples of alkenyl radicals include ethenyl, allyl, propenyl, butenyl and 4-methylbutenyl. The terms “alkenyl” and “lower alkenyl”, embrace radicals having “cis” and “trans” orientations, or alternatively, “E” and “Z” orientations. The term “alkynyl” embraces linear or branched radicals having at least one carbon-carbon triple bond of two to about twenty carbon atoms or, preferably, two to about twelve carbon atoms. More preferred alkynyl radicals are “lower alkynyl” radicals having two to about six carbon atoms. Examples of alkynyl radicals include propargyl, 1-propynyl, 2-propynyl, 1-butyne, 2-butynyl and 1-pentynyl. The term “cycloalkyl” embraces saturated carbocyclic radicals having three to about twelve carbon atoms. The term “cycloalkyl” embraces saturated carbocyclic radicals having three to about twelve carbon atoms. More preferred cycloalkyl radicals are “lower cycloalkyl” radicals having three to about eight carbon atoms. Examples of such radicals include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. The term “cycloalkylalkylene” embraces alkyl radicals substituted with a cycloalkyl radical. More preferred cycloalkylalkylene radicals are “lower cycloalkylalkylene” which embrace lower alkyl radicals substituted with a lower cycloalkyl radical as defined above. Examples of such radicals include cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl and cyclohexylmethyl. The term “cycloalkenyl” embraces partially unsaturated carbocyclic radicals having three to twelve carbon atoms. Cycloalkenyl radicals that are partially unsaturated carbocyclic radicals that contain two double bonds (that may or may not be conjugated) can be called “cycloalkyldienyl”. More preferred cycloalkenyl radicals are “lower cycloalkenyl” radicals having four to about eight carbon atoms. Examples of such radicals include cyclobutenyl, cyclopentenyl and cyclohexenyl. The term “halo” means halogens such as fluorine, chlorine, bromine or iodine. The term “haloalkyl” embraces radicals wherein any one or more of the alkyl carbon atoms is substituted with halo as defined above. Specifically embraced are monohaloalkyl, dihaloalkyl and polyhaloalkyl radicals. A monohaloalkyl radical, for one example, may have either an iodo, bromo, chloro or fluoro atom within the radical. Dihalo and polyhaloalkyl radicals may have two or more of the same halo atoms or a combination of different halo radicals. “Lower haloalkyl” embraces radicals having one to six carbon atoms. Examples of haloalkyl radicals include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl. The term “hydroxyalkyl” embraces linear or branched alkyl radicals having one to about ten carbon atoms any one of which may be substituted with one or more hydroxyl radicals. More preferred hydroxyalkyl radicals are “lower hydroxyalkyl” radicals having one to six carbon atoms and one or more hydroxyl radicals. Examples of such radicals include hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl and hydroxyhexyl. The terms “alkoxy” and “alkyloxy” embrace linear or branched oxy-containing radicals each having alkyl portions of one to about ten carbon atoms. More preferred alkoxy radicals are “lower alkoxy” radicals having one to six carbon atoms. Examples of such radicals include methoxy, ethoxy, propoxy, butoxy and tert-butoxy. The term “alkoxyalkyl” embraces alkyl radicals having one or more alkoxy radicals attached to the alkyl radical, that is, to form monoalkoxyalkyl and dialkoxyalkyl radicals. The “alkoxy” radicals may be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide haloalkoxy radicals. The term “aryl”, alone or in combination, means a carbocyclic aromatic system containing one, two or three rings wherein such rings may be attached together in a pendent manner or may be fused. The term “aryl” embraces aromatic radicals such as phenyl, naphthyl, tetrahydronaphthyl, indane and biphenyl. Aryl moieties may also be substituted at a substitutable position with one or more substituents selected independently from halo, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, alkylthio, arylthio, alkylthioalkylene, arylthioalkylene, alkylsulfinyl, alkylsulfinylalkylene, arylsulfinylalkylene, alkylsulfonyl, alkylsulfonylalkylene, arylsulfonylalkylene, alkoxy, aryloxy, aralkoxy, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl, aryloxycarbonyl, haloalkyl, amino, cyano, nitro, alkylamino, arylamino, alkylaminoalkylene, arylaminoalkylene, aminoalkylamino, hydroxy, alkoxyalkyl, carboxyalkyl, alkoxycarbonylalkyl, aminocarbonylalkylene, acyl, carboxy, and aralkoxycarbonyl. The term “heterocyclyl” embraces saturated, partially unsaturated and unsaturated heteroatom-containing ring-shaped radicals, which can also be called “heterocyclyl”, “heterocycloalkenyl” and “heteroaryl” correspondingly, where the heteroatoms may be selected from nitrogen, sulfur and oxygen. Examples of saturated heterocyclyl radicals include saturated 3 to 6-membered heteromonocyclic group containing 1 to 4 nitrogen atoms (e.g. pyrrolidinyl, imidazolidinyl, piperidino, piperazinyl, etc.); saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms (e.g. morpholinyl, etc.); saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms (e.g., thiazolidinyl, etc.). Examples of partially unsaturated heterocyclyl radicals include dihydrothiophene, dihydropyran, dihydrofuran and dihydrothiazole. Heterocyclyl radicals may include a pentavalent nitrogen, such as in tetrazolium and pyridinium radicals. The term “heteroaryl” embraces unsaturated heterocyclyl radicals. Examples of heteroaryl radicals include unsaturated 3 to 6 membered heteromonocyclic group containing 1 to 4 nitrogen atoms, for example, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl (e.g., 4H-1,2,4-triazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, etc.) tetrazolyl (e.g. 1H-tetrazolyl, 2H-tetrazolyl, etc.), etc.; unsaturated condensed heterocyclyl group containing 1 to 5 nitrogen atoms, for example, indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl, tetrazolopyridazinyl (e.g., tetrazolo[1,5-b]pyridazinyl, etc.), etc.; unsaturated 3 to 6-membered heteromonocyclic group containing an oxygen atom, for example, pyranyl, furyl, etc.; unsaturated 3 to 6-membered heteromonocyclic group containing a sulfur atom, for example, thienyl, etc.; unsaturated 3- to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms, for example, oxazolyl, isoxazolyl, oxadiazolyl (e.g., 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, etc.) etc.; unsaturated condensed heterocyclyl group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms (e.g. benzoxazolyl, benzoxadiazolyl, etc.); unsaturated 3 to 6-membered heteromonocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms, for example, thiazolyl, thiadiazolyl (e.g., 1,2,4- thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, etc.) etc.; unsaturated condensed heterocyclyl group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms (e.g., benzothiazolyl, benzothiadiazolyl, etc.) and the like. The term “heterocycle” also embraces radicals where heterocyclyl radicals are fused with aryl or cycloalkyl radicals. Examples of such fused bicyclic radicals include benzofuran, benzothiophene, and the like. Said “heterocyclyl group” may have 1 to 3 substituents such as alkyl, hydroxyl, halo, alkoxy, oxo, amino, alkylthio and alkylamino. The term “heterocyclylalkylene” embraces heterocyclyl-substituted alkyl radicals. More preferred heterocyclylalkylene radicals are “lower heterocyclylalkylene” radicals having one to six carbon atoms and a heterocyclyl radicals. The term “alkylthio” embraces radicals containing a linear or branched alkyl radical, of one to about ten carbon atoms attached to a divalent sulfur atom. More preferred alkylthio radicals are “lower alkylthio” radicals having alkyl radicals of one to six carbon atoms. Examples of such lower alkylthio radicals are methylthio, ethylthio, propylthio, butylthio and hexylthio. The term “alkylthioalkylene” embraces radicals containing an alkylthio radical attached through the divalent sulfur atom to an alkyl radical of one to about ten carbon atoms. More preferred alkylthioalkylene radicals are “lower alkylthioalkylene” radicals having alkyl radicals of one to six carbon atoms. Examples of such lower alkylthioalkylene radicals include methylthiomethyl. The term “alkylsulfinyl” embraces radicals containing a linear or branched alkyl radical, of one to about ten carbon atoms, attached to a divalent —S(═O)— radical. More preferred alkylsulfinyl radicals are “lower alkylsulfinyl” radicals having alkyl radicals of one to six carbon atoms. Examples of such lower alkylsulfinyl radicals include methylsulfinyl, ethylsulfinyl, butylsulfinyland hexylsulfinyl. The term “sulfonyl”, whether used alone or linked to other terms such as “alkylsulfonyl”, “halosulfonyl” denotes a divalent radical, —SO₂—. “Alkylsulfonyl” embraces alkyl radicals attached to a sulfonyl radical, where alkyl is defined as above. More preferred alkylsulfonyl radicals are “lower alkylsulfonyl” radicals having one to six carbon atoms. Examples of such lower alkylsulfonyl radicals include methylsulfonyl, ethylsulfonyl and propylsulfonyl. The “alkylsulfonyl” radicals may be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide haloalkylsulfonyl radicals. The term “halosulfonyl” embraces halo radicals attached to a sulfonyl radical. Examples of such halosulfonyl radicals include chlorosulfonyl, and bromosulfonyl. The terms “sulfamyl”, “aaminosulfonyll” and “sulfonamidyl” denote NH₂O₂S—. The term “acyl” denotes a radical provided by the residue after removal of hydroxyl from an organic acid. Examples of such acyl radicals include alkanoyl and aroyl radicals. Examples of such alkanoyl radicals include formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, and radicals formed from succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, mandelic, pantothenic, β-hydroxybutyric, galactaric and galacturonic acids. The term “carbonyl”, whether used alone or with other terms, such as “alkoxycarbonyl”, denotes —(C═O)—. The terms “carboxy” or “carboxyl”, whether used alone or with other terms, such as “carboxyalkyl”, denotes —CO₂H. The term “carboxyalkyl” embraces alkyl radicals substituted with a carboxy radical. More preferred are “lower carboxyalkyl” which embrace lower alkyl radicals as defined above, and may be additionally substituted on the alkyl radical with halo. Examples of such lower carboxyalkyl radicals include carboxymethyl, carboxyethyl and carboxypropyl. The term “alkoxycarbonyl” means a radical containing an alkoxy radical, as defined above, attached via an oxygen atom to a carbonyl radical. More preferred are “lower alkoxycarbonyl” radicals with alkyl portions having one to six carbons. Examples of such lower alkoxycarbonyl (ester) radicals include substituted or unsubstituted methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl and hexyloxycarbonyl. The term “alkoxycarbonylalkyl” embraces alkyl radicals substituted with a alkoxycarbonyl radical as defined above. More preferred are “lower alkoxycarbonylalkyl” radicals with alkyl portions having one to six carbons. Examples of such lower alkoxycarbonylalkyl radicals include substituted or unsubstituted methoxycarbonylmethyl, ethoxycarbonylmethyl, methoxycarbonyl-ethyl and ethoxycarbonylethyl. The term “alkylcarbonyl”, includes radicals having alkyl, hydroxylalkyl, radicals, as defined herein, attached to a carbonyl radical. Examples of such radicals include substituted or unsubstituted methylcarbonyl, ethylcarbonyl, propylcarbonyl, butylcarbonyl, pentylcarbonyl, hydroxymethylcarbonyl, hydroxyethylcarbonyl. The term “aralkyl” embraces aryl-substituted alkyl radicals such as benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, and diphenylethyl. The aryl in said aralkyl may be additionally substituted with one or more substituents selected independently from halo, alkyl, alkoxy, halkoalkyl, haloalkoxy, amino and nitro. The terms benzyl and phenylmethyl are interchangeable. The term “heterocyclylalkylene” embraces saturated and partially unsaturated heterocyclyl-substituted alkyl radicals (also can be called heterocycloalkylalkylene and heterocycloalkenylalkylene correspondingly), such as pyrrolidinylmethyl, and heteroaryl-substituted alkyl radicals (also can be called heteroarylalkylene), such as pyridylmethyl, quinolylmethyl, thienylmethyl, furylethyl, and quinolylethyl. The heteroaryl in said heteroaralkyl may be additionally substituted with halo, alkyl, alkoxy, halkoalkyl and haloalkoxy. The term “aryloxy” embraces aryl radicals attached through an oxygen atom to other radicals. The term “aralkoxy” embraces aralkyl radicals attached through an oxygen atom to other radicals. The term “aminoalkyl” embraces alkyl radicals substituted with amino radicals. More preferred are “lower aminoalkyl” radicals. Examples of such radicals include aminomethyl, aminoethyl, and the like. The term “alkylamino” denotes amino groups which are substituted with one or two alkyl radicals. Preferred are “lower alkylamino” radicals having alkyl portions having one to six carbon atoms. Suitable lower alkylamino may be monosubstituted N-alkylamino or disubstituted N,N-alkylamino, such as N-methylamino, N-ethylamino, N,N-dimethylamino, N,N-diethylamino or the like. The term “arylamino” denotes amino groups which are substituted with one or two aryl radicals, such as N-phenylamino. The “arylamino” radicals may be further substituted on the aryl ring portion of the radical. The term “aminocarbonyll” denotes an amide group of the formula —C(═O)NH₂. The term “alkylaminocarbonyl” denotes an aminocarbonyl group which has been substituted with one or two alkyl radicals on the amino nitrogen atom. Preferred are “N-alkylaminocarbonyl” and “N,N-dialkylaminocarbonyl” radicals. More preferred are “lower N-alkylaminocarbonyl” and “lower N,N-dialkylaminocarbonyl” radicals with lower alkyl portions as defined above. The term “alkylcarbonylamino” embraces amino groups which are substituted with one alkylcarbonyl radicals. More preferred alkylcarbonylamino radicals are “lower alkylcarbonylamino” having lower alkylcarbonyl radicals as defined above attached to amino radicals. The term “alkylaminoalkylene” embraces radicals having one or more alkyl radicals attached to an aminoalkyl radical.

The “hydrocarbon” moieties described herein are organic compounds or radicals consisting exclusively of the elements carbon and hydrogen. These moieties include alkyl, alkenyl, alkynyl, and aryl moieties. These moieties also include alkyl, alkenyl, alkynyl, and aryl moieties substituted with other aliphatic or cyclic hydrocarbon groups, such as alkaryl, alkenaryl and alkynaryl. Preferably, these moieties comprise 1 to 20 carbon atoms.

The heterosubstituted hydrocarbon moieties described herein are hydrocarbon moieties which are substituted with at least one atom other than carbon, including moieties in which a carbon chain atom is substituted with a hetero atom such as nitrogen, oxygen, sulfur, or a halogen atom. These substituents include lower alkoxy such as methoxy, ethoxy, butoxy; halogen such as chloro or fluoro; ethers; acetals; ketals; esters; heterocyclyl such as furyl or thienyl; alkanoxy; hydroxy; protected hydroxy; acyl; acyloxy; nitro; cyano; amino; and amido.

The additional terms used to describe the substituents of the pyrazole ring and not specifically defined herein are defined in a similar manner to that illustrated in the above definitions. As above, more preferred substituents are those containing “lower” radicals. Unless otherwise defined to contrary, the term “lower” as used in this application means that each alkyl radical of a pyrazole ring substituent comprising one or more alkyl radicals has one to about six carbon atoms; each alkenyl radical of a pyrazole ring substituent comprising one or more alkenyl radicals has two to about six carbon atoms; each alkynyl radical of a pyrazole ring substituent comprising one or more alkynyl radicals has two to about six carbon atoms; each. cycloalkyl or cycloalkenyl radical of a pyrazole ring substituent comprising one or more cycloalkyl and/or cycloalkenyl radicals is a 3 to 8 membered ring cycloalkyl or cycloalkenyl radical, respectively; each aryl radical of a pyrazole ring substituent comprising one or more aryl radicals is a monocyclic aryl radical; and each heterocyclyl radical of a pyrazole ring substituent comprising one or more heterocyclyl radicals is a 4-8 membered ring heterocyclyl.

The present invention comprises the tautomeric forms of compounds of Formulae I and IX (as well as the compounds of Formulae (IA and IXA). As illustrated below, the pyrazoles of Formula I and I′ are magnetically and structurally equivalent because of the prototropic tautomeric nature of the hydrogen:
embedded image

The present invention also comprises compounds of Formula I, IA, IX, IXA, X, XA and XI having one or more asymmetric carbons. It is known to those skilled in the art that those pyrazoles of the present invention having asymmetric carbon atoms may exist in diastereomeric, racemic, or optically active forms. All of these forms are contemplated within the scope of this invention. More specifically, the present invention includes enantiomers, diastereomers, racemic mixtures, and other mixtures thereof.

The present invention comprises a pharmaceutical composition for the treatment of a TNF mediated disorder, a p38 kinase mediated disorder, inflammation, and/or arthritis, comprising a therapeutically-effective amount of a compound of Formula I and/or IA, or a therapeutically-acceptable salt or tautomer thereof, in association with at least one pharmaceutically-acceptable carrier, adjuvant or diluent.

The present invention further encompasses substituted pyrazoles that specifically bind to the ATP binding site of p38 kinase. Without being held to a particular theory, applicants hypothesize that these substituted pyrazoles interact with p38 kinase as set forth below. As the substituent at the 3-position of the pyrazole ring approaches the ATP binding site of p38 kinase, a hydrophobic cavity in the p38 kinase forms around the 3-position substitutent at the binding site. This hydrophobic cavity is believed to form as the 3-position substituent binds to a specific peptide sequence of the enzyme. In particular, it is believed to bind to the sidechains of Lys₅₂, Glu₆₉, Leu₇₃, Ile₈₂, Leu₈₄, Leu₁₀₁, and the methyl group of the Thr₁₀₃sidechain of p38 kinase at the ATP binding site (wherein the numbering scheme corresponds to the numbering scheme conventionally used for ERK-2). Where the 3-position substituent is aryl or heteroaryl, such aryl or heteroaryl may be further substituted. It is hypothesized that such ring substituents may be beneficial in preventing hydroxylation or further metabolism of the ring.

The substituent at the 4-position of the pyrazole ring is one that is a partial mimic of the adenine ring of ATP, although it may be further elaborated. Preferably, it is a planar substituent terminated by a suitable. hydrogen bond acceptor functionality. It is hypothesized that this acceptor hydrogen bonds to the backbone N—H of the Met₁₀₆residue while one edge of this substituent is in contact with bulk solvent.

Substitution at the 5-position of the pyrazole ring is well tolerated and can provide increased potency and selectivity. It is hypothesized that such substituents extend out in the direction of the bulk solvent and that suitable polar functionality placed at its terminus can interact with the sidechain of Asp¹⁰⁹, leading to increased potency and selectivity.

Similarly, substitution on the nitrogen atom at the 1- or 2-position of the pyrazole ring is well tolerated and can provide increased potency. It is hypothesized that a hydrogen substituent attached to one of the ring nitrogen atoms is hydrogen bonded to Asp₁₆₅. Preferably, the nitrogen atom at the 2-position is double bonded to the carbon atom at the 3-position of the pyrazole while the nitrogen atom at the 1-position of the pyrazole is available for substitution with hydrogen or other substituents.

The 5-position substitutent and the 1- or 2-position substituent of the pyrazole can be selected so as to improve the physical characteristics, especially aqueous solubility and drug delivery performance, of the substituted pyrazole. Preferably, however, these substituents each have a molecular weight less than about 360 atomic mass units. More preferably, these substituents each have a molecular weight less than about less than about 250 atomic mass units. Still more preferably, these substituents have a combined molecular weight less than about 360 atomic mass units.

A class of substituted pyrazoles of particular interest consists of those compounds having the formula:
embedded image

wherein

R¹is a hydrocarbyl, heterosubstituted hydrocarbyl or heterocyclyl radical having a molecular weight less than about 360 atomic mass units; and

R²is a hydrocarbyl, heterosubstituted hydrocarbyl or heterocyclyl radical that binds with p38 kinase at said ATP binding site of p38 kinase; and

R³is a hydrocarbyl, heterosubstituted hydrocarbyl or heterocyclyl radical having a hydrogen bond acceptor functionality; and

R⁴is a hydrocarbyl, heterosubstituted hydrocarbyl or heterocyclyl radical having a molecular weight less than about 360 atomic mass units;

a pharmaceutically-acceptable salt or tautomer thereof.

In this embodiment of the invention, one or more of R¹, R², R³and R⁴preferably are selected from the corresponding groups of the compounds of Formula I and/or IA. More preferably, R³is an optionally substituted pyridinyl or pyrimidinyl, R⁴is a halo substituted phenyl, and R¹and R²have the definitions set forth immediately above.

A class of substituted pyrazoles of particular interest consists of those compounds of Formula XI wherein

R¹is a hydrocarbyl, heterosubstituted hydrocarbyl or heterocyclyl radical having a molecular weight less than about 360 atomic mass units; and

R²is a hydrocarbyl, heterosubstituted hydrocarbyl or heterocyclyl radical wherein said radical binds with Lys₅₂, Glu₆₉, Leu₇₃, Ile₈₂, Leu₈₄, Leu₁₀₁, and Thr₁₀₃sidechains at said ATP binding site of p38 kinase, said radical being substantially disposed within a hydrophobic cavity formed during said binding by p38 kinase at the ATP binding site; and

R³is a hydrocarbyl, heterosubstituted hydrocarbyl or heterocyclyl radical having a hydrogen bond acceptor functionality that hydrogen bonds with the N—H backbone of Met₁₀₆of p38 kinase; and

R⁴is a hydrocarbyl, heterosubstituted hydrocarbyl or heterocyclyl radical having a molecular weight less than about 360 atomic mass units.

The present invention also comprises a therapeutic method of treating a TNF mediated disorder, a p38 kinase mediated disorder, inflammation and/or arthritis in a subject, the method comprising treating a subject having or susceptible to such disorder or condition with a therapeutically-effective amount of a compound of Formula I and/or IA.

For example, in one embodiment the present invention comprises a therapeutic method of treating a TNF mediated disorder, a p38 kinase mediated disorder, inflammation and/or arthritis in a subject, the method comprising treating a subject having or susceptible to such disorder or condition with a therapeutically-effective amount of a compound of Formula I
embedded image

wherein

- R¹has the formula

wherein:

i is an integer from 0 to 9;

R²⁶is selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkylalkylene, aralkyl, alkoxycarbonylalkylene, and alkylaminoalkyl; and

R²is selected from hydrido, halogen, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, haloalkyl, hydroxyalkyl, aralkyl, alkylheterocyclyl, heterocyclylalkyl, alkylamino, alkenylamino, alkynylamino, arylamino, heterocyclylamino, heterocyclylalkylamino, aralkylamino, aminoalkyl, aminoaryl, aminoalkylamino, arylaminoalkylene, alkylaminoalkylene, arylaminoarylene, alkylaminoarylene, alkylaminoalkylamino, cycloalkyl, cycloalkenyl, alkoxy, heterocyclyloxy, alkylthio, arylthio, heterocyclylthio, carboxy, carboxyalkyl, carboxycycloalkyl, carboxycycloalkenyl, carboxyalkylamino, alkoxycarbonyl, heterocyclylcarbonyl, alkoxycarbonylalkyl, alkoxycarbonylheterocyclyl, alkoxycarbonylheterocyclylcarbonyl, alkoxyalkylamino, alkoxycarbonylaminoalkylamino, and heterocyclylsulfonyl; wherein the aryl, heterocyclyl, heterocyclylalkyl, cycloalkyl and cycloalkenyl groups are optionally substituted with one or more radicals independently selected from halo, keto, amino, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, aralkyl, heterocyclylalkyl, epoxyalkyl, amino(hydroxyalkyl) carboxy, alkoxy, aryloxy, aralkoxy, haloalkyl, alkylamino, alkynylamino, alkylaminoalkylamino, heterocyclylalkylamino, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl, arylsulfonyl, and aralkylsulfonyl; or

- R²has the formula:

wherein:

j is an integer from 0 to 8; and

m is 0 or 1; and

R³⁴is selected from hydrogen, alkyl, aminocarbonyl, alkylaminocarbonyl, and arylaminocarbonyl; or

R²is —CR⁴¹R⁴²wherein R⁴¹is aryl, and R⁴²is hydroxy; and

R³is selected from pyridinyl, pyrimidinyl, quinolinyl, purinyl,
embedded image

wherein R⁴³is selected from hydrogen, alkyl, aminoalkyl, alkoxyalkyl, alkenoxyalkyl, and arylcxyalkyl; and

provided R³is not 2-pyridinyl when R⁴is a phenyl ring containing a 2-hydroxy substituent and when R¹is hydrido; further provided Ra is selected from aryl, heterocyclyl, unsubstituted cycloalkyl and cycloalkenyl when R⁴is hydrido; and further provided R⁴is not methylsulfonylphenyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

The present invention also is directed to the use of the compounds of Formula I and/or IA in the preparation of medicaments useful in the treatment and/or prophylaxis of p38 kinase mediated conditions and disorders.

Also included in the family of compounds of Formulae I and/or IA are the pharmaceutically-acceptable salts and prodrugs thereof. The term “pharmaceutically-acceptable salts” embraces salts commonly used to form alkali metal salts and to form addition salts of free acids or free bases. The nature of the salt is not critical, provided that it is pharmaceutically-acceptable. Suitable pharmaceutically-acceptable acid addition salts of compounds of Formulae I and/or IA may be prepared from an inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric and phosphoric acid. Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclyl, carboxylic and sulfonic classes of organic acids, example of which are formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, mesylic, stearic, salicylic, p-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, toluenesulfonic, 2-hydroxyethanesulfonic, sulfanilic, cyclohexylaminosulfonic, algenic, β-hydroxybutyric, galactaric and galacturonic acid. Suitable pharmaceutically-acceptable base addition salts of compounds of Formula I and/or IA include metallic salts and organic salts. More preferred metallic salts include, but are not limited to appropriate alkali metal (group Ia) salts, alkaline earth metal (group IIa) salts and other physiological acceptable metals. Such salts can be made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc. Preferred organic salts can be made from tertiary amines and quaternary ammonium salts, including in part, tromethamine, diethylamine, N,N′-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine. All of these salts may be prepared by conventional means from the corresponding compound of Formulae I and/or IA by reacting, for example, the appropriate acid or base with the compound of Formulae I and/or IA.

The present invention additionally comprises a class of compounds defined by Formula XX:
embedded image

wherein R³and R⁴are as defined for the compounds of Formulae I and/or IA. Also included in the family of compounds of Formula XX are the pharmaceutically-acceptable salts and prodrugs thereof.

The compounds of Formula XX are useful as intermediates in the preparation of the compounds of Formulae I and/or IA. In addition, the compounds of Formula XX themselves have been found to show usefulness as p38 kinase inhibitors. These compounds are useful for the prophylaxis and treatment of the same p38 kinase mediated disorders and conditions as the compounds of formulae I and/or IA. Accordingly, the present invention provides a method of treating a cytokine-mediated disease which comprises administering an effective cytokine-interfering amount of a compound of Formula XX or a pharmaceutically acceptable salt or prodrug thereof.

The present invention further comprises a pharmaceutical composition for the treatment of a TNF mediated disorder, a p38 kinase mediated disorder, inflammation, and/or arthritis, comprising a therapeutically-effective amount of a compound of Formula XX, or a therapeutically-acceptable salt or prodrug thereof, in association with at least one pharmaceutically-acceptable carrier, adjuvant or diluent.

The compounds of the invention can be prepared according to the following procedures of Schemes I-XXIX wherein R¹, R², R³, R⁴, R⁵and Ar¹are as previously defined for the compounds of Formula I, IX, X and XI except where expressly noted.
embedded image

Scheme I shows the synthesis of pyrazole 5 by two routes. Condensation of the pyridylmethyl ketone 1 with aldehyde 2 in the presence of a base, such as piperidine, in a solvent, such as toluene or benzene, either in the absence or the presence of acetic acid at reflux, provides the α,β-unsaturated ketone 3. In route 1, ketone 3 is first converted to epoxide 4, such as by treatment with hydrogen peroxide solution at room temperature, in the presence of base such as sodium hydroxide. Treatment of epoxide 4 with hydrazine in ethanol or other suitable solvent at a temperature ranging up to reflux, yields pyrazole 5. In route 2, ketone 3 is condensed directly with tosyl hydrazide in the presence of an acid such as acetic acid, at reflux, to provide pyrazole 5. Alternatively, the intermediate tosyl hydrazone 6 may be isolated, conversion of it to pyrazole 5 is effected by treatment with a base, such as potassium hydroxide, in a suitable solvent, such as ethylene glycol, at a temperature ranging from 25° C. up to 150° C.
embedded image

Scheme II shows the synthesis of pyrazole 12 of the present invention. The treatment of pyridine derivative 7 with ester 8 in the presence of a base, such as sodium bis(trimethylsilyl)amide, in a suitable solvent, such as tetrahydrofuran, gives ketone 9. Treatment of ketone 9 or a hydrohalide salt of ketone 9 with a halogenating agent, such as bromine, N-bromosuccinimide or N-chlorosuccinimide, in suitable solvents, such as acetic acid, methylene chloride, methanol, or combinations thereof, forms the a-halogenated ketone 10 (wherein X is halo). Examples of suitable hydrohalide salts include the hydrochloride and hydrobromide salts. Reaction of haloketone 10 with thiosemicarbazide 11 (where R⁶and R⁷can be hydrido, lower alkyl, phenyl, heterocyclyl and the like or where R⁶and R⁷form a heterocyclyl ring optionally containing an additional heteroatom) provides pyrazole 12. Examples of suitable solvents for this reaction are ethanol and dimethylformamide. The reaction may be carried out in the presence or absence of base or acid at temperatures ranging from room temperature to 100° C.

Thiosemicarbazides which are not commercially available may be conveniently prepared by one skilled in the art by first reacting an appropriate amine with carbon disulfide in the presence of a base, followed by treatment with an alkylating agent such as methyl iodide. Treatment of the resultant alkyl dithiocarbamate with hydrazine results in the desired thiosemicarbazide. This chemistry is further described in E. Lieber and R. C. Orlowski, J. Org. Chem., Vol. 22, p. 88 (1957). An alternative approach is to add hydrazine to appropriately substituted thiocyanates as described by Y. Nomoto et al., Chem. Pharm. Bull., Vol. 39, p.86 (1991). The Lieber and Nomoto publications are incorporated herein by reference.

Where Compound 12 contains a second derivatizable nitrogen atom, a wide range of substituents may be placed on that atom by methods known to those skilled in the art. For examlple, in cases where R⁶and R⁷together with the nitrogen atom to which they are attached comprise a piperazine ring, the distal nitrogen of that ring may be, for example, (i) methylated by reaction with formic acid and formaldehyde; (ii) propargylated by reaction with propargyl bromide in a suitable solvent such as dimethylformamide in the presence of a suitable base such as potassium carbonate; (iii) acylated or sulfonylated by reaction with a suitable acyl or sulfonyl derivative in pyridine; or (iv) cyclopropanated by reaction with [1(1-ethoxycyclopropyl)oxy]trimethylsilane using sodium cyanoborohydride in the presence of acetic acid.

Additionally, one of the nitrogen atoms of the pyrazole ring optionally may be alkylated by reaction with an alkyl halide, such as propargyl bromide, in the presence of a strong base such as sodium hydride.
embedded image

Scheme III shows the synthesis of pyrazole 19 in more general form by three routes. In Route 1, ketone 13 is condensed with hydrazine 14 to give the substituted hydrazide 16, which is then reacted with acyl halide or anhydride 17 at low temperature to provide acyl hydrazone 18. Upon heating at a temperature up to 200° C., acyl hydrazone 18 is converted to pyrazole 19. In Route 2, acyl hydrazone 18 is formed directly by reaction of ketone 13 with acyl hydrazide 15, formed by reaction of hydrazine with a carboxylic acid ester, at room temperature. Heating acyl hydrazone 18 as above then provides pyrazole 19. In Route 3, ketone 13 is treated with acyl hydrazide 15 at a suitable temperature, ranging from room temperature to about 200° C., to give pyrazole 19 directly. Alternatively, this condensation may be carried out in an acidic solvent, such as acetic acid, or in a solvent containing acetic acid.
embedded image

Synthetic Scheme IV describes the preparation of pyrazole 19.
embedded image

Scheme V shows the two step synthesis of the 3-substituted 4-pyridyl-5-arylpyrazoles 33 of the present invention by cyclization of hydrazone dianions with carboxylates. In step 1, the reaction of substituted pyridylmethyl ketones 31 (prepared, for example, as later described in Scheme IX) with hydrazines in the presence of solvents such as ethanol gives ketohydrazones 32. Examples of suitable hydrazines include, but are not limited to, phenylhydrazine and p-methoxyphenylhydrazine. In step 2, the hydrazones 32 are treated with two equivalents of a base such as sodium bis(trimethylsilyl)amide in a suitable solvent such as tetrahydrofuran to generate dianions. This reaction may be carried out at temperatures of about 0° C. or lower. In the same step, the dianions then are condensed with esters such as methyl isonicotinate, methyl cyclopropanecarboxylate, to give the desired pyrazoles 33. It may be necessary to treat the product from this step with a dehydrating agent, such as a mineral acid, to produce the target pyrazole in some instances.
embedded image

Scheme VI shows an alternative method for synthesizing pyrazoles which are unsubstituted at the 5 position of the ring. In accordance with this method, a heteroarylmethyl ketone 34 is synthesized by first treating a heteroarylmethane with a strong base such as lithium hexamethyldisilazide or lithium diisopropylamide. Examples of suitable heteroarylmethanes are 4-methylpyridine, 4-methylpyrimidine, 2,4-dimethylpyridine, 2-chloro-4-methylpyrimidine, 2-chloro-4-methylpyridine and 2-fluoro-4-methylpyridine. The resulting heteroarylmethyl lithium species is then reacted with a substituted benzoate ester to produce ketone 34. Examples of suitable benzoate esters are methyl and ethyl p-fluorobenzoate and ethyl and methyl p-chlorobenzoate. Ketone 34 is converted to the aminomethylene derivative 35 by reaction with an aminomethylenating agent such as dimethylformamide dimethyl acetal or tert-butoxybis(dimethylamino)methane. Ketone 35 is converted to pyrazole 36 by treatment with hydrazine.

A modification of this synthetic route serves to regioselectively synthesize pyrazole 38 which contains a substituted nitrogen at position 1 of the ring. Ketone 34 is first converted to hydrazone 37 by reaction with the appropriate substituted hydrazine. Examples of suitable hydrazines are N-methylhydrazine and N-(2-hydroxyethyl)hydrazine. Reaction of hydrazone 37 with an aminomethylenating agent produces pyrazole 38. Examples of suitable aminomethylenating agents include dimethylformamide dimethyl acetal and tert-butoxybis(dimethylamino)methane.

In cases where the R³substituent of pyrazoles 36 and 38 bears a leaving group such as a displaceable halogen, subsequent treatment with an amine produces an amino-substituted heteroaromatic derivative. Examples of such amines include benzylamine, cyclopropylamine and ammonia. The leaving group may also be replaced with other nucleophiles such as mercaptides and alkoxides. Examples of substitutable R³groups include, but are not limited to, 2-chloropyridinyl and 2-bromopyridinyl groups.
embedded image

Scheme VII describes the preparation of derivatives from pyrazole 5 (prepared in accordance with Scheme I) when R²=CH₃. Oxidation of pyrazole 5 gives carboxylic acid 39, which is then reduced to hydroxymethyl compound 40, or coupled with amine NR¹⁰R¹¹(wherein R¹⁰and R¹¹are independently selected, for example, from hydrogen, alkyl and aryl, or together with the nitrogen atom to which they are attached form a 4-8 membered ring that may contain one or more additional heteroatoms selected from oxygen, nitrogen or sulfur) to form amide 41 followed by reduction to generate amine derivative 42.
embedded image

Scheme VIII illustrates the synthesis of pyrazoles 44 and 45 from pyrazole 43. The alkylation of the ring nitrogen atoms of pyrazole 43 can be accomplished using conventional techniques. Treatment of pyrazole 43 with an appropriate base (for example, sodium hydride) followed by treatment with an alkyl halide (for example, CH₃I)yields a mixture of isomers 44 and 45.
embedded image

Scheme IX illustrates the synthesis of 3-aryl-4-pyridyl-pyrazoles of the present invention. Benzoate 46 is reacted with pyridine 47 in the presence of a strong base, such as an alkali metal hexamethyldisilazide (preferably sodium hexamethyldisilazide or lithium hexamethyldisilazide), in a suitable solvent, such as tetrahydrofuran, to give desoxybenzoin 48. Desoxybenzoin 48 is then converted to ketone 49 by treatment with an excess of dimethylformamide dimethyl acetal. Ketone 49 is then reacted with hydrazine hydrate in a suitable solvent such as ethanol to yield pyrazole 50. In Scheme IX, R¹²represents one or more radicals independently selected from the optional substituents previously defined for R⁴. Preferably, R¹²is hydrogen, alkyl, halo, trifluoromethyl, methoxy or cyano, or represents methylenedioxy.

The 3-aryl-4-pyrimidinyl-pyrazoles of the present invention can be synthesized in the manner of Scheme IX by replacing pyridine 47 with the corresponding pyrimidine. In a similar manner, Schemes X through XVII can be employed to synthesize 3-aryl-4-pyrimidinyl-pyrimidines corresponding to the 3-aryl-4-pyrimidinyl-pyrazoles shown in those schemes.
embedded image

Scheme X illustrates one variation of Scheme IX that can be used to synthesize 3-aryl-4-pyridyl-pyrazoles that are further substituted on the nitrogen atom at position 1 of the pyrazole ring. If desoxybenzoin 48 (prepared in accordance with Scheme IX) instead is first converted to hydrazone 51 by treatment with hydrazine and hydrazone 51 is then treated with dimethylformamide dimethyl acetal, then the resulting product is pyrazole 52.

Schemes XI through XVIII illustrate further modifications that can be made to Scheme IX to synthesize other 3-aryl-4-pyridyl-pyrazoles having alternative substituents.
embedded image

In Scheme XII, X is chloro, fluoro or bromo; R¹³is, for example, hydrogen, alkyl, phenyl, aralkyl, heteroarylalkyl, amino or alkylamino; and R₂₀is, for example, hydrogen or alkyl.
embedded image

In Scheme XV, n is 1, 2, 3, 4 or 5; and R¹⁴and R¹⁵are independently selected from, for example, hydrogen, alkyl or aryl, or together with the nitrogen atom to which they are attached form a 4-7 membered ring that may contain one or more additional heteroatoms selected from oxygen, nitrogen or sulfur.
embedded image

In Scheme XVI, R¹⁶is selected, for example, from hydrogen, alkyl and phenyl.
embedded image

In Scheme XVII, R¹⁷is selected, for example, from alkyl, phenylalkyl and heterocyclylalkyl.
embedded image

Compounds wherein the 2-position of the pyridine ring is substituted by a carboxyl group or a carboxyl derivative may be synthesized according to the procedures outline in Scheme XVIII. The starting pyridyl pyrazole 67 is converted to the 2-cyano derivative 68 by first conversion to its pyridine N-oxide by reaction with an oxidizing agent such as m-chloroperoxybenzoic acid. Treatment of the pyridine N-oxide with trimethylsilyl cyanide followed by dimethylcarbamoyl chloride produces the 2-cyano compound 68. Compound 68 is converted to its carboxamide 69 by reaction with hydrogen peroxide in the presence of a suitable base. Examples of suitable bases include potassium carbonate and potassium bicarbonate. Carboxamide 69 is converted to its methyl ester 70 by reaction with dimethylformamide dimethyl acetal in methanol. The ester 70 is converted to its carboxylic acid 71 by saponification. Typical saponification conditions include reaction with a base such as sodium hydroxide or potassium hydroxide in a suitable solvent such as ethanol or ethanol and water or methanol and water or the like. Ester 70 is also convertible to substituted amide 72 by treatment with a desired amine, such as methylamine at a suitable temperature. Temperatures may range from room temperature to 180° C. In Scheme XVIII, R¹⁸and R¹⁹are independently selected, for example, from hydrogen, alkyl and aryl, or together with the nitrogen atom to which they are attached form a 4-8 membered ring that may contain one or more additional heteroatoms selected from oxygen, nitrogen or sulfur.
embedded image

The synthesis of compound 77, wherein the amino group is extended two methylene units from the pyrazole ring is illustrated in Scheme XIX above. Reaction of pyrazole 73 with a protecting reagent such as 2-(trimethylsilyl)ethoxymethyl chloride (SEM-Cl) in the presence of a base such. as sodium hydride yields protected pyrazole 74. This reaction results in a mixture of regioisomers wherein the 2-(trimethylsilyl)-ethoxymethyl (SEM) group may be attached to either of the nitrogen atoms of the pyrazole ring. Alternatively, protecting reagents such as 2-methoxyethoxymethyl chloride (MEMCl) also may be used.

Reaction of compound 74 with a suitable derivative of dimethyl formamide, followed by exposure to water, leads to aldehyde 75. Examples of suitable derivatives of dimethylformamide include tert.-butoxybis(dimethylamino)methane and dimethylformamide dimethyl acetal. One skilled in the art will understand that this leads to the formation of a reactive vinyl amine as an intermediate. The reaction may be carried out in the reagent itself or in the presence of dimethylformamide as solvent. Suitable reaction temperatures range from about 50° C. to about 153° C. The contacting of the intermediate vinyl amine with water may be carried out in solution in a suitable solvent such as methanol, ethanol, acetone, or dioxane. Alternatively, a solution of the vinyl amine in a suitable solvent may be contacted with hydrated silica gel.

Aldehyde 75 may be reductively aminated to amine 76 by reaction with the desired amine in the presence of a reducing agent. Typical reducing agents include sodium cyanoborohydride, sodium borohydride or hydrogen in the presence of a catalyst, such as a palldium/carbon catalyst or a Raney nickel catalyst, either at atmospheric pressure or in a pressurized system. An acid catalyst such as acetic acid or dilute hydrochloric acid may also be employed. The reaction may be run at ambient temperature or may be heated.

Pyrazole 77 is obtained by removal of the pyrazole nitrogen protecting group. The deprotection reaction employed will depend upon the specific protecting group removed. A 2-(trimethylsilyl)ethoxymethyl group can be removed, for example, by reaction of amine 76 with tetrabutylammonium fluoride while a 2-methoxyethoxymethyl group can be removed, for example, by acid hydrolysis.
embedded image

Scheme XX shows the syntheses of pyrazole 82 and its derivatives 83 and 85. A substituted 4-picoline 78 is condensed with ethyl ester derivative 79 in the presence of a base such as lithium diisopropylamide to give ketone derivative 80. An example of a suitable picoline is 4-picoline. Suitable ethyl ester derivatives include ethyl 4-piperidinylacetate (Compound 79, n=1). Ester 79 may be synthesized, for example, by hydrogenation of ethyl 4-pyridylacetate and protection of the resulting piperidine nitrogen as the tert.-butoxycarbonyl (Boc) derivative by reaction with tert.-butoxycarbonyl chloride. The hydrogenation may be carried out, for example, at pressures from atmospheric to 100 psi. Suitable catalysts include 5% platinum on carbon. The presence of an acid such as hydrochloric acid may also improve reaction performance.

Treatment of 80 with a substituted benzaldehyde provides unsaturated ketone 81. Pyrazole 82 may be synthesized by treatment of 81 with p-toluenesulfonylhydrazide in the presence of acetic acid. During this reaction, the protecting tert.-butoxycarbonyl group is removed. Derivatization of pyrazole 82 by appropriate methods as described in Scheme II for analogous piperazine derivatives gives various pyrazole derivatives 83.

Alternatively, unsaturated ketone 81 can be converted to pyrazole 84 by first reaction with hydrogen peroxide in the presence of sodium or postassium hydroxide, followed by reaction with hydrazine. Using trifluoroacetic acid, the tert.-butoxycarbonyl group may be removed from pyrazole 84 to give pyrazole 82.

Alternatively, the tert.-butoxycarbonyl group of 84 may be reduced with a reagent such as lithium aluminum hydride to provide the methyl derivative 85.
embedded image

Scheme XXI shows the synthesis of pyrazoles 92. Treatment of compound 86 with ester 87 in the presence of a base, such as sodium bis(trimethylsilyl)amide, in a suitable solvent such as tetrahydrofuran, gives ketone 88. Substituent R³is typically heteroaryl, preferably pyridinyl or pyrimidinyl, and more preferably 4-pyridinyl. Substituent R⁴is typically aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkyl or aralkyl, and is preferably a substitued phenyl. R¹⁰³can be, for example, lower alkyl.

Treatment of ketone 88 with carbon disulfide, dibromomethane, and a base such as potassium carbonate in a suitable solvent such as acetone gives dithietane 89. Other suitable bases include, but are not limited to, carbonates such as sodium carbonate, tertiary amines such as triethylamine or diazabicycloundecane (DBU), and alkoxides such as potassium tert-butoxide. Other suitable solvents include, but are not limited to, low molecular weight ketones, methyl ethyl ketone, tetrahydrofuran, glyme, acetonitrile, dimethylformamide, dimethylsulfoxide, dichloromethane, benzene, substituted benzenes and toluene.

Dithietane 89 may be reacted with an appropriate amine, with or without heating, in an acceptable solvent such as toluene or acetonitrile to make thioamide 90. Thioamide 90 is treated with hydrazine or a substituted hydrazine in an appropriate solvent such as tetrahydrofuran or an alcohol, with or without heating, to produce pyrazole 92 and/or its tautomer.

Alternatively, thioamide 90 can be reacted with an alkyl halide or a sulphonic acid ester to yield substituted thioamide 91. Substituted thioamide 91 is treated with hydrazine or a substituted hydrazine in an appropriate solvent such as tetrahydrofuran or an alcohol, with or without heating, to produce pyrazole 92 or its tautomer.

R¹⁰⁴and R¹⁰⁵can be independent radicals or can form a heterocyclyl ring that is optionally substituted and/or contains an additional heteroatom.
embedded image

Scheme XXII shows the synthesis of substituted 5-amino pyrazoles 98 and 99. Desoxybenzoin 93 (prepared, for example, as illustrated in Scheme IX, supra, or Example C-1, infra) is reacted with an aminomethylenating agent, such as N,N-dimethylformamide dimethyl acetal, to form aminomethylene ketone 94. Aminomethylene ketone 94 is converted to isoxazole 95 by treatment with a hydroxylamine in a suitable solvent such as ethanol. Isoxazole 95 is treated with a base, such as dilute aqueous sodium hydroxide, to form cyanoketone 96. Cyanoketone 96 is then reacted with a chlorinating agent, such as phosphorous trichloride, to form a vinyl chloride which is then treated with hydrazine hydrate (or a substituted hydrazine hydrate) to form amino pyrazole 97. Amino pyrazole 97 can be reacted further with a variety of alkyl halides, such as methyl bromoacetate, bromoacetonitrile, and chloroethylamine, to form the appropriate mono- or disubstituted, cyclic or acyclic amino pyrazole 98. Typical R¹⁰⁶and R¹⁰⁷substituents include, for example, hydrogen and alkyl. In addition, amino pyrazole 97 can be reacted further with a variety of acylating agents, such as benzyliminodiacetic acid and N,N-dimethylglycine, to give the corresponding mono- or disubstituted, cyclic or acyclic amide or imide 99. Typical R¹⁰⁸and R¹⁰⁹substituents include, for example, hydrogen, alkyl and acyl.
embedded image

Scheme XXIII shows the synthesis of sulfoxide/sulfone 103. Ketone 100, wherein X is preferably halo such as fluoro or chloro, in a solvent, such as tetrahydrofuran, is treated with a suitable base, such as sodium hydride or potassium t-butoxide, to yield an enolate intermediate. The enolate intermediate is reacted with carbon disulfide and then alkylated with an appropriate alkylating agent, such as methyl iodide, benzyl bromide, or trimethylsilylchloride, to form dithioketene acetal 101. Dithioketene acetal 101 can be cyclized to pyrazole 102 using hydrazine, or its hydrate (or a substituted hydrazine or its hydrate), in a suitable solvent, such as tetrahydrofuran or ethanol. Pyrazole 102 is then treated with an oxidizing agent, such as potassium peroxymonosulfate, ammonium persulfate, or 3-chloroperoxybenzoic acid, to generate sulfoxide 103 (n=1) and/or sulfone 103 (n=2).
embedded image

Scheme XXIV shows the synthesis of pyrazole 106. Dithioketene acetal 104 in a suitable solvent, such as toluene, is combined with a secondary amine, wherein Z is preferably S or —NCH₃, and heated to about 80-110° C. After the solution has been heated for several hours, any insoluble bis substituted material may be removed by filtration. Mono substituted product 105 is then reacted with hydrazine, or its hydrate (or a substituted hydrazine or its hydrate), in a solvent, such as tetrahydrofuran or ethanol, at ambient up to reflux temperatures, to form pyrazole 106.
embedded image

Scheme XXV shows the synthesis of pyrazole 109. Dithietane 107 is added to a solution of a sodium or potassium alkoxide in tetrahydrofuran. The alkoxide may be generated by treating an alcohol, in tetrahydrofuran, with a suitable base, such as sodium hydride, sodium hexamethyldisilazide, or potassium hexamethyldisilazide. The reaction mixture is stirred from 4 to 72 hours at room temperature. The resulting thionoester 108 is reacted with hydrazine, or its hydrate (or a substituted hydrazine or its hydrate), in ethanol, methanol, or tetrahydrofuran at room temperature for about 2-18 hours to generate pyrazole 109.
embedded image

Scheme XXVI shows the synthesis of pyrazole 112. To dithietane 107 in a suitable solvent, such as toluene, is added an amine, such as thiomorpholine and heated to about 80-110° C., to form thioamide 110. Thioamide 110 may be isolated or used directly in the next reaction step. To thioamide 110 in tetrahydrofuran is added a suitable base, such as potassium t-butoxide, and the resulting thiol anion alkylated with iodomethane to form alkylated thioamide 111. Alkylated thioamide 111 can be cyclized with hydrazine (or substituted hydrazine), in a solvent, such as tetrahydrofuran or ethanol, to generate pyrazole 112.
embedded image

Scheme XXVII shows the synthesis of pyrazole 114. Dithietane 107 in a suitable solvent, such as tetrahydrofuran or ethanol, is reacted with hydrazine, or its hydrate (or a substituted hydrazine or its hydrate), at room temperature up to the reflux temperature of the solvent to generate thiopyrazole 113. The thiol group of thiopyrazole 113 may be alkylated with a variety of alkylating agents, such as alkyl halides or Michael acceptors, including, but not limited to, methyl chloroacetate, ethyl acrylate, and benzyl bromide, in the presence of a suitable base such as potassium carbonate, sodium ethoxide or triethylamine, in a solvent such as dimetliylformainide or ethanol to generate pyrazole 114.
embedded image

Scheme XXVIII shows the synthesis of pyrazole 117. Pyrazoles containing acid labile amine protecting groups, such as pyrazole 115, may be treated with a suitable acid catalyst, such as trifluoroacetic acid in dichloromethane or HCl in ethanol or dioxane to yield amine 116. Amine 116 can then be acylated or alkylated by methods known to one of ordinary skill in the art, such as reacting amine 116 with a reagent such as acetyl chloride or methyl iodide in the presence of a suitable base, such as potassium carbonate or triethylamine. In addition, N-methylation can be performed directly, using formaldehyde and formic acid in ethanol/water at reflux to give pyrazole 117 wherein R¹¹⁴is methyl.
embedded image

Scheme XXIX shows the synthesis of pyrazole 120. Pyrazoles containing base labile esters, such as pyrazole 118, may be treated with a suitable base, such as, sodium hydroxide to generate free acid 119. Acid 119 can then be aminated by methods known to one of ordinary skill in the art, such as treating acid 119 with a suitable coupling reagent, such as 1-(3-dimethylaminopropyl)3-ethylcarbodiiminde hydrochloride or O-benzotriazol-1-yl-N,N,N′,N′-tetramethyluronium tetrafluoroborate, with or without catalysts, such as 1-hydroxybenzotriazole or N-hydroxysuccinimide, and an appropriate amine. In addition, amidation can be performed directly, by treating the methyl ester with an appropriate amine, for example N-methylpiperazine, in a suitable solvent such as dimethylformamide or methanol, at a temperature from room temperature up to reflux to generate pyrazole 120.

The following examples contain detailed descriptions of the methods of preparation of compounds of Formulas I, IA, XI, X, XI, and XX. These detailed descriptions fall within the scope, and serve to exemplify, the above described General Synthetic Procedures which form part of the invention. These detailed descriptions are presented for illustrative purposes only and are not intended as a restriction on the scope of the invention. All parts are by weight and temperatures are in Degrees centigrade unless otherwise indicated. All compounds showed NMR spectra consistent with their assigned structures. In some cases, the assigned structures were confirmed by nuclear Overhauser effect (NOE) experiments.

The following abbreviations are used:

HCl—hydrochloric acid

MgSO₄—magnesium sulfate

Na₂SO₄—sodium sulfate

NaIO₄—sodium periodate

NaHSO₃—sodium bisulfite

NaOH—sodium hydroxide

KOH—potassium hydroxide

P₂O₅—phosphorus pentoxide

Me—methyl

Et—ethyl

MeOH—methanol

EtOH—ethanol

HOAc (or AcOH)—acetic acid

EtOAc—ethyl acetate

H₂O—water

H₂O₂—hydrogen peroxide

CH₂Cl₂—methylene chloride

K₂CO₃—potassium carbonate

KMnO₄—potassium permanganate

NaHMDS—sodium hexamethyldisilazide

DMF—dimethylformamide

EDC—1-(3-dimethylaminopropyl)3-ethylcarbodiiminde

hydrochloride

HOBT—1-hydroxybenzotriazole

mCPBA—3-chloroperoxybenzoic acid

Ts—tosyl

TMSCN—trimethylsilyl cyanide

Me₂NCOCl—N,N-dimethylcarbamoyl chloride

SEM-Cl—2-(trimethylsilyl)ethoxymethyl chloride

h—hour

hr—hour

min—minutes

THF—tetrahydrofuran

TLC—thin layer chromatography

DSC—differential scanning calorimetry

b.p.—boiling point

m.p.—melting point

eq—equivalent

RT—room temperature

DMF DMA—dimethylformamide dimethyl acetal

TBAF—tetrabutylammonium fluoride

Boc—tert.-butoxycarbonyl

DBU—diazabicycloundecane

DMF(OMe)₂—N,N-dimethylformamide dimethyl acetal

Et₃N—triethylamine

TMSCl—trimethylsilylchloride

TFA—trifluoroacetic acid

TBTU—O-benzotriazol-1-yl-N,N,N′,N′-tetramethyluronium tetrafluoroborate

psi—pounds per square inch

ESHRMS—electron spray high resolution mass spectroscopy

EXAMPLE A-1

embedded image

4-[5-(3-fluoro-4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine

Step 1: Preparation of 4-(3-fluoro-4-methoxylphenyl)-3-pyridyl-3-butene-2-one

A solution of 4-pyridylacetone (1.0 g, 7.4 mmol), 3-fluoro-p-anisaldehyde (1.25 g, 8.1 mmol), and piperidine (0.13 g, 1.5 mmol) in toluene (50 ml) was heated to reflux. After 18 hours, the reaction was cooled to room temperature and the solvent was removed under reduced pressure. The crude product (3.0 g) was purified by column chromatography (silica gel, 65:35 ethyl acetate/hexane) to give 4-(3-fluoro-4-methoxylphenyl)-3-pyridyl-3-butene-2-one as a pale yellow solid (1.60 g, 80%).

Step 2: Preparation of 4-[5-(3-fluoro-4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine

To a solution of 3-pyridyl-4-(3-fluoro-4-methoxylphenyl)-3-butene-2-one (step 1) (0.99 g, 3.65 mmol) in acetic acid (25 ml), p-toluenesulfonyl hydrazide (0.68 g, 3.65 mol) was added. The reaction solution was heated to reflux for 6 hours. Acetic acid was removed by distillation from the reaction solution. The resulting residue was diluted with CH₂Cl₂(150 ml), washed with H₂O (2×100 ml), dried (Na₂SO₄), filtered, and concentrated. The crude product (1.5 g) was purified by chromatography (silica gel, ethyl acetate) to give 4-[5-(3-fluoro-4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine as a pale yellow solid (213 mg, 20.7%): Anal. Calc'd for C₁₆H₁₄N₃OF.0.1 H₂O: C, 67.41; H, 5.02; N, 14.74. Found: C, 67.37; H, 4.88; N, 14.35.

EXAMPLE A-2

embedded image

4-(3-methyl-5-phenyl-1H-pyrazol-4-y1) pyridine

Step 1: Preparation of 4-pyridylacetone

4-Pyridylacetone was prepared according to the method of Ippolito et al, U.S. Pat. 4,681,944.

Step 2: Preparation of 4-phenyl-3-(4-pyridyl)-3-butene-2-one

Using the procedure of Example A-1, step 1, 4-pyridylacetone (step 1) (1 g, 7.4 mmol) was condensed with benzaldehyde (790 mg, 7.4 mmol) in benzene (15 mL) containing piperidine (50 mg) at reflux. The desired 4-phenyl-3-(4-pyridyl)-3-butene-2-one (1.3 g, 78%) was obtained as a crystalline solid: m. p. 101-103° C. Anal. Calc'd for C₁₅H₁₃NO (223.28): C, 80.69; H, 5.87; N, 6.27. Found: C, 80.59; H, 5.79; N, 6.18.

Step 3: Preparation of 4-phenyl-3-(4-pyridyl)-3,4-epoxy-2-butanone

Using the procedure of Example A-1, step 2, a solution of 4-phenyl-3-(4-pyridyl)-3-butene-2-one (step 2) (1.25 g, 5.6 mmol) in methanol (20 ml) was treated with 30% aqueous hydrogen peroxide (1 ml) in the presence of sodium hydroxide (230 mg, 5.7 mmol). The crude product was purified by chromatography (silica gel, 1:1 ethyl acetate/hexane) to give 4-phenyl-3-(4-pyridyl)-3,4-epoxy-2-butanone (270 mg, 20%).

Step 4: Preparation of 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine

Using the procedure of Example A-1, step 3, a solution of 4-phenyl-3-(4-pyridyl)-3,4-epoxy-2-butanone (step 3) (250 mg, 1 mmol) in ethanol (15 ml) was treated with anhydrous hydrazine (50 mg, 1.5 mmol) and heated to reflux for 4 hours. The crude product was purified by chromatography (silica gel, 1:1 acetone/hexane). The product was recrystallized from ethyl acetate and hexane to give 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine (81 mg, 35%) as a crystalline solid: m. p. 212-214° C. Anal. Calc'd for C₁₅H₁₃N₃(235.29): C, 76.57; H, 5.57; N, 17.86. Found: C, 76.49; H, 5.42; N, 17.39.

EXAMPLE A-3

embedded image

4-[5-methyl-3-(2-methylphenyl)-1H-pyrazol-4-y1]pyridine

Step 1: Preparation of 4-(2-methylphenyl)-3-(4-pyridyl)-3-butene-2-one

A solution of 4-pyrridylacetone (Example A-5, step 1) (0.75 g, 5.56 mmol), o-tolualdehyde (0.73 g, 5.56 mmol) and piperidine (100 mg) in toluene (50 ml) was heated to reflux. Water generated during the reaction was removed by a Dean-Stark trap. After heating at reflux for 5 hours, the reaction mixture was stirred at room temperature for 15 hours. The mixture was concentrated to an orange color oily residue. The crude ketone was purified by chromatography to give 4-(2-methylphenyl)-3-(4-pyridyl)-3-butene-2-one: Anal. Calc'd for C₁₆H₁₅NO (237.30): C, 80.98; H, 6.37; N, 5.90. Found: C, 80.78; H, 6.61; N, 5.85.

Step 2: Preparation of 4-(2-methylphenyl)-3-(4-pyridyl)-3,4-epoxy-2-butanone

To a solution of 4-(2-methylphenyl)-3-(4-pyridyl)-3-butene-2-one (step 1) (1.0g, 4.2 mmol) in methyl alcohol (18 ml), a solution of H202 (30% by wt.) (0.95 g, 8.4 mmol) and sodium hydroxide (0.18 g 4.6 mmol) in water (4 ml) was added. The reaction was stirred at room temperature for 70 hours. After methyl alcohol was removed, water (25 ml) and ethyl acetate (100 ml) were added and the two phase mixture was stirred for 30 minutes. The layers were separated, and the aqueous layer was washed with ethyl acetate (100 ml). The combined organic layer was dried with Na₂SO₄, filtered and concentrated to give an oil. 4-(2-Methylphenyl)-3-(4-pyridyl)-3,4-epoxy-2-butanone was isolated from the oil residue by chromatography.

Step 3: Preparation of 4-[5-methyl-3-(2-methylphenyl)1H-pyrazol-4-yl]pyridine

A solution of 4-(2-methylphenyl)-3-(4-pyridyl)-3,4-epoxy-2-butanone (step 2) (0.11 g, 0.434 mmol) and hydrazine hydrate (0.043 g, 0.868 mmol) in ethyl alcohol (50 ml) was heated at reflux for 20 hours. The solvent was removed and the resulting residue was purified by chromatography to give 4-[5-methyl-3-(2-methylphenyl)-1H-pyrazol-4-yl]pyridine: Anal. Calc'd for C₁₆H₁₅N₃(249.32): C, 77.08; H, 6.06; N, 16.85. Found: C, 76.66; H, 5.91; N, 16.84.

EXAMPLE A-4

embedded image

4-[5-methyl-3-(4-flurophenyl)-1H-pyrazol-4-yl]pyridine

By following the method of Example A-3 and substituting p-fluorobenzaldehyde for o-tolualdehyde, the titled compound was prepared: Anal. Calc'd for C₁₅H₁₂N₃F+0.1 H₂O: (249.32): C, 70.63; H, 4.82; N. 16.47. Found: C, 70.63; H, 4.78; N, 16.40.

EXAMPLE A-5

embedded image

4-[5-methyl-3-(4-methylphenyl)-1H-pyrazol-4-y1]pyridine

By following the method of Example A-3 (with one minor modification: in Step 2, the preparation of the intermediate epoxide was accomplished at 0-10° C. for 1 hour, and the reaction was quenched by being partitioned between water, containing 2 eq. sodium bisulfite, and ethyl acetate) and substituting p-tolualdehyde for o-tolualdehyde, the titled product was isolated: Anal. Calc'd for C₁₆H₁₅N₃(249.32): C, 77.08; H, 6.06; N, 16.85. Found: C, 76.97; H, 6.09; N; 16.90.

EXAMPLE A-6

embedded image

4-[5-methyl-3-[4-(methylthio)phenyl]-1H-pyrazol-4-y1]pyridine

By following the method of Example A-5 and substituting 4-(methylthio)benzaldehyde for p-tolualdehyde, the titled product was prepared: Anal. Calc'd for C₁₆H₁₅N₃S (281.38): C, 68.30; H, 5.37; N, 14.93. Found: C, 68.34; H, 5.09; N. 14.78.

EXAMPLE A-7

embedded image

4-[3-(4-chlorophenyl)-5-methyl-1H-pyrazol-4-y1]pyridine

By following the method of Example A-5 and substituting p-chlorobenzaldehyde for p-tolualdehyde, the titled product was obtained. Anal. Calc'd for C₁₅H₁₂N₃Cl (269.77): C, 66.79; H, 4.48; N, 15.58. Found: C, 66.43; H, 4.44; N, 15.78.

EXAMPLE A-8

embedded image

4-[3-methyl-5-(3-methylphenyl)-1H-pyrazol-4-y1]pyridine

By following the method of Example A-5 and substituting m-tolualdehyde for p-tolualdehyde, the titled product was obtained: Anal. Calc'd for C₁₆H₁₅N₃+0.2 H₂O: C, 75.98; H, 6.14; N, 16.61. Found: C, 76.06; H, 6.05; N, 16.38.

EXAMPLE A-9

embedded image

4-[5-(2,5-dimethylphenyl)-3-methyl-1H-pyrazol-4-y1]pyridine

By following the method of Example A-5 and substituting 2,5-dimethylbenzaldehyde for p-tolualdehyde, the titled product was obtained: Anal. Calc'd for C₁₇H₁₇N₃+0.1 H₂O: C, 77.01; H, 6.54; N, 15.85. Found: C, 76.96; H, 6.81; N, 15.51.

EXAMPLE A-10

embedded image

4-[5-(1,3-benzodioxol-5-y1)-3-methyl-1H-pyrazol-4-y1]pyridine

4-Pyridylacetone (1.5 9, 12 mmol), piperonal (1.6 g, 10.6 mmol), acetic acid (110 mg, 1.8 mmol), and piperidine (110 mg, 1.3 mmol) were dissolved in toluene (30 mL) and heated for 2 hours at reflux in a flask equipped with a Dean-Stark trap. The solution was cooled to room temperature, and ethyl acetate was added to precipitate a solid, which was collected on a filter plate (1.25 g). A sample (500 mg) of this solid was heated with p-toluensulfonyl hydrazide (348 mg, 1.81 mmol) in acetic acid (5 mL) at 80° C. for 1 hour. The reaction was heated to reflux for 1 hour. The reaction was cooled to room temperature and the solvent was evaporated. The residue was dissolved in ethyl acetate, washed with 5% aqueous potassium carbonate, and water. The organic layer was dried (MgSO₄), filtered and evaporated to obtain a yellow solid. This solid was triturated with methylene chloride, yielding 4-[5-(1,3-benzodioxol-5-yl)-3-methyl-1H-pyrazol-4-yl]pyridine which was collected on a filter plate (220 mg, 42% yield). Anal. Calc'd for C₁₆H₁₃N₃O₂: C, 68.81; H, 4.69; N. 15.04. Found: C, 68.02; H, 4.54; N, 14.76. MS (M+H): 280 (base peak).

EXAMPLE A-11

embedded image

4-[3-methyl-5-(4-phenoxyphenyl)-1H-pyrazol-4-y1]pyridine

4-Pyridylacetone (1.5 g, 12 mmol), 4-phenoxybenzoldehyde 92.1 g, 10.6 mmol), acetic acid (110 mg, 1.8 mmol), and piperidine (110 mg, 1.3 mmol) were dissolved in toluene (30 mL) and heated for 2 hours at reflux in a flask equipped with a Dean-Stark trap. The solution was cooled to room temperature and ethyl acetate was added to precipitate a solid, which was collected on a filter plate. A sample (223 mg) of this solid was heated with p-toluensulfonyl hydrazide (348 mg, 1.81 mmol) in ethylene glycol with potassium hydroxide (77 mg) at 110° C. for 0.5 hour. The work up procedure was the same as that in Example A-10. 4-[3-Methyl-5-(4-phenoxyphenyl)-1H-pyrazol-4-yl]pyridine was obtained (100 mg, 66% yield): Anal. Calc'd for C₂₁H₁₇N₃O+0.1 H₂O: C, 76.62; H, 5.27; N, 12.76. Found: C, 76.37; H, 5.19; N, 12.64. MS (M+H): 328 (base peak).

EXAMPLE A-12

embedded image

4-[5-[[1,1-biphenyl]-4-y1]-3-methyl 1H-pyrazol-4-y1]pyridine

The same procedure as for the preparation of Example A-10 was used, substituting 4-formylbiphenyl in place of piperonal, to give 4-[5-[(1,1′-biphenyl)-4-yl]-3-methyl-1H-pyrazol-4-yl]pyridine as a white solid: MS (M+H): 312 (base peak).

EXAMPLE A-13

embedded image

4-[3-methyl-5-[3-(phenoxyphenyl)-1H-pyrazol-4-y1]pyridine

The same procedure for the preparation of Example A-10 was used, substituting 3-phenoxybenzaldehyde in place of piperonal, to give 4-[3-methyl-5-[3-(phenoxyphenyl)-1H-pyrazol-4-yl]pyridine as a white solid.

EXAMPLE A-14

embedded image

4-[3-methyl-5-[3-(phenylmethoxy)phenyl]-1H-pyrazol-4-y1]pyridine

The same procedure for the preparation of Example A-10 was used, substituting 3-benzyloxybenzaldehyde in place of piperonal, to give 4-[3-methyl-5-[3-(phenylmethoxy)phenyl]-1H-pyrazol-4-yl]pyridine as a white solid: MS (M⁺H): 342 (base peak).

EXAMPLE A-15

embedded image

4-[3-methyl-5-[2-(phenylmethoxy)-phenyl]-1H-pyrazol-4-y1]pyridine

The same procedure for the preparation of Example A-10 was used, substituting 2-benzyloxybenzaldehyde in place of piperonal, to give 4-[3-methyl-5-[2-(phenylmethyloxy)phenyl]-1H-pyrazol-4-yl]pyridine. MS (M⁺H): 342 (base peak).

EXAMPLE A-16

embedded image

2-[3-methyl-4-(4-pyridinyl)-1H-pyrazol-4-y1]phenol

The same procedure for the preparation of Example A-10 was used, substituting 2-hydroxybenzaldehyde in place of piperonal, to give 2-[3-methyl-4-(4-pyridinyl)-1H-pyrazol-4-yl]phenol: MS (M⁺H): 252 (base peak).

EXAMPLE A-17

embedded image

3-[3-methyl-4-(4-pyridinyl)-1H-pyrazol-4-y1]phenol

The same procedure for the preparation of Example A-10 was used, substituting 3-hydroxybenzaldehyde in place of piperonal, to give 3-[3-methyl-4-(4-pyridinyl)-1H-pyrazol-4-yl]phenol: MS (M⁺H): 252 (base peak).

EXAMPLE A-18

embedded image

1-hydroxy-4-[3-methyl-5-phenyl-1H-pyrazol-4-y1]pyridinium

To a solution of 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine (Example A-2) (2.06 g, 8.76 mmol) in a mixture of CH₂Cl₂(10 mL) and MeOH (20 mL), was added 3-chloroperoxybenzoic acid (57-86%) (2.65 g, 8.76 mmol). The reaction was stirred at room temperature for 2 h, quenched with K₂CO₃solution (25%, 15 mL), and concentrated. The resulting residue was partitioned between EtOAc (2.0 L) and H₂O (500 mL). The organic layer was separated, washed with H₂O (500 mL), dried over MgSO₄, filtered and concentrated to give 1-hydroxy-4-[3-methyl-5-phenyl-1H-pyrazol-4-yl]pyridinium (1.12 g, 54.5%): MS (M+H): 252 (base peak).

EXAMPLE A-19

embedded image

5-(4-fluorophenyl)-N,N-dimethyl-4-(4-pyridinyl)-1H-pyrazol-3-amine

Step 1: Preparation of 1-fluoro-4-(4′-pyridylacetyl)benzene

To a solution of sodium bis(trimethylsilyl)amide (200 mL, 1.0 M in THF) at 0° C. was added a solution of 4-picoline (18.6 g, 0.20 mol) in dry THF (200 mL) over 30 minutes. The reaction mixture was stirred at 0-10° C. for another 30 minutes, then was added to a solution of ethyl 4-fluorobenzoate (16.8 g, 0.10 mol) in dry THF (200 mL) at such a rate that the internal temperature didn't exceed 15° C. After the addition, the resulting yellow suspension was stirred at room temperature for 3 hours. Water (600 mL) was added and the aqueous phase was extracted with ethyl acetate (3×200 mL). The combined organic layers were washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated in vacuo to give 1-fluoro-4-(4′-pyridylacetyl)benzene (19.9 g, 92%) as an oil which solidified upon standing: m.p.: 90-91 IC; Anal. Calc'd for C₁₃H₁₀FNO: C, 72.55; H, 4.68; N, 6.51. Found: C, 72.07; H, 4.66; N, 6.62.

Step 2: Preparation of 1-fluoro-4-(4′-pyridylbromoacetyl)benzene

To a solution of 1-fluoro-4-(4′-pyridylacetyl)benzene (step 1) (10.0 g, 0.046 mol) in acetic acid (200 mL) was added a solution of bromine (8.2 g, 0.052 mol) in acetic acid (20 mL) dropwise. The reaction mixture was stirred at room temperature overnight. After the solvent was removed, the residue was triturated with ethyl acetate. A yellow solid formed, which was filtered and air-dried to give 1-fluoro-4-(41 -pyridylbromoacetyl)benzene (14.5 g). The compound was used in next step without further purification.

Step 3: Preparation of 5-(4-fluorophenyl)-N,N-dimethyl-4-(4-pyridinyl)-1H-pyrazol-3-amine

A mixture of 1-fluoro-4-(4′-pyridylbromoacetyl)-benzene (step 2) (3.8 g, 0.01 mol) and 4,4-dimethylamino-3-thiosemicarbazide (1.2 g, 0.01 mol) in ethanol (10 mL) was heated at reflux for 30 minutes. The dark green solution was cooled and poured into water (100 mL). The aqueous phase was extracted with methylene chloride (100 mL). The combined organic layers were washed with brine, dried over magnesium sulfate, filtered, and concentrated. The resulting residue was purified by chromatography (silica gel, ethyl acetate) to give 0.3 g 5-(4-fluorophenyl)-N,N-dimethyl-4-(4-pyridinyl)-1H-pyrazol-3-amine (0.3 g, 11%) as a light yellow solid: m.p.: 245-247° C. Anal. Calc'd for C₁₆H₁₅FN₄: C, 68.07; H, 5.36; N, 19.84. Found: C, 68.00; H, 5.37; N, 19.61.

EXAMPLE A-20

embedded image

5-(4-fluorophenyl)-N-phenyl-4-(4-pyridinyl)-1H-pyrazol-3-amine

5-(4-Fluorophenyl)-N-phenyl-4-(4-pyridinyl)-1H-pyrazol-3-amine was prepared by the same procedure as described for Example A-19: m.p. 218-219° C. Anal. Calc'd for C₂₀H₁₅FN₄+0.1 H₂O: C, 72.33; H, 4.61; N, 16.87. Found: C, 72.16; H, 4.56; N, 16.77.

EXAMPLE A-21

embedded image

4-[5-(4-fluorophenyl)-3-phenyl-1H-pyrizol-4-y1]pyridine

Step 1: Preparation of 1-fluoro-4-(4Õ-pyridylacetyl) benzene N-benzoylhydrazone

To a solution of benzoic hydrazide (1.36 g, 0.01 mol) in THF (20 mL) was added 1-fluoro-4-(4′-pyridylacetyl)benzene (2.15 g, 0.011 mol) in one portion followed by a drop of conc. HCl. The reaction mixture was stirred at room temperature overnight. There was white precipitate formed, which was filtered, washed with ether and air-dried to give 1-fluoro-4-(4′-pyridylacetyl)benzene N-benzoylhydrazone (2.90 g, 79%) as a mixture of cis and trans (ratio, 1:9) isomers.

Step 2: Preparation of 4-[5-(4-fluorophenyl)-3-phenyl-1H-Pyrazol-4-yl]pyridine

1-Fluoro-4-(4′-pyridylacetyl)benzene N-benzoylhydrazone (step 1) (0.50 g, 1.5 mmol) was heated at 180° C. under N₂for 15 minutes, then cooled. The resulting solid was purified by chromatography (silica gel, 1:1 ethyl acetate/hexane) to give 4-[5-(4-fluorophenyl)-3-phenyl-1H-pyrazol-4-yl]pyridine (0.25 g, 53%) as a pale yellow solid: m.p.: 265-267° C. Anal. Calc'd for C₂₀H₁₄FN₃+0.25 H₂O: C, 75.10; H, 4.57; N, 13.14. Found: C, 74.98; H, 4.49; N, 12.87.

EXAMPLE A-22

embedded image

4-[5-(3-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-4-yl]pyridine

Step 1: Preparation of 3-(4′-pyridylacetyl)toluene

3-(4′-Pyridylacetyl)toluene was prepared by the same method as described for Example A-19, step 1 in 70% yield.

Step 2: Preparation of trifluoroacetyl hydrazide

A mixture of ethyl trifluoroacetate (14.2 g, 0.10 mol) and hydrazine hydrate (5.54 g, 0.11 mol) in ethanol (25 mL) was heated at reflux for 6 hours. Solvent was removed and the resulting residue was dried in vacuum to give trifluoroacetyl hydrazide (12.3 g, 96%) as a clear oil which solidified upon standing.

Step 3: Preparation of 4-[5-(3-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-4-yl]pyridine

A mixture of 3-(4′-pyridylacetyl)toluene (2.11 g, 0.01 mol) and trifluoroacetyl hydrazide (step 2) (1.0 g, 0.01 mol) was heated at 200° C. under N₂for 15 minutes. The crude residue was purified by chromatography (silica gel, 35:65 ethyl acetate/hexane) to give 4-[5-(3-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-4-yl]pyridine (0.56 g) as a white solid: m.p. 237-239° C. Anal. Calc'd for C₁₆H₁₂F₃N₃: C, 63.36; H, 3.99; N, 13.85. Found: C, 63.6; H, 4.00; N, 13.70.

EXAMPLE A-23

embedded image

A mixture of l-fluoro-4-(4′-pyridylacetyl)benzene (1.0 9, 4.6 mmol) and isonicotinic hydrazide (0.63 g, 4.6 mmol) in THF (25 mL) was heated to dissolution and then evaporated to dryness. The resulting solid was heated first to 140° C., which caused a phase change, and subsequently melted on further heating until 180° C. whereupon a solid crystallized out. The reaction was immediately cooled, diluted with 10% HCl (50 mL) and washed with chloroform. The aqueous layer was neutralized with bicarbonate and a tan colored solid was precipitated out. The solid was purified by treatment with activated carbon (Darco®) in boiling MeOH (100 mL), followed by filtration and concentration, to give 4-[3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]pyridine (1.05 g, 69%) as a shiny tan solid: m.p. 304° C. (DSC). Mass (MH⁺) 137 (100%). Anal. Calc'd for C₁₉H₁₃N₄F.1/4H₂O: C, 71.13; H, 4.24; N. 17.46. Found: C, 70.88; H, 3.87; N, 17.38.

EXAMPLE A-24

embedded image

4-(5-cyclohexyl)-3-methyl-1H-pyrazol-4-y1)pyridine

Step 1: Preparation of 4-cyclohexyl-3-pyridyl-3-butene-2-one

4-Cyclohexyl-3-pyridyl-3-butene-2-one was prepared by the method of Example A-1, step 1 by replacing of 3-fluoro-p-anisaldehyde with cyclohexanecarboxaldehyde.

Step 2: Preparation of 4-(5-cyclohexyl)-3-methyl-1H-pyrazol-4-yl)pyridine

4-(5-Cyclohexyl)-3-methyl-1H-pyrazol-4-yl)pyridine was prepared by the method for Example A-1, step 2, by replacing 4-(3-fluoro-4-methoxylphenyl)-3-pyridyl-3-butene-2-one with 4-cyclohexyl-3-pyridyl-3-butene-2-one (step 1): Anal. Calc'd for C₁₅H₁₉N₃: C, 73.56; H, 7.98; N, 17.16. Found: C, 73.72; H, 7.91; N, 19.98.

EXAMPLE A-25

embedded image

4-[5-(3-fluoro-5-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine

4-{5-(3-Fluoro-5-methoxyphenyl)-3-methyl-3-methyl-1H-pyrazol-4-yl}pyridine was prepared by the method of Example A-1, steps 1 and 2 by replacing 3-fluoro-p-anisaldehyde with 3-fluoro-m-anisaldehyde: Anal. Calc'd for C₁₆H₁₄N₃OF: C, 67.83; H, 4.98; N, 14.83. Found: C, 67.68, H, 4.92; N, 14.92.

The following examples (No 26-55) listed in Table 1 were prepared by the procedures described above:

Nom.p. orAnal.Calc'dAnal. Calc'd (calcd/found)A-R¹R²R³R⁴DSC(° C.)FormulaCHN44H embedded image

175.6C₁₆H₁₅N₃O.0.15H₂O71.70/71.925.75/5.7615.68/15.2945H embedded image

—C₁₇H₁₉N₃77.54/77.136.51/6.2815.96/15.6946H embedded image

412.1C₁₅H₁₁N₃F₂66.42/66.124.09/3.8615.49/15.2547H embedded image

168.5C₁₇H₁₇N₃O.0.15H₂O72.40/72.396.18/5.8714.90/14.5048H embedded image

211.2C₁₆H₁₂N₃F₃.0.2H₂O62.62/62.644.07/4.0613.69/13.3549H embedded image

—C₁₃H₁₁N₃S64.71/64.444.59/4.5817.41/17.2750H embedded image

189.2C₁₅H₁₁N₃Cl₂59.23/59.223.65/3.2413.81/13.8151H embedded image

211.7C₁₅H₁₂N₃Cl.0.15H₂O66.13/66.334.55/4.6215.42/15.0552H embedded image

219.8C₁₆H₁₄N₃Cl64.11/63.854.71/4.6914.02/13.9353H embedded image

163.4C₁₉H₁₇N₃O₂Cl64.32/63.984.83/5.0811.84/11.8054 embedded image

H—C₁₅H₁₂N₃F.0.2H₂O70.15/70.184.86/4.6016.35/16.4755H embedded image

H—C₁₄H₁₀N₃F70.28/69.974.21/3.8417.56/17.53

The following pyrazoles could be prepared by the procedures described above:

Example A-56 5-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyrimidin-2-amine;
Example A-57 5-[3-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyrimidin-2-amine;
Example A-58 5-[3-methyl-5-(2-methylphenyl)-1H-pyrazol-4-yl]pyrimidin-2-amine;
Example A-59 5-[5-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyrimidin-2-amine;
Example A-60 5-[5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]pyrimidin-2-amine;
Example A-61 5-[5-(4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyrimidin-2-amine;
Example A-62 5-5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl)pyridin-2-amine;
Example A-63 4-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-amine;
Example A-64 4-[5-(3-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-amine;
Example A-65 4-[5-(2-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-amine;
Example A-66 4-[5-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-amine;
Example A-67 4-[5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-amine;
Example A-68 4-[5-(4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-amine;
Example A-69 5-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]-2-methoxypyridine;
Example A-70 2-methoxy-5-[3-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine;
Example A-71 2-methoxy-5-[5-(4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
Example A-72 4-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]-2-methoxypyridine;
Example A-73 2-methoxy-4-[3-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine;
Example A-74 2-methoxy-4-[3-methyl-5-(2-methylphenyl)-1H-pyrazol-4-yl]pyridine;
Example A-75 4-[5-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]-2-methoxypyridine;
Example A-76 4-[5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]-2-methoxypyridine;
Example A-77 2-methoxy-4-[3-methyl-5-(4-methylphenyl)-1H-pyrazol-4-yl]pyridine;
Example A-78 5-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-ol;
Example A-79 4-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-ol;
Example A-80 4-[5-(3-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-ol;
Example A-81 4-[5-(2-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-ol;
Example A-82 4-[5-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-ol;
Example A-83 4-[5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-ol;
Example A-84 4-[5-(4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-ol;
Example A-85 5-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine;
Example A-86 4-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine;
Example A-87 4-[5-(3-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine;
Example A-88 4-[5-(2-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine;
Example A-89 4-[5-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine;
Example A-90 4-[5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine;
Example A-91 4-[5-(4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine;
Example A-92 5-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-carboxamide;
Example A-93 4-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-carboxamide;
Example A-94 4-[5-(3-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-carboxamide;
Example A-95 4-[5-(2-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-carboxamide;
Example A-96 4-[5-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-carboxamide;
Example A-97 4-[5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-carboxamide;
Example A-98 4-[5-(4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-carboxamide;
Example A-99 4-[5-(3-fluoro-4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
Example A-100 4-[5-(4-fluoro-3-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
Example A-101 4-[5-(4-chloro-3-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
Example A-102 4-[5-(2,3-dihydrobenzofuran-6-yl)-3-methyl-1H-pyrazol-4-yl]pyridine;
Example A-103 4-[5-(benzofuran-6-yl)-3-methyl-1H-pyrazol-4-yl]pyridine;
Example A-104 4-[5-(3-fluoro-5-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
Example A-105 4-[5-(3-chloro-5-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
Example A-106 4-[5-(1-cyclohexyen-1-yl)-3-methyl-1H-pyrazol-4-yl]pyridine;
Example A-107 4-[5-(1,3-cyclohexadien-1-yl)-3-methyl-1H-pyrazol-4-yl]pyridine;
Example A-108 4-[5-(5,6-dihydro-2H-pyran-4-yl)-3-methyl-1H-pyrazol-4-yl]pyridine;
Example A-109 4-(5-cyclohexyl-3-methyl-1H-pyrazol-4-yl)pyridine;
Example A-110 4-[5-(4-methoxy-3-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
Example A-111 4-[5-(3-methoxy-4-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
Example A-112 4-[5-(3-methoxy-5-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
Example A-113 4-[5-(3-furanyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
Example A-114 2-methyl-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine;
Example A-115 2-methoxy-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine;
Example A-116 methyl 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine-2-carboxylate;
Example A-117 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine-2-carboxamide;
Example A-118 1-[4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridin-2-yl]ethanone;
Example A-119 N,N-dimethyl-4-(3-methyl-5-phenyl-1H-pyrazol-2-yl)pyridin-2-amine;
Example A-120 3-methyl-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine;
Example A-121 3-methoxy-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine;
Example A-122 methyl 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine-3-carboxylate;
Example A-123 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine-3-carboxamide;
Example A-124 1-[4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridin-3-yl]ethanone;
Example A-125 3-bromo-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine;
Example A-126 N,N-dimethyl-4-(3-methyl-5-phenyl-1H-pyrazol-2-yl)pyridin-3-amine;
Example A-127 2-methyl-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyrimidine;
Example A-128 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyrimidine;
Example A-129 2-methoxy-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyrimidine;
Example A-130 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyrimidin-2-amine;
Example A-131 N,N-dimethyl-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyrimidin-2-amine;
Example A-132 4-(5,6-dihydro-2H-pyran-4-yl)-3-methyl-5-phenyl-1H-pyrazole;
Example A-133 3-methyl-5-phenyl-4-(3-thienyl)-1H-pyrazole;
Example A-134 4-(3-furanyl)-3-methyl-5-phenyl-1H-pyrazole;
Example A-135 3-methyl-5-phenyl-4-(2-thienyl)-1H-pyrazole;
Example A-136 4-(2-furanyl)-3-methyl-5-phenyl-1H-pyrazole;
Example A-137 4-(3-isothiazolyl)-3-methyl-5-phenyl-1H-pyrazole;
Example A-138 4-(3-isoxazolyl)-3-methyl-5-phenyl-1H-pyrazole;
Example A-139 4-(5-isothiazolyl)-3-methyl-5-phenyl-1H-pyrazole;
Example A-140 4-(5-isoxazolyl)-3-methyl-5-phenyl-1H-pyrazole;
Example A-141 3-methyl-5-phenyl-4-(5-thiazolyl)-1H-pyrazole;
Example A-142 3-methyl-4-(5-oxazolyl)-5-phenyl-1H-pyrazole;
Example A-143 2-methyl-4-[3-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine;
Example A-144 4-(1-methyl-3-phenyl-1H-pyrazol-4-yl)pyridine;
Example A-145 4-(3-phenyl-1H-pyrazol-4-yl)pyridine;
Example A-146 2-methyl-4-(3-phenyl-1H-pyrazol-4-yl)pyridine;
Example A-147 4-[3-(3-chlorophenyl)-1-methyl-pyrazol-4-yl]pyridine;
Example A-148 4-[3-(4-chlorophenyl)-1-methyl-pyrazol-4-yl]pyridine;
Example A-149 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]pyridine;
Example A-150 4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]pyridine;
Example A-151 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-2-methylpyridine;
Example A-152 4-[3-(3-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine;
Example A-153 4-[3-(3-fluorophenyl)-1H-pyrazol-4-yl]pyridine; and
Example A-154 4-[3-(3-chlorophenyl)-1-methyl-pyrazol-4-yl]-2-methylpyridine.

The compounds of Examples A-155 through A-172 were synthesized in accordance with the chemistry described above (particularly Scheme II) and illustrated by many of the previously disclosed Examples by selection of the corresponding starting reagents:

EXAMPLE A-155

embedded image

5-(4-chlorophenyl)-N-phenyl-4-(4-pyridinyl)-1H-pyrazol-3-amine: DSC 261 ° C. Anal. Calc'd for C₂₀H₁₅ClN₄+0.25 H₂O (MW 351.32): C, 68.38, H, 4.30, N, 15.95. Found: C, 68.25, H, 4.41, N, 15.74.

EXAMPLE A-156

embedded image

5-(4-chlorophenyl)-N-methyl-4-(4-pyridinyl)-1H-pyrazol-3-amine: DSC 260° C. Anal. Calc'd for C₁₅H₁₃ClN₄+0.125 H₂O (MW 287.00): C, 62.77, H, 4.57, N, 19.52. Found: C, 62.78, H, 4.33, N, 19.22.

EXAMPLE A-157

embedded image

5-(4-chlorophenyl)-N,N-dimethyl-4-(4-pyridinyl)-1H-pyrazol-3-amine dihydrate: DSC 230 ° C. Anal. Calc'd for C₁₆H₁₅ClN₄+2 H₂O (MW 334.81): C, 57.40, H, 4.52, N, 16.73. Found: C, 57.72, H, 4.85, N, 16.54.

EXAMPLE A-158

embedded image

5-(3-fluorophenyl)-N,N-dimethyl-4-(4-pyridinyl)-1H-pyrazol-3-amine: DSC 227 ° C. Anal. Calc'd for C₁₆H₁₅FN₄+0.125 H₂O (MW 284.57): C, 67.53, H, 5.31, N, 19.69. Found: C, 67.60, H, 5.20, N, 19.84.

EXAMPLE A-159

embedded image

N,N-dimethyl-5-(3-methylphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-amine: DSC 222 ° C. Anal. Calc'd for C₁₇H₁₈N₄+0.25 H₂O (MW 282.86): C, 72.19, H, 6.41, N, 19.81. Found: C, 71.99, H, 6.46, N, 19.90.

EXAMPLE A-160

embedded image

N-methyl-5-(3-methylphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-amine: DSC 226 ° C. Anal. Calc'd for C₁₆H₁₆N₄+0.125 H₂O (MW 266.58): C, 72.09, H, 6.05, N, 21.02. Found: C, 72.12, H, 6.12, N, 20.83.

EXAMPLE A-161

embedded image

N-ethyl-5-(3-methylphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-amine: DSC 227° C. Anal. Calc'd for C₁₇H₁₈N₄+0.125 H₂O (MW 280.61): C, 72.77, H, 6.47, N, 19.97. Found: C, 72.63, H, 6.40, N, 19.73.

EXAMPLE A-162

embedded image

N,N-diethyl-5-(3-methylphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-amine: DSC 234° C. Anal. Calc'd for C₁₉H₂₂N₄(MW 306.41): C, 74.48, H, 7.24, N, 18.29. Found: C, 74.12, H, 7.18, N, 18.13.

EXAMPLE A-163

embedded image

5-(4-chlorophenyl)-N,N-diethyl-4-(4-pyridinyl)-1H-pyrazol-3-amine: m.p. 260-261° C. Anal. Calc'd for C₁₈H₁₉ClN₄(MW 326.83): C, 66.15, H, 5.86, N, 17.14. Found: C, 66.03, H, 5.72, N, 17.23.[ text missing or illegible when filed

EXAMPLE A-164

embedded image

4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]morpholine: DSC 279 ° C. Anal. Calc'd for C₁₆H₁₇ClN₄O+0.25 H₂O (MW 345.32): C, 62.61, H, 4.96, N, 16.23. Found: C, 62.52, H, 4.77, N, 16.52.

EXAMPLE A-165

embedded image

5-(4-chlorophenyl)-N-propyl-4-(4-pyridinyl)-1H-pyrazol-3-amine: DSC 244° C. Anal. Calc'd for C₁₇H₁₇ClN₄+0.125 H₂O (MW 315.06): C, 64.81, H, 5.44, N, 17.78. Found: C, 64.94, H, 5.43, N, 17.78.

EXAMPLE A-166

embedded image

Isolated as 5-(4-chlorophenyl)-N-(phenylmethyl)-4-(4-pyridinyl)-1H-pyrazol-3-amine hydrate (2:1): DSC 237° C. Anal. Calc'd for C₂₁H₁₇ClN₄+0.5 H₂O (MW 369.86): C, 68.20, H, 4.63, N, 15.15. Found: C, 68.09, H, 4.55, N, 15.15.

EXAMPLE A-167

embedded image

Isolated as 5-(4-chlorophenyl)-N-(2-methoxyethyl)-4-(4-pyridinyl)-1H-pyrazol-3-amine monohydrate: DSC 223° C. Anal. Calc'd for C₁₇H₁₇ClN₄O+H₂O (MW 346.82): C, 58.87, H, 4.94, N, 16.15. Found: C, 58.59, H, 4.79, N, 16.02.

EXAMPLE A-168

embedded image

1,1-dimethylethyl 4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-i-piperazinecarboxylate: DSC 251° C. Anal. Calc'd for C₂₃H₂₆ClN₅O (MW 439.95): C, 62.79, H, 5.96, N, 15.92. Found: C, 62.40, H, 5.82, N, 15.82.

EXAMPLE A-169

embedded image

Isolated as 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]piperazine trihydrochloride: DSC 99° C. Anal. Calc'd for C₁₈H₁₈ClN₄+3 HCl (MW 449.21): C, 48.13, H, 4.71, N, 15.59. Found: C, 47.76, H, 5.07, N, 15.51.

EXAMPLE A-170

embedded image

1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine: m.p. 247-249° C. Anal. Calc'd for C₁₉H₂₀ClN₅+0.75 H₂O (MW 367.33): C, 62.12, H, 5.49, N, 19.06. Found: C, 62.45, H, 5.86, N, 19.32.

EXAMPLE A-171

embedded image

1,1-dimethylethyl 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazinecarboxylate: m.p. 243-244° C. Anal. Calc'd for C₂₃H₂₆FN₅O₂+0.5 CH₃CH₂CO₂CH₂CH₃(MW 467.55): C, 64.22, H, 6.47, N, 14.98. Found: C, 63.90, H, 6.61, N, 4.88.

EXAMPLE A-172

embedded image

1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]piperazine trihydrochloride: m.p. 204-206° C. Anal. Calc'd for C₁₈H₁₈Fn₅+3 HCl+0.5 H₂O (MW 441.77): C, 48.94, H, 4.79, N, 15.85. Found: C, 48.66, H, 4.88, N, 15.50.

1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]piperazine: m.p. 264-265° C. Anal. Calc'd for C₁₈H₁₈ClN₅+0.125 H₂O (MW 342.08): C, 63.20, H, 5.30, N, 20.47. Found: C, 63.04, H, 5.36, N, 20.33.

Additional compounds that were synthesized in accordance with the chemistry described in Scheme II by selection of the corresponding starting reagents further include the compounds disclosed in Table 2.

TABLE 2GeneralMicroanalysisDSCExampleProcedureFormulaC calcC foundH calcH foundN calcN founddeg C.A-173Sch. IIC24H25ClN6.3HCl.1.5H2O50.6350.584.965.0314.7614.68182A-174Sch. IIC25H24ClN5.0.125H2O69.4769.335.605.5616.2016.11259A-175Sch. IIC17H17FN6.1.25H2O48.6448.454.564.8620.0220.24 82A-176Sch. IIC22H26ClN5O261.7561.576.126.0416.3716.34217A-177Sch. IIC17H18ClN5.3HCl.H2O44.8544.964.654.8715.3815.17220A-178Sch. IIC21H24ClN5O2.0.125H2O60.6160.515.815.8116.8316.64232A-179Sch. IIC25H30ClN5O362.0461.766.256.2514.4714.37220A-180Sch. IIC22H25FN6O2.0.5H2O60.9660.865.816.2119.3919.47N.D.A-181Sch. IIC22H25ClFN5O259.2658.985.655.5515.7115.36210A-182Sch. IIC20H22ClN5.0.75H2O62.9862.975.815.6418.3617.83271A-183Sch. IIC16H19Cl4N5.3HCl45.4145.374.534.74120

EXAMPLE A-173

embedded image

N-[5-(4-chlorophenyl)-4-[2-(phenylmethyl)amino]-4-pyridinyl]-1H-pyrazol-3-yl]-1,3-propanediamine, trihydrochloride

EXAMPLE A-174

embedded image

1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-(phenylmethyl)piperazine

EXAMPLE A-175

embedded image

Isolated as 4-[3-(4-fluorophenyl)-5-(1-piperazinyl)-1H-pyrazol-4-yl]pyrimidine, dihydrochloride

EXAMPLE A-176

embedded image

1,1-dimethylethyl [3-[[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]amino]propyl]carbamate

EXAMPLE A-177

embedded image

Isolated as N-[5-[4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,3-propanediamine, trihydrochloride monohydrate

EXAMPLE A-178

embedded image

1,1-dimethylethyl [2-[[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]amino]ethyl]carbamate

EXAMPLE A-179

embedded image

1,1-dimethylethyl 4-[5-(4-chlorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazinecarboxylate

EXAMPLE A-180

embedded image

1,1-dimethylethyl 4-[5-(4-fluorophenyl)-4-(4-pyrimidinyl)-1H-pyrazol-3-yl]-1-piperazinecarboxylate

EXAMPLE A-181

embedded image

1,1-dimethylethyl [3-[[5-(4-chlorophenyl)-4-(2-fluoro-4-pyridinyl)-1H-pyrazol-3-yl]amino)propyl]carbamate

EXAMPLE A-182

embedded image

1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-ethylpiperazine

EXAMPLE A-183

embedded image

N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,2-ethanediamine

The compounds of Examples A-184 through A-189 were synthesized in accordance with the chemistry described above (particularly in Schemes I and IV) and illustrated by the previously disclosed Examples by selection of the corresponding starting reagents:

EXAMPLE A-184

embedded image

4-[3-(2,6-difluorophenyl)-5-methyl-1H-pyrazol-4-yl]pyridine: Anal. Calc'd for C₁₅H₁₁F₂N₃: C, 66.42; H, 4.09; N, 15.49. Found: C, 66.20; H, 3.94; N, 15.16; m.p. 236.67° C.

EXAMPLE A-185

embedded image

4-[3-(3-ethylphenyl)-5-methyl-1H-pyrazol-4-yl]pyridine: Anal. Calc'd for C₁₇H₁₇N₃: C, 77.54; H. 6.51; N, 15.96. Found; C, 77.16; H. 6.27; N. 15.69. m.p. (DSC): 189.25° C.

EXAMPLE A-186

embedded image

4-[3-(3-chlorophenyl)-5-ethyl-1H-pyrazol-4-yl]pyridine: Anal Calc'd for C₁₆H₁₄ClN₃.0.1 mole H₂O: C, 67.15; H, 4.91; N, 14.33. Found: C, 66.95; H, 5.00; N, 14.36. DSC: 176.18° C.

EXAMPLE A-187

embedded image

4-[3-ethyl-5-(3-ethylphenyl)-1H-pyrazol-4-yl]pyridine: Anal. Calc'd for C₁₈H₁₉N₃.0.1 mole H₂O: C, 77.44; H, 6.93; N, 15.05. Found: C, 77.39; H, 6.94; N, 14.93. m.p. (DSC): 192.66° C.

EXAMPLE A-188

embedded image

4-[3-(4-chlorophenyl)-5-(1-methylethyl)-1H-pyrazol-4-yl]pyridine: Anal. Calc'd for C₁₇H₁₆ClN₂.0.4M EtOAc: C, 67.08; H, 5.81; N, 12.62. Found: C, 67.40; H, 6.15; N, 12.34.

EXAMPLE A-189

embedded image

4-[3-cyclopropyl-5-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine: Anal. Calc'd for C₁₇H₁₄FN₃: C, 73.1; H, 5.05; N, 15.04. Found: C, 73.23; H, 4.89; N, 14.63; m.p.: 239-240° C.

The compound of Example A-190 was synthesized in accordance with the chemistry described above (particularly in Scheme III) and illustrated by the previously disclosed Examples by selection of the corresponding starting reagents:

EXAMPLE A-190

embedded image

4-[3-(4-fluorophenyl)-5-(trifluoromethyl)-1H -pyrazol-4-yl]pyridine

This compound was prepared by the same procedure as described for Example A-22 by replacing 3-(4′-pyridylacetyl)toluene with 1-fluoro-4-(4′-pyridylacetyl) benzene (prepared as set forth in Example A-19).

Anal. Calc'd for C₁₅H₉F₄N₃: C, 58.64; H, 2.95; N, 13.68. Found: C, 58.57; H, 3.07; N, 13.31. m.p. (DSC): 281.94° C.

The compounds of Examples A-191 through A-198 were synthesized in accordance with the chemistry described above (particularly in Scheme V) by selection of the corresponding starting reagents:

EXAMPLE A-191

embedded image

4-[5-(cyclopropyl-3-(4-(fluorophenyl)-1-methyl-1H -pyrazol-4-yl]pyridine

Step 1: Preparation of 1-(4-fluorophenyl)-2-(4-pyridinyl)ethanone methylhydrazone
embedded image

1-(4-fluorophenyl)-2-(4-pyridinyl)ethanone methylhydrazone

To a solution of 4-fluorobenzoyl-4′-pyridinyl methane (8.60 g, 0.04 mol) and methyl hydrazine (2.14 g, 0.044 mol) in 50 mL of ethanol was added two drops of concentrated sulfuric acid. The reaction mixture was stirred at room temperature overnight. After the removal of solvent, the residue was partitioned between ethyl acetate and water. The organic layer was washed with saturated sodium carbonate solution, washed with brine, and dried over magnesium sulfate. The filtrate was concentrated and the crude product was recrystallized from diethyl ether and hexane to afford 7.5 g of a yellow solid product (77% yield), 1-(4-fluorophenyl)-2-(4-pyridinyl)ethanone methylhydrazone.

Step 2: Preparation of 4-[5-(cyclopropyl-3-(4-(fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine

To a solution of sodium hexamethyldisilazide (5.5 mL, 1.0 M in THF) at 0° C. was added a solution of the compound prepared in step 1 (0.67 g, 0.0028 mol) in 10 mL of dry THF dropwise. The dark brown solution was stirred at this temperature for 30 minutes. Then a solution of methyl cyclopropanecarboxylate (0.34 g, 0.0034 mol) in 5 mL of dry THF was added. The reaction mixture was allowed to warm up to room temperature and stirred for 3 hours. Water was added and the aqueous phase was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and purified by chromatography on silica gel (ethyl acetate/hexane/acetone, 10:9:1) to give 0.45 g of product, 4-[5-(cyclopropyl-3-(4-(fluorophenyl)-1-methyl -1H-pyrazol-4-yl]pyridine, as a light yellow solid (55% yield), mp: 129-130° C.; ¹H NMR (CDCL₃): δ8.53 (m, 2H), 7.32 (m, 2H), 7.14 (m, 2H), 6.97 (m, 2H), 4.00 (s, 3H), 1.83 (m, 1H), 0.95 (m, 2H), 0.36 (m, 2H); Anal. Calc'd For C₁₈H₁₆FN₃: C, 73.70; H, 5.50; N, 14.32. Found: C, 73.63; H. 5.57; N, 14.08.

EXAMPLE A-192

embedded image

5-cyclopropyl-3-(4-fluorophenyl)-4-(4-pyridinyl)-1H -pyrazole-1-ethanol

Step 1: Preparation of 1-(4-fluorophenyl)-2-(4-pyridinyl)ethanone (2-hydroxyethyl)hydrazone
embedded image

1-(4-fluorophenyl)-2-(4-pyridinyl)ethanone (2-hydroxyethyl)hydrazone

To a flask containing hydroxyethyl hydrazine (3.4 g, 0.04 mol) at 80° C. was added 4-fluorobenzoyl-4′-pyridinyl methane (8.6 g, 0.04 mol) portionwise. The yellow oil was stirred at this temperature overnight. The cooled reaction mixture was dissolved with hot ethyl acetate and then triturated with hexane to give 8.9 g of product, 1-(4-fluorophenyl)-2-(4-pyridinyl)ethanone (2-hydroxyethyl)hydrazone, as a yellow crystal (81%), mp: 122-123° C.

Step 2: Preparation of 1-(4-fluorophenyl)-2-(4-pyridinyl)ethanone [2-[[(1.1-dimethylethyl)dimethylsilyl]oxy]ethyl]hydrazone
embedded image

1-(4-fluorophenyl)-2-(4-pyridinyl)ethanone (2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]hydrazone

To a solution of the 1-(4-fluorophenyl)-2-(4-pyridinyl)ethanone (2-hydroxyethyl)hydrazone prepared in step 1 (2.73 g, 0.01 mol) and (1,1-dimethylethyl)dimethylsilyl chloride (1.5 g, 0.01 mol) in 25 mL of DMF was added imidazole portionwise. The reaction mixture was stirred at room temperature overnight. Water was added and extracted with ethyl acetate, the organic layer was washed with water, washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated to give 3.8 g of crude product, 1-(4-fluorophenyl)-2-(4-pyridinyl)ethanone [2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]hydrazone, as a yellow oil that was used in the next step without further purification.

Step 3: 5-cyclopropyl-1-[2-[[(1,1-dimethylethyl) dimethylsilyl]oxy]ethyl)-3,4-diphenyl-1H-pyrazole
embedded image

3: 5-cyclopropyl-1-[2-[[(1,1-dimethylethyl) dimethylsilyl]oxy]ethyl)-3,4-diphenyl-1H-pyrazole

To a solution of sodium hexamethyldisilazide (4.2 mL, 1.0 M in THF) at 0° C. was added a solution of the compound prepared in step 2 (0.78 g, 0.002 mol) in 10 mL of dry THF dropwise. The dark brown solution was stirred at this temperature for 30 minutes. Then a solution of methyl cyclopropanecarboxylate (0.27 g, 0.0026 mol) in 5 mL of dry THF was added. The reaction mixture was allowed to warm up to room temperature and stirred for 3 hours. Water was added and the aqueous phase was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and purified by chromatography on silica gel (ethyl acetate/hexane, 3:7) to give 0.30 g of product, 5-cyclopropyl-1-[2-[[(1,1-dimethylethyl) dimethylsilyl]oxy]ethyl)-3,4-diphenyl-1H -pyrazole, as a light yellow oil (35% yield), ¹H NMR (CDCL₃): δ8.53 (m, 2H), 7.32 (m, 2H), 7.14 (d, J=5.6 Hz, 2H), 6.97 (m, 2H), 4.47 (t, J=4.8 Hz, 2H), 4.14 (t, J=4.8 Hz, 2H), 1.93 (m, 1H), 0.95 (m, 2H), 0.87 (s, 9H), 0.41(m, 2H); Anal. Calc'd For C₂₅H₃₂FN₃OSi: C, 68.61; H, 7.37; N, 9.60. Found: C, 68.39; H, 7.81; N, 9.23.

Step 4: Preparation of 5-cyclopropyl-3-(4-fluorophenyl) -4-(4-pyridinyl)-1H-pyrazole-1-ethanol

To a solution of the compound prepared in step 3 (0.27 g, 0.00062 mol) in 5 mL of THF was added tetrabutylammonium fluoride (1.9 mL of 1.0 M THF solution) at room temperature. After 1 hour, water was added and extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and purified by chromatography on silica gel (ethyl acetate/hexane, 9:1) to give 0.16 g of product, 5-cyclopropyl-3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol, as a pale yellow solid, mp: 155-157° C.; ¹H NMR (CDCL₃): δ8.53 (br s, 2H), 7.32 (m, 2H), 7.14 (d, J=5.6 Hz, 2H), 6.97 (m, 2H), 4.42 (t, J=4.8 Hz, 2H), 4.14 (t, J=4.8 Hz, 2H), 1.83 (m, 1H), 0.93 (m, 2H), 0.35 (m, 2H); Anal. Calc'd For C₁₉H₁₈FN₃O: C, 70.57; H, 5.61; N. 12.99. Found: C, 70.46; H, 5.87; N, 12.84.

EXAMPLE A-193

embedded image

3-(4-fluorophenyl)-5-(2-methoxy-4-pyridinyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol

To a solution of sodium hexamethyldisilazide (7.4 mL, 1.0 M in THF) at 0° C. was added a solution of the compound prepared in step 2 of Example A-192 (1.25 g, 0.0034 mol) in 15 mL of dry THF dropwise. The dark brown solution was stirred at this temperature for 30 minutes. Then a solution of methyl 4-(2-methoxy)pyridinecarboxylate (0.0.59 9, 0.0035 mol) in 5 mL of dry THF was added. The reaction mixture was allowed to warm up to room temperature and stirred for 3 hours. Water was added and the aqueous phase was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and purified by chromatography on silica gel (ethyl acetate/hexane, 1:1) to give 0.28 g of product, 3-(4-fluorophenyl)-5-(2-methoxy-4-pyridinyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol, as a yellow solid, mp: 168-169° C.; ¹H NMR (CDCL₃): δ8.42 (m, 2H), 8.20 (dd, J=0.7, 5.2 Hz, 1H), 7.37 (m, 2H), 7.02 (m, 2H), 6.95 (m, 2H), 6.71 (dd, J=1.4, 5.2 Hz, 1H), 6.66 (t, J=0.7 Hz, 1H), 4.20 (m, 2H), 4.14 (m, 2H), 3.95 (s, 3H); Anal. Calc'd for C₂₂H₁₉FN₄O₂: C, 67.86; H, 4.91; N, 14.35. Found: C, 67.46; H, 5.08; N, 14.03.
embedded image

4-[1-[2-[[(1,1-dimethylethyl)dimethylsilyl]-oxy]ethyl]-3-(4-fluorophenyl-4-(4-pyridinyl)-1H-pyrazol-5-yl]-2-methoxypyridine

A second compound, 4-[l-[2-[[(1,1-dimethylethyl) dimethylsilyl]oxy]ethyl]-3-(4-fluorophenyl-4-(4-pyridinyl)-1H-pyrazol-5-yl]-2-methoxypyridine also was isolated from the above reaction as a yellow oil by chromatography. ¹H NMR (CDCL₃): δ8.45 (m, 2H), 8.20 (m, 1H), 7.40 (m, 2H), 7.04 (m, 2H), 6.93 (m, 2H), 6.81 (m, 2H), 4.24 (m, 2H), 4.14 (m, 2H), 3.98 (s, 3H), 0.83 (s, 9H), 0.02 (s, 6H).

EXAMPLE A-194

embedded image

4-(3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]-2(1H)-pyridinone

To a solution of 3-(4-fluorophenyl)-5-(2-methoxy-4-pyridinyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol (0.28 g, 0.0006 mol) in 5 mL of acetic acid was added 3 mL of 48% hydrobromic acid. The reaction mixture was heated at reflux for 3 hour. The cooled mixture was then treated with water, basified with ammonium hydroxide and extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and purified by chromatography on silica gel (MeOH/CH₂Cl₂/NH4OH, 5:94:1) to give 0.07 g of product, 4-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]-2(1H)-pyridinone, as a yellow solid (32% yield), mp: 250-251° C; ¹H NMR (DMSO-d₆): δ11.74 (s, 1H), 8.45 (d, J=5.0 Hz, 2H), 7.35 (m, 3H), 7.16 (m, 2H), 7.03 ( d, J=5.0 Hz, 2H), 6.37 (s, 1H), 6.05 (d, J=5.2 Hz, 1H), 5.0 (m, 1H), 4.13 (m, 2H), 3.81 (m, 2H); Anal. Calc'd for C₂₁H₁₇FN₄O₂.0.2 H₂O: C, 66.06; H, 4.65; N, 14.67. Found: C, 66.31; H, 4.49; N, 14.27.

EXAMPLE A-195

embedded image

1-acetyl-4-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]-2(1H)-pyridinone

1-acetyl-4-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]-2(1H)-pyridinone was obtained as a by product of the reaction of Example A-194 in the form of a yellow solid (38% yield), mp: 220-221° C.; ¹H NMR (CDCl₃): δ8.50 (m, 2H), 7.39 (m, 3H), 7.02 (m, 4H), 6.59 (m, 1H) 6.08 (dd, J=1.4, 5.2 Hz, 1H), 4.52 (t, J=6.0 Hz, 2H), 4.43 (t, J=6.0 Hz, 2H), 2.04 (s, 3H); Anal. Calc'd for C₂₃H₁₉FN₄O₃.0.3 H₂O: C, 65.46; H, 4.63; N, 13.28. Found: C, 65.09; H, 4.64; N, 12.99.

EXAMPLE A-196

embedded image

Ethyl 2-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]cyclopropanecarboxylate

To a solution of sodium hexamethyldisilazide (17.0 mL, 1.0 M in THF) at 0° C. was added a solution of the compound prepared in step 1 of Example A-192 (1.37 g, 0.005 mol) in 20 mL of dry THF dropwise. The dark brown solution was stirred at this temperature for 30 minutes. Then a solution of diethyl 1,2-cyclopropanedicarboxylate (1.12 g, 0.006 mol) in 10 mL of dry THF was added. The reaction mixture was allowed to warm up to room temperature and stirred for 2 hours. Water was added and the aqueous phase was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and purified by chromatography on silica gel (ethyl acetate/hexane, 8:2) to give 0.18 9 of product, ethyl 2-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]cyclopropanecarboxylate, as a light yellow oil (35% yield), ¹H NMR (CDCL₃): δ8.55 (m, 2H), 7.32 (m, 2H), 7.11 (m, 2H), 6.97 (m, 2H), 4.38 (m,2H), 4.16 (m, 4H), 2.47 (m, 1H), 1.53 (m, 2H), 1.26 (t, J=7.0 Hz, 3H), (m, 2H), 0.90 (m, 2H); Anal. Calc'd for C₂₂H₂₂FN₃O₃.0.25 H₂O: C, 66.07; H, 5.67; N, 10.51 Found: C, 65.89; H, 5.80; N, 9.95.

EXAMPLE A-197

embedded image

2-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]cyclopropanecarboxylic acid

To a solution of ethyl 2-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl] cyclopropanecarboxylate prepared in accordance with Example A-196 (0.21 g, 0.00045 mol) in 10 mL of methanol was added a solution of sodium hydroxide (0.09 g, 0.0022 mol) in 2 mL of water. The reaction mixture was stirred at reflux for 6 hours. After the solvent was removed, the residue was dissolved with 10 mL of 1N HCl and stirred for 30 minutes. The pH was then adjusted to 5-6 by addition of 1N sodium hydroxide solution and then extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium and filtered. The filtrate was concentrated and the crude was purified by recrystallization from ethanol and ether to give 0.1 g of product, 2-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]cyclopropanecarboxylic acid, as a white solid (60% yield), mp: 253-255° C.; ¹H NMR (CD₃OD):b 8.46 (m, 2H), 7.32 (m, 2H), 7.25 (m, 2H), 7.04 (m, 2H), 4.39 (t, J=5.0 Hz, 2H), 4.03 (m, 2H), 2.60 (m, 1H), 1.51 (m, 2H), 0.97 (m, 2H); Anal. Calc'd For C₂₀H₁₈FN₃O₃: C, 65.39; H, 4.94; N, 11.44. Found: C, 64.92; H, 4.77; N, 11.20.

EXAMPLE A-198

embedded image

3-(4-fluorophenyl)-5-(4-imidazolyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol

Step 1: Preparation of methyl 1-r[2-(trimethylsilyl) ethoxylmethyl]-1H-pyrrole-3-carboxylate
embedded image

methyl 1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-pyrrole-3-carboxylate

To a suspension of sodium hydride (1.0 g, 0.025 mol) in 50 mL of DMF was added methyl 4-imidazolecarboxylate (2.95 g, 0.023 mol) portionwise at room temperature. The mixture was stirred at room temperature for 0.5 hours. Then SEM-CL (4.17 g, 0.025 mol) was added dropwise over 5 minutes. The reaction mixture was stirred for 4 hours and quenched by adding water. The aqueous phase was extracted with ethyl acetate and the organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and the crude was purified by chromatography on silica gel (ethyl acetate/hexane, 8:2) to give 4.0 g of the major regioisomer as a clear oil.

Step 2: Preparation of 4-[1-[2-[[(1,1-dimethylethyl) dimethylsilyl]oxy]ethyl]-3-(4-fluorophenyl-5-[1-[[(2-trimethysilyl)ethoxy]methyl-1H-imidazole-4-yl]-1H-pyrazol -4-yl]pyridine
embedded image

4-[1-[2[[(1,1-dimethylethyl)dimethylsilyl]-oxy]ethyl]-3-(4-fluorophenyl)-5-[1-[[2-trimethylsilyl)ethoxy]methyl]-1H-imidazole-4-yl]-1H -pyrazol-4-yl]pyridine

To a solution of sodium hexamethyldisilazide (4.5 mL, 1.0 M in THF) at 0° C. under Ar was added a solution of the compound prepared in step 2 of Example A-192 (0. 8 g, 0.002 mol) in 10 mL of dry THF dropwise. The dark brown solution was stirred at this temperature for 30 minutes. Then a solution of the compound prepared in step 1 of the present Example (0.54 g, 0.0021 mol) in 5 mL of dry THF was added. The reaction mixture was allowed to warm up to room temperature and stirred for 1 hour. Water was added and the aqueous phase was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and purified by chromatography on silica gel (ethyl acetate/hexane, 8:2) to give 0.98 g of product as a light yellow oil which solidified upon standing (91% yield), mp: 79-80° C.; ¹H NMR (CDCL₃): δ8.48 (d, J=6.0 Hz, 2H), 7.68 (d, J=1.3 Hz, 1H), 7.38 (d, J=6.0 Hz, 2H), 7.10 (m, 2H), 7.00 (m, 2H), 6.93 (d, J=1.3 Hz , 1H), 5.25 (s, 2H), 4.53 (t, J=6.0 Hz, 2H), 4.12 (t, J=6.0 Hz, 2H), 3. 84 (t, J=8.0 Hz , 2H), 0.92 (t, J=8.0 Hz, 2H), 0.84 (s, 9H), 0.021 (s, 18H); Anal. Calc'd For C₃₁H₄₄FN₅O₂Si₂: C, 62.70; H, 7.47; N, 11.79. Found: C, 62.98; H, 7.74; N, 11.88.

Step 3: Preparation of 3-(4-fluorophenyl)-5-(4-imidazolyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol

To a solution of the compound prepared in step 2 of the present Example (0.54 g, 0.001 mol) in 10 mL of THF was added a solution of tetrabutylammonium fluoride (1.0M in THF). After the mixture was heated at reflux for 3 hours, the solvent was removed and the residue was partitioned between ethyl acetate and water. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and the crude product was purified on silica gel (methylene chloride/methanol, 95:5) to give 0.22 g of the product, 3-(4-fluorophenyl)-5-(4-imidazolyl) 4-(4-pyridinyl)-1H -pyrazole-1-ethanol, as a white solid (63% yield), mp: 227-228° C; ¹H NMR (DMSO-d₆): δ8.45 (m, 2H), 7.83 (s, 1H), 7.35 (m, 2H), 7.15 (m, 4H), 7.09 (s, 1H), 5.20 (br s, 1H), 4.32 (s, 2H), 3.81 (m, 2H); Anal. Calc'd For C₁₉H₁₆FN₅O: C, 65.32; H, 4.62; N, 20.05. Found: C, 64.98; H, 4.55; N, 19.79.

The compound of Example A-199 was synthesized in accordance with the chemistry described above (particularly in Scheme VI) by selection of the corresponding starting reagents:

EXAMPLE A-199

embedded image

4-[3-(4-chloro-3-methylphenyl)-1H-pyrazol-4-yl]pyridine

Anal. Calc'd for C₁₅H₁₂N₃Cl (269.74): C, 66.79; H, 4.48; N, 15.58. Found: C, 66.57; H, 4.15; N, 15.54. m.p. (DSC): 198.17° C.

The compounds of Examples A-200 through A-202 were synthesized in accordance with the chemistry described above (particularly in Scheme VII) by selection of the corresponding starting reagents:

EXAMPLE A-200

embedded image

5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-3-carboxylic acid

A mixture of 4-[3-(4-fluorophenyl)-5-methyl-1H-pyrazol-4-yl]pyridine prepared as set forth in Example A-4 (5.83 g, 24.0909 mmol) and potassium permanganate (7.6916 g, 48.1818 mmol) in water (7.5 ml) and tert-butanol (10 ml) was heated at reflux for 6 hours (or until all the potassium permanganate was consumed). The mixture was then stirred at room temperature overnight and then diluted with water (150 ml). Manganese dioxide was removed from the mixture by filtration. The filtrate was extracted with ethyl acetate to remove unreacted starting material. The aqueous layer was acidified with 1N HCl to increase the pH to about 6. A white precipitate formed, was collected by filtration, washed with water, and dried in a vacuum oven to give 5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-3-carboxylic acid (isolated as the monohydrate salt)(2.9777 g, 43.7 %). Anal. Calc'd for C₁₅H₁₀N₃FO₂. H₂O (283+18): C, 59.80; H, 4.01; N, 13.95; Found: C, 59.48; H, 3.26; N, 13.65. MS (MH^+):284 (base peak).

EXAMPLE A-201

embedded image

5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-3-methanol

To a suspension of 5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-3-carboxylic acid, monohydrate prepared in accordance with Example A-200 (0.526 g, 2.0 mmol) in dry THF (15 ml) at reflux under nitrogen, a solution of 1N lithium aluminum hydride in THF (4.0 ml, 4.0 mmol) was added dropwise over 15 minutes. A precipitate formed. The mixture was boiled for an additional hour. Excess lithium aluminum hydride was then decomposed by cautiously adding a solution of 4N potassium hydroxide in water (0.5 ml). Upon hydrolysis, a white salt precipitated. After the addition was complete, the mixture was heated at reflux for 15 minutes. The hot solution was filtered by suction through a Buchner funnel, and remaining product was extracted from the precipitate by refluxing with THF (15 ml) for 1 hour, followed again by suction filtration. The combined filtrates were concentrated under reduced pressure. The resulting residue was taken into ethyl acetate, washed with water and brine, dried over MgSO, to give a crude product (0.45 g). Recrystallization of the crude product from methanol gave 5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-3-methanol (0.2808 g, 56.5%). DSC: 260.26° C.; Anal. Calc'd for C₁₅H12N₃FO (269): C, 66.91; H, 4.49; N, 15.60; Found: C, 66.07; H, 4.63; N, 15.20. MS (MH^+):270 (base peak).

EXAMPLE A-202

embedded image

1-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl)piperazine

Step 1: Preparation of 1,1-dimethylethyl 4-E r5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]-1-piperazinecarboxylate
embedded image

To a solution of 5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-3-carboxylic acid, monohydrate prepared in accordance with Example A-200 (0.9905 g, 3.5 mmol) and 1-hydroxybenzotriazole (0.4824 g, 3.57 mmol) in DMF (20 ml) at 0° C. under nitrogen, 1-(3-dimethylaminopropyl)3-ethylcarbodiiminde hydrochloride (0.6984 g, 3.57 mmol, Aldrich Chemical Co.) was added. The solution was stirred at 0° C. under nitrogen for 1 hour then 1-butoxycarbonylpiperazine (0.6585 g, 3.5 mmol) was added followed by N-methylmorpholine (0.40 ml, 3.6 mmol). The reaction was stirred from 0° C. to room temperature overnight. After 19 hours, the solvent was removed under reduced pressure, and resulting residue was diluted with ethyl acetate, washed with saturated NaHCO₃solution, water and brine, and dried over MGSO₄. After filtration, the solvent was removed under reduced pressure to give a crude product (1.7595 g). 1,1-Dimethylethyl 4-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl)carbonyl]-1-piperazinecarboxylate (1.2372 g, 78.4%) was obtained by chromatography. Anal. Calc'd for C₂₄H₂₆N₅O₃F. (451): C, 63.85; H, 5.80; N, 15.51; Found: C, 63.75; H, 5.71; N, 15.16. MS (MH+): 452 (base peak).

Step 2: Preparation of 1-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl[carbonyl]piperazine bis(trifluoroacetate), monohydrate

A solution of the compound prepared in step 1 (0.1804 g, 0.4 mmol) in methylene chloride (1.0 ml) and TFA ( 0.3 ml) was stirred at room temperature under nitrogen for 2 hours. The solvent was removed under reduced pressure and TFA was chased by methylene chloride and methanol. The resulting colorless oily residue was dried in a vacuum oven overnight to give 1-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]piperazine (isolated as the bis(trifluoroacetate), monohydrate salt) (0.2400 g, 100%) as a white solid. Anal. Calc'd for C₁₉H₁₈N₅OF.2CF₃COOH.H₂O(351+228+18): C, 46.24; H, 3.71; N, 11.72; Found: C, 45.87; H, 3.43; N, 11.45. MS (MH+) 352 (base peak).

The compounds of Examples A-203 through A-206 were synthesized in accordance with the chemistry described above (particularly in Scheme VIII) by selection of the corresponding starting reagents:

EXAMPLE A-203

embedded image

4-(1,5-dimethyl-3-phenyl-1H-pyrazol-4-yl)pyridine

embedded image

4-(1,3-dimethyl-5-phenyl-1H-pyrazol-4-yl]pyridine

A 60% dispersion of sodium hydride (41 mg, 0.00172 moles)(prewashed with hexane) in mineral oil (69 mg) was added with 5 ml of dioxane to a stirred solution of 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine (200 mg, 0.00086 moles) (prepared as set forth in Example A-2) in 50 ml of dioxane. After 3 hours a solution of CH₃I (122 mg, 0.00086 mole) in 10 ml dioxane was added and the mixture was stirred at room temperature for 20 hours. The mixture was concentrated to a solid. The products were partitioned between water (15 ml) and ethyl acetate (50 ml). The organic layer was dried over Na₂SO₄, filtered and concentrated to a solid. The products were purified and separated by radial chromatography. NMR (NOE experiments) showed that the first component off the column (the minor component) was 4-(1,3-dimethyl-5-phenyl-1H-pyrazol-4-yl]pyridine, and the second material off the column was 4-(1,5-dimethyl-3-phenyl-1H-pyrazol-4-yl)pyridine.

Major isomer (4-(1,5-dimethyl-3-phenyl-1H-pyrazol-4-yl)pyridine): m.p.: 94-99° C. Anal. calc'd for C₁₆H₁₅N₃.0.1MH₂O: C, 77.08; H, 6.06; N, 16.85. Found: C, 76.59; H, 5.70; N, 16.62.

EXAMPLE A-204

embedded image

4-[3-(4-chlorophenyl)-1,5-dimethyl-1H-pyrazol-4-yl]pyridine

embedded image

4-[5-(4-chlorophenyl)-1,3-dimethyl-1H-pyrazol-4-yl]pyridine (the compound of Example A-32)

4-[3-(4-chlorophenyl)-1,5-dimethyl-1H-pyrazol-4-yl]pyridine and 4-[5-(4-chlorophenyl)-1,3-dimethyl-1H-pyrazol-4-yl]pyridine were prepared by the same procedure as described for Example A-203 by replacing 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine with 4-(3-(4-chlorophenyl)-5-methyl-1H-pyrazol-4-yl)pyridine (prepared as set forth in Example A-7).

Major Isomer (4-[3-(4-chlorophenyl)-1,5-dimethyl-1H-pyrazol-4-yl]pyridine): Anal. calc'd for C₁₆H₁₄N₃Cl (283.76): C, 67.72; H, 4.97; N, 14.81; Found: C, 67.45; H, 4.71; N, 14.63. m.p. (DSC): 190.67° C.

Minor Isomer (4-[5-(4-chlorophenyl)-1,3-dimethyl-1H-pyrazol-4-yl]pyridine): m.p.: 82-88° C. Anal. calc'd for C₁₆H₁₄N₃Cl: C, 67.72; H, 4.97; N, 14.81; Found: C, 67.56; H, 4.96; N, 14.73.

EXAMPLE A-205

embedded image

4-[5-ethyl-1-methyl-3-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine

embedded image

4-[3-ethyl-1-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine

4-[5-ethyl-1-methyl-3-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine and 4-[3-ethyl-1-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine were prepared by the same procedure as described for Example A-203 by replacing 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine with 4-(3-(4-methylphenyl)-5-ethyl-1H-pyrazol-4-yl)pyridine (prepared as set forth in Example A-45).

Major Isomer (4-[5-ethyl-1-methyl-3-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine): Anal. Calc'd for C₁₈H₁₉NO₃.0.45 MH₂O: C, 75.73; H, 7.03; N, 14.77. Found: C, 76.03; H, 6.87 N, 14.28.

Minor Isomer (4-[3-ethyl-1-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine): Anal. Calc'd for C₁₈H₁₉NO₃.0.3MH₂O: C, 76.46; H, 6.99; N, 14.86. Found: C, 76.58; H, 6.98; N, 14.63.

EXAMPLE A-206

embedded image

4-[3-(4-chlorophenyl)-1-ethyl-5-methyl-1H-pyrazol-4-yl]pyridine: Anal. Calc'd for C₁₇H₁₆N₃Cl (297.79): C, 68.57; H. 5.42; N, 14.11. Found: C, 68.33; H, 5.27; N, 14.08; m.p. (DSC) 164.36° C.
EXAMPLE A-207

embedded image

4-[3-(4-chlorophenyl)-2-ethyl-5-methyl-1H-pyrazol-4-yl]pyridine: Anal. Calc'd for C₁₇H₁₆N₃Cl (297.79): C, 68.57; H, 5.42; N, 14.11. Found: C, 68.25; H, 5.36; N, 13.74; m.p. (DSC) 153.46° C.

The compounds of Examples A-208 and A-209 were prepared in accordance with the chemistry described above (particularly in Scheme IX):

EXAMPLE A-208

embedded image

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl] pyridine

Step 1: Preparation of 4-fluorobenzoyl-4′-pyridyl methane

To a mixture of 4-picoline (32.6 g, 0.35 moles) and ethyl-4-fluorobenzoate (50.45 g, 0.3 moles), maintained at 20° C., was added lithium bis(trimethylsilylamide) (600 mL (1M)) in a steady but rapid stream so as to maintain ambient temperature. The initial yellow solution turned into a suspension which was then stirred for an additional 2 hours. Toluene (250 mL) was added and the mixture cooled to 0° C. The reaction mixture was quenched with concentrated HCl at 0° C. to lower the pH to about 7. The organic layer was separated and the aqueous layer re-extracted with of toluene (100 mL). The organic layer was dried (sodium sulfate) and concentrated, to furnish a yellow solid which on trituration with hexanes (200 mL) provided the pure desoxybenzoin, 4-fluorobenzoyl-4′-pyridyl methane, in 90% yield (58 g). ₁H NMR was consistent with the proposed structure.

Step 2:

To a suspension of the desoxybenzoin prepared in step 1 (30 g, 0.14 moles) in tetrahydrofuran (50 mL) was added dimethylformamide dimethyl acetal (50 mL) and the mixture stirred at ambient temperature for two days. The solution was then concentrated to dryness and the solid paste obtained was triturated with hexanes (150 mL) to furnish a yellow solid which was of sufficient purity (as determined by NMR) and was used for the next step without additional purification. Yield: 33.9 g (90%). ¹H NMR was consistent with the proposed structure.

Step 3:

The vinyl amine prepared in step 2 (33.9 g, 0.1255 moles) was dissolved in 125 mL of ethanol and cooled to 0° C. Hydrazine hydrate (8.0 g of anhydrous or 16.0 g. of hydrate, 0.25 moles) was then added in one portion. The mixture was stirred well and allowed to warm up to ambient temperature for a total reaction time of 3 hours. The mixture was concentrated and taken up in 200 mL of chloroform. After washing with water (100 mL), the organic layer was extracted with 150 mL of 10% HC1. The water layer was then treated with 0.5 g of activated charcoal at 70° C. for 10 minutes, filtered through celite and neutralized cautiously to pH 7-8 with vigorous stirring and cooling (20% sodium hydroxide was used). The fine off-white precipitate was filtered and dried to give 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl)pyridine. Yield: 27.3 g. (91%). Mass spectrum: m/z=240. ¹H NMR was consistent with the proposed structure. Anal. calc'd for C₁₄H₁₀FN₃: C, 70.28; H, 4.21; N, 17.56. Found: C, 70.11; H, 4.33; N, 17.61.

EXAMPLE A-209

embedded image

4-[3-(2-chlorophenyl)-1H-pyrazol-4-yl]pyridine

This compound was prepared by the same procedure described for Example A-208 using the corresponding starting reagents.

Anal. Calc'd for C₁₄H₁₀ClN₃: C, 65.76; H, 3.94; N, 16.43. Found: C, 65.22; H, 3.91; N, 16.50. m.p. (DSC): 208.46° C.

The compounds of Examples A-210 and A-211 illustrate were prepared in accordance with the chemistry described above (particularly in Scheme X):

EXAMPLE A-210

embedded image

3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol

The desoxybenzoin prepared in step 1 of Example A-208, 4-fluorobenzoyl-4′-pyridyl methane, (12.79, 0.059 moles) was mixed with 90% hydroxyethyl hydrazine (5.3 g, 0.062 moles) in 30 mL of ethanol containing 0.5 mL of acetic acid in a 500 mL Erlenmeyer flask. After gentle boiling (1 hour), a small sample was evacuated at high vacuum and examined by ¹H NMR to confirm completion of hydrazone formation. On cooling to ambient temperature, the reaction mass solidified to a yellow cake. DMF dimethylacetal (36 mL, 0.27 moles) was then added and the mixture heated to 80° C. for 10 min, at which point all the solids dissolved and a clear yellow viscous solution was obtained. The reaction mixture was immediately allowed to cool slowly to 25° C., and water (20 mL) was added dropwise with stirring, at which point a cloudy yellow oily suspension was obtained. The solution was now warmed to approximately 50-60° C., whereupon the solution turned clear yellow. Slow cooling to ambient temperature with stirring (a crystal seed if available speeds up the process) results in a copious formation of crystals. Suction filtration followed by washing with 10% ethanol-water (50 mL), followed by drying, furnishes 3(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol as a light yellow crystalline solid. Re-heating the filtrate to clarity as before, followed by cooling, yields additional product. The third and fourth recovery from the mother liquor on standing overnight furnishes the remaining 3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol. Total yield: {12.3+3.3+0.4+0.4}=16.4 g. (97.6%). Mass spectrum, m/z=284. ¹H NMR was consistent with the proposed structure. Anal. calc'd for C₁₆H₁₄FN₃O+H₂O: C, 63.78; H, 5.35; N, 13.95. Found: C, 63.55; H, 5.07; N, 13.69.

EXAMPLE A-211

embedded image

3-(4-fluorophenyl)-4-(4-pyrimidinyl)-1H-pyrazole-1-ethanol

This compound was prepared by the same procedure as described for Example A-210 except that the 4-picoline used to synthesize the desoxybenzoin was replaced with 4-methyl-pyrimidine.

The compound of Example A-212 was prepared in accordance with the chemistry of Scheme XI:

EXAMPLE A-212

embedded image

4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine

The vinyl amine prepared in

Step 2 of Example A-208 (5.0 g, 0.0185 moles) was taken up in ethanol (75 mL) and cooled to 0° C. Methyl hydrazine (1.7 g, 0.037 moles) in ethanol (75 mL) was added in one portion while maintaining the temperature at 0 to 10° C. After 3 hours at ambient temperature the solvent was removed and the residue taken up in methylene chloride (150 mL) and water (100 mL). The organic layer was separated, dried and concentrated to provide the crude regio-isomeric mixture as a light tan colored solid (80:20 by NMR in favor of the title compound). The crude isomeric mixture was taken up in 10% HCl (100 mL) and washed with methylene chloride (100 mL) and the water layer treated with activated charcoal (0.5 g). After filtration through Celite, the solution was neutralized with sodium hydroxide (20%) to pH 8 with good stirring and cooling. The cream colored precipitate was filtered, washed with water and dried. The solid (5 g) was dissolved in hot 10% heptane/toluene (70 mL) and allowed to cool slowly, first to ambient temperature and then to 15° C. Scratching the sides of the flask starts the crystallization process. After 2 hours of standing, the solids formed were filtered, washed with cold 50% toluene/heptane (25 mL) followed by hexane (25 mL) and dried to yield the pure title compound. ¹H NMR confirmed the structure (including regiochemistry using NOE experiments). Yield: 2. 1 g. (45%). Mass spectrum, m/z=254 (base peak). Anal. calc'd for C₁₅H₁₂FN₃+0.2 H₂O: C, 70.15; H, 4.86; N, 16.4. Found: C, 70.18; H, 4.6; N, 16.47.

The compound of Example A-213 was prepared in accordance with the chemistry of Scheme XII:

EXAMPLE A-213

embedded image

2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-1-butanol

An intimate mixture of 2-fluoro-pyridinyl pyrazole (0.2 g, (prepared by the same procedure as described for Example A-210 except that the 4-picoline used to synthesize the desoxybenzoin was replaced with 2-fluoro-4-methylpyridine) and (R,S)-2-amino-1-butanol (4 fold molar excess) was heated to 210-220° C. in a sealed vial for 1.5 hours. After cooling to 100° C. the vial was cautiously opened and 5 mL of toluene and 5 mL of water were added and stirred well for 1 hour. The solid obtained, 2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-1-butanol, was suction-filtered and washed with an additional 5 mL of water followed by toluene and dried. Yield: 190mg. (71%). Mass spectrum, m/z 343. ¹H NMR was consistent with the proposed structure.

The compound of Example A-214 was prepared in accordance with the chemistry of Scheme XIII:

EXAMPLE A-214

embedded image

4-[5-bromo-3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine

To a solution of 4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine (2.7 g, 10.67 mmol) (prepared in accordance with Example A-212) in acetic acid (30 mL) and DMF (13 mL) was added bromine (19.5 g, 122.0 mmol). The solution was heated at 80° C. overnight. TLC indicated that the reaction was complete. The mixture was quenched slowly with K₂CO₃(25 g). When pH was about 5, a precipitate was formed. The precipitate was washed with water (50 mL×5) to give 4-[5-bromo-3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine (1.24 g, 35%): mp 174.38° C.; Mass spectrum m/z=332, 334; ¹H NMR was consistent with the proposed structure. Anal. Calc'd for C₁₅H₁₁N₃FBr.0.2 H₂O: C, 53.66; H, 3.42; N, 12.51. Found: C, 53.58; H. 3.12;, N, 12.43.

The compound of Example A-215 was prepared in accordance with the chemistry of Scheme XIV:

EXAMPLE A-215

embedded image

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarbonitrile

Step 1:

To a solution of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine (4.3 g, 17.97 mmol) (prepared in accordance with Example A-208) in methanol (100 mL) was added 3-chloroperoxybenzoic acid (5.44 g in 57 % purity, 17.97 mmol). The solution was stirred at 25° C. for overnight. The mixture was concentrated. K₂CO₃(10%, 100 mL) was added to the residue. A precipitate was formed, filtered and washed with water (30 mL×3) to give the corresponding N-oxide (3.764 g, 81.66%).

Step 2:

To a suspension of the N-oxide prepared in step 1 (0.40 g, 1.567 mmol) in DMF (5 mL) was added trimethysilyl cyanide (0.3 mL, 2.25 mmol). The mixture was stirred for 15 minutes at 25° C. Dimethylcarbamyl chloride (0.8 mL, 8.69 mmol) was added. The mixture was stirred at 25° C. for 2 hours. TLC indicated that the starting materials were gone. The mixture was partitioned into ethyl acetate:water (100 mL:20 mL). The organic layer was washed with K₂CO₃(10%, 20 mL), water (50 mL), brine (50 mL), dried over MgSO₄, filtered and concentrated to give 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarbonitrile (0.23 g, 56 % yield): mp 209.22° C ; Mass spectrum (chemical ionization): m/z=265; ¹H NMR was consistent with the proposed structure. Anal. Calc'd for C₁₅H₉N₄Fe.0.2 H₂O: C, 67.26; H, 3.54; N, 20.92. Found: C, 67.44; H, 3.40; N, 20.69.

The compound of Example A-216 was prepared in accordance with the chemistry of Scheme XV:

EXAMPLE A-216

embedded image

4-[2-[3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-1-yl]ethyl]morpholine

Step 1:

3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol (prepared in accordance with Example A-210) (10.0 g, 0.0353 moles) was suspended in pyridine (100 mL) and cooled to 0° C. Methane sulfonyl chloride (4.4 g, 0.0388 moles) was added slowly while maintaining the temperature at 0° C. After stirring overnight at 10° C., chilled water (100 mL) and methylene chloride (150 mL) was added and the two layers separated. The water layer was re-extracted with 100 mL of methylene chloride and the organic layer dried and concentrated to a paste. After drying at high vacuum, a light tan colored cake was obtained which was triturated with ether (75 mL), filtered and dried to furnish a cream colored solid in 79% yield (10.1 g). ¹H NMR was consistent with the proposed structure. The compound was used as such for step 2.

Step 2:

The mesylate prepared in step 1 (5.0 g, 0.0138 moles) was dissolved in an eight fold excess of morpholine (9.6 g, 0.11 moles) in methanol (50 mL) and heated at reflux for 3 to 4 hours. After an NMR sample confirmed completion, the mixture was concentrated and taken up in methylene chloride (150 mL) and washed with water (100 mL) and then with 75 mL of 5% HCl. The water layer was neutralized to pH 8 and extracted with methylene chloride (100 mL). On drying and concentration a light yellow pasty solid was obtained which was triturated with 25 mL of ether to furnish a solid. Re-crystallization from toluene/hexane provided 4-[2-[3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-1-yl]ethyl]morpholine as a solid. Yield: 4.5 g (86%). Mass spectrum, m/z=353. ¹H NMR was consistent with the proposed structure. Anal. calc'd for C₂₀H₂₁FN₄O: C, 68.16; H, 6.01; N, 15.90. Found: C, 68.20; H, 6.21; N, 15.80.

The compound of Example A-217 was prepared in accordance with the chemistry of Scheme XVI:

EXAMPLE A-217

embedded image

3-(4-fluorophenyl)-1-methyl-α-phenyl-4-(4-pyridinyl)-1H-pyrazole-5-methanol

To solid magnesium (60 mg, 5 mmol) under nitrogen was added a solution of 4-[5-bromo-3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine (450 mg, 1.35 mmol) (prepared in accordance with Example A-214) in tetrahydrofuran (7 mL). The mixture was heated at 40° C. for 2 hours. Benzaldehyde (1 mL) was added. The mixture was heated to 45° C. for 2 hours. It was quenched with HCl (10 mL, 1N) and washed with ethyl acetate. The aqueous acid layer was basified and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over MgSO₄, filtered and concentrated to give a residue. The residue was purified with a silica gel column to give the title compound (59 mg, 12% yield). MS: m/z=360 (M+1); ¹H NMR was consistent with the proposed structure. Anal. Calc'd for C₂₂H₁₈N₂OF.0.6EtOAC: C, 71.1; H, 5.6; N, 10.2; Found: C, 70.9; H, 5.47; N, 10.2.

The compound of Example A-218 was prepared in accordance with the chemistry described above (particularly Scheme XVII):

EXAMPLE A-218

embedded image

N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-morpholineethanamine

The starting desoxybenzoin prepared in step 1 of EXAMPLE A-208, 4-fluorobenzoyl-4′-pyridyl methane, (1.0 g, 0.0046 moles) was dissolved in 10 mL of DMF and cooled to −10° C. (dry ice-aqueous isopropanol). N-chlorosuccinimide (0.62 9, 0.0046 moles) was added in one portion while maintaining the temperature at −10° C. After 5 minutes the thiosemicarbazide (0.0046 moles) was added in one portion at 0° C. and allowed to warm to ambient temperature slowly over 1 hour. After stirring overnight, the solvent was removed at high vacuum and water and toluene (25 mL each) added and stirred well. The toluene layer was separated and the water layer (starting pH of 5.5) treated with bicarbonate to pH 8. The fine precipitate formed was filtered and washed with water, toluene and ether. A final trituration with ether (25 mL) furnished an off white solid, N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-morpholineethanamine, which was re-filtered and dried. Yield: 0.95 g. (56%). Mass Spec. m/z: 368 (base peak). Anal. Calc'd for C₂₀H₂₂FN₅O. C, 65.38; H, 6.04; N, 19.06. Found: C, 64.90; H, 5.92; N, 18.67.

EXAMPLE A-219

embedded image

4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-2(1H) -pyridinone hydrazone

Step 1: Preparation of (E)-2-(2-bromo-4-pyridinyl)-N,N-dimethylethenamine
embedded image

4-Methyl-2-bromopyridine (1.0 g, 5.8 mmol) and t-butoxybis(dimethylamino)methane (5 ml) were heated to 150° C. for 16 hours. 4-Methyl-2-bromopyridine was prepared as set forth in B. Adger et al., J. Chem. Soc., Perkin Trans. 1, pp. 2791-2796 (1988), which is incorporated herein by reference. The contents were evaporated and the residue dissolved in ethyl acetate and washed with water. The organic layer was dried over magnesium sulfate and solvent removed in vacuo to give 1.0 g of (E)-2-(2-bromo-4-pyridinyl)-N,N-dimethylethenamine as an oil suitable for use in step 2.

Step 2: Preparation of (Z)-2-(2-bromo-4-pyridinyl)-1-(3-chlorophenyl)-3-(dimethylamino)-2-propen-1-one
embedded image

The product from step 1 (1.0 g, 4.4 mmol) was dissolved in methylene chloride (15 ml). Triethylamine (900 mg, 8.8 mmol) was added at 0° C., followed by the addition of 3-chlorobenzoyl chloride (350 mg, 4.5 mmol). The mixture was stirred under nitrogen for 16 hours. Solvent was evaporated in vacuo and the residue was dissolved in ether (25 ml), stirred with magnesium sulfate (500 mg) and silica gel (500mg), and filtered. Ether was evaporated and the residue was chromatographed on silica gel using mixtures of acetone and methylene chloride as eluents to give 670 mg of the product, (Z)-2-(2-bromo-4-pyridinyl)-1-(3-chlorophenyl)-3-(dimethylamino)-2-propen-1-one, as a glass which was used in step 3 without further purification.

Step 3: Preparation of 2-bromo-4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]pyridine
embedded image

A solution of the product from step 2 (650 mg, 1.8 mmol) and hydrazine monohydrate (100 mg) in ethanol (10 ml) was refluxed for 24 hours. Solvent was evaporated and the residue was chromatographed on silica gel using mixtures of ethyl acetate and toluene as eluents to give 2-bromo-4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]pyridine (190 mg, 31%) as an oil: Anal. Calc'd for C₁₄H₉BrClN₃: C, 50.25; H, 2.71; N, 12.56. Found: C, 50.10; H, 2.60; N, 12.40.

Continued elution with mixtures of ethyl acetate and methanol gave 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl)-2(1H)-pyridinone hydrazone (190 mg, 36%) as a crystalline solid: m.p. 163-164° C.; MS (M+H)=286. Anal. Calc'd for C₁₄H₁₂N₅Cl: C, 58.85; H, 4.23; N, 24.51. Found: C, 58.53; H, 4.28; N, 24.87.

EXAMPLE A-220

embedded image

4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-(phenylmethyl)-2-pyridinamine

A solution of the bromopyridine compound prepared in step 3 of Example A-219 (150 mg, 0.5 mmol) in benzylamine (5 ml) was heated at 175° C. for six hours. After cooling, excess benzylamine was removed by high vacuum distillation and ethyl acetate added to the residue. After washing the organic phase with water and drying over magnesium sulfate, the solvent was removed in vacuo and the residue chromatographed on silica gel using. mixtures of ethyl acetate and toluene to give 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-(phenylmethyl)-2-pyridinamine (110 mg, 61%) as a solid, m.p. 179-180° C.

Anal. Calc'd For C₂₁H₁₇ClN₄: C, 69.90; H, 4.75; N, 15.53. Found: C, 69.69; H, 4.81; N, 15.11.

EXAMPLE A-221

embedded image

4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-(phenylethyl)-2-pyridinamine

A solution of the bromopyridine compound prepared in step 3 of Example A-219 (250 mg, 0.75 mmol) in phenethylamine (5 ml) was heated at 175° C. for six hours under a nitrogen atmosphere. The excess amine was distilled off under high vacuum and the residue was dissolved in ethyl acetate and washed with water. After drying over magnesium sulfate and removal of solvent, the residue was chromatographed on silica gel with mixtures of ethyl acetate and toluene to give 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-(phenylethyl)-2-pyridinamine (230 mg, 81%) as a solid, m.p. 185-186° C.

Anal. Calc'd For C₂₂H₁₉ClN₄: C, 70.49; H, 5.11; N, 14.95. Found: C, 70.29; H, 5.15; N, 14.66.

EXAMPLE A-222

embedded image

4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-ethyl-2-pyridinamine

A solution of the bromopyridine compound prepared in step 3 of Example A-219 (300 mg, 0.9 mmol) in ethylamine (3.5 ml) and ethanol (5 ml) as heated at 150° C. in a sealed tube for 9 hours. The solvent was removed in vacuo and the residue chromatographed on silica gel with 70 ethyl acetate/30 toluene to give 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-ethyl-2-pyridinamine (125 mg, 46%) as a solid, m.p. 186-187° C. Anal. Calc'd For C₁₆H₁₅ClN₄: C, 64.32; H, 7.06; N, 18.75. Found: C, 64.42; H, 7.01; N, 18.45.

The compounds of Examples A-223 through A-226 were synthesized in accordance with the chemistry described above (particularly in Scheme XVIII) by selection of the corresponding starting reagents:

EXAMPLE A-223

embedded image

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarboxamide

Step 1:

To a suspension of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine (prepared as set forth in Example A-208) (8.8 9, 0.037 mol) in methylene chloride was added m-chloroperoxybenzoic acid (mCPBA) in one portion at room temperature. After stirring for 16 hours, solvent was removed and the residue was treated with saturated sodium bicarbonate solution. The precipitate was filtered, air-dried to give 8.2 g of a product as a white solid (87%), mp: 207-209° C.

Step 2: Preparation of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarbonitrile

To a solution of the product of step 1 (5.1 g, 0.02 mol) in 20 mL of DMF was added trimethylsilyl cyanide (2.5 g, 0.025 mol), followed by a solution of N, N-dimethylcarbamoyl chloride (2.7 g, 0.025 mol) in 5 mL of DMF at room temperature. After stirring overnight, the reaction mixture was basified by 200 mL of 10% potassium carbonate water solution. The aqueous phase was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and the crude was triturated with hexane and filtered to give 4.3 g of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarbonitrile (90%) as a pale yellow solid, mp: 238-239° C.

Step 3: Preparation of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarboxamide:

To a solution of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarbonitrile from step 2 (0.45 g, 0.0017 mol) in 10 mL of DMSO was added hydrogen peroxide (0.24 mL of 30% aqueous solution, 1.7 mmol) and potassium carbonate (0.04 g, 0.4 mmol) at 0° C. The mixture was stirred for 1 hour while allowing it to warm to room temperature. Water was added and the precipitate was collected by filtration and air-dried to give 0.32 g of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarboxamide as a white solid (67% yield), mp: 230-231° C. Anal. Calc'd for C₁₅H₁₁FN₄O: C, 63.83; H, 3.93; N, 19.85. Found C, 63.42; H, 3.66; N, 19.58.

EXAMPLE A-224

embedded image

Methyl 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarboxylate

To a suspension of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarboxamide prepared as set forth in Example A-223 (2.9 g, 0.01 mol) in 50 mL of methanol was added N,N-dimethylformamide dimethyl acetal (3.67 g, 0.03 mol) dropwise. The reaction mixture was stirred at room temperature overnight and heated at reflux for 4 hours. After cooling, the precipitate was collected by filtration and air-dried to give 2.0 g of methyl 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarboxylate as a white solid (69% yield), mp: 239-241° C. Anal. Calc'd for C₁₆H₁₂FN₃O₂: C, 64.64; H, 4.07; N, 14.13. Found: C, 64.36; H, 4.10; N, 14.27.

EXAMPLE A-225

embedded image

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-methyl-2-pyridinecarboxamide

A mixture of methyl 4-[3-(4-fluorophenyl)-1H -pyrazol-4-yl]-2-pyridinecarboxylate prepared as set forth in Example A-224 (0.45 g, 1.5 mmol) and 20 mL of methylamine (40% aqueous solution) was heated at 120° C. in a sealed tube for 16 hours. After cooling, water was added and the aqueous phase was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated to afford 0.4 g of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-methyl-2-pyridinecarboxamide as a white solid, mp: 88-89° C. Anal. Calc'd for C₁₆H₁₃FN₄O+0.4 H₂O: C, 63.32; H, 4.58; N, 18.46. Found C, 63.10; H, 4.62; N, 18.35.

EXAMPLE A-226

embedded image

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarboxylic acid

To a solution of 4-[3-(4-fluorophenyl)-!H-pyrazol-4-yl]-2-pyridinecarboxylate prepared as set forth in Example A-224 (0.90 9, 0.003 mol) in 10 mL of ethanol was added a solution of sodium hydroxide (0.24 g, 0.006 mol) in 5 mL of water. The reaction mixture was heated at reflux for 10 hours. After the removal of solvent, the residue was dissolved in water and acidified with citric acid solution to pH 5. Then the aqueous phase was extracted with ethyl acetate and the organic phase was dried over magnesium sulfate and concentrated. The crude was, purified by treating with ether to give 0.62 g of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarboxylic acid as a white solid (73% yield), mp: 245° C. (dec). Anal Calc'd for C₁₅H₁₀FN₃O+0.2 H₂O: C, 62.80; H, 3.65; N, 14.65. Found: C, 62.77; H, 3.42; N, 14,58.

Additional compounds of the present invention which were prepared according to one or more of above reaction schemes (particularly Schemes IX through XVIII) are disclosed in Table 3. The specific synthesis scheme or schemes as well as the mass spectroscopy and elemental analysis results for each compound also are disclosed in Table 3.

TABLE 3MicroanalysisGeneralMSwaterEtOAcExampleProcedureM + 1C calcC foundH calcH foundN calcN foundaddedaddedA-227IX24069694.34.617.216.80.25A-228IX26665.6965.694.414.3315.3214.98A-229XI25470.670.64.84.516.516.30.1A-230IX25665.7665.483.943.7816.4316.52A-231XI28064.1863.954.394.3113.8613.90A-232XI27166.7966.794.484.2415.5815.32A-233XI28466.966.85514.614.90.2A-234XI27065.965.64.64.615.415.40.2A-235XI2647776.76.56.515.815.70.1A-236IX22175.3875.445.065.118.84190.1A-237IX29061.5261.673.583.5114.3514.32A-238XI30463.3663.283.993.9113.8513.83A-239IX25865.3765.393.533.5216.3316.31A-240IX27461.4461.143.313.0115.3514.95A-241IX30056.0255.993.363.2614.0014.01A-242XI27266.4266.414.094.0415.4915.32A-243XI31457.3457.223.853.6813.3713.27A-244IX34276.3976.164.814.5112.3112.050.25A-245XII34164.8964.656.366.1715.9315.820.6A-246XII39166.0866.185.045.5614.0112.260.5A-247XII36264.4664.164.654.3418.7918.650.6A-249XII25864.9164.843.583.6316.2215.980.1A-250IX34848.4448.072.92.8212.112.01A-251XI36249.8849.893.353.5111.6311.54A-252XI30463.3663.343.993.9613.8513.81A-253XII37768.2468.1754.7114.4714.340.6A-254XII36366.3166.124.774.3114.7314.61A-215XIV26567.367.43.53.420.920.70.2A-255XII29864.6364.645.425.4123.5523.32A-256XI27266.4266.584.094.2615.4914.78A-257IX27660.1160.43.063.1815.0214.730.25A-258IX254A-259XI26871.8971.635.285.2415.7215.84A-260X29062.2862.413.483.4814.5314.51A-261X, XV31169.2669.26.26.2517.9517.890.1A-262XI37672.7172.55.174.9811.0610.990.25A-263XII42870.8170.596.286.4515.8815.080.75A-264XII32663.7963.766.396.0920.6620.450.75A-265IX40066.1866.774.14.2316.7815.831A-266XII36862.3262.386.286.518.1717.561A-267XI30262.6662.854.474.3413.713.530.4A-268XII34962.963.25.24.822.722.50.750.1A-269XI, XV37161.8561.845.715.2414.4214.171A-270XI, XV40470.6670.74.824.6110.310.150.25A-271XI, XV32965.865.35.55.617.116.8A-272XI40669.9570.135.355.2810.149.890.5A-273XI35466.967.26.96.619.118.70.20.1A-274XI, XII,43463.663.16.35.814.41420.2XVA-275XI, XV43370.4470.746.186.312.6412.050.6A-276XI, XII,47665.966.26.16.113.313.60.50.5XVA-277XII33861.1163.026.486.3918.7516.61A-278XI, XV35764.263.86.561514.81A-279XI, XII,46267.467.16.76.213.613.70.60.5XVA-280XII29961.2761.475.375.1117.8617.210.9A-281XII31364.6364.945.555.6317.7317.480.2A-282XII31364.6364.815.555.4317.7317.380.3A-283XI, XII40767.26755.213.613.20.25A-284XI, XV3397070.36.96.916.316.20.25A-285XI, XII,47668.268.55.76.214.713.6XVA-286XVII38259.7759.696.816.5616.616.652.25A-287XVII34056.0756.267.317.117.2117.273.75A-288XVII29369.4269.44.524.619.0519.090.1A-289XI, XII4076867.554.513.813.5A-290XI, XII4076464.55.34.91312.41.4A-291IX29074.774.94.24.214.514.5A-292XVII32661.2261.464.774.5316.816.970.4A-293XVII31355.7555.984.854.0216.2516.371.8A-294XI27873.673.24.44.215.215A-295XI27867.967.74.94.31413.71.3A-296IX70.370.44.54.725.225.4A-297IX57.957.73.12.914.514.5

EXAMPLE A-227

embedded image

4-[3-(3-fluorophenyl)-1H-pyrazol-4-yl]pyridine
EXAMPLE A-228

embedded image

4-[3-(1,3-benzodioxol-5-yl)-1H-pyrazol-4-yl]pyridine
EXAMPLE A-229

embedded image

4-[3-(3-fluorophenyl) 1-methyl-1H-pyrazol-4-yl pyridine

embedded image

EXAMPLE A-230

embedded image

4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]pyridine
EXAMPLE A-231
4-[3-(1,3-benzodioxol-5-y)-1-methyl-1H-pyrazol-4-yl]pyridine
EXAMPLE A-232
4-[3-(4-chlorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine
EXAMPLE A-233

embedded image

4-[3-(3-chlorophenyl)-1-methyl-1H-pyrazol-4-yl]-2-methylpyridine and 4-[5-(3-chlorophenyl)-1-methyl-1H-pyrazol-4-yl]-2-methylpyridine
EXAMPLE A-234

embedded image

4-[3-(3-chlorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine and 4-[5-(3-chlorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine
EXAMPLE A-235

embedded image

2-methyl-4-[1-methyl-3 (or 5)-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine
EXAMPLE A-236

embedded image

4-(3-phenyl-1H-pyrazol-4-yl)pyridine
EXAMPLE A-237

embedded image

4-[3-[3-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]pyridine
EXAMPLE A-238

embedded image

4-[1-methyl-3-[3-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]pyridine
EXAMPLE A-239

embedded image

4-[3-(3,4-difluorophenyl)-1H-pyrazol-4-yl]pyridine
EXAMPLE A-240

embedded image

4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl)-2-fluoropyridine
EXAMPLE A-241

embedded image

4-[3-(4-bromophenyl)-1H-pyrazol-4yl]pyridine
EXAMPLE A-242

embedded image

4-[3-(3,4-difluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine
EXAMPLE A-243

embedded image

4-[3-(4-bromophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine
EXAMPLE A-244

embedded image

(E)-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-(2-phenylethenyl)pyridine
EXAMPLE A-245

embedded image

(S)-4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-N-(2-methylbutyl)-2-pyridinamine
EXAMPLE A-246

embedded image

4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-N-[(4-methoxyphenyl)methyl]-2-pyridinamine
EXAMPLE A-247

embedded image

N-[4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-2-pyridinemethanamine
EXAMPLE A-248

embedded image

N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-2-pyridinemethanamine

Anal Calc'd: C, 41.12; H, 3.58; N, 9.22. Found: C, 41.74; H, 5.05; N, 11.11.

EXAMPLE A-249

embedded image

2-fluoro-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine
EXAMPLE A-250

embedded image

4-[3-(4-iodophenyl)-1H-pyrazol-4-yl]pyridine
EXAMPLE A-251

embedded image

4-[3-(4-iodophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine
EXAMPLE A-252

embedded image

4-[1-methyl-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]pyridine
EXAMPLE A-253

embedded image

N-[1-(4-fluorophenyl)ethyl]-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinamine
EXAMPLE A-254

embedded image

N-[(3-fluorophenyl)methyl]-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinamine
EXAMPLE A-255

embedded image

4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-2-(1-methylhydrazino)pyridine
EXAMPLE A-256

embedded image

2-fluoro-4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine
EXAMPLE A-257

embedded image

4-[3-(3,4-difluorophenyl)-1H-pyrazol-4-yl]-2-fluoropyridine
EXAMPLE A-258

embedded image

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-3-methylpyridine
EXAMPLE A-259

embedded image

4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-3-methylpyridine
EXAMPLE A-260

embedded image

4-[3-(3,4-difluorophenyl)-1-methyl-1H-pyrazol-4-yl]-2-fluoropyridine
EXAMPLE A-261

embedded image

3-(4-fluorophenyl)-N,N-dimethyl-4-(4-pyridinyl)-1H-pyrazole-1-ethanamine
EXAMPLE A-262

embedded image

2-[2-(4-fluorophenyl)ethyl]-4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine
EXAMPLE A-263

embedded image

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[1-(phenylmethyl)-4-piperidinyl]-2-pyridinamine
EXAMPLE A-264

embedded image

N′-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-N,N-dimethyl-1,2-ethanediamine
EXAMPLE A-265

embedded image

2,4-bis[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine
EXAMPLE A-266

embedded image

N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-4-morpholineethanamine
EXAMPLE A-267

embedded image

3-(4-fluorophenyl)-4-(2-fluoro-4-pyridinyl)-1H-pyrazole-1-ethanol
EXAMPLE A-268

embedded image

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-(2-(1H-imidazol-1-yl)ethyl]-2-pyridinamine
EXAMPLE A-269

embedded image

4-[2-[3-(4-fluorophenyl)-4-(2-fluoro-4-pyridinyl)-1H-pyrazol-1-yl]ethyl]morpholine
EXAMPLE A-270

embedded image

(E)-3-(4-fluorophenyl)-4-[2-[2-(4-fluorophenyl)ethenyl]-4-pyridinyl]-1H-pyrazole-1-ethanol
EXAMPLE A-271

embedded image

3-(4-fluorophenyl)-4-(2-fluoro-4-pyridinyl)-N,N-dimethyl-1H-pyrazole-1-ethanamine
EXAMPLE A-272

embedded image

3-(4-fluorophenyl)-4-[2-[2-(4-fluorophenyl)ethyl]-4-pyridinyl]-1H-pyrazole-1-ethanol
EXAMPLE A-273

embedded image

4-[1-[(2-(dimethylamino)ethyl]-3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N,N-dimethyl-2-pyridinamine
EXAMPLE A-274

embedded image

4-[1-[2-(dimethylamino)ethyl]-3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[(4-fluorophenyl)methyl]-2-pyridinamine
EXAMPLE A-275

embedded image

3-(4-fluorophenyl)-4-[2-[2-(4-fluorophenyl)ethyl]-4-pyridinyl]-N,N-dimethyl-1H-pyrazole-1-ethanamine
EXAMPLE A-276

embedded image

N-[(4-fluorophenyl)methyl]-4-[3(or 5)-(4-fluorophenyl)-1-[[2-(4-morpholinyl)ethyl]-1H-pyrazol-4-yl]-2-pyridinamine
EXAMPLE A-277

embedded image

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-4-piperadinyl-2-pyridinamine
EXAMPLE A-278

embedded image

N,N-diethyl-3-(4-fluorophenyl)-4-(2-fluoro-4-pyridinyl)-1H-pyrazole-1-ethanamine
EXAMPLE A-279

embedded image

4-[1-[2-(diethylamino)ethyl]-3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[(4-fluorophenyl)methyl]-2-pyridinamine
EXAMPLE A-280
2-[[4-[3-(4-(fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]ethanol
EXAMPLE A-281

embedded image

2-[[4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-2-pyridinyl]amino]ethanol
EXAMPLE A-282

embedded image

3-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-1-propanol
EXAMPLE A-283

embedded image

3 (or 5)-(4-fluorophenyl)-4-[2-[[(4-fluorophenyl)methyl]amino]-4-pyridinyl]-1H-pyrazole-1-ethanol
EXAMPLE A-284

embedded image

N,N-diethyl-3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanamine
EXAMPLE A-285

embedded image

N-[(4-fluorophenyl)methyl]-4-[3-(4-fluorophenyl)-1-[2-(4-morpholinyl)ethyl]-1H-pyrazol-4-yl]-2-pyridinamine
EXAMPLE A-286

embedded image

N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-morpholinepropanamine
EXAMPLE A-287

embedded image

N′-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-N,N-dimethyl-1,3-propanediamine
EXAMPLE A-288

embedded image

5-(4-fluorophenyl)-N-2-propynyl-4-(4-pyridinyl)-1H-pyrazol-3-amine
EXAMPLE A-289

embedded image

3-(4-fluorophenyl)-4-[2-[[(4-fluorophenyl)methyl]amino]-4-pyridinyl]-1H-pyrazole-1-ethanol
EXAMPLE A-290

embedded image

5-(4-fluorophenyl)-4-[2-[[(4-fluorophenyl)methyl]amino]-4-pyridinyl]-1H-pyrazole-1-ethanol
EXAMPLE A-291

embedded image

4-[3-[(4-fluorophenyl)-1H-pyrazol-4-yl]quinoline
EXAMPLE A-292

embedded image

N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]glycine methyl ester
EXAMPLE A-293

embedded image

N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]glycine
EXAMPLE A-294

embedded image

4-[3-(4-fluorophenyl)-1-(2-propynyl)-1H-pyrazol-4-yl]pyridine
EXAMPLE A-295

embedded image

4-[5-(4-fluorophenyl)-1-(2-propynyl)-1H-pyrazol-4-yl]pyridine
EXAMPLE A-296

embedded image

4,4′-(1H-pyrazole-3,4-diyl)bis[pyridine]
EXAMPLE A-297

embedded image

4-[3-(3,4-dichlorophenyl)-1H-pyrazol-4-yl]pyridine
EXAMPLE A-298

embedded image

N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-piperidinamine

The pyrimidine-substituted compounds of Examples A-299 through A-312 were synthesized in accordance with the chemistry described in Schemes I-XVIII by selection of the corresponding starting reagents:

EXAMPLE A-299

embedded image

2-Chloro-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine

Step 1:
embedded image

A mixture of 2,6-dichloro-4-methylpyrimidine (5.0 g, 0.031 mol), triethylamine (6.23 g, 0.062 mol) and catalytic amount of 5% Pd/C in 100 mL of THF was hydrogenated on a Parr apparatus under 40 psi at room temperature. After 0.5 hour, the catalyst was filtered and the filtrate was concentrated. The crude was purified by chromatography on silica gel (ethyl acetate/hexane, 3:7) to give 2.36 g of product as a pale yellow crystal (50% yield); mp: 47-49° C.

Step 2: Preparation of 2-(2-chloro-4-pyrimidinyl)-1-(4-fluorophenyl)ethanone
embedded image

2-(2-chloro-4-pyrimidinyl)-1-(4-fluorophenyl)ethanone

To a solution of lithium diisopropylamide (generated from BuLi (0.045 mol) and diisopropylamine (0.048 mol) in THF) at −78° C. was added a solution of the compound prepared in step 1 (5.5 g, 0.037 mol) in THF slowly over 30 minutes. After 1 hour, a solution of ethyl 4-fluorobenzoate (7.62 g, 0,045 mol) in THF was added and the reaction mixture was stirred overnight and allowed to warm up to room temperature. Water was added and the aqueous phase was extracted with ethyl acetate. Organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and the crude product purified by chromatography on silica gel (ethyl acetate/hexane, 3:7) to give 4.78 g of a yellow solid (51% yield), mp: 112-113° C.

Step 3: Preparation of (E)-2-(2-chloro-4-pyrimidinyl)-3-(dimethylamino)-1-(4-fluorophenyl)-2-propen-1-one
embedded image

(E)-2-(2-chloro-4-pyrimidinyl)-3-(dimethylamino)-1-(4-fluorophenyl)-2-propen-1-one

A mixture of the compound prepared in step 2 (4.7 g, 0.017 mol) in 100 mL of dimethylformamide dimethyl acetal was stirred at room temperature overnight. Excess dimethylformamide dimethyl acetal was removed under vacuum to give 4.5 g of crude product as a thick brown oil, which was used without further purification.

Step 4: Preparation of 2-chloro-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine

A solution of the compound prepared in step 3 (4.4 g) and hydrazine hydrate (0.82 g, 0.014 mol) was stirred at room temperature for 6 hours. The yellow precipitate was collected by filtration and air-dried to give 1.85 g of 2-chloro-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine as a yellow solid, mp: 204-205° C.; Anal. Calc'd for C₁₃H₈ClFN₄: C, 56.84; H, 2.94; N, 20.40; Cl, 12.91. Found: C, 56.43; H, 2.76; N, 20.02; Cl, 12.97.

EXAMPLE A-300

embedded image

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2(1H)-pyrimidinone hydrazone

A solution of the compound prepared in step 3 of Example A-299 (1.5 g) and hydrazine hydrate (5 mL) in ethanol was heated at reflux overnight. After the reaction mixture was cooled, the solvent was removed. The residue was partitioned between ethyl acetate and water. The organic phase was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and the crude product was purified by recrystallization from ethyl acetate and hexane to give 0.5 g of product, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2(1H)-pyrimidinone hydrazone, as a pale yellow solid (38% yield), mp: 149-150° C.; Anal. Calc'd for C₁₃H₁₁FN₆: C, 57.77; H, 4.10; N, 31.10. Found: C, 57.70; H, 4.31; N, 30.73.

EXAMPLE A-301

embedded image

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N,N-dimethyl-2-pyrimidinamine

Step 1: Preparation of
embedded image

A solution of the compound prepared in step 2 of Example A-299 (3.0 g, 0.02 mol) and tert-butylbis(dimethylamino)methane (10.45 g, 0.06 mol) in 40 mL of DMF was stirred at 110° C. overnight. After the solvent was removed under vacuum, water was added and extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and purified by recrystallization from ethyl acetate and hexane to give 1.23 g of a yellow solid product (32% yield), mp: 76-77° C.; Anal. Calc'd for C₁₀H₁₆N₄: C, 62.47; H, 8.39; N, 29.14. Found: C, 62.19; H, 8.58; N, 29.02.

Step 2: Preparation of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N,N-dimethyl-2-pyrimidinamine

To a solution of the compound prepared in step 1 of the present Example (1.2 g, 0.0064 mol) and triethylamine (0.65 g, 0.0064 mol) in 10 mL of toluene was added 4-fluorobenzoyl chloride dropwise. The mixture was heated at reflux for 10 hours and the solvent was removed. The residue was partitioned between ethyl acetate and water. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and the crude (1.6 g) was then dissolved in 50 mL of ethanol. The solution was treated with hydrazine hydrate (0.36 g, 0.006 mol) and the mixture was heated at reflux for 2 hours. After ethanol was removed, the residue was partitioned between water and ethyl acetate. The organic phase was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and the crude was purified by chromatography on silica gel (ethyl acetate/hexane, 1:1) to give 0.6 g of product, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N,N-dimethyl-2-pyrimidinamine, as a yellow solid (33% yield), mp: 155-156° C.; Anal. Calc'd for C₁₅H₁₄FN₅: C, 63.59; H, 4.98; N, 24.72. Found: C, 63.32; H, 4.92; N, 24.31.

EXAMPLE A-302

embedded image

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-methyl-2-pyrimidinamine

A suspension of 2-chloro-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine prepared in accordance with Example A-299 (0.3 g, 0.0011 mol) in 10 mL of methylamine (40% water solution) was heated in a sealed tube at 100° C. overnight. The mixture was then cooled to room temperature and the precipitate was filtered, air-dried to give 0.2 g of product, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-methyl-2-pyrimidinamine, as a white solid (68% yield), mp: 217-218° C.; Anal Calc'd for C₁₄H₁₂FN₅: C, 62.45; H, 4.49; N, 26.01. Found: C, 62.58; H, 4.36; N, 25.90.

EXAMPLE A-303

embedded image

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-(phenylmethyl)-2-pyrimidinamine

This compound was synthesize by refluxing 2-chloro-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine prepared in accordance with Example A-299 in benzylamine overnight. The product, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-(phenylmethyl)-2-pyrimidinamine, was obtained as a white solid in 95% yield; mp: 216-217° C.; Anal. Calc'd for C₂₀H₁₆FN₅: C, 69.55; H, 4.67; N, 20.28. Found: C, 69.73; H, 4.69; N, 19.90.

EXAMPLE A-304

embedded image

N-cyclopropyl-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinamine

This compound was synthesized by stirring 2-chloro-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine prepared in accordance with Example A-299 with excess cyclopropylamine in methanol at 50° C. for 12 hours. The product, N-cyclopropyl-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinamine, was obtained as a white solid in 26% yield, mp: 203-204° C.; Anal. Calc'd for C₁₆H₁₄FN₅: C, 65.07; H, 4.78; N, 23.71. Found: C, 64.42; H, 4.82; N, 23.58.

EXAMPLE A-305

embedded image

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[(4-methoxyphenyl)methyl]-2-pyrimidinamine

This compound was synthesized by refluxing 2-chloro-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine prepared in accordance with Example A-299 in 4-methoxybenzylamine overnight. The product, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[(4-methoxyphenyl)methyl]-2-pyrimidinamine, was obtained as a off-white solid in 80% yield, mp: 183-185° C.; Anal. Calc'd for C₂₁H₁₈FN₅O: C, 67.19; H, 4.83, N, 18.66. Found: C, 67.01; H, 5.11; N, 18.93.

EXAMPLE A-306

embedded image

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinamine

A solution of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[(4-methoxyphenyl)methyl]-2-pyrimidinamine prepared in accordance with Example A-305 (0.35 g, 0.00093 mol) in 15 mL of trifluoroacetic acid was heated at reflux for 16 hours. Solvent was removed and the residue was partitioned between ethyl acetate and 1 N ammonia hydroxide. Organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and purified by chromatography on silica gel (ethyl acetate) to give 0.14 g of product, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinamine, as a pale yellow solid (59% yield), mp: 273-274° C.; Anal. Calc'd for C₁₃H₁₀FN₅.0.25H₂O: C, 60.11; H, 4.07; N, 26.96. Found: C, 60.15; H, 3.82; N, 26.38.

EXAMPLE A-307

embedded image

N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]-N-(phenylmethyl)acetamide

To a mixture of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-(phenylmethyl)-2-pyrimidinamine prepared in accordance with Example A-303 (0.15 g, 0.00043 mol), DMAP (0.027 g, 0.00022 mol) and acetic anhydride (0.066 g, 0.00066 mol) in 10 mL of THF was added triethylamine (0.053 g, 0.00052 mol). The solution was stirred at room temperature overnight. After the removal of solvent, the residue was partitioned between ethyl acetate and water. The organic layer was washed with saturated NaHCO₃, washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and the crude product was triturated with ether to give 0.1 g of product, N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]-N-(phenylmethyl)acetamide, as a white solid (60% yield), mp: 176-178° C.; Anal. Calc'd for C₂₂H₁₈FN₅: C, 68.21; H, 4.68; N, 18.08. Found: C, 67.67; H, 4.85; N, 17.79.

EXAMPLE A-308

embedded image

Ethyl [4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]carbamate

To a suspension of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinamine prepared in accordance with Example A-306 (0.26 g, 0.001 mol) in 5 mL of pyridine was added ethyl chloroformate dropwise. After the addition, the clear solution was stirred at room temperature for 6 hours. Water was added and the aqueous phase was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and the crude was trituated with ether to give 0.15 g of product, ethyl [4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]carbamate, as a white solid (46% yield), mp: 163-165° C.; Anal. Calc'd for C₁₆H₁₄FN₅O₂: C, 58.71; H, 4.31; N, 21.04. Found: C, 59.22; H, 4.51; N, 21.66.

EXAMPLE A-309

embedded image

4-[3-(3-methylphenyl)-1H-pyrazol-4-yl]pyrimidine

This compound was prepared by the same procedure as described for Example A-208 except that 1-methyl-3-(4′-pyrimidinylacetyl)benzene (prepared as set forth in Step 1 of Example A-19 from 4-methyl-pyrimidine and methyl 3-methylbenzoate) was used in place of 4-fluorobenzoyl-4-pyridinyl methane.

Anal. Calc'd for C₁₄H₁₂N₄(236.27): C, 71.17; H, 5.12; N, 23.71. Found C, 70.67; H, 5.26; N, 23.53. m.p. (DSC); 151.67° C.

EXAMPLE A-310

embedded image

4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]pyrimidine

This compound was prepared according to the chemistry described in Schemes VI and IX by selection of the corresponding pyrimidine starting material in place of the pyridine starting material.

Anal. Calc'd for C₁₃H₉N₄Cl.25MH₂O: C, 59.78; H, 3.67; N, 21.45. Found: C, 59.89; H, 3.32; N, 21.56. m.p. (DSC): 218.17° C.

EXAMPLE A-311

embedded image

4-[3-(3-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine

This compound was prepared according to the chemistry described in Schemes VI and IX by selection of the corresponding pyrimidine starting material in place of the pyridine starting material.

Anal. Calc'd for C₁₃H₉N₄F (240.24): C, 64.99; H, 3.78; N, 23.22. Found: C, 64.78; H, 3.75; N, 23.31. m.p. (DSC): 168.58° C.

EXAMPLE A-312

embedded image

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine

This compound was prepared according to the chemistry described in Schemes VI and IX by selection of the corresponding pyrimidine starting material in place of the pyridine starting material.

Anal. Calc'd for C₁₃H₉N₄F (240.24): C, 64.99; H, 3.78; N, 23.32. Found: C, 64.94; H, 3.56; N, 23.44. m.p. (DSC): 191.47° C.

EXAMPLE A-313

The compound 1-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]methyl]-4-methylpiperazine was prepared in accordance with general synthetic Scheme VII:
embedded image

Step 1: Preparation of 5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-3-carboxylic acid, monohydrate

A mixture of 4-[3-(4-fluorophenyl)-5-methyl-1H-pyrazol-4-yl)pyridine (5.8 g, 24.0909 mmol; prepared as set forth in Example A-4) and potassium permanganate (7.6916 g, 48.1818 mmol) in water (7.5 mL) and tert-butanol (10 mL) was heated to reflux at 95 to 100° C. for 6 hours (or until all the potassium permanganate was consumed) and stirred at room temperature overnight. The mixture was diluted with water (150 mL) and filtered to remove manganese dioxide. The aqueous filtrate (pH >10) was extracted with ethyl acetate to remove unreacted starting material. The aqueous layer was acidified with 1N HCl to a pH of about 6.5. A white precipitate was formed. This precipitate was collected by filtration, dried in air, and then dried in a vacuum oven overnight at 50° C. to give 5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-3-carboxylic acid, monohydrate (2.7677 g, 40.6%). The remaining product (0.21 g, 3.1%) was isolated from the mother liquid by reverse phase chromotograhpy. The total isolated yield of 5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-3-carboxylic acid, monohydrate was 43.7%. Anal. Calc'd for C₁₅H₁₀N₃FO₂.H₂O: C, 59.80; H, 4.01; N, 13.95; Found: C, 59.48; H, 3.26; N, 13.65. MS (MH⁺): 284 (base peak).

Step 2: Preparation of 1,1-dimethylethyl 4-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]-1-piperazinecarboxylate
embedded image

In a solution of 5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-3-carboxylic acid, monohydrate (0.9905 g, 3.5 mmol) from step 1 and 1-hydroxybenzotriazole hydrate (0.4824 g, 3.57 mmol) in dimethylformamide (20 mL) at 0° C. under N₂, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.6983 g, 3.57 mmol) was added. The solution was stirred at 0° C. under N₂for 1 hour, then was added 1-tert.-butoxycarbonylpiperazine (0.6585 g, 3.5 mmol) followed by N-methyl morpholine (0.40 mL, 3.6 mmol). The reaction was stirred from 0° C. to room temperature overnight. The reaction mixture was diluted with ethyl acetate and saturated NaHCO₃solution, extracted. The organic layer was washed with water and brine, and dried over MgSO₄. After filtration, the solvent was removed under reduced pressure, and crude product was obtained (1.7595 g). The desired product 1,1-dimethylethyl 4-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]-1-piperazinecarboxylate (1.2375 g, 78.4%) was isolated by chromatography (silica gel, 10:90 isopropyl alcohol/toluene). Anal. Calc'd for C₂₄H₂₆N₅FO₃: C, 63.85; H, 5.80; N, 15.51; Found: C, 63.75; H, 5.71; N, 15.16. MS (MH⁺): 452 (base peak).

Step 3: Preparation of 1-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]methyl]-4-methylpiperazine

To a suspension of 1,1-dimethylethyl 4-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]-1-piperazinecarboxylate (0.451 g, 1.0 mL) in dry tetrahydrofuran (8 mL), 1.0N LiAlH₄in tetrahydrofuran (2.5 mL, 2.5 mmol) was added dropwise at such a rate as to maintain reflux over 15 minutes. Upon the addition, the suspension became a clear light yellow solution, which was kept boiling for an additional 1.5 hours. Excess LiAlH₄was decomposed by cautious addition of a solution of KOH (0.5611 g, 10.0 mmol) in water (3.5 mL). Upon hydrolysis, a white salt precipitated. After the addition was completed, the mixture was heated to reflux for 1 hour. The hot solution was filtered by suction through a buchner funnel. Any remaining product was extracted from the precipitate by refluxing with tetrahydrofuran (10 mL) for 1 hour, followed again by suction filtration. The combined filtrates were concentrated under reduced pressure to give a crude residue, which was then diluted with ethyl acetate and washed with water and brine. The organic layer was dried over MgSO₄. After filtration, the solvent was removed under reduced pressure, and a crude product was obtained. The desired product 1-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]methyl]-4-methylpiperazine (0.1509 g, 50.1%) was obtained by chromatography (silica gel, 70:30:1 methanol/ethyl acetate/NH₄OH). Anal. Calc'd for C₂₀H₂₂N₅F.0.6H₂O: C, 66.32; H, 6.46; N, 19.33; Found: C, 66.31; H, 5.96; N, 18.83. MS (MH⁺): 352 (base peak).

EXAMPLE A-314

The compound 1-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]methyl]-4-piperazine was prepared in accordance with general synthetic Scheme VII:
embedded image

Step 1: Preparation of 1-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]piperazine, monhydrate

A solution of 1,1-dimethylethyl 4-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]-1-piperazinecarboxylate (0.6349 g; 1,4077 mmol; prepared as set forth in step 2 of Example A-313) in methylene chloride (3.5 mL) and TFA (1.1 mL, 14.077 mmol) was stirred at room temperature under N₂for 2 hours. The solvents were removed under reduced pressure, and TFA was chased by methylene chloride and methanol. The resulting colorless oily residue was triturated with methanol. The resulting solid was collected by filtration and dried in a vacuum oven overnight to give the desired product 1-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]piperazine, monohydrate (0.7860 g, 96.4%). Anal. Calc'd for C₁₉H₁₈N₅OF.2TFA.H₂O: C, 46.24; H, 3.71; N, 11.72; Found: C, 45.87; H, 3.43; N, 11.45. MS (MH⁺): 352 (base peak).

Step 2: Preparation of 1-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]methyl]-4-piperazine

By following the method of Example A-313, step 3 and substituting of 1-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]piperazine, monohydrate (prepared in step 1 of this Example) for 1,1-dimethylethyl 4-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]-1-piperazinecarboxylate, the title product 1-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]methyl]-4-piperazine was obtained. Anal. Calc'd for C₁₉H₂₀N₅F.0.75H₂O: C, 65.03, H, 6.18, N, 19.96. Found: C, 65.47, H, 5.83, N, 19.35. MS (MH⁺): 338 (base peak).

EXAMPLE A-315

The compound 4-[3-(4-fluorophenyl)-5-(4-piperidinylmethyl)-1H-pyrazol-4-yl]pyridine was prepared in accordance with general synthetic Scheme XX:
embedded image

Step 1: Preparation of ethyl 1-[(1,1-dimethylethoxy)carbonyl]-4-piperidineacetate

Ethyl 4-pyridyl acetate was converted to 2-(4-piperidinyl)ethyl acetate hydrochloride by hydrogenation (60 psi H₂) catalyzed by 5% Pt/C at 40° C. in ethanol and HCl solution. To a solution of 2-(4-piperidinyl)ethyl acetate hydrochloride (21.79 g, 0.105 mol) in tetrahydrofuran (500 mL) at 0° C., triethylamine (32.06 mL, 0.230 mL) was added followed by di-tert-butyldicarbonate (23.21 g, 0.105 mol). The reaction mixture was stirred under N₂from 0° C. to room temperature overnight. After removing tetrahydrofuran, the reaction mixture was diluted with ethanol, washed with saturated NaHCO₃, 10% citric acid, water and brine, and dried over MgSO₄. After filtration, the solvent was removed under reduced pressure. The resulting oily product was dried under vacuum to give ethyl 1-[(1,1-dimethylethoxy)carbonyl]-4-piperidineacetate (27.37 g, 95.9%). The structure of this product was confirmed by NMR.

Step 2: Preparation of 1,1-dimethylethyl 4-[2-oxo-3-(4-pyridinyl)propyl]-1-piperidinecarboxylate
embedded image

To a solution of diisopropylamide (6.15 mL, 43.91 mmol) in dry tetrahydrofuran (40 mL) at 0° C. was added 2.5 M butyl lithium solution in hexane (16.22 mL, 40.53 mmol) dropwise over 10 minutes. After the addition, the lithium diisopropylamide solution was stirred at 0° C. for 20 minutes, then cooled to −78° C. 4-Picoline (3.98 mL, 40.53 mmol) was added to the above lithium diisopropylamide solution under N₂dropwise over 10 minutes. The resulting solution was stirred at −78° C. under N₂for 1.5 hours, then transfered into a suspension of anhydrous cerium chloride (10.0 g, 40.53 mmol) in tetrahydrofuran (40 mL) at −78° C. under N₂. The mixture was stirred at −78° C. under N₂for 2 hours, then a solution of ethyl 1-[(1,1-dimethylethoxy)carbonyl]-4-piperidineacetate (from step 1 of this Example) (10.98 g, 40.53 mmol) in tetrahydrofuran (40 mL) was added slowly for 1 hour. The mixture was stirred under N₂from −78° C. to room temperature overnight. The reaction was quenched with water, diluted with ethyl acetate, and washed with a pH 7 buffer. The organic layer was washed with water and brine. After filtration, the solvent was removed under reduced pressure to give a crude product mixture. The desired product 1,1-dimethylethyl 4-[2-oxo-3-(4-pyridinyl)propyl]-1-piperidinecarboxylate (3.19 g, 25%) was isolated by chromatography (silica gel, 50:50-75:25-100:0 ethyl acetate/hexane).

Step 3: Preparation of 1.1-dimethylethyl 4-[4-(4-fluorophenyl)-2-oxo-3-(4-pyridinyl)-3-butenyl]-1-piperidinecarboxylate
embedded image

1,1-Dimethylethyl 4-[4-(4-fluorophenyl)-2-oxo-3-(4-pyridinyl)-3-butenyl]-1-piperidinecarboxylate was prepared by the same method as described for step 1 of Example A-1 by replacing 4-pyridylacetone and 3-fluoro-p-anisaldehyde with the ketone of step 2 of the present Example and 4-fluorobenzaldehyde, respectively.

Step 4: Preparation of 1,1-dimethylethyl 4-[2-[3-(4-fluorophenyl)-2-(4-pyridinyl)oxiranyl]-2-oxoethyl]-1-piperidinecarboxylate
embedded image

1,1-Dimethylethyl 4-[2-[3-(4-fluorophenyl)-2-(4-pyridinyl)oxiranyl]-2-oxoethyl]-1-piperidinecarboxylate was prepared by the same method as described for step 3 of Example A-2 by replacing 4-phenyl-3-(4-pyridyl)-3-butene-2-one with the α,β unsaturated ketone of step 3 of the present Example.

Step 5: Preparation of 1,1-dimethylethyl 4-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]methyl]-1-piperidinecarboxylate
embedded image

To a solution of 1,1-dimethylethyl 4-[2-[3-(4-fluorophenyl)-2-(4-pyridinyl)oxiranyl]-2-oxoethyl]-1-piperidinecarboxylate prepared in step 4 of this Example (3.45 g, 7.8409 mmol) in ethanol (15 mL), anhydrous hydrazine (0.50 mL, 15.6818 mmol) was added. The reaction was heated to reflux overnight. The reaction solution was cooled to room temperature and ethanol was removed under reduced pressure. The resulting residue was taken into ethyl acetate, washed with water and brine, and dried over MgSO₄. After filtration the solvent was removed under reduced pressure. The crude residue was purified by chromatography (silica gel, 2:1-1:1-1:2 hexane/ethyl acetate) to give 1,1-dimethylethyl 4-[[5-(4-fluorophenyl)-4,5-dihydro-4-hydroxy-4-(4-pyridinyl)-1H-pyrazol-3-yl]methyl]-1-piperidinecarboxylate (1.9187 g, 53.9%). This intermediate (1.8611 g, 4.0993 mmol) was dissolved in dry methylene chloride (40 mL) and treated with Martin sulfurane dehydrating reagent (4.13 g, 6.1490 mmol). The reaction solution was stirred at room temperature under N₂overnight, then diluted with ethyl acetate, washed with 1N sodium hydroxide solution, water and brine, dried over MgSO₄. After filtration the solvents were removed. The resulting crude pruduct mixture was purified by flash chromatoghaphy (silica gel, 2:1-1:1-1:2 Hexane/ethyl acetate) to give 1,1-dimethylethyl 4-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]methyl]-1-piperidinecarboxylate (0.6964 g, 39%).

Step 6: Preparation of 4-[3-(4-fluorophenyl)-5-(4-piperidinylmethyl)-1H-pyrazol-4-yl]pyridine

4-[3-(4-Fluorophenyl)-5-(4-piperidinylmethyl)-1H-pyrazol-4-yl]pyridine was prepared using the same method as described for Example A-314, step 1 by replacing 1-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]piperazine, monohydrate with the pyrazole of step 5 of the present Example. Anal. Calc'd for C₂₀H₂₁N₄F.2TFA.1.25H₂O: C, 49.11; H, 4.38; N, 9.54; Found: C, 48.74; H, 4.02; N, 9.57. MS (MH⁺): 337 (base peak).

EXAMPLE A-316

embedded image

4-[3-(4-fluorophenyl)-5-[(1-methyl-4-piperidinyl)methyl]-1H-pyrazol-4-yl]pyridine was prepared by the same method as described for step 3 of Example A-313 by replacing 1,1-dimethylethyl 4-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]-1-piperazinecarboxylate with the pyrazole of step 5 of the present Example. Anal. Calc'd for C₂₁H₂₃N₄F.0.2H₂O: C, 71.24; H, 6.66; N, 15.82; Found: C, 71.04; H, 6.54; N, 15.56. MS (MH⁺): 351 (base peak).

EXAMPLE A-317

The compound 1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine, dihydrate was prepared in accordance with general synthetic Scheme II:
embedded image

2-(4-Pyridyl)-1-(4-fluorophenyl)ethanone hydrochloride (5.9 g, 0.023 moles) was dissolved in a methylene chloride/methanol solution (70/15) at room temperature and N-chlorosuccinimide (3.25 g, 0.024 moles) was added as a solid. The mixture was stirred at room temperature for 2.5 hours.

N-methylpiperazinylthiosemicarbazide (4.1 g, 0.023 moles) was added as a solid and the mixture was stirred for 3 days at room temperature. The mixture was diluted with 100 mL of methylene chloride and washed with saturated aqueous sodium bicarbonate solution. The organic phase was dried (MgSO₄) and solvent removed using a rotary evaporator. The residue was treated with ethyl acetate with stirring while cooling in an ice bath. The solid formed was filtered and recrystallized from ethyl acetate with a small amount of methanol to give 1.7 g (22%) of 1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine, dihydrate. Anal. Calc'd. for C₁₉H₂₀FN₅.2H₂O: C, 61.11; H, 6.48; N, 18.75. Found: C, 60.59; H, 6.41; N, 18.44. M.p. (DSC) 262-264° C.; MH+=338.

EXAMPLE A-318

The compound 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1-(2-propynyl)-1H-pyrazol-3-yl]piperazine, trihydrochloride monohydrate was prepared in accordance with general synthetic Scheme VII:
embedded image

To a mixture of sodium hydride (30 mg, 1.5 mmol) in dimethylformamide (25 mL) stirred under a nitrogen atmosphere at room temperature was added 3-(4-chlorophenyl)-4-(4-pyridyl)-5-(4-N-tert.-butoxycarbonylpiperazinyl)pyrazole (500 mg, 1.1 mmol; prepared as set forth in Example A-169). After stirring for 1 hour, propargyl bromide (225 mg, 1.5 mmol, 80% solution in toluene) was added. After stirring for an additional 2 hour at room temperature, the reaction mixture was poured into water and extracted with ethyl acetate. The organic layer was dried with MgSO₄, filtered and concentrated in vacuo. The residue was chromatographed on silica gel using 70% ethyl acetate/hexane as the eluent to give 110 mg of 3-(4-chlorophenyl)-4-(4-pyridyl)-5-(4-N-tert.-butoxycarbonyl-piperazinyl)pyrazole (24%), m. p. 204-205° C. Anal. Calc'd. for C₂₆H₂₈ClN₅O₂: C, 65.33; H, 5.90; N, 14.65. Found: C, 65.12; H, 5.81; N, 14.70.

A solution of HCl in methanol (5 mL) was generated by addition of acetyl chloride (200 mg) to methanol while cooling (5° C.). 3-(4-Chlorophenyl)-4-(4-pyridyl)-5-(4-N-tert. -butoxycarbonylpiperazinyl)pyrazole (100 mg, 0.2 mmol) prepared above was added and the reaction stirred in the cold for one hour. The reaction mixture was concentrated in vacuo and the residue azeotroped with toluene to give 100 mg of 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1-(2-propynyl)-1H-pyrazol-3-yl]piperazine, trihydrochloride monohydrate (90%), m.p.=231-233° C. (dec.). Anal. Calc'd. for C₂₁H₂₀N₅Cl.3HCl.H₂O: C, 49.92; H, 4.99; N, 13.86. Found: C, 49.71; H, 4.89; N, 13.61.

EXAMPLE A-319

The compound methyl 4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazinecarboxylate, monohydrate was prepared in accordance with general synthetic Scheme II:
embedded image

Methyl chloroformate (55 mg) was added to a solution of 3-(4-chlorophenyl)-4-(4-pyridyl)-5-(4-piperazinyl)pyrazole (200 mg, 0.54 mmol; prepared as set forth in Example A-169) and 4-dimethylaminopyridine (5 mg) in pyridine (10 mL). The mixture was stirred at room temperature for 3 hours. Additional methyl chloroformate (30 mg) was added and stirring was continued for 24 hours. The solvent was removed in vacuo. The residue was treated with water and extracted with ethyl acetate. After drying the organic layer (MgSO₄), the solvent was blown down to a volume of 10 mL and refrigerated. The resultant crystalline solid was filtered and air dried to give 103 mg (48%) of methyl 4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazinecarboxylate, monohydrate, mp 264-265° C. Anal. Calc'd. for C₂₀H₂₀ClN₅O₂.H₂O: C, 57.76; H, 5.33; N, 16.84. Found: C, 57.98; H, 4.89; N, 16.44.

EXAMPLE A-320

The compound 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-(methylsulfonyl)piperazine, monohydrate was prepared in accordance with general synthetic Scheme II:
embedded image

A solution of 3-(4-chlorophenyl)-4-(4-pyridyl)-5-(4-piperazinyl)pyrazole (200 mg; 0.54 mmol; prepared as set forth in Example A-169), methanesulfonyl chloride (75 mg) and 4-dimethylaminopyridine (5 mg) in pyridine was stirred at room temperature for 3 hours. The solvent was removed in vacuo and the residue was treated with water. The resultant crystalline solid was filtered, air dried and recrystallized from methanol and water to give 118 mg (37%) of 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-(methylsulfonyl)piperazine, monohydrate, m.p. 245-248° C. Anal. Calc'd. for C₁₉H₂₀ClN₅SO₂.H₂O: C, 52.35; H, 5.09; N, 16.07. Found: C, 52.18; H, 5.31; N, 16.00.

EXAMPLE A-321

The compounds 4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-γ-oxo-1-piperazinebutanoic acid, dihydrate, and 4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-γ-oxo-1-piperazinebutanoic acid, monosodium salt dihydrate, were prepared in accordance with general synthetic Scheme II:
embedded image

A solution of 3-(4-chlorophenyl)-4-(4-pyridyl)-5-(4-piperzinyl)pyrazole (200 mg; 0.54 mmol; prepared as set forth in Example A-169), succinic anhydride (60 mg, 0.55 mmol) and 4-dimethylaminopyridine (5 mg) was stirred at room temperature for 24 hours. The solvent was removed in vacuo and the residue treated with methanol and water (1:1). The resultant crystalline solid was filtered and air dried to give 170 mg (58%) of 4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-γ-oxo-1-piperazinebutanoic acid, dihydrate, m. p. 281-283° C. (dec.). Anal. Calc'd. for C₂₂H₂₂ClN₅O₃.2H₂O: C, 55.52; H, 5.51; N, 14.72. Found: C, 55.11; H, 5.20; N, 14.44.

A slurry of 4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-γ-oxo-1-piperazinebutanoic acid, dihydrate (150 mg, 0.31 mmol) from above in methanol (10 mL) was treated with a solution of sodium hydroxide (12 mg, 0.31 mmol) in methanol (2 mL). The reaction was stirred at room temperature for 15 minutes until dissolution was completed. The solvent was removed in vacuo. The residue was treated with tetrahydrofuran and filtered and air dried to give 150 mg (97%) of 4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-γ-oxo-1-piperazinebutanoic acid, monosodium salt dihydrate as a solid. Anal. Calc'd. for C₂₂H₂₁ClN₅O₃Na.2H₂O: C, 53.07; H, 5.06; N, 14.07. Found: C, 52.81; H, 5.11; N, 13.90.

EXAMPLE A-322

The compound 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl)-4-cyclopropylpiperazine was prepared in accordance with general synthetic Scheme II:
embedded image

To a solution of 3-(4-chlorophenyl)-4-(4-pyridyl)-5-(4-piperazinyl)pyrazole (1.95 g; 5.8 mmoles; prepared as set forth in Example A-169) and acetic acid (3.6 g, 60 mmol) containing 5A molecular sieves (6 g) was added [(1-ethoxycyclopropyl)oxy]trimethylsilane (6 g, 35 mmol). After stirring for 5 minutes, sodium cyanoborohydride (1.7 g, 26 mmol) was added and the mixture was refluxed under a nitrogen atmosphere for 6 hours. The reaction mixture was filtered hot and the filtrate concentrated in vacuo. Water (50 mL) was added and the solution made basic with 2N sodium hydroxide. The resultant gel was extracted with dichloroethane and the combined organic extracts dried (MgSO₄). Evaporation again yielded a gel which was treated with hot methanol. Upon cooling, the product crystallized to give 1.4 g (63%) of 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl)-4-cyclopropylpiperazine, m. p. 264-265° C. Anal. Calc'd. for C₂₁H₂₂ClN₅.1.5H₂O: C, 61.99; H, 6.19; N, 17.21. Found: C, 62.05; H, 5.81; N, 16.81.

EXAMPLE A-323

The compound 4-[3-(4-fluorophenyl)-5-(1H-imidazol-4-yl)-1-(4-methoxyphenyl)-1H-pyrazol-4-yl]pyridine was prepared in accordance with general synthetic Scheme V:
embedded image

To a suspension of sodium hydride (1.0 g, 0.025 mol) in 50 mL of dimethylformamide was added methyl 4-imidazolecarboxylate (2.95 g, 0.023 mol) portionwise at room temperature. The mixture was stirred at room temperature for 0.5 hour. Then 2-(trimethylsilyl)ethoxymethyl chloride (4.17 g, 0.025 mol) was added dropwise over 5 minutes. The reaction mixture was stirred for 4 hours and quenched by cautiously adding water. The aqueous phase was extracted with ethyl acetate and the organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and the crude was purified by chromatography on silica gel using ethyl acetate/hexane (8:2) as the eluent to give 4.0 g of the major regioisomer as a clear oil.

To a solution of 4-fluorobenzoyl-4′-pyridyl methane (8.6 g, 0.04 mol, prepared as set forth in Step 1 of Example A-208) in 150 mL of ethanol was added p-methoxyphenylhydrazine hydrochloride (7.34 g, 0.042 mol), followed by triethylamine (4.05 g, 0.04 mol). The reaction mixture was refluxed for 16 hours. After the removal of solvent, the residue was partitioned between water and ethyl acetate. The organic layer was washed with brine, dried over MgSO₄and filtered. The filtrate was concentrated and the crude residue was purified by recrystallization from ethyl acetate and hexane to give 8.45 g of the product hydrazone as a yellow solid. To a solution of sodium hexamethyldisilazide (9 mL of 1.0 M tetrahydrofuran solution, 0.009 mol) was added a solution of this hydrazone (1.35 g, 0.004 mol) in 10 mL of dry tetrahydrofuran at 0° C. After stirring for 30 minutes at this temperature, a solution of the regioisomer prepared above (1.1 g, 0.0042 mol) in 5 mL of dry tetrahydrofuran was added dropwise. The reaction mixture was stirred for 3 hours at room temperature. Water was added and the aqueous phase was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and the crude product was purified by chromatography on silica gel using ethyl acetate as the eluent to give 0.74 g of the desired product as an orange solid (34%). Deprotection of the above solid by using tetrabutylammonium fluoride afforded 0.37 g of 4-[3-(4-fluorophenyl)-5-(1H-imidazol-4-yl)-1-(4-methoxyphenyl)-1H-pyrazol-4-yl]pyridine as a yellow solid (75%), mp: 124-126° C. Anal. Calc'd. for C₂₄H₁₈FN₅O.0.5H₂O: C, 68.56; H, 4.55; N, 16.66. Found: C, 68.44; H, 4.39; N, 16.00.

EXAMPLE A-324

The compound 4-[3-(4-fluorophenyl)-1H-pyazol-4-yl]-N-2-propynyl-2-pyrimidinamine was prepared in accordance with general synthetic Scheme XII:
embedded image

A mixture of 2-chloro-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine (0.28 g; 0.001 mol; prepared as set forth in Example A-299) and 10 mL propargylamine was heated at reflux for 16 hour. Excess amine was removed in vacuo and the residue was partitioned between water and ethyl acetate. The organic layer was washed with brine, dried over MgSO₄and filtered. The filtrate was concentrated and the residue purified by chromatography on silica gel using ethyl acetate/hexane (1:1) as the eluent to give 0.21 g of 4-[3-(4-fluorophenyl)-1H-pyazol-4-yl]-N-2-propynyl-2-pyrimidinamine as a pale yellow solid (68% yield), mp: 186-187° C. Anal. Calc'd. for C₁₆H₁₂FN₅: C, 65.52; H, 4.12; N, 23.88. Found: C, 64.99; H, 4.15; N, 23.91.

EXAMPLE A-325

The compound N-(2-fluorophenyl)-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinamine was prepared in accordance with general synthetic Scheme XII:
embedded image

A mixture of 2-chloro-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine (0.37 g; 0.0013 mol; prepared as set forth in Example A-299), 7 mL of 2-fluoroaniline and 2 drops of methanol was heated at 180° C. in a sealed tube for 16 hours. Excess amine was removed by vacuum distillation and the residue was treated with ethyl acetate to give 0.35 g of N-(2-fluorophenyl)-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinamine as a yellow solid (77%), mp: 239-240° C. Anal. Calc'd. for C₁₉H₁₃F₂N₅: C, 65.33; H, 3.75; N, 20.05. Found: C, 64.95; H, 3.80; N, 19.77.

EXAMPLE A-326

The compound 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-(2-methoxyphenyl)-2-pyrimidinamine was prepared in accordance with general synthetic Scheme XII:
embedded image

4-[3-(4-Fluorophenyl)-1H-pyrazol-4-yl]-N-(2-methoxyphenyl)-2-pyrimidinamine was synthesized in 41% yield using the same method described for the preparation of N-(2-fluorophenyl)-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinamine in Example A-325 using 2-methoxyaniline in place of 2-fluoroaniline; mp: 265° C. (dec.). Anal. Calc'd. for C₂₀H₁₆FN₅O: C, 66.47; H, 4.46; N, 19.38. Found: C, 66.70; H, 4.53; N, 19.20.

EXAMPLE A-327

The compound 1-[5-(3-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine was prepared in accordance with general synthetic Scheme II:
embedded image

1-[5-(3-Chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine was synthesized in 12% yield as a pale yellow solid using the same method described for the preparation of 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine in Example A-170 using 2-(4-pyridyl)-1-(3-chlorophenyl)ethanone in place of 2-(4-pyridyl)-1-(4-chlorophenyl)ethanone; mp: 229-231° C. Anal. Calc'd. for C₁₉H₂₀ClN₅.0.4H₂O: C, 63.21; H, 5.81; N, 19.40. Found: C, 62.85; H, 5.57; N, 19.77.

Additional aminopyrazole compounds that were synthesized in accordance with the chemistry described in Scheme II by selection of the corresponding starting reagents include the compounds disclosed in Table 3-1 below.

TABLE 3-1TheoreticalFoundEXAMPLEFORMULAMWCHNCHNDSC (mp)A-328C₁₈H₁₈ClN₅.1/8H₂O342.0863.205.3020.4763.045.3620.33199° C.A-329C₂₃H₃₃ClN₆O₂533.0865.346.2415.7764.986.1115.58(168-171° C.)A-330C₂₃H₂₅ClN₅O₂457.9460.335.5015.2959.975.5215.17(253-255° C.)A-331C₂₂H₂₄ClN₅O₂425.9262.045.6816.4461.645.9416.29(273-275° C.)A-332C₁₉H₂₃Cl₄N₅.H₂O481.2647.424.8214.3547.665.1113.74(217-219° C.)A-333C₂₁H₂₀ClN₅.2.5H₂O422.9259.644.7716.5659.674.8815.96(247° C.) (d)A-334C₂₀H₂₂ClN₅.1/4H₂O372.3964.515.9618.8164.795.9718.95242° C.A-335C₂₄H₂₂ClN₅.3/4H₂O429.4467.135.1616.3167.045.3116.32230° C.A-336C₂₅H₂₄ClN₅O.1/4H₂O450.4666.665.3715.5566.645.1115.69(270-271° C.)A-337C₂₂H₂₄FN₅O₂.H₂O427.4861.815.6616.3861.885.9616.41249° C.A-338C₂₀H₂₂FN₅.1/2H₂O360.4466.656.1519.4366.746.5919.37241° C.A-339C₁₉H₂₀FN₅.3HCl.1/2H₂O455.7950.075.0915.3049.875.4715.30(237-239° C.)

EXAMPLE A-328

embedded image

1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]piperazine
EXAMPLE A-329

embedded image

1,1-dimethylethyl [3-[[5-(4-chlorophenyl)-4-(2-[(phenylmethyl)amino]-4-pyridinyl-1H-pyrazol-3-yl]amino]propyl]carbamate
EXAMPLE A-330

embedded image

1,1-dimethylethyl 4-[5-(4-chlorophenyl)-4-(2-fluoro-4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazinecarboxylate

EXAMPLE A-331

embedded image

ethyl 4-[[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]amino]-1-piperidinecarboxylate
EXAMPLE A-332

embedded image

N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-3H-pyrazol-3-yl]-4-piperidineamine, trihydrochloride, monohydrate
EXAMPLE A-333

embedded image

The compound 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-(2-propynyl)piperazine was prepared in accordance with general synthetic Scheme II. To a suspension of of 1-[5-(4-Chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]piperazine (92 mg, 0.27 mmole) in 2 mL of dimethylformamide was added 75 mg (0.54 mmole) of anhydrous potassium carbonate and then 60 microliters of 80% propargyl bromide solution in toluene (containing 64 mg, 0.54 mmole). The resulting mixture was stirred for 30 minutes and then partitioned betwen ethyl acetate and water. The aqueous layer was further extracted with ethyl acetate, and the combined organic extracts filtered through silica gel using 10% methanol-ethyl acetate as eluent to give, after evaporation of the appropriate fractions, 34 mg of 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-(2-propynyl)piperazine as a pale yellowish solid, m.p. 247° C. (decomp.). Anal. Calc'd. for C₂₁H₂₀ClN₅.2.5H₂O (MW 422.92): C, 59.64, H, 4.77, N, 16.56. Found: C, 59.67, H, 4.88, N, 15.96.

EXAMPLE A-334

embedded image

N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-4-piperidinamine
EXAMPLE A-335

embedded image

1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-phenylpiperazine
EXAMPLE A-336

embedded image

1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-(2-methoxyphenyl)piperazine
EXAMPLE A-337

embedded image

Ethyl 4-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]amino]-1-piperidinecarboxylate, monohydrate
EXAMPLE A-338

embedded image

N-[5-(4-fluorophenyl)-4-(pyridinyl)-1H-pyrazol-3-yl]-1-methyl-4-piperidinamine
EXAMPLE A-339

embedded image

N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-piperidinamine, trihydrochloride
EXAMPLE A-340

The compound of Example A-170 was also synthesized in the following manner. 1-[5-(4-Chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]piperazine (12.2 g, 36 mmol, prepared as set forth in Example A-169), 88% formic acid (20 mL), and formaldehyde (37% formalin solution; 44 g, 540 mmol) were combined and stirred at 60° C. for 16 hours under a nitrogen atmosphere. Excess solvent was removed on the rotary evaporator and the residue was dissolved in water (150 mL). The pH was adjusted to 8-9 by addition of solid sodium bicarbonate. The resulting precipitate was filtered and air dried. It was then treated with hot methanol (400 mL), filtered and blown down to a volume of 75 mL, cooled and filtered. After drying in a vacuum oven at 80° C. overnight, there was obtained 8.75 g (68%) of 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine, m. p. 262-264° C. Anal. Calc'd. for C₁₉H₂₀N₅Cl: C, 64.49; H, 5.70; N, 19.79. Found: C, 64.04; H, 5.68; N, 19.63.

The compounds of Examples A-341 through A-345 were synthesized, for example, in accordance with the chemistry described in Scheme XXI by selection of the corresponding starting reagents.

EXAMPLE A-341

The compound of Example A-170 was also synthesized in the following manner:

Step 1: Preparation of 1-(4-chlorophenyl)-2-(1,3-dithietan-2-ylidene)-2-(4-pyridinyl)ethanone

To a solution of 2-(4-pyridyl)-1-(4-chlorophenyl)ethanone (70.0 g, 0.3 mol) prepared in a similar manner as the compound of Step 1 of Example A-19, dibromomethane (200 mL) and carbon disulfide (25.9 g, 0.34 mol) in acetone (800 mL) was added potassium carbonate (83.0 g, 0.6 mol). The reaction mixture was stirred at room temperature for 24 hours. An additional two equivalents of potassium carbonate and one equivalent of carbon disulfide was added and the stirring was continued for another 24 hours. Solvent was removed and the residue was partitioned between dichloromethane and water. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and the crude was stirred with 1000 mL of a mixture of ethyl acetate and ether (1:9) to give 78.4 g of pure product, 1-(4-chlorophenyl)-2-(1,3-dithietan-2-ylidene)-2-(4-pyridinyl)ethanone, as a yellow solid (82%), mp: 177-179° C. Anal. Calc'd. for C₁₅H₁₀ClNOS₂: C, 56.33; H, 3.15; N, 4.38. Found: C, 55.80; H, 2.84; N, 4.59.

Step 2: Preparation of 1-[3-(4-chlorophenyl)-3-oxo-2-(4-pyridinyl)-1-thiopropyl]-4-methylpiperazine
embedded image

A mixture of 1-(4-chlorophenyl)-2-(1,3-dithietan-2-ylidene)-2-(4-pyridinyl)ethanone (78.3 g, 0.24 mol) and 1-methylpiperazine (75.0 g, 0.73 mol) in 800 mL of toluene was heated at reflux for 2 hours. Solvent and excess 1-methylpiperazine was removed under vacuum and the residue was triturated with a mixture was ethyl acetate and ether (1:3) to give 53.0 g of product, 1-[3-(4-chlorophenyl)-3-oxo-2-(4-pyridinyl)-1-thiopropyl]-4-methylpiperazine, as yellow crystals (60%), mp: 149-151° C. Anal. Calc'd. for C₁₉H₂₀ClN₃OS: C, 61.03; H, 5.39; N, 11.24. Found: C, 60.74; H, 5.35; N, 11.14.

Step 3: Preparation of 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine

To a suspension of 1-[3-(4-chlorophenyl)-3-oxo-2-(4-pyridinyl)-1-thiopropyl]-4-methylpiperazine (52.0 g, 0.14 mol) in 500 mL of dry tetrahydrofuran was added anhydrous hydrazine (8.9 g, 0.28 mol) dropwise. The reaction mixture was stirred at room temperature for 16 hours. The pale yellow precipitate was filtered and recrystallized from hot methanol to give 30.2 g of 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine as a white powder (60%), mp: 267-268° C. Anal. Calc'd. for C₁₉H₂₀ClN₅: C, 64.49; H, 5.70; N, 19.79. Found: C, 64.89; H, 5.55; N, 19.99.

EXAMPLE A-342

embedded image

1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-3,5-dimethylpiperazine

A mixture of 1-(4-chlorophenyl)-2-(1,3-dithietan-2-ylidene)-2-(4-pyridinyl)ethanone (3.2 g, 0.01 mol; prepared as set forth in Step 1 of Example A-341) and 2,6-dimethylpiperazine (3.43 g, 0.03 mol) in 35 mL of toluene was heated at reflux for 12 hours. Toluene and excess 2,6-dimethylpiperazine were then removed under vacuum and the crude thiamide produced was used without purification. A solution of the crude thiamide and anhydrous hydrazine (0.65 g, 0.02 mol) in 40 mL of dry tetrahydrofuran was stirred at room temperature overnight. After the removal of tetrahydrofuran, the residue was stirred with a mixture of ethyl acetate and ammonium hydroxide for one hour. The precipitate was filtered and air dried to give 1.6 g of 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-3,5-dimethylpiperazine as a white solid (43% overall yield), mp: 236-238° C. Anal. Calc'd. for C₂₀H₂₂ClN₅.0.25H₂O: C, 64.51; H, 6.09; N, 18.81; Cl, 9.52. Found: C, 64.28; H, 5.85; N, 18.70; Cl, 9.67.

EXAMPLE A-343

embedded image

1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-3-methylpiperazine

1-[5-(4-Chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-3-methylpiperazine was prepared according to the same procedure set forth above in Example A-342 except that 2-methylpiperazine was used in place of 2,6-dimethylpiperazine (4% overall yield), mp: 235-237° C. Anal. Calc'd. for C₁₉H₂₀ClN₅.0.75H₂O: C, 62.12; H, 5.90; N, 19.06. Found: C, 62.23; H, 5.53; N, 18.80.

EXAMPLE A-344

The compound of Example A-317 was also synthesized in the following manner:

Step 1: Preparation of 1-(4-pyridyl)-1-(methylenedithioketene)-2-(4-fluorophenyl)-ethanone

To a solution of 4-fluorobenzoyl-4′-pyridyl methane (70.0 g, 0.3 mol, prepared as set forth in Step 1 of Example A-208) and dibromomethane (125 mL) was added solid anhydrous potassium carbonate (55.0 g, 0.4 mol) portionwise over five minutes. Carbon disulfide (17 g, 0.22 mol) was added dropwise over 15 minutes at room temperature. After stirring for 16 hours under a nitrogen atmosphere, the reaction was incomplete. Additional carbon disulfide (15 g) was added and the reaction mixture was stirred for an additional 24 hours. The reaction mixture was filtered and the potassium carbonate was washed on the filter with methylene chloride. The filtered solid was dissolved in water and extracted with methylene chloride. The extract was combined with the filtrate and dried over magnesium sulfate. The drying agent was filtered and the filtrate concentrated in vacuo. The residue was treated with ethyl acetate/ether (1:1), filtered and air dried to give 1-(4-pyridyl)-1-(methylenedithioketene)-2-(4-fluorophenyl)-ethanone (26 g, 86%) as a solid, m.p. 182-183° C.; Anal. Calc'd. for C₁₅H₁₀FNOS₂: C, 59.39; H, 3.32; N, 4.62. Found: C, 59.18; H, 3.41; N, 4.49.

Step 2: Preparation of 1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine, dihydrate

A mixture of the 1-(4-pyridyl)-1-(methylenedithioketene)-2-(4-fluorophenyl)-ethanone (3 g, 0.01 mol) prepared in Step 1 and 1-methylpiperazine (3 g, 0.03 mol) in 30 mL of toluene was refluxed under a nitrogen atmosphere for three hours. The mixture was cooled and solvent was removed under vacuum. The residue was dissolved in dry tetrahydrofuran (30 mL) and anyhydrous hydrazine (640 mg, 0.02 mol) was added. The reaction mixture was stirred at room temperature for 16 hours and the resulting precipitate was filtered. The precipitate was warmed in methanol and a few drops of concentrated ammonium hydroxide were added. The mixture was filtered hot and the filtrate blown down to half the volume. As the filtrate cooled, a product crystallized and was filtered to give 1.5 g (42%) of 1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine, dihydrate, mp: 238-240° C.; Anal. Calc'd. for C₁₉H₂₀FN₅.2H₂O: C, 61.11; H, 65.48; N, 18.75. Found: C, 60.79; H, 6.21; N, 18.98.

EXAMPLE A-345

embedded image

N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-N,1-dimethyl-4-piperidinamine, dihydrate

Step 1: Preparation of 1-methyl-4-methylaminopiperidine

A mixture of 1-methyl-4-piperidone (20 g, 0.18 mol) in methanol:tetrahydrofuran (100 mL, 1:1) and methyl amine (2 M in tetrahydrofuran, 3 mole excess) was placed in a Parr shaker with 5% Pd/C and hydrogenated for two hours at 60 psi and 70° C. The catalyst was filtered and the filtrate concentrated on the rotary evaporator. The crude material was distilled at 44-45° C. at 0.3 mm Hg to give 20 g (87%) of 1-methyl-4-methylaminopiperidine. Anal. Calc'd for C₇H₁₆N₂: C, 65.57; H, 12.58; N, 21.85. Found: C, 65.49; H, 12.44; N: 21,49.

Step 2: Preparation of N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-N,1-dimethyl-4-piperidinamine, dihydrate

A solution of 1-(4-chlorophenyl)-2-(1,3-dithietan-2-ylidene)-2-(4-pyridinyl)ethanone (3.2 g, 0.01 mol; prepared as set forth in Step 1 of Example A-341) and 1-methyl-4-methylaminopiperidine (3.8 g, 0.03 mol) in 30 mL of toluene refluxed for six hours under nitrogen. The mixture was cooled and solvent was removed under vacuum. The residue was dissolved in dry tetrahydrofuran (30 mL) and anyhydrous hydrazine (650 mg, 0.02 mol) was added. The reaction mixture was stirred at room temperature under nitrogen for 16 hours. The resulting precipitate was filtered and warmed in methanol and a few drops of concentrated ammonium hydroxide. The mixture was filtered hot and the filtrate blown down to half the volume. As the filtrate cooled, a product separated and was filtered to give 395 of pure N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-N,1-dimethyl-4-piperidinamine, dihydrate, m.p. 260-261° C. Anal. Calc'd for C₂₁H₂₄ClN₅.2H₂O: C, 60.35; H, 6.75; N, 16.76. Found: C, 59.89; H, 6.56; N: 16.40.

Additional compounds of the present invention that were prepared according to one or more of above reaction schemes (particularly Schemes IX through XVIII) are disclosed in Table 3-2. The specific synthesis scheme or schemes as well as the mass spectroscopy and elemental analysis results for each compound also are disclosed in Table 3-2.

TABLE 3-2MicroanalysisMSCCHHNNWaterEtOAcCHCl₃TolueneHClExampleGeneralM+FoundFoundCalcFoundCalcFoundAddedAddedAddedAddedAddedA-346XIIA-347XII32959.3359.595.655.4715.5515.410.80.2A-348XII43968.4666.598.048.4819.1616.17A-349XII39761.8561.997.797.5217.4517.391.30.7A-350XII44966.2966.757.607.6817.8417.001.25A-351XII35268.3657.516.317.3119.9317.17A-352XII36669.0266.276.626.5919.1618.22A-353XII43069.2671.507.406.9118.3614.87A-354XII35570.4870.126.807.1513.9913.910.5A-355XII34166.7367.096.296.7716.0415.780.1A-356XVII41063.4263.616.006.0616.8116.630.4A-357XVII39254.3753.935.916.3213.7814.680.4A-358XII39470.2068.507.177.6817.8016.58A-359XVII39669.2169.337.688.0117.5517.610.2A-360XVII36650.8150.745.975.8014.1114.001.23A-361XII38971.1268.675.455.6414.4212.90A-362XII37570.5768.545.125.3914.9613.90A-363XII38971.1268.865.455.5814.4213.09A-364XVII36868.3168.397.157.4918.9718.930.1A-365XVII33848.7248.575.475.4514.9514.791.23A-366XII39756.3456.217.317.0317.9217.8921A-367XVII32170.2569.835.435.6217.2517.820.25A-368XII31364.6664.285.735.6216.7616.930.25A-369XII41266.7666.607.367.6116.9316.740.1A-370XII31364.6664.365.735.5916.7616.820.25A-371XVII63.7863.636.376.0917.7117.241A-372XII68.6368.807.267.5317.4017.140.5A-373XVII38958.1057.995.004.8817.8317.480.25A-374XII35467.9767.236.846.8119.8119.38A-375XII36668.1868.066.676.8018.9318.560.25A-376XII37570.5768.195.126.0614.9613.13A-377XII39664.1464.446.996.7816.0216.020.35A-378XVII33766.4266.445.224.9116.3116.270.4A-379XVII33962.7662.806.045.4315.4115.171.4A-380XVII38163.3163.405.195.8214.0613.8411A-381XVII30770.5769.694.945.0018.2917.68A-382XVIIA-383XVIIA-38432055.4853.445.645.0017.0321.60A-385XI28052.6552.515.985.1710.8311.121A-386XII35164.9664.775.825.3414.8515.0310.1A-387XII35365.2965.626.326.1414.6414.470.70.2A-38839454.9355.346.216.7913.9314.013

EXAMPLE A-346

embedded image

N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-4-methyl-1-piperazinepropanamine(2E)-2-butenedioate (1:1)
EXAMPLE A-347

embedded image

3-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-1,2-propanediol;

EXAMPLE A-348

embedded image

N,N,N″-triethyl-N′-[2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]ethyl]-1,3-propanediamine;

EXAMPLE A-349

embedded image

N-[2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2pyridinyl]amino]ethyl]-N,N′,N′-trimethyl-1,3-propanediamine;

EXAMPLE A-350

embedded image

N-(2-[1,4′-bipiperidin]-1′-ylethyl)-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinamine;

EXAMPLE A-351

embedded image

4-(3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-(4-piperidinylmethyl)-2-pyridinamine;

EXAMPLE A-352

embedded image

N-(1-ethyl-4-piperidinyl)-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl)-2-pyridinamine;

EXAMPLE A-353

embedded image

N2,N2-diethyl-N1-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-1-phenyl-1,2-ethanediamine;

EXAMPLE A-354

embedded image

(2S)-2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl)-2-pyridinyl]amino]-4-methyl-1-pentanol;

EXAMPLE A-355

embedded image

2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-3-methyl-1-butanol;

EXAMPLE A-356

embedded image

ethyl 4-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-1-piperidinecarboxylate;

EXAMPLE A-357

embedded image

4-[3-(4-fluorophenyl)-5-(4-(1-pyrrolidinyl)-1-piperidinyl]-1H-pyrazol-4-yl]pyridine, trihydrochloride;

EXAMPLE A-358

embedded image

N-[2-(1-ethyl-2-piperidinyl)ethyl]-4-(3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinamine;

EXAMPLE A-359

embedded image

N1,N1,-diethyl-N4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,4-pentanediamine;

EXAMPLE A-360

embedded image

1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-N,N-dimethyl-4-piperidinamine, trihydrochloride;

EXAMPLE A-361

embedded image

(βR)-β-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]benzene propanol;

EXAMPLE A-362

embedded image

(βS)-β-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]benzene ethanol;

EXAMPLE A-363

embedded image

(βS)-β-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]benzene propanol;

EXAMPLE A-364

embedded image

N,N-diethyl-N′-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,3-propanediamine;

EXAMPLE A-365

embedded image

1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-piperidinamine, trihydrochloride;

EXAMPLE A-366

embedded image

N1,N1-diethyl-N4-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]-1,4-pentanediamine;

EXAMPLE A-367

embedded image

1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,2,3,6-hexahydropyridine;

EXAMPLE A-368

embedded image

(2R)-1-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-2-propanol;

EXAMPLE A-369

embedded image

N4-[4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-N1,N1-diethyl-1,4-pentanediamine;

EXAMPLE A-370

embedded image

(2S)-1-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-2-propanol;

EXAMPLE A-371

embedded image

ethyl 4-[5-phenyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazinecarboxylate;

EXAMPLE A-372

embedded image

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[3-(2-inethyl-1-piperidinyl)propyl]-2-pyridinamine;

EXAMPLE A-373

embedded image

1-[5-(3,4-dichlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine;

EXAMPLE A-374

embedded image

N,N-diethyl-N′-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-1,2-ethanediamine;

EXAMPLE A-375

embedded image

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[2-(1-piperidinyl)ethyl]-2-pyridinamine;

EXAMPLE A-376

embedded image

(βR)-β-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]benzene ethanol;

EXAMPLE A-377

embedded image

N1,N1-diethyl-N4-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-1,4-pentanediamine;

EXAMPLE A-378

embedded image

1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-piperidinone;

EXAMPLE A-379

embedded image

1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-piperidinol;

EXAMPLE A-380

embedded image

8-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,4-dioxa-8-azaspiro[4.5]decane;

EXAMPLE A-381

embedded image

5-(4-fluorophenyl)-N-methyl-N-2-propynyl-4-(4-pyridinyl)-1H-pyrazol-3-amine;

EXAMPLE A-382

embedded image

4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]morpholine;

EXAMPLE A-383

embedded image

1-[5-(3,4-difluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine;

EXAMPLE A-384

embedded image

1-methyl-4-[5-phenyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]piperazine;

EXAMPLE A-385

embedded image

4-[3-(4-fluorophenyl)-1-(2-propenyl)-1H-pyrazol-4-yl]pyridine, monohydrochloride;

EXAMPLE A-386

embedded image

trans-4-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]cyclohexanol;

EXAMPLE A-387

embedded image

4-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]cyclohexanone;

EXAMPLE A-388

embedded image

1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-N,N-diethyl-4-piperidinamine, trihydrochloride;

EXAMPLE A-389

embedded image

1-[5-(3-tolyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl-4-methylpiperazine:

Step 1. Preparation of 1-tolyl-2-(4-pyridyl)ethanone
embedded image

Methyl 3-methylbenzoate (6.0 g, 40 mmol), 20 tetrahydrofuran (50 mL), and 4-picoline (4.1 g, 44 mmol) were stirred at −78° C. under an atmosphere of nitrogen. Sodium (bis)trimethylsilylamide 1.0 M in tetrahydrofuran (88 mL, 88 mmol) was added dropwise. The mixture was allowed to warm to room temperature, stirred for 16 hours and then was poured into saturated aqueous sodium bicarbonate solution. The mixture was then extracted with ethyl acetate (3×50 mL). The combined organics were washed with brine (2×50 mL), dried over magnesium sulfate, and concentrated. The product was recrystallized from ethyl acetate/hexane to yield a light yellow solid (5.7 g, 67%), mp 118.0-119.0° C.; ¹H NMR (acetone-d6/300 MHz) 8.50 (m, 2H), 7.90 (m, 2H), 7.44 (m, 2H), 7.29 (m, 2H), 4.45 (s, 2H), 2.41 (s, 3H); ESHRMS m/z 212.1067 (M+H, C₁₄H₁₃NO requires 212.1075); Anal. Calc'd for C₁₄H₁₃NO: C, 79.59; H, 6.20; N, 6.63. Found: C, 79.54; H, 6.30; N, 6.56.

Step 2. Preparation of 1-(3-tolyl)-2-(1,3-dithietan-2-ylidene)-2-(4-pyridyl)ethanone
embedded image

1-tolyl-2-(4-pyridyl)ethanone (4.22 g, 20 mmol), acetone (100 mL), potassium carbonate (8.3 g, 60 mmol), carbon disulfide 4.56 g, 60 mmol), and dibromomethane (10.43 g, 60 mmol) were stirred at room temperature for 16 hours. Water (100 mL) was added and the mixture was extracted with ethyl acetate (3×50 mL). The combined organic extracts were washed with brine (2×50 mL), dried over magnesium sulfate and concentrated. This crude material was purified by either flash column chromatography eluting with ethyl acetate:hexane or crystallization from ethyl acetate/hexane to yield a yellow solid (4.8 g, 80%), mp 178.6-179.2° C.; ¹H NMR (acetone-d6/300 MHz) 8.47 (m, 2H), 7.08 (m, 6H), 4.37 (s, 2H), 2.21 (s, 3H); ESHRMS m/z 300.0521 (M+H, C₁₆H₁₃NOS₂requires 300.0517); Anal. Calc'd for C₁₆H₁₃NOS₂: C, 64.18; H, 4.38; N, 4.68. Found: C, 64.08; H, 4.25; N, 4.62.

Step 3. Preparation of 1-[3-(3-tolyl)-3-oxo-2-(4-pyridinyl)-1-thiopropyl]-4-methylpiperazine
embedded image

The dithietane compound from step 2 above (3.0 g, 10 mmol), N-methylpiperazine (5.0 g, 50 mmol), and toluene (50 mL) were refluxed using a Dean-Stark apparatus for one to three hours. The reaction was allowed to cool to room temperature and was concentrated to dryness under high vacuum. This thick, oily material was crystallized from ethyl acetate/hexane (2.9 g, 82%), mp 124.8-125.8° C.; ¹H NMR (acetone-d6/300 MHz) 8.57 (m, 2H), 7.75 (m, 2H), 7.54 (m, 2H), 7.37 (m, 2H) 6.54 (s, 1H), 4.27 (m, 2H), 4.19 (m, 1H), 3.83 (m, 1H), 2.47-2.28 (m, 6H), 2.22 (9, 3H), 2.17 (m, 1H); ESHRMS m/z 354.1669 (M+H, C₂₀H₂₃N₃OS requires 354.1640); Anal. Calc'd for C₂₀H₂₃N₃OS: C, 67.96; H, 6.56; N, 11.89. Found: C, 67.79; H, 6.66; N, 11.88.

Step 4. Preparation of 1-[5-(3-tolyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl-4-methylpiperazine.

The thioamide compound from step 3 above (1.06 g, 3 mmol), tetrahydrofuran (50 mL), and hydrazine (15 mL, 15 mmol, 1.0 M) in tetrahydrofuran were stirred at room temperature for 16 hours. A white solid was collected by filtration. Purification when necessary was by trituration or recrystallization (0.98 g, 97%), mp 261.9-262.0° C.; ¹H NMR (DMSO-d6/300 MHz) 12.6 (brs, 1H), 8.42 (m, 2H), 7.2 (m, 4H), 7.12 (s, 1H), 7.0 (m, 1H), 2.86 (m, 4H), 2.34 (m, 4H) 2.25 (s, 3H), 2.16 (5, 3H); ESHRMS m/z 334.2049 (M+H, C₂₀H₂₃N₅requires 334.2032); Anal. Calc'd for C₂₀H₂₃N₅: C, 72.04; H, 6.95; N, 21.00. Found: C, 71.83; H, 7.06; N, 20.83.

Additional dithietanes and pyrazoles that were synthesized by selection of the corresponding starting reagents in accordance with the chemistry described in Scheme XXI and further illustrated in Example 389 above include compounds A-390 through A-426 disclosed below.

EXAMPLE A-390

embedded image

mp 185.3-185.4° C.; ¹H NMR (acetone-d6/300 MHz) 8.49 (m, 2H), 7.31 (m, 4H), 7.09 (m, 2H), 4.39 (s, 2H); ESHRMS m/z 319.9981 (M+H, C₁₅H₁₀ClNOS₂requires 319.9971); Anal. Calc'd for C₁₅H₁₀ClNOS₂: C, 56.33; H, 3.15; N, 4.38. Found: C, 56.47; H, 3.13; N, 4.44.

EXAMPLE A-391

embedded image

1-(4-chloro-3-methylphenyl)-2-1,3-dithietan-2-ylidene-2-pyridin-4-yl-ethanone

mp 164.0-165.0° C.; ¹H NMR (acetone-d6/300 MHz) 8.49 (m, 2H), 7.25 (m, 2H), 7.0 (m, 3H), 4.38 (s, 2H), 2.24 (s, 3H); ESHRMS m/z 334.0130 (M+H, C₁₆H₁₂ClNOS₂requires 334.0127); Anal. Calc'd for C₁₆H₁₂ClNOS₂: C, 57.56; H, 3.62; N, 4.20. Found: C, 57.68; H, 3.67; N, 4.17.

EXAMPLE A-392

embedded image

mp 126.5-126.6° C.; ¹H NMR (acetone-d6/300 MHz) 8.40 (m, 2H), 7.17 (m, 2H), 7.0 (m, 4H), 4.39 (s, 2H), 2.85 (s, 3H); ESHRMS m/z 300.0483 (M+H, C₁₆H₁₃NOS₂requires 300.0517); Anal. Calc'd for C₁₆H₁₃NOS₂: C, 64.18; H, 4.38; N, 4.68. Found: C, 64.05; H, 4.27; N, 4.59.

EXAMPLE A-393

embedded image

mp 159.6-159.7° C.; ¹H NMR (acetone-d6/300 MHz) 8.52 (m, 2H), 7.6 (m, 1H), 7.50 (s, 1H), 7.21 (m, 2H), 7.13 (m, 2H), 4.40 (s, 2H); ESHRMS m/z 363.9503 (M+H, C₁₅H₁₀BrNOS₂requires 363.9465); Anal. Calc'd for C₁₅H₁₀BrNOS₂: C, 49.46; H, 2.77; N, 3.84. Found: C, 49.51; H, 2.68; N, 3.74.

EXAMPLE A-394

embedded image

mp 198.8-198.9° C.; ¹H NMR (acetone-d6/300 MHz) 8.45 (m, 2H), 7.05 (m, 3H), 6.95 (m, 1H), 6.82 (m, 1H), 4.29 (s, 2H), 2.14 (s, 3H), 2.08 (s, 3H); ESHRMS m/z 314.0691 (M+H, C₁₇H₁₅NOS₂requires 314.0673).

EXAMPLE A-395

embedded image

mp 182.6-183.0° C. ¹H NMR (acetone-d6/300 MHz) 8.50 (m, 2H), 7.42 (d, 2H, J=8.5 Hz), 7.23 (d, 2H, J=8.5 Hz), 7.10 (m, 2H), 4.40 (s, 2H). ESHRMS m/z 370.0173 (M+H, C₁₆H₁₀F₃NO₂S₂requires 370.0183).

EXAMPLE A-396

embedded image

mp 193.3-193.4° C. ¹H NMR (acetone-d6/300 MHz) 8.49 (m, 2H), 7.69 (d, 2H, J=8.2 Hz), 7.46 (d, 2H, J=8.2 Hz), 7.01 (m, 2H), 4.43 (s, 2H). ESHRMS m/z 311.0327 (M+H, C₁₆H₁₀N₂₀S₂requires 311.0313).

EXAMPLE A-397

embedded image

mp 191.5-192.5° C.; ¹H NMR (CDCl₃/300 MHz) 8.55 (dd, 2H, J=4.6, 1.6 Hz), 7.4 (m, 1H), 7.09-7.03 (m, 3H), 6.67 (d, 1H, J=8.7 Hz), 4.17 (s, 2H), 3.86 (s, 3H); ESHRMS m/z 350.0090 (M+H, C₁₆H₁₂ClNO₃S₂requires 350.0076); Anal. Calc'd. for C₁₆H₁₂ClNO₂S₂: C, 54.93; H, 3.60; N, 4.00; Cl, 10.13; S, 18.33. Found: C, 54.74; H, 3.60; N, 3.89; Cl, 10.45; S, 18.32.

EXAMPLE A-398

embedded image

mp 172.1-173.1° C.; ¹H NMR (CDCl₃/300 MHz) 8.51 (dd, 2H, J=4.4, 1.6 Hz), 7.23-7.21 (m, 4H), 7.04 (dd, 2H, J=4.6, 1.6 Hz), 4.17 (s, 2H), 1.25 (s, 9H); ESHRMS m/z 342.1004 (M+H, C₁₉H₁₉NOS₂requires 342.0986); Anal. Calc'd for C₁₉H₁₉NOS₂: C, 66.83; H, 5.61; N, 4.10; S, 18.78. Found: C, 66.97; H, 5.89; N, 4.02; S, 18.64.

EXAMPLE A-399

embedded image

mp 203.0-204.1° C.; ¹H NMR (CDCl₃/300 MHz) 8.52 (dd, 2H, J=4.4, 1.6 Hz), 7.29 (d, 1H, J=6.8 Hz), 7.28 (d, 1H, J=7.0 Hz), 7.05 (dd, 2H, J=4.4, 1.6 Hz), 6.70 (d, 1H, J=6.8 Hz), 6.69 (d, 1H, J=6.8 Hz), 4.17 (s, 2H), 3.79 (s, 3H); ESHRMS m/z 316.0475 (M+H, C₁₆H₁₃NO₂S₂requires 316.0466); Anal. Calc'd. for C₁₆H₁₃NO₂S₂: C, 60.93; H, 4.15; N, 4.44; S, 20.33. Found: C, 60.46; H, 4.17; N, 4.37; S, 19.84.

EXAMPLE A-400

embedded image

mp 209.1-215.1° C.; ¹H NMR (CDCl₃/300 MHz) 8.50 (dd, 2H, J=4.4, 1.6 Hz), 7.20 (d, 2H, J=8.0 Hz), 7.03-6.99 (m, 4H), 4.18 (s, 2H), 2.30 (s, 3H); ESHRMS m/z 300.0517 (M+H, C₁₆H₁₃NOS₂requires 300.0517); Anal. Calc'd. for C₁₆H₁₃NOS₂: C64.18; H, 4.38; N, 4.69; S, 21.42. Found: C, 64.02; H, 4.62; N, 4.54; S, 21.24.

EXAMPLE A-401

embedded image

mp 257.6-257.7° C.; ¹H NMR (CDCl₃/300 MHz) 8.51 (dd, 2H, J=4.4, 1.6 Hz), 7.57 (d, 2H, J=8.5 Hz), 7.27-6.99 (m, 4H), 4.18 (s, 2H); ESHRMS m/z 411.9348 (M+H, C₁₅H₁₀NIOS₂requires 411.9327); Anal. Calc'd. for C₁₅H₁₀NIOS₂: C, 43.81; H, 2.45; N, 3.41. Found: C, 43.71; H, 2.27; N, 3.41.

EXAMPLE A-402

embedded image

mp 197.3-202.2° C.; ¹H NMR (CDCl₃/300 MHz) 8.53 (dd, 2H, J=4.4, 1.6 Hz), 7.26 (d, 2H, J=9.3 Hz), 7.09 (dd, 2H, J=4.4, 1.6 Hz), 6.43 (d, 2H, J=9.3 Hz), 4.14 (s, 2H), 2.97 (s, 6H); ESHRMS m/z 329.0789 (M+H, C₁₇H₁₆N₂OS₂requires 329.0782); Anal. Calc'd. for C₁₇H₁₆N₂OS₂: C, 62.17; H, 4.91; N, 8.53; S, 19.53. Found: C, 61.93; H, 5.12; N, 8.46; S, 19.26.

EXAMPLE A-403

embedded image

mp 176.6-176.7° C.; ¹H NMR (CDCl₃/300 MHz) 8.51 (dd, 2H, J=4.4, 1.6 Hz), 7.29-7.22 (m, 4H), 7.03 (dd, 2H, J=4.4, 1.6 Hz), 6.64 (dd, 1H, J=17.5, 10.9 Hz), 5.76 (d, 1H, J=17.7 Hz), 5.31 (d, 1H, J=10.9 Hz), 4.19 (s, 2H); ESHRMS 312.0513 (M+H, C₁₇H₁₃NOS₂requires 312.0517); Anal. Calc'd. for C₁₇H₁₃NOS₂: C, 65.56; H, 4.21; N, 4.50. Found: C, 65.75; H, 4.11; N, 4.46.

EXAMPLE A-404

embedded image

mp 174.8-175.0° C.; ¹H NMR (CDCl₃/300 MHz) 8.50 (dd, 2H, J=4.4, 1.6 Hz), 7.23-7.20 (m, 4H), 7.03 (dd, 2H, J=4.6, 1.6 Hz), 4.17 (s, 2H), 2.59 (q, 2H, J=7.6 Hz), 1.17 (t, 3H, J=7.7 Hz); ESHRMS m/z 314.0677 (M+H, C₁₇H₁₅NOS₂requires 314.0673); Anal. Calc'd. for C₁₇H₁₅NOS₂: C, 65.14; H, 4.82; N, 4.47. Found: C, 64.90; H, 4.62; N, 4.45.

EXAMPLE A-405

embedded image

mp 167.1-167.5° C.; ¹H NMR (CDCl₃/300 MHz) 8.52 (dd, 1H, J=4.4, 1.6 Hz), 7.33 (d, 1H, J=8.3 Hz), 7.02-7.00 (m, 3H), 6.87-6.83 (m, 1H), 4.19 (s, 2H), 2.28 (s, 3H); ESHRMS m/z 379.9577 (M+H, C₁₆H₁₂BrNOS₂requires 379.9622); Anal. Calc'd. for C₁₆H₁₂BrNOS₂: C, 50.80; H, 3.20; N, 3.70. Found: C, 50.69; H, 3.19; N, 3.71.

EXAMPLE A-406

embedded image

mp 168.6-168.7° C.; ¹H NMR (CDCl₃/300 MHz) 8.54 (dd, 2H, J=4.6, 1.8 Hz), 7.68-7.62 (m 2H), 7.43-7.39 (m, 1H), 7.33-7.28 (m, 1H), 6.99 (dd, 2H, J=4.4, 1.6 Hz), 4.22 (s, 2H); ESHRMS m/z 311.0330 (M+H, C₁₆H₁₀N₂OS₂requires 311.0313); Anal. Calc'd. for C₁₆H₁₀N₂OS₂: C, 61.91; H, 3.25; N, 9.02. Found: C, 61.45; H, 3.18; N, 8.91.

EXAMPLE A-407

embedded image

1-[5-(3-methyl-4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine.

mp 236.7-239.3° C.; ¹H NMR (DMSO-d6/300 MHz) 12.6 (brs, 1H), 8.45 (m, 2H), 7.41 (m, 1H), 7.26 (m, 3H), 7.0 (m, 1H), 2.86 (m, 4H), 2.35 (m, 4H), 2.27 (s, 3H), 2.16 (s, 3H); ESHRMS m/z 368.4653 (M+H, C₂₀H₂₂ClN₅requires 368.1642).

EXAMPLE A-408

embedded image

1-[5-(2-tolyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine

mp 244.0-244.2° C.; ¹H NMR (acetone-d6/300 MHz) 11.6 (brs, 1H), 8.35 (m, 2H), 7.35 (m, 2H), 7.25 (m, 4H), 3.05 (m, 4H), 2.47 (m, 4H), 2.25 (s, 3H), 2.00 (s, 3H); ESHRMS m/z 334.2018 (M+H, C₂₀H₂₃N₅requires 334.2032); Anal. Calc'd for C₂₀H₂₃N₅: C, 72.04; H, 6.95; N, 21.00. Found: C, 72.03; H, 7.00; N, 20.85.

EXAMPLE A-409

embedded image

1-[5-(3-broomophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine

mp 222.5-223.4° C.; ¹H NMR (acetone-d6/300 MHz) 11.8 (brs, 1H), 8.51 (m, 2H), 7.55 (m, 2H), 7.34 (m, 4H), 3.0 (m, 4H), 2.41 (m, 4H), 2.22 (s, 3H); ESHRMS m/z 398.0982 (M+H, C₁₉H₂₀BrN₅requires 398.0980).

EXAMPLE A-410

embedded image

1-[5-(3,4-dimethylphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine

mp 270.9-272.7° C.; ¹H NMR (DMSO-d6/300 MHz) 12.5 (brs, 1H), 8.41 (m, 2H), 7.24 (m, 2H), 7.26 (m, 3H), 7.10 (m, 2H), 6.92 (m, 1H), 2.86 (m, 4H), 2.38 (m, 4H), 2.21 (s, 3H), 2.19 (s, 3H), 2.16 (s, 3H); ESHRMS m/z 348.2183 (M+H, C₂₁H₂₅N₅requires 348.2188).

EXAMPLE A-411

embedded image

1-[5-(4-trifluoromethoxyphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine

mp 221.0-221.2° C.; ¹H NMR (DMSO-d6/300 MHz) 12.7 (brs, 1H), 8.45 (m, 2H), 7.38 (s, 4H), 7.24 (m, 2H), 2.86 (m, 4H), 2.34 (m, 4H), 2.16 (s, 3H); ESHRMS m/z 404.1698 (M+H, C₂₀H₂₀F₃N₅O requires 404.1698).

EXAMPLE A-412

embedded image

1-[5-(4-cyanophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine

mp >300° C.; ¹H NMR (DMSO-d6/300 MHz) 12.8 (brs, 1H), 8.47 (m, 2H), 7.83 (m, 2H), 7.42 (m, 2H), 2.88 (m, 4H), 2.39 (m, 4H), 2.20 (s, 3H); ESHRMS m/z 345.1848 (M+H, C₂₀H₂₀N₆requires 345.1828).

EXAMPLE A-413

embedded image

1-[5-(3-chloro-4-methoxyphenyl)-4-(4-pyridinyl-1H-pyrazol-3-yl]-4-methylpiperazine

mp 272.7-276.4° C.; ¹H NMR (DMSO-d6/300 MHz) 8.44 (dd, 2H, J=4.6, 1.6 Hz), 7.32-7.13 (m, 5H), 3.84 (s, 3H), 2.90-2.85 (m, 4H), 2.38-2.35 (m, 4H), 2.16 (s, 3H); ESHRMS m/z 384.1580 (M+H C₂₀H₂₂ClN₅O requires 384.1591).

EXAMPLE A-414

embedded image

1-[5-(4-tert-butylphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine

mp 243.6-244.3° C.; ¹H NMR (DMSO-d6/300 MHz) 8.44 (dd, 2H, J=4.6, 1.6, Hz), 7.40 (d, 2H, J=8.3 Hz), 7.28-7.18 (m, 4H), 2.90-2.85 (m, 4=H), 2.38-2.34 (m, 4H), 2.16 (s,3H), 1.26 (s, 9H); ESHRMS m/z 376.2491 (M+H, C₂₃H₂₉N₅requires 376.2501).

EXAMPLE A-415

embedded image

1-[4-(4-methoxyphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine

mp 259.0-260.2° C.; ¹H NMR (DMSO-d6/300 MHz) 8.53 (dd, 2H, J=4.4, 1.6 Hz), 7.24 (dd, 2H, J=4.4, 1.6 Hz), 7.18 (d, 2H, J=8.9 Hz), 6.94 (d, 2H, J=8.9 Hz), 3.75 (s, 3H), 2.90-2.85 (m, 4H), 2.39-2.35 (m, 4H), 2.16 (s, 3H); ESHRMS m/z 350.1991 (M+H, C₂₀H₂₃N₅O requires 350.1981); Anal. Calc'd. for C₂₀H₂₃N₅O+3.93%H2O: C, 66.04; H, 6.81; N, 19.25. Found: C, 66.01; H, 6.62; N, 19.32.

EXAMPLE A-416

embedded image

1-[5-(4-methylphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine

mp 243.0-246.8° C.; ¹H NMR (DMSO-d6/300 MHz) 8.41 (dd, 2H, J=4.6, 1.6 Hz), 7.24 (m, 6H), 2.91-2.86 (m, 4H), 2.40-2.35 (m, 4H), 2.29 (s, 3H), 2.16 (s, 3H); ESHRMS m/z 334.2041 (M+H, C₂₀H₂₃N₅requires 334.2032); Anal. Calc'd for C₂₀H₂₃N₅+4.09%H2O: C, 69.10; H, 7.13; N, 20.14. Found: C, 69.10; H, 7.08; N, 20.13.

EXAMPLE A-417

embedded image

1-[5-(4-iodophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine

mp 265.2-265.8° C.; ¹H NMR (CD₃OD/300 MHz) 8.41 (dd, 2H, J=4.6, 1.6 Hz), 7.76-7.74 (m, 2H), 7.41-7.39 (m, 2H), 7.08-7.05 (m, 2H), 3.08-3.04 (m, 4H), 2.61-2.58 (m, 4H), 2.35 (s, 3H); ESHRMS m/z 446.0847 (M+H, C₁₉H₂₀IN₅requires 446.0842); Anal. Calc'd. for C₁₉H₂₀IN₅+12.09%H₂O: C, 44.60; H, 5.39; N, 13.69. Found: C, 44.50; H, 4.56; N, 13.66.

EXAMPLE A-418

embedded image

1-[5-(4-ethenylphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine

mp >300° C.; ¹H NMR (CD₃OD/300 MHz) 8.49 (dd, 2H, J=4.6, 1.6 Hz), 7.4.7-7.44 (m, 4H), 7.26 (d, 2H, J=8.4 Hz), 6.75 (dd, J=17.7, 11.1 Hz), 5.83 (d, 1H, J=17.5 Hz), 5.28 (d, 1H, J=11.1 Hz), 3.07-3.03 (m, 4H), 2.58-2.53(m, 4H), 2.31 (s, 3H); ESHRMS m/z 346.2034 (M+H, C₂₁H₂₃N₅requires 346.2032); Anal. Calc'd. for C₂₁H₂₃N₅+2.83 %H₂O: C, 70.95; H, 6.84; N, 19.70. Found: C, 70.97; H, 6.49; N, 19.54.

EXAMPLE A-419

embedded image

1-[5-(4-ethylphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine

mp 221.6-222.6° C.; ¹H NMR (CD₃OD/300 MHz) 8.38 (dd, 2H, J=4.6, 1.6 Hz), 7.44-7.40 (m, 2H), 7.26-7.19 (m, 4H), 3.06-3.02 (m, 4H), 2.66 (q, 2H, J=7.5 Hz), 2.59-2.54 (m, 4H), 2.32 (s, 3H), 1.23 (t, 3H, J=7.5 Hz); ESHRMS m/z 348.2188 (M+H, C₂₁H₂₅N₅requires 348.2188); Anal. Calc'd for C₂₁H₂₅N₅+2.59%H₂O: C, 70.71; H, 7.35; N, 19.63. Found: C, 70.76; H, 7.40; N, 19.46.

EXAMPLE A-420

embedded image

1-[5-(4-bromo-3-methylphenyl)-4-(4-pyrdinyl)-1H-pyrazol-3-yl]-4-methylpiperazine

mp 294.7° C. decomp.; ¹H NMR (CD₃OD/300 MHz) 8.41 (dd, 2H, J=4.6, 1.6 Hz), 7.55 (d, 1H, J=8.2 Hz), 7.45-7.42 (m, 2H), 7.27-7.25 (m, 1H), 7.00-6.97 (m 2H), 3.08-3.03 (m, 4H), 2.59-2.54 (m, 4H), 2.35 (s, 3H), 2.31 (s, 3H); ESHRMS m/z 412.1124 (M+H, C₂₀H₂₂BrN₅requires 412.1137).

EXAMPLE A-421

embedded image

1-[5-(4-dimethylaminophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine

mp >300° C. (decomposed); ¹H NMR (CD₃OD/300 MHz) 8.37 (d, 2H, J=4.6 Hz), 7.44 (d, 2H, J=4.8 Hz), 7.12, (d, 2H, J=8.9 Hz), 6.73 (d, 2H, J=8.7 Hz), 3.04-3.02 (m, 4H), 2.96 (s, 6H), 2.54-2.49 (m, 4H), 2.31 (s, 3H); ESHRMS m/z 363.2266 (M+H, C₂₁H₂₆N₆requires 363.22972).

EXAMPLE A-422

embedded image

1-[5-(3-cyanophenyl)-4-(4-pyrdinyl)-1H-pyrazol-3-yl]4-methylpiperazine

mp 223.4-224.3° C.; ¹H NMR (CD₃OD/300 MHz) 8.44 (dd, 2H, J=4.6, 1.4 Hz), 7.75-7.69 (m, 2H), 7.56-7.54 (m, 2H), 7.40-7.38 (m, 2H), 3.05-3.03 (m, 4H), 2.54-2.49 (m, 4H), 2.53 (s, 3H); ESHRMS m/z 345.1840 (M+H, C₂₀H₂₀N₆requires 345.1828).

EXAMPLE A-423

embedded image

1-[5-(4-thiomethoxyphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine

mp 275.6-281.9° C.; ¹H NMR (CD₃OD/300 MHz) 8.44-8.40 (m, 2H), 7.46-7.41 (m, 2H), 7.28-7.23 (m, 4H), 3.04-3.00 (m, 4H), 2.59-2.53 (M, 4H), 2.48 (s, 3H), 2.31 (s, 3H); ESHRMS m/z 366.1777 (M+H, C₂₀H₂₃N₅S requires 366.1752).

EXAMPLE A-424

embedded image

1-[5-(3-trifluoromethylphenyl)-4-(4-pyridinyl-1H-pyrazol-3-yl]-4-methylpiperazine

mp 212.6-213.7° C.; ¹H NMR (CD₃OD/300 MHz) 8.43 (d, 2H, J=4.8 Hz), 7.69-7.56 (m, 4H), 7.41 (s, 2H), 3.07-3.04 (m, 4H), 2.56-2.53 (m, 4H), 2.32 (s, 3H); ESHRMS m/z 388.1764 (M+H, C₂₀H₂₀F₃N₅requires 388.1749).

EXAMPLE A-425

embedded image

1-[5-(4-trifluoromethylphenyl)-4-(4-pyridinyl-1H-pyrazol-3-yl]-4-methylpiperazine

mp 240.5° C. (decomposed); ¹H NMR (CD₃OD/300 MHz) 8.43 (dd, 2H, J=4.6, 1.6 Hz), 7.70-7.67 (m, 2H), 7.51-7.48 (m, 2H), 7.42-7.38 (m 2H), 3.09-3.04 (m, 4H), 2.59-2.53 (m, 4H), 2.31 (s, 3H); ESHRMS m/z 388.1768 (M+H, C₂₀H₂₀F₃N₅requires 388.1749).

EXAMPLE A-426

embedded image

1-[5-(2-thienyl)-4-(4-pyridinyl-1H-pyrazol-3-yl]-4-methylpiperazine

mp 199.7° C. (decomposed); ¹H NMR (CD₃OD/300 MHz) 8.44 (d, 2H, J=5.8 Hz), 7.47 (d, 2H, J=5.6 Hz), 7.13-7.07 (m, 3H), 3.04-3.00 (m, 4H), 2.53-2.49 (m, 4H), 2.30 (s, 3H); ESHRMS m/z 326.1454 (M+H, C₁₇H₁₉N₅S requires 326.1439).

EXAMPLE A-427

embedded image

Step 1: Preparation of 3-dimethylamino-1-(4-chlorophenyl)-2-(pyridin-4-yl)-2-propene-1-one

A solution of 4-chlorophenyl-2-(pyridin-4-yl)ethan-1-one (20.0 g, 86.4 mmol) and N,N-dimethylformamide dimethylacetal (57.6 mL, 0.43 mole) was heated at 100° C. for 3½ hours. The reaction mixture was concentrated in vacuo, and the residue crystallized from methyl butyl ether to give 3-dimethylamino-1-(4-chlorophenyl)-2-(pyridin-4-yl)-2-propen-1-one (22.80 g, 93%). ¹H NMR (CDCl₃/300 MHz) δ 8.52 (d, 2H), 7.38 (d, 2H), 7.29 (d, 2H), 7.08 (d, 2H), 2.83 (s, 6H).

Step 2: Preparation of 5-(4-chlorophenyl)-4-(pyridin-4-yl)isoxazole

A solution of 3-dimethylamino-1-(4-chlorophenyl)-2-(pyridin-4-yl)-2-propen-1-one (22.80 g, 79.7 mmol), hydroxylamine hydrochloride (18.01 g, 0.26 mole), and 150 mL ethanol was heated to reflux for 30 minutes. The reaction mixture was then cooled to room temperature and concentrated in vacuo. The residue was dissolved in 1N hydrochloric acid and then treated with an aqueous saturated solution of sodium bicarbonate. The precipitates were collected by filtration, washed with water and ethanol, and dried to yield 5-(4-chlorophenyl)-4-(pyridin-4-yl)isoxazole (20.50 g, 93%). m.p. 120.8-120.9° C. ¹H NMR (CDCl₃/CD₃OD/300 MHz) δ 8.53 (d, 2H), 8.46(s, 1H), 7.51(d, 2H), 7.41-7.34 (m, 4H). ESLRMS m/z 257 (M+H). ESHRMS m/z 257.0457 (M+H, C₁₄H₉N₂OCl requires 257.0482).

Step 3: Preparation of 3-(4-chlorophenyl)-3-oxo-2-(pyridin-4-yl)propanenitrile:

A solution of 5-(4-chlorophenyl)-4-(pyridin-4-yl)isoxazole (20.5 g, 79.9 mmol) and 150 mL of a 1N sodium hydroxide solution was stirred at 60° C. for 1 hour. The reaction mixture was cooled to room temperature and adjusted to pH 6 with concentrated hydrochloric acid. The precipitates were filtered, washed with water and ethanol, and dried to give 3-(4-chlorophenyl)-3-oxo-2-(pyridin-4-yl)propanenitrile (20.0 g, quantitative yield). m.p. 225.4-234.9° C. ¹H NMR (CDCl₃/CD₃OD/300 MHz) δ 8.12 (brs, 2H), 7.73-7.59 (m, 5H), 7.30 (d, 3H). ESLRMS m/z 257 (M+H). ESHRMS m/z 257.0481 (M+H, C₁₄H₉N₂₀Cl requires 257.0482).

Step 4: 5-amino-3-(4-chlorophenyl)-4-(pyridin-4-yl)-pyrazole

A solution of 3-(4-chlorophenyl)-3-oxo-2-(pyridin-4-yl)propanenitrile (3.50 g, 13.6 mmol) in 40 mL acetonitrile and phosphorous trichloride (14.2 ml, 163 mmol) was stirred at 100° C. for 5 hours. The reaction mixture was concentrated in vacuo, and the residue taken up in toluene and concentrated again. The residue was then taken up in ethanol (150 mL) and treated with anhydrous hydrazine (1.71 mL, 54.4 mmol). The reaction mixture was heated to reflux for 3 hours, cooled, and concentrated in vacuo. The residue was triturated with a mixture of ethanol and dichloromethane (1:4), and filtered. The solid was washed with the ethanol/dichloromethane mixture, and dried to give 5-amino-3-(4-chlorophenyl)-4-(pyridin-4-yl)-pyrazole (2.0 g, 54%): m.p. >300° C. ¹H NMR (DMSO/300 MHz) δ 8.40 (d, 2H), 7.40 (d, 2H), 7.29 (d, 2H), 7.11 (d, 2H), 5.05 (s, 2H). ESLRMS m/z 271 (M+H). ESHRMS m/z 271.0752 (M+H, C₁₄H₁₁N₄Cl requires 271.0750).

EXAMPLE A-428

embedded image

A solution of 1,1′-carbonyldiimidazole (1.19 g, 7.38 mmol) and N-benzyliminodiacetic acid (0.824 g, 3.69 mmol) in dimethylformamide was heated at 75° C. for 30 minutes. To this mixture the 5-amino-3-(4-chlorophenyl)-4-(pyridin-4-yl)-pyrazole (1.0 g, 3.69 mmol) was added, and heating was continued at 75° C. overnight. The white solid was filtered, was washed with diethyl ether, methylene chloride, 5% methanol/methylene chloride, and ethanol, and was dried to give the desired imide as an off-white solid (0.9 g, 53%): m.p. >300° C. ¹H NMR (DMSO/300 MHz) δ 8.53 (m, 2H), 7.5(d, 2H), 7.44-7.16 (m, 7H), 6.98(m, 2H), 3.64 (m, 4H), 3.48 (m, 2H). ESLRMS m/z 458 (M+H). ESHRMS m/z 458.1380 (M+H, C₂₅H₂₀N₅O₂Cl requires 458.1384).

EXAMPLE A-429

embedded image

Methyl 2-{[3-94-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]amino}acetate

A solution of 5-amino-3-(4-chlorophenyl)-4-(pyridin-4-yl)-pyrazole (1.0 g, 3.7 mmol) in dimethylformamide (30 mL) was heated to 95° C. and methyl bromo acetate (0.34 mL, 3.7 mmol) was added dropwise. The resulting solution was stirred at 95° C. for 4 hours, cooled, and concentrated in vacuo to an orange viscous oil (1.79 g). A portion of this product mixture (1.20 g) was crystallized from ethanol and diethyl ether to give methyl 2-{[3-4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]amino}acetate as a bright yellow solid (805 mg): m.p. 195.4-196.8° C. ¹H NMR (CD₃OD/300 MHz) δ 8.49 (d, 2H), 7.68 (d, 2H), 7.44 (m, 4H), 5.37 (s, 2H), 3.84 (s, 3H). ESLRMS m/z 343 (M+H). ESHRMS m/z 343.0975 (M+H, C₁₇H₁₆N₄O₂Cl requires 343.0962).

EXAMPLE A-430

embedded image

Lithium 2-{[3-4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]amino}acetate

To a solution of methyl 2-{[3-4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]amino}acetate (500 mg, 1.5 mmol) in 15 mL of methanol and 5 mL of water was added lithium hydroxide (189 mg, 4.5 mmol). The reaction mixture was stirred at room temperature for 5 hours. The solvent was removed in vacuo, and the residue taken up in ethanol. The precipitate was filtered and washed with methanol, and the filtrate was concentrated to give lithium 2-{[3-4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]amino}acetate as a yellow/orange solid (479 mg, 95%). mp >300° C. ¹H NMR (CD₃OD/300 MHz) δ 8.06 (d, 2H), 7.43 (d, 2H), 7.37 (m, 4H), 3.34 (s, 2H). ESLRMS m/z 329 (M+H), 335 (M+Li), 351 (M+Na). ESHRMS m/z 329.0772 (M+H, C₁₆H₁₄N₄O₂Cl requires 329.0805).

EXAMPLE A-431

embedded image

The above 4-chlorophenylketone was prepared according to the procedure used in Step 1 of Example C-1, infra, substituting methyl 4-chlorobenzoate for ethyl 4-fluorobenzoate. Yield; (74%), yellow solid, mp=95.5-97.3° C.; 1H-NMR (DMSO-d6/300 MHz) 8.57 (br d, 2H), 7.92 (d, 2H), 7.46 (d, 2H), 7.20 (d, 2H), 4.28 (s, 2H); ESLRMS m/z 232 (M+H).

EXAMPLE A-432

embedded image

To the ketone (1.0 gm, 4.7 mmol) from Step 1 of Example C-1, infra, in anhydrous tetrahydrofuran (10 mL) was added 1M potassium t-butoxide in tetrahydrofuran (10 mL, 10 mmol). The reaction mixture was stirred for 15 minutes at room temperature, then carbon disulfide (0.31 mL, 5.1 mmol) was added. After several minutes, methyl iodide (0.64 mL, 10.3 mmol) was added and the reaction allowed to stir for 4 hours. The reaction mixture was diluted with saturated sodium bicarbonate solution (25 mL) and extracted twice with ethyl acetate (35 mL). The combined ethyl acetate layers were washed with water (25 mL) and brine (25 mL). The organic solution was dried (MgSO₄), filtered and concentrated to an orange oil. The oil solidified on standing. Yield 1.4 gm (94%), mp 80.2-82.1° C.; ¹H-NMR (CDCl₃/300 MHz) 8.59 (d, 2H), 7.96 (m, 2H), 7.38 (m, 2H), 7.14 (m, 2H), 2.33 (s, 3H), 2.23 (s, 3H); Anal. Calc'd for C₁₆H₁₄FNOS₂: C, 60.16; H, 4.42; N, 4.39; S, 20.08. Found: C, 59.89; H, 4.09; N, 4.31; S, 20.14.

EXAMPLE A-433

embedded image

The above compound was prepared in a manner analogous to Example A-432 starting with the product of Example A-431. Crude yield: 100%; mp 87.6-88.2° C.; ¹H-NMR (CDCl₃/300 MHz) 8.60 (d, 2H), 7.87 (d, 2H), 7.44 (d, 2H), 7.37 (m, 2H), 2.33 (s, 3H), 2.22 (s, 3H); ESHRMS m/z 336.0297 (M+H, C₁₆H₁₅ClNOS₂requires 336.0283); Anal. Calc'd for C₁₆H₁₄ClNOS₂: C, 57.22; H, 4.20; N, 4.17. Found: C, 57.44; H, 3.97; N, 4.04.

EXAMPLE A-434

embedded image

To the compound of Example A-432 (1.4 gm, 4.4 mmol) in ethanol (15 mL) was added 1M hydrazine in acetic acid (5 mL, 5 mmol). The reaction was stirred at room temperature for 18 hours. No reaction had occurred, so additional hydrazine hydrate (1.08 mL, 22 mmol) was added and the reaction heated to reflux for 6 hours. The product began to precipitate from the reaction mixture. The reaction was cooled to room temperature and water was added to precipitate the product. The solid was collected by suction filtration and air dried. Yield: 675 mg (53%). The product was recrystallized from ethanol: 494 mg; mp 249.9-249.9° C.; ¹H-NMR (DMSO-d6/300 MHz) 13.51 (br s, 1H), 8.50 (d, 2H), 7.34 (m, 2H), 7.23 (m, 2H), 7.16 (m, 2H), 2.43 (s, 3H); ESHRMS m/z 286.0807 (M+H, C₁₅H₁₃FN₃S requires 286.0814); Anal. Calc'd for C₁₅H₁₂FN₃S: C, 63.14; H, 4.24; N, 14.73. Found: C, 63.01; H, 4.43; N, 14.81.

EXAMPLE A-435

embedded image

The above compound was made in an analogous manner to Example A-434 starting with the compound of Example A-433. Yield: 750 mg (33%); mp 250.2-250.2° C.; ¹H NMR (DMSO-d6/300 MHz) 13.57 (br s, 1H), 8.51 (m, 2H), 7.45 (br s, 2H), 7.32 (m, 2H), 7.17 (m, 2H), 2.43 (s, 3H); ESHRMS m/z 302.0537 (M+H, C₁₅H₁₃ClN₃S requires 302.0518); Anal. Calc'd for C₁₅H₁₂ClN₃S: C, 59.70; H, 4.01; N, 13.92. Found: C, 59.56; H, 3.96; N, 13.96.

EXAMPLE A-436

embedded image

3-(4-fluorophenyl)-4-(methylsulfinyl)-4-pyridin-4-yl-1H-pyrazole

To the compound of Example A-434 (150 mg, 0.52 mmol) in ethanol (15 mL) was added ammonium persulfate (450 mg, 1.97 mmol). The reaction mixture was stirred at ambient temperature. After several hours an additional amount of ammonium persulfate (450 mg) was added. The reaction mixture was monitored by TLC (silica) using 5% methanol in dichloromethane as the eluting solvent. When the stating material had been consumed, the reaction mixture was quenched with saturated sodium bicarbonate (25 mL) and extracted with ethyl acetate (2×25 mL). The ethyl acetate layers were combined, washed with brine (25 mL) and dried (MgSO₄). Filtration and concentration produced a white solid. The solid was triturated with diethyl ether, collected by suction filtration, and air dried.

Yield 150 mg (96%), mp 262.9-262.9° C.; ¹H NMR (DMSO-d6/300 MHz) 14.22 (br s, 1H), 8.56 (d, 2H), 7.42-7.23 (br m, 6H), 2.94 (s, 3H); Anal. Calc'd for C₁₅H₁₂FN₃OS.0.25 H₂O: C, 58.91; H, 4.12; N, 13.74; Found: C, 58.88; H, 4.17; N, 13.39.

EXAMPLE A-437

embedded image

3-(4-fluorophenyl)-5-(methylsulfonyl)-4-pyridin-4-yl-1H-pyrazole

To the compound of Example A-434 (285 mg, 1 mmol) in ethanol (10 mL) was added potassium peroxymonosulfate (2.45 gm, 4 mmol) and water (5 mL). The reaction mixture was stirred at ambient temperature. After 6 hours the reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (2×30 mL). The ethyl acetate layers were combined, washed with brine (25 mL) and dried (MgSO₄). The ethyl acetate did not efficiently extract the product from the aqueous phase, so the aqueous layer was saturated with sodium chloride and extracted with acetonitrile (50 mL). The acetonitrile solution was dried (MgSo₄), filtered, and combined with the filtered ethyl acetate solution. The solvents were evaporated and the resulting solid was triturated with a small amount of acetonitrile, collected by suction filtration, and air dried. Yield: 203 mg (64%); mp 297.1->300° C.; ¹H NMR (DMSO-d6/300 MHz) 14.37 (br s, 1H), 8.54 (m, 2H), 7.29 (m, 6H), 3.26 (s, 3H); Anal. Calc'd for C₁₅H₁₂FN₃O₂S: C, 56.77; H, 3.81; N, 13.24. Found: C, 56.52; H, 4.03; N, 13.11.

EXAMPLE A-438

embedded image

To the compound of Example A-432 (638 mg, 2 mmol) in toluene (6 mL) was added thiomorpholine (502 uL, 5 mmol). The reaction mixture was heated to between 80 and 110° C. After about three hours the bis-thiomorpholine substituted product began to precipitate from the reaction mixture. When the dithioketene acetal had been completely consumed, the reaction mixture was cooled to room temperature and the insoluble bis-thiomorpholine compound removed by filtration. To the toluene solution was added hydrazine hydrate (1 mL) and sufficient ethanol to create a homogeneous solution. The reaction mixture was then stirred at room temperature for 72 hours. The reaction mixture was diluted with ethyl acetate (50 mL) and extracted twice with water (25 mL) and once with brine (25 mL). The organic solution was dried (MgSO₄), filtered and concentrated to a reddish solid. The solid was triturated with acetonitrile, collected by suction filtration, and dried in-vacuo. The solid was then suspended in acetonitrile and heated to reflux. Ethyl acetate was then added until the solid almost completely dissolved. A small amount of ethanol was then added and the homogeneous yellow solution concentrated until a solid began to form. Allow to cool to room temperature. Collected a white solid by suction filtration. Yield: 63 mg, (7%); ¹H NMR (DMSO-d6/300 MHz) 12.65 (br s, 1H), 8.45 (d, 2H), 7.27 (m, 6H), 3.14 (m, 4H), 2.63 (m, 4H). ESLRMS m/z 341 (M+H); ESHRMS m/z 341.1241 (M+H, C₁₈H₁₈FN₄S requires 341.1236).

EXAMPLE A-439

embedded image

The above compound was prepared in a similar manner to Example A-438 starting with the appropriate dithioketene acetal and N-methylpiperazine. A white solid was obtained, mp 270.2-270.7° C.; ¹H NMR (DMSO-d6/300 MHz) 12.7 (br s, 1H), 8.47 (m, 2H), 7.57 (m, 2H), 7.21 (m, 2H), 2.85 (m, 4H), 2.34 (m, 4H) 2.15 (s, 3H); ESHRMS 398.0993 (M+H, C₁₉H₂₁BrN₅requires 398.0980).

EXAMPLE A-440

embedded image

To N-(2-hydroxyethyl)morpholine (363 uL, 3 mmol) in anhydrous tetrahydrofuran (7 mL), under nitrogen, was added 1M sodium hexamethyldisilamide (3 ml, 3 mmol) in tetrahydrofuran at ambient temperature. The reaction mixture was stirred for 15 minutes, then the dithietane prepared as set forth in Step 1 of Example A-341 (636 mg, 2 mmol) was added as a solid. The reaction mixture gradually became dark orange. After about 18 hours at ambient temperature, the reaction was quenched with saturated sodium bicarbonate solution (30 mL) and extracted twice with ethyl acetate (30 mL). The organic solutions were combined and washed with saturated NaCl solution (20 mL), then dried (MgSO₄), filtered, and concentrated to an orange oil. The oil was taken up in methanol (10 mL) and reconcentrated to remove any remaining ethyl acetate. The oil was then taken up in methanol (5 mL) and anhydrous hydrazine (69 uL) was added. The reaction mixture was allowed to stir at ambient temperature 18 hours, then quenched with saturated sodium bicarbonate solution (30 mL) and extracted twice with ethyl acetate (30 mL). The organic solutions were combined and washed with water (20 mL) and saturated NaCl solution (20 mL), then dried (MgSO₄), filtered, and concentrated to an orange semi-solid. The solid was triturated with acetonitrile (5 mL), collected by suction filtration, washed with acetonitrile and dried in-vacuo. Yield: off-white solid, 114 mg (14.8%); mp 198.9-199.9° C.; ¹H-NMR (DMSO-d6/300 MHz) 12.61 (br s, 1H), 8.41 (d, 2H), 7.52 (d, 2H), 7.38 (d, 2H), 7.21 (d, 2H), 4.33 (t, 2H), 3.54 (m, 4H), 2.70 (t, 2H), 2.44 (m 4H); ESHRMS m/z 385.1444 (M+H, C₂₀H₂₂ClN₄O₂requires 385.1431).

EXAMPLE A-441

embedded image

The above compound was prepared in an analogous manner to that of Example A-440, starting with 4-hydroxy-N-t-boc piperidine. Recrystallized from acetone/methanol. Yield: white solid 263 mg (29%); mp 230.1-231.8° C.; ¹H-NMR (DMSO-d6/300 MHz) 12.61 (br s, 1H), 8.42 (d, 2H), 7.52 (d, 2H), 7.38 (d, 2H), 7.20 (d, 2H), 4.88 (m, 1H), 3.52 (m, 2H), 3.30 (m, 2H), 1.93 (m, 2H), 1.65 (m, 2H), 1.39 (s, 9H); Anal. Calc'd for C₂₄H₂₇ClN₄O₃: C,63.36; H, 5.98; N, 12.31; Found: C, 63.34; H, 5.97; N, 12.22.

EXAMPLE A-442

embedded image

Example A-441 (130 mg, 0.28 mmol) was treated with concentrated HCl (0.5 mL) in ethanol (5 mL) for two hours. The solvent was removed in-vacuo and the resulting residue dissolved in ethanol and reconcentrated twice. The resulting solid was triturated with acetonitrile to afford a white solid. Yield: 119 mg (91%) tri-hydrochloride salt; mp 220.6-222.1° C.; ¹H-NMR (DMSO-d6/300 MHz) 13.25 (br s, 1H), 9.10 (br s, 2H), 8.67 (d, 2H), 7.75 (d, 2H), 7.60 (d, 2H), 7.50 (d, 2H), 5.04 (m, 1H), 3.17 (br d, 4H), 2.21 (m, 2H), 2.03 (m, 2H); Anal. Calc'd for C₁₉H₁₉ClN₄O.3 HCl: C, 49.16; H, 4.78; N, 12.07. Found: C, 49.24; H, 4.72; N, 12.02.

EXAMPLE A-443

embedded image

The above compound was prepared in a manner analogous to Example A-440 starting with (+/−)3-hydroxytetrahydrofuran. Recrystallized from ethanol.

Yield: white crystalline solid, 57 mg (8%); mp >300° C.; ¹H-NMR (DMSO-d6/300 MHz) 12.65 (br s, 1H), 8.42 (d, 2H), 7.52 (d, 2H), 7.38 (d, 2H), 7.18 (d, 2H), 5.28 (m, 1H), 3.86 (m, 2H), 3.82 (m, 1H), 3.75 (m, 1H), 2.26-2.01 (br m, 2H); Anal. Calc'd for C₁₈H₁₆ClN₃O₂: C, 63.25; H, 4.72; N, 12.29. Found: C, 63.12; H, 4.51; N, 12.31.

EXAMPLE A-444

embedded image

The above compound was prepared in a manner analogous to Example A-440 starting with p-methoxybenzyl alcohol. Yield: off-white solid, 252 mg (21%); mp=229.1-229.2° C.; ¹H-NMR (acetone-d6/300 MHz) 11.62 (br s, 1H), 8.40 (br s, 2H), 7.76 (s, 2H), 7.39 (m, 4H), 7.30 (br s, 2H), 6.87 (d, 2H), 5.27 (s, 2H), 3.77 (s, 3H); Anal. Calc'd for C₂₂H₁₈ClN₃O₂.0.25H₂O: C, 66.67; H, 4.70; N, 10.60. Found: C, 66.79; H, 4.95; N, 10.54.

EXAMPLE A-445

embedded image

The above compound was prepared in a manner analogous to Example A-440 starting with N-tert-butoxycarbonyl-ethanolamine. Recrystallized from ethyl acetate/methanol. Yield: white solid, 75 mg (4%); mp >300° C.; ¹H-NMR (DMSO-d6/300 MHz) 12.60 (br s, 1H), 8.38 (d, 2H), 7.53 (d, 2H), 7.38 (d, 2H), 7.22 (d, 2H), 7.02 (t, 1H), 4.20 (t, 2H), 3.34 (m, 2H), 1.36 (s, 9H); ESHRMS m/z 415.1551 (M+H, C₂₁H₂₄ClN₄O₃requires 415.1537)

EXAMPLE A-446

embedded image

The above compound was prepared in a manner analogous to Example A-440 starting with methanol.

Yield: off-white solid, 119 mg (14%); mp=265.3-265.3° C.; ¹H-NMR (DMSO-d6/300 MHz) 12.61 (br s, 1H), 8.41 (d, 2H), 7.52 (d, 2H), 7.38 (d, 2H), 7.17 (d, 2H), 3.90 (s, 3H); ESHRMS m/z 286.0766 (M+H, C₁₅H₁₃ClN₃O requires 286.0747); Anal. Calc'd for C₁₅H₁₂ClN₃O, 0.25H2O: C, 62.08; H, 4.34; N, 14.48. Found: C, 62.24; H, 4.11; N, 14.16.

EXAMPLE A-447

embedded image

To the dithietane of Step 1 of Example A-341 (638 mg, 2 mmol) in toluene (15 mL) was added thiomorpholine (800 uL, 8 uL). The reaction mixture was heated to reflux for 6 hours, then cooled to room temperature and diluted with toluene (20 mL). The reaction mixture was then extracted twice with water (20 mL) and brine (20 mL). The organic solution was dried (MgSO₄), filtered, and concentrated to an oil. Hexane was added to the residue and heated to reflux, then decanted. The oil became semi-solid. The semi-solid was dissolved in tetrahydrofuran (10 mL) and potassium t-butoxide 1M in tetrahydrofuran (2 mL, 2 mmol) was added. This was followed by iodomethane (125 uL, 2 mmol). The reaction was stirred at room temperature for 1 hour, then quenched with water (20 mL). The reaction mixture was extracted with ethyl acetate (2×30 mL). The organic layers were pooled, washed with brine (20 mL) and dried (MgSO₄). Filtration and concentration produced an oil which was chased once with toluene to remove any ethyl acetate. The residue was dissolved in ethanol (10 mL) and hydrazine hydrate (97 uL, 2 mmol) was added. The reaction mixture was stirred at room temperature for 4 hours then partitioned between ethyl acetate and saturated sodium bicarbonate solution (30 mL each). The layers were separated and the aqueous layer extracted again with ethyl acetate (30 mL). The combined organic layers were washed with brine (20 mL) and dried (MgSO₄). Filtration and concentration produced an orange residue which was triturated with acetonitrile to generate a tan solid. Yield: 295 mg (43%); mp >300° C.; ¹H NMR (DMSO-d6/300 MHz) 12.70 (br s, 1H), 8.47 (d, 2H), 7.46 (d, 2H), 7.26 (m, 4H), 3.13 (m, 4H), 2.62 (m, 4H); ESHRMS m/z 357.0942 (M+H, C₁₈H₁₈ClN₄S requires 357.0941); Anal. Calc'd for C₁₈H₁₇ClN₄S: C, 60.58; H, 4.80; N, 15.70. Found: C, 60.32; H, 4.96; N, 15.60.

EXAMPLE A-448

embedded image

3-(4-chlorophenyl)-5-[(1-methylpiperidin-4-yl)-oxy]-4-pyridin-4-yl-1H-pyrazole

The compound of Example A-441 (455 mg, 1.5 mmol) was combined with 98% formic acid (6 mL) and heated to 100° C. After three hours, 37% formaldehyde (1.22 mL, 15 mmol) was added and the reaction was heated for an additional five hours at 100° C. The reaction mixture was allowed to cool to room temperature and filtered. The solution was diluted with water (15 mL) and extracted once with ethyl acetate (30 mL). The aqueous solution was then basified with 2.5 N sodium hydroxide to pH 8. The cloudy mixture was then extracted twice with 1:1 tetrahydrofuran:ethyl acetate (30 mL). The organic layers were pooled and washed once with brine (25 mL), dried (MgSO₄), filtered and concentrated to an oil which solidified on standing. The solid was triturated with acetonitrile and collected by suction filtration. The solid was suspended in ethanol:water 2:1 (15 mL) and 1 mL of concentrated HCl was added. The solution was allowed to stir at room temperature for one hour, then filtered and concentrated. The residue was combined with ethanol (10 mL) and reconcentrated twice. The resulting solid was triturated with acetonitrile (10 mL) containing a small amount of ethanol (0.5 mL) to remove some colored impurities. The solid was collected by suction filtration, washed with acetonitrile and dried in-vacuo.

Yield: 490 mg (88%); mp 255.9-256.8° C.; ¹H NMR (D₂O/DMSO-d6/NaOD/300 MHz) 7.93 (d, 2H), 7.09 (s, 4H), 7.00 (d, 2H), 4.42 (m, 1H), 2.26 (br m, 2H,) 2.12 (br m, 2H), 1.92 (s, 3H), 1.68 (br m, 2H), 1.57 (br m , 2H); ESLRMS m/z 369 (M+H).

EXAMPLE A-449

embedded image

To the compound of Example C-1, infra, (4′-fluoro-1-(4-pyridyl)acetophenone, 14.0 g, 0.065 mol) in anhydrous tetrahydrofuran (200 mL) was added dropwise potassium t-butoxide (1M in tetrahydrofuran, 150 mL). The mixture was stirred 30 minutes. Carbon disulfide (4.2 mL, 0.07 mol) in tetrahydrofuran (25 mL) was added dropwise and stirred 15 minutes. 2-Bromomethyl-1,3-dioxolane (25.0 g, 0.15 mol) in tetrahydrofuran (25 mL) was added dropwise and contents were refluxed 10 hours. The mixture was allowed to cool and partitioned between ethyl acetate and water. The ethyl acetate layer was dried over MGSO₄and concentrated in vacuo leaving a red oil (29.3 g). Chromatography on silica gel eluting with 25% ethyl acetate/hexanes gave the desired compound as a red oil, (5.5 g, 18% yield). ¹H NMR (CDCl³) 8.62-8.52 (m, 2H); 8.07-7.95 (m, 2H); 7.48-7.40 (m, 2H); 7.20-7.05 (m, 2H); 5.15-5.05 (m, 1H); 4.98-4.90 (m, 1H); 4.00-3.77 (m, 8H); 3.08 (d, J=6 Hz, 2H); 3.03 (d, J=6 Hz, 2H); ESHRMS m/z 464.0966 (M+H, C₂₂H₂₃FNO₅S₂requires 464.1001); Anal. Calc'd for: C₂₂H₂₂FNO₅S₂(0.1 H₂O): C, 56.79; H, 4.81; N, 3.01. Found: C, 56.45; H, 4.71; N, 3.02.

EXAMPLE A-450

embedded image

To the compound of Example C-1, infra, (4′-fluoro-1-(4-pyridyl)acetophenone, 7.0 g, 0.0325 mol) in anhydrous tetrahydrofuran (200 mL) was added dropwise potassium t-butoxide (1M in tetrahydrofuran, 75 mL). The mixture was stirred 30 minutes. Carbon disulfide (2.1 mL, 0.035 mol) in tetrahydrofuran (25 mL) was added dropwise and stirred 15 minutes. 4-Methoxybenzyl chloride (10.2 mL, 0.075 mol) in tetrahydrofuran (10 mL) was added dropwise and contents were stirred overnight. The contents were partitioned between ethyl acetate and water. The ethyl acetate layer was dried over MgSO₄and concentrated in vacuo leaving a red oil (19.1 g). Chromatography on silica gel eluting with 25% ethyl acetate/hexanes gave the desired as a white solid (11.8 g, 68% yield). Recrystallization from ethyl acetate/hexanes gave the desired as colorless crystals: mp 118.5-120.6° C.; ¹H NMR (CDCl₃) 8.43 (d, J=7 Hz, 2H); 7. 62-7.52 (m, 2H); 7.20-6.72 (m, 12H); 3.98 (d, J=6 Hz, 4H); 3.83 (s, 3H); 3.81 (s, 3H); ESHRMS m/z 532.1408 (M+H, C₃₀H₂₇FNO₃S₂requires 532.1416); Anal. Calc'd for: C₃₀H₂₆FNO₃S₂(0.5 H₂₀): C, 66.65; H, 5.03; N, 2.59. Found: C, 66.34; H, 4.96; N, 2.55.

EXAMPLE A-451

embedded image

The compound of Example A-449 (4.0 g, 9.2 mmol) and hydrazine monohydrate (2.2 mL, 46 mmol) were refluxed in ethanol (100 mL) for three hours. The mixture was allowed to cool and stand overnight. A yellow precipitate was filtered to give the desired product as a yellow solid, (1.34 g, 41% yield); mp 202.1-205.4° C.; ¹H NMR (DMSO-d6) 13.5 (br s, 1H); 8.55-8.45 (m, 2H); 7.40-7.12 (m, 6H); 5.01 (s, 1H); 3.92-3.70 (m, 4H); 3.13 (s, 2H); ESHRMS m/z 358.1025 (M+H, C₁₆H₁₇FN₃O₂S requires 358.1025); Anal. Calc'd for: C₁₈H₁₆FN₃O₂S: C, 60.49; H, 4.51; N, 11.76. Found: C, 60.26; H, 4.55 N, 11.87.

EXAMPLE A-452

embedded image

The above compound was prepared similarly to the compound of Example A-451 starting with the compound prepared in Example A-450. The desired product was obtained as a white solid (2.15 g, 49% yield); mp 214.7-215.8C; ¹H NMR (DMSO-d6+approx. 10%TFA) 8.70 (d, 2H); 7.60 (d, 2H); 7.42-7.38 (m, 2H); 7.30-7.20 (m, 2H); 6.70 (d, 2H); 4.10 (s, 2H); 3.68 (s, 3H); ESHRMS m/z 392.1225 (M+H, C₂₂H₁₉FN₃OS requires 392.1232); Anal. Calc'd for: C₂₂H₁₈FN₃OS: C, 67.50; H, 4.63; N, 10.73. Found: C, 67.46; H, 4.67 N, 10.77.

EXAMPLE A-453

embedded image

The compound prepared in step 1 of Example A-341 (50 g, 0.156 mol) and anhydrous hydrazine (25 mL, 0.8 mol) were refluxed in ethanol (500 mL) for five hours. The mixture was allowed to cool and the precipitate filtered to afford the desired product as a yellow-orange solid (21.8 g). The filtrate was diluted with water (200 mL) and a second crop was obtained as a yellow-orange solid (18.0 g). The pH of the filtrate was adjusted to pH 8 with 3N HCl and the precipitated solid filtered to give more desired as a yellow-orange solid (2.0 g). The product was obtained in 93% yield. mp 266.3-268.9° C.; ¹H NMR (DMSO-d6) 13.80 (br, 1H); 12.20 (br s, 1H); 8.32 (s, 4H); 7.50-7.30 (m, 4H); ESHRMS m/z 288.0358 (M+H, C₁₄H₁₁ClN₃S requires 288.0362); Anal. Calc'd for: C₁₄H₁₀ClN₃S (0.4 H₂O): C, 57.01; H, 3.69; N, 14.25. Found: C, 56.95; H, 3.50 N, 14.14.

EXAMPLE A-454

embedded image

The above compound was prepared similarly to the compound of Example A-453. mp 261.3-263.9° C.; ¹H NMR (DMSO-d6) 11.55 (br s, 1H); 8.25-8.13 (m, 2H); 7.61-7.50 (m, 2H); 7.36-7.20 (m, 2H); 7.19-7.05 (m, 2H); ESHRMS m/z 272.0691 (M+H, C₁₄H₁₁FN₃S requires 272.0657); Anal. Calc'd for: C₁₄H₁₀FN₃S (0.25 H₂O): C, 60.97; H, 3.84; N, 15.24. Found: C, 61.05; H, 3.64 N, 15.12.

EXAMPLE A-455

To the compound prepared in Example A-453 (100 mg, 0.35 mmol) in methanol (2 mL) was added 0.5 M sodium methoxide (0.7 mL, 0.35 mmol). The mixture was stirred for 15 minutes and filtered to remove some small particles. The filtrate was concentrated in vacuo, dissolved in water and concentrated in vacuo leaving the desired product as a white solid. ¹H NMR (DMSO-d6) 11.60 (br s, 1H); 8.20 (d, 2H); 7.60-7.50 (m, 2H); 7.40-7.20 (m, 4H); Anal. Calc'd for: C₁₄H₉ClN₃NaS (2.5 H2O): C, 47.40; H, 3.98; N, 11.84. Found: C, 47.39; H, 3.33; N, 11.50.

EXAMPLE A-456

embedded image

[3-(4-chlorophenyl)-4-pyridin-4-yl-1H-pyrazole-5-yl]thio]-acetonitrile

To the compound prepared in Example A-453 (584 mg, 2.0 mmol) and bromoacetonitrile (140 ul, 2.0 mmol) in dimethylformamide (5 mL) was added anhydrous potassium carbonate (276 mg, 2.0 mmol). The contents were stirred overnight, then partitioned between ethyl acetate and water. The ethyl acetate layer was dried over MgSO₄and concentrated in vacuo leaving a tan solid. The solid was triturated with methanol and filtered to give the desired as a off-white solid (369 mg, 56% yield). mp 230.0-230.5° C.; ¹H NMR (DMSO-d6) 13.90 (br s, 1H); 8.58 (d, 2H); 7.60-7.13 (m, 6H); 4.10 (s, 2H); ESHRMS m/z 327.0482 (M+H, C₁₆H₁₂ClN₄S requires 327.0471); Anal. Calc'd for: C₁₆H₁₁C₁₁N₄S (0.3 H₂O): C, 57.85, H, 3.52; N, 16.87. Found C, 57.88; H, 3.31; N, 16.77.

EXAMPLE A-457

embedded image

The above compound was prepared similarly to the compound of Example A-456 except that when the contents were partitioned between ethyl acetate and water, an insoluble solid was filltered to give the desired product as a white solid (2.16 g). A second crop (1.68 g) of desired product gave a total yield of 61% . mp 192.8-195.2° C.; ¹H NMR (DMSO-d6+approximately 10%TFA) 9.80 (d, 2H); 7.80 (d, 2H); 7.52-7.34 (m, 4H); 3.92 (s, 2H); 3.57 (s, 3H); ESHRMS m/z 360.05735 (M+H, C₁₇H₁₄ClNl₃O₂S requires 360.05732); Anal. Calc'd for: C₁₇H₁₄ClN₃O₂S (0.25 H₂O): C, 56.05, H, 4.01; N, 11.53. Found C, 56.10; H, 3.72; N, 11.51.

EXAMPLE A-458

embedded image

The compound prepared in Example A-453 (1.2 g, 4.2 mmol), potassium carbonate (630 mg, 4.6 mmol), N-tert-butoxycarbonyl-4-bromo piperidine (1.2 g, 4.5 mmol) were heated in dimethylformamide (15 mL) at 105° C. for three hours. Contents were allowed to cool and partitioned between ethyl acetate and water. The ethyl acetate layer was dried over MgSO₄and concentrated in vacuo. The residue was triturated with ethyl acetate and filtered to give the desired as a white solid (1.2 g, 61% yield). mp 220.9-221.0° C.; ¹H NMR (DMSO-d6) 13.70 (br, 1H); 8.60-8.50 (m, 2H); 7.58-7.10 (m, 6H); 3.80-3.60 (m, 2H); 3.40-3.20 (m, 1H); 3.00-2.63 (m, 2H); 2.00-1.53 (m, 2H); 1.50-1.05 (m, 2H); 1.40 (S, 9H); ESHRMS m/z 471.1605 (M+H, C₂₄H₂₈ClN₄OS requires 471.1622); Anal. Calc'd for: C₂₄H₂₇ClN₄OS (0.5 H₂O): C, 60.05; H, 5.88; N, 11.67. Found: C, 60.04; H, 5.57; N, 11.31.

EXAMPLE A-459

embedded image

3-(4-chlorophenyl)-5-[(piperidin-4-yl)-thio]-4-pyridin-4-yl-1H-pyrazole

The compound prepared in Example A-458 (5.0 g, 11 mmol), and TFA (30 mL) were mixed in methylene chloride (50 mL) and stirred overnight. The mixture was concentrated in vacuo leaving a pale yellow oil which was dissolved in water. The pH was adjusted with 2.5 N sodium hydroxide to pH 9, precipitating a white solid which was filtered to give the desired product as a white solid (3.7 g, 93% yield). mp 211.1-211.2° C.; ¹H NMR (DMSO-d6) 13.80 (br, 1H); 8.55 (d, 2H); 8.40 (br, 1H); 7.50-7.15 (m, 6H); 3.50-3.00 (m, 3H); 3.00-2.80 (m, 2H); 2.05-1.80 (m, 2H); 1.65-1.42 (m, 2H); ESHRMS m/z 371.1103 (M+H, C₁₉H₂₀ClN₄S requires 371.1097); Anal. Calc'd for: C₁₉H₁₉ClN₄S (H₂O): C, 58.68; H, 5.44; N, 14.41. Found: C, 58.86; H, 5.28; N, 14.25.

EXAMPLE A-460

embedded image

To 1-(2-chloroethyl)pyrrolidine hydrochloride (306 mg, 1.8 mmol) in methanol (10 mL) was added 0.5 M sodium methoxide (7.0 mL, 3.6 mmol). The mixture was stirred 10 minutes and the compound of Example A-453 (500 mg, 1.8 mmol) added. The contents were refluxed one hour, allowed to cool and partitioned between ethyl acetate and water. The ethyl acetate layer was dried over MgSO₄and concentrated in vacuo leaving a light amber solid. The solid was recrystallized from methanol (15 mL) to give the desired product as a white solid (213 mg, 33% yield). mp 189.9-190.1° C.; ¹H NMR (DMSO-d6) 13.65 (br, 1H); 8.52 (d, 2H); 7.42 (d, 2H); 7.38-7.10 (m, 4H); 3.10-2.93 (m, 2H); 2.63-2.51 (m, 2H); 2.38 (br s, 4H); 1.70-1.52 (m, 4H); ESHRMS m/z 385.1262 (M+H, C₂₀H₂₂ClN₄S requires 385.1254); Anal. Calc'd for: C₂₀H₂₁ClN₄S: C, 62.41, H, 5.50; N, 14.56. Found C, 62.22; H, 5.62; N, 14.48.

EXAMPLE A-461

embedded image

Method A: The compound prepared in Example A-457 (1.3 g, 3.6 mmol) in methanol (10 mL), 2.5N sodium hydroxide (4 mL) and water (10 mL) were stirred overnight. The mixture was concentrated in vacuo to remove the methanol and the aqueous solution left was made acidic to pH 6 with 3N HCl, precipitating a solid. The solid was extracted into ethyl acetate, dried over MgSO₄and concentrated in vacuo leaving light tan crystals (205 mg). Brine was added to the aqueous layer precipitating more solid. The solid did not extract into ethyl acetate, but was filtered to give more desired product as a light tan powder (529 mg). Total yield was 61% yield. ¹H NMR (DMSO-d6+10%TFA) 8.80 (d, 2H); 7.83 (d, 2H); 7.55-7.35 (m, 4H); 3.87 (s, 2H).

Method B: The compound prepared in Example A-457 (3.8 g, 11 mmol) and 3N HCl (30 mL) were reluxed for three hours. The mixture was allowed to cool and concentrated in vacuo. The residue was mixed with CH₃CN (50 mL). Upon standing overnight, pale yellow crystals grew and were filtered to give the desired product as the HCl salt (2.9 g, 69% yield). ¹H NMR (DMSO-d6) 8.79 (d, 2H); 7.75 (d, 2H); 7.51-7.38 (m, 4H); 3.88 (s, 2H); ESHRMS m/z 346.0435 (M+H, C₁₇H₁₆ClN₄OS requires 346.0417); Anal. Calc'd for: C₁₆H₁₂ClN₃O₂S (HCl, 0.5 H₂O): C, 49.12; H, 3.61; N, 10.74. Found: C, 49.36; H, 3.48; N, 10.72.

EXAMPLE A-462

embedded image

The compound prepared in Example A-457 (400 mg, 11 mmol) and a 2M solution of methyl amine in tetrahydrofuran (25 mL) were refluxed for three hours. The mixture was stirred overnight at room temperature before filtering to give the desired as a light amber solid (335 mg, 85% yield). mp 284.0-288.4° C.; ¹H NMR (DMSO-d6) 13.58 (br, 1H); 8.60-8.45 (m, 2H); 7.98 (br s, 1H); 7.55-7.12 (m, 6H); 3.60 (s, 2H); 2.46 (s, 3H); ESHRMS m/z 359.0733 (M+H, C₁₇H₁₆ClN1₁₄OS requires 359.0745); Anal. Calc'd for: C₁₇H₁₅ClN₄OS: C, 56.90; H, 4.21; N, 15.61. Found: C, 56.74; H, 4.11; N, 15.17.

EXAMPLE A-463

embedded image

The compound prepared in Example A-457 (415 mg, 12 mmol) and N,N-dimethylaminopropylamine were refluxed in methanol (25 mL) for three hours. The mixture was stirred overnight at room temperature before concentrating in vacuo leaving a solid. The solid was triturated with ethyl acetate and filtered to give the desired as a white solid (256 mg, 50% yield). mp 168.8-169.5° C.; ¹H NMR (DMSO-d6) 13.80 (br, 1H); 8.55-8.50 (m 2H); 8.02 (t, 1H); 7.50-7.40 (m, 6H); 3.61 (s, 2H); 3.30-2.98 (m, 2H); 2.14-2.10 (m, 2H); 2.04 (s, 6H); 1.50-1.40 (m, 2H); ESHRMS m/z 430.1472 (M+H, C₂₁H₂₄ClN12₅OS requires 430.1468); Anal. Calc'd for: C₂₁H₂₄ClN₅OS (0.5 H2O): C, 57.46; H, 5.74; N, 15.95. Found: C, 57.71; H, 5.56; N, 16.12.

EXAMPLE A-464

embedded image

To the compound prepared in Example A-458 (1.0 g, 2.1 mmol) in methylene chloride (25 mL) was added meta-chloroperbenzoic acid (425 mg, 2.1 mmol). The mixture was stirred 15 minutes and chromatographed on silica gel (20 g) eluting with ethyl acetate. The desired product precipitated out of the ethyl acetate elutant upon standing and was filtered to give the desired product as a white solid (958 mg, 93% yield). mp 215.8-215.9° C.; ¹H NMR (DMSO-d6) 14.34 (br s, 1H); 8.57-8.54 (m, 2H); 7.51-7.25 (m, 6H); 4.00-3.82 (m, 2H); 3.60-3.40 (m, 1H); 2.85-2.70 (m, 2H); 2.10-1.95 (m, 1H); 1.56-1.10 (m, 3H); 1.36 (s, 9H); ESHRMS m/z 487.1580 (M+H, C₁₇H₁₆ClN₄OS requires 487.1571); Anal. Calc'd for: C₂₄H₂₇ClN12₂₄O₃S: C, 59.19; H, 5.59; N, 11.50. Found: C, 59.00; H, 5.76; N, 11.46.

EXAMPLE A-465

embedded image

To the compound prepared in Example A-458 (320 mg, 0.68 mmol) in ethanol (5 mL) was added an aqueous solution of potassium peroxymonosulfate (420 mg, 0.68 mmol). The mixture was stirred two hours and extracted into ethyl acetate which was dried over MGSO₄and concentrated in vacuo leaving a white solid. The solid was triturated with methanol and filtered to give the desired as a white solid (90 mg, 26% yield). mp 228.0-230.8° C.; ¹H NMR (DMSO-d6) 8.61 (d, 2H); 7.48 (d, 2H); 7.31-7.20 (m, 4H); 4.05-3.90 (m, 2H); 3.54-3.35 (m, 1H); 2.85-2.60 (m, 2H); 1.92-1.80 (m, 2H); 1.48-1.25 (m, 2H); 1.32 (s, 9H); ESHRMS m/z 503.1541 (M+H, C₂₄H₂₇ClN₄O₄S requires 503.1520); Anal. Calc'd for: C₂₄H₂₇ClN₄O₄S (H₂O): C, 56.30; H, 5.51; N, 10.94. Found: C, 56.41; H, 5.78; N, 10.54.

EXAMPLE A-466

embedded image

The above compound was prepared similarly to the compound of Example A-464. After chromatography the solid obtained was recrystallized from CH₃CN to give the desired product as white crystals (64 mg, 33% yield). mp 189.5-189.5° C.; ¹H NMR (DMSO-d6) 14.28 (br s, 1H); 8.50 (d, 2H); 7.40-7.20 (m, 4H); 7.20-7.05 (m, 4H); 6.85 (d, 2H); 4.41 (s, 2H); 3.70 (s, 3H); ESHRMS m/z 408.1168 (M+H, C₂₂H₁₉FN₃O₂S requires 408.1182); Anal. Calc'd for: C₂₂H₁₈FN₃O₂S: C, 64.85; H, 4.45; N, 10.31. Found: C, 64.44; H, 4.34; N, 10.70.

EXAMPLE A-467

embedded image

To the compound prepared in Example A-466 (1.2 g, 2.5 mmol) in methylene chloride (50 mL) was added meta-chloroperbenzoic acid (1.0 g, 5.0 mmol). The mixture was stirred 1.5 hours and filtered a white solid (620 mg) which was inorganic salts. The filtrate was chromatographed on silica gel (20 g) eluting with ethyl acetate to give the desired product as a white solid (98 mg, 9% yield). mp 241.9-242.0° C.; ¹H NMR (DMSO-d6) 8.48-8.40 (m, 2H); 7.33-6.80 (m, 10H); 4.55 (s, 2H); 3.72 (s, 3H); ESHRMS m/z 424.1143 (M+H, C₂₄H₂₇ClN₄O₄S requires 424.1131); Anal. Calc'd for: C₂₂H₁₈FN₃O₃S: C, 62.40; H, 4.28; N, 9.92. Found: C, 62.14; H, 4.42; N, 9.68.

EXAMPLE A-468

embedded image

3-(4-chlorophenyl)-5-[(1-methylpiperidin-4-yl)-thio]-4-pyridin-4-yl-1H-pyrazole

The compound prepared in Example A-458 (5.0 g, 0.01 mol) and formic acid (96% , 7 mL) were heated at 100° C. for one hour. The mixture was allowed to cool to about 50° C. and formaldehyde (37%, 13 mL) was added. The contents were heated at 80° C. for two hours. The contents were allowed to cool, diluted with water (200 mL) and made basic to pH 11 with 2.5N sodium hydroxide, precipitating a white solid. The solid was filtered and recrystallized from methanol to give the desired as a white solid (174 mg. 33% yield). mp 227.7-227.7° C.; ¹H NMR (DMSO-d6) 13.70 (br s, 1H); 8.56-8.48 (m, 2H); 7.50-7.15 (m, 6H); 3.10-2.92 (m, 1H); 2.63-2.50 (m, 2H); 2.05 (s, 3H); 1.95-1.65 (m, 4H); 1.50-1.30 (m, 2H); ESHRMS m/z 385.1233 (M+H, C₂₀H₂₂ClN₄S requires 385.1254); Anal. Calc'd for: C₂₀H₂₁ClN₄S: C, 62.41; H, 5.50; N, 14.56. Found: C, 62.40; H, 5.80; N, 14.61.

EXAMPLE A-469

embedded image

3-(4-chlorophenyl)-5-[(2-methoxyethyl)-thio]-4-pyridin-4-yl-1H-pyrazole

The above compound was prepared similarly to the compound of Example A-456 using bromoethyl methyl ether except contents were heated at 70° C. for one hour before partitioning between ethyl acetate and water. The crude product was recrystallized from methanol/ethyl acetate to give the desired product as a white solid (210 mg, 35% yield). mp 189.2-190.2° C.; ¹H NMR (DMSO-d6) 8.60-8.45 (m, 2H); 7.60-7.10 (m, 6H); 3.60-2.85 (m, 7H); ESHRMS m/z 346.0799) M+H, C₁₇H₁₇ClN₃OS requires 346.0781); Anal. Calc'd for: C₁₇H₁₆ClN₃OS (H₂O): C, 58.73; H, 4.70; N, 12.09. Found: C, 58.67; H, 4.86; N, 12.03.

EXAMPLE A-470

embedded image

The above compound was prepared similarly to the compound of Example A-456 using 2-chloromethylbenzimidazole except contents were heated at 70° C. for one hour before partitioning between ethyl acetate and water. An insoluble solid was filtered from the two layers and triturated with methanol to give the desired product as a light amber solid (292 mg, 40% yield). mp 257.7-257.7° C.; ¹H NMR (DMSO-d6) 13.75 (br s, 1H); 12.30 (br s, 1H); 8.55-8.30 (m, 2H); 7.65-6.90 (m, 10H); 4.40 (br s, 2H); ESHRMS m/z 418.0895 (M+H, C₂₂H₁₇ClN₅S requires 418.0893); Anal. Calc'd for: C₂₂H₁₆ClN₅S (0.75 H₂O): C, 61.25; H, 4.09; N, 16.23. Found: C, 61.27; H, 3.90; N, 15.92.

EXAMPLE A-471

embedded image

The above compound was prepared similarly to the compound of Example A-456 using DL-alpha-bromo-beta-(5-imidazolyl)propionic acid except the mixture was heated at 70° C. for one hour. The mixture contained an insoluble solid which was diluted with water and the pH was adjusted with 3N HCl to pH 7. The mixture was filtered and triturated with methanol to give the desired product as a white solid (1.5 g, 81% yield). mp 163.0-165.5° C.; ¹H NMR (DMSO-d6+approx. 10%TFA) 8.92 (d, 1H); 8.83-8.75 (m, 2H); 7.80 (d, 2H); 7.55-7.30 (m, 5H); 4.20-4.05 (m, 1H); 3.25-3.00 (m, 2H). ESHRMS m/z 426.0799 (M+H, C₂₀H₁₇ClN₅O₂S requires 426.0791); Anal. Calc'd for: C₂₀H₁₆ClN₅O₂S (1.8 H2O): C, 52.41 H, 4.31; N, 15.28. Found: C, 52.68; H, 4.58; N, 15.37.

EXAMPLE A-472

embedded image

To the compound prepared in Example A-453 (264 mg, 0.9 mmol) and alpha-methylenebutyrolactone (0.08 mL, 0.9 mmol) in ethanol was added a drop of triethylamine. The mixture was stirred overnight. The resulting solid was filtered and triturated with methanol to give the desired product as a pale yellow solid (181 mg, 51% yield). mp 224.2-225.9° C.; ¹H NMR (DMSO-d6+approx. 10%TFA) 8.80 (d, 2H); 7.80 (d, 2H); 7.53-7.33 (m, 4H); 4.30-4.05 (m, 2H); 3.50-3.40 (m, 1H); 3.15-2.90 (m, 2H); 2.32-2.20 (m, 1H) 2.10-1.90 (m, 1H); ESHRMS m/z 386.0760 (M+H, C₁₉H₁₇ClN₃O₂S requires 386.0730); Anal. Calc'd for: c₁₉H₁₆ClN₃O₂S: C, 59.14 H, 4.18; N, 10.89. Found: C, 58.97; H, 4.21; N, 10.96.

EXAMPLE A-473

embedded image

The above compound was prepared similarly to the compound of Example A-456 using 2-bromomethyl-1,3-dioxolane except the mixture was heated at 80° C. for two hours. The mixture was diluted with water and filtered to give a white solid (502 mg). The solid was recrystallized from ethanol to give the desired product as off-white crystals (280 mg, 43% yield). mp 197.0-198.2° C.; ¹H NMR (DMSO-d6) 13.60 (br s, 1H); 8.60-8.45 (m, 2H); 7.60-7.10 (m, 6H); 5.15-4.85 (m, 1H); 3.95-3.62 (m, 4H); 3.40-2.95 (m, 2H); ESHRMS m/z 374.0741 (M+H, C₁₈H₁₇ClN₃O₂S requires 374.0730); Anal. Calc'd for: C₁₈H₁₆ClN₃O₂S: C, 57.83 H, 4.31; N, 11.24. Found: C, 57.69; H, 4.41; N, 11.15.

EXAMPLE A-474

embedded image

The above compound was prepared similarly to the compound of Example A-456 using 2-(2-bromoethoxy)tetrahydro-2H-pyran except that the mixture was heated at 80° C. for four hours. The mixture was allowed to cool and partitioned between ethyl acetate and water. The ethyl acetate layer was dried over MgSO₄and concentrated in vacuo leaving a solid (737 mg). The solid was recrystallized from ethanol to give the desired product as pale yellow crystals (281 mg, 39% yield). mp 163.2-163.5° C.; ¹H NMR (DMSO-d6) 13.80-13.70 (m, 1H), 8.60-8.42 (br s, 1H); 7.60-7.10 (m, 6H); 4.60-4.30 (m, 1H); 3.90-2.90 (m, 6H); 1.70-1.20 (m, 6H); ESHRMS m/z 416.1200 (M+H, C₂₁H₂₃ClN₃O₂S requires 416.1198); Anal. Calc'd for: C₂₁H₂₂ClN₃O₂S: C, 60.64 H, 5.33; N, 10.10. Found: C, 60.49; H, 5.71; N, 9.96.

EXAMPLE A-475

embedded image

The above compound was prepared similarly to the compound of Example A-456 using 4-bromobutyronitrile except the mixture was heated at 55° C. for one hour. The mixture was diluted with water (75 mL) and filtered to give a white solid (567 mg). The solid was recrystallized from methanol to give the desired product as white crystals (333 mg, 54% yield). mp 216.7-216.9° C.; ¹H NMR (DMSO-d6+approx. 10%TFA) 8.80-8.75 (m, 2H); 7.83-7.75 (m, 2H); 7.50-7.35 (m, 4H); 3.10-3.00 (m, 2H); 2.60-2.45 (m, 2H); 1.95-1.80 (m, 2H); ESHRMS m/z 355.0818 (M+H, C₁₈H₁₆ClN₄S requires 355.0784); Anal. Calc'd for: C₁₈H₁₅ClN₄S (0.5 H₂O). C, 59.42 H, 4.43; N, 15.40. Found: C, 59.64; H, 4.11; N, 15.44.

EXAMPLE A-476

embedded image

The compound prepared in Example A-461 (416 mg, 1.1 mmol), morpholine (4 mL), O-benzotriazol-1-yl-N,N,N′,N′-tetramethyluronium tetrafluoroborate (481 mg, 1.5 mmol) and dimethylformamide (10 mL) were stirred overnight. The mixture was diluted with water (75 mL) and the resulting solid was filtered (363 mg). The solid was recrystallized from ethanol to give the desired product as a white solid (219 mg, 48% yield). mp 215.4-215.5° C.; ¹H NMR (DMSO-d6) 13.70-13.60 (m, 1H); 8.60-8.50 (m, 2H); 7.50-7.10 (m, 6H); 3.93-3.80 (m, 2H); 3.60-3.20 (m, 8H); ESHRMS m/z 415.0995 (M+H, C₂₀H₂₀ClN₄O₂S requires 415.1001); Anal. Calc'd for: C₂₀H₁₉ClN₄O₂S: C, 57.90 H, 4.62; N, 13.50. Found: C, 57.87; H, 4.86; N, 13.53.

EXAMPLE A-477

embedded image

The above compound was prepared similarly to the compound of Example A-456 using 2-bromopropionitrile except the mixture was heated at 70° C. for one hour. The mixture was diluted with water (75 mL) and filtered to give an off-white solid (662 mg). The solid was recrystallized from methanol to give the desired product as a white solid (220 mg, 37% yield). mp 211.1-212.8° C.; ¹H NMR (DMSO-d6+approx. 10%TFA) 8.87-8.80 (m, 2H); 7.90-7.80 (m, 2H); 7.55-7.45 (m, 6H); 4.42 (q, 1H); 1.50 (d, 3H); ESHRMS m/z 341.0628 (M+H, C₁₇H ₁₆ClN₄S requires 341.0628); Anal. Calc'dfor: C₁₇H₁₃ClN₄S: C, 59.91 H, 3.84; N, 16.44. Found: C, 59.64; H, 4.01; N, 16.18.

EXAMPLE A-478

embedded image

The above compound was prepared similarly to the compound of Example A-456 using propargyl bromide. The mixture was diluted with water (75 mL) and filtered to give a pale yellow solid (577 mg). The solid was triturated with methanol to give the desired product as a white solid (388 mg, 68% yield). mp 212.7-213.2° C.; ¹H NMR (DMSO-d6+approx. 10%TFA) 8.80 (d, J=6.8 Hz, 2H); 7.82 (d, J=6.8 Hz, 2H); 7.50-7.35 (m, 4H); 3.81 (d, J=2.6 Hz, 2H); 3.05 (t, J=2.6 Hz, 1H); ESHRMS m/z 326.0533 (M+H, C₁₇H₁₃ClN₃S requires 326.0519); Anal. Calc'd for: C₁₇H₁₂ClN₃S (0.2 H₂O): C, 61.98 H, 3.79; N, 12.76. Found: C, 61.89; H, 3.45; N, 12.67.

EXAMPLE A-479

embedded image

The above compound was prepared similarly to the compound of Example A-456 using allyl bromide. The mixture was diluted with water (75 mL) and filtered to give a pale yellow solid (509 mg). The solid was recrystallized from methanol to give the desired product as a pale yellow solid (187 mg, 33% yield). mp 207.3-208.1° C.; ¹H NMR (DMSO-d6+approx. 10%TFA) 8.80 (d, 2H); 7.80 (d, 2H); 7.50-7.30 (m, 4H); 5.90-5.70 (m, 1H); 5.10-4.95 (m, 2H); 3.62 (d, 2H); ESHRMS m/z 328.0693 (M+H, C₁₇H₁₅ClN₃S requires 328.0675); Anal. Calc'd for: C₁₇H₁₄ClN₃S (0.1 H₂O): C, 61.94 H, 4.34; N, 12.75. Found: C, 61.83; H, 4.21; N, 12.76.

EXAMPLE A-480

embedded image

The above compound was prepared similarly to the compound of Example A-456 using 2-bromoethylamine except two equivalents of potassium carbonate were used. The mixture was diluted with water (75 mL) and filtered to give a pale yellow solid (509 mg). The solid was recrystallized from methanol to give the desired product as a pale yellow solid (262 mg, 45% yield). mp 186.8-187.8° C.; ¹H NMR (DMSO-d6+approx. 10%TFA) 8.85-8.75 (m, 2H); 8.90 (br s, 2H); 8.85-8.75 (m, 2H); 7.55-7.35 (m, 4H); 3.30-3.00 (m, 4H); ESHRMS m/z 331.0779 (M+H, C₁₆H₁₆ClN₄S requires 331.0784); Anal. Calc'd for: C₁₆H₁₅ClN₄S (0.5 H₂O): C, 56.55; H, 4.75; N, 16.49. Found: C, 56.28; H, 4.38; N, 16.20.

EXAMPLE A-481

embedded image

The above compound was prepared similarly to the compound of Example A-456 using 3-(2-bromoethyl)indole. The mixture was diluted with water (75 mL) and filtered to give a pale yellow solid (752 mg). The solid was triturated with methanol to give the desired product as a white solid (682 mg, 91% yield). mp 211.9-213.20C; ¹H NMR (DMSO-d6+approx. 10%TFA) 10.80 (s, 1H); 8.72 (d, 2H); 7.71 (d, 2H); 7.55-7.35 (m, 5H); 7.29 (d, 1H); 7.12-6.88 (m, 3H); 3.40-3.30 (m, 2H); 3.05-2.95 (m, 2H); ESHRMS m/z 431.1095 (M+H, C₂₄H₂₀ClN₄S requires 431.1097); Anal. Calc'd for: C₂₄H₁₉ClN₄S (0.15 H₂O): C, 66.47 H, 4.49; N, 12.92. Found: C, 66.44; H, 4.51; N, 12.84.

EXAMPLE A-482

embedded image

The compound of Example A-464 (464 mg, 0.95 mmol) and TFA (8 mL) were mixed in methylene chloride (10 mL) and stirred overnight. The mixture was concentrated in vacuo and the residue was partitioned between ether and water. The aqueous layer was made basic to pH 10 with 2.5N sodium hydroxide and extracted with ethyl acetate (2×100 mL). Upon standing overnight, a solid precipitated from the aqueous layer and was filtered to give the desired product as a white solid (183 mg, 50% yield). mp 189.1-190.8° C.; ¹H NMR (DMSO-d6+approx. 10%TFA) 8.85 (d, 2H); 8.80-8.60 (m 1H); 8.45-8.25 (m, 1H); 7.90 (d, 2H); 7.55-7.30 (m, 4H); 3.65-3.20 (m 3H); 3.10-2.80 (m 2H); 2.20-2.00 (m, 1H); 1.90-1.50 (m, 3H); ESHRMS m/z 387.1032 (M+H, C₁₉H₂₀ClN₄OS requires 387.1046); Anal. Calc'd for: C₁₉H₂₀ClN₄OS (2 H₂O): C, 53.96 H, 5.48; N, 13.25. Found: C, 53.75; H, 4.99; N, 13.21.

EXAMPLE A-483

embedded image

The above compound was prepared similarly to the compound of Example A-456 using 3-bromopropionitrile. The mixture was diluted with water (75 mL) and extracted into ethyl acetate, which was dried over MGSO₄and concentrated in vacuo leaving an orange waxy solid (523 mg). The solid was dissolved in CH₃CN and filtered through a pad of silica gel and eluted with ethyl acetate to give a white solid. The solid was triturated with ethyl acetate and filtered to give the desired product as a white solid (76 mg, 13% yield). mp 205.7-206.5° C.; ¹H NMR (DMSO-d6+approx. 10%TFA) 8.80 (d, 2H); 7.80 (d, 2H); 7.55-7.35 (m, 4H); 3.30-3.20 (m, 2H); 2.90-2.80 (m, 2H); ESHRMS m/z 341.0639 (M+H, C₁₉H₂₀ClN₄OS requires 341.0628); Anal. Calc'd for: C₁₇H₁₃ClN₄S (0.25 H₂O): C, 59.13 H, 3.94; N, 16.22. Found: C, 59.03; H, 3.93; N, 15.90.

EXAMPLE A-484

embedded image

A solution of 5-amino-3-(4-chlorophenyl)-4-(pyridin-4-yl)-pyrazole (200 mg, 0.74 mmol) and toluene sulfonyl chloride (564 mg, 2.94 mmol, prepared as set forth in Example A-427) in pyridine (5 mL) was stirred at 100° C. for two days. The mixture was concentrated in vacuo to a brown residue. The residue was chromatographed on a silica gel column eluting with 10% methanol/dichloromethane. The fractions containing the desired product were combined and concentrated to a yellow solid which was washed with diethyl ether and filtered to afford 78 mg (25% ) of the desired sulfonamide as a white solid. m.p.284.3-284.4° C. ¹H NMR (DMSO/300 MHz) δ 13.33 (brs, 0.8H), 9.94 (brs, 0.75H), 8.48 (brs, 1.75H), 8.22 (brs, 0.3H), 7.63 (d, 1.7H), 7.47 (d, 1.85H), 7.24 (m, 6.45H), 7.02 (brs, 0.25H), 6.81 (brs, 0.20H). ESLRMS m/z 425 (M+H). ESHRMS m/z 425.0848 (M+H, C₂₁H₁₈N₄ClS requires 425.0839).

EXAMPLE A-485

embedded image

1-[cyclohexyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine

mp >300° C. (decomposed). ¹H NMR (CD₃OD/300 MHz) 8.50 (d, 2H, J=6.0 Hz), 7.51 (d, 2H, J=5.8 Hz), 2.99-2.93, (m, 4H), 2.52-2.48 (m, 4H), 3.04-3.02 (m, 4H), 2.96 (s, 3H), 2.54-2.49 (m, 1H), 2.31-2.26 (m, 4H), 1.84-1.33 (m, 10H). FABLRMS m/z 326 (M+H).

Additional compounds of the present invention which could be prepared using one or more of the reaction schemes set forth in this application include, but are not limited to, the following:
embedded image

4-[3-(4-chlorophenyl)-5-(1-piperazinyl)-1H-pyrazol-4-yl]pyrimidine

embedded image

1-[5-(4-bromophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]piperazine

embedded image

1-[4-(4-pyridinyl)-5-[4-(trifluoromethyl)phenyl]-1H-pyrazol-3-yl]piperazine

embedded image

4-[5-(1-piperazinyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]benzonitrile

embedded image

1-[5-(4-ethynylphyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]piperazine

embedded image

5-(4-fluorophenyl)-4-(4-pyridinyl)-N-3-pyrrolidinyl-1H-pyrazol-3-amine

embedded image

5-(4-chlorophenyl)-4-(4-pyridinyl)-N-3-pyrrolidinyl-1H-pyrazol-3-amine

embedded image

N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-piperidinamine

embedded image

3-(4-fluorophenyl)-5-(1-piperazinyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol

embedded image

3-(4-chlorophenyl)-5-(1-piperazinyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol

embedded image

4-[2-aminoethyl)-2-(4-fluorophenyl)-4,5,6,7-tetrahydro-3-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-6-ol

embedded image

4-(2-aminoethyl)-2-(4-chlorophenyl)-4,5,6,7-tetrahydro-3-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-6-ol

embedded image

3-(4-chlorophenyl)-4-(4-pyrimidinyl)-1H-pyrazole-1-ethanol

embedded image

5-(4-fluorophenyl)-4-(4-pyrimidinyl)-1H-pyrazole-3-ethanamine

embedded image

5-(4-chlorophenyl)-4-(4-pyrimidinyl)-1H-pyrazole-3-ethanamine

embedded image

4-[3-(4-fluorophenyl)-5-(4-piperidinyl)-1H-pyrazol-4-yl]pyrimidine

embedded image

4-[3-(4-chlorophenyl)-5-(4-piperidinyl)-1H-pyrazol-4-yl]pyrimidine

embedded image

N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]acetamide

embedded image

N-[4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]acetamide

embedded image

N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinylpropanamide

embedded image

N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]propanamide

embedded image

6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-1H-purine

embedded image

6-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-1H-purine

embedded image

N-[4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]-N-(phenylmethyl)acetamide

embedded image

N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]-N-(phenylmethyl)propanamide

embedded image

N-[4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]-N-(phenylmethyl)propanamide

embedded image

1-[2-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]ethyl]piperazine

embedded image

1-[2-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]ethyl]-4-methylpiperazine

embedded image

1-[2-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]ethyl]piperazine

embedded image

1-[2-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]ethyl]-4-methylpiperazine

embedded image

1-[[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]methylpiperazine

embedded image

1-[[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]methyl]-4-methylpiperazine

embedded image

4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazineethanol

embedded image

4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazineethanamine

embedded image

4-[5-[4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazineethanol

embedded image

4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazineethanamine

embedded image

4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,2,6-trimethylpiperazine

embedded image

1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-3,5-dimethylpiperazine

embedded image

4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,2,6-trimethylpiperazine

embedded image

4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,2-dimethylpiperazine

embedded image

1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-3-methylpiperazine

embedded image

4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,2-dimethylpiperazine

embedded image

5-(4-chlorophenyl)-4-(4-pyridinyl)-N-3-pyrrolidinyl-1H-pyrazol-3-amine

embedded image

5-(4-chlorophenyl)-N-(1-methyl-3-pyrrolidinyl)-4-(4-pyridinyl)-1H-pyrazol-3-amine

embedded image

5-(4-fluorophenyl)-4-(4-pyridinyl)-N-3-pyrrolidinyl-1H-pyrazol-3-amine

embedded image

5-(4-fluorophenyl)-N-(1-methyl-3-pyrrolidinyl)-4-(4-pyridinyl)-1H-pyrazol-3-amine

embedded image

1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-3-pyrrolidinamine

embedded image

1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-N,N-dimethyl-3-pyrrolidinamine

embedded image

1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-3-pyrrolidinamine

embedded image

1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-N,N-dimethyl-3-pyrrolidinamine

embedded image

5-(4-chlorophenyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-4-(4-pyridinyl)-1H-pyrazol-3-amine

embedded image

5-(4-fluorophenyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-4-(4-pyridinyl)-1H-pyrazol-3-amine

embedded image

N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-3-piperidinamine

embedded image

N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-3-piperidinamine

embedded image

N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-3-piperidinamine

embedded image

N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-3-piperidinamine

embedded image

4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-2-piperazinemethanol

embedded image

4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-2-piperazinemethanamine

embedded image

4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-2-piperazinemethanol

embedded image

4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-2-piperazinemethanamine

embedded image

4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-2-piperazinemethanol

embedded image

4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-2-piperazinemethanamine

embedded image

4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-2-piperazinemethanol

embedded image

4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-2-piperazinemethanamine

embedded image

4-[3-(4-chlorophenyl)-5-(4-methyl-1-piperazinyl)-1H-pyrazol-4-yl]-N-methyl-2-pyrimidinamine

embedded image

4-[3-(4-fluorophenyl)-5-(4-methyl-1-piperazinyl)-1H-pyrazol-4-yl]-N-methyl-2-pyrimidinamine

embedded image

1-[[5-(4-chliorophlenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]methyl]-4-piperidinol

embedded image

1-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]methyl-4-piperidinol

embedded image

4-[3-(4-chlorophenyl)-5-(4-methyl-1-piperazinyl)-1H-pyrazol-4-yl]pyrimidine

embedded image

4-[3-(4-fluorophenyl)-5-(4-methyl-1-piperazinyl)-1H-pyrazol-4-yl]pyrimidine

embedded image

4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-2-piperazinecarboxylic acid

embedded image

ethyl 4-[5[-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-2-piperazinecarboxylate

embedded image

4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-2-piperazinecarboxylic acid

embedded image

ethyl 4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-2-piperazinecarboxylate

embedded image

4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-2-piperazinecarboxamide

embedded image

4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-2-piperazinecarboxamide

embedded image

4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-2-piperazinecarboxylic acid

embedded image

ethyl 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-2-piperazinecarboxylate

embedded image

4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-2-piperazinecarboxamide

embedded image

4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-2-piperazinecarboxylic acid

embedded image

ethyl 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-2-piperazinecarboxylate

embedded image

4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-2-piperazinecarboxamide

embedded image

N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-ethyl-4-piperidinamine

embedded image

N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(phenylmethyl)-4-piperidinamine

embedded image

1-acetyl-N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-piperidinamine

embedded image

N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(2-propynyl)-4-piperidinamine

embedded image

N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-cyclopropyl-4-piperidinamine

embedded image

N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(methoxyacetyl)-4-piperidinamine

embedded image

N-[5-(40-chlrophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(methylethyl)-4-piperidinamine

embedded image

N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-propyl-4-piperidinamine

embedded image

ethyl 4-[[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]amino]-1-piperidinecarboxylate

embedded image

Additional compounds of specific interest include the compounds of Tables 3-3, 3-4, 3-5 and 3-6:

TABLE 3-3

R²R⁵R¹²4-piperidinylmethylm- or p-fluoro4-piperidinylethylm- or p-fluoro4-piperidinylaminom- or p-fluoro4-piperidinylmethylaminom- or p-fluoro4-piperidinyldimethylaminom- or p-fluoro4-piperidinylethylaminom- or p-fluoro4-piperidinyldiethylaminom- or p-fluoro4-piperidinylpropylaminom- or p-fluoro4-piperidinyldipropylaminom- or p-fluoro4-piperidinylhydroxyethylaminom- or p-fluoro4-piperidinyl1-hydroxy-1,1-m- or p-fluorodimethylethyl4-piperidinylmethoxyethylaminom- or p-fluoro4-piperidinylmethylm- or p-chloro4-piperidinylethylm- or p-chloro4-piperidinylaminom- or p-chloro4-piperidinylmethylaminom- or p-chloro4-piperidinyldimethylaminom- or p-chloro4-piperidinylethylaminom- or p-chloro4-piperidinyldiethylaminom- or p-chloro4-piperidinylpropylaminom- or p-chloro4-piperidinyldipropylaminom- or p-chloro4-piperidinylhydroxyethylaminom- or p-chloro4-piperidinyl1-hydroxy-1,1-m- or p-chlorodimethylethyl4-piperidinylmethoxyethylaminom- or p-chloro4-piperidinylmethylm- or p-methyl4-piperidinylethylm- or p-methyl4-piperidinylaminom- or p-methyl4-piperidinylmethylaminom- or p-methyl4-piperidinyldimethylaminom- or p-methyl4-piperidinylethylaminom- or p-methyl4-piperidinyldiethylaminom- or p-methyl4-piperidinylpropylaminom- or p-methyl4-piperidinyldipropylaminom- or p-methyl4-piperidinylhydroxyethylaminom- or p-methyl4-piperidinyl1-hydroxy-1,1-m- or p-methyldimethyl ethyl4-piperidinylmethoxyethylaminom- or p-methyl4-piperazinylmethylm- or p-fluoro4-piperazinylethylm- or p-fluoro4-piperazinylaminom- or p-fluoro4-piperazinylmethylaminom- or p-fluoro4-piperazinyldimethylaminom- or p-fluoro4-piperazinylethylaminom- or p-fluoro4-piperazinyldiethylaminom- or p-fluoro4-piperazinylpropylaminom- or p-fluoro4-piperazinyldipropylaminom- or p-fluoro4-piperazinylhydroxyethylaminom- or p-fluoro4-piperazinyl1-hydroxy-1,1-m-or p-fluorodimethylethyl4-piperazinylmethoxyethylaminom- or p-fluoro4-piperazinylmethylm- or p-chloro4-piperazinylethylm- or p-chloro4-piperazinylaminom- or p-chloro4-piperazinylmethylaminom- or p-chloro4-piperazinyldimethylaminom- or p-chloro4-piperazinylethylaminom- or p-chloro4-piperazinyldiethylaminom- or p-chloro4-piperazinylpropylaminom- or p-chloro4-piperazinyldipropylaminom- or p-chloro4-piperazinylhydroxyethylaminom- or p-chloro4-piperazinyl1-hydroxy-1,1-m- or p-chlorodimethylethyl4-piperazinylmethoxyethylaminom- or p-chloro4-piperazinylmethylm- or p-methyl4-piperazinylethylm- or p-methyl4-piperazinylaminom- or p-methyl4-piperazinylmethylaminom- or p-methyl4-piperazinyldimethylaminom- or p-methyl4-piperazinylethylaminom- or p-methyl4-piperazinyldiethylaminom- or p-methyl4-piperazinylpropylaminom- or p-methyl4-piperazinyldipropylaminom- or p-methyl4-piperazinylhydroxyethylaminom-or p-methyl4-piperazinyl1-hydroxy-1,1-m- or p-methyldimethylethyl4-piperazinylmethoxyethylaminom- or p-methylaminocyclohexylmethylm- or p-fluoroaminocyclohexylethylm- or p-fluoroaminocyclohexylaminom- or p-fluoroaminocyclohexylmethylaminom- or p-fluoroaminocyclohexyldimethylaminom- or p-fluoroaminocyclohexylethylaminom- or p-fluoroaminocyclohexyldiethylaminom- or p-fluoroaminocyclohexylpropylaminom- or p-fluoroaminocyclohexyldipropylaminom- or p-fluoroaminocyclohexylhydroxyethylaminom- or p-fluoroaminocyclohexyl1-hydroxy-1,1-m- or p-fluorodimethylethylaminocyclohexylmethoxyethylaminom- or p-fluoroaminocyclohexylmethylm- or p-chloroaminocyclohexylethylm- or p-chloroaminocyclohexylaminom- or p-chloroaminocyclohexylmethylaminom- or p-chloroaminocyclohexyldimethylaminom- or p-chloroaminocyclohexylethylaminom- or p-chloroaminocyclohexyldiethylaminom- or p-chloroaminocyclohexylpropylaminom- or p-chloroaminocyclohexyldipropylaminom- or p-chloroaminocyclohexylhydroxyethylaminom- or p-chloroaminocyclohexyl1-hydroxy-1,1-m- or p-chlorodimethylethylaminocyclohexylmethoxyethylaminom- or p-chloroaminocyclohexylmethylm- or p-methylaminocyclohexylethylm- or p-methylaminocyclohexylaminom- or p-methylaminocyclohexylmethylaminom- or p-methylaminocyclohexyldimethylaminom- or p-methylaminocyclohexylethylaminom- or p-methylaminocyclohexyldiethylaminom- or p-methylaminocyclohexylpropylaminom- or p-methylaminocyclohexyldipropylaminom- or p-methylaminocyclohexylhydroxyethylaminom- or p-methylaminocyclohexyl1-hydroxy-1,1-m- or p-methyldimethylethylaminocyclohexylmethoxyethylaminom- or p-methyl

Still other compounds of specific interest include those compounds of Table 3-3 modified as follows:

(1) The 4-piperidinyl moiety is replaced with a 1-, 2-or 3-piperidinyl moiety; and/or

(2) The 4-piperidinyl, 3-piperidinyl, 2-piperidinyl or piperazinyl ring is substituted at a nitrogen ring atom with methyl, ethyl, isopropyl, cyclopropyl, propargyl, benzyl, hydroxyethyl, methoxyethyl, or methoxyacetyl; and/or

(3) The 1-piperidinyl ring is substituted at a carbon ring atom with methylamino, dimethylamino, ethylamino, diethylamino, isopropylamino, cyclopropylamino, propargylamino, benzylamino, hydroxyethylamino, methoxyethylamino, or methoxyacetylamino; and/or

(4) The amino group of the aminocyclohexyl is replaced with methylamino, dimethylamino, ethylamino, diethylamino, isopropylamino, methoxyethylamino, or methoxyacetylamino; and/or

(5) A linking group selected from the group consisting of methylene, —S—, —O—, and —NH— separates the piperidinyl, piperazinyl or cyclohexyl moiety from the pyrazole nucleus.

TABLE 3-4

R⁴R³R²⁰⁰R²⁰¹4-pyridyl4-methylphenylHO4-pyridyl4-methylphenylCH₃O4-pyrimidyl4-methylphenylHO4-pyrimidyl4-methylphenylCH₃O4-pyridyl4-methylphenylHS4-pyridyl4-methylphenylCH₃S4-pyrimidyl4-methylphenylHS4-pyrimidyl4-methylphenylCH₃S4-pyridyl3-methylphenylHO4-pyridyl3-methylphenylCH₃O4-pyrimidyl3-methylphenylHO4-pyrimidyl3-methylphenylCH₃O4-pyridyl3-methylphenylHS4-pyridyl3-methylphenylCH₃S4-pyrimidyl3-rnethylphenylHS4-pyrimidyl3-methylphenylCH₃S

TABLE 3-5

R⁴
n
X

4-chlorophenyl
1
S

4-chlorophenyl
2
SO

4-chlorophenyl
2
SO

4-chlorophenyl
2
CH2

4-chlorophenyl
2
CHCH₃

4-chlorophenyl
2
CHOH

4-chlorophenyl
1
CH2

4-chlorobenzyl
2
NCH₃

2-chlorophenyl
2
NCH₃

3,4-methylenedioxyphenyl
2
NCH₃

cyclohexyl
2
NCH₃

2-thienyl
2
NCH₃

5-chloro-2-thienyl
2
NCH₃

4-propynylphenyl
2
NCH₃

4-methylsulfoxylphenyl
2
NCH₃

4-methylsulfonylphenyl
2
NCH₃

2-(1-methyl-5-chloro)indolyl
2
NCH₃

TABLE 3-6

R⁴
R³
R⁴⁰⁰

p-Cl phenyl
4-pyridyl
—SO₂CH₃

p-Cl phenyl
4-pyridyl
—CH₂CN

p-Cl phenyl
4-pyridyl

embedded image

p-Cl phenyl

embedded image

BIOLOGICAL EVALUATION

p38 Kinase Assay

Cloning of Human p38a:

The coding region of the human p38a cDNA was obtained by PCR-amplification from RNA isolated from the human monocyte cell line THP.1. First strand CDNA was synthesized from total RNA as follows: 2 μg of RNA was annealed to 100 ng of random hexamer primers in a 10 μl reaction by heating to 70° C. for 10 minutes followed by 2 minutes on ice. cDNA was then synthesized by adding 1 μl of RNAsin (Promega, Madison Wis.), 2 μl of 50 mM dNTP's, 4 μl of 5× buffer, 2 μl of 100 mM DTT and 1 μl (200 U) of Superscript II™ AMV reverse transcriptase. Random primer, dNTP's and Superscript™ reagents were all purchased from Life-Technologies, Gaithersburg, Mass. The reaction was incubated at 42° C. for 1 hour. Amplification of p38 cDNA was performed by aliquoting 5 μl of the reverse transcriptase reaction into a 100 μl PCR reaction containing the following: 80 μl dH₂O, 2 μl 50 mM dNTP's, 1 μl each of forward and reverse primers (50 pmol/μl), 10 μl of 10× buffer and 1 μl Expand™ polymerase (Boehringer Mannheim). The PCR primers incorporated Bam HI sites onto the 5′ and 3′ end of the amplified fragment, and were purchased from Genosys. The sequences of the forward and reverse primers were 5′-GATCGAGGATTCATGTCTCAGGAGAGGCCCA-3′ and 5′GATCGAGGATTCTCAGGACTCCATCTCTTC-3′ respectively. The PCR amplification was carried out in a DNA Thermal Cycler (Perkin Elmer) by repeating 30 cycles of 94° C. for 1 minute, 60° C. for 1 minute and 68° C. for 2 minutes. After amplification, excess primers and unincorporated dNTP's were removed from the amplified fragment with a Wizard TM PCR prep (Promega) and digested with Bam HI (New England Biolabs). The Bam HI digested fragment was ligated into BamHI digested pGEX 2T plasmid DNA (PharmaciaBiotech) using T-4 DNA ligase (New England Biolabs) as described by T. Maniatis, Molecular Cloning: A Laboratory Manual, 2nd ed. (1989). The ligation reaction was transformed into chemically competent E. coli DH10B cells purchased from Life-Technologies following the manufacturer's instructions. Plasmid DNA was isolated from the resulting bacterial colonies using a Promega Wizard™ miniprep kit. Plasmids containing the appropriate Bam HI fragment were sequenced in a DNA Thermal Cycler (Perkin Elmer) with Prism™ (Applied Biosystems Inc.). cDNA clones were identified that.coded for both human p38a isoforms (Lee et al. Nature 372, 739). One of the clones which contained the cDNA for p38a-2 (CSBP-2) inserted in the cloning site of pGEX 2T, 3′ of the GST coding region was designated pMON 35802. The sequence obtained for this clone is an exact match of the cDNA clone reported by Lee et al. This expression plasmid allows for the production of a GST-p38a fusion protein.

Expression of Human p38a:

GST/p38a fusion protein was expressed from the plasmid pMON 35802 in E. coli, stain DH10B (Life Technologies, Gibco-BRL). Overnight cultures were grown in Luria Broth (LB) containing 100 mg/ml ampicillin. The next day, 500 ml of fresh LB was inoculated with 10 ml of overnight culture, and grown in a 2 liter flask at 37° C. with constant shaking until the culture reached an absorbance of 0.8 at 600 nm. Expression of the fusion protein was induced by addition of isopropyl b-D-thiogalactosidse (IPTG) to a final concentration of 0.05 mM. The cultures were shaken for three hours at room temperature, and the cells were harvested by centrifugation. The cell pellets were stored frozen until protein purification.

Purification of p38 Kinase-α:

All chemicals were from Sigma Chemical Co. unless noted. Twenty grams of E. coli cell pellet collected from five 1 L shake flask fermentations was resuspended in a volume of PBS (140 mM NaCl, 2.7 mM KCl, 10 mM Na₂HPO₄, 1.8 mM KH₂PO₄, pH 7.3) up to 200 ml. The cell suspension was adjusted to 5 mM DTT with 2 M DTT and then split equally into five 50 ml Falcon conical tubes. The cells were sonnicated (Ultrasonics model W375) with a 1 cm probe for 3×1 minutes (pulsed) on ice. Lysed cell material was removed by centrifugation (12,000×g, 15 minutes) and the clarified supernatant applied to glutathione-sepharose resin (Pharmacia).

Glutathione-Sepharose Affinity Chromatography:

Twelve ml of a 50% glutathione sepharose-PBS suspension was added to 200 ml clarified supernatant and incubated batchwise for 30 minutes at room temperature. The resin was collected by centrifugation (600×g, 5 min) and washed with 2×150 ml PBS/1% Triton X-100, followed by 4×40 ml PBS. To cleave the p38 kinase from the GST-p38 fusion protein, the glutathione-sepharose resin was resuspended in 6 ml PBS containing 250 units thrombin protease (Pharmacia, specific activity >7500 units/mg) and mixed gently for 4 hours at room temperature. The glutathione-sepharose resin was removed by centrifugation (600×g, 5 min) and washed 2×6 ml with PBS. The PBS wash fractions and digest supernatant containing p38 kinase protein were pooled and adjusted to 0.3 mM PMSF.

Mono Q Anion Exchange Chromatography:

The thrombin-cleaved p38 kinase was further purified by FPLC-anion exchange chromatography. Thrombin-cleaved sample was diluted 2-fold with Buffer A (25 mM HEPES, pH 7.5, 25 mM beta-glycerophosphate, 2 mM DTT, 5% glycerol) and injected onto a Mono Q HR 10/10 (Pharmacia) anion exchange column equilibrated with Buffer A. The column was eluted with a 160 ml 0.1 M-0.6 M NaCl/Buffer A gradient (2 ml/minute flowrate). The p38 kinase peak eluting at 200 mM NaCl was collected and concentrated to 3-4 ml with a Filtron 10 concentrator (Filtron Corp.).

Sephacryl S100 Gel Filtration Chromatography:

The concentrated Mono Q-p38 kinase purified sample was purified by gel filtration chromatography (Pharmacia HiPrep 26/60 Sephacryl S100 column equilibrated with Buffer B (50 mM HEPES, pH 7.5, 50 mM NaCl, 2 mM DTT, 5% glycerol)). Protein was eluted from the column with Buffer B at a 0.5 ml/minute flowrate and protein was detected by absorbance at 280 nm. Fractions containing p38 kinase (detected by SDS-polyacrylamide gel electrophoresis) were pooled and frozen at −80° C. Typical purified protein yields from 5 L E. coli shake flasks fermentations were 35 mg p38 kinase.

In Vitro Assay

The ability of compounds to inhibit human p38 kinase alpha was evaluated using two in vitro assay methods. In the first method, activated human p38 kinase alpha phosphorylates a biotinylated substrate, PHAS-I (phosphorylated heat and acid stable protein-insulin inducible), in the presence of gamma ³²P-ATP (³²P-ATP). PHAS-I was biotinylated prior to the assay and provides a means of capturing the substrate which is phosphorylated during the assay. p38 Kinase was activated by MKK6. Compounds were tested in 10 fold serial dilutions over the range of 100 μM to 0.001 μM using 1% DMSO. Each concentration of inhibitor was tested in triplicate.

All reactions were carried out in 96 well polypropylene plates. Each reaction well contained 25 mM HEPES pH 7.5, 10 mM magnesium acetate and 50 μM unlabeled ATP. Activation of p38 was required to achieve sufficient signal in the assay. Biotinylated PHAS-I was used at 1-2 μg per 50 μl reaction volume, with a final concentration of 1.5 μM. Activated human p38 kinase alpha was used at 1 μg per 50 μl reaction volume representing a final concentration of 0.3 μM. Gamma ³²P-ATP was used to follow the phosphorylation of PHAS-I. ³²P-ATP has a specific activity of 3000 Ci/mmol and was used at 1.2 μCi per 50 μl reaction volume. The reaction proceeded either for one hour or overnight at 30° C.

Following incubation, 20 μl of reaction mixture was transferred to a high capacity streptavidin coated filter plate (SAM-streptavidin-matrix, Promega) prewetted with phosphate buffered saline. The transferred reaction mix was allowed to contact the streptavidin membrane of the Promega plate for 1-2 minutes. Following capture of biotinylated PHAS-I with ³²P incorporated, each well was washed to remove unincorporated ³²P-ATP three times with 2M NaCl, three washes of 2M NaCl with 1% phosphoric, three washes of distilled water and finally a single wash of 95% ethanol. Filter plates were air dried and 20 μl of scintillant was added. The plates were sealed and counted. Results are shown in Table 4.

A second assay format was also employed that is based on p38 kinase alpha induced phosphorylation of EGFRP (epidermal growth factor receptor peptide, a 21 mer) in the presence of ³³P-ATP. Compounds were tested in 10 fold serial dilutions over the range of 100 μM to 0.001 μM in 10% DMSO. Each concentration of inhibitor was tested in triplicate. Compounds were evaluated in 50 μl reaction volumes in the presence of 25 mM Hepes pH 7.5, 10 mM magnesium acetate, 4% glycerol, 0.4% bovine serum albumin, 0.4mM DTT, 50 μM unlabeled ATP, 25 μg EGFRP (200 μM), and 0.05 uCi gamma ³³P-ATP. Reactions were initiated by addition of 0.09 μg of activated, purified human GST-p38 kinase alpha. Activation was carried out using GST-MKK6 (5:1, p38:MKK6) for one hour at 30° C. in the presence of 50 μM ATP. Following incubation for 60 minutes at room temperature, the reaction was stopped by addition of 150 μl of AG 1×8 resin in 900 mM sodium formate buffer, pH 3.0 (1 volume resin to 2 volumes buffer). The mixture was mixed three times with pipetting and the resin was allowed to settle. A total of 50 μl of clarified solution head volume was transferred from the reaction wells to Microlite-2 plates. 150 μl of Microscint 40 was then added to each well of the Microlite plate, and the plate was sealed, mixed, and counted.

TABLE 4p38 kinaseExampleIC50 (μM)14.621.58<0.1163.8231.5252.6260.7280.3332.5348.03612.1380.8391.1401.3420.343<0.144<0.145<0.146<0.1473.2481.8502.351<0.1520.1530.9540.7556.4143<0.1

TNF Cell Assays

Method of Isolation of Human Peripheral Blood Mononuclear Cells:

Human whole blood was collected in Vacutainer tubes containing EDTA as an anticoagulant. A blood sample (7 ml) was carefully layered over 5 ml PMN Cell Isolation Medium (Robbins Scientific) in a 15 ml round bottom centrifuge tube. The sample was centrifuged at 450-500×g for 30-35 minutes in a swing out rotor at room temperature. After centrifugation, the top band of cells were removed and washed 3 times with PBS w/o calcium or magnesium. The cells were centrifuged at 400×g for 10 minutes at room temperature. The cells were resuspended in Macrophage Serum Free Medium (Gibco BRL) at a concentration of 2 million cells/ml.

LPS Stimulation of Human PBMs:

PBM cells (0.1 ml, 2 million/ml) were co-incubated with 0.1 ml compound (10-0.41 μM, final concentration) for 1 hour in flat bottom 96 well microtiter plates. Compounds were dissolved in DMSO initially and diluted in TCM for a final concentration of 0.1% DMSO. LPS (Calbiochem, 20 ng/ml, final concentration) was then added at a volume of 0.010 ml. Cultures were incubated overnight at 37° C. Supernatants were then removed and tested by ELISA for TNF-a and IL1-b. Viability was analyzed using MTS. After 0.1 ml supernatant was collected, 0.020 ml MTS was added to remaining 0.1 ml cells. The cells were incubated at 37° C. for 2-4 hours, then the O.D. was measured at 490-650 nM.

Maintenance and Differentiation of the U937 Human Histiocytic Lymphoma Cell Line:

U937 cells (ATCC) were propagated in RPMI 1640 containing 10% fetal bovine serum, 100 IU/ml penicillin, 100 μg/ml streptomycin, and 2 mM glutamine (Gibco). Fifty million cells in 100 ml media were induced to terminal monocytic differentiation by 24 hour incubation with 20 ng/ml phorbol 12-myristate 13-acetate (Sigma). The cells were washed by centrifugation (200×g for 5 min) and resuspended in 100 ml fresh medium. After 24-48 hours, the cells were harvested, centrifuged, and resuspended in culture medium at 2 million cells/ml.

LPS Stimulation of TNF Production by U937 Cells:

U937 cells (0.1 ml, 2 million/ml) were incubated with 0.1 ml compound (0.004-50 μM, final concentration) for 1 hour in 96 well microtiter plates. Compounds were prepared as 10 mM stock solutions in DMSO and diluted in culture medium to yield a final DMSO concentration of 0.1% in the cell assay. LPS (E coli, 100 ng/ml final concentration) was then added at a volume of 0.02 ml. After 4 hour incubation at 37° C., the amount of TNF-α released in the culture medium was quantitated by ELISA. Inhibitory potency is expressed as IC50 (μM). Results of these TNF Cell Assays are shown in Table 5.

TNF Inhibition: Human Whole Blood Assay

Human peripheral blood is obtained in heparinized tubes. A 190 μL aliquot of blood is placed in each well of a 96 well u-bottom plate. A compound or control vehicle (phosphate buffered saline with dimethylsulfoxide and ethanol) is added to the blood in 10 μL aliquots for serial dilutions providing final concentrations of 25, 5, 1 and 0.25 μM. The final dimethylsulfoxide and ethanol concentrations are 0.1% and 1.5%, respectively. After one hour of incubation at 37° C., 10 mL of lipopolysaccharide (Salmonella typhosa, Sigma) in phosphate buffered saline is added resulting in a final concentration of 10 mg/mL. After four to five hours of incubation at 37° C., the supernatants are harvested and assayed at 1:10 or 1:20 dilutions for human TNF using ELISA.

TABLE 5Human PBM AssayU937 Cell AssayExampleIC50 (μM)IC50 ((μM)10.521.60.57840.10.22250.27470.20.2018<0.190.4100.71.687128.5134.8141.2171.1190.30.484201.089210.077223.2248.226<0.10.029272.7280.1292.2302.6310.81.053322.696330.4340.5350.7361.4371.50.099380.20.208390.70.244400.4411.0420.743<0.10.243440.40.47745<0.10.04460.329472.359482.20.522496.8500.9510.074540.20.1355<0.10.2281430.301

Rat Assay

The efficacy of the novel compounds in blocking the production of TNF also was evaluated using a model based on rats challenged with LPS. Male Harlen Lewis rats [Sprague Dawley Co.] were used in this model. Each rat weighed approximately 300 g and was fasted overnight prior to testing. Compound administration was typically by oral gavage (although intraperitoneal, subcutaneous and intravenous administration were also used in a few instances) 1 to 24 hours prior to the LPS challenge. Rats were administered 30 μg/kg LPS [salmonella typhosa, Sigma Co.] intravenously via the tail vein. Blood was collected via heart puncture 1 hour after the LPS challenge. Serum samples were stored at −20° C. until quantitative analysis of TNF-α by Enzyme Linked-Immuno-Sorbent Assay (“ELISA”) [Biosource]. Additional details of the assay are set forth in Perretti, M., et al., Br. J. Pharmacol. (1993), 110, 868-874, which is incorporated by reference in this application.

Mouse Assay

Mouse Model of LPS-Induced TNF Alpha Production:

TNF alpha was induced in 10-12 week old BALB/c female mice by tail vein injection with 100 ng lipopolysaccharide (from S. Typhosa) in 0.2 ml saline. One hour later mice were bled from the retroorbital sinus and TNF concentrations in serum from clotted blood were quantified by ELISA. Typically, peak levels of serum TNF ranged from 2-6 ng/ml one hour after LPS injection.

The compounds tested were administered to fasted mice by oral gavage as a suspension in 0.2 ml of 0.5% methylcellulose and 0.025% Tween 20 in water at 1 hour or 6 hours prior to LPS injection. The 1 hour protocol allowed evaluation of compound potency at Cmax plasma levels whereas the 6 hour protocol allowed estimation of compound duration of action. Efficacy was determined at each time point as percent inhibition of serum TNF levels relative to LPS injected mice that received vehicle only.

Additional results obtained using the above-described assays are set forth in Table 6 below. p38 assay and U937 cell assay results are expressed as IC₅₀(μm). Mouse-LPS assay results are expressed as percent inhibition.

TABLE 6mLPSmLPSmLPSExamplep38¹p38²U9378 h6 h dose1 h, 30 mpkA-2120.490.740.0967201093A-2080.1040.0490.1896983097A-2270.0696A-2280.760.3390.4173323092A-2291.40.46227691A-2300.420.17896A-2310.1740.3225863094A-2320.04896A-2330.04453A-2340.103A-2350.10456A-2360.23794A-2370.0930.08760A-2380.1770.4016A-2390.034513087A-2400.961783085A-2410.338793087A-2420.047953087A-2430.72982A-2440.099A-245<.0010.033765A-2460.4030.5920.4952A-247<0.010.166A-2490.432733086A-2502.873A-2510.6373287A-2520.7741.197483075A-253<.0010.004461A-2540.0810.1411A-2152.340.2976383080A-2560.8130.4562A-2571.081<.010.5167A-2130.2257A-2580.481.208368A-2590.170.757462A-2100.160.1983853093A-2600.231.2821473079A-2140.061.400670A-2610.0080.2542483092A-2160.0181.8287273091A-262<0.10.326745A-263<0.01<0.10.543449A-2640.259461A-265<0.10.601632A-2660.53930A-2670.432.668180A-268<0.010.007411A-2170.6970.34869A-269>10 uM51A-2700.0150.346653A-2710.2164.214468A-2720.0730.583−8A-2736.98>1043A-274<0.10.922130A-27510.142>10A-2760.1760.45−2430A-2770.0263330A-2780.2852.36230A-2790.0050.76430A-2800.1341530A-2810.0532230A-2180.0441830A-2820.0450.09733030A-283<0.10.7998−2030A-2840.980.5088−1A-285<0.10.17951130A-2860.0570.092930A-2870.0410.27−2430A-2880.0170.34030A-289<0.10.144430A-2906.0191430A-2910.3881.13093630A-2921.15>10A-2930.73A-2940.0150.56130A-2957.66>109430A-29626A-2970.520.178930
¹p38α in vitro assay results based on PHAS-I assay procedure

²p38α in vitro assay results based on EGFRP assay procedure

Induction And Assessment Of Collagen-Induced Arthritis In Mice:

Arthritis was induced in mice according to the procedure set forth in J. M. Stuart, Collagen Autoimmune Arthritis, Annual Rev. Immunol. 2:199 (1984), which is incorporated herein by reference. Specifically, arthritis was induced in 8-12 week old DBA/1 male mice by injection of 50 μg of chick type II collagen (CII) (provided by Dr. Marie Griffiths, Univ. of Utah, Salt Lake City, Utah) in complete Freund's adjuvant (Sigma) on day 0 at the base of the tail. Injection volume was 100 μl. Animals were boosted on day 21 with 50 μg of CII in incomplete Freund's adjuvant (100 μl volume). Animals were evaluated several times each week for signs of arthritis. Any animal with paw redness or swelling was counted as arthritic. Scoring of arthritic paws was conducted in accordance with the procedure set forth in Wooley et al., Genetic Control of Type II Collagen Induced Arthritis in Mice: Factors Influencing Disease Suspectibility and Evidence for Multiple MHC Associated Gene Control., Trans. Proc., 15:180 (1983). Scoring of severity was carried out using a score of 1-3 for each paw (maximal score of 12/mouse). Animals displaying any redness or swelling of digits or the paw were scored as 1. Gross swelling of the whole paw or deformity was scored as 2. Ankylosis of joints was scored as 3. Animals were evaluated for 8 weeks. 8-10 animals per group were used.

Preparation And Administration Of Compounds:

The compounds tested on mice having collagen-induced arthritis were prepared as a suspension in 0.5% methylcelluose (Sigma, St. Louis, Mo.), 0.025% Tween 20 (Sigma). The compound suspensions were administered by oral gavage in a volume of 0.1 ml b. i. d. Administration began on day 20 post collagen injection and continued daily until final evaluation on day 56. Scoring of arthritic paws was conducted as set forth above. Assay results are set forth in Table 7.

TABLE 7Compound% Inhibition of ArthritisA-21058.5 @ 15 mpkA-17249.3 @ 100 mpkA-18951.6 @ 30 mpkA-20897.5 @ 60 mpkA-20875.0 @ 60 mpk

Additional results for selected compounds obtained using the above-described assays are set forth in Tables 8, 9 and 10 below:

TABLE 8Rat LPSTNFAssay %Inhibition-p38α KinaseInhibitionHuman WholeAssay(Dose inBlood AssayIC₅₀in μMExamplemg/kg)(μM)(% DMSO)A-313, Step 11.34 (1) A-313, Step 396.0 (20.0)0.120.036 (1) 0.37 (10)A-314, Step 10.85 (1) 0.37 (10)A-314, Step 2 0 (1.0)0.470.032 (10) 53.0 (5.0) 85.0 (20.0)A-3151.750.049 (10) A-31758.0 (3.0) 0.450.07 (10)10.0 (3.0) 0.11 (10)69.0 (10.0)A-31854.0 (3.0) 0.1670.29 (1) 0.58 (10)0.37 (10) 0.6 (10)A-31962.0 (3.0) >25.06.06 (1) 0.13 (10)A-3201.0 (3.0)0.27 (1) 0.05 (10)0.15 (10)A-321>25.00.77 (1) (dihydrate)A-32114.0 (3.0) (monosodiumsaltdihydrate)A-32251.5 (3.0) 4.20.15 (10)0.25 (10)A-32340.0 (30.0)0.39 (10)54.0 (30.0)A-32444.0 (3.0) 0.08 (10)A-32525.0 (3.0) 0.0570.021 (1) 11.0 (30.0)<0.1 (10)A-326 0 (10.0)>25.00.97 (10)A-32783.0 (20.0)0.180.15 (10)A-3280.012 (1) A-33113.0 (20.0) >100 (1) 0.64 (10)A-33233.0 (1.0) 0.450.04 (1) 26.0 (3.0) 0.04 (10)25.0 (5.0) 0.015 (10) −85.0 (10.0) <0.1 (10)A-33369.0 (5.0) 0.5850.052 (10) A-33495.0 (20.0)0.220.07 (10)57.0 (5.0) 36.0 (1.0) A-335>25.089.9 (10)A-3361.16 (10)A-337>25.01.35 (10)A-3380.0590.018 (10) A-3390.0560.052 (10) A-34298.0 (20.0)0.310.012 (10) A-34396.0 (20.0)0.016 (10)

TABLE 9

Rat LPS
TNF

Assay %
Inhibition-
p38α Kinase

Inhibition
Human Whole
Assay

(Dose in
Blood Assay
IC₅₀in μM

Example
mg/kg)
(μM)
(10% DMSO)

A-350
65 (20)

A-351
0 (20)
0.49
0.27

A-352
36 (20)
9.8
0.13

A-353
49 (20)
5.3
0.037

A-354
0 (20)
25
0.22

A-355
0 (20)
0.095
0.05

A-356
73 (20)
5.3
<0.01

A-357
74 (20)
0.25
0.12

A-358
71 (20)
4
0.23

A-359
70 (20)
1
0.3

A-360
95 (20)
0.5
0.06

14 (5)

0 (1)

A-361
9 (20)
1

A-362
0 (20)
5.5
0.69

A-363
6 (20)
25
1.5

A-364
79 (20)
0.255
0.49

A-365
95 (20)
0.057
0.032

50 (5)

12 (1)

A-366
92 (20)
0.29
0.041

DR:

0.06

6 (1)

0.04

45 (5)

97 (20)

A-368
88 (20)
0.66
0.042

DR:

28 (1)

41 (5)

97 (20)

A-369
94 (20)
0.84
0.019

52 (5)

0.011

0.0027

A-370
90 (20)
1.92
0.16

46 (5)

A-371
52 (20)
25
7.9

A-372
56 (20)
21
0.53

A-374
88 (20)
0.31
0.38

0 (5)

3 (1)

A-375
43 (20)
28%
2.3

A-376
24 (20)
1
0.032

A-377
84 (20)
0.67
0.004

DR:

0.0019

32 (1)

67 (5)

96 (20)

A-378
73 (10)
49%
6.2

A-379
61 (10)
44%
0.19

A-380
85 (30)
32%
0.85

62 (10)

33 (3)

A-385

0.18

1.25

A-386
91 (20)
0.16
0.016

A-387
83 (20)
0.11
0.005

A-388
97 (20)
0.34
0.21

67 (5)

TABLE 10

Rat LPS

Assay %
TNF
p38α Kinase

Inhibition
Inhibition-
Assay IC₅₀

(Dose in
Human Whole
(μm)

mg/kg @ 4.0
Blood Assay
(10% DMSO; @

Example
hours)
(μm)
1.0 hour)

A-389, Step 4
55.0 (5.0)

0.16

94.0 (20.0)

A-389, Step 1

1.72

A-390

>25.0
15.1

A-391
53.0 (20.0)
>25.0
4.83

A-392

29.7

A-393

2.32

A-394

9.11

A-395

>100

A-397

30.0

A-398

>25.0
45.6

A-399

22.9

A-400

>25.0
4.77

A-401

21.2

A-402

28.9

A-403

>25.0
4.89

A-404

>25.0
4.13

A-405

>25.0
4.85

A-406

>25.0
7.24

A-407
21.0 (5.0)
3.86
0.18

82.0 (20.0)

A-408
20.0 (5.0)
11.7
5.59

49.0 (20.0)

A-409
41.0 (5.0)
5.27
0.21

89.0 (20.0)

A-410
11.0 (5.0)

0.21

0 (20.0)

A-411
40.0 (5.0)

3.37

0 (20.0)

A-412
0 (5.0)

2.15

0 (20.0)

A-413
45.0 (5.0)
6.51
0.91

85.0 (20.0)

A-414
3.0 (5.0)
11.2
9.51

14.0 (20.0)

A-415
17.0 (5.0)

0.51

84.0 (84.0)

A-416

5.07
0.041

A-417
40.0 (5.0)
12.0
0.19

70.0 (20.0)

A-418

0.12

A-419
24.0 (5.0)

1.31

58.0 (10.0)

A-420
47.0 (5.0)

0.32

91.0 (20.0)

A-427
56.0 (5.0)
24.1
0.19

77.0 (20.0)

A-428

0.68
0.4

A-429

56.3

A-430

>100

A-434

5.84

A-435
10.0 (1.0)
>25.0
0.35

0 (5.0)

14.0 (20.0)

A-436

4.61
2.81

A-437

>25.0
7.76

A-438
49.0 (20.0)
>25.0
0.56

A-439
58.0 (5.0)
5.63
0.15

93.0 (20.0)

A-440

A-441
14.0 (5.0)
>25.0
1.21

62.0 (20.0)

A-442
51.0 (1.0)
0.16
0.022

56.0 (5.0)

92.0 (20.0)

A-443

4.89
0.47

A-444

6.99

A-445

>25.0
1.08

A-446

3.38
0.9

A-447

>25.0
0.77

A-448
73.0 (5.0)
0.12
0.084

97.0 (20.0)

A-449

59.0

A-450

>100

A-451

15.0
0.078

A-452

0.24
2.87

A-454

8.41

A-453

10.2

A-455

12.9

A-456
36.0 (1.0)
0.98
0.12

48.0 (5.0)

53.0 (20.0)

A-457

>25.0
0.4

A-458

>25.0
8.7

A-459
0 (1.0)
0.26
0.027

54.0 (5.0)

80.0 (20.0)

A-459 (salt)

0.28
0.1

A-460

8.91
1.84

A-461

30.6

A-462

>25.0
1.66

A-463

>25.0
1.66

A-464

>100

A-465

>100

A-466

20.1

A-467

21.4

A-468
46.0 (1.0)

0.3

50.0 (5.0)

94.0 (20.0)

A-469
51.0 (5.0)
7.17
0.095

68.0 (20.0)

A-470

10.4

A-471

4.92

A-472

>25.0
0.39

A-473
58.0 (20.0)
0.56
0.17

A-474
59.0 (20.0)
1.47
0.11

A-475

5.11
0.28

A-476
35.0 (20.0)
0.97
1.01

A-477

0.34

A-478

0.49
0.18

A-479

2.97
0.072

A-480

0.16
0.11

A-481

>25.0
0.2

A-482
15.0 (20.0)
0.69
1.62

A-483

0.51
0.3

Also embraced within this invention is a class of pharmaceutical compositions comprising the active compounds of this invention in association with one or more non-toxic, pharmaceutically-acceptable carriers and/or diluents and/or adjuvants (collectively referred to herein as “carrier” materials) and, if desired, other active ingredients. The active compounds of the present invention may be administered by any suitable route, preferably in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended. The active compounds and composition may, for example, be administered orally, intravascularly (IV), intraperitoneally, subcutaneously, intramuscularly (IM) or topically. For oral administration, the pharmaceutical composition may be in the form of, for example, a tablet, hard or soft capsule, lozenges, dispensable powders, suspension or liquid. The pharmaceutical composition is preferably made in the form of a dosage unit containing a particular amount of the active ingredient. Examples of such dosage units are tablets or capsules. The active ingredient may also be administered by injection (IV, IM, subcutaneous or jet) as a composition wherein, for example, saline, dextrose, or water may be used as a suitable carrier. The pH of the composition may be adjusted, if necessary, with suitable acid, base, or buffer. Suitable bulking, dispersing, wetting or suspending agents, including mannitol and PEG 400, may also be included in the composition. A suitable parenteral composition can also include a compound formulated as a sterile solid substance, including lyophilized powder, in injection vials. Aqueous solution can be added to dissolve the compound prior to injection. The amount of therapeutically active compounds that are administered and the dosage regimen for treating a disease condition with the compounds and/or compositions of this invention depends on a variety of factors, including the age, weight, sex and medical condition of the subject, the severity of the inflammation or inflammation related disorder, the route and frequency of administration, and the particular compound employed, and thus may vary widely. The pharmaceutical compositions may contain active ingredients in the range of about 0.1 to 1000 mg, preferably in the range of about 7.0 to 350 mg. A daily dose of about 0.01 to 100 mg/kg body weight, preferably between about 0.1 and about 50 mg/kg body weight and most preferably between about 0.5 to 30 mg/kg body weight, may be appropriate. The daily dose can be administered in one to four doses per day. In the case of skin conditions, it may be preferable to apply a topical preparation of compounds of this invention to the affected area two to four times a day. For disorders of the eye or other external tissues, e.g., mouth and skin, the formulations are preferably applied as a topical gel, spray, ointment or cream, or as a suppository, containing the active ingredients in a total amount of, for example, 0.075 to 30% w/w, preferably 0.2 to 20% w/w and most preferably 0.4 to 15% w/w. When formulated in an ointment, the active ingredients may be employed with either paraffinic or a water-miscible ointment base. Alternatively, the active ingredients may be formulated in a cream with an oil-in-water cream base. If desired, the aqueous phase of the cream base may include, for example at least 30% w/w of a polyhydric alcohol such as propylene glycol, butane-1,3-diol, mannitol, sorbitol, glycerol, polyethylene glycol and mixtures thereof. The topical formulation may desirably include a compound which enhances absorption or penetration of the active ingredient through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethylsulfoxide and related analogs. The compounds of this invention can also be administered by a transdermal device. Preferably topical administration will be accomplished using a patch either of the reservoir and porous membrane type or of a solid matrix variety. In either case, the active agent is delivered continuously from the reservoir or microcapsules through a membrane into the active agent permeable adhesive, which is in contact with the skin or mucosa of the recipient. If the active agent is absorbed through the skin, a controlled and predetermined flow of the active agent is administered to the recipient. In the case of microcapsules, the encapsulating agent may also function as the membrane. The transdermal patch may include the compound in a suitable solvent system with an adhesive system, such as an acrylic emulsion, and a polyester patch. The oily phase of the emulsions of this invention may be constituted from known ingredients in a known manner. While the phase may comprise merely an emulsifier, it may comprise a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. Preferably, a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabilizer. It is also preferred to include both an oil and a fat. Together, the emulsifier(s) with or without stabilizer(s) make-up the so-called emulsifying wax, and the wax together with the oil and fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of the cream formulations. Emulsifiers and emulsion stabilizers suitable for use in the formulation of the present invention include Tween 60, Span 80, cetostearyl alcohol, myristyl alcohol, glyceryl monostearate, and sodium lauryl sulfate, among others. The choice of suitable oils or fats for the formulation is based on achieving the desired cosmetic properties, since the solubility of the active compound in most oils likely to be used in pharmaceutical emulsion formulations is very low. Thus, the cream should preferably be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers. Straight or branched chain, mono- or dibasic alkyl esters such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters may be used. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils can be used. Formulations suitable for topical administration to the eye also include eye drops wherein the active ingredients are dissolved or suspended in suitable carrier, especially an aqueous solvent for the active ingredients. The anti-inflammatory active ingredients are preferably present in such formulations in a concentration of 0.5 to 20%, advantageously 0.5 to 10% and particularly about 1.5% w/w. For therapeutic purposes, the active compounds of this combination invention are ordinarily combined with one or more adjuvants appropriate to the indicated route of administration. If administered per os, the compounds may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration. Such capsules or tablets may contain a controlled-release formulation as may be provided in a dispersion of active compound in hydroxypropylmethyl cellulose. Formulations for parenteral administration may be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions may be prepared from sterile powders or granules having one or more of the carriers or diluents mentioned for use in the formulations for oral administration. The compounds may be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers. Other adjuvants and modes of administration are well and widely known in the pharmaceutical art.

All patent documents listed herein are incorporated by reference.

Although this invention has been described with respect to specific embodiments, the details of these embodiments are not to be construed as limitations.

Description of parallel array synthesis methodology utilized to prepare compounds of Examples B-i, B-ii, and B-iii.

Scheme B-1 describes the parallel array reaction blocks that were utilized to prepare compounds of Examples B-0001 through B-1574, and by analogy could also be used to prepare compounds of Examples B-1575 through B-2269. Parallel reactions were performed in multi-chamber reaction blocks. A typical reaction block is capable of performing 48 parallel reactions, wherein a unique compound is optionally prepared in each reaction vessel B1. Each reaction vessel B1 is made of either polypropylene or pyrex glass and contains a frit B2 toward the base of the vessel. Each reaction vessel is connected to the reaction block valve assembly plate B3 via leur-lock attachment or through a threaded connection. Each vessel valve B4 is either opened or closed by controlling the leur-lock position or by the opening or closing of levers B5 within a valve assembly plate row. Optionally, solutions can be either drained or maintained above the vessel frits by leaving the valves in the opened position and controlling the back pressure beneath the valve assembly plate by control of inert gas flow through the inert gas inlet valve B6. The parallel reactions that are performed in these reaction blocks are allowed to progress by incubation in a jacketed, temperature controlled shaking station. Temperature control of the reaction chambers is effected by passing a heat-transfer liquid through jacketed aluminum plates that make contact with the reaction block mantle B7. Mixing is effected at the shaking station by either vertical orbital shaking of the up-right reaction block or by lateral shaking of the reaction block tilted on its side.

Functionalized resins are optionally added to each reaction vessel B1 during the course of reaction or at the conclusion of the reaction. These functionalized resins enable the rapid purification of each reaction vessel product. Vacuum filtration of the reaction block apparatus by opening of the vacuum valve B8 allows purified products to be separated from resin-sequestered non-product species. Valve B8 is located on the bottom reaction block chamber B10 which houses the quadrant collection vial racks B11. The desired products are obtained as filtrates in unique collection vials B9. Removal of solvent from these collection vials affords desired products.
embedded image

Scheme B-2 illustrates the various utilizations of functionalized resins to purify reaction vessel products B22 prior to filtration from the fritted vessels B1into

collection vials B9. Said functionalized resins perform as 1) resin-bound reagents B12, which give rise to resin-bound reagent byproducts 313; 2) sequestrants B14 or B15 of excess solution-phase reactants B16 or B17, respectively. Solution-phase reactants B16 and B17 contain inherent reactive functionality -rf₁and -rf₂which enable their chemoselective sequestration by the complementary reactive functionality -Crf₁and -Crf₂attached to resins B14 and B15; 3) sequestrants B18 of solution-phase byproducts B19. Byproduct B19 contains molecular recognition functionality -mr₂which enables its chemoselective sequestration by the complementary functionality -Cmr₂attached to resin B18; 4) reaction-quenching resins B20 which give rise to quenched resins 321. Resin B30 contains functionality -Q which mediates reaction quenching (for instance, proton transfer) of product B22 to form a desired isolable form of, product B22. Upon performing reaction quench, the resin B20 is converted to resin B21 wherein -q represents the spent functionality on resin B21 ; 5) secuestrants B23 of chemically-tagged reagents B24 and their corresponding reagent byproducts B25. The soluble reagent B24 contains a bifunctional chemical group, -tag, which is inert to the reaction conditions but is used to enable the post-reaction sequestration of B24 by the complementary functionality -Ctag attached to resin B23. Additionally, the soluble reagent byproduct B25, formed during the course of reaction, contains the same chemical function -tag that also enables its sequestration by resin B23. Additionally, some reactants B16, particularly sterically-hindered reactants and/or electron deficient nucleophiles, contain poorly sequestrable functionality (rf1 in this case is a poorly sequestable functionality). These poorly sequestable reactants B16 can be transformed in situ to more robustly sequestrable species B27 through their reaction with sequestration-enabling-reagents B26. B26 contain highly reactive, complementary functionality Crf₁which reacts with B16 to form B27 in situ. The bifunctional molecular recognition functionality, mr, contained within B26 is also present on the in situ derivatized B27. Both B26 and 327 are sequestered by the complementary molecular recognition functionality attached to resin B28. By analogy, some reactions contain poorly sequestable byproducts B19, wherein the molecular recognition functionality mr₂in this case is not able to mediate the direct sequestration of B19 by the complementary functionality attached to resin B18. Similar use of the bifunctional sequestration-enabling-reagent B29 transforms B19 into the more readily sequestrable species B30. The imparted molecular recognition functionality, mr, present in B30 is readily sequestered by the complementary functionality, Cmr, attached to resin B31. In some reactions, multiple sequestration resins are utilized simultaneously to perform reaction purifications. Even resins containing incompatible (mutually reactive) functional groups can be used simultaneously because these resins scavenge complementary functionalized solution phase reactants, reagents, or byproducts from solution phase faster than resin cross-neutralization. Similarly, resins containing mutually reactive or neutralizing reaction-quenching functionality are able to quench solution phase reactants, products, or byproducts faster than resin cross-neutralization.
embedded image

Scheme B3 describes the modular robotics laboratory environment that was utilized to prepare compounds of Examples B0001 through Bxxxx. Chemicals that are utilized in the robotics laboratory are weighed and then dissolved or suspended into solvents at Station #1 (Automated Chemistry Prep Station). Thus, solutions or suspensions of known molarity are prepared for use at the other robotics workstations. Station #1 also optionally bar-code labels each chemical solution so that its identity can be read by bar-code scanning at this and other robotics workstations.

Reactions are initiated at the modular Stations #2 and #2 DUP. Station #2DUP is defined as a duplicate of Station #2 and is used to increase capacity within the robotics laboratory. A reaction block is mounted at Station #2 or #2 DUP. Also, racks containing reactants, reagents, solvents, and resin slurries are also mounted at Station #2 or #2 DUP. Under the control of a chemical informatics mapping file, reactions are initiated by the transfer of reactant solutions, reagent solutions, solvents, and/or resin slurries into each mounted reaction block vessel. The transfer of known volumes of solutions, suspensions, or solvents is mediated by syringes which control a one-up septum piercing/argon purging cannula, a wide-bore resin slurry-despensing cannula, or by a six-up cannula which can simultaneously deliver volumes to a row of six reaction vessels. The reaction block and/or chemical solution racks may be optionally cooled below room temperature during the chemical solution transfer operations. After the transfer of chemical solutions and solvents has been performed by Station #2 or #2DUP, incubation of the reaction block may occur while the reaction block is mounted at the robot station. Preferably, however, the reaction block is removed after all volume transfers are complete and the reaction block is brought to ambient temperature. The reaction block is transferred off-line to either a vertical- or lateral shaking Incubator Station #5.

The Automated weighing/archival Station #3 performs the functions of weighing empty collection vials (to obtain tare weights of collection vials) and also performs the functions of weighing collection vials containing filtered, purified products (to obtain gross weights of collection vials). After product-containing collection vials have been weighed (gross weight determinations) at workstation #3, the collection vial products are optionally redissolved into an organic solvent at workstation #3. Transfer of solvents is accomplished with syringes which control a mounted one-up septum-piercing/argon purging cannula. Each product-containing collection vial is pr epared as a solution of known molarity as directed and recorded by the chemical informatics system. These product solutions may be subsequently mounted at Station #2 or #2DUP for subsequent reaction steps or taken to Station #7 or #7DUP for analytical processing.

Rapid solvent evaporation of product-containing collection vials is accomplished by mounting the collection racks at Savant Automated Solvent Evaporation Stations #4, #4 DUP, or #4 TRIP, wherein 44DUP and #4TRI are defined as a duplicate and a triplicate of Station #4 to increase the capacity for solvent removal within the robotics laboratory. Commercially available solvent removal stations were purchased from the Savant Company (model #SC210A speedvac unit equipped with model #RVT4104 vapor trap and model #VN100 vapornet cryopump).

Stations #7 and #7DUP perform analytical processing functions. Station #7DUP is defined as a duplicate of Station #7 to increase capacity within the robotics laboratory. Product-containing collection racks are mounted at either of these stations. Each product-containing collection vial is then prepared as a solution of known molarity as directed and recorded by the chemical informatics mapping file. Optionally, this dissolution function is performed by prior processing of the collection vial rack at Station #3 as described above. Station #7 or #7DUP, under the control of the chemical informatics mapping file, transfers aliquots of each product vial into unique and identifable microtiter plate wells that are utilized to perform analytical determinations. One such microtiter plate is prepared at. Station #7 or #7DUP for subsequent utilization at the Automated HPLC/Mass Spectrometer Station #8 or #8DUP. Station #8DUP is a duplicate of Station #8 to increase the analytical capacity of the robotics laboratory. Stations #8 and #8DUP are commercially available benchtop LC/Mass spec units purchased from Hewlett Packard (model HP1100 HPLC connected to HP100 MSD (G1946A) mass spectrometer; this unit is also equipped with a model#G1322A solvent degasser, model #1312A binary pump, a model #G1316A column heater, and a model #G1315A diode array detector. The HP unit has been interfaced with a commercially available autosanpler rack (Gilson Company #215 autosampler). Station #8 or #8DUP is utilized for the determination of product purity and identity by performing high performance liquid chromatography (H?LC) and companion atmospheric pressure chemi-ionization (APCI) or electrospray mass spectrometry for molecular weight determination.

Another microtiter plate is prepared at Station #7 or #7DUP for subsequent utilization at a commercially available flow-probe Varian NMR spectrometer Station #10 (Varian Instruments flow probe NMR, 300 MHz, interfaced with a commercially available Gilson 215 autosampler). Proton, ¹³-Carbon, and/or ¹⁹-Fluorine NMR spectra are determined at this Station #10.

Other microtiter plates are optionally mounted at Station #7 or #7DUP for the purpose of preparing product-containing plates for biological assays. Aliquots of product-containing collection vials are transferred to these biological assay microtiter plates under the control of the chemical informatics mapping file. Identity and amount of each transferred product is recorded by the chemical informatics system for retrieval by biologists who perform the biological assaying of products.

The Fourier Transfrom InfraRed (FT-IR) Spectrometer Station #11 is utilized to analyze resins for the identity of organic functional groups chemically attached to these resins. The resins, as mentioned above, contain chemical functionality utilized as reagents, chemoselective sequestrants, or reaction quenching media for the workup and purification of the crude product mixtures contained within reaction block vessels. The robotics laboratory utilizes a commercially available FT-IR spectrometer purchased from Nicolet Instruments (model # MagnaIR 560 interfaced with an InspectIR microscope for resin mounting and positioning).

Scheme B-3

The lines interconnecting the modular Stations denote the transfer of chemical racks, reaction blocks, and/or collection vial racks from one modular Station to another.
embedded image

The ChemLib IT system is a composite of software running on the client's desktop and software running on a remote server.

The ChemLib IT system is a client/server software application developed to support and document the data handling flow in the robotics laboratory described above. This IT system integrates the chemist with the robotics synthesis laboratory and manages the data generated by this processes.

The software running on the server warehouses all the electronic data for the robotics chemistry unit. This server, a Silicon Graphics IRIX station v6.2, runs the database software, Oracle 7 v7.3.3.5.0, that warehouses the data. Connection from the client's desktop to the server is provided by Oracle's TCP/IP Adapter v2.2.2.1.0 and SQL*Net v2.2.2.1. OA. SQL*Net is Oracle's network interface that allows applications running on the client's desktop to access data in Oracles' database. The client's desktop is Microsoft Windows 95. The ChemLib IT system client software is composed of Omnis7 v3.5 and Microsoft Visual C++v5.0. This composition on the client side is what is herein referred to as ChemLib. ChemLib communicates with the server for its data via Oracle's PL/SQL v2.3.3.4.0. These PL/SQL calls within ChemLib creates a network socket connection to Oracle's SQL*Net driver and the TCP/IP Adapter thereby allowing access to the data on the server.

A “library” is defined as a composite number of wells, where each well defines a single compound. ChemLib defines a library in a module called the Electronic Spreadsheet. The Electronic Spreadsheet is then a composite of n-number of wells containing the components that are required to synthesize the compound that exist in each these well(s).

The chemist begins by populating the Electronic Spreadsheet with those components required for the compound synthesis. The identity and the availability of these components are defined in the Building Block Catalog module of ChemLib. The Building Block Catalog is a catalog of a listing of all reagents, solvents, peripherals available in the robotics laboratory. Upon selecting the components for each compound we also declare the quantity of each component to be utilized. The quantity of each component can be identified by its molarity and volumetric amounts (μl) or by it's solid state form (mg). Therefore a well in the Electronic Spreadsheet defines a compound that is identified by its components and the quantity of each of these components.

The assembly or the synthesis of these components for each compound in the Electronic Spreadsheet is defined in the WS Sequence module of ChemLib. The Define WS Sequence module identifies the synthesis steps to be performed at the robotics workstations and any activities to be performed manually or off-line from the robotics workstation. With this module we identify which components from the Electronic Spreadsheet and the activity that should be performed with this component in the robotics laboratory. In the Define WS Sequence module the chemist chooses from a list of activities to be performed in the robotics laboratory and assembles them in the order in which they are to occur. The ChemLib system takes these set of activities identified, and with the component data in the Electronic Spreadsheet assembles and reformats these instructions into terminology for the robotics workstation use. This robotics terminology is stored in a ‘sequence’ file on a common server that is accessible by the robotics workstation.

The robotics workstation performs the synthesis in a reaction block apparatus as described. Each well in the Electronic Spreadsheet is tracked and mapped to a unique location in the reaction block apparatus on the robotics workstation. The compound or product synthesized at the robotics workstation in the reaction block is then captured into collection vials.

The collection vials are first tarred then grossed on the robotics workstation after collecting their products from the reaction block. These weights (tare and gross) are recorded into the ChemLib system with the Tare/Gross Session module. The Tare/Gross Session module then calculates the product or compound yields and its final mass.

Preparation of the compound for analytical analysis and screening is defined by the Analytical WS Setup module in ChemLib. The Analytical WS Setup module identifies the dilution factor for each well in the Electronic Spreadsheet, based on the compound's product yield and the desired molar concentration. This identifies the quantity, in μL, to be transferred at the robotics workstation, to a specific location on the MTP (microtiter plate) to be sent for analysis and/or biological assaying. The mass spectrometric and HPLC results for each well are recorded and scored into the ChemLib system.

The Dilute/Archive WS module further identifies each compound by mapping the compounds well from the Electronic Spreadsheet to a specific MX block location for long term storage and archival as part of the registration process.

All communications between ChemLib and the robotics workstations are by ASCII files. These files are placed on a server by the ChemLib system that is accessible by the robotics workstations. Reports generated by the robotics workstations are also placed on the server where the ChemLib system can read these files to record the data generated. Each robotics workstation consists of 5 robotics hardware by Bohdan Automation, Inc. Mundelein, Ill., and a PC currently running Microsoft Windows for Workgroup v3.11 and Ethernet software. The robotics workstation PC is logged into the network for one-way communication that allows the workstation to access the server for file access only.

General Scheme B4

Scaffold C-i with a primary amine functionaliy contained within the R⁴substituent is reacted in spatially addressed, parallel array reaction block vessels with excess of electrophiles R^J-Q wherein Q is chloro, bromo, or an acid activating group including but not limited to N-hydroxysuccinimide. R^J-Q includes acid chlorides, alkyl chloroformates, sulfonyl chlorides, activated esters of carboxylic acids, activated carbamates, and isocyanates. Reaction of scaffold C-i with R^J-Q is effected in the presence of a tertiary amine base at room temperature in a mixture of a polar aprotic solvent and/or a halogenated solvent. As illustrated in Scheme B-4 the products of the general formulae B-i are isolated in purified form by addition of a carbonyl-functionalized resin B32 which covalently sequesters any unreacted primary amine scaffold C-i as resin-bound adduct B35, and also by the addition of a primary amine-functionalized resin B33 which covalently sequesters any remaining electrophile R^J-Q from each reaction mixture as resin-bound adduct B34. Resin B33 also sequesters the HQ byproduct from the reaction mixture by proton transfer from solution-phase Base-HQ. Incubation at room temperature, filtration, rinsing of the resin cake, and concentration of the filtrates affords purified products B-i filtered away from resin-bound adducts B32, B33, B34, B35, and B36.
embedded image

Scheme B-5 specifically illustrates the derivatization of the primary amine-containing scaffold C1 to afford the desired products B-i in a parallel array synthesis format. In a parallel array synthesis reaction block, individual reaction products are prepared in each of multiple reaction block vessels in a spatially addressed format. A solution of the desired primary amine-containing scaffold C1 (limiting amount,) in dimethylformamide (DMF) is added to the reaction vessels followed by a 4.0 fold stoichiometric excess solution of N-methylmorpholine in DMF. To each reaction vessel is then added the electrophiles: either a 2.0 fold stoichiometric excess when R^J-Q is an acid chloride or alkyl chloroformate, or a 1.5 fold stoichiometric excess when R^J-Q is a sulfonyl chloride, or a 1.25 fold stoichiometric excess when R^J-Q is an isocyanate. Excess electrophiles and N-methylmorpholine were used to effect more rapid and/or more complete conversion of scaffold C1 to products B-0001-B-0048 compared to reactions that do not utilize stoichiometric excesses of electrophiles and N-methylmorpholine. The reaction mixtures are incubated at ambient temperature for 2-3 h. Each reaction vessel is then charged with a large excess (15-20 fold stoichiometric excess) of the amine-functionalized resin B33 and the aldehyde-functionalized resin B32. The resin-charged reaction block is shaken vertically for 14-20 h on an orbital shaker at ambient temperature to allow optimum agitation of the resin-containing vessel mixtures. The excess electrophiles R^J-Q and any unreacted scaffold amine C1 are removed from the reaction medium as insoluble adducts B34 and B37 respectively. In addition the N-methylmorpholine hydrochloride salt formed during the course of the reaction is also neutralized to its free base form by proton transfer reaction to the amine-functionalized resin B33. Simple filtration of the insoluble resin- adducts B32, B33, B34, B36, and B37, rinsing of the resin cake with dichloroethane, and evaporation of the filtrates affords the desired products B-i in purified form.
embedded image

Scheme B-6 illustrates a general synthetic method involving the parallel array reaction of a scaffold C-ii containing a secondary amine functionality within the definition of the R⁴substituent. Each reaction vessel is charged with the secondary amine-containing scaffold C-ii, followed by the introduction of a stoichiometric excess of an optionally unique electrophile R^L-Q into each vessel, wherein Q is chloro, bromo, or an acid activating group including but not limited to N-hydroxysuccinimide. R^L-Q includes acid chlorides, alkyl chloroformates, sulfonyl chlorides, activated esters of carboxylic acids, activated carbamates, and isocyanates. Reaction of scaffold C-ii with R^L-Q is effected in the presence of tertiary amine base at room temperature or elevated temperature in a mixture of a polar aprotics solvent and/or a halogenated solvent. After solution-phase reactions have progressed to afford crude product mixtures in each vessel, the products B-ii are isolated in purified form by the addition of the isocyanate-functionalized resin B38 which covalently sequesters remaining secondary amine scaffold C-ii as resin-bound adduct B39, and also by the addition of the primary amine-functionalized resin B33 which covalently sequesters remaining electrophile R^L-Q from each reaction vessel as resin-bound adducts B40. Resin B33 also sequesters the HQ byproduct in each vessel as B36, formed by proton transfer from solution-phase Base-HQ. Incubation with these resins, either simultaneously or sequentially, followed by filtration, rinsing, and concentration of the filtrates affords purified products B-ii filtered away from resin-adducts B33, B36, B38, B39, and B40.
embedded image

Scheme B-7 illustrates the conversion of the secondary-amine containing scaffold C-2 to the desired products B-ii. In a parallel array synthesis reaction block, individual reaction products are prepared in each of 48 multiple reaction block vessels. A solution of the scaffold C-2 (limiting amount) in dimethylformamide (DMF) is added to the reaction vessels followed by a 4.0-fold stoichiometric excess solution of N-methylmorpholine in DMF. To each reaction vessel is then added an electrophile R^L-Q as a dichloroethane (DCE) solution: either a 2.0 fold stoichiometric excess is used when R^L-Q is an acid chloride or alkyl chloroformate, or a 1.5 fold stoichiometric excess when R^L-Q is a sulfonyl chloride, or a 1.25 fold stoichiometric excess when R^L-Q is an isocyanate. The reaction mixtures are incubated at ambient temperature for 2-6 h. Each reaction vessel is then charged with a large excess (15-2.0 fold stoichiometric excess) of the amine-functionalized resin B33 and the isocyanate-functionalized resin B32. The resin-charged reaction block is shaken vertically for 14-20 h on an orbital shaker at ambient temperature to allow optimum agitation of the resin-containing vessel mixtures. The excess electrophiles R^L-Q and unreacted scaffold amine C-2 are removed from the reaction medium as insoluble adducts B40 and B39, respectively. Resin B33 also sequesters the HQ byproduct in each vessel as B36, formed by proton transfer from solution-phase Base-HQ. Incubation with these resins, followed by filtration and rinsing with solvent mixtures of DMF and/or DCE, affords purified product solutions in collection vials filtered away from resin-adducts B33, B36, B38, B39, and B40. Concentration of filtrates affords purified products B-ii.
embedded image

Scheme B-8 illustrates another general synthetic method involving the parallel array reaction of a scaffold C-ii containing a secondary amine functionality within the definition of the R⁴substituent. Each reaction vessel is charged with the secondary amine-containing scaffold C-ii, followed by the introduction of a stoichiometric excess of an optionally unique electrophile R^L-Q into each vessel. Reaction of scaffold C-ii with R^L-Q is effected in the presence of tertiary amine base at room temperature or elevated temperature in a mixture of a polar aprotic solvent and/or a halogenated solvent.

Excess electrophiles and N-methylmorpholine are used to effect more rapid and/or more complete conversion of scaffold C-ii to products B-ii compared to reactions that do not utilize stoichiometric excesses of electrophiles and N-methylmorpholine. The reaction mixtures are incubated at ambient temperature for 2-8 h. Each reaction vessel is then charged with the sequestration-enabling reagent phenylsulfonylisocyanate B41. This reagent B41 reacts with remaining secondary amine scaffold C-ii, converting C-41 to the in situ-derivatized compound B42. Subsequent incubation of these vessel mixtures with a large excess (15-20 fold stoichiometric excess) of the amine-functionalized resin B33 sequesters the solution-phase species R^L-Q, HQ, 341, and B42 as the resin-bound adducts B40, B36, 844, and B43, respectively. The resin-charged reaction block is shaken vertically for 14-20 h on an orbital shaker at ambient temperature to allow optimum agitation of the resin-containing vessel mixtures. Filtration of the insoluble resin- adducts B33, B36, B40, B43 and B44 and subsequent rinsing of the vessel resin-bed with DMF and/or DCE affords filtrates containing the purified products B-ii. Concentration of the filtrates affords the purified products B-ii.
embedded image

Scheme B-9 illustrates the method of Scheme B-8 using scaffold C-2. A solution of the scaffold C-2 (limiting amount) in dimethylformamide (DMF) is added to the reaction vessels followed by a 4.0-fold stoichiometric excess solution of N-methylmorpholine in DMF. To each reaction vessel is then added an electrophile R^L-Q as a dichloroethane (DCE) solution: either a 2.0 fold stoichiometric excess is used when R^L-Q is an acid chloride or alkyl chloroformate, or a 1.5 fold stoichiometric excess when R^L-Q is a sulfonyl chloride, or a 1.25 fold stoichiometric excess when R^L-Q is an isocyanate. The reaction mixtures are incubated at ambient temperature for 2-6 h. After solution-phase reactions have progressed to afford crude product mixtures, each reaction vessel is then charged with a dichloroethane solution of the sequestration-enabling reagent phenylsulfonylisocyanate B41. This reagent B41 reacts with remaining secondary amine scaffold C-2, converting C-2 to the in situ-derivatized compound B45. Subsequent incubation of these vessel mixtures with a large excess (15-20 fold stoichiometric excess) of the amine-functionalized resin B33 sequesters the solution-phase species R^L-Q, HQ, B41, and B45 as the resin-bound adducts B40, B36, B44, and B46, respectively. The resin-charged reaction block is shaken vertically for 20 h on an orbital shaker at ambient temperature to allow optimum agitation of the resin-containing vessel mixtures. Filtration of the insoluble resin- adducts B33, B36, B40, B44, and B46 and subsequent rinsing of the vessel resin-bed with DCE affords filtrates containing the purified products B-ii. Concentration of the filtrates affords the purified products B-ii.
embedded image

Another general method for the parallel array reaction block synthesis is illustrated in Scheme B-10 for the derivatization of the carboxylic acid-containing scaffold C-iii. Scaffold C-iii with a free carboxylic acid functionality is reacted in spatially addressed, parallel array reaction block vessels with excesses of optionally different primary or secondary amines B47 in the presence of the polymer-bound carbodiimide reagent B48 and a tertiary amine base in a mixture of a polar aprotic solvent and/or a halogenated solvent. After filtration of each crude vessel product misture away from resins B48 and B49, each reaction mixture is purified by treatment with the sequestration-enabling-reagent BSO (tetra-fluorophthalic anhydride). The reagent B50 reacts with remaining excess amine B47 to afford the in situ-derivatized intermediates B51 which contain carboxylic acid molecular recognition functionality. Subsequent incubation of each reaction mixture with a 15-20-fold stoichiometric excess of the primay amine-functonalized resin B33 sequesters B51, BSO, and any remaining acid scaffold C-iii as resin-bound adducts B52, B53, and B54, respectively. Filtration of solution-phase products B-iii away from these resin-bound adducts and rinsing of the resin beds with a polar aprotic solvent and/or halogenated solvent affords filtrates containing purified products B-iii. Concentration of the filtrates affords purified B-iii.
embedded image

Scheme B-11 illustrates the conversion of the acid containing scaffold C-49 to the desired amide products B-iii in a parallel synthesis format. A limiting amount of the scaffold C-49 is added as a solution in dimethylformamide to each reaction vessel containing the polymer bound carbodiimide reagent B48 (5 fold stoichiometric excess). A solution of pyridine (4 fold stoichiometric excess) in dichloromethane is added to this slurry, followed by addition of an excess amount of a dimethylformamide solution of a unique amine B47 (1.5 fold stoichiometric excess) to each vessel. The parallel reaction block is then agitated vertically on an orbital shaker for 16-18 h at ambient temperature and filtered to separate the solution phase product mixture away from resin-bound reagent B48 and resin-bound reagent byproduct B49. The resulting solutions (filtrates) containing a mixture of the desired amide products B-iii, excess amines B47 and any unreactedacid containing scaffold C-49, are treated with tetrafluorophthalic anhydride B50. B50 converts the excess amines B47 in each filtrate vessel to its respective sequestrable half acid form B51. After two h incubation time, an excess of the amine-functionalized resin B33 and dichloromethane solvent are added to each reaction vessel. The amine-containing resin B33 converts B51, any remaining B50, and any remaining C-49 to their resin-bound adducts B52, B53, and B55, respectively. The resin-charged reaction block is shaken vertically for 16 h on an orbital shaker at ambient temperature to allow optimum agitation of the resin-containing vessel mixtures. Filtration of the insoluble resin- adducts B33, B52, B53., and B55 and subsequent rinsing of the vessel resin-bed with dimethylformamide affords filtrates containing the purified products B-iii. Concentration of the filtrates affords the purified products B-iii.
embedded image

Although Schemes B-1 through B-11 describe the use of parallel array chemical library technology to prepare compounds of general formulae B-i, B-ii, and B-iii, it is noted that one with ordinary skill in the art of classical synthetic organic chemistry would be able to prepare B-i, B-ii, and B-iii by conventional means (one compound prepared at a time in conventional glassware and purified by conventional means such as chromatography and/or crystallization).

A general synthesis of pyridylpyrazole scaffolds C-i, C-ii, and C-iii is depicted in Scheme C-1.

Step A: Picoline is treated with a base chosen from but not limited to n-butyllithium (n-BuLi), lithium di-iso-propylamide (LDA), lithium hexamethyldisilazide (LiHMDS), potassium t-butoxide (tBuOK), or sodium hydride (NaH) in an organic solvent such as tetrahydrofuran (THF), diethyl ether, t-butyl methyl ether, t-BuOH or dioxane from −78° C. to 50° C. for a period of time from 10 minutes to 3 hours. The metallated picoline solution is then added to a solution of ester B56. The reaction is allowed to stir from 30 minutes to 48 hours during which time the temperature may range from −20° C. to 120° C. The mixture is then poured into water and extracted with an organic solvent. After drying and removal of solvent the pyridyl monoketone B57 is isolated as a crude solid which can be purified by crystallization and/or chromatography.

Step B: A solution of the pyridyl monoketone B57 in ether, THF, tBuOH, or dioxane is added to a base chosen from but not limited to n-BuLi, LDA, LiHMDS, tBuOK, or NaH contained in hexane, THF, diethyl ether, t-butyl methyl ether, or t-BuOH from −78° C. to 50° C. for a period of time from ranging from 10 minutes to 3 hours. An appropriately substituted activated ester or acid halide derived from R⁴—CO₂H is then added as a solution in THF, ether, or dioxane to the monoketone anion of B57 while the temperature is maintained between −50° C. and 50° C. The resulting mixture is allowed to stir at the specified temperature for a period of time from 5 minutes to three hours. The resulting pyridyl diketone intermediate B58 is utilized without purification in Step C.

Step C: The solution containing the pyridyl diketone B58 is quenched with water and the pH is adjusted to between 4 and 8 utilizing an inorganic or organic acid chosen from HOAc, H₂SO₄, HC1, or HNO³. The temperature during this step is maintained between −20° C. and room temperature. Hydrazine or hydrazine hydrate was then added to the mixture while maintaining the temperature between −20° C. and 40° C. for a period of 30 minutes to three hours. The mixture is then poured into water and extracted with an organic solvent. The pyridyl pyrazole C-i or C-ii is obtained as a crude solid which is purified by chromatography or crystallization.

Step: D In some cases the pyridyl pyrazole C-i or C-ii is alkylated with Q-C(R^A)-(CH2)_nCO₂alkyl wherein Q is halogen. C-i or C-ii is treated with a base chosen from NaH, NaOEt, KOtBu, or NEt₃in an organic solvent such as THF, methylene chloride, dioxane, or DMF at temperatures between 31 20° C. and 150° C. and reaction times between 30 minutes and 12 hours. The resulting alkylated pyridyl pyrazole ester is then hydrolyzed to the acid by treament with NaOH or LiOH in aqueous/alcohol solvent mixtures or in THF/water solvent mixtures. Alternatively, the ester function is removed by treatment with an organic or inorganic acid if the alkyl residue is t-butyl. Acidification, followed by extraction with an organic solvent affords. C-iii which may be purified by chromatography or crystallography. In some cases, regioisomeric alkylated products C-iv are also formed. The desired C-iii can be separated away from C-iv by chromatographic purification or by fractional crystallization.
embedded image

A synthesis of pyridylpyrazole scaffold C-1 is depicted in Scheme C-2.

Step A:

Picoline is added to a solution of LiHMDS in THF at room temperature over a time period ranging from 30 minutes to 1 hour. The resulting solution is stirred for an additional 30 minutes to 1 hour at room temperature. This solution is then added to neat ethyl p-fluorobenzoate B60 at room temperature over 1-2 h. The mixture is then allowed to stir at room temperature for 16-24 h. Equal portions of water and ethyl acetate are then added to the reaction and the mixture is partitioned in an extraction funnel. The organic layer is dried, filtered, and evaporated to give an oily solid. Hexanes are then added and the solid is filtered and washed with cold hexanes leaving the pyridyl monoketone B61 for use in Step B.

Step B:

The pyridyl monoketone B61 is added as a solution in THF to a flask maintained at room temperature which contains t-BuOK in a THF/t-BuOH cosolvent. A yellow precipitate forms and stirring at room temperature is continued for 1-3 h. After this time, N-Cbz-protected glycine N-hydroxysuccinimide B62 is added dropwise at room temperature as a solution in THF over 1-3 h. This solution, containing crude diketone B63, is used directly in Step C.

Step C:. The solution from step C is treated with water and the pH is adjusted to between 6 and 7 with acetic acid. Hydrazine hydrate is then added dropwise to the mixture as a solution in water over 30 minutes to 1 h at room temperature. Water and ethyl acetate are then added to the flask and the mixture is then partitioned in a separatory funnel. The organic layer is dried, filtered, and evaported to give a crude oil which is purified by silica gel chromatography, giving rise to purified C-1Cbz.

Step: D

The Cbz protecting group contained in compound C-1Cbz is cleaved using hydrogen gas under pressure and Pd-C in methanol solvent. The resulting amine C-1 is obtained by filtration and concentration.
embedded image

A number of pyridyl pyrazole scaffolds of type C-v are prepared as shown in Scheme C-3.

Step A: Picoline is treated with a base chosen from but not limited to n-BuLi, LDA, LiHMDS, tBuOK, or NaH in an organic solvent such as THF, ether, t-BUOH or dioxane from −78° C. to 50° C. for a period of time from 10 minutes to 3 hours. The metallated picoline solution is then added to a solution of an appropriately activated ester analog of a carboxylic acid CbzNRH—(CH₂) _nCR^F(R^G)—CO₂H or BocNR^H—(CH₂) _nCR^F(R^G)—CO₂H, preferably but not limited to the N-hydroxysuccinimide B64. The reaction is allowed to stir from 30 minutes to 48 hours during which time the temperature may range from −20° C. to 120° C. The mixture is then poured into water and extracted with an organic solvent. After drying and removal of solvent the pyridyl monoketone B65 is isolated as a crude solid which can be purified by crystallization and/or chromatography.

Step B: A solution of the pyridyl monoketone B65 in ether, THF, tBuOH, or dioxane is added to a base chosen from but not limited to n-BuLi, LDA, LiHNDS, tBuOK, or NaH contained in hexane, THF, ether, dioxane, or tBuOH from −78° C. to 50° C. for a period of time from 10 minutes to 3 hours. The anion sometimes precipitates as a yellow solid. An appropriately substituted activated ester such as the N-hydroxysuccinimide B66 is then added as a solution in THF, ether, or dioxane to the monoketone anion while the temperature is maintained between −50° C. and 50° C. The resulting mixture is allowed to stir at the specified temperature for a period of time from ranging from 5 minutes to 3 hours. The resulting pyridyl diketone intermediate B67 is utilized without further purification in Step C.

Step C: The solution containing the pyridyl diketone B67 is quenched with water and the pH is adjusted to between 4 and 8 utilizing an inorganic or organic acid chosen from HOAc, H₂SO₄, HCl, or HNO₃. The temperature during this step is maintained between −20° C. and room temperature. Hydrazine or hydrazine hydrate is then added to the mixture while maintaining the temperature between −20° C. and 40° C. for a period of 30 minutes to three hours. The mixture is then poured into water and extracted with an organic solvent. The pyridyl pyrazole C-vBoc or C-vCbz is obtained as a crude solid which is purified by chromatography or crystallization.

Step: D

The carbamate protecting groups from C-vBoc or C-vCbz are removed to afford the scaffolds C-v containing either a free primary amine (RH is hydrogen) or a free secondary amine (RH not equal to hydrogen). The Boc protecting carbamate groups are cleaved utilizing 1:1 trifluoroacetic acid (TFA)/methylene chloride at room temperature for several hours. The CBZ carbamate protecting groups are cleaved using hydrogen gas under pressure and Pd-C in an alcoholic solvent. The resulting amines C-v are then optionally crystallized or purified by chromatography.
embedded image

The synthesis of scaffolds C-vi is accomplished as shown in Scheme C-4.

Step A:

A Boc protected pyridylpyrazole B68 is treated with benzaldehyde in methylene chloride at room temperature in the presence of a drying agent for a period of time ranging from 1-24 h. Solvent is then evaporated and the resulting imine B69 is used in step B without further purification.

Step B:

The pyridylpyrazole imine B69 is dissolved in THF and stirred under nitrogen at temperatures ranging from −78 to −20° C. A base such as LDA, n-BuLi, or LiHMDS is added dropwise to the mixture which is then stirred for an additional 10 minutes to 3 h. Two-five equivalents of an alklyating agent R^F-Q are then added to the mixture and stirring is continued for several hours. The mixture is then quenched with acid and allowed to warm to room temperature and stirred several hours until cleavage of the Boc and the imine functions is complete. The pH is adjusted to 12 and then the mixture is extracted with an organic solvent, which is dried and evaporated. The crude pyridylpyrazole is then crystallized and/or chromatographed to give C-vi.
embedded image

The synthesis of maleimide-containing scaffolds C-vii is accomplished as shown in Scheme C-5.

The maleimide pyrazole scaffolds C-vii are synthesized as depicted in scheme C-5. Condensation reaction of a primary amine H₂N—R with a maleic anhydride B70 that is substituted at position 3 with either a bromo, chloro, or triflate group generates compound B71. The formed maleimide derivative B71 then reacts with an acetophenone derivative B72 in the presence of a Pd(0) catalyst and base to afford compound B73. The methylene position of B73 is then acylated with an acid anhydride B74 or an activated acid ester B75, forming the di-ketone derivative B76. The di-ketone B76 condenses with hydrazine to afford the desired maleimide pyrazole scaffold C-vii.
embedded image

Scheme C-6 illustrates the synthesis of the maleimide pyrazole scaffold C-63 wherein R⁴is hydrogen. The synthesis starts with the condensation reaction of bromomaleic anhydride B77 with 2,4-dimethoxybenzylamine in acetic acid and acetic anhydride, giving rise to intermediate B78. The maleimide B78 is then treated with 4′-fluoroacetophenone in the presence of catalytic amount Pd₂(dba)₃and sodium t-butoxide to form the fluoroacetophenone substituted maleimide B79. The B79 is treated with tert-butoxybis(dimethylamino)methane to yield the a-ketoenamine B80. The a-ketoenamine B80 is condensed with hydrazine to form the maleimide pyrazole skeleton B81. The 2,4-dimethoxybenzyl group protecting group is optionally removed with ceric ammonium nitrate (CAN) to give compound C-63.
embedded image

Scheme C-7 illustrates the synthesis of maleimide-containing scaffolds C-64 and C-65. These scaffolds C-49 and C-50 are synthesized according to the general methods illustrated in Scheme C-5 and exemplified with the utilization of N-hydroxysuccinimides B82 and B83 to afford the maleimide-containing pyrazoles B86 and B87, respectively. Optional removal of the 2,4-dimethoxylbenzyl groups with CAN and subsequent removal of the Boc-protecting groups with trifluoroacetic acid (TFA) affords the scaffolds C-64 and C-65.
embedded image

The various functionalized resins and sequestration-enabling-reagents utilized to prepare and purify parallel reaction mixtures are more fully described below, including their commercial source or literature reference to their preparation.
embedded image

Experimental procedure for the parallel synthesis of a series of amides, carbaqnates, ureas and sulfonamides B-0001 through B-0048 from scaffold C-1.

EXAMPLES B-0001 THROUGH B-0048

To each reaction vessel (polypropylene syringe tubes fitted with a porous frit, closed at the bottom) of a parallel reaction apparatus was added 200 uL of dimethylformamide. A stock solution of the scaffold amine C-1 in dimethylformamide (0.1 M, 500 uL) was added to each reaction vessel followed by the addition of a stock solution of N-methylmorpholine in dimethylformamide (1.0 M., 200 uL). A stock solution of each of the electrophiles was then added to the appropriate reaction vessels: a) 500 uL of a 0.2 M solution of the acid chlorides in dichloroethane or b) 500 uL of a 0.2 M solution of the chloroformates in dichloroethane or c) 313 uL of a 0.2 M solution of the isocyanates in dichloroethane or d) 375 uL of a 0.2 M solution of the sulfonyl chlorides in dichloroethane. The parallel reaction apparatus was then. orbitally shaken (Labline Benchtop orbital shaker) at 200 RPM at ambient temperature (23-30° C.) for a period of 2-3 h, under a gentle flow of nitrogen. At this time each reaction vessel was treated with approximately 250 mg of polyamine resin B33 (4.0 meq N/g resin) and approximately 100 mg of polyaldehyde resin B32 (2.9 mmol/g resin). Each reaction vessel was diluted with 1 mL dimethylformamide and 1 mL dichloroethane and the orbital shaking was continued at 200 RPM for a period of 14-20 h at ambient temperature. Each reaction vessel was then opened and the desired solution phase products separated from the insoluble quenched byproducts by filtration and collected in individual conical vials. Each vessel was rinsed twice with dichloroethane (1 mL) and the rinsings were also collected. The solutions obtained were then evaporated to dryness in a Savant apparatus (an ultracentrifuge equipped with high vacuum, scalable temperature settings and a solvent trap to condense the volatile solvent vapors). The resulting amide, carbamate, urea and sulfonamide products were then weighed and characterized. The yields and analytical data for the products obtained using this method are shown below.

ObservedCalcd.Mass SpecExample#R²R^J% YieldMass Spec(M + H)B-0001 embedded image

85397398B-0002 embedded image

94412413B-0003 embedded image

91340341B-0004 embedded image

79368369B-0005 embedded image

92498499B-0006 embedded image

92416417B-0007 embedded image

86450451B-0008 embedded image

86448449B-0009 embedded image

83368369B-0010 embedded image

86338339B-0011 embedded image

92402403B-0012 embedded image

74442443B-0013 embedded image

91446447B-0014 embedded image

84352353B-0015 embedded image

94380381B-0016 embedded image

89440441B-0017 embedded image

83498499B-0028 embedded image

92456457B-0029 embedded image

89428429B-0030 embedded image

37498499B-0031 embedded image

18407408B-0032 embedded image

86462463B-0033 embedded image

3352—B-0034 embedded image

92446447B-0035 embedded image

28569570B-0036 embedded image

93416417B-0037 embedded image

91422423B-0038 embedded image

84390393B-0039 embedded image

87402403B-0040 embedded image

92416417B-0041 embedded image

75444445B-0042 embedded image

54390391B-0043 embedded image

80396397B-0044 embedded image

81310311B-0045 embedded image

91408409B-0046 embedded image

25464465B-0047 embedded image

88430431B-0048 embedded image

95414415

By analogy to the procedure identified above for the preparation of Examples B0001-B0048, the following examples B-0049 through B-1573 were prepared.

Calcd.Observed%MassSpecExample#R²R^JYieldSpec(M + H)B-0049 embedded image

85414415B-0050 embedded image

9458459B-0051 embedded image

91426427B-0052 embedded image

79407408B-0053 embedded image

92407408B-0054 embedded image

92363364B-0055 embedded image

86505506B-0056 embedded image

86487488B-0057 embedded image

83394395B-0058 embedded image

86462463B-0059 embedded image

92466467B-0060 embedded image

74456457B-0061 embedded image

35458459B-0062 embedded image

94458459B-0063 embedded image

87372373B-0064 embedded image

5394395B-0065 embedded image

87420395B-0066 embedded image

89350351B-0067 embedded image

92386387B-0068 embedded image

89432433B-0069 embedded image

37390391B-0070 embedded image

18432433B-0071 embedded image

86440441B-0072 embedded image

3432433B-0073 embedded image

92450451B-0074 embedded image

28390391B-0075 embedded image

93402403B-0076 embedded image

91400401B-0077 embedded image

84382383B-0078 embedded image

87396397B-0079 embedded image

92364365B-0080 embedded image

75447448B-0081 embedded image

54370371B-0082 embedded image

80430431B-0083 embedded image

81382383B-0084 embedded image

91464465B-0085 embedded image

25462463B-0086 embedded image

88432433B-0087 embedded image

95416417B-0088 embedded image

438439B-0090 embedded image

444445B-0091 embedded image

368369B-0092 embedded image

506507B-0093 embedded image

436437B-0094 embedded image

461462B-0095 embedded image

408409B-0097 embedded image

14486487B-0098 embedded image

8465—B-0099 embedded image

75464465B-0100 embedded image

72388389B-0101 embedded image

23408409B-0102 embedded image

37487488B-0103 embedded image

11492493B-0114 embedded image

14453454B-0115 embedded image

33453B-0116 embedded image

11459487B-0117 embedded image

77438439B-0118 embedded image

52422423B-0119 embedded image

82434435B-0120 embedded image

49422423B-0121 embedded image

64414415B-0122 embedded image

87501502B-0123 embedded image

100450451B-0124 embedded image

87456457B-0125 embedded image

45472473B-0126 embedded image

100476477B-0127 embedded image

100433434B-0128 embedded image

100482—B-0129 embedded image

96480481B-0130 embedded image

93468469B-0131 embedded image

90468469B-0132 embedded image

78436437B-0133 embedded image

76426427B-0134 embedded image

87444445B-0135 embedded image

67476477B-0136 embedded image

100570—B-0137 embedded image

35480481B-0138 embedded image

60500—B-0139 embedded image

73585586B-0140 embedded image

62434459B-0141 embedded image

100483484B-0142 embedded image

90444445B-0143 embedded image

61492493B-0144 embedded image

49448449B-0145 embedded image

48433434B-0146 embedded image

32415416B-0147 embedded image

67471472B-0148 embedded image

79465—B-0149 embedded image

65353354B-0150 embedded image

53465466B-0151 embedded image

68401402B-0152 embedded image

39383—B-0153 embedded image

96427428B-0154 embedded image

44459460B-0155 embedded image

74479480B-0156 embedded image

44459460B-0157 embedded image

72415416B-0158 embedded image

96445446B-0159 embedded image

97411412B-0160 embedded image

49417418B-0161 embedded image

93459460B-0162 embedded image

91405406B-0163 embedded image

94455456B-0164 embedded image

84455456B-0165 embedded image

52411412B-0166 embedded image

72417418B-0167 embedded image

66447448B-0168 embedded image

27415416B-0169 embedded image

91415416B-0170 embedded image

8351352B-0171 embedded image

10437438B-0172 embedded image

62471472B-0173 embedded image

40455456B-0174 embedded image

92405406B-0175 embedded image

96387388B-0176 embedded image

25415416B-0177 embedded image

100397398B-0178 embedded image

34429430B-0179 embedded image

72429430B-0180 embedded image

91463464B-0181 embedded image

100463464B-0182 embedded image

50447448B-0183 embedded image

22455456B-0184 embedded image

63465466B-0185 embedded image

65471472B-0186 embedded image

42429430B-0187 embedded image

62481482B-0188 embedded image

98439440B-0189 embedded image

21453454B-0190 embedded image

57417418B-0191 embedded image

24477478B-0192 embedded image

35455456B-0193 embedded image

42378379B0194 embedded image

65365366B-0195 embedded image

93587588B-0196 embedded image

82365366B-0197 embedded image

100587588B-0198 embedded image

86373374B-0199 embedded image

81373374B-0200 embedded image

78373374B-0201 embedded image

95352353B-0202 embedded image

100416417B-0203 embedded image

69354355B-0204 embedded image

93340341B-0205 embedded image

94354355B-0206 embedded image

79424425B-0207 embedded image

82326327B-0208 embedded image

88378379B-0209 embedded image

83362363B-0210 embedded image

100364365B-0211 embedded image

60325326B-0212 embedded image

79339340B-0213 embedded image

71353354B-0214 embedded image

77311312B-0215 embedded image

24353354B-0216 embedded image

339340B-0217 embedded image

381382B-0218 embedded image

365366B-0219 embedded image

401402B-0220 embedded image

415416B-0221 embedded image

367368B-0222 embedded image

96486487B-0223 embedded image

100465466B-0224 embedded image

75486509aB-0225 embedded image

100442443B-0226 embedded image

88482483B-0227 embedded image

73482483B-0228 embedded image

37452—B-0229 embedded image

100476477B-0230 embedded image

94476477B-0231 embedded image

100460461B-0232 embedded image

90440441B-0233 embedded image

99476477B-0234 embedded image

100486487, 489B-0235 embedded image

89486487, 489B-0236 embedded image

100476477B-0237 embedded image

100476477B-0238 embedded image

92438—B-0249 embedded image

100516517, 519B-0250 embedded image

72458—B-0251 embedded image

100427428B-0252 embedded image

100450451B-0253 embedded image

100472473B-0254 embedded image

100433434B-0255 embedded image

84547548B-0256 embedded image

100484507aB-0257 embedded image

85534535B-0258 embedded image

100491492B-0259 embedded image

100554555B-0260 embedded image

91500501B-0261 embedded image

100486487B-0262 embedded image

100481482B-0263 embedded image

100554555B-0264 embedded image

75375376B-0265 embedded image

71459460B-0266 embedded image

100412413B-0267 embedded image

100386387B-0268 embedded image

89406407B-0269 embedded image

84386387B-0270 embedded image

92440441B-0271 embedded image

98428429B-0272 embedded image

57498499B-0273 embedded image

100440441B-0274 embedded image

94397398B-0275 embedded image

90422423B-0276 embedded image

100408409B-0277 embedded image

88408409B-0278 embedded image

100426427B-0279 embedded image

54440441B-0280 embedded image

79414415B-0281 embedded image

82458459B-0282 embedded image

89426427B-0283 embedded image

90458459B-0284 embedded image

100458459B-0285 embedded image

94458459B-0286 embedded image

100458459B-0287 embedded image

96458459B-0288 embedded image

100458459B-0289 embedded image

96406407B-0290 embedded image

96386387B-0291 embedded image

95440441B-0292 embedded image

94390391B-0293 embedded image

100408409B-0294 embedded image

100440441B-0295 embedded image

91408409B-0296 embedded image

96426427B-0297 embedded image

88390391B-0298 embedded image

95408409B-0299 embedded image

90408409B-0300 embedded image

95406407B-0301 embedded image

99450451, 453B-0302 embedded image

94440441B-0303 embedded image

100378379B-0304 embedded image

100391392B-0305 embedded image

70326327B-0306 embedded image

59340341B-0307 embedded image

59354355B-0308 embedded image

60368369B-0309 embedded image

61352353B-0310 embedded image

61366367B-0311 embedded image

65356357B-0322 embedded image

64474475B-0323 embedded image

58474475B-0324 embedded image

60422423B-0325 embedded image

64422423B-0326 embedded image

58422423B-0327 embedded image

63378379B-0328 embedded image

68389390B-0329 embedded image

63362363B-0330 embedded image

48376377B-0331 embedded image

66424425B-0332 embedded image

61442443B-0333 embedded image

60458459B-0334 embedded image

55502503B-0335 embedded image

60454455B-0336 embedded image

100500501B-0337 embedded image

65458—B-0338 embedded image

69502503B-0339 embedded image

68454—B-0340 embedded image

77492493B-0341 embedded image

64458459B-0342 embedded image

41438—B-0343 embedded image

63430431B-0344 embedded image

96464465B-0345 embedded image

62507508B-0346 embedded image

56497498B-0347 embedded image

61341342B-0348 embedded image

3367—B-0349 embedded image

57403404B-0350 embedded image

57481482B-0351 embedded image

31355356B-0352 embedded image

51397398

Calcd.Observed%MassSpecExample#R²R^JYieldSpec(M + H)B-0353 embedded image

71382383B-0354 embedded image

35512513B-0355 embedded image

37352353B-0356 embedded image

57404405B-0357 embedded image

88366367B-0358 embedded image

88410411B-0359 embedded image

100324325B-0360 embedded image

56364365B-0361 embedded image

70350351B-0362 embedded image

100464465B-0363 embedded image

73512513B-0364 embedded image

88377378B-0365 embedded image

70396397B-0366 embedded image

100354355B-0367 embedded image

71416417B-0368 embedded image

100354355B-0369 embedded image

40440441B-0370 embedded image

94364365B-0371 embedded image

88460461B-0372 embedded image

69430431B-0373 embedded image

100430431B-0374 embedded image

75400401B-0375 embedded image

74386387B-0376 embedded image

53378379B-0377 embedded image

71387388B-0378 embedded image

69387388B-0379 embedded image

66387388B-0380 embedded image

85416417B-0381 embedded image

93430431B-0382 embedded image

84382383B-0383 embedded image

74583584B-0384 embedded image

63438439B-0392 embedded image

100440441B-0393 embedded image

75388389B-0394 embedded image

92402403B-0395 embedded image

87374375B-0396 embedded image

86360361B-0397 embedded image

81452453B-0398 embedded image

88428429B-0399 embedded image

99436437B-0400 embedded image

82482483B-0401 embedded image

94367368B-0402 embedded image

73325326B-0403 embedded image

91415416B-0404 embedded image

41379380B-0405 embedded image

88395396B-0406 embedded image

100419420B-0407 embedded image

52353354B-0408 embedded image

83339340B-0409 embedded image

74415416B-0410 embedded image

100419420B-0411 embedded image

94429430B-0412 embedded image

91365366B-0413 embedded image

79367368B-0414 embedded image

85429430B-0415 embedded image

82401402B-0416 embedded image

93429430B-0417 embedded image

97429430B-0418 embedded image

100419420B-0419 embedded image

100431432B-0420 embedded image

36381382B-0421 embedded image

96353354B-0422 embedded image

100461462B-0423 embedded image

100408407B-0424 embedded image

76366367B-0425 embedded image

21368369B-0426 embedded image

100354344B-0427 embedded image

100379380B-0428 embedded image

100379380B-0429 embedded image

86368369B-0430 embedded image

51500501B-0431 embedded image

76479480B-0432 embedded image

90500501B-0433 embedded image

96456457B-0434 embedded image

75496497B-0435 embedded image

52496497B-0436 embedded image

73506B-0437 embedded image

19466B-0438 embedded image

100490491B-0439 embedded image

67464465B-0440 embedded image

96472473B-0441 embedded image

87472473B-0442 embedded image

72481482B-0443 embedded image

66473474B-0444 embedded image

80515516B-0445 embedded image

94490491B-0446 embedded image

84464465B-0447 embedded image

89470471B-0448 embedded image

100490491B-0449 embedded image

100474475B-0450 embedded image

100447445B-0451 embedded image

100454455B-0452 embedded image

95495497B-0453 embedded image

100490491B-0454 embedded image

100500501B-0455 embedded image

96500501B-0456 embedded image

89494495

Calcd.
Observed

%
Mass
Spec

Example#
R²
R^J
Yield
Spec
(M + H)

B-0457

embedded image

93
482
483

B-0458

embedded image

100
490
491

B-0459

embedded image

100
490
491

B-0460

embedded image

93
450
451

B-0461

embedded image

84
452
453

B-0462

embedded image

96
456
457

B-0463

embedded image

66
456
457

B-0464

embedded image

69
490
491

B-0465

embedded image

86
490
491

B-0466

embedded image

78
474
475

B-0467

embedded image

78
470
471

B-0468

embedded image

91
450
451

B-0469

embedded image

85
436
437

B-0470

embedded image

99
466
467

B-0471

embedded image

100
490
491

B-0472

embedded image

37
482
483

B-0473

embedded image

92
462
463

B-0474

embedded image

99
530
532

B-0475

embedded image

55
472
473

B-0476

embedded image

89
441
442

B-0477

embedded image

79
464
465

B-0478

embedded image

92
486
487

B-0479

embedded image

97
447
448

B-0480

embedded image

75
561
562

B-0481

embedded image

74
498
499

B-0482

embedded image

57
548
549

B-0483

embedded image

83
505
506

B-0484

embedded image

100
568
569

B-0485

embedded image

100
495
496

B-0486

embedded image

100
426
427

B-0487

embedded image

32
389
390

B-0488

embedded image

100
588
569

B-0489

embedded image

91
500
501

B-0490

embedded image

40
473
474

B-0491

embedded image

73
514
515

B-0492

embedded image

89
400
401

B-0493

embedded image

100
420
421

B-0494

embedded image

100
400
401

B-0495

embedded image

100
454
455

B-0496

embedded image

100
442
443

B-0497

embedded image

50
512
513

B-0498

embedded image

100
454
455

B-0499

embedded image

98
411
412

B-0500

embedded image

100
436
437

B-0501

embedded image

100
422
423

B-0502

embedded image

100
422
423

B-0503

embedded image

92
440
441

B-0504

embedded image

67
454
455

B-0505

embedded image

68
428
429

B-0506

embedded image

98
472
473

B-0507

embedded image

82
440
441

B-0508

embedded image

99
472
473

B-0509

embedded image

100
472
473

B-0510

embedded image

96
472
473

B-0511

embedded image

100
472
473

B-0512

embedded image

100
472
473

B-0513

embedded image

100
472
473

B-0514

embedded image

100
420
421

B-0515

embedded image

100
400
401

B-0516

embedded image

100
454
455

B-0517

embedded image

100
404
405

B-0518

embedded image

99
422
423

B-0519

embedded image

100
454
455

B-0520

embedded image

98
422
423

B-0521

embedded image

99
440
441

B-0522

embedded image

88
404
405

B-0523

embedded image

100
422
423

B-0524

embedded image

100
422
423

B-0525

embedded image

100
420
421

B-0526

embedded image

100
464
465

B-0527

embedded image

100
454
455

B-0528

embedded image

100
392
393

B-0529

embedded image

94
405
406

embedded image

Calcd.
Observed

%
Mass
Spec

Example#
R²
R^J
Yield
Spec
(M + H)

B-0530

embedded image

67
382
383

B-0531

embedded image

66
512
513

B-0532

embedded image

37
352
353

B-0533

embedded image

56
404
405

B-0534

embedded image

100
366
367

B-0535

embedded image

100
410
411

B-0536

embedded image

41
324
325

B-0537

embedded image

100
364
365

B-0538

embedded image

29
350
351

B-0539

embedded image

70
464
465

B-0540

embedded image

50
512
513

B-0541

embedded image

61
377
378

B-0542

embedded image

61
396
397

B-0543

embedded image

59
354
355

B-0544

embedded image

45
416
417

B-0545

embedded image

100
454
455

B-0546

embedded image

44
440
441

B-0547

embedded image

64
364
365

B-0548

embedded image

89
460
461

B-0549

embedded image

100
430
431

B-0550

embedded image

100
4.30
431

B-0551

embedded image

81
400
401

B-0552

embedded image

38
386
387

B-0553

embedded image

31
378
379

B-0554

embedded image

100
387
388

B-0555

embedded image

66
387
388

B-0556

embedded image

32
387
388

B-0557

embedded image

70
416
417

B-0558

embedded image

57
430
431

B-0559

embedded image

74
382
383

B-0560

embedded image

36
583
584

B-0561

embedded image

51
438
439

B-0562

embedded image

88
440
441

B-0563

embedded image

68
422
423

B-0564

embedded image

47
388
389

B-0565

embedded image

100
448
449

B-0566

embedded image

76
436
437

B-0567

embedded image

99
458
459

B-0568

embedded image

45
414
415

B-0569

embedded image

88
440
441

B-0570

embedded image

61
388
389

B-0571

embedded image

58
402
403

B-0572

embedded image

75
374
375

B-0573

embedded image

72
360
361

B-0574

embedded image

97
452
453

B-0575

embedded image

71
428
429

B-0576

embedded image

88
436
437

B-0577

embedded image

72
482
483

B-0578

embedded image

89
367
388

B-0579

embedded image

100
325
326

B-0580

embedded image

75
415
416

B-0581

embedded image

44
379
380

B-0582

embedded image

75
395
396

B-0583

embedded image

80
419
420

B-0584

embedded image

57
353
354

B-0585

embedded image

83
339
340

B-0586

embedded image

71
415
416

B-0587

embedded image

100
419
420

B-0588

embedded image

94
429
430

B-0589

embedded image

78
365
386

B-0590

embedded image

82
367
368

B-0591

embedded image

72
429
430

B-0592

embedded image

82
401
402

B-0593

embedded image

88
429
430

B-0594

embedded image

100
429
430

B-0595

embedded image

99
419
420

B-596

embedded image

93
431
432

B-597

embedded image

40
381
382

B-0598

embedded image

93
353
354

B-0599

embedded image

100
461
462

B-0600

embedded image

98
406
407

B-0601

embedded image

66
366
367

B-0602

embedded image

25
368
369

B-0603

embedded image

90
354
355

B-0604

embedded image

86
379
380

B-0605

embedded image

87
379
380

B-0606

embedded image

72
368
369

B-0607

embedded image

34
500
501

B-0608

embedded image

100
479
480

B-0609

embedded image

82
500
501

B-0610

embedded image

100
456
457

B-0611

embedded image

76
496
497

B-0612

embedded image

69
496
497

B-0613

embedded image

61
506

B-0614

embedded image

18
466

B-0615

embedded image

100
490
491

B-0616

embedded image

77
464
465

B-0617

embedded image

93
472
473

B-0618

embedded image

84
472
473

B-0619

embedded image

71
481
482

B-0620

embedded image

89
473
474

B-0621

embedded image

68
515
516

B-0622

embedded image

70
490
491

B-0623

embedded image

92
464
465

B-0624

embedded image

98
470
471

B-0625

embedded image

96
490
491

B-0626

embedded image

100
474
475

B-0627

embedded image

100
447
448

B-0628

embedded image

64
454
455

B-0629

embedded image

100
496
497

B-0630

embedded image

85
490
491

B-0631

embedded image

75
500
501

B-0632

embedded image

83
500
501

B-0633

embedded image

58
494
495

B-0634

embedded image

63
482
483

B-0635

embedded image

95
490
491

B-0636

embedded image

100
490
491

B-0637

embedded image

91
450
451

B-0638

embedded image

96
436
437

B-0639

embedded image

100
456
457

B-0640

embedded image

100
456
457

B-0641

embedded image

88
490
491

B-0642

embedded image

99
490
491

B-0643

embedded image

92
474
475

B-0644

embedded image

100
470
471

B-0645

embedded image

92
450
451

B-0646

embedded image

100
436
437

B-0647

embedded image

90
466
467

B-0648

embedded image

94
490
491

B-0649

embedded image

57
482

B-0650

embedded image

82
462
463

B-0651

embedded image

100
530
531

B-0652

embedded image

53
472

B-0653

embedded image

84
441
442

B-0654

embedded image

92
464
465

B-0655

embedded image

100
486
487

B-0656

embedded image

98
447
448

B-0657

embedded image

85
561
562

B-0658

embedded image

92
498
499

B-0659

embedded image

46
548
549

B-0660

embedded image

80
505
506

B-0661

embedded image

100
568
569

B-0662

embedded image

98
495
496

B-0663

embedded image

74
426
427

B-0664

embedded image

30
389
390

B-0665

embedded image

100
568
569

B-0666

embedded image

93
500
501

B-0667

embedded image

54
473
474

B-0668

embedded image

66
514
515

B-0669

embedded image

65
400
401

B-0670

embedded image

45
420
421

B-0671

embedded image

43
400
401

B-0672

embedded image

45
454
455

B-0673

embedded image

41
442
443

B-0674

embedded image

16
512
513

B-0675

embedded image

39
454
455

B-0676

embedded image

34
411
412

B-0677

embedded image

46
436
437

B-0678

embedded image

37
422
423

B-0679

embedded image

34
422
423

B-0680

embedded image

60
440
441

B-0681

embedded image

31
454
455

B-0682

embedded image

37
428
429

B-0683

embedded image

46
472
473

B-0684

embedded image

50
440
441

B-0685

embedded image

44
472
473

B-0686

embedded image

66
472
473

B-0687

embedded image

57
472
473

B-0688

embedded image

52
472
473

B-0689

embedded image

42
472
473

B-0690

embedded image

34
472
473

B-0691

embedded image

52
420
421

B-0692

embedded image

41
400
401

B-0693

embedded image

56
454
455

B-0694

embedded image

38
404
405

B-0695

embedded image

43
422
423

B-0696

embedded image

57
454
455

B-0697

embedded image

51
422
423

B-0698

embedded image

59
440
441

B-0699

embedded image

46
404
405

B-0700

embedded image

47
422
423

B-0701

embedded image

46
422
423

B-0702

embedded image

43
420
421

B-0703

embedded image

57
464
465

B-0704

embedded image

44
454
455

B-0705

embedded image

33
392
393

B-0706

embedded image

35
405
406

embedded image

Calcd.
Observed

%
Mass
Spec

Example#
R²
R^J
Yield
Spec
(M + H)

B-0707

embedded image

76
516
517

B-0708

embedded image

61
498
499

B-0709

embedded image

37
464
465

B-0710

embedded image

76
524
525

B-0711

embedded image

75
512
513

B-0712

embedded image

91
534
535

B-0713

embedded image

42
490
491

B-0714

embedded image

87
516
517

B-0715

embedded image

60
464
465

B-0716

embedded image

59
478
479

B-0717

embedded image

61
450
451

B-0718

embedded image

65
436
437

B-0719

embedded image

84
528
529

B-0720

embedded image

69
504
505

B-0721

embedded image

63
512
513

B-0722

embedded image

88
558
559

B-0723

embedded image

68
443
444

B-0724

embedded image

75
401
402

B-0725

embedded image

83
491
492

B-0726

embedded image

24
455
456

B-0727

embedded image

67
471
472

B-0728

embedded image

89
495
496

B-0729

embedded image

38
429
430

B-0730

embedded image

76
415
416

B-0731

embedded image

60
491
492

B-0732

embedded image

86
495
496

B-0733

embedded image

81
505
506

B-0734

embedded image

87
441
442

B-0735

embedded image

83
443
444

B-0736

embedded image

91
505
506

B-0737

embedded image

9
477
—

B-0738

embedded image

87
505
506

B-0739

embedded image

82
505
506

B-0740

embedded image

85
495
496

B-0741

embedded image

68
507
508

B-0742

embedded image

14
457
—

B-0743

embedded image

77
429
430

B-0744

embedded image

88
537
538

B-0745

embedded image

82
482
483

B-0746

embedded image

74
442
443

B-0747

embedded image

83
444
445

B-0748

embedded image

94
430
431

B-0749

embedded image

100
455
456

B-0750

embedded image

100
455
456

B-0751

embedded image

48
444
445

B-0752

embedded image

84
516
517

B-0753

embedded image

67
498
499

B-0754

embedded image

31
464
465

B-0755

embedded image

85
524
525

B-0756

embedded image

77
512
513

B-0757

embedded image

57
534
535

B-0758

embedded image

36
490
491

B-0759

embedded image

79
516
517

B-0760

embedded image

53
464
465

B-0761

embedded image

50
478
479

B-0762

embedded image

60
450
451

B-0763

embedded image

75
436
437

B-0764

embedded image

43
528
529

B-0765

embedded image

75
504
505

B-0766

embedded image

67
512
513

B-0767

embedded image

43
558
559

B-0768

embedded image

78
443
444

B-0769

embedded image

76
401
402

B-0770

embedded image

57
491
492

B-0771

embedded image

14
455
456

B-0772

embedded image

72
471
472

B-0773

embedded image

100
495
496

B-0774

embedded image

41
429
430

B-0775

embedded image

91
415
416

B-0776

embedded image

64
491
492

B-0777

embedded image

90
495
496

B-0778

embedded image

19
505
506

B-0779

embedded image

79
441
442

B-0780

embedded image

40
443
444

B-0781

embedded image

93
505
506

B-0782

embedded image

57
477
478

B-0783

embedded image

99
505
506

B-0784

embedded image

100
505
506

B-0786

embedded image

91
507
508

B-0787

embedded image

15
457
458

B-0788

embedded image

48
429
430

B-0789

embedded image

91
537
538

B-0790

embedded image

93
482
483

B-0791

embedded image

76
442
443

B-0792

embedded image

96
444
445

B-0793

embedded image

54
430
431

B-0794

embedded image

100
455
456

B-0795

embedded image

100
455
456

B-0796

embedded image

94
444
445

B-0797

embedded image

90
458
459

B-0799

embedded image

82
428
429

B-0800

embedded image

92
480
481

B-0801

embedded image

82
442
443

B-0802

embedded image

95
486
487

B-0803

embedded image

89
400
401

B-0804

embedded image

87
440
441

B-0805

embedded image

100
426
427

B-0806

embedded image

99
540
541

B-0807

embedded image

96
588
559

B-0808

embedded image

82
453
454

B-0809

embedded image

92
472
473

B-0810

embedded image

98
430
431

B-0811

embedded image

88
492
493

B-0812

embedded image

81
530
531

B-0813

embedded image

98
516
517

B-0814

embedded image

100
440
441

B-0815

embedded image

100
536
537

B-0816

embedded image

99
506
507

B-0817

embedded image

98
506
507

B-0818

embedded image

86
476
477

B-0819

embedded image

90
462
463

B-0820

embedded image

91
454
455

B-0821

embedded image

69
463
464

B-0822

embedded image

79
463
464

B-0823

embedded image

79
463
464

B-0824

embedded image

82
492
493

B-0825

embedded image

100
506
507

B-0826

embedded image

97
458
459

B-0827

embedded image

100
659
660

B-0828

embedded image

97
514
515

B-0829

embedded image

63
458
459

B-830

embedded image

70
588
589

B-0831

embedded image

100
428
429

B-0832

embedded image

81
480
481

B-0833

embedded image

73
442
443

B-0834

embedded image

79
486
487

B-0835

embedded image

5
400
401

B-0836

embedded image

28
440
441

B-0837

embedded image

81
426
427

B-0838

embedded image

84
540
541

B-0839

embedded image

80
588
589

B-0840

embedded image

71
453
454

B-0841

embedded image

55
472
473

B-0842

embedded image

71
430
431

B-0843

embedded image

68
492
493

B-0844

embedded image

61
530
531

B-0845

embedded image

84
516
517

B-0846

embedded image

87
440
441

B-0847

embedded image

86
536
537

B-0848

embedded image

79
506
507

B-0849

embedded image

81
506
507

B-0850

embedded image

69
476
477

B-0851

embedded image

83
462
463

B-0852

embedded image

77
454
455

B-0853

embedded image

87
463
464

B-0854

embedded image

73
463
464

B-0855

embedded image

92
463
464

B-0856

embedded image

75
492
493

B-0857

embedded image

86
506
507

B-0858

embedded image

84
458
459

B-0859

embedded image

80
659
660

B-0860

embedded image

94
514
515

embedded image

Calcd.
Observed

%
Mass
Spec

Example#
R²
R^J
Yield
Spec
(M + H)

B-0861

embedded image

84
583
584

B-0862

embedded image

96
475
476

B-0863

embedded image

69
423
424

B-0864

embedded image

86
437
438

B-0865

embedded image

62
395
—

B-0866

embedded image

81
421
422

B-0867

embedded image

100
535
536

Observed

Calcd.
Mass

%
Mass
Spec

Example#
R²
R^J
Yield
Spec
(M + H)

B-0868

embedded image

89
583
584

B-0869

embedded image

100
448
449

B-0870

embedded image

100
425
426

B-0871

embedded image

100
487
488

B-0872

embedded image

78
501
502

B-0873

embedded image

78
471
472

B-0874

embedded image

92
475
476

B-0875

embedded image

37
458
459

B-0876

embedded image

69
507
508

B-0877

embedded image

70
445
446

B-0878

embedded image

91
431
432

B-0879

embedded image

92
511
512

B-0880

embedded image

89
410
411

B-0881

embedded image

84
490
491

B-0882

embedded image

85
500
501

B-0883

embedded image

85
424
425

B-0884

embedded image

86
532
533

embedded image

Observed

Calcd.
Mass

%
Mass
Spec

Example#
R²
R^J
Yield
Spec
(M + H)

B-0885

embedded image

51
583
—

B-0886

embedded image

97
475
—

B-0887

embedded image

29
423
424

B-0888

embedded image

82
437
438

B-0889

embedded image

93
395
396

B-0890

embedded image

91
421
422

B-0891

embedded image

43
535
536

B-0892

embedded image

62
583
584

B-0893

embedded image

95
448
449

B-0894

embedded image

100
425
426

B-0895

embedded image

76
487
488

B-0896

embedded image

62
501
502

B-0897

embedded image

80
471
472

B-0898

embedded image

79
475
476

B-0899

embedded image

70
458
459

B-0900

embedded image

62
507
508

B-0901

embedded image

43
445
446

B-0902

embedded image

93
431
432

B-0903

embedded image

100
511
512

B-0904

embedded image

95
410
411

B-0905

embedded image

89
490
491

B-0906

embedded image

69
500
501

B-0907

embedded image

28
424
425

B-0908

embedded image

64
532
533

embedded image

Observed

Calcd.
Mass

%
Mass
Spec

Example#
R²
R^J
Yield
Spec
(M + H)

B-0909

embedded image

83
542
543

B-0910

embedded image

80
434
435

B-0911

embedded image

91
382
383

B-0912

embedded image

100
396
397

B-0913

embedded image

94
354
355

B-0914

embedded image

95
380
381

B-0915

embedded image

98
494
495

B-0916

embedded image

84
542
543

B-0917

embedded image

79
407
408

B-0918

embedded image

89
384
385

B-0919

embedded image

91
446
447

B-0920

embedded image

99
460
461

B-0921

embedded image

84
430
431

B-0922

embedded image

81
434
435

B-0923

embedded image

76
417
418

B-0924

embedded image

70
466
467

B-0925

embedded image

64
404
405

B-0926

embedded image

47
390
391

B-0927

embedded image

89
470
471

B-0928

embedded image

53
369
370

B-0929

embedded image

100
449
450

B-0930

embedded image

14
459
460

B-0931

embedded image

41
383
384

B-0932

embedded image

94
491
492

embedded image

Observed

Calcd.
Mass

%
Mass
Spec

Example#
R²
R^J
Yield
Spec
(M + H)

B-0933

embedded image

48
447
448

B-0934

embedded image

44
429
430

B-0935

embedded image

33
485
486

B-0936

embedded image

30
479
—

B-0937

embedded image

68
367
368

B-0938

embedded image

72
479
480

B-0939

embedded image

76
415
416

B-0940

embedded image

36
397
398

B-0941

embedded image

41
441
442

B-0942

embedded image

27
473
474

B-0943

embedded image

55
493
494

B-0944

embedded image

53
473
474

B-0945

embedded image

82
429
430

B-0946

embedded image

100
459
460

B-0947

embedded image

60
425
426

B-0948

embedded image

100
431
432

B-0949

embedded image

98
473
474

B-0950

embedded image

64
419
420

B-0951

embedded image

100
469
470

B-0952

embedded image

61
469
470

B-0953

embedded image

67
425
426

B-0954

embedded image

62
431
432

B-0955

embedded image

39
461
462

B-0956

embedded image

66
429
430

B-0957

embedded image

93
429
430

B-0958

embedded image

86
365
366

B-0959

embedded image

73
451
452

B-0960

embedded image

98
485
486

B-0961

embedded image

100
469
470

B-0962

embedded image

100
419
420

B-0963

embedded image

83
401
402

B-0964

embedded image

38
429
430

B-0965

embedded image

90
411
412

B-0966

embedded image

76
443
444

B-0967

embedded image

100
443
444

B-0968

embedded image

100
477
478

B-0969

embedded image

77
477
478

B-0970

embedded image

38
461
462

B-0971

embedded image

95
469
470

B-0972

embedded image

98
479
480

B-0973

embedded image

96
485
486

B-0974

embedded image

74
443
444

B-0975

embedded image

100
495
496

B-0976

embedded image

70
453
454

B-0977

embedded image

100
467
468

B-0978

embedded image

91
431
432

B-0979

embedded image

54
491
492

B-0980

embedded image

65
469
470

B-0981

embedded image

78
382
383

B-0982

embedded image

82
512
813

B-0983

embedded image

94
352
353

B-0984

embedded image

81
404
405

B-0985

embedded image

84
366
367

B-0986

embedded image

80
410
411

B-0987

embedded image

85
324
325

B-0988

embedded image

91
364
365

B-0989

embedded image

88
350
351

B-0990

embedded image

68
464
465

B-0991

embedded image

86
512
513

B-0992

embedded image

79
377
378

B-0993

embedded image

81
396
397

B-0994

embedded image

100
354
355

B-0995

embedded image

75
416
417

B-0996

embedded image

65
454
455

B-0997

embedded image

64
440
441

B-0998

embedded image

81
364
355

B-0999

embedded image

79
460
461

B-1000

embedded image

84
430
431

B-1001

embedded image

78
430
431

B-1002

embedded image

85
400
401

B-1003

embedded image

53
386
387

B-1004

embedded image

87
378
379

B-1005

embedded image

57
387
388

B-1006

embedded image

80
387
388

B-1007

embedded image

54
387
388

B-1008

embedded image

64
416
417

B-1009

embedded image

81
430
431

B-1010

embedded image

81
382
383

B-1011

embedded image

66
583
584

B-1012

embedded image

69
438
439

B-1013

embedded image

53
440
441

B-1014

embedded image

61
422
423

B-1015

embedded image

47
388
389

B-1016

embedded image

74
448
449

B-1017

embedded image

63
436
437

B-1018

embedded image

82
458
459

B-1019

embedded image

41
414
415

B-1020

embedded image

100
440
441

B-1021

embedded image

100
388
389

B-1022

embedded image

74
402
403

B-1023

embedded image

76
374
375

B-1024

embedded image

73
360
361

B-1025

embedded image

100
452
453

B-1026

embedded image

95
428
429

B-1027

embedded image

98
436
437

B-1028

embedded image

100
482
483

B-1029

embedded image

98
367
368

B-1030

embedded image

88
325
326

B-1031

embedded image

97
415
416

B-1032

embedded image

64
379
380

B-1033

embedded image

83
395
396

B-1034

embedded image

67
419
420

B-1035

embedded image

73
353
354

B-1036

embedded image

79
339
340

B-1037

embedded image

78
415
416

B-1038

embedded image

100
419
420

B-1039

embedded image

95
429
430

B-1040

embedded image

91
365
366

B-1041

embedded image

88
367
368

B-1042

embedded image

78
429
430

B-1043

embedded image

79
401
402

B-1044

embedded image

93
429
430

B-1045

embedded image

100
429
430

B-1046

embedded image

94
419
420

B-1047

embedded image

100
431
432

B-1048

embedded image

58
381
382

B-1049

embedded image

97
353
354

B-1050

embedded image

100
461
462

B-1051

embedded image

88
406
407

B-1052

embedded image

82
366
367

B-1053

embedded image

21
368

B-1054

embedded image

98
354
355

B-1055

embedded image

100
379
380

B-1056

embedded image

85
379
380

B-1057

embedded image

30
368
369

B-1058

embedded image

35
500
501

B-1059

embedded image

77
479
480

B-1060

embedded image

37
500
501

B-1061

embedded image

86
456
457

B-1062

embedded image

58
496
497

B-1063

embedded image

59
496
497

B-1064

embedded image

58
506
—

B-1065

embedded image

24
466
—

B-1066

embedded image

100
490
491

B-1067

embedded image

74
464
465

B-1068

embedded image

79
472
473

B-1069

embedded image

97
472
473

B-1070

embedded image

54
481
482

B-1071

embedded image

67
473
474

B-1072

embedded image

35
515
516

B-1073

embedded image

100
490
491

B-1074

embedded image

100
464
465

B-1075

embedded image

100
470
471

B-1076

embedded image

93
490
491

B-1077

embedded image

100
474
475

B-1078

embedded image

80
447
448

B-1079

embedded image

85
454
455

B-1080

embedded image

100
496
497

B-1081

embedded image

100
490
491

B-1082

embedded image

100
500
501

B-1083

embedded image

93
500
501

B-1084

embedded image

81
494
495

B-1085

embedded image

93
482
483

B-1086

embedded image

92
490
491

B-1087

embedded image

100
490
491

B-1088

embedded image

97
450
451

B-1089

embedded image

100
436
437

B-1090

embedded image

100
456
457

B-1091

embedded image

100
456
457

B-1092

embedded image

96
490
491

B-1093

embedded image

100
490
491

B-1094

embedded image

100
474
475

B-1095

embedded image

81
470
471

B-1096

embedded image

77
450
451

B-1097

embedded image

100
436
437

B-1098

embedded image

93
466
467

B-1099

embedded image

100
490
491

B-1100

embedded image

47
482
—

B-1101

embedded image

64
462
463

B-1102

embedded image

98
530
531

B-1103

embedded image

65
472
—

B-1104

embedded image

88
441
442

B-1105

embedded image

100
464
465

B-1106

embedded image

91
486
487

B-1107

embedded image

96
447
448

B-1108

embedded image

55
561
562

B-1109

embedded image

100
498
499

B-1110

embedded image

73
548
549

B-1111

embedded image

94
505
506

B-1112

embedded image

100
568
569

B-1113

embedded image

100
495
496

B-1114

embedded image

73
426
427

B-1115

embedded image

30
389
390

B-1116

embedded image

100
568
569

B-1117

embedded image

83
500
501

B-1118

embedded image

55
473
—

B-1119

embedded image

70
514
515

B-1120

embedded image

84
400
401

B-1121

embedded image

86
420
421

B-1122

embedded image

90
400
401

B-1123

embedded image

100
454
455

B-1124

embedded image

91
442
443

B-1125

embedded image

50
512
513

B-1126

embedded image

85
454
455

B-1127

embedded image

93
411
412

B-1128

embedded image

87
436
437

B-1129

embedded image

78
422
423

B-1130

embedded image

96
422
423

B-1131

embedded image

84
440
441

B-1132

embedded image

77
454
455

B-1133

embedded image

62
428
429

B-1134

embedded image

91
472
473

B-1135

embedded image

85
440
441

B-1136

embedded image

82
472
473

B-1137

embedded image

95
472
473

B-1138

embedded image

100
472
473

B-1139

embedded image

100
472
473

B-1140

embedded image

92
472
473

B-1141

embedded image

100
472
473

B-1142

embedded image

88
420
421

B-1143

embedded image

90
400
401

B-1144

embedded image

87
454
455

B-1145

embedded image

93
404
405

B-1146

embedded image

90
422
423

B-1147

embedded image

100
454
455

B-1148

embedded image

87
422
423

B-1149

embedded image

87
440
441

B-1150

embedded image

90
404
405

B-1151

embedded image

82
422
423

B-1152

embedded image

85
422
423

B-1153

embedded image

90
420
421

B-1154

embedded image

78
464
465

B-1155

embedded image

79
454
455

B-1156

embedded image

95
392
393

B-1157

embedded image

81
405
406

embedded image

Observed

Calcd.
Mass

%
Mass
Spec

Example#
R²
R^J
Yield
Spec
(M + H)

B-1158

embedded image

54
396
397

B-1159

embedded image

42
526
527

B-1160

embedded image

27
366
367

B-1161

embedded image

58
418
419

B-1162

embedded image

62
380
381

B-1163

embedded image

58
424
425

B-1164

embedded image

67
338
339

B-1165

embedded image

66
378
379

B-1166

embedded image

65
364
365

B-1167

embedded image

64
478
479

B-1168

embedded image

76
526
527

B-1169

embedded image

70
391
392

B-1170

embedded image

76
410
411

B-1171

embedded image

82
368
369

B-1172

embedded image

73
430
431

B-1173

embedded image

74
468
469

B-1174

embedded image

83
454
455

B-1175

embedded image

76
378
379

B-1176

embedded image

96
474
475

B-1177

embedded image

94
444
445

B-1178

embedded image

90
444
445

B-1179

embedded image

57
414
415

B-1180

embedded image

75
400
401

B-1181

embedded image

66
392
393

B-1182

embedded image

74
401
402

B-1183

embedded image

62
401
402

B-1184

embedded image

51
401
402

B-1185

embedded image

90
430
431

B-1186

embedded image

86
444
445

B-1187

embedded image

74
396
397

B-1188

embedded image

76
597
598

B-1189

embedded image

60
452
453

B-1190

embedded image

44
454
455

B-1191

embedded image

47
436
437

B-1192

embedded image

50
402
403

B-1193

embedded image

62
462
463

B-1194

embedded image

49
450
451

B-1195

embedded image

61
472
473

B-1196

embedded image

52
428
429

B-1197

embedded image

54
454
455

B-1198

embedded image

44
402
403

B-1199

embedded image

67
416
417

B-1200

embedded image

45
388
389

B-1201

embedded image

52
374
375

B-1202

embedded image

100
466
467

B-1203

embedded image

91
442
443

B-1204

embedded image

100
450
451

B-1205

embedded image

83
496
497

B-1206

embedded image

97
381
382

B-1207

embedded image

100
339
340

B-1208

embedded image

90
429
430

B-1209

embedded image

69
393
394

B-1210

embedded image

35
409
410

B-1211

embedded image

100
433
434

B-1212

embedded image

83
367
368

B-1213

embedded image

78
353
354

B-1214

embedded image

68
429
430

B-1215

embedded image

65
433
434

B-1216

embedded image

91
443
444

B-1217

embedded image

99
379
380

B-1218

embedded image

92
381
382

B-1219

embedded image

74
443
444

B-1220

embedded image

67
415
416

B-1221

embedded image

14
443
444

B-1222

embedded image

19
443
444

B-1223

embedded image

71
433
434

B-1224

embedded image

100
445
446

B-1225

embedded image

75
395
396

B-1226

embedded image

58
367
368

B-1227

embedded image

98
475
476

B-1228

embedded image

71
420
421

B-1229

embedded image

85
380
381

B-1230

embedded image

10
382
—

B-1231

embedded image

66
368
369

B-1232

embedded image

100
393
394

B-1233

embedded image

96
393
394

B-1234

embedded image

66
382
383

B-1235

embedded image

50
514
515

B-1236

embedded image

100
493
494

B-1237

embedded image

91
514
515

B-1238

embedded image

100
470
471

B-1239

embedded image

71
510
511

B-1240

embedded image

27
510
511

B-1241

embedded image

73
520

B-1242

embedded image

26
480
481

B-1243

embedded image

100
504

B-1244

embedded image

52
478
479

B-1245

embedded image

100
486
487

B-1246

embedded image

56
486
487

B-1247

embedded image

43
495
496

B-1248

embedded image

61
487
488

B-1249

embedded image

32
529
530

B-1250

embedded image

56
504
505

B-1251

embedded image

58
478
479

B-1252

embedded image

98
484
485

B-1253

embedded image

59
504
505

B-1254

embedded image

100
488
489

B-1255

embedded image

96
461

B-1256

embedded image

79
468
469

B-1257

embedded image

63
510
511

B-1258

embedded image

100
504
505

B-1259

embedded image

95
514
515

B-1260

embedded image

92
514
515

B-1261

embedded image

98
508
509

B-1262

embedded image

97
496
497

B-1263

embedded image

100
504
505

B-1264

embedded image

100
504
505

B-1265

embedded image

100
464
465

B-1266

embedded image

79
466
451

B-1267

embedded image

100
470
471

B-1268

embedded image

87
470
471

B-1269

embedded image

100
504
505

B-1270

embedded image

100
504
505

B-1271

embedded image

56
488
489

B-1272

embedded image

98
484
485

B-1273

embedded image

90
464
465

B-1274

embedded image

87
450
451

B-1275

embedded image

94
480
481

B-1276

embedded image

100
504
505

B-1277

embedded image

60
496
511

B-1278

embedded image

68
476
477

B-1279

embedded image

100
544
545

B-1280

embedded image

68
486
—

B-1281

embedded image

98
455
456

Calcd.
Observed

%
Mass
Spec

Example#
R²
R^J
Yield
Spec
(M + H)

B-1282

embedded image

100
478
479

B-1283

embedded image

58
500
501

B-1284

embedded image

58
461
462

B-1285

embedded image

65
575
576

B-1286

embedded image

87
512
513

B-1287

embedded image

79
562
563

B-1288

embedded image

100
519
520

B-1289

embedded image

77
582
583

B-1290

embedded image

100
509
510

B-1291

embedded image

91
440
441

B-1292

embedded image

35
403
404

B-1293

embedded image

73
582
583

B-1294

embedded image

49
514
515

B-1295

embedded image

48
487
—

B-1296

embedded image

76
528
529

B-1297

embedded image

62
447
448

B-1298

embedded image

66
452
453

B-1299

embedded image

65
479
431

B-1300

embedded image

71
444
445

B-1301

embedded image

100
472
473

B-1302

embedded image

75
410
411

B-1303

embedded image

74
424
425

B-1304

embedded image

11
430
431

B-1305

embedded image

2
424
—

B-1306

embedded image

30
433
434

B-1307

embedded image

100
522
523

B-1308

embedded image

100
508
509

B-1309

embedded image

100
448
449

B-1310

embedded image

26
430
431

B-1311

embedded image

45
397
398

B-1312

embedded image

14
507
508

B-1313

embedded image

67
450
451

B-1314

embedded image

69
444
445

B-1315

embedded image

57
450
451

B-1316

embedded image

75
393
394

B-1317

embedded image

100
461
462

B-1318

embedded image

31
450
451

B-1319

embedded image

23
464
465

B-1320

embedded image

59
512
513

B-1321

embedded image

63
414
415

B-1322

embedded image

45
434
435

B-1323

embedded image

53
414
415

B-1324

embedded image

32
468
469

B-1325

embedded image

45
456
457

B-1326

embedded image

50
526
527

B-1327

embedded image

55
468
469

B-1328

embedded image

29
425
426

B-1329

embedded image

67
450
451

B-1330

embedded image

59
436
437

B-1331

embedded image

45
436
437

B-1332

embedded image

81
454
455

B-1333

embedded image

23
468
469

B-1334

embedded image

53
442
443

B-1335

embedded image

81
486
487

B-1336

embedded image

69
454
455

B-1337

embedded image

67
486
487

B-1338

embedded image

39
486
487

B-1339

embedded image

61
486
487

B-1340

embedded image

49
486
487

B-1341

embedded image

55
486
487

B-1342

embedded image

51
486
487

B-1343

embedded image

72
434
435

B-1344

embedded image

52
414
415

B-1345

embedded image

43
468
469

B-1346

embedded image

40
418
419

B-1347

embedded image

67
436
437

B-1348

embedded image

39
468
469

B-1349

embedded image

68
436
437

B-1350

embedded image

73
454
455

B-1351

embedded image

54
418
419

B-1352

embedded image

77
436
437

B-1353

embedded image

66
436
437

B-1354

embedded image

58
434
435

B-1355

embedded image

77
478
479

B-1356

embedded image

50
468
469

B-1357

embedded image

36
406
407

B-1358

embedded image

39
419
420

embedded image

Calcd.
Observed

%
Mass
Spec

Example#
R²
R^J
Yield
Spec
(M + H)

B-1359

embedded image

95
552
553

B-1360

embedded image

77
444
445

B-1361

embedded image

100
392
393

B-1362

embedded image

85
406
407

B-1363

embedded image

100
364
365

B-1364

embedded image

99
390
391

B-1365

embedded image

92
504
505

B-1366

embedded image

100
552
553

B-1367

embedded image

100
417
418

B-1368

embedded image

86
394
395

B-1369

embedded image

100
456
457

B-1370

embedded image

100
470
471

B-1371

embedded image

77
440
441

B-1372

embedded image

100
444
445

B-1373

embedded image

42
427
428

B-1374

embedded image

60
476
477

B-1375

embedded image

94
414
415

B-1376

embedded image

87
400
401

B-1377

embedded image

100
480
481

B-1378

embedded image

95
379
380

B-1379

embedded image

93
459
460

B-1380

embedded image

89
469
470

B-1381

embedded image

84
393
394

B-1382

embedded image

85
501
502

B-1383

embedded image

46
416
417

B-1384

embedded image

56
432
433

B-1385

embedded image

59
426
427

B-1386

embedded image

50
427
428

B-1387

embedded image

12
427
428

B-1388

embedded image

66
504
505

B-1389

embedded image

48
460
461

B-1390

embedded image

44
494
495

B-1391

embedded image

50
456
457

B-1392

embedded image

47
451
452

B-1393

embedded image

44
444
445

B-1394

embedded image

52
460
461

B-1395

embedded image

77
440
441

B-1396

embedded image

58
451
452

B-1397

embedded image

64
460
461

B-1398

embedded image

65
504
505

B-1399

embedded image

50
494
495

B-1400

embedded image

74
440
441

B-1401

embedded image

76
462
463

B-1402

embedded image

65
462
463

B-1403

embedded image

64
445
446

B-1404

embedded image

70
512
513

B-1405

embedded image

57
512
513

B-1406

embedded image

73
512
513

B-1407

embedded image

80
512
513

B-1408

embedded image

2
512
513

B-1409

embedded image

62
512
513

B-1410

embedded image

42
512
513

B-1411

embedded image

19
462
463

B-1412

embedded image

74
462
463

B-1413

embedded image

75
494
495

B-1414

embedded image

68
462
463

B-1415

embedded image

48
462
463

B-1416

embedded image

48
494
495

B-1417

embedded image

57
494
495

B-1418

embedded image

49
494
495

B-1419

embedded image

39
494
495

B-1420

embedded image

72
378
379

B-1421

embedded image

74
406
407

B-1422

embedded image

68
394
395

B-1423

embedded image

57
408
409

B-1424

embedded image

77
422
423

B-1425

embedded image

26
408
409

B-1426

embedded image

41
406
407

B-1427

embedded image

37
404
405

B-1428

embedded image

60
456
457

B-1429

embedded image

2
418
419

B-1430

embedded image

61
442
443

B-1431

embedded image

64
428
429

B-1432

embedded image

71
429
430

B-1433

embedded image

74
462
463

B-1434

embedded image

88
466
467

B-1435

embedded image

75
481
482

B-1436

embedded image

71
504
505

B-1437

embedded image

63
468
469

B-1438

embedded image

78
502
503

B-1439

embedded image

70
545
546

B-1440

embedded image

62
535
536

B-1441

embedded image

82
608

B-1442

embedded image

79
555
556

B-1443

embedded image

28
513
514

B-1444

embedded image

75
522
523

B-1445

embedded image

74
526
527

B-1446

embedded image

70
570
571

B-1447

embedded image

73
506
507

B-1448

embedded image

76
530
531

B-1449

embedded image

82
530
531

B-1450

embedded image

83
530
531

B-1451

embedded image

74
530
531

B-1452

embedded image

76
530
531

B-1453

embedded image

73
530
531

B-1454

embedded image

81
498
499

B-1455

embedded image

83
498
499

B-1456

embedded image

78
498
499

B-1457

embedded image

74
496
497

B-1458

embedded image

82
540
541

B-1459

embedded image

80
476
477

B-1460

embedded image

78
530
531

B-1461

embedded image

82
487
488

B-1462

embedded image

71
540
541

B-1463

embedded image

78
506
507

B-1464

embedded image

83
480
481

B-1465

embedded image

84
496
497

B-1466

embedded image

80
540
541

B-1467

embedded image

79
476
477

B-1468

embedded image

79
530
531

B-1469

embedded image

75
487
488

B-1470

embedded image

80
480
481

B-1471

embedded image

74
496
497

B-1472

embedded image

75
540
541

B-1473

embedded image

77
476
477

B-1474

embedded image

81
530
531

B-1475

embedded image

70
487
488

B-1476

embedded image

54
540
541

B-1477

embedded image

79
546
547

B-1478

embedded image

87
394
395

B-1479

embedded image

41
504
505

B-1480

embedded image

87
451
452

B-1481

embedded image

18
416
417

B-1482

embedded image

77
427
428

B-1483

embedded image

74
406
407

B-1484

embedded image

82
422
423

B-1485

embedded image

85
460
461

B-1486

embedded image

64
406
407

B-1487

embedded image

71
392
393

B-1488

embedded image

82
427
428

B-1489

embedded image

87
444
445

B-1490

embedded image

81
462
463

B-1491

embedded image

87
462
463

B-1492

embedded image

69
364
365

B-1493

embedded image

53
417
418

B-1494

embedded image

17
426
427

B-1495

embedded image

79
460
461

B-1496

embedded image

80
444
445

B-1497

embedded image

82
460
461

B-1498

embedded image

72
378
379

B-1499

embedded image

70
432
433

B-1500

embedded image

68
390
391

B-1501

embedded image

63
394
395

B-1502

embedded image

78
408
409

B-1503

embedded image

55
404
405

B-1504

embedded image

39
418
419

B-1505

embedded image

69
540
541

B-1506

embedded image

69
462
463

B-1507

embedded image

70
496
497

B-1508

embedded image

65
480
481

B-1509

embedded image

56
414
415

B-1510

embedded image

62
400
401

B-1511

embedded image

30
468
469

B-1512

embedded image

50
476
477

B-1513

embedded image

44
540
541

B-1514

embedded image

42
530
531

B-1515

embedded image

68
496
497

B-1516

embedded image

27
429
430

B-1517

embedded image

92
466
467

B-1518

embedded image

33
379
380

B-1519

embedded image

50
393
394

B-1520

embedded image

82
435
436

B-1521

embedded image

86
509
510

B-1522

embedded image

12
405
406

B-1523

embedded image

59
459
460

B-1524

embedded image

81
459
460

B-1525

embedded image

57
419
420

B-1526

embedded image

73
410
411

B-1527

embedded image

66
520
521

B-1528

embedded image

91
467
468

B-1529

embedded image

73
432
433

B-1530

embedded image

91
443
444

B-1531

embedded image

74
422
423

B-1532

embedded image

68
438
439

B-1543

embedded image

82
476
477

B-1544

embedded image

76
460
461

B-1545

embedded image

77
476
477

B-1546

embedded image

76
394
395

B-1547

embedded image

58
448
449

B-1548

embedded image

83
406
407

B-1549

embedded image

67
410
411

B-1550

embedded image

37
424
425

B-1551

embedded image

55
420
421

B-1552

embedded image

23
434
435

B-1553

embedded image

83
556
557

B-1554

embedded image

84
478
479

B-1555

embedded image

93
512
513

B-1556

embedded image

83
496
497

B-1557

embedded image

62
430
431

B-1558

embedded image

45
416
417

B-1559

embedded image

67
484
485

B-1560

embedded image

16
492
493

B-1561

embedded image

84
556
557

B-1562

embedded image

74
546
547

B-1563

embedded image

72
512
513

B-1564

embedded image

57
445
446

B-1565

embedded image

64
482
483

B-1566

embedded image

71
395
396

B-1567

embedded image

54
409
410

B-1568

embedded image

76
451
452

B-1569

embedded image

70
525
526

B-1570

embedded image

79
421
422

B-1571

embedded image

60
475
476

B-1572

embedded image

77
475
476

B-1573

embedded image

65
435
436

proton NMR data for selected members from Examples B-0001 through B-1573 sre shown in the following table.

Plate ID1H NMR(solvent), d ppmB-0120(DMF-d7) d 8.53(bd, J=4.99Hz, 2H), 7.44-7.24(m, 11H), 4.41(s, 2H), 4.31(br, 2H)B-0224(DMF-d7) d 8.56(bd, J=4.98Hz, 2H), 7.78-7.69(m, 4H), 7.39-7.19(m, 6H),4.23(br, 2H)B-0235(DMF-d7) d 8.47(br, 2H), 7.91-7.75(m, 3H), 7.57-7.53(m, 1H), 7.38-7.34(m,2H), 7.21-7.13(m, 4H), 4.20(br, 2H)B-0244(CDCl3/CD3OD) d 8.38(d, J=5.38Hz, 1H), 7.62-7.32(m, 9H), 7.04-6.95(m,4H, 6.86-6.80(m, 2H), 4.52(q, J=6.96Hz, 1H), 1.40(d, J=6.88Hz, 3H)B-0256(DMF-d7) d 8.45(bd, J=2.85, 2H), 7.87(br s, 4H), 7.76-7.75(m, 2H), 7.53-7.33(m,5H), 7.18-7.13(br, 4H)B-0426(DMF-d7), 1.32(br, 3H), 1.67(br, 3H), 4.17(br, 2H), 5.12(br, 1H), 7.50(m, 6H),8.77(m, 2H), 13.54(br, 1H).B-0438(DMSO), 1.14(t, J=6.9Hz, 3H), 4.54(m, 1H), 6.99(br, 2H), 7.21(br, 4H),7.45(s, 1H), 7.61(q, J=8.7Hz, 2H), 8.52(d, J=5.2Hz, 2H).B-0466(DMF-d7), 1.61(brd, J=30.6Hz, 3H), 4.61(br, 1H), 7.25(m, 6H), 7.65(m, 3H),8.59(br, 2H), 13.34(brd, J=34.8Hz, 1H).B-0473(CD3OD), 1.53(d, J=7.2Hz, 3H), 4.59(q, J=7.2Hz, 1H), 6.88(d, J=4Hz,1H), 7.09(m, 3H), 7.15(dd, J=4.4, 1.6Hz, 2H), 7.26(m, 2H), 8.46(d, J=6.0Hz, 2H).B-0477(DMF), 1.80(br, 3H), 2.35(s, 1H), 4.98(br, 1H), 7.38(m, 6H), 7.85(m, 2H),8.45(br, 1H), 8.75(d, J=6.0Hz, 2H).B-0479(Methanol-d4), 1.57(d, J=5.6Hz, 3H), 4.74(br, 1H), 7.23(m, 4H), 7.60(m, 2H),7.81(m, 4H), 8.67(br, 2H).B-0487(DMF), 1.78(s, 3H), 2.76(br, 6H), 4.85(br, 1H), 7.42(br, 2H), 7.54(br, 2H),7.66(br, 3H), 8.82(s, 2H).B-0566(CD3OD), 1.38(d, J=7.2Hz, 3H), 4.15(br, 2H), 4.50(br, 1H), 7.04(br, 2H),7.18(br, 2H), 7.30(m, 7H), 8.45(m, 2H).B-0569(CD3OD), 1.56(br, 3H), 4.66(q, J=6.7Hz, 1H), 7.17(m, 8H), 7.56(m, 2H),8.47(s, 2H).B-0574(Methanol-d4), 1.49(br, 3H), 3.86(br, 3H), 4.60(br, 1H), 6.92(br, 2H), 7.19(br,2H), 7.31(br, 2H), 7.76(m, 4H), 8.60(br, 2H).B-0639(DMF-d7), 1.58(brd, J=30.0Hz, 3H), 4.62(br, 1H), 7.25(m, 6H), 7.60(m, 4H),8.59(br, 2H), 13.30(brd, J=12.3Hz).B-06437.18(m, 2H), 7.32(dd, J=6.0, 4.4Hz, 1H), 7.70(dd, J=9.0, 5.8Hz, 1H),8.43(dd, J=4.8, 3.2Hz, 2H).B-0650(CD3OD), 1.58(br, 3H), 4.62(q, J=6.6Hz, 1H), 6.93(br, 1H), 7.17(m, 5H),7.31(br, 2H), 8.51(br, 2H).B-0656(CDCl3/CD3OD) d 8.48(d, J=5.30Hz, 2H), 7.72-7.59(m, 4H), 7.14-7.10(m,2H), 7.03-6.97(m, 4H), 4.60(q, J=7.57Hz, 1H), 1.43(d, J=7.26Hz, 3H)B-0663(CD3OD), 1.52(d, J=6.8Hz, 3H), 3.75(s, 3H), 7.21(m, 2H), 7.42(m, 2H),7.57(s, 1H), 7.76(s, 1H), 7.98(br, 2H), 8.76(br, 2H).B-1165Hz, 2H), 3.06(m, 1H), 3.43(q, J=6.1Hz, 2H), 7.02(m, 2H), 7.14(m, 2H),7.41(m, 2H), 8.59(d, J=5.6Hz, 2H).B-1169= 1.6Hz, 1H), 7.04(t, J=8.6Hz, 2H), 7.14(m, 2H), 7.36(m, 2H), 8.39(d, J=1.8Hz,1H), 8.60(m, 2H).B-11716.83(br, 1H), 7.02(t, J=8.7Hz, 2H), 7.15(d, J=5.6Hz, 2H), 7.40(m, 2H),8.59(d, J=5.0Hz, 2H).B-1179(CDCl3), 1.94(br, 2H), 2.53(s, 3H), 2.85(t, J=6.2Hz, 2H), 3.65(br, 2H),6.15(br, 1H), 7.04(m, 3H), 7.22(m, 3H), 7.41(br, 4H), 8.60(br, 2H).B-1183(CDCl3), 2.00(br, 2H), 2.85(br, 2H), 3.64(br, 2H), 7.03(br, 3H), 7.17(br, 2H),7.36(br, 2H), 7.66(br, 2H), 8.60(br, 2H), 8.77(br, 2H).B-1194(DMSO), 1.76(br, 2H), 2.66(br, 2H), 2.91(br, 2H), 4.30(s, 2H), 7.18(br, 5H),7.35(m, 6H), 8.54(d, J=5.8Hz, 2H).B-1200(DMSO), 1.17(br, 3H), 1.76(br, 2H), 2.71(br, 2H), 2.97(br, 4H), 7.18(br, 4H),7.36(br, 2H), 8.54(br, 2H).B-1206(DMSO), 1.03(s, 6H), 1.68(br, 2H), 2.63(br, 2H), 3.00(br, 2H), 3.65(br, 1H),5.69(m, 2H), 7.16(br, 4H), 7.35(br, 2H), 8.54(br, 2H).B-1216(DMSO), 1.75(m, 2H), 2.14(s, 6H), 2.66(br, 2H), 3.10(br, 2H), 7.04(br, 3H),7.18(br, 4H), 7.35(m, 2H), 7.47(br, 1H), 8.54(d, J=4.8Hz, 2H).B-1226(DMF), 1.25(br, 3H), 2.01(br, 2H), 3.35(br, 4H), 6.20(s, 1H), 6.30(s, 1H),7.42(br, 4H), 7.65(br, 2H), 8.77(s, 2H).B-1360(DMSO-d6), 1.80(br, 4H), 2.82(br, 1H), 2.94(br, 1H), 3.10(br, 1H), 3.60(br, 1H),4.54(br, 1H), 7.18(m, 4H), 7.30(m, 4H), 7.46(m, 2H), 8.54(br, 2H).B-1361(DMSO-d6), 0.99(br, 6H), 1.73(br, 4H), 2.89(br, 2H), 3.03(m, 1H), 4.04(br, 2H),4.44(m, 1H), 7.18(m, 4H), 7.30(m, 2H), 8.57(d, J=4.64Hz, 2H).B-1363(DMSO-d6), 1.78(br, 4H), 2.01(s, 3H), 2.89(br, 1H), 3.05(br, 1H), 3.34(br, 1H),3.85(br, 1H), 4.48(br, 1H), 7.12(br, 2H), 7.21(br, 2H), 7.30(br, 2H), 8.69(br, 2H).B-1364(CDCl3), 0.78(dd, J=3.0, 2.9Hz, 2H), 1.00(s, 2H), 1.78(m, 1H), 1.86(b, 4H),2.64(m, 1H), 2.99(m, 1H), 3.16(m, 1H), 4.33(br, 1H), 4.70(br, 1H), 6.99(m, 2H),7.14(s, 2H), 7.29(m, 2H), 8.64(s, 2H).B-1368(CDCl3), 1.89(s, 4H), 2.65(m, 1H), 2.96(m, 1H), 3.06(m, 1H), 3.43(s, 3H),3.93(d, J=13.2Hz, 1H), 4.09(d, J=13.5Hz, 1H), 4.18(d, J=13.5Hz, 1H),4.68(d, J=12.4Hz, 1H), 7.60(m, 2H), 7.12(s, 2H), 7.26(m, 2H), 8.63(s, 2H).

By analogy to the procedure identified above for the preparation of Examples B0001-B0048, the following examples B-1574through B-2269 are prepared.

Example #R²R^L embedded image

Examples B-1574 through B-1597 are prepared from Scaffold C-27B-1574 embedded image

B-1575

B-1576

B-1577

B-1578

B-1579

B-1580

B-1581

B-1582

B-1583

B-1584

B-1585

B-1586

B-1587

B-1588

B-1589

B-1590

B-1591

B-1592

B-1593

B-1594

B-1595

B-1596

B-1597

Examples B-1598 through B-1621 are prep ared from Scaffold C-28B-1598 embedded image

B-1599

B-1600

B-1601

B-1602

B-1603

B-1604

B-1605

B-1606

B-1607

B-1608

B-1609

B-1610

B-1611

B-1612

B-1613

B-1614

B-1615

B-1616

B-1617

B-1618

B-1619

B-1620

B-1621

Examples B-1622 through B-1645 are prepared from Scaffold C-38B-1622 embedded image

B-1623

B-1624

B-1625

B-1626

B-1627

B-1628

B-1629

B-1630

B-1631

B-1632

B-1633

B-1634

B-1635

B-1636

B-1637

B-1638

B-1639

B-1640

B-1641

B-1642

B-1643

B-1644

B-1645

Examples B-1646 through B-1669 are prepared from Scaffold C-39B-1646 embedded image

B-1647

B-1648

B-1649

B-1650

B-1651

B-1652

B-1653

B-1654

B-1655

B-1656

B-1657

B-1658

B-1659

B-1660

B-1661

B-1662

B-1663

B-1664

B-1665

B-1666

B-1667

B-1668

B-1669

Examples B-1670 through B-1693 are prepared from Scaffold C-65B-1670 embedded image

B-1671

B-1672

B-1673

B-1674

B-1675

B-1676

B-1677

B-1678

B-1679

B-1680

B-1681

B-1682

B-1683

B-1684

B-1685

B-1686

B-1687

B-1688

B-1689

B-1690

B-1691

B-1692

B-1693

Examples B-1694 through B-1717 are prepared from Scaffold C-66B-1694 embedded image

B-1695

B-1696

B-1697

B-1698

B-1699

B-1700

B-1701

B-1702

B-1703

B-1704

B-1705

B-1706

B-1707

B-1708

B-1709

B-1710

B-1711

B-1712

B-1713

B-1714

B-1715

B-1716

B-1717

Examples B-1718 through B-1741 are prepared from Scaffold C-69B-1718 embedded image

B-1719

B-1720

B-1721

B-1722

B-1723

B-1724

B-1725

B-1726

B-1727

B-1728

B-1729

B-1730

B-1731

B-1732

B-1733

B-1734

B-1735

B-1736

B-1737

B-1738

B-1739

B-1740

B-1741

Examples B-1742 through B-1765 are prepared from Scaffold C-70B-1742 embedded image

B-1743

B-1744

B-1745

B-1746

B-1747

B-1748

B-1749

B-1750

B-1751

B-1752

B-1753

B-1754

B-1755

B-1756

B-1757

B-1758

B-1759

B-1760

B-1761

B-1762

B-1763

B-1764

B-1765

Examples B-1766 through B-1789 are prepared from Scaffold C-71B-1766 embedded image

B-1767

B-1768

B-1769

B-1770

B-1771

B-1772

B-1773

B-1774

B-1775

B-1776

B-1777

B-1778

B-1779

B-1780

B-1781

B-1782

B-1783

B-1784

B-1785

B-1786

B-1787

B-1788

B-1789

Examples B-1790 through B-1813 are prepared from Scaffold C-72B-1790 embedded image

B-1791

B-1792

B-1793

B-1794

B-1795

B-1796

B-1797

B-1798

B-1799

B-1800

B-1801

B-1802

B-1803

B-1804

B-1805

B-1806

B-1807

B-1808

B-1809

B-1810

B-1811

B-1812

B-1813

Examples B-1814 through B-1837 are prepared from Scaffold C-73B-1814 embedded image

B-1815

B-1816

B-1817

B-1818

B-1819

B-1820

B-1821

B-1822

B-1823

B-1824

B-1825

B-1826

B-1827

B-1828

B-1829

B-1830

B-1831

B-1832

B-1833

B-1834

B-1835

B-1836

B-1837

Examples B-1838 through B-1861 are prepared from Scaffold C-33B-1838 embedded image

B-1839

B-1840

B-1841

B-1842

B-1843

B-1844

B-1845

B-1846

B-1847

B-1848

B-1849

B-1850

B-1851

B-1852

B-1853

B-1854

B-1855

B-1856

B-1857

B-1858

B-1859

B-1860

B-1861

Examples B-1862 through B-1885 are prepared from Scaffold C-45B-1862 embedded image

B-1863

B-1864

B-1865

B-1866

B-1867

B-1868

B-1869

B-1870

B-1871

B-1872

B-1873

B-1874

B-1875

B-1876

B-1877

B-1878

B-1879

B-1880

B-1881

B-1882

B-1883

B-1884

B-1885

Examples B-1886 through B-1909 prepared from Scaffold C-42B-1886 embedded image

B-1887

B-1888

B-1889

B-1890

B-1891

B-1892

B-1893

B-1894

B-1895

B-1896

B-1897

B-1898

B-1899

B-1900

B-1901

B-1902

B-1903

B-1904

B-1905

B-1906

B-1907

B-1908

B-1909

Examples B-1910 through B-1933 are prepared from Scaffold C-44B-1910 embedded image

B-1911

B-1912

B-1913

B-1914

B-1915

B-1916

B-1917

B-1918

B-1919

B-1920

B-1921

B-1922

B-1923

B-1924

B-1925

B-1926

B-1927

B-1928

B-1929

B-1930

B-1931

B-1932

B-1933

Examples B-1934 through B-1957 are prepared from Scaffold C-41B-1934 embedded image

B-1935

B-1936

B-1937

B-1938

B-1939

B-1940

B-1941

B-1942

B-1943

B-1944

B-1945

B-1946

B-1947

B-1948

B-1949

B-1950

B-1951

B-1952

B-1953

B-1954

B-1955

B-1956

B-1957

Examples B-1958 through B-1981 are prepared from Scaffold C-43B-1958 embedded image

B-1959

B-1960

B-1961

B-1962

B-1963

B-1964

B-1965

B-1966

B-1967

B-1968

B-1969

B-1970

B-1971

B-1972

B-1973

B-1974

B-1975

B-1976

B-1977

B-1978

B-1979

B-1980

B-1981

Examples B-1982 through B-2005 are prepared from Scaffold C-30B-1982 embedded image

B-1983

B-1984

B-1985

B-1986

B-1987

B-1988

B-1989

B-1990

B-1991

B-1992

B-1993

B-1994

B-1995

B-1996

B-1997

B-1998

B-1999

B-2000

B-2001

B-2002

B-2003

B-2004

B-2005

Examples B-2006 through B-2029 are prepared from Scaffold C-60B-2006 embedded image

B-2007

B-2008

B-2009

B-2010

B-2011

B-2012

B-2013

B-2014

B-2015

B-2016

B-2017

B-2018

B-2019

B-2020

B-2021

B-2022

B-2023

B-2024

B-2025

B-2026

B-2027

B-2028

B-2029

Examples B-2030 through B-2053 are prepared from Scaffold C-36B-2030 embedded image

B-2031

B-2032

B-2033

B-2034

B-2035

B-2036

B-2037

B-2038

B-2039

B-2040

B-2041

B-2042

B-2043

B-2044

B-2045

B-2046

B-2047

B-2048

B-2049

B-2050

B-2051

B-2052

B-2053

Examples B-2054 through B-2077 are prepared from Scaffold C-34B-2054 embedded image

B-2055

B-2056

B-2057

B-2058

B-2059

B-2060

B-2061

B-2062

B-2063

B-2064

B-2065

B-2066

B-2067

B-2068

B-2029

B-2070

B-2071

B-2072

B-2073

B-2074

B-2075

B-2076

B-2077

Examples B-2078 through B-2101are prepared from Scaffold C-57B-2078 embedded image

B-2079

B-2080

B-2081

B-2082

B-2083

B-2084

B-2085

B-2086

B-2087

B-2088

B-2089

B-2090

B-2091

B-2092

B-2093

B-2094

B-2095

B-2096

B-2097

B-2098

B-2099

B-2100

B-2101

Examples B-2102 through B-2125 are prepared from Scaffold C-52B-2102 embedded image

B-2103

B-2104

B-2105

B-2106

B-2107

B-2108

B-2109

B-2110

B-2111

B-2112

B-2113

B-2114

B-2115

B-2116

B-2117

B-2118

B-2119

B-2120

B-2121

B-2122

B-2123

B-2124

B-2125

Examples B-2126 through B-2149 are prepared from Scaffold C-56B-2126 embedded image

B-2127

B-2128

B-2129

B-2130

B-2131

B-2132

B-2133

B-2134

B-2135

B-2136

B-2137

B-2138

B-2139

B-2140

B-2141

B-2142

B-2143

B-2144

B-2145

B-2146

B-2147

B-2148

B-2149

Examples B-2150 through B-2173 are prepared from Scaffold C-32B-2150 embedded image

B-2151

B-2152

B-2153

B-2154

B-2155

B-2156

B-2157

B-2158

B-2159

B-2160

B-2161

B-2162

B-2163

B-2164

B-2165

B-2166

B-2167

B-2168

B-2169

B-2170

B-2171

B-2172

B-2173

Examples 2174 through B-2197 are prepared from Scaffold C-64B-2174 embedded image

B-2175

B-2176

B-2177

B-2178

B-2179

B-2180

B-2181

B-2182

B-2183

B-2184

B-2185

B-2186

B-2187

B-2188

B-2189

B-2190

B-2191

B-2192

B-2193

B-2194

B-2195

B-2196

B-2197

Examples B-2198 through B-2221 re prepared from Scaffold C-22B-2198 embedded image

B-2199

B-2200

B-2201

B-2202

B-2203

B-2204

B-2205

B-2206

B-2207

B-2208

B-2209

B-2210

B-2211

B-2212

B-2213

B-2214

B-2215

B-2216

B-2217

B-2218

B-2219

B-2220

B-2221

Examples B-2222 through B-2245 are prepared from Scaffold C-29B-2222 embedded image

B-2223

B-2224

B-2225

B-2226

B-2227

B-2228

B-2229

B-2230

B-2231

B-2232

B-2233

B-2234

B-2235

B-2236

B-2237

B-2238

B-2239

B-2240

B-2241

B-2242

B-2243

B-2244

B-2245

Examples B-2246 through B-2269 are prepared from Scaffold C-35B-2246 embedded image

B-2247

B-2248

B-2249

B-2250

B-2251

B-2252

B-2253

B-2254

B-2255

B-2256

B-2257

B-2258

B-2259

B-2260

B-2261

B-2262

B-2263

B-2264

B-2265

B-2266

B-2267

B-2268

B-2269

EXAMPLES B-2270 THROUGH B-2317

In a parallel array reaction block containing 48 fritted vessels, each reaction vessel was charged with 250 mg of polymer bound carbodiimide B48 (1.0 mmol/g resin) and a solution of the acid-containing scaffold C-49 in dimethylformamide (0.1 M, 500 uL). To each slurry was added a solution of pyridine in dichloromethane (0.2 M, 1000 uL) followed by a solution of a unique amine B47 (0.2 M, 375 uL) in dimethylformamide. The reaction mixtures were agitated on a Labline benchtop orbital shaker at 250 RPM for 16-20 h at ambient temperature. The reaction mixtures were filtered into conical vials and the polymer was washed with 1.5 mL of dimethylformamide and 2.0 mL of dichloromethane. The filtrates were evaporated to dryness in a Savant apparatus and dimethylformamide (350 uL) was added to each conical vial to dissolve the residue. A solution of tetrafluorophthalic anhydride (1.0 M, 150 uL) in dimethylformamide was added to the reconstituted conical vials and the mixture incubated for 2 hours at ambient temperature. Polyamine polymer B33 (4.0 meq N/g resin, 250 mg) and 1.0 mL dichloromethane was then added to the reaction mixture in each conical vial. After agitating the reaction mixtures for 16 h at 250 RPM on an orbital shaker at ambient temperature, the mixtures were filtered through a polypropylene syringe tube fitted with a porous frit. The polymers were washed twice with dimethylformamide (1.0 mL. each) and the filtrates and washings collected in conical vials. The filtrates were evaporated to dryness and weighed to afford the desired amide products B-2270 through B-2317 as oils or solids. The analytical data and yields for the products prepared in this manner are listed below.

R²

YieldCalcd. Mass Spec.Observed Mass Spec M + HB-2270 embedded image

12352353B-2271 embedded image

39432433B-2272 embedded image

26400—B-2273 embedded image

14396397B-2274 embedded image

40434435B-2275 embedded image

43443—B-2276 embedded image

35364365B-2277 embedded image

33490—B-2278 embedded image

53460461B-2279 embedded image

10420—B-2280 embedded image

7435436B-2281 embedded image

18401402B-2282 embedded image

22390413^a^aM + NaB-2283 embedded image

10394417^a^aM + Nap B-2284 embedded image

7423—B-2285 embedded image

23450—B-2286 embedded image

4506—B-2287 embedded image

5437438B-2288 embedded image

8435436B-2289 embedded image

4450451B-2290 embedded image

9456457B-2291 embedded image

9415416B-2292 embedded image

5368369B-2293 embedded image

5366367B-2294 embedded image

5381382B-2295 embedded image

16410411B-2296 embedded image

4483—B-2297 embedded image

7490—B-2298 embedded image

4537—B-2299 embedded image

4507508B-2300 embedded image

7442—B-2301 embedded image

20396397B-2302 embedded image

30459—B-2303 embedded image

6482B-2304 embedded image

5395396B-2305 embedded image

10460—B-2306 embedded image

11466467B-2307 embedded image

5421422B-2308 embedded image

26470—B-2309 embedded image

24424425B-2310 embedded image

9348—B-2311 embedded image

21338339B-2312 embedded image

29398399B-2313 embedded image

6410—B-2314 embedded image

15363364B-2315 embedded image

11444—B-2316 embedded image

11418—B-2317 embedded image

36428—

By analogy to the procedure identified above for the preparation of Examples B-2270 through B-2317, the following examples B-2318 through B-2461 were prepared.

R²

YieldCalcd. Mass Spec.Observed Mass Spec M + HB-2318 embedded image

23426427B-2319 embedded image

23394—B-2320 embedded image

50490491B-2321 embedded image

49426427B-2322 embedded image

40366367B-2323 embedded image

68410411B-2324 embedded image

57456457B-2325 embedded image

41382383B-2326 embedded image

71440441B-2327 embedded image

36464465B-2328 embedded image

32467468B-2329 embedded image

34465466B-2330 embedded image

26364365B-2331 embedded image

38464465B-2332 embedded image

33483484B-2333 embedded image

36378379B-2334 embedded image

44428429B-2335 embedded image

27406407B-2336 embedded image

41428429B-2337 embedded image

26423424B-2338 embedded image

33469470B-2339 embedded image

52518519B-2340 embedded image

64442443B-2341 embedded image

41350351B-2342 embedded image

34414415B-2343 embedded image

29424425B-2344 embedded image

33492493B-2345 embedded image

30420421B-2346 embedded image

35474475B-2347 embedded image

34392393B-2348 embedded image

51458459B-2349 embedded image

73517518B-2350 embedded image

22448449B-2351 embedded image

64486487B-2352 embedded image

41482483B-2353 embedded image

57438439B-2354 embedded image

63484485B-2355 embedded image

28536537B-2356 embedded image

29408409B-2357 embedded image

41436437B-2358 embedded image

41451452B-2359 embedded image

57502503B-2360 embedded image

46496497B-2361 embedded image

13476477B-2362 embedded image

46493494B-2363 embedded image

57396397B-2364 embedded image

61438439B-2365 embedded image

72424425B-2366 embedded image

34380381B-2367 embedded image

52480481B-2368 embedded image

35407407B-2369 embedded image

31435436B-2370 embedded image

33414415B-2371 embedded image

28366367B-2372 embedded image

37422423B-2373 embedded image

50432433B-2374 embedded image

29382383B-2375 embedded image

35395396B-2376 embedded image

36428429B-2377 embedded image

68438439B-2378 embedded image

55446447B-2379 embedded image

33364365B-2380 embedded image

51421422B-2381 embedded image

52429430B-2382 embedded image

48407408B-2383 embedded image

53382383B-2384 embedded image

38447448B-2385 embedded image

59498450B-2386 embedded image

45429430B-2387 embedded image

74558—B-2388 embedded image

53475—B-2389 embedded image

33493494B-2390 embedded image

53487488B-2391 embedded image

30435436B-2392 embedded image

57464465B-2393 embedded image

50418419B-2394 embedded image

65488489B-2395 embedded image

59437438B-2396 embedded image

34534535B-2397 embedded image

32516517B-2398 embedded image

81533534B-2399 embedded image

55502—B-2400 embedded image

34381382B-2401 embedded image

32378379B-2402 embedded image

71519520B-2403 embedded image

68527528B-2404 embedded image

62447448B-2405 embedded image

71536537B-2406 embedded image

47394395B-2407 embedded image

65508509B-2408 embedded image

34495496B-2409 embedded image

47448449B-2410 embedded image

73542543B-2411 embedded image

81489490B-2412 embedded image

54409410B-2413 embedded image

37493494B-2414 embedded image

14473474B-2415 embedded image

19421422B-2416 embedded image

13386387B-2417 embedded image

29414415B-2418 embedded image

6420421B-2419 embedded image

10454—B-2420 embedded image

5442443B-2421 embedded image

28454455B-2422 embedded image

47420421B-2423 embedded image

53400401B-2424 embedded image

15400401B-2425 embedded image

18522523B-2426 embedded image

38464465B-2427 embedded image

26468469B-2428 embedded image

22432433B-2429 embedded image

41404405B-2430 embedded image

15476477B-2431 embedded image

6446447B-2432 embedded image

37404405B-2433 embedded image

8428429B-2434 embedded image

13476477B-2435 embedded image

23442443B-2436 embedded image

5486487B-2437 embedded image

4492493B-2438 embedded image

58422423B-2439 embedded image

12454455B-2440 embedded image

8521522B-2441 embedded image

6443444B-2442 embedded image

37514515B-2443 embedded image

15518—B-2444 embedded image

52520—B-2445 embedded image

33517518B-2446 embedded image

70500501B-2447 embedded image

56488489B-2448 embedded image

51522523B-2449 embedded image

19512513B-2450 embedded image

16538539B-2451 embedded image

71511512B-2452 embedded image

71500501B-2453 embedded image

61470—B-2454 embedded image

15472473B-2455 embedded image

39520—B-2456 embedded image

51533534B-2457 embedded image

55540—B-2458 embedded image

22488489B-2459 embedded image

8486487B-2460 embedded image

13534535B-2461 embedded image

13542—

EXAMPLE C-1
5-Aminomethyl-4-(4-Pyridyl)-3-(4-Fluorophenyl) Payrazole

embedded image

1-(4-fluorophenyl)-2-(4-pyridyl)-1-ethanone. 4-picoline (40 g, 0.43 mol) was added to a LiHMDS solution (0.45 mol, 450 mL of a 1.0 M solution in THF) over 30 minutes at room temperature (a slight exotherm was observed) The resulting solution was stirred for 1 h. This solution was added to ethyl 4-fluorobenzoate (75.8 g, 0.45 mol, neat) over 1 h. The mixture was stirred overnight (16 h). Water (200 mL) was added and the mixture was extracted with EtOAc (2×200 mL). The organic layer was washed with brine (1×200 mL) and dried over Na₂SO₄. The organic layer was filtered and the solvent was removed to leave oily solid. Hexane was added to the oil and the resulting solid was filtered and washed with hexane (cold). A yellow solid was isolated (50 g, 54%): ¹H NMR (CDCl₃) δ 8.58 (d, J=5.7 Hz, 2H), 8.02 (dd, J=5.5, 8.0, 2H), 7.12-7.21 (m, 4H), 4.23 (s, 2H); ¹⁹F NMR (CDCl₃) δ −104.38 (m); LC/MS, t_r=2.14 minutes (5 to 95% acetonitrile/water over 15 minutes at 1 mL/min, at 254 nm at 50° C.), M+H=216; High Resolution MS Calcd for C₂₃H₂₀N₄O₂F (M+H): 216.0825. Found: 216.0830 (Δmmu=0.5).

N-benzyloxycarbonyl-5-aminomethyl-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole. A 3L round bottom flask fitted with a mechanical stirrer, N₂inlet and an addition funnel was was charged with 557 mL (0.56 mol) of 1 M t-BuOK in THF and 53 mL (0.56 mol) of t-BuOH. The ketone, 1 (60 g, 0.28 mol) was dissolved in 600 mL of THF and added to the stirred mixture at room temperature. A yellow precipitate formed and the mixture was stirred for 1 h. N-benzyloxycarbonyl-glycinyl N-hydroxysuccinimide (128.6 g, 0.42 mol) was dissolved in 600 mL of THF and added dropwise at r.t. over 1 h. The mixture was stirred for another 5 minutes and 150 mL of water was added, the pH was adjusted to 6.7 with 70 mL of AcOH. Hydrazine monohydrate (41 mL in 100 mL of water) was added via an addition funnel. The mixture was stirred for 1 h and was diluted with 500 mL of water and 500 mL of ethyl acetate. The biphasic mixture was transferred to a sep funnel and the layers were separated. The aqueous layer was extracted with EtOAc (3×300 mL). The organic layer was dried (Na₂SO₄), filtered and evaporated to leave 157 g of a crude reddish oil.

The oil was suspended in CH₂Cl₂and filtered to remove any insoluble material (DCU, hydrazone of the monoketone). The solution was split into two portions and each portion was chromatographed (Biotage 75L, 3% EtOH/CH₂Cl₂then 6% EtOH/CH₂Cl₂). The appropriate fractions were concentrated (some contamination from the monoketone and the hydrazone) from each portion to leave a yellow solid. The solid was suspended in ethyl acetate and heated to boiling for 10 minutes. The solution was allowed to cool to R. T. overnight. The precipitate was filtered to give 30 g of a white solid (27% yield of 2): ¹H NER (DMF-d₇) δ 13.36 (s, 1H), 8.57 (d, J=5.8 Hz, 2H), 7.16-7.52 (m, 11H), 5.11 (s, 2H), 4.48 (d, J=5.4 Hz, 2H); ¹⁹F No (DMF-d₇) δ −114.9 (m), −116.8 (m) (split fluorine signal is due to the pyrazple tautomers); LC/MS, t_r=3.52 minutes (5 to 95% acetonitrile/water over 15 minutes at 1 mL/min, at 254 nm at 50° C.), M+H=403; High Resolution MS Calcd for C₂₃H₂₀N₄O₂F (M+H): 403.1570. Found: 403.1581 (Δmmu=1.1).

5-aminomethyl-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole. To a 1L Parr bottle was added 7 g (17.4 mmol) of 2 and 180 mL of MeOH and 90 mL of THF to give a clear solution. The bottle was purged with nitrogen and 1.5 g of 10% Pd/C (wet Degussa type E101) was added. The Parr bottle was pressured to 40 psi (H₂) and was agitated. Hydrogen uptake was 5 psi after 5 h. The bottle was repressured to 42 psi and was agitated overnight. The bottle was purged with N2 and was filtered through Celite. The Celite was washed with MeOH (3×50 mL) and the filtrate was concentrated to give 4.5 g of an off-white solid (94%). ¹H NMR (DMSO-d₆) δ 8.52 (d, J=4.63 Hz, 2H), 7.36 (dd, J=5.64, 8.1 Hz, 2H), 7.16-7.30 (m, 4H), 3.79 (s, 2H); ¹⁹F NMR (DMSO-d₆) δ −114.56 (m); LC/MS, t_r=1.21 minutes (5 to 95% acetonitrile/water over 15 minutes at 1 mL/min, at 254 nm at 50° C.), M+H=269 m/z; High Resolution MS Calcd for C₁₅H₁₄N₄F (M+H): 269.1202. Found: 269.1229 (Δmmu=2.7).

The following pyridylpyrazoles (C-2 through C-21, Table C-1) were prepared according to the experimental procedure described above for example C-1.

TABLE C-1MW, M + HExampleCalculatedNo.StructureFound⁺H NMR (solvent), ppmC-2 embedded image

323.1672 323.1670(DMF-d₇): 8.77(t, J=4.4 Hz, 2H), 7.60(m, 2H), 7.44(t, J=4.4 Hz, 2H), 7.35(m, 2H), 3.22(bd, 2H) 3.01(septet, J=5.3 Hz, 1H), 2.74(m, 2H), 1.95(m, 4H)C-3 embedded image

282.127 (M) 282.1245 (M, EI)(DMF-d₇): 8.77(br s, 2H), 7.64-7.62(m, 2H), 7.50(br s, 2H), 7.38-7.34 (m, 2H), 4.40-4.37(m, 1H), 1.56(br s, 3H)C-4 embedded image

282.127 (M) 282.1147 (M, EI)(DMF-₇): 8.77(br s, 2H), 7.64-7.62(m, 2H), 7.50(br s, 2H), 7.38-7.35 (m, 2H), 4.40-4.37(m, 1H), 1.57(br s, 3H)C-5 embedded image

323.1672 323.1687(DMSO-d₆): 8.56(br, 2H), 7.32(m, 2H), 7.18(m, 4H), 2.91(m, 2H), 2.71 (m, 2H), 1.88(m, 1H), 1.65 (m, 2H), 1.40(m, 2H)C-6 embedded image

359 359(DMSO-d₆): 8.46(d, J=4.6 Hz, 2H), 7.32-7.13(m, 7H), 6.98-6.96(m, 4H), 4.06(t, J=7.0 Hz, 1H), 2.98-2.95(m, 2H)C-7 embedded image

359 359(DMSO-d₆): 8.46(d, J=5.4 Hz, 2H), 7.32-7.28(m, 2H), 7.20-7.12(m, 5H), 6.98-6.96(m, 4H), 4.06 (t, J=7.0 Hz, 1H), 2.98-2.94(m, 2H)C-8 embedded image

313.1465 313.1492(DMSO-d₆): 13.83(bs, 1H), 8.61(d, J=5.7 Hz, 2H), 8.33(bs, 1H), 7.33 (m, 6HB), 4.44(m, 1H), 3.63(m, 2H), 3.27(s, 3H)C-9 embedded image

313.1465 313.1457(DMSO-d₆): 8.55(dd, J=1.5, 4.4 Hz, 2H), 7.37-7.32(m, 2H), 7.26(dd, J=1.6, 4.4 Hz, 2H), 7.22-7.16(m, 2H), 4.06(t, J=6.5 Hz, 1H), 3.49(d, J=6.6 Hz, 2H), 3.20(s, 3H)C-10 embedded image

354 354(DMSO-d₆): 13.03(bs, 1H), 8.50(dd, J=1.6, 2.7 Hz, 2H), 7.58(bq, J=4.3 Hz, 1), 7.3(m, 2H), 7.12-7.21(m, 4H), 3.77 (t, J=6.3Hz, 1H), 2.45 (d, J=4.5 Hz, 3H), 1.97 (t, J=7.4 Hz, 2H), 1.85 (dt, J=7.3, 7.1 Hz, 2H)C-11 embedded image

354 354(DMSO-d₆): 13.03(bs, 1H), 8.50(dd, J=1.6, 2.7 Hz, 2H), 7.58(bq, J=4.3 Hz, 1H), 7.3(m, 2H), 7.12-7.21(m, 4H), 3.77 (t, J=6.3 Hz, 1H), 2.45 (d, J=4.5 Hz, 3H), 1.97 (t, J=7.4 Hz, 2H), 1.85 (dt, J=67.3, 7.1 Hz, 2H)C-12 embedded image

283.1359 283.1363(DMSO-d₆): 8.53(d, J=5.0 Hz, 2H), 7.37-7.32(m, 2H), 7.21-7.17(m, 4H), 2.83(d, J=6.0 Hz, 2H), 2.77(d, J=6.0 Hz, 2H)C-13 embedded image

297.1515 297.1515(DMSO-d₆): 8.53(d, J=5.4 Hz, 2H), 7.34(dd, J=5.8, 8.2 Hz, 2H), 7.18 (dd, J=5.8, 9.8 Hz, 4H), 2.68(t, J=7.3 Hz, 2H), 252(m, 2H), 1.64(m, 2H)C-14 embedded image

284.0829 284.0806(CD₃OD): 8.74(br, 2H), 7.77(br, 2H), 7.45-7.58 (m, 3H), 7.30-7.40(m, 1H), 4.43(s, 2H)C-15 embedded image

285 285(DMSO-d₆): 8.53(br, 2H), 7.56(br, 2H), 7.26(m, 4H), 3.75(br, 2H)C-16 embedded image

329, 331 329, 331(DMSO-d₆): 8.53(d, J=4.4 Hz, 2H), 7.42(d, J=7.9 Hz, 2H), 7.34(d, J=8.5 Hz, 2H), 7.24(d, J=4.6 Hz, 2H), 3.76(bs, 2H)C-17 embedded image

339 339(DMSO-d₆): 8.53(t, J=4.3 Hz, 2H), 7.33(m, 3H), 7.19(t, J=4.6 Hz, 2H), 7.154(d, J=7.3 Hz, 1H), 3.23(m, 2H), 2.88(m, 3H), 1.92, (m, 3H), 1.70 (m, 1H)C-18 embedded image

339 339(DMSO-d₆): 8.57 (d, J=4.6 Hz, 2H), 7.41(d, J=8.3 Hz, 2H), 7.29(d, J=8.5 Hz, 2H), 7.20(d, J=4.8 Hz, 2H), 3.18(bd, 2H), 2.88(m, 1H), 2.76 (m, 2H), 1.82(br, 4H)C-19 embedded image

383, 385 383, 385(DMSO-d₆): 8.56(br, 2H) 7.52(br, 2H), 7.14-7.29 (m, 4H), 2.99(br, 2H), 2.71(br, 1H), 2.51(br, 2H), 1.68(br, 4H)

The following pyridylpyrazoles (C-22 through C-40, Table C-2) are prepared utilizing the general schemes C-1 and C-2 and the experimental procedure described for example C-1 above.

TABLE C-2Cmpd.No.StructureC-22 embedded image

C-23

C-24

C-25

C-26

C-27

C-28

C-29

C-30

C-31

C-32

C-33

C-34

C-35

C-36

C-37

C-38

C-39

C-40

C-41

C-42

C-43

C-44

C-45

C-46

C-47

C-48

embedded image

Step A

The pyrazole (2.60 g, 10.3 mmol) from example C-4 was suspended in 52 mL of dichloroethane and 52 mL of 2.5 M NaOH. Tetrabutylammonium hydroxide (0.5 mL of a 1 M aqueous solution) was added to the stirred mixture. To this mixture was added t-butyl bromoacetate (2.10 g, 10.8 mmol). The reaction mixture was stirred at room temperature for 4 h. The mixture was poured onto 200 mL of CH₂Cl₂and 200 mL of H₂O. The phases were separated and the organic phase was washed with water (1×100 mL) and brine (1×100 mL). The organic layer was dried over Na₂SO₄and was filtered. The solvent was removed to leave an off-white solid. This solid was triturated with hexane and the resulting solid isolated by filtration. The solid was washed with hexane to leave 3.4 g of a white solid (90%).

Step B

The alkylated pyrazole (3.7 g, 10.1 mmol) from Step A was treated with 57 mL of 4 N HCL in dioxane. The solution was stirred at room temperature for 4 h. The solvent was removed under reduced pressure and the residue was dissolved in THF. The solution was treated with propylene oxide (10.3 mmol) and was stirred for 1 h at room temperature. The solvent was removed to leave an oil. The residual solvent was chased with several portions of EtOH. The resulting solid was triturated with Et₂O and the title compound Example C-49 was isolated by filtration to afford 3.0 g of an off-white solid (95%). Mass spec: M+H cald: 312; found 312. ¹H NMR (DMSO-d6): 8.81 (d, J=6.4 Hz, 2H), 7.73 (d, J=5.8 Hz, 2H), 7.40 (m, 2H), 7.23 (t, J=8.5 Hz, 1H), 5.16 (s, 2H), 2.40 (s, 3H).

EXAMPLE C-50

embedded image

According to the procedure described above in Example C-49, Example C-50 was also prepared starting from 4-[3-(4-fluorophenyl)-1H-pyrazole-4-yl]pyridine. Mass spec: M+H cald: 298; found 298. ¹H NMR (DMSO-d6): 8.75 (d, J=6.4 Hz, 2H), 8.68 (s, 1H), 7.78 (d, J=6.6 Hz, 2H), 7.52 (dd, J=5.4, 8.5 Hz, 2H), 7.31 (t, J=8.9 Hz, 2H), 5.16 (s, 2H).

EXAMPLE C-51

embedded image

Starting with the N-Boc-piperidinyl analog of Example C-2, Example C-51 is also prepared according to the methods described in Scheme C-1.

EXAMPLE C-52

embedded image

Step A: Picoline is treated with a base chosen from but not limited to n-BuLi, LDA, LiHMDS, tBuOK, or NaH in an organic solvent such as THF, ether, t-BuOH or dioxane from −78° C. to 50° C. for a period of time from 10 minutes to 3 hours. The picoline solution is then added to a solution of N-Cbz-(L)-phenylalaninyl N-hydroxysuccinimide. The reaction is allowed to stir from 30 minutes to 48 hours during which time the temperature may range from −20° C. to 120° C. The mixture is then poured into water and extracted with an organic solvent. After drying and removal of solvent the pyridyl monoketone is isolated as a crude solid which could be purified by crystallization and/or chromatography.
embedded image

Step B: A solution of the pyridyl monoketone in ether, THF, tBuOH, or dioxane is added to a base chosen from but not limited to n-BuLi, LDA, LiHMDS, tBuOK, or NaH contained in hexane, THF, ether, dioxane, or tBuOH from −78° C. to 50° C. for a period of time from 10 minutes to 3 hours. Formyl acetic anhydride is then added as a solution in THF, ether, or dioxane to the monoketone anion while the temperature is maintained between −50° C. and 50° C. The resulting mixture is allowed to stir at the specified temperature for a period of time from 5 minutes to several hours. The resulting pyridyl diketone intermediate is utilized without purification in Step C.
embedded image

Step C: The solution containing the pyridyl diketone is quenched with water and the pH is adjusted to between 4 and 8 utilizing an inorganic or organic acid chosen from HOAc, H₂SO₄, HCl, or HNO₃. The temperature during this step is maintained between −20° C. and room temperature. Hydrazine or hydrazine hydrate is then added to the mixture while maintaining the temperature between −20° C. and 40° C. for a period of 30 minutes to several hours. The mixture is then poured into water and extracted with an organic solvent. The N-Cbz-protected pyridyl pyrazole is obtained as a crude solid which is purified by chromatography or crystallization.
embedded image

Step: D

The CBZ protecting group is cleaved using hydrogen gas under pressure and Pd—C in an alcohol solvent, affording scaffold C-52 after filtration and concentration.
embedded image

The following compounds C-53 through C-59 in Table C-3 are prepared according to the general procedure described above for the preparation of C-52.

TABLE C-3Example No.StructureC-53 embedded image

C-54

C-55

C-56

C-57

C-58

C-59

EXAMPLE C-60

Step A:

A Boc protected pyridylpyrazole is treated with benzaldehyde in methylene chloride at room temperature in the presence of a drying agent for a period of time ranging from 1-24 h. Solvent is then evaporated and the resulting imine is used in step B without further purification.
embedded image

Step B:

The pyridylpyrazole imine is dissolved in THF and stirred under nitrogen at temperatures ranging from −78 to −20° C. A base such as LDA, n-BuLi, or LiHMDS is added dropwise to the mixture which is then stirred for an additional 10 minutes to 3 h. Two equivalents of a methyl iodide are then added to the mixture and stirring is continued for several hours. The mixture is then quenched with acid and allowed to warm to room temperature and stirred several hours until cleavage of the Boc and the imine functions is complete. The pH is adjusted to 12 and then the mixture is extracted with an organic solvent, which is dried and evaporated. The crude pyridylpyrazole is then crystallized and/or chromatographed to give purified C-60.
embedded image

EXAMPLE C-61

embedded image

Example C-61 is prepared according to the method described in example C-60, substituting 1,4-dibromobutane for methyl iodide.

EXAMPLE C-62

embedded image

Example C-62 is prepared according to the method described in example C-60, substituting 1,3-dibromoethane for methyl iodide.

EXAMPLE C-63

The synthesis of compound C-63 starts with the condensation reaction of bromomaleic anhydride B77 with 2,4-dimethoxybenzylamine in acetic acid and acetic anhydride. The maleimide B78 is then treated with 4′-fluoroacetophenone in the presence of catalytic amount Pd₂(dba)₃and sodium t-butoxide to form the fluoroacetophenone substituted maleimide B79. B79 is then treated with tert-butoxybis(dimethylamino)methane to yield the a-ketoenamine B80. The a-ketoenamine B80 is condensed with hydrazine to form the N-protected maleimide pyrazole B81. The 2,4-dimethoxybenzyl group is cleaved with ceric ammonium nitrate (CAN) to give the title compound C-63.
embedded image

EXAMPLE C-64

embedded image

Using the method described in Schemes C-6 and C-7, Example 64 is prepared.

EXAMPLE C-65

embedded image

Using the method described in Schemes C-6 and C-7, Example 65 is prepared.

EXAMPLE C-66

embedded image

Using the method described in Schemes C-6 and C-7, Example C-66 is synthesized, substituting N-2,4-dimethoxybenzyl-4-bromopyridone for B78.

EXAMPLE C-67

embedded image

Using the method described in Schemes C-6 and C-7, Example C-67 is synthesized, substituting N-2,4-dimethoxybenzyl-4-bromopyridone for B78, and substituting N-Boc-glycyl N-hydroxysuccinimide for B82.

EXAMPLE C-68

embedded image

Using the method described in Schemes C-6 and C-7, Example C-68 is synthesized, substituting N-2,4-dimethoxybenzyl-4-bromopyridone for B78.

EXAMPLE C-69

embedded image

Using the method described in Schemes C-6 and C-7, Example 69 is prepared, substituting N-Boc-nipecotyl N-hydroxysuccinimide for B83.

EXAMPLE C-70

embedded image

Using the method described in Schemes C-6 and C-7, Example 70 is prepared, substituting N-Boc-nipecotyl N-hydroxysuccinimide for B83.

EXAMPLE C-71

embedded image

Using the method described in Schemes C-6 and C-7, Example 71 is prepared, substituting N-methyl-3-bromomaleimide for B78.

EXAMPLE C-72

embedded image

Using the method described in Schemes C-6 and C-7, Example 72 is prepared, substituting N-methyl-3-bromomaleimide for B78, and substituting N-Boc-nipecotyl N-hydroxysuccinimide for B83.

EXAMPLE C-73

embedded image

Using the method described in Schemes C-6 and C-7, Example 73 is prepared, substituting N-methyl-3-bromomaleimide for B78 and substituting N-Boc-nipecotyl N-hydroxysuccinimide for B83.

General Synthetic Procedures

Scheme C-8 illustrates a general method that can be used for the introduction of various groups on an unsubstituted nitrogen atom that is present as part of pyrazole (Cviii) with appropriately substituted aldehydes (R₃₀₂CHO) or ketones (R₃₀₂COR₃₀₃) in the presence of a reducing agent such as sodium cyanoborohydride or sodium triacetoxyborohydride affords the desired products (Cix). Typical conditions for the reductive alkylation include the use of an alcoholic solvent at temperatures ranging from 20° C. to 80° C. In Scheme C-8, R₃₀₂and R₃₀₃are selected from but not limited to alkyl, benzyl, substituted benzyl, arylalkyl, heteroarylalkyl.
embedded image

Scheme C-9 illustrates another method for introduction of substituents on the unsubstituted nitrogen atom present as part of the C-3 position of the pyrazole (Cviii). Treatment of the pyrazole (Cviii) with a suitable alkylating agent (R₃₀₄X) such as an alkyl chloride, alkyl bromide, alkyl iodide or with an alkyl methanesulfonate or alkyl p-toluenesulfonate in the presence of a suitable base affords the desired alkylated pyrazoles (Cx). Examples of suitable bases include diisopropylethylamine, triethylamine, N-methylmorpholine, potassium carbonate and potassium bicarbonate.
embedded image

Typical conditions for the alkylation include reaction with the suitable base in a polar aprotic solvent such as acetonitrile, dimethylformamide, dimethylacetamide or dimethyl sulfoxide at temperatures ranging from 20° C. to 150° C. Typical R₃₀₄substituents are selected from but are not limited to alkyl, substituted benzyl, heteroaromatic, substituted heteroalkyl and substituted heteroarylalkyl groups.

Compounds containing acyl, sulfonyl or ureidyl groups at the nitrogen atom can be prepared as shown in Scheme C-10. Treatment of the pyrazole Cviii with a suitable acylating agent in the presence of a base such as N-methylmorpholine, triethylamine, diisopropylethylamine or dimethylamino pyridine in an organic solvent such as dichloromethane, dichloroethane or dimethylformamide at temperatures ranging from 20° C. to 120° C. affords the desired acylated pyrazoles (Cxi). Suitable acylating agents include acid halides, activated esters of acids such as the N-hydroxysuccinimde esters, p-nitrophenyl esters, pentafluorophenyl esters, sulfonyl halides, isocyanates, and isothiocyanates.
embedded image

A general synthesis of 2-substituted pyrimidinylpyrazole compounds of type Cxv is shown in Scheme C-11.

Step A:

4-Methyl-2-methylmercaptopyrimidine is treated with a base selected from but not limited to n-BuLi, LDA, LiHMDS, t-BuOK, NaH in an organic solvent such as THF, ether, t-BuOH, dioxane from −78° C. to 50° C. for a period of time from 30 minutes to 5 hours. The resulting 4-methyl anion is then added to a solution of an appropriate ester B86. The reaction is allowed to stir from 30 minutes to 48 hours during which time the temperature may range from 0° C. to 100° C. The reaction mixture is then poured into water and extracted with an organic solvent. After drying and removal of solvent the desired monoketone B89 is isolated as a crude solid which can be recrystallized or purified by chromatography.

Step B:

Monoketone B89 is treated with a base selected from but not limited to n-BuLi, LDA, LiHMDS, t-BuOK, NaH, K₂CO₃or Cs₂Co₃in an organic solvent such as THF, ether, t-BuOH, dioxane, toluene or DMF from −78° C. to 50° C. for a period of time from 30 minutes to 5 hours. A solution of an appropriately activated ester of a carboxylic acid CbzNR^H—(CH₂)_nCR^F(R^G)—COOH or BocNR^H—(CH₂)_nCR^F(R^G)—COOH, preferably but not limited to the N-hydroxysuccinimide ester B90 is then added to the monoketone anion while maintaining the temperature between 0° C. to 100° C. The reaction is allowed to stir at the specified temperature for a period of time ranging from 30 minutes to 48 hours. The resulting pyrimidine diketone intermediate B91 is utilized without further purification in Step C.

Step C:

The solution or suspension containing the diketone intermediate B91 is quenched with water and the pH adjusted to between 4 and 8 using an acid chosen from AcOH, H₂SO₄, HCl or HNO₃while maintaining the temperature between 0° C. to 40° C. Hydrazine or hydrazine monohydrate is then added to the mixture while maintaining the temperature between 0° C. to 40° C. The mixture is stirred for a period of 30 minutes to 16 hours maintaining the temperature between 20° C. to 50° C., poured into water and extracted with an organic solvent. The pyrimidinyl pyrazole CxiiBoc or CxiiCbz is obtained as crude solid which is purified by chromatography or crystallization.

Step D:

The 2-methylmercapto group in the pyrimidinyl pyrazole (CxiiBoc or CxiiCbz) is oxidized to the 2-methylsulfone (where n=2) or the 2-methylsulfoxide (where n=1) using either Oxone or m-chloroperbenzoic acid as an oxidizing agent in a suitable solvent at temperatures ranging from 25° C. to 100° C. Solvents of choice for the oxidation include dichloromethane, acetonitrile, tetrahydrofuran or hydroalcoholic mixtures. The 2-methylsulfone (n =2) or the 2-methylsulfoxide (n=1) (CxiiiBoc or CxiiiCbz) is purified by crystallization or chromatography.

Step E:

The 2-methylsulfone/2-methylsulfoxide group in CxiiiBoc or CxiiiCBz is conveniently displaced with various amines or alkoxides at temperatures ranging from 20° C. to 200° C. in solvents that include but are not limited to dimethylformamide, acetonitrile, tetrahydrofuran and dioxane. The alkoxides can be generated from their alcohols by treatment with a base selected from but not limited to sodium hydride, lithium hexamethyldisilazide, potassium tertiary-butoxide in solvents such as tetrahydrofuran, dimethylformamide and dioxane at temperatures ranging from 0° C. to 100° C. The resulting 2-amino or 2-oxo derivatives (CxivBOC or CxivCbz) are purified by either chromatography or crystallization.

Step F:

The carbamate protecting groups from CxivBoc or CxivCbz are removed to afford the desired compounds Cxv containing either a free primary amine (R^His hydrogen) or a free secondary amine (R^His not equal to hydrogen). The Boc protecting groups are cleaved utilizing either trifluoroacetic acid in methylene chloride or hydrochloric acid in dioxane at room temperature for several hours. The Cbz protecting groups are cleaved using hydrogen gas at atmospheric or higher pressures and a catalyst (palladium on charcoal) in an alcoholic solvent. The resulting amines Cxv are then crystallized or purified by chromatography.
embedded image

The following examples contain detailed descriptions of the methods of preparation of compounds that form part of the invention. These descriptions are presented for illustrative purposes only and are not intended as a restriction on the scope of the invention. All compounds showed NMR spectra consistant with their assigned structures.

EXAMPLE C-74
5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole

embedded image

By following the method of Example C-1 and substituting methyl-4-chlorobenzoate for ethyl-4-fluorobenzoate and N-t-butoxycarbonyl-isonipecotyl N-hydroxysuccinimide for N-benyloxycarbonyl-glycinyl N-hydroxysuccinimide the title compound was prepared as the N-t-butoxycarbonyl protected compound. The deprotection of the N-t-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound as the hydrochloride salt: ¹HNMR (d₆-DMSO) δ 8.57 (d, J=4.83 Hz, 2H), 7.41 (d, J=8.26 Hz, 2H), 7.29 (d, J=8.26 Hz, 2H), 7.20 (d, J=4.63 Hz, 2H), 3.18 (bd, J=12.08 Hz, 2H), 2.88 (m, 1H), 2.76 (m, 2H), 1.82 (bs, 4H). MS (M+H): 339 (base peak).

EXAMPLE C-75
5-(N-methyl-4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole

embedded image

To a solution of 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) (25 g, 61 mmol) in 140 mL of formic acid (96%) was added 50 g of formaldehyde (37%). The solution was stirred at 75° C. for 48 h and was cooled to room temperature. The excess formic acid was removed under reduced pressure and the residue was dissolved in 100 mL of water. The solution was added to concentrated NH₆OH/H₂O and the mixture was extracted with ethyl acetate (3×200 mL). The combined organic layers were washed with brine (1×250 mL) and was dried over Na₂SO₄. The solution was filtered and concentrated to leave a white solid. The solid was triturated with ether and was filtered to afford the title compound: MS (M+H): 353 (base peak).

EXAMPLE C-76
5-(N-acetyl-4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole

embedded image

To a stirred suspension of 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) (1 g, 2.4 mmol) in 24 mL of CH₂Cl₂was added 4-dimethylamino pyridine (0.88 g, 7.2 mmol) and acetyl chloride (0.21 g, 2.6 mmol). The solution was stirred for 3 h and the solvent was removed under reduced pressure. The residue was treated with saturated NH₄OH (20 mL) and the suspension was extracted with ethyl acetate (3×30 mL). The combined extracts were washed with brine (1×50 mL), dried over MgSO₄, filtered and concentrated to leave a solid. The solid was triturated with ether and was filtered to leave the title compound: MS (M+H): 381 (base peak).

EXAMPLE C-77
5-(N-methoxyacetyl-4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole

embedded image

By following the method of Example C-76 and substituting methoxy acetyl chloride for acetyl chloride the title compound was prepared: ¹HNMR (DMSO-d₆) δ 8.75 (d, J=6.72 Hz, 2H), 7.70 (d, J=6.72 Hz, 2H), 7.38 (d, J=8.60 Hz, 2H), 7.29 (dd, J=6.72, 1.88 Hz, 2H), 4.40 (d, J=11.8 Hz, 1H), 4.05 (m, 2H), 3.70 (d, J=12.70 Hz, 1H), 3.25 (s, 3H), 3.0 (m, 2H), 2.55 (m, 1H), 1.7 (m, 4H). MS (M+H): 411 (base peak).

EXAMPLE C-78
5-(N-methylsulfonyl-4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole

embedded image

By following the method of Example C-76 and substituting methylsulfonyl chloride (2.0 equivalents) for acetyl chloride the title compound was prepared: ¹HNMR (DMSO-d₆) δ 8.70 (d, J=6.72 Hz, 2H), 7.72 (d, J=6.72 Hz, 2H), 7.38 (d, J=7.66 Hz, 2H), 7.30 (dd, J=6.72, 1.88 Hz, 2H), 3.58 (bd, J=11.8 Hz, 2H), 2.87 (m, 1H), 2.82 (s, 3H), 2.72 (m, 2H), 1.85 (m, 4H). MS (M+H): 417 (base peak).

EXAMPLE C-79
5-[N-methoxyethyl-4-piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole

embedded image

To a stirred suspension of 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) (500 mg, 1.2 mmol) in 12 mL of DMF was added Hunig's base (790 mg, 6.1 mmol) and 2-bromoethyl methyl ether (850 mg, 6.1 mmol). The solution was stirred at room temperature for 5 days. The solution was poured onto 2.5 N NaOH and was extracted with ethyl acetate (3×100 mL). The combined extracts were washed with water (3×100 mL) and brine (1×100 mL). The organic phase was dried over Na₂SO₄and was filtered. The solvent was removed under reduced pressure to leave a solid. The solid was triturated and filtered to leave the title compound: ¹HNMR (CDCl₃) δ 8.63 (d, J=4.23 Hz, 2H), 7.28 (m, 4H), 7.14 (d, J=4.43 Hz, 2H), 3.57 (t, J=5.24 Hz, 2H), 3.38 (s, 3H), 3.14 (bd, J=10.1 Hz, 2H), 2.79 (m, 1H), 2.68 (t, J=5.04, 2H), 2.08 (m, 4H), 1.92 (m, 2H). MS (M+H): 397 (base peak).

EXAMPLE C-80
5-(N-allyl-4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole

embedded image

By following the method of example C-79 and substituting allyl bromide for 2-bromoethyl methyl ether the title compound was prepared: MS (M+H): 379 (base peak)

EXAMPLE C-81
5-(N-propargyl-4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole

embedded image

By following the method of example C-79 and substituting propargyl bromide for 2-bromoethyl methyl ether the title compound was prepared: MS (M+H): 377 (base peak)

EXAMPLE C-82

embedded image

5-[N-(2-methylthiazolyl)-4-piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole

To a suspension of 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) in 12 mL of MeOH was added trimethyl orthoformate (2.6 g, 24.4 mmol) and 27thiazolecarboxaldehyde (1.4 g, 12.2 mmol). The suspension was stirred at room temperature for 2 h. To this mixture was added NaCNBH, (1.5 g, 24.4 mmol) and the resulting suspension was stirred at room temperature for 7 days. The mixture was poured onto 2.5 N NaOH and was extracted with ethyl acetate (2×100 mL). The combined extracts were washed with brine (1×100 mL), dried over Na₂SO₄, filtered and concentrated to leave a solid. This solid was triturated with ether and filtered to afford the title compound: MS (M+H): 436 (base peak).

EXAMPLE C-83
5-(4-piperidyl)-4-(4-pyridyl)-3-[4-(trifluoromethyl)phenyl] pyrazole

embedded image

By following the method of Example C-1 and substituting methyl-4-(trifluoromethyl)benzoate for ethyl-4-fluorobenzoate and N-t-butoxycarbonyl-isonipecotyl N-hydroxysuccinimide for N-benyloxycarbonyl-glycinyl N-hydroxysuccinimide the title compound was prepared as the N-t-butoxycarbonyl protected compound. The deprotection of the N-t-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound as its hydrochloride salt: MS (M+H):. 373 (base peak).

EXAMPLE C-84
5-(N-methyl-4-piperidyl)-4-(4-pyridyl)-3-[4-(trifluoromethyl) phenyl] pyrazole

embedded image

By following the method of Example C-75 and substituting 5-(4-piperidyl)-4-(4-pyridyl)-3-[4-(trifluoromethyl)phenyl] pyrazole hydrochloride (Example C-83) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 387 (base peak)

EXAMPLE C-85
5-[N-(2-propyl)-4-piperidyl]-4-(4-pyridyl)-3-[4-(trifluoromethyl)phenyl] pyrazole

embedded image

To a solution of 5-(4-piperidyl)-4-(4-pyridyl)-3-[4-(trifluoromethyl)phenyl] pyrazole (Example C-83) (300 mg, 0.7 mmol) in 50 mL of acetone was added 1 mL of ACOH and NaBH(OAc)₃(15 g, 70.8 mmol). The mixture was warmed to reflux and was stirred for 5 days. The reaction mixture was poured onto 100 mL of 2.5 N NaOH and was extracted with ethyl acetate (2×100 mL). The extracts were combined and washed with brine (1×100 mL). The organic phase was dried over Na₂SO₄, filtered, and concentrated to afford the title compound: MS (M+H): 415 (base peak).

EXAMPLE C-86
5-(4-piperidyl)-4-(4-pyridyl)-3-[3-(trifluoromethyl) phenyl] pyrazole

embedded image

By following the method of Example C-1 and substituting methyl-3-(trifluoromethyl)benzoate for ethyl-4-fluorobenzoate and N-t-butoxycarbonyl-isonipecotyl N-hydroxysuccinimide for N-benyloxycarbonyl-glycinyl N-hydroxysuccinimide the title compound was prepared as the N-t-butoxycarbonyl protected compound. The deprotection of the N-t-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound as its hydrochloride salt: MS (M+H): 373 (base peak).the pyrazole C-3 substituent (Cviii). Treatment of the

EXAMPLE C-87
5-(N-methyl-4-piperidyl)-4-(4-pyridyl)-3-[3-(trifluoromethyl) phenyl] pyrazole

embedded image

By following the method of Example C-75 and substituting 5-(4-piperidyl)-4-(4-pyridyl)-3-[3-(trifluoromethyl)phenyl] pyrazole hydrochloride (Example C-86) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 387 (base peak).

EXAMPLE C-88
5-(4-piperidyl)-4-(4-pyridyl)-3-(3-chlorophenyl) pyrazole

embedded image

By following the method of Example C-1 and substituting methyl-3-chlorobenzoate for ethyl-4-fluorobenzoate and N-t-butoxycarbonyl-isonipecotyl N-hydroxysuccinimide for N-benyloxycarbonyl-glycinyl N-hydroxysuccinimide the title compound was prepared as the N-t-butoxycarbonyl protected compound. The deprotection of the N-t-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound: MS (M+H): 339 (base peak).

EXAMPLE C-89
5-(N-methyl-4-piperdyl)-4-(4-pyridyl)-3-(3-chlorophenyl) pyrazole

embedded image

By following the method of Example C-75 and substituting 5-(4-piperidyl)-4-(4-pyridyl)-3-(3-chlorophenyl) pyrazole hydrochloride (Example C-88) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 353 (base peak).

EXAMPLE C-90
5-(3-piperidyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole

embedded image

By following the method of Example C-1 and substituting N-t-butoxycarbonyl-nipecotyl N-hydroxysuccinimide for N-benyloxycarbonyl-glycinyl N-hydroxysuccinimide the title compound was prepared as the N-t-butoxycarbonyl protected compound. The deprotection of the N-t-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound as its hydrochloride salt: MS (M+H): 323 (base peak).

EXAMPLE C-91
5-(N-methyl-3-piperidyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole

embedded image

By following the method of Example C-75 and substituting 5-(3-piperidyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole hydrochloride (Example C-90) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 337 (base peak).

EXAMPLE C-92
5-cis-(4-aminocyclohexyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole

embedded image

By following the method of Example C-1 and substituting methyl-4-chlorobenzoate for ethyl-4-fluorobenzoate and N-c-butoxycarbonyl-cis-4-aminocyclohexanoyl N-hydroxysuccinimide for N-benyloxycarbonyl-glycinyl N-hydroxysuccinimide the title compound was prepared as the N-t-butoxycarbonyl protected compound. The deprotection of the N-t-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound: ¹HNMR (d₆-DMSO) δ 8.56 (d, J=6.04 Hz, 2H), 7.39 (d, J=8.66 Hz, 2H), 7.31 (d, J=8.46 Hz, 2H), 7.17 (d, J=5.84 Hz, 2H), 3.05 (m, 1H), 2.62 (m, 1H), 1.99 (m, 2H), 1.53 (m, 6H). MS (M+H): 353 (base peak).

EXAMPLE C-93
5-cis-(4-N, N-dimetylaminocyclohexyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole

embedded image

By following the method of Example C-75 and substituting 5-cis-(4-aminocyclohexyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole (Example C-92) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 381 (base peak).

EXAMPLE C-94
5-[cis-4-N-(2-propyl)aminocyclohexyl]-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole

embedded image

To a slurry of 5-cis-(4-aminocyclohexyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole (Example C-92) (1.0 g, 2.8 mmol, 1.0 eq) in methylene chloride (28 mL) was added acetone (0.5 mL), acetic acid (0.5 mL) and solid sodium triacetoxyborohydride. The slurry was stirred for 5 h and the volatiles were removed. The residue was partitioned between 2.5 M NaOH (25 mL) and ethyl acetate (25 mL) and the aqueous layer was extracted with ethyl acetate (3×25 mL). The combined organic layer was washed with brine (50 mL), dried over MgSO₄and evaporated. The residue was triturated with ether to yield the title compound as a white powder: ¹HNMR (d₆-DMSO) δ 8.56 (d, J=5.84 Hz, 2H), 7.40 (d, J=8.26 Hz, 2H), 7.30 (d, J=8.66 Hz, 2H), 7.18 (d, J=5.64 Hz, 2H), 2.95 (m, 2H), 2.72 (m, 1H), 1.90 (m, 2H), 1.73 (m, 2H), 1.55 (m, 4H), 1.07 (d, J=5.64 Hz, 6H). MS (M+H): 395 (base peak).

EXAMPLE C-95
5-cis-[4-N-(acetyl)aminocyclohexyl]-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole

embedded image

By following the method of Example C-76 and substituting 5-cis-(4-aminocyclohexyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole (Example C-92) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 395 (base peak).

EXAMPLE C-96
5-cis-[4-N-(methoxyacetyl)aminocyclohexyl]-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole

embedded image

By following the method of Example C-76 and substituting 5-cis-(4-aminocyclohexyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole (Example C-92) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) and methoxy acetyl chloride for acetyl chloride the title compound was prepared: MS (M+H): 425 (base peak).

EXAMPLE C-97
5-cis-[4-N-(methylsulfonyl)aminocyclohexyl]-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole

embedded image

By following the method of Example C-76 and substituting 5-cis-(4-aminocyclohexyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole (Example C-92) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) and methylsulfonyl chloride for acetyl chloride the title compound was prepared: MS (M+H): 431 (base peak).

EXAMPLE C-98
5-cis-(4-aminocyclohexyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole

embedded image

By following the method of Example C-1 and substituting N-t-butoxycarbonyl-cis-4-aminocyclohexanoyl N-hydroxysuccinimide for N-benyloxycarbonyl-glycinyl N-hydroxysuccinimide the title compound was prepared as the N-t-butoxycarbonyl protected compound. The deprotection of the N-t-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound: MS (M+H): 337 (base peak).

EXAMPLE C-99
5-(cis-4-N,N-dimethylaminocyclohexyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole

embedded image

By following the method of Example C-75 and substituting 5-cis-(4-aminocyclohexyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole (Example C-98) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 365 (base peak).

EXAMPLE C-100
5-cis-[4-N-(2-propyl)aminocyclohexyl]-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole

embedded image

By following the method of Example C-94 and substituting cis-5-(4-aminocyclohexyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole (Example C-98) for 5-(cis-4-n-(2-propyl)aminocyclohexyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole (Example C-92) the title compound was prepared: MS (M+H): 379 (base peak).

EXAMPLE C-101
5-cis-(4-aminocyclohexyl)-4-(4-pyridyl)-3-[4-(trifluoromethyl)phenyl] pyrazole

embedded image

By following the method of Example C-1 and substituting methyl-4-(trifluoromethyl)benzoate for ethyl-4-fluorobenzoate and N-t-butoxycarbonyl-cis-4-aminocyclohexanoyl N-hydroxysuccinimide for N-benyloxycarbonyl-glycinyl N-hydroxysuccinimide the title compound was prepared as the N-t-butoxycarbonyl protected compound. The deprotection of the N-t-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound: MS (M+H): 387 (base peak).

EXAMPLE C-102
5-cis-(4-N,N-dimethylaminocyclohexyl)-4-(4-pyridyl)-3-[4-(trifluoromethyl)phenyl] pyrazole

embedded image

By following the method of Example C-75 and substituting 5-cis-(4-aminocyclohexyl)-4-(4-pyridyl)-3-[4-(trifluoromethyl)phenyl] pyrazole (Example C-101) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 415 (base peak).

EXAMPLE C-103
5-cis-(4-aminocyclohexyl)-4-(4-pyridyl)-3-[3-(trifluoromethyl)phenyl] pyrazole

embedded image

By following the method of Example C-1 and substituting methyl-3-(trifluoromethyl)benzoate for ethyl-4-fluorobenzoate and N-t-butoxycarbonyl-cis-4-aminocyclohexanoyl N-hydroxysuccinimide for N-benyloxycarbonyl-glycinyl N-hydroxysuccinimide the title compound was prepared as the N-t-butoxycarbonyl protected compound. The deprotection of the N-t-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound: MS (M+H): 387 (base peak).

EXAMPLE C-104
5-cis-(4-N,N-dimethylaminocyclohexyl)-4-(4-pyridyl)-3-[3-(trifluoromethyl)phenyl] pyrazole

embedded image

By following the method of Example C-75 and substituting 5-cis-(4-aminocyclohexyl)-4-(4-pyridyl)-3-(3-(trifluoromethyl)phenyl) pyrazole (Example C-103) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 415 (base peak).

EXAMPLE C-105
5-cis-(4-aminocyclohexyl)-4-(4-pyridyl)-3-(3-chlorophenyl) pyrazole

embedded image

By following the method of Example C-1 and substituting methyl-3-chlorobenzoate for ethyl-4-fluorobenzoate and N-t-butoxycarbonyl-cis-4-aminocyclohexanoyl N-hydroxysuccinimide for N-benyloxycarbonyl-glycinyl N-hydroxysuccinimide the title compound was prepared as the N-t-butoxycarbonyl protected compound. The deprotection of the N-t-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound: MS (M+H): 353 (base peak).

EXAMPLE C-106
5-cis-(4-N,N-dimethylaminocyclohexyl)-4-(4-pyridyl)-3-(3-chlorophenyl) pyrazole

embedded image

By following the method of Example C-75 and substituting 5-cis-(4-aminocyclohexyl)-4-(4-pyridyl)-3-(3-chlorophenyl) pyrazole hydrochloride (Example C-105) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 381 (base peak).

EXAMPLE C-107
5-(N-acetimido-4-piperidyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole

embedded image

To a suspension of 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole (Example C-2) (0.11 g, 0.35 mmol) in 2 mL EtOH was added ethyl acetamidate hydrochloride (0.065 g, 0.53 mmol) and the mixture was refluxed for 30 minutes. The solution was left at 5-10° C. for 16 h and filtered to obtain the title compound as a white solid: MS (M+H): 364 (base peak).

EXAMPLE C-108
5-(N-carboxamidino-4-piperidyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole

embedded image

To a stirred suspension of 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole (C-2) (1.5 g, 4.7 mmol) in 47 mL of DMF was added Hunig's base (0.60 g, 4.7 mmol) and pyrazole carboxamide hydrochloride (0.68 g, 4.7 mmol). The slurry was allowed to stir at room temperature for 4 days. The reaction mixture was poured onto 300 mL of ether. The resulting precipitate was filtered to leave the title compound as the hydrochloride salt: MS (M+H): 365 (base peak).

EXAMPLE C-109
5-(N-cyclopropanoyl-4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole

embedded image

By following the method of Example C-76 and substituting cyclopropanoyl chloride for acetyl chloride the title compound was prepared: MS (M+H): 407 (base peak).

EXAMPLE C-110
5-[N-(2-fluoro)benzoyl-4-piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole

embedded image

By following the method of Example C-76 and substituting 2-fluorobenzoyl chloride for acetyl chloride the title compound was prepared: MS (M+H) 461 (base peak).

EXAMPLE C-111
5-(N-methylsulfonyl-4-piperidyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole

embedded image

By following the method of Example C-76 and substituting 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole (Example C-2) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole (Example C-74) and methylsulfonyl chloride for acetyl chloride the title compound was prepared: MS (M+H): 401 (base peak).

EXAMPLE C-112
5-(N-methoxyacetyl-4-piperidyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole

embedded image

By following the method of Example C-76 and substituting 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole (Example C-2) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole (Example C-74) and methoxy acetyl chloride for acetyl chloride the title compound was prepared: MS (M+H): 395 (base peak).

EXAMPLE C-113
5-((N-acetyl-4-piperidyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole

embedded image

By following the method of Example C-76 and substituting 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole Example (C-2) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole Example (C-74) the title compound was prepared: MS (M+H): 365 (base peak).

EXAMPLE C-114
5-[2-(1,1-dimethyl)aminoethyl]-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole

embedded image

By following the method of Example C-1 and substituting N-t-butoxycarbonyl-2-amino-2,2-dimethylpropanoyl N-hydroxysuccinimide for N-benyloxycarbonyl-glycinyl N-hydroxysuccinimide the title compound was prepared as the N-t-butoxycarbonyl protected compound. The deprotection of the N-t-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound as the hydrochloride salt: MS (M+H): 327 (base peak).

EXAMPLE C-115
5-(methoxymethyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole

embedded image

By following the method of Example C-1 and substituting methyl-4-chlorobenzoate for ethyl-4-fluorobenzoate and 2-methoxyacetyl N-hydroxysuccinimide for N-benyloxycarbonyl-glycinyl N-hydroxysuccinimide the title compound was prepared: MS (M+H): 300 (base peak).

EXAMPLE C-116
5-(4-aminobenzyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole

embedded image

By following the method of Example C-1 and substituting methyl-4-chlorobenzoate for ethyl-4-fluorobenzoate and N-t-butoxycarbonyl-4-aminophenyl acetyl N-hydroxysuccinimide for N-benyloxycarbonyl-glycinyl N-hydroxysuccinimide the title compound was prepared as the N-t-butoxycarbonyl protected compound. The deprotection of the N-t-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound as the hydrochloride salt: MS (M+H): 361 (base peak).

EXAMPLE C-117
5-[4-(N, N-dimethyl)aminobenzyl]-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole

embedded image

By following the method of Example C-75 and substituting 5-(4-aminobenzyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole (Example C-116) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 389 (base peak).

EXAMPLE C-118
5-[4-(N-acetyl)aminobenzyl]-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole

embedded image

By following the method of Example C-76 and substituting 5-(4-aminobenzyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole (Example C-116) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 403 (base peak).

EXAMPLE C-119
5-(N-methylaminomethyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole

embedded image

5-(N-formylaminomethyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole. To a suspension of 5-aminomethyl-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole (Example C-1) (8.04 g, 30 mmol) in 120 mL dichloromethane was added p-nitrophenylformate (6.01 g, 36 mmol) as a solid. The suspension was stirred for 24 h at room temperature and the solvents removed under reduced pressure. The residue was triturated with ether and filtered to obtain the desired 5-(N-formylaminomethyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole derivative as a white solid: MS (M+H): 297 (base peak).

5-(N-methylaminomethyl)-6-(4-pyridyl)-3-(4-fluorophenyl) pyrazole. To a suspension of 5-(N-formylaminomethyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole (8.74 g, 29.5 mmol) in 90 mL anhydrous tetrahydrofuran was added a 1.0 M solution of borane in tetrahydrofuran (90 mL, 90 mmol) and the mixture was stirred at room temperature for 24 h. 1 N aqueous hydrochloric acid (100 mL) was then added to this mixture and the solution was refluxed for 5 hours and cooled to room temperature. The solution was extracted with ether (2×250 mL) and the pH of the aqueous layer adjusted to 9 by addition of concentrated ammonium hydroxide. The aqueous layers (pH ˜9) were then extracted with ethyl acetate (4×150 mL). The organic extracts were dried over sodium sulfate, filtered and evaporated to dryness under reduced pressure. The residue was triturated with acetonitrile and filtered to obtain the title compound as a white solid: MS (M+H): 283 (base peak).

EXAMPLE C-120
5-[N-(2-amino-2,2-dimethylacetyl)aminomethyl]-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole

embedded image

5-(N-t-butoxycarbonylaminomethyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole. To a solution of 5-aminomethyl-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole (Example C-1) (0.27 g, 1 mmol) in anhydrous dimethylformamide (4 mL) was added N-tert-butoxycarbonyl aminoisobutyric acid N-hydroxysuccinimide ester (0.33 g, 1.1 mmol) and the mixture stirred at 40° C. for 24 h. The resulting solution was evaporated to dryness under reduced pressure. The residue was dissolved in dichloromethane (30 mL) and washed with a saturated solution of sodium bicarbonate (2×20 mL) and brine (20 mL). The organic layers were dried over sodium sulfate, filtered and evaporated under reduced pressure to dryness to afford 5-(N-t-butoxycarbonylaminomethyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole as a white solid.

5-(N-(2-amino-2,2-dimethylacetyl)aminomethyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole. To a solution of the above compound in acetonitrile (2 mL) was added 1 mL of a 4.0 M solution of hydrochloric acid in dioxane. The reaction mixture was stirred at room temperature for 6 hours. The suspension was evaporated to dryness under reduced pressure. The resulting residue was stirred in acetonitrile (5 mL), filtered and dried in a vacuum dessicator to afford the title compound as a hydrochloride salt: MS (M+H): 354 (base peak).

EXAMPLE C-121
5-[N-(2-amino-2,2-dimethylacetyl)aminomethyl]-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole

embedded image

By following the method of Example C-120 and substituting 5-aminomethyl-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole (Example C-15) for 5-aminomethyl-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole (Example C-1) the title compound was prepared: MS (M+H): 370 (base peak).

EXAMPLE C-122
5-[4-N-(2-dimethylaminoacetyl)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole

embedded image

To a solution of N,N-dimethylglycine hydrochloride (0.28 g, 2 mmol) in dimethylformamide (4 mL) was added hydroxybenzotriazole (0.27 g, 2 mmol), N,N-diisopropylethyl amine (0.7 mL, 4 mmol) and polymer supported ethyl carbodimide (Example B-49) (1 g, 2.39 mmol). To this solution after 30 minutes at room temperature was added 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74), 0.41 g, 1 mmol). The suspension was agitated on a labtop orbital shaker for 24 h. The suspension was filtered, washed with dimethylformamide (2×5 mL) and the filtrates evaporated under high pressure. The residue was dissolved in dichloromethane (30 mL), washed with a saturated solution of sodium bicarbonate (50 mL) and brine (50 mL). The organic layers were dried over sodium sulfate, filtered and evaporated under high vacuum to afford the title compound as a white solid: MS (M+H): 424 (base peak).

EXAMPLE C-123
(S)-5-(2-pyrolidinyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole

embedded image

By following the method of Example C-1 and substituting (S)-N-t-butoxycarbonyl-prolinyl N-hydroxysuccinimide for N-benyloxycarbonyl-glycinyl N-hydroxysuccinimide the title compound was prepared as the N-t-butoxycarbonyl protected compound. The deprotection of the N-t-butoxycarbonyl intermediate was accomplished with 4, N HCl in dioxane to afford the title compound: MS (M+H): 309 (base peak).

EXAMPLE C-124
(S)-5-(N-methyl-2-pyrolidinyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole

embedded image

By following the method of Example C-75 and substituting (S)-5-(2-pyrolidinyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole (Example C-123) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 323 (base peak).

EXAMPLE C-125
(R)-5-(2-pyrolidinyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole

embedded image

By following the method of Example C-1 and substituting (R)-N-t-butoxycarbonyl-prolinyl N-hydroxysuccinimide for N-benyloxycarbonyl-glycinyl N-hydroxysuccinimide the title compound was prepared as the N-t-butoxycarbonyl protected compound. The deprotection of the N-t-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound: MS (M+H): 309 (base peak).

EXAMPLE C-126
(R)-5-(N-methyl-2-pyrolidinyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole

embedded image

By following the method of Example C-75 and substituting (R)-5-(2-pyrolidinyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole (Example C-125) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 323 (base peak).

EXAMPLE C-127
(R)-5-(3-piperidyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole

embedded image

By following the method of Example C-1 and substituting (R)-N- t-butoxycarbonyl-nipecotyl N-hydroxysuccinimide for N-benyloxycarbonyl-glycinyl N-hydroxysuccinimide the title compound was prepared as the N-t-butoxycarbonyl protected compound. The deprotection of the N-t-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound: MS (M+H): 323 (base peak).

EXAMPLE C-128
(R)-5-(N-methyl-3-piperidyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole

embedded image

By following the method of Example C-75 and substituting (R)-5-(3-piperidyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole (Example C-125) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 337 (base peak).

EXAMPLE C-129
2,2-dimethyl-4-[4-(4-pyridyl)-3-(4-chlorophenyl) pyrazolyl] butyric acid

embedded image

By following the method of Example C-1 and substituting methyl-4-chlorobenzoate for ethyl-4-fluorobenzoate and 2,2-dimethyl glutaric anhydride for N-benyloxycarbonyl-glycinyl N-hydroxysuccinimide the title compound was prepared: MS (M+H): 370 (base peak).

EXAMPLE C-130
4-[4-(4-pyridyl)-3-(4-fluorophenyl) pyrazolyl] butyric acid

embedded image

By following the method of Example C-1 and substituting glutaric anhydride for N-benzyloxycarbonyl-glycinyl N-hydroxysuccinimide the title compound was prepared: MS (M+H): 326 (base peak).

EXAMPLE C-131
4-[4-(4-pyridyl)-3-(4-fluorophenyl) pyrazolyl] butyramide

embedded image

Methyl 4-(4-(4-pyridyl)-3-(4-fluorophenyl) pyrazolyl) butyrate. To a solution of 4-(4-(4-pyridyl)-3-(4-fluorophenyl) pyrazolyl) butyric acid (Example C-130) (40 g 123 mmol) in 650 mL of MeOH was added 20 mL of concentrated H₂SO₄. The solution was stirred overnight at room temperature. The solution was concentrated and diluted with 200 mL of water. The solution was cooled with an ice/water bath and to the solution was added 150 mL of saturated NaHCO₃. The solution was neutralized further with 50% NaOH to pH 7. The resulting slurry was extracted with CH₂Cl₂(3×250 mL). The combined extracts were washed with water (1×300 mL) and saturated NaHCO₃(1×500 mL). The organic phase was dried over Na₂SO₄, filtered and concentrated to afford methyl 4-(4-(4-pyridyl)-3-(4-fluorophenyl) pyrazolyl) butyrate: MS (M+H): 340 (base peak).

4-(4-(4-pyridyl)-3-(4-fluorophenyl) pyrazolyl) butyramide. A solution of methyl 4-(4-(4-pyridyl)-3-(4-fluorophenyl) pyrazolyl) butyrate (39 g, 120 mmol) in 600 mL of MeOH was saturated with NH₃. The solution was periodically treated with additional NH₃over a 24 h period. The solution was degassed with a stream of nitrogen and the solution was concentrated to leave a yellow solid. The solid was slurried in ether and filtered to leave the title compound: MS (M+H): 325 (base peak).

EXAMPLE C-132
5-[4-(1-hydroxy)butyl]-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole

embedded image

A stirred suspension of 4-(4-(4-pyridyl)-3-(4-fluorophenyl) pyrazolyl) butyric acid (Example C-130) (2 g, 6.15 mmol) in 100 ml of anhydrous ether was cooled to 0° C. under nitrogen. Lithium aluminum hydride (467 mg, 12.3 mmol) was added to this suspension slowly. After the addition was complete, the mixture was warmed to room temperature and stirred for additional 2 h. The reaction was quenched slowly with 1N KHSO₄(80 ml). The mixture was transferred to a separatory funnel and the aqueous layer was removed. The aqueous layer was then made basic with K₂CO₃(pH 8). The aqueous solution was extracted with ethyl acetate (2×100 mL). The combined ethyl acetate extracts were washed with water (1×100 mL), dried over MgSO₄, filtered and concentrated to give the title compound: MS (M+H): 312 (base peak).

EXAMPLE C-133
5-[4-(1,1-dimethyl-1-hydroxy)butyl]-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole

embedded image

A solution of 4-(4-(4-pyridyl)-3-(4-fluorophenyl) pyrazolyl) butyric acid (Example C-130) (200 mg, 0.615 mmol) in 50 ml of MeOH was treated with 10 ml of 4 N HCl/dioxane. The reaction mixture was stirred for 5 hours and evaporated to dryness. To this residue was added 15 ml of 1N methyl magnesium bromide in butyl ether and 5 ml of anhydrous THF. The reaction was heated to reflux under nitrogen for 64 h.

The reaction was quenched with 20 ml of saturated ammonium chloride. This mixture was transferred to a separatory funnel and was extracted with 100 ml ethyl acetate (2×100 mL). The combined ethyl acetate extracts were washed with water (1×100 mL), dried over MgSO₄, filtered and concentrated to afford a crude oil. The crude oil was subjected to column chromatography by using 3.5 % MeOH/CH₂Cl₂followed by 6 % MeOH/CH₂Cl₂to give the title compound: MS (M+H): 340 (base peak).

EXAMPLE C-134
5-(4-(1-amino)butyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole

embedded image

To a suspension of 4-(4-(4-pyridyl)-3-(4-fluorophenyl) pyrazolyl) butyramide (Example C-131) (2 g, 6.2 mmol) in 100 ml of anhydrous ether was added lithium aluminum hydride (467 mg, 12.3 mmol). After the addition was complete, the mixture was warmed to room temperature and stirred for additional 2 h. The reaction was quenched with 20 mL of ethyl acetate and was poured onto 100 mL of 2.5 N NaOH. The mixture was extracted with ethyl acetate (3×50 mL). The combined extracts were washed with brine (1×100 mL), dried over Na₂SO₄, filtered and concentrated to afford the title compound: MS (M+H): 311 (base peak).

EXAMPLE C-135
4(4-(4-pyridyl)-3-(4-fluorophenyl) pyrazolyl) propionic acid

embedded image

By following the method of Example C-1 and substituting succinic anhydride for N-benyloxycarbonyl-glycinyl N-hydroxysuccinimide the title compound was prepared: MS (M+H): 312 (base peak).

EXAMPLE C-136
5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl) pyrazole

embedded image

By following the method of Example C-1 and substituting methyl-4-chlorobenzoate for ethyl-4-fluorobenzoate, N-t-butoxycarbonyl-isonipecotyl N-hydroxysuccinimide for N-benyloxycarbonyl-glycinyl N-hydroxysuccinimide and 4-methylpyrimidine for 4-picoline the title compound was prepared as the N-t-butoxycarbonyl protected compound. The deprotection of the N-t-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound as the hydrochloride salt: ¹H NMR (CDCl₃) δ 9.2 (s, 1H), 8.48 (d, J=5.19 Hz, 1H), 7.31 (m, 4H), 6.94 (d, J=4.79 Hz, 1H), (3.69 (m, 3H), 3.12 (m, 2H), 2.3 (m, 3H), 1.24 (m, 2H). MS (M+H): 340 (base peak).

EXAMPLE C-137
5-(N-methyl-4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl) pyrazole

embedded image

By following the method of Example C-75 and substituting 5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl) pyrazole (Example C-136) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) the title compound was prepared: ¹H NMR (CDCl₃) δ 9.2 (d, J=1.2 Hz, 1H), 8.48 (d, J=5.59 Hz, 1H), 7.31 (m, 4H), 6.95 (dd, J=1.2, 5.6 Hz, 1H), 3.39 (m, 1H), 3.03 (d, J=11.6 Hz, 2H), 2.38 (s, 3H), 2.06 (m, 4H), 1.24 (m, 2H). MS (M+H): 354 (base peak).

EXAMPLE C-138
5-(M-acetyl-3-piperidyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole

embedded image

By following the method of Example C-76 and substituting 5-(3-piperidyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole (C-90) for S-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole (C-74) the title compound was prepared: MS (M+H): 365 (base peak).

EXAMPLE C-139
5-(N-methoxyacetyl-3-piperidyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole

embedded image

By following the method of Example C-76 and substituting 5-(3-piperidyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole (C-90) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole (C-74) and methoxy acetyl chloride for acetyl chloride the title compound was prepared: MS (M+H): 395 (base peak).

Additional compounds of the present invention which could be prepared using one or more of the reaction schemes set forth in this application include, but are not limited to, the following:

EXAMPLE C-140
5-(4-N-t-butoxycarbonylpiperidinyl)-4-[4-(2-thiomethyl)pyrimidinyl]-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-141
5-(4-piperidinyl)-4-[4-(2-thiomethyl)pyrimidinyl]-3-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-142
5-(4-N-methylpiperidinyl)-4-[4-(2-thiomethyl)pyrimidinyl]-3-4-(chloropbenyl) pyrazole

embedded image

EXAMPLE C-143
5-(4-N-t-butoxycarbonylpiperidinyl)-4-[4-(2-methanesulfonyl)pyrimidinyl]-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-144
5-(4-piperidinyl)-4-[4-(2-methanesulfonyl)pyrimidinyl]-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-145
5-(4-N-methylpiperidinyl)-4-[4-(2-methanesulfonyl)pyrimidinyl]-3-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-146
5-(4-N-t-butoxycarbonylpiperidinyl)-4-[4-(2-amino)pyrimidinyl]-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-147
5-(4-piperidinyl)-4-[4-(2-amino)pyrimidinyl]-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-148
5-(4-N-methylpiperidinyl)-4-[4-(2-amino)pyrimidinyl]-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-149
5-(4-N-t-butoxycarbonylpiperidinyl)-4-[4-(2-methylamino)pyrimidinyl]-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-150
5-(4-piperidinyl)-4-[4-(2-methylamino)pyrimidinyl]-3-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-151
5-(4-N-methylpiperidinyl)-4-[4-(2-methylamino)pyrimidinyl]-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-152
5-(4-N-t-butoxycarbonylpiperidinyl)-4-[4-(2-isopropylamino)pyrimidinyl]-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-153
5-(4-piperidinyl)-4-[4-(2-isopropylamino)pyrimidinyl]-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-154
5-(4-N-methylpiperidinyl)-4-[4-(2-isopropylamino)pyrimidinyl]-3-(4-chlorophenyl) pyrazole

embedded image

EXAMPLE C-155
5-(4-N-t-butoxycarbonylpiperidinyl)-4-[4-(2-(2-methoxyethylamino))pyrimidinyl]-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-156
5-(4-piperidinyl)-4-[4-(2-(2-methoxyethylamino))pyrimidinyl]-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-157
5-(4-N-methylpiperidinyl)-4-[4-(2-(2-methoxyethylamino))pyrimidinyl]-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-158
5-(4-N-t-butoxycarbonylpiperidinyl)-4-[4-(2-methoxy)pyrimidinyl]-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-159
5-(4-piperidinyl)-4-[4-(2-methoxy)pyrimidinyl]-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-160
5-(4-N-methylpiperidinyl)-4-[4-(2-methoxy)pyrimidinyl]-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-161
5-(4-N-t-butoxycarbonylpiperidinyl)-4-[4-(2-isopropoxy)pyrimidinyl]-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-162
5-(4-piperidinyl)-4-[4-(2-isopropoxy)pyrimidinyl]-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-163
5-(4-N-methylpiperidinyl)-4-[4-(2-isopropoxy)pyrimidinyl]-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-164
5-(4-N-t-butoxycarbonylpiperidinyl)-4-[4-(2-(2-N,N-dimethylamino)ethoxy)pyrimidinyl]-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-165
5-(4-piperidinyl)-4-[4-(2-(2-N,N-dimethylamino)ethoxy)pyrimidinyl]-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-166
5-(4-N-methylpiperidinyl)-4-[4-(2-(2-N,N-dimethylamino)ethoxy)pyrimidinyl]-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-167
5-(N-acetylhydroxylimido-4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-168
5-(N-benzylhydroxylimido-4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-169
5-(N-phenylacethydroxylimido-4-piperidyl)-4-(4-pyridyl) -3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-170
5-[N-methyl-4-(3,4-dehydro)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-171
5-[N-isopropyl-4-(3,4-dehydro)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-172
5-[N-benzyl-4-(3,4-dehydro)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-173
5-[N-methyl-4-(4-fluoro)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-174
5-[N-methyl-4-(4-hydroxy)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-175
5-[N-methyl-4-(4-methoxy)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-176
5-[N-methyl-4-(2,5-tetramethyl-4-fluoro)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-177
5-[N-methyl-4-(2,5-tetramethyl-4-hydroxy)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-178
5-[N-methyl-4-(2,5-tetramethyl-4-methoxy)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-179
5-[4-(3-fluoro)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-180
5-[4-(N-methyl-3-fluoro)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-181
5-[4-(N-isopropyl-3-fluoro)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-182
5-[4-(N-benzyl-3-fluoro)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-183
5-[4-(N-acetyl-3-fluoro)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-184
5-[4-(2-oxo)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-185
5-[4-(N-methyl-2-oxo)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-186
5-[4-(N-isopropyl-2-oxo)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-187
5-[4-(N-benzyl-2-oxo)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-188
5-[4-(N-acetyl-2-oxo)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-189
5-[5-(2-oxo)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-190
5-[5-(N-methyl-2-oxo)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-191
5-[5-(N-isopropyl-2-oxo)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-192
5-[5-(N-benzyl-2-oxo)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-193
5-[5-(N-acetyl-2-oxo)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-194
5-(N-acethydroxylimido-3-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-195
5-(N-benzhydroxylimido-3-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-196
5-(N-phenacethydroxylimido-3-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-197
5-(2-morpholinyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-198
5-(N-methyl-2-morpholinyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-199
5-(N-isopropyl-2-morpholinyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-200
5-(N-benzyl-2-morpholinyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-201
5-(N-acetyl-2-morpholinyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-202
5-[trans-4-(N-t-butoxycarbonylamino)methylcyclohexyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-203
5-(trans-4-aminomethylcyclohexyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-204
5-[trans-4-(N-isopropylamino)methylcyclohexyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-205
5-[trans-4-(N,N-dimethylamino)methylcyclohexyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-206
5-[trans-4-(N-acetylamino)methylcyclohexyl)]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-207
5-[trans-4-(N-t-butoxycarbonylamino)cyclohexyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-208
5-(trans-4-aminocyclohexyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-209
5-[trans-4-(N,N-dimethylamino)cyclohexyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-210
5-[trans-4-(N-isopropylamino)cyclohexyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-211
5-[trans-4-(N-acetylamino)cyclohexyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-212
5-[cis-4-(N-t-butoxycarbonyl)methylaminocyclohexyl)]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-213
5-(cis-4-methylaminocyclohexyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-214
5-[cis-4-(N,N-dimethyl)methylaminocyclohexyl)]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-215
5-[cis-4-(N-isopropyl)methylaminocyclohexyl)]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-216
5-[cis-4-(N-acetyl)methylaminocyclohexyl)]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-217
5-[3-(1,1-dimethyl-1-(N-t-butoxycarbonylamino)propyl-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-218
5-[3-(1,1-dimethyl-1-amino)propyl-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-219
5-[3-(1,1-dimethyl-1-(N,N-dimethylamino)propyl-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-220
5-[3-(1,1-dimethyl-1-(N-isopropylamino)propyl-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-221
5-[3-(1,1-dimethyl-1-(N-acetylamino)propyl-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-222
5-[4-(1-carboxamidino)benzyl-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-223
5-[4-(1-N-methylcarboxamidino)benzyl-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-224
5-[4-(1-N-benzylcarboxamidino)benzyl-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-225
5-[3-(1-carboxamidino)benzyl-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-226
5-[3-(1-N-methylcarboxamidino)benzyl-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-227
5-[3-(1-N-benzylcarboxamidino)benzyl-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-228
5-[3-(N-t-butoxycarbonyl)aminobenzyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-229
5-(3-aminobenzyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-230
5-8 3-(N,N-dimethylamino)benzyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-231
5-[3-(N-isopropylamino)benzyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-232
5-[3-(N-benzylamino)benzyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-233
5-[3-(N-acetylamino)benzyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-234
5-[4-(2-amino)methylimidazolyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-235
5-[4-(2-N,N-dimethylamino)methylimidazolyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-236
5-[4-(2-N-isopropylamino)methylimidazolyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-237
5-[4-(2-N-benzylamino)methylimidazolyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-238
5-[4-(2-N-acetylamino)methylimidazolyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-239
5-[4-(2-amino)methyloxazolyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-240
5-[4-(2-N,N-dimethylamino)methyloxazolyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-241
5-[4-(2-N-isopropylamino)methyloxazolyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-242
5-[4-(2-N-benzylamino)methyloxazolyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-243
5-[4-(2-N-acetylamino)methyloxazolyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-244
5-[4-(2-amino)methylthiazolyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-245
5-[4-(2-N,N-dimethylamino)methylthiazolyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-246
5-[4-(2-N-isopropylamino)methylthiazolyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-247
5-[4-(2-N-benzylamino)methylthiazolyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE C-248
5-[4-(2-N-acetylamino)methylthiazolyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

embedded image

Biological data from compounds of Examples B-0001 through B-1573 and of Examples B-2270 through B-2462 are shown in the following tables.

In vitro P38-alpha kinase inhibitory data are shown in the column identified as:

“P38 alpha kinase IC₅₀, uM or % inhib @ conc. (uM),”

In vitro whole cell assay for measuring the ability of the compounds to inhibit TNF production in human U937 cells stimulated with LPS are shown in the column identified as:

“U937 Cell IC₅₀, uM or % inhib @ conc., (uM)”

In vivo assessment of the ability of the compounds to inhibit LPS-stimulated TNF release in the mouse is shown in the column identified as:

“Mouse LPS Model, % TNF inhib @ dose @ predose time”

wherein in the dose is milligram per kilogram (mpk) administered by oral gavage and the predose time indicates the number of hours before LPS challenge when the compound is administered.

In vivo assessment of the ability of the compounds to inhibit LPS-stimulated TNF release in the rat is shown in the column identified as:

“Rat LPS Model, % TNF inhib @ dose @ predose time”

wherein in the dose is milligram per kilogram (mpk) administered by oral gavage and the predose time indicates the number of hours before LPS challenge when the compound is administered.

P38 alpha kinaseU937 Cell IC50, uMMouse LPS Model %Rat LPS Model %IC50, uM or %or %TNF inhib @ doseinhib @ doseExample#inhib@conc. (uM)inhib@conc. (uM)@predose time@predose timeB-000153.0% @1.0uM40.0% @1.0uMB-000271.0% @1.0uM28.0% @10.0uMB-000370.0% @1.0uM76.0% 10.0uMB-000480.0% @1.0uM4.61uMB-000595.0% @1.0uM2.97uMB-000682.0% @1.0uM80% @10.0uMB-000774.0% @1.0uM85.0% @10.0uMB-000842.0% @1.0uM65.0% @10.0uMB-00090.04uM0.72uMB-00100.52uM0.65uMB-00110.03uM4.47uMB-001230.0% @1.0uM44.0% @1.0uMB-001370.0% @1.0uM84.0% @10.0uMB-001479.0% @1.0uM80.0% @10.0uMB-001582.0% @1.0uM80.0% @10.0uMB-001694.0% @1.0uM3.98uMB-001756.0% @1.0uM79.0% @10.0uMB-001860.0% @1.0uM59.0% @10.0uMB-001984.0% @1.0uM100.0% @10.0uMB-002073.0% @1.0uM81.0% @10.0uMB-002168.0% @1.0uM76.0% @10.0uMB-002269.0% @1.0uM44.0@1.0uMB-002390.0% @1.0uM77.0% @10.0uMB-002494.0% @1.0uM52.0% @1.0uMB-002589.0% @1.0uM79.0% @10.0uMB-002696.0% @1.0uM3.27uMB-002794.0% @1.0uM11.0uMB-002869.0% @1.0uM45.0% @10.0uMB-002991.0% @1.0uM58.0% @10.0uMB-003092.0% @1.0uM75.0% @10.0uMB-003194.0% @1.0uM100.0% @10.0uMB-003294.0% @1.0uM78.0% @10.0uMB-003397.0% @1.0uM10.0uMB-003495.0% @1.0uM10.0uMB-003594.0% @1.0uM10.0uMB-003692.0% @1.0uM8.24uMB-003791.0% @1.0uM86.0% @10.0uMB-003871.0% @1.0uM84.0% @10.0uMB-003989.0% @1.0uM72.0% @10.0uMB-004093.0% @1.0uM2.3uMB-004165.0% @1.0uM66.0% @10.0uMB-004294.0% @1.0uM2.76uMB-00430.22uM0.54uMB-00440.14uM0.19uMB-004594.0% @1.0uM1.01uMB-004696.0% @1.0uM54.0% @1.0uMB-004794.0% @1.0uM74.0% @10.0uMB-004894.0% @1.0uM76.0% @10.0uMB-004988% @1.0uM33.0% @1.0uMB-005073% @1.0uM34.0% @1.0uMB-00513.3uM2.15uM47% @100 mpk@-6 h 79% @3 mpk@-4 hB-005292% @1.0uM15.0% @1.0uMB-005395% @1.0uM34.0% @1.0uMB-005490% @1.0uM30.0% @1.0uMB-005593% @1.0uM>1.0uMB-005696% @1.0uM21.0% @1.0uMB-005796% @1.0uM29.0% @1.0uMB-005879% @1.0uM18.0% @1.0uMB-005983% @1.0uM35.0% @1.0uMB-006073% @1.0uM22.0% @1.0uMB-006162% @1.0uM27.0% @1.0uMB-006294% @1.0uM36.0% @1.0uMB-006396% @1.0uM40.0% @1.0uMB-006490% @1.0uM4.0% @1.0uMB-006583% @1.0uM21.0% @1.0uMB-006694% @1.0uM28.0% @1.0uMB-006791% @1.0uM1.0% @1.0uMB-006872% @1.0uM22.0% @1.0uMB-006996% @1.0uM37.0% @1.0uMB-007092% @1.0uM30.0% @1.0uMB-007186% @1.0uM31.0% @1.0uMB-007277% @1.0uM32.0% @1.0uMB-007391% @1.0uM24.0% @1.0uMB-007492% @1.0uM42.0% @1.0uMB-007591% @1.0uM35.0% @1.0uMB-007658% @1.0uM21.0% @1.0uMB-00770.8uM10.0uMB-007880% @1.0uM20.0% @1.0uMB-007993% @1.0uM13.0% @1.0uMB-008073% @1.0uM73.0% @1.0uMB-008192% @1.0uM13.0% @1.0uMB-008247% @1.0uM27.0% @1.0uMB-00830.22uM6.51uMB-008456% @1.0uM30.0% @1.0uMB-008583% @1.0uM21.0% @1.0uMB-008691% @1.0uM37.0% @1.0uMB-00870.55uM2.26uM 38% @30 mpk@-6 hB-008896% @1.0uM9.0% @1.0uMB-00890.04uM3.33uMB-009098% @1.0uM52.0% @1.0uMB-009196% @1.0uM40.0% @1.0uMB-009297% @1.0uM34.0% @1.0uMB-00933.18uM1.25uM 30% @30 mpk@-6 hB-009496% @1.0uM52.0% @1.0uMB-009598% @1.0uM38.0% @1.0uMB-009691% @1.0uM22.0% @1.0uMB-009772.0% @10.0uM38.0% @1.0uMB-009866.0% @10.0uM12.0% @1.0uMB-009943.0% @1.0uM>1.0uMB-010075.0% @1.0uM5.0uMB-010171.0% @1.0uM2.11uMB-010281.0% @1.0uM15.0% @1.0uMB-010371.0% @1.0uM6.0% @1.0uMB-010456.0% @1.0uM2.78uMB-010578.0% @1.0uM5.0uMB-010662.0% @1.0uM5.0uMB-01070.27uM5.0uMB-010861.0% @1.0uM4.85uMB-010945.0% @1.0uM19.0% @1.0uMB-011066.0% @1.0uM13.0% @1.0uMB-011157.0% @1.0uM>1.0uMB-011297.0% @1.0uM1.12uMB-011375.0% @1.0uM43.0% @1.0uMB-011445.0% @1.0uM3.92uMB-011547.0% @1.0uM2.0% @1.0uMB-011673.0% @1.0uM35.0% @1.0uMB-01170.46uM1.78uM 30% @30 mpk@-6 hB-01181.18uM1.29uMB-011989.0% @10.0uM2.78uMB-01200.008uM0.21uM 77% @100 mpk@-6 h70% @3 mpk@-4 hB-012179.0% @1.0uM1.22uMB-012279.0% @10.0uM2.0% @1.0uMB-012359.0% @1.0uM>1.0uMB-012473.0% @1.0uM15.0% @1.0uMB-012570.0% @10.0uM17.0% @1.0uMB-012666.0% @1.0uM1.57uMB-012782.0% @1.0uM0.96uMB-012878.0% @1.0uM1.81uMB-012951.0% @1.0uM31.0% @1.0uMB-013069.0% @1.0uM58.0% @1.0uMB-013143.0% @1.0uM46.0% @1.0uMB-013276.0% @1.0uM8.0% @1.0uMB-013351.0% @1.0uM42.0% @1.0uMB-013460.0% @1.0uM2.17uMB-013578.0% @1.0uM58.0% @1.0uMB-013677.0% @1.0uM44.0% @1.0uMB-013741.0% @1.0uM37.0% @1.0uMB-013850.0% @1.0uM32.0% @1.0uMB-013954.0% @10.0uM17.0% @1.0uMB-014067% @10.0uM9.0% @1.0uMB-014178.0% @1.0uM10.0% @1.0uMB-014286.0% @1.0uM12.0% @1.0uMB-014342.0% @1.0uM3.63uMB-014486.0% @1.0uM43.0% @1.0uMB-014554.0% @10.0uM12.0% @1.0uMB-014677.0% @10.0uM28.0% @1.0uMB-014744.0% @1.0uM22.0% @1.0uMB-014851.0% @1.0uM>1.0uMB-01491.15uM10.0uMB-015027.0% @10.0uM35.0% @1.0uMB-015143.0% @1.0uM30.0% @1.0uMB-015251.0% @1.0uM24.0% @1.0uMB-015357.0% @1.0uM21.0% @1.0uMB-015465.0% @10.0uM14.0% @1.0uMB-015540.0% @10.0uM26.0% @1.0uMB-015642.0% @10.0uM13.0% @1.0uMB-015748.0% @10.0uM9.0% @1.0uMB-015858.0% @10.0uM39.0% @1.0uMB-015954.0% @10.0uM5.0% @1.0uMB-016059.0% @10.0uM26.0% @1.0uMB-016172.0% @10.0uM13.0% @1.0uMB-016223% @1.0uM2.05uMB-016320.0% @10.0uM10.0% @1.0uMB-016437.0% @10.0uM20.0% @1.0uMB-016570.0% @10.0uM19.0% @1.0uMB-016645.0% @10.0uM37.0% @1.0uMB-016740.0% @1.0uM37.0% @1.0uMB-016844% @1.0uM2.36uMB-016943.0% @1.0uM21.0% @1.0uMB-017043.0% @1.0uM30.0% @1.0uMB-017161.0% @10.0uM21.0% @1.0uMB-017216.0% @10.0uM11.0% @1.0uMB-017333.0% @10.0uM48.0% @1.0uMB-017454.0% @10.0uM43.0% @1.0uMB-017541.0% @10.0uM31.0% @1.0uMB-017650.0% @1.0uM30.0% @1.0uMB-017770.0% @10.0uM27.0% @1.0uMB-017812.0% @10.0uM35.0% @1.0uMB-017927.0% @10.0uM37.0% @1.0uMB-018034.0% @10.0uM23.0% @1.0uMB-01815.0% @1.0uM2.0% @1.0uMB-018239.0% @10.0uM40.0% @1.0uMB-018312.0% @10.0uM34.0% @1.0uMB-018466.0% @10.0uM17.0% @1.0uMB-018565.0% @10.0uM25.0% @1.0uMB-018640.0% @1.0uM25.0% @1.0uMB-01874.0% @10.0uM14.0% @1.0uMB-018870.0% @10.0uM35.0% @1.0uMB-018942.0% @10.0uM9.0% @1.0uMB-019059.0% @10.0uM31.0% @1.0uMB-019140.0% @1.0uM29.0% @1.0uMB-019212.0% @10.0uM47.0% @1.0uMB-01930.54uM6% @1.0uMB-01941.31uM22% @1.0uMB-01951.03uM55% @1.0uMB-01962.24uM>1.0uMB-01972.0uM14% @1.0uMB-01981.2uM2% @1.0uMB-01991.34uM3% @1.0uMB-02001.31uM16% @1.0uMB-02010.29uM59% @1.0uMB-02020.55uM2.26uMB-02030.16uM65% @1.0uMB-02040.21uM48% @1.0uMB-02050.096uM54% @1.0uMB-02065.76uM14% @1.0uMB-02070.12uM52% @1.0uMB-02080.067uM>1.0uMB-02090.29uM8% @1.0uMB-02100.057uM67% @1.0uMB-02110.25uM30% @1.0uMB-02120.12uM28% @1.0uMB-02130.31uM39% @1.0uMB-02140.16uM50% @1.0uMB-02150.11uM51% @1.0uMB-02160.56uM>1.0uMB-02170.55uM>1.0uMB-02180.53uM18% @1.0uMB-02190.91uM18% @1.0uMB-02200.13uM40% @1.0uMB-02212.4uM>1.0uMB-02220.4uM29.0% @1.0uMB-02230.2uM1.0% @1.0uMB-0224<0.1uM93.0% @1.0uMB-02250.047uM37.0% @1.0uMB-02260.074uM20.0% @1.0uMB-02270.045uM1.0% @1.0uMB-02280.15uM44.0% @1.0uMB-0229<0.1uM61.0% @1.0uMB-02300.041uM30.0% @1.0uMB-02310.055uM40.0% 1.0uMB-02320.048uM24.0% @1.0uMB-02330.095uM43.0% @1.0uMB-02340.11uM68.0% @1.0uMB-02351.31uM90.0% @1.0uMB-02360.077uM46.0% @1.0uMB-02370.13uM60.0% @1.0uMB-02380.47uM82.0% @1.0uMB-02395.73uM84.0% @1.0uMB-02400.2uM70.0% @1.0uMB-02410.1uM45.0% @1.0uMB-0242<0.1uM78.0% @1.0uMB-02430.039uM53.0% @1.0uMB-02440.02uM57.0% @1.0uMB-02450.13uM24.0% @1.0uMB-0246<0.1uM>1.0uMB-02470.082uM75.0% @1.0uMB-0248<0.1uM11.0% @1.0uMB-0249<0.1uM75.0% @1.0uMB-02500.28uM36.0% @1.0uMB-02510.31uM1.0% @1.0uMB-02520.041uM54.0% @1.0uMB-02530.061uM74.0% @1.0uMB-02540.12uM59.0% @1.0uMB-02550.32uM68.0% @1.0uMB-0256<0.1uM88.0% @1.0uMB-02571.71uM11.0% @1.0uMB-02580.37uM63.0% @1.0uMB-02590.35uM58.0% @1.0uMB-02600.56uM23.0% @1.0uMB-02610.49uM23.0% @1.0uMB-02620.41uM89.0% @1.0uMB-02630.62uM64.0% @1.0uMB-02640.14uM18.0% @1.0uMB-02650.92uM24.0% @1.0uMB-02660.25uM24.0% @1.0uMB-02670.48uM11.0% @1.0uMB-02683.39uM19.0% @1.0uMB-02699.81uM19.0% @1.0uMB-02705.79uM13.0% @1.0uMB-02717.55uM12.0% @1.0uMB-02721.81uM48.0% @1.0uMB-02735.03uM13.0% @1.0uMB-02742.68uM25.0% @1.0uMB-02752.67uM33.0% @1.0uMB-02761.25uM26.0% @1.0uMB-02770.68uM34.0% @1.0uMB-02781.26uM36.0% @1.0uMB-02791.39uM33.0% @1.0uMB-02800.86uM18.0% @1.0uMB-02817.37uM24.0% @1.0uMB-02820.75uM38.0% @1.0uMB-02836.66uM29.0% @1.0uMB-02840.083uM65.0% @1.0uMB-02854.57uM29.0% @1.0uMB-02860.33uM50.0% @1.0uMB-02874.0uM22.0% @1.0uMB-02884.46uM26.0% @1.0uMB-02890.15uM55.0% @1.0uMB-02900.66uM44.0% @1.0uMB-02911.33uM20.0% @1.0uMB-02920.22uM28.0% @1.0uMB-02930.66uM53.0% @1.0uMB-02940.68uM45.0% @1.0uMB-02950.82uM45.0% @1.0uMB-02968.03uM36.0% @1.0uMB-02970.78uM30.0% @1.0uMB-02980.58uM48.0% @1.0uMB-02990.87uM54.0% @1.0uMB-03000.78uM32.0% @1.0uMB-03010.19uM50.0% @1.0uMB-03024.02uM24.0% @1.0uMB-03030.22uM10.0% @1.0uMB-03040.56uM28.0% @1.0uMB-0305B-0306B-0307B-0308B-0309B-0310B-0311B-0312B-0313B-0314B-0315B-0316B-0317B-0318B-0319B-0320B-0321B-0322B-0323B-0324B-0325B-0326B-0327B-0328B-0329B-0330B-0331B-0332B-0333B-0334B-0335B-0336B-0337B-0338B-0339B-0340B-0341B-0342B-0343B-0344B-0345B-0346B-0347B-0348B-0349B-0350B-0351B-0352B-03531.37uM55% @1.0uMB-03541.0uM0.66uM 51% @30 mpk@-6 h54% @3 mpk@-4 hB-03550.75uM40.0% @1.0uMB-03560.66uM24.0% @1.0uMB-03571.46uM0.66uMB-03580.37uM17.0% @1.0uMB-03590.45uM47.0% @1.0uMB-03601.6uM19.0% @1.0uMB-03610.33uM46.0% @1.0uMB-03620.52uM27.0% @1.0uMB-03634.67uM25.0% @1.0uMB-03641.44uM27.0% @1.0uMB-03650.96uM27.0% @1.0uMB-03660.7uM46.0% @1.0uMB-03671.0uM23.0% @1.0uMB-03681.0uM0.64uM 37% @30 mpk@-6 hB-03690.16uM57.0% @1.0uMB-03700.65uM28.0% @1.0uMB-03710.49uM28.0% @1.0uMB-03720.35uM29.0% @1.0uMB-03730.45uM18.0% @1.0uMB-03741.38uM12.0% @1.0uMB-03751.0uM19.0% @1.0uMB-03762.99uM12.0% @1.0uMB-03771.29uM36.0% @1.0uMB-03781.1uM36.0% @1.0uMB-03790.53uM24.0% @1.0uMB-03801.41uM32.0% @1.0uMB-03810.22uM47.0% @1.0uMB-03820.41uM32.0% @1.0uMB-03831.43uM10.0% @1.0uMB-03844.02uM16.0% @1.0uMB-03850.057uM0.9uM 30% @30 mpk@-6 h 0% @3 mpk@-4 hB-03860.13uM54.0% @1.0uMB-03870.41uM52.0% @1.0uMB-0388<0.1uM36.0% @1.0uMB-03890.01uM0.05uM62% @3 mpk@-4 hB-03900.089uM55.0% @1.0uMB-03910.86uM18.0% @1.0uMB-03920.13uM57.0% @1.0uMB-03930.043uM66.0% @1.0uMB-03940.13uM45.0% @1.0uMB-03950.087uM48.0% @1.0uMB-03960.097uM0.44uMB-03970.17uM41.0% @1.0uMB-03980.054uM66.0% @1.0uMB-03990.14uM39.0% @1.0uMB-04000.16uM25.0% @1.0uMB-04010.46uM52.0% @1.0uMB-04020.14uM1.51uMB-04031.77uM2.42uMB-04040.31uM48.0% @1.0uMB-04050.79uM30.0% @1.0uMB-04060.54uM35.0% @1.0uMB-04070.76uM27.0% @1.0uMB-04080.5uM50.0% @1.0uMB-04090.53uM30.0% @1.0uMB-04100.38uM44.0% @1.0uMB-04110.62uM50.0% @1.0uMB-04120.24uM48.0% @1.0uMB-04130.18uM55.0% @1.0uMB-04142.54uM25.0% @1.0uMB-04150.42uM43.0% @1.0uMB-04160.32uM34.0% @1.0uMB-04170.91uM28.0% @1.0uMB-04180.22uM27.0% @1.0uMB-04190.85uM41.0% 21.0uMB-04200.83uM49.0% @1.0uMB-04210.46uM57.0% @1.0uMB-0422<0.1uM40.0% @1.0uMB-04230.18uM33.0% @1.0uMB-04240.083uM32.0% @1.0uMB-04250.26uM54.0% @1.0uMB-04260.055uM0.74uM41% @3 mpk@-4 hB-04270.63uM39.0% @1.0uMB-04280.99uM27.0% @1.0uMB-04290.27uM45.0% @1.0uMB-04300.29uM75.0% @1.0uMB-04310.21uM64.0% @1.0uMB-0432<0.1uM89.0% @1.0uMB-0433<0.1uM92.0% @1.0uMB-04340.12uM65.0% @1.0uMB-04350.3uM61.0% @1.0uMB-04361.11uM71.0% @1.0uMB-04370.58uM59.0% @1.0uMB-0438<0.1uM91.0% @1.0uMB-04392.12uM65.0% @1.0uMB-04400.66uM63.0% @1.0uMB-04410.8uM58.0% @1.0uMB-0442<0.1uM91.0% @1.0uMB-04432.01uM71.0% @1.0uMB-04441.01uM51.0% @1.0uMB-0445<0.1uM83.0% @1.0uMB-04460.78uM80.0% @1.0uMB-04470.19uM71.0% @1.0uMB-04480.4uM79.0% @1.0uMB-04490.83uM81.0% @1.0uMB-04500.26uM81.0% @1.0uMB-04510.071uM83.0% @1.0uM 42% @30 mpk@-6 hB-04520.7uM75.0% @1.0uMB-04530.47uM75.0% @1.0uMB-04540.11uM80.0% @1.0uMB-0455<0.1uM95.0% @1.0uM36% @3 mpk %-4 hB-04561.81uM67.0% @1.0uMB-04570.089uM81.0% @1.0uMB-04580.033uM70.0% @1.0uMB-04590.099uM76.0% @1.0uMB-04600.061uM92.0% @1.0uMB-04610.025uM96.0% @1.0uMB-0462<0.1uM97.0% @1.0uMB-04630.052uM95.0% @1.0uMB-0464<0.1uM91.0% @1.0uMB-04650.084uM98.0% @1.0uMB-0466<0.1uM98.0% @1.0uM 0% @3 mpk@-4 hB-0467<0.1uM77.0% @1.0uMB-04680.031uM93.0% @1.0uMB-04690.056uM92.0% @1.0uMB-04700.063uM92.0% @1.0uMB-04710.027uM97.0% @1.0uMB-04720.19uM54.0% @1.0uMB-04730.004uM95.0% @1.0uMB-04740.024uM86.0% @1.0uMB-04750.21uM74.0% @1.0uMB-04760.56uM69.0% @1.0uMB-04771.48uM96.0% @1.0uMB-04780.034uM87.0% @1.0uMB-04790.031uM90.0% @1.0uM15% @3 mpk@-4 hB-04800.12uM88.0% @1.0uMB-04810.014uM95.0% @1.0uM56% @3 mpk@-4 hB-04820.97uM68.0% @1.0uMB-04830.57uM68.0% @1.0uMB-04840.28uM62.0% @1.0uMB-04850.04uM95.0% @1.0uMB-04860.24uM80.0% @1.0uMB-04870.11uM89.0% @1.0uM54% @3 mpk@-4 hB-04880.62uM88.0% @1.0uMB-04890.3uM80.0% @1.0uMB-04900.91uM74.0% @1.0uMB-04910.43uM66.0% @1.0uMB-04920.069uM42.0% @1.0uMB-04930.3uM36.0% @1.0uMB-04940.13uM30.0% @1.0uMB-04950.12uM25.0% @1.0uMB-04960.83uM16.0% @1.0uMB-04970.44uM31.0% @1.0uMB-04980.33uM11.0% @1.0uMB-04990.39uM37.0% @1.0uMB-05000.26uM41.0% @1.0uMB-05010.049uM52.0% @1.0uMB-05020.065uM48.0% @1.0uMB-05030.16uM73.0% @1.0uMB-05040.4uM43.0% @1.0uMB-05050.28uM44.0% @1.0uMB-05060.94uM43.0% @1.0uMB-05070.18uM75.0% @1.0uMB-05082.0uM48.0% @1.0uMB-05090.1uM86.0% @1.0uMB-05100.69uM61.0% @1.0uMB-05110.007uM90.0% @1.0uMB-05121.0uM53.0% @1.0uMB-05130.72uM52.0% @1.0uMB-05140.14uM87.0% @1.0uMB-05150.42uM61.0% @1.0uMB-05160.37uM84.0% @1.0uMB-05170.094uM52.0% @1.0uMB-05180.11uM64.0% @1.0uMB-05190.043uM87.0% @1.0uMB-05200.4uM67.0% @1.0uMB-05211.37uM52.0% @1.0uMB-05220.15uM75.0% @1.0uMB-05230.19uM83.0% @1.0uMB-05240.4uM77.0% @1.0uMB-05250.16uM76.0% @1.0uMB-05260.031uM87.0% @1.0uMB-05271.09uM63.0% @1.0uMB-05280.14uM70.0% @1.0uMB-05290.11uM73.0% @1.0uMB-05305.53uM45.0% @1.0uMB-05310.5uM48.0% @1.0uMB-05320.45uM1.01uM 41% @30 mpk@-6 hB-05331.23uM47.0% @1.0uMB-05340.41uM54.0% @1.0uMB-05350.44uM0.87uMB-05360.46uM0.15uMB-05373.44uM51.0% @1.0uMB-05381.13uM45.0% @1.0uMB-05392.84uM21.0% @1.0uMB-05403.62uM54.0% @1.0uMB-05413.24uM28.0% @1.0uMB-05421.55uM50.0% @1.0uMB-05431.56uM43.0% @1.0uMB-05441.12uM27.0% @1.0uMB-05451.06uM41.0% @1.0uMB-05461.04uM18.0% @1.0uMB-05471.24uM21.0% @1.0uMB-05481.77uM28.0% @1.0uMB-05492.22uM22.0% @1.0uMB-05502.41uM14.0% @1.0uMB-05511.08uM56.0% @1.0uMB-05520.13uM46.0% @1.0uMB-05531.44uM47.0% @1.0uMB-05542.58uM20.0% @1.0uMB-05551.87uM34.0% @1.0uMB-05560.49uM39.0% @1.0uMB-05571.37uM32.0% @1.0uMB-05580.85uM33.0% @1.0uMB-05590.53uM49.0% @1.0uMB-05602.57uM31.0% @1.0uMB-05612.07uM40.0% @1.0uMB-05620.22uM0.3uM 5% @3 mpk@-4 hB-05630.18uM0.13uMB-05640.82uM58% @1.0uMB-05650.23uM0.59uMB-0566<0.1uM0.17uM 0% @3 mpk@-4 hB-05670.14uM0.28uMB-05681.22uM46.0% @1.0uMB-05690.15uM0.26uMB-05700.27uM46.0% @1.0uMB-05710.38uM44.0% @1.0uMB-05720.27uM41.0% @1.0uMB-05730.36uM1.7uMB-05740.13uM0.66uM37% @3 mpk@-4 hB-05750.032uM0.17uMB-05760.068uM0.39uM65% @3 mpk@-4 hB-05770.091uM66.0% @1.0uMB-05781.88uM47.0% @1.0uMB-05790.11uM79.0% @1.0uMB-05802.23uM0.84uMB-05810.26uM2.17uMB-05821.03uM37.0% @1.0uMB-05833.93uM26.0% @1.0uMB-05840.66uM54.0% @1.0uMB-05850.83uM79.0% @1.0uM 50% @30 mpk@-6 hB-05860.81uM51.0% @1.0uMB-05876.84uM38% @1.0uMB-058812.8uM42% @1.0uMB-05891.71uM42% @1.0uMB-05901.57uM38.0uMB-05913.59uM29.0% @1.0uMB-05921.62uM45.0% @1.0uMB-05931.22uM36.0% @1.0uMB-0594—41.0% @1.0uMB-05952.42uM22.0% @1.0uMB-059620.0uM41.0% @1.0uMB-05971.68uM63.0% @1.0uMB-05982.12uM50.0% @1.0uMB-05994.16uM21.0% @1.0uMB-06000.002uM28.0% @1.0uMB-06010.089uM1.31uM43% @3 mpk %-4 hB-06020.97uM61.0% @1.0uMB-06030.09uM51.0% @1.0uMB-06040.3uM20.0% @1.0uMB-06050.18uM47.0% @1.0uMB-06060.17uM53.0% @1.0uMB-06072.79uM70.0% @1.0uMB-06080.059uM73.0% @1.0uMB-0609<0.1uM87.0% @1.0uMB-0610<0.1uM88.0% @1.0uMB-06110.65uM60.0% @1.0uMB-06120.16uM60.0% @1.0uMB-06130.17uM76.0% @1.0uMB-06140.76uM70.0% @1.0uM 0% @3 mpk@-4 hB-06150.08uM83.0% @1.0uMB-06160.38uM87.0% @1.0uMB-06170.045uM92.0% @1.0uMB-06180.37uM80.0% @1.0uMB-0619<0.1uM88.0% @1.0uMB-06201.59uM58.0% @1.0uMB-06210.36uM68.0% @1.0uMB-06220.076uM78.0% @1.0uMB-06230.12uM76.0% @1.0uMB-06240.085uM54.0% @1.0uMB-06250.023uM88.0% @1.0uMB-0626<0.1uM85.0% @1.0uMB-06270.25uM69.0% @1.0uMB-06280.023uM72.0% @1.0uMB-06290.2uM79.0% @1.0uMB-06300.06uM77.0% @1.0uMB-06310.065uM81.0% @1.0uMB-0632<0.1uM79.0% @1.0uMB-06330.6uM80.0% @1.0uMB-06340.6uM40.0% @1.0uMB-06350.15uM55.0% @1.0uMB-0636<0.1uM86.0% @1.0uMB-06370.11uM92.0% @1.0uMB-06380.25uM89.0% @1.0uMB-06390.051uM93.0% @1.0uM50% @3 mpk@-4 hB-06400.36uM94.0% @1.0uMB-06410.58uM65.0% @1.0uMB-06420.49uM90.0% @1.0uMB-06430.069uM85.0% @1.0uM 0% @3 mpk@-4 hB-06440.058uM89.0% @1.0uMB-06450.58uM80.0% @1.0uMB-06460.26uM94.0% @1.0uMB-06471.61uM76.0% @1.0uMB-0648<0.1uM83.0% @1.0uMB-06490.83uM39.0% @1.0uMB-06500.006uM95.0% @1.0uM 8% @3 mpk@-4 hB-06511.78uM81.0% @1.0uMB-06520.19uM83.0% @1.0uMB-06532.01uM74.0% @1.0uMB-06545.97uM78.0% @1.0uMB-06551.25uM76.0% @1.0uMB-06560.007uM95.0% @1.0uM28% @3 mpk@-4 hB-06570.17uM83.0% @1.0uMB-06581.14uM91.0% @1.0uMB-06592.64uM87.0% @1.0uMB-06600.088uM92.0% @1.0uMB-0661<0.1uM90.0% @1.0uMB-0662<0.1uM95.0% @1.0uMB-06630.88uM74.0% @1.0uMB-06640.39uM80.0% @1.0uMB-06650.47uM72.0% @1.0uMB-06660.17uM73.0% @1.0uMB-06670.83uM75.0% @1.0uMB-06680.27uM78.0% @1.0uMB-06690.89uM34.0% @1.0uMB-06703.15uM32.0% @1.0uMB-06716.38uM36.0% @1.0uMB-06726.59uM32.0% @1.0uMB-06738.54uM48.0% @1.0uMB-06742.81uM42.0% @1.0uMB-06755.42uM3.0% @1.0uMB-06762.09uM22.0% @1.0uMB-06771.63uM25.0% @1.0uMB-06780.38uM52.0% @1.0uMB-06790.062uM45.0% @1.0uMB-06800.42uM67.0% @1.0uMB-06811.96uM17.0% @1.0uMB-06820.76uM39.0% @1.0uMB-068313.0uM32.0% @1.0uMB-06840.54uM68.0% @1.0uMB-068515.4uM33.0% @1.0uMB-06860.42uM59.0% @1.0uMB-068710.1uM15.0% @1.0uMB-06880.66uM58.0% @1.0uMB-068914.6uM27.0% @1.0uMB-069027.1uM36.0% @1.0uMB-06910.16uM48.0% @1.0uMB-06920.38uM29.0% @1.0uMB-06930.39uM28.0% @1.0uMB-06940.62uM21.0% @1.0uMB-06950.23uM32.0% @1.0uMB-06960.085uM35.0% @1.0uMB-06970.45uM44.0% @1.0uMB-06982.33uM43.0% @1.0uMB-06990.34uM31.0% @1.0uMB-07000.24uM56.0% @1.0uMB-07010.39uM45.0% @1.0uMB-07020.036uM39.0% @1.0uMB-07030.12uM39.0% @1.0uMB-07042.19uM29.0% @1.0uMB-07050.44uM21.0% @1.0uMB-07060.44uM32.0% @1.0uMB-07071.7uMB-07082.1uMB-07090.84uMB-07101.99uMB-07111.99uMB-07122.9uMB-07134.3uMB-07143.7uMB-07153.2uMB-07164.6uMB-07174.3uMB-07181.4uMB-07193.4uMB-07201.3uMB-07213.8uMB-07220.07uM>1.0uMB-07230.47uMB-07240.06uM17.0% @1.0uMB-07259.7uMB-07261.4uMB-07270.51uMB-072820.0uMB-07290.87uMB-07300.25uM11.0% @1.0uMB-07310.87uM>1.0uMB-073214.0uMB-073332.0uMB-07340.92uMB-07351.0uMB-073626.0uMB-07372.6uMB-07382.7uMB-07394.1uMB-07404.4uMB-074126.0uMB-07422.2uMB-07431.2uMB-074423.0uMB-07456.0uMB-07460.01uM22.0% @1.0uMB-07471.1uMB-07481.2uMB-07494.4uMB-07500.92uMB-07511.6uMB-07520.33uMB-07530.37uMB-07540.55uMB-07552.3uMB-07560.94uMB-07570.54uM16.0% @1.0uMB-07581.5uMB-07590.3uMB-07600.01uM13.0% @1.0uMB-0761<0.1uMB-07620.13uM5.0% @1.0uMB-07630.015uM17.0% @1.0uMB-07640.67uM26.0% @1.0uMB-07650.3uM29.0% @1.0uMB-07660.95uMB-07670.08uMB-07681.4uMB-076912.7uMB-07702.3uMB-07710.5uMB-07720.8uMB-077314.0uMB-07741.5uMB-07750.6uM>1.0uMB-07760.9uM>1.0uMB-077721.0uMB-077851.0uMB-07790.5uMB-07801.1uMB-078148.0uMB-078222.0uMB-07838.0uMB-07847.0uMB-078523.0uMB-078624.0uMB-07871.5uMB-07881.2uMB-078933.0uMB-07901.0uM4.0% @1.0uMB-07910.3uM>1.0uMB-07921.1uMB-07930.3uMB-07942.9uM2.0% @1.0uMB-07951.9uM11.0% @1.0uMB-07961.4uMB-07971.04uM—B-07981.73uM—B-0799—>1.0uMB-08001.01uM>1.0uMB-08010.67uM>1.0uMB-0802—>1.0uMB-08030.057uM53.0% @1.0uMB-08040.3uM32.0% @1.0uMB-08050.71uM>1.0uMB-08063.28uM>1.0uMB-080710.8uM—B-08083.09uM>1.0uMB-08091.22uM7.0% @1.0uMB-08101.11uM>1.0uMB-08112.79uM2.0% @1.0uMB-08122.12uM>1.0uMB-08133.02uM>1.0uMB-0814—>1.0uMB-08152.11uM>1.0uMB-08163.46uM>1.0uMB-08173.07uM33.0% @1.0uMB-08184.97uM>1.0uMB-08191.08uM>1.0uMB-08201.64uM3.0% @1.0uMB-08211.44uM—B-08221.33uM—B-08232.39uM>1.0uMB-08243.41uM—B-0825——B-08261.74uM—B-082715.6uM—B-08287.9uM—B-08290.61uM65.0% @1.0uMB-08300.54uM34.0% @1.0uMB-08310.9uM>1.0uMB-08321.49uM—B-08330.95uM23.0% @1.0uMB-08341.25uM—B-0835——B-08361.24uM—B-08371.96uM>1.0uMB-08383.1uM—B-08394.3uM—B-08400.63uM47.0% @1.0uMB-08410.32uM36.0% @1.0uMB-08420.74uM63.0% @1.0uMB-08430.61uM>1.0uMB-08440.4uM25.0% @1.0uMB-08451.78uM—B-08461.8uM—B-08470.73uM21.0% @1.0uMB-08481.56uM—B-08491.25uM—B-08501.81uM—B-08510.91uM390% @1.0uMB-08521.02uM—B-0853—38.0% @1.0uMB-0854—25.0% @1.0uMB-0855—8.0% @1.0uMB-0856—38.0% @1.0uMB-08576.25uM—B-08582.1uM48.0% @1.0uMB-085939.5uM—B-086038.1uM—B-08611.32uM12.0% @1.0uMB-08622.15uM4.0% @1.0uMB-08630.81uM25.0% @1.0uMB-08640.39uM40.% @1.0uMB-08650.66uM46.0% @1.0uMB-08661.38uM28.0% @1.0uMB-08670.62uM>1.0uMB-08683.28uM8.0% @1.0uMB-08694.19uM>1.0uMB-08703.13uM>1.0uMB-08711.9uM>1.0uMB-08723.13uM3.0% @1.0uMB-08736.92uM>1.0uMB-08741.92uM>1.0uMB-08752.13uM8% @1.0uMB-08760.89uM>1.0uMB-08771.17uM13.0% @1.0uMB-08780.65uM19.0% @1.0uMB-08790.87uM1.0% @1.0uMB-08800.15uM40.0% @1.0uMB-08811.36uM>1.0uMB-08821.48uM9% @1.0uMB-08831.06uM>1.0uMB-08841.89uM—B-0885B-0886B-0887B-0888B-0889B-0890B-0891B-0892B-0893B-0894B-0895B-0896B-0897B-0898B-0899B-0900B-0901B-0902B-0903B-0904B-0905B-0906B-0907B-0908B-0909B-0910B-0911B-0912B-0913B-0914B-0915B-0916B-0917B-0918B-0919B-0920B-0921B-0922B-0923B-0924B-0925B-0926B-0927B-0928B-0929B-0930B-0931B-0932B-093347.0% @1.0uM37.0% @1.0uMB-093467.0% @1.0uM36.0% @1.0uMB-093569.0% @1.0uM54.0% @1.0uMB-093669.0% @1.0uM>1.0uMB-093764.0% @1.0uM1.74uMB-093851.0% @1.0uM29.0% @1.0uMB-093978.0% @1.0uM14.0% @1.0uMB-094056.0% @1.0uM22.0% @1.0uMB-094181.0% @1.0uM25.0% @1.0uMB-094282.0% @1.0uM2.0% @1.0uMB-094363.0% @10.0uM24.0% @1.0uMB-094445.0% @1.0uM27.0% @1.0uMB-094596.0% @1.0uM0.93uMB-094676.0% @1.0uM31.0% @1.0uMB-094769.0% @1.0uM34.0% @1.0uMB-094868.0% @1.0uM1.81uMB-094990.0% @1.0uM17.0% @1.0uMB-095081.0% @1.0uM0.58uMB-095182.0% @1.0uM20.0% @1.0uMB-095244.0% @1.0uM21.0% @1.0uMB-095363.0% @1.0uM25.0% @1.0uMB-095462.0% @1.0uM0.52uMB-095549.0% @1.0uM0.54uMB-095656.0% @1.0uM1.33uMB-095779.0% @1.0uM22.0% @1.0uMB-095874.0% @1.0uM0.38uMB-095983.0% @1.0uM3.90% @1.0uMB-096048.0% @1.0uM4.0% @1.0uMB-096179.0% @1.0uM23.0% @1.0uMB-096285.0% @1.0uM2.71uMB-096376.0% @1.0uM39.0% @1.0uMB-096494.0% @1.0uM5.0uMB-096574.0% @1.0uM1.1uMB-096650.0% @1.0uM5.0% @1.0uMB-096780.0% @1.0uM29.0% @1.0uMB-096835.0% @1.0uM26.0% @1.0uMB-096963.0% @1.0uM35.0% @1.0uMB-097076.0% @10.0uM0.88uMB-097161.0% @1.0uM39.0% @1.0uMB-097285.0% @1.0uM2.0% @1.0uMB-097366.0% @10.0uM48.0% @1.0uMB-097457.0% @1.0uM47.0% @1.0uMB-097582.0% @1.0uM32.0% @1.0uMB-097679.0% @1.0uM36.0% @1.0uMB-097760.0% @1.0uM26.0% @1.0uMB-097859.0% @1.0uM36.0% @1.0uMB-097956.0% @10.0uM23.0% @1.0uMB-098068.0% @1.0uM31.0% @1.0uMB-098162.0% @1.0uM57.0% @1.0uMB-098265.0% @1.0uM23.0% @1.0uMB-098375.0% @1.0uM0.8uMB-098460.0% @1.0uM51.0% @1.0uMB-098586.0% @1.0uM0.75uMB-098670.0% @1.0uM71.0% @1.0uMB-098778.0% @1.0uM79.0% @1.0uMB-098872.0% @1.0uM65.0% @1.0uMB-098985.0% @1.0uM0.85uMB-0990—26.0% @1.0uMB-099158.0% @1.0uM33.0% @1.0uMB-099277.0% @1.0uM45.0% @1.0uMB-099357.0% @1.0uM73.0% @1.0uMB-099455.0% @1.0uM43.0% @1.0uMB-099553.0% @1.0uM14.0% @1.0uMB-099654.0% @1.0uM27.0% @1.0uMB-099769.0% @1.0uM22.0% @1.0uMB-099867.0% @1.0uM25.0% @1.0uMB-099961.0% @1.0uM24.0% @1.0uMB-100055.0% @1.0uM42.0% @1.0uMB-100163.0% @1.0uM31.0% @1.0uMB-100270.0% @1.0uM41.0% @1.0uMB-100374.0% @1.0uM29.0% @1.0uMB-100479.0% @1.0uM45.0% @1.0uMB-100558.0% @1.0uM23.0% @1.0uMB-100669.0% @1.0uM38.0% @1.0uMB-100752.0% @1.0uM34.0% @1.0uMB-100854.0% @1.0uM23.0% @1.0uMB-100980.0% @1.0uM55.0% @1.0uMB-101075.0% @1.0uM1.0uMB-101172.0% 21.0uM17.0% @1.0uMB-1012—20.0% @1.0uMB-101385.0% @1.0uM7.0% @1.0uMB-101488.0% @1.0uM20.0% @1.0uMB-101577.0% @1.0uM34.0% @1.0uMB-101658.0% @1.0uM10.0% @1.0uMB-101796.0% @1.0uM58.0% @1.0uMB-101888.0% @1.0uM34.0% @1.0uMB-101982.0% @1.0uM66.0% @1.0uMB-102087.0% @1.0uM36.0% @1.0uMB-102182.0% @1.0uM35.0% @1.0uMB-102284.0% @1.0uM53.0% @1.0uMB-102393.0% @1.0uM70.0% @1.0uMB-102489.0% @1.0uM57.0% @1.0uMB-102561.0% @1.0uM23.0% @1.0uMB-102687.0% @1.0uM53.0% @1.0uMB-102758.0% @1.0uM18.0% @1.0uMB-102870.0% @1.0uM17.0% @1.0uMB-102969.0% @1.0uM54.0% @1.0uMB-103076.0% @1.0uM60.0% @1.0uMB-103169.0% @1.0uM42.0% @1.0uMB-103276.0% @1.0uM37.0% @1.0uMB-103386.0% @1.0uM34.0% @1.0uMB-103466.0% @1.0uM39.0% @1.0uMB-103575.0% @1.0uM52.0% @1.0uMB-103668.0% @1.0uM68.0% @1.0uMB-1037—41.0% @1.0uMB-103857.0% @1.0uM0.57uMB-1039—133uMB-104072.0% @1.0uM0.38uMB-104170.0% @1.0uM73.0% @1.0uMB-104279.0% @1.0uM12.0% @1.0uMB-104364.0% @1.0uM53.0% @1.0uMB-104494.0% @1.0uM0.93uMB-104578.0% @1.0uM25.0% @1.0uMB-104672.0% @1.0uM66.0% @1.0uMB-104772.0% @1.0uM58.0% @1.0uMB-104867.0% @1.0uM19.0% @1.0uMB-104967.0% @1.0uM65.0% @1.0uMB-1050—0.54uMB-105168.0% @1.0uM41% @1.0uMB-105269.0% @1.0uM66% @1.0uMB-105378.0% @1.0uM0.4uMB-105479.0% @1.0uM55.0% @1.0uMB-105589.0% @1.0uM63.0% @1.0uMB-105689.0% @1.0uM0.76uMB-105785.0% @1.0uM0.72uMB-10580.66uM43.0% @1.0uMB-10590.18uM24.0% @1.0uMB-10600.11uM32.0% @1.0uMB-10610.03uM19.0% @1.0uMB-1062<0.1uM26.0% @1.0uMB-10630.16uM44.0% @1.0uMB-10640.39uM50.0% @1.0uMB-10650.56uM40.0% @1.0uMB-1066<0.1uM39.0% @1.0uMB-10671.6uM32.0% @1.0uMB-10680.48uM24.0% @1.0uMB-10690.22uM27.0% @1.0uMB-1070<0.1uM44.0% @1.0uMB-1071<0.1uM48.0% @1.0uMB-10720.38uM28.0% @1.0uMB-1073<0.1uM21.0% @1.0uMB-10740.23uM33.0% @1.0uMB-10750.03uM29.0% @1.0uMB-10760.08uM31.0% @1.0uMB-1077<0.1uM38.0% @1.0uMB-10780.26uM48.0% @1.0uMB-1079<0.1uM40.0% @1.0uMB-10800.19uM28.0% @1.0uMB-1081<0.1uM37.0% @1.0uMB-1082<0.1uM54.0% @1.0uMB-1083<0.1uM23.0% @1.0uMB-10840.43uM29.0% @1.0uMB-1085<0.1uM29.0% @1.0uMB-1086<0.1uM42.0% @1.0uMB-10870.05uM32.0% @1.0uMB-10880.73uM49.0% @1.0uMB-1089<0.1uM39.0% @1.0uMB-1090<0.1uM90.0% @1.0uMB-1091<0.1uM73.0% @1.0uMB-10920.27uM85.0% @1.0uMB-10930.33uM36.0% @1.0uMB-10940.013uM69.0% @1.0uMB-1095<0.1uM70.0% @1.0uMB-1096<0.1uM32.0% @1.0uMB-1097<0.1uM44.0% @1.07uMB-1098<0.1uM82.0% @1.0uMB-10990.26uM74.0% @1.0uMB-11000.22uM56.0% @1.0uMB-11010.026uM82.0% @1.0uMB-11020.035uM83.0% @1.0uMB-11030.094uM90.0% @1.0uMB-11040.12uM69.0% @1.0uMB-1105<0.1uM84.0% @1.0uMB-1106<0.1uM86.0% @1.0uMB-11070.057uM84.0% @1.0uMB-11080.22uM81.0% @1.0uMB-11090.054uM80.0% @1.0uMB-11100.47uM64.0% @1.0uMB-11110.19uM64.0% @1.0uMB-11120.58uM43.0% @1.0uMB-1113<0.1uM72.0% @1.0uMB-11140.069uM51.0% @1.0uMB-11150.024uM89.0% @1.0uMB-11160.41uM81.0% @1.0uMB-11170.13uM73.0% @1.0uMB-11180.33uM91.0% @1.0uMB-11190.35uM80.0% @1.0uMB-11200.47uM9.0% @1.0uMB-11213.58uM29.0% @1.0uMB-11221.84uM32.0% @1.0uMB-11232.93uM27.0% @1.0uMB-11241.49uM52.0% @1.0uMB-11250.56uM41.0% @1.0uMB-11261.5uM>1.0uMB-11270.71uM7.0% @1.0uMB-11282.55uM26.0% @1.0uMB-11291.07uM46.0% @1.0uMB-11300.5uM29.0% @1.0uMB-11310.076uM34.0% @1.0uMB-11320.72uM11.0% @1.0uMB-11330.38uM33.0% @1.0uMB-11341.71uM33.0% @1.0uMB-11350.23uM38.0% @1.0uMB-11361.17uM40.0% @1.0uMB-11370.038uM35.0% @1.0uMB-11381.82uM>1.0uMB-11390.041uM29.0% @1.0uMB-11401.68uM39.0% @1.0uMB-11412.47uM32.0% @1.0uMB-11420.11uM37.0% @1.0uMB-11430.17uM40.0% @1.0uMB-11440.44uM72.0% @1.0uMB-11451.07uM71.0% @1.0uMB-11460.47uM61.0% @1.0uMB-11470.095uM53.0% @1.0uMB-11480.43uM61.0% @1.0uMB-11491.55uM48.0% @1.0uMB-11500.47uM75.0% @1.0uMB-11510.32uM72.0% @1.0uMB-11520.73uM53.0% @1.0uMB-11532.22uM52.0% @1.0uMB-11540.085uM46.0% @1.0uMB-11553.22uM30.0% @1.0uMB-11560.27uM78.0% @1.0uMB-11570.26uM66.0% @1.0uMB-115874% @1.0uM0.68uM 53% @30 mpk@-6 hB-115966.0% @1.0uM1.03uM 60% @30 mpk@-6 hB-116079.0% @1.0uM0.38uMB-116164.0% 21.0uM0.93uM 40% @30 mpk@-6 h45% @3 mpk@-4 hB-116279.0% @1.0uM0.59uM 40% @30 mpk@-6 hB-116374.0% @1.0uM0.37uMB-1164—0.35uMB-116566.0% @1.0uM0.99uMB-116677.0% @1.0uM0.39uM 50% @30 mpk@-6 h50% @3 mpk@-4 hB-116770.0% @1.0uM1.06uMB-116866.0% @1.0uM0.63uMB-116980.0% @1.0uM0.11uMB-117082.0% @1.0uM0.57uMB-117178.0% @1.0uM0.23uMB-117268.0% @1.0uM1.95uMB-117365.0% @1.0uM62% @1.0uMB-117480.0% @1.0uM0.86uMB-117572.0% @1.0uM1.83uMB-117667.0% @1.0uM67.0% @1.0uMB-117770.0% @1.0uM1.16uMB-117892.0% @1.0uM1.61uMB-117986.0% @1.0uM0.41uMB-118078.0% @1.0uM0.53uMB-118179.0% @1.0uM66% @1.0uMB-118272.0% @1.0uM0.65uMB-118377.0% @1.0uM0.2uMB-118469.0% @1.0uM0.63uMB-118571.0% @1.0uM0.79uMB-118683.0% @1.0uM60% @1.0uMB-118776.0% @1.0uM1.89uMB-1188—36.0% @1.0uMB-118968.0% @1.0uM0.83uMB-119078.0% @1.0uM62.0% @1.0uMB-119174.0% @1.0uM57.0% @1.0uMB-119284.0% @1.0uM0.47uMB-119369.0% @1.0uM65.0% @1.0uMB-119487.0% @1.0uM0.58uMB-119552.0% @1.0uM60.0% @1.0uMB-119674.0% @1.0uM68.0% @1.0uMB-119777.0% @1.0uM45.0% @1.0uMB-119892.0% @1.0uM0.46uMB-119987.0% @1.0uM49.0% @1.0uMB-120095.0% @1.0uM0.64uMB-120184.0% @1.0uM0.51uMB-120271.0% @1.0uM58.0% @1.0uMB-120384.0% @1.0uM58.0% @1.0uMB-120468.0% @1.0uM59.0% @1.0uMB-120574.0% @1.0uM46.0% @1.0uMB-120681.0% @1.0uM0.34uMB-120790.0% @1.0uM58.0% @1.0uMB-120882.0% @1.0uM51.0% @1.0uMB-120986.0% @1.0uM55.0% @1.0uMB-121082.0% @1.0uM57.0% @1.0uMB-121188.0% @1.0uM59.0% @1.0uMB-121290.0% @1.0uM57.0% @1.0uMB-121384.0% @1.0uM0.62uMB-121476.0% @1.0uM58.0% @1.0uMB-121586.0% @1.0uM0.23uMB-121688.0% @1.0uM0.18uMB-121787.0% @1.0uM0.46uMB-121888.0% @1.0uM76.0% @1.0uMB-121985.0% @1.0uM37.0% @1.0uMB-122081.0% @1.0uM53.0% @1.0uMB-122182.0% @1.0uM44.0% @1.0uMB-122265.0% @1.0uM9.0% @1.0uMB-122380.0% @1.0uM61.0% @1.0uMB-122482.0% @1.0uM74.0% @1.0uMB-122589.0% @1.0uM73.0% @1.0uMB-122689.0% @1.0uM0.18uMB-122783.0% @1.0uM0.22uMB-122890.0% @1.0uM0.72uMB-122987.0% @1.0uM0.65uMB-123090.0% @1.0uM0.25uMB-123194.0% @1.0uM0.56uMB-123281.0% @1.0uM54.0% @1.0uMB-123385.0% @1.0uM0.36uMB-123489.0% @1.0uM0.49uMB-12350.04uM76.0% @1.0uMB-12360.1uM53.0% @1.0uMB-12370.22uM39.0% @1.0uMB-12380.14uM16.0% @1.0uMB-1239<0.1uM38.0% @1.0uMB-1240<0.1uM59.0% @1.0uMB-12410.04uM81.0% @1.0uMB-12420.08uM83.0% @1.0uMB-12430.04uM47.0% @1.0uMB-12440.26uM44.0% @1.0uMB-12450.49uM42.0% @1.0uMB-12460.27uM40.0% @1.0uMB-1247<0.1uM58.0% @1.0uMB-1248<0.1uM68.0% @1.0uMB-12490.24uM60.0% @1.0uMB-12500.14uM18.0% @1.0uMB-12510.41uM38.0% @1.0uMB-12520.17uM46.0% @1.0uMB-12530.15uM57.0% @1.0uMB-12540.16uM68.0% @1.0uMB-125512.9uM75.0% @1.0uMB-12560.12uM41.0% @1.0uMB-12571.48uM40.0% @1.0uMB-12580.07uM56.0% @1.0uMB-1259<0.1uM0.48uMB-12600.11uM48.0% @1.0uMB-12610.74uM44.0% @1.0uMB-1262<0.1uM63.0% @1.0uMB-12631.05uM57.0% @1.0uMB-12640.32uM47.0% @1.0uMB-12650.43uM51.0% @1.0uMB-1266<0.1uM58.0% @1.0uMB-1267<0.1uM73.0% @1.0uMB-1268<0.1uM79.0% @1.0uMB-12690.46uM84.0% @1.0uMB-12700.47uM83.0% @1.0uMB-12710.13uM74.0% @1.0uMB-12720.014uM38.0% @1.0uMB-1273<0.1uM36.0% @1.0uMB-1274<0.1uM41.0% @1.0uMB-1275<0.1uM50.0% @1.0uMB-12760.062uM11.0% @1.0uMB-1277<0.1uM47.0% @1.0uMB-12780.12uM85.0% @1.0uMB-1279<0.1uM79.0% @1.0uMB-12800.039uM83.0% @1.0uMB-1281<0.1uM85.0% @1.0uMB-1282<0.1uM75.0% @1.0uMB-1283<0.1uM64.0% @1.0uMB-1284<0.1uM75.0% @1.0uMB-12850.057uM80.0% @1.0uMB-12860.15uM78.0%21.0uMB-12870.25uM55.0% @1.0uMB-12880.15uM74.0% @1.0uMB-12890.73uM35.0% @1.0uMB-12900.26uM75.0% @1.0uMB-12910.097uM55.0% @1.0uMB-12920.01uM74.0% @1.0uMB-12930.31uM48.0% @1.0uMB-12940.013uM54.0% @1.0uMB-12950.079uM74.0% @1.0uMB-12960.038uM48.0% @1.0uMB-12970.02uM>1.0uMB-12980.055uM20.0% @1.0uMB-12990.091uM>1.0uMB-13000.071uM18.0% @1.0uMB-13010.12uM15.0% @1.0uMB-13020.023uM11.0% @1.0uMB-13030.08uM>1.0uMB-13040.11uM10.0% @1.0uMB-13050.64uM9.0% @1.0uMB-13060.11uM>1.0uMB-13070.009uM16.0% @1.0uMB-1308<0.1uM>1.0uMB-13090.045uM>1.0uMB-13100.12uM11.0% @1.0uMB-13110.05uM57.0% @1.0uMB-13120.35uM>1.0uMB-13130.035uM37.0% @1.0uMB-13140.045uM24.0% @1.0uMB-13150.055uM12.0% @1.0uMB-13160.026uM36.0% @1.0uMB-13170.019uM9.0% @1.0uMB-1318<0.1uM1.0% @1.0uMB-13190.24uM>1.0uMB-13200.047uM43.0% @1.0uMB-13210.47uM66.0% @1.0uMB-13220.12uM87.0% @1.0uMB-13230.013uM85.0% @1.0uMB-13240.16uM83.0% @1.0uMB-13250.27uM95.0% @1.0uMB-13260.092uM84.0% @1.0uMB-13270.13uM65.0% @1.0uMB-13280.032uM86.0% @1.0uMB-13290.66uM54.0% @1.0uMB-13300.053uM85.0% @1.0uMB-13310.004uM85.0% @1.0uMB-13320.007uM81.0% @1.0uMB-13330.45uM76.0% @1.0uMB-13340.13uM73.0% @1.0uMB-13350.097uM63.0% @1.0uMB-13360.072uM83.0% @1.0uMB-13370.4uM90.0% @1.0uMB-13380.18uM73.0% @1.0uMB-13390.12uM67.0% @1.0uMB-13400.043uM63.0% @1.0uMB-13410.42uM52.0% @1.0uMB-13420.25uM59.0% @1.0uMB-13430.065uM83.0% @1.0uMB-13440.014uM86.0% @1.0uMB-13450.27uM73.0% @1.0uMB-13460.043uM86.0% @1.0uMB-13470.021uM84.0% @1.0uMB-13480.009uM69.0% @1.0uMB-13490.037uM86.0% @1.0uMB-13500.019uM78.0% @1.0uMB-13510.068uM78.0% @1.0uMB-13520.013uM76.0% @1.0uMB-13530.062uM80.0% @1.0uMB-13540.013uM83.0% @1.0uMB-13550.07uM75.0% @1.0uMB-13560.059uM91.0% @1.0uMB-13570.18uM84.0% @1.0uMB-13580.16uM76.0% @1.0uMB-13590.00584.0% @1.0uMB-13600.110.15uM54% @3 mpk@-4 hB-13610.030.29uMB-13620.0030.29uMB-13630.0090.28uM51.0% @30 pmk @-53% @3 mpk@-4 h6 HB-13640.0090.27uM53.0% @30 mpk@-17% @3 mpk@-4 h6.0 HB-13650.1788.0% @1.0uMB-13660.040.27uMB-1367<0.10.22uMB-13680.0310.33uM44.0% @30 mpk @-B-1369<0.10.29uMB-1370<0.10.77uMB-13710.0683.0% @1.0uMB-1372<0.10.41uM48.0% @30 mpk @-B-13730.0160.17uMB-1374<0.10.28uMB-13750.010.25uMB-13760.0090.26uM 3.0% @30 mpk @-6 HB-13770.125.0uMB-13780.021.04uMB-1379<0.10.092uMB-1380<0.10.26uMB-13810.0550.73uMB-1382<0.10.44uMB-13830.00120.15uMB-13840.570.37uMB-1385<0.10.11uMB-1386<0.10.25uMB-1387<0.10.1uMB-13880.571.38uMB-13890.060.57uMB-1390<0.171.0% @1.0uMB-13910.016uM82.0% @1.0uMB-13920.059uM82.0% @1.0uMB-13933.17uM80.0% @1.0uMB-13940.32uM78.0% @1.0uMB-13951.4861.0% @1.0uMB-13961.5573.0% @1.0uMB-13970.9285.0% @1.0uMB-13980.6783.0% @1.0uMB-13990.1474.0% @1.0uMB-14000.02483.0% @1.0uMB-14010.03375.0% @1.0uMB-14020.1276.0% @1.0uMB-14034.5471% @1.0uMB-14040.670% @1.0uMB-14050.2870% @1.0uMB-14061.3956.0% @1.0uMB-14070.471.0% @1.0uMB-14080.2769.0% @1.0uMB-1409<0.172.0% @1.0uMB-1410<0.169% @1.0uMB-1411<0.181.0% @1.0uMB-14120.09780.0% @1.0uMB-14130.01678.0% @1.0uMB-14140.02583.0% @1.0uMB-14151.4179.0% @1.0uMB-14160.1481.0% @1.0uMB-14170.06969.0% @1.0uMB-14181.0182.0% @1.0uMB-14190.384.0% @1.0uMB-1420<0.182.0% @1.0uMB-14210.01475.0% @1.0uMB-14220.5868.0% @1.0uMB-14231.5884.0% @1.0uMB-14240.8676.0% @1.0uMB-14250.0983.0% @1.0uMB-14260.1980.0% @1.0uMB-1427<0.184.0% @1.0uMB-1428<0.186.0% @1.0uMB-1429<0.187.0% @1.0uMB-14300.75uM35.0% @1.0uMB-14310.36uM58.0% @1.0uMB-14320.11uM51.0% @1.0uMB-14330.26uM21.0% @1.0uMB-14340.19uM28.0% @1.0uMB-14351.8uM45.0% @1.0uMB-14361.0uM20.0% @1.0uMB-14370.3uM23.0% @1.0uMB-14382.01uM27.0% @1.0uMB-14391.7uM17.0% @1.0uMB-14400.87uM3.0% @1.0uMB-14411.95uM66.0% @1.0uMB-14421.54uM18.0% @1.0uMB-14430.014uM83.0% @1.0uMB-14440.3uM24.0% @1.0uMB-14450.43uM27.0% @1.0uMB-14460.77uM36.0% @1.0uMB-14470.5uM34.0% @1.0uMB-14481.43uM22.0% @1.0uMB-14491.61uM50.0% @1.0uMB-14502.1uM49.0% @1.0uMB-14512.88uM50% @1.0uMB-14522.41uM47.0% @1.0uMB-14532.53uM49.0% @1.0uMB-14541.6uM12.0% @1.0uMB-14551.21uM8.0% @1.0uMB-14561.29uM>1.0uMB-14570.43uM43.0% @1.0uMB-14580.95uM65.0% @1.0uMB-14590.67uM46.0% @1.0uMB-14600.96uM29.0% @1.0uMB-14610.4uM39.0% @1.0uMB-14620.22uM50.0% @1.0uMB-14632.34uM26.0% @1.0uMB-14641.18uM27.0% @1.0uMB-14653.23uM31.0% @1.0uMB-14661.69uM>1.0uMB-14671.22uM1.0% @1.0uMB-14681.61uM10.0% @1.0uMB-14690.37uM14.0% @1.0uMB-14700.6uM28.0% @1.0uMB-14710.85uM25.0% @1.0uMB-14720.93uM12.0% @1.0uMB-14731.24uM14.0% @1.0uMB-14741.23uM31.0% @1.0uMB-14752.1uM24.0% @1.0uMB-14760.047uM42.0% @1.0uMB-14772.5uM34.0% @1.0uMB-1478B-1479B-22700.72uM31% @10.0uMB-22710.93uM38% @10.0uMB-22720.26uM53.0% @10.0uMB-22731.92uM39.0% @10.0uMB-22740.26uM59.0% @10.0uMB-22752.16uM53.0% @10.0uMB-227611.5uM37.0% @10.0uMB-227714.9uM44.0% @10.0uMB-22780.8uM51.0% @10.0uMB-22790.32uM36.0% @10.0uMB-22800.4uM57.0% @10.0uMB-22810.81uM60.0% @10.0uMB-22820.91uM41.0% @10.0uMB-22830.04uM53.0% @10.0uMB-22844.61uM62.0% @10.0uMB-22852.29uM49.0% @10.0uMB-22860.017uM0.78uM 25% @30 mpk@-1 hB-22872.56uM61.0% @10.0uMB-22886.51uM46.0% @10.0uMB-22893.0uM30.0% @10.0uMB-22902.37uM59.0% @10.0uMB-22910.019uM41% @10.0uMB-22928.82uM57.0% @10.0uMB-22932.11uM56.0% @10.0uMB-22941.68uM50.0% @10.0uMB-22951.79uM56.0% @10.0uMB-229617.3uM63.0% @10.0uMB-22973.59uM57.0% @10.0uMB-22980.29uM4.22uMB-22991.97uM62.0% @10.0uMB-23000.07uM43.0% @10.0uMB-23010.18uM44.0% @10.0uMB-23021.0uM58.0% @1.0uMB-23030.011uM54.0% @10.0uMB-23041.41uM50.0% @10.0uMB-23050.54uM60.0% @10.0uMB-23065.88uM39.0% @10.0uMB-23072.29uM69.0% @10.0uMB-23080.66uM56.0% @10.0uMB-23090.29uM47.0% @10.0uMB-23100.12uM1.2uM 50% @30 mpk@-6 hB-23117.18uM60% @10.0uMB-23122.93uM43.0% @10.0uMB-231342.3uM58.0% @10.0uMB-231411.0uM66.0% @10.0uMB-23150.49uM36.0% @10.0uMB-23160.46uM58.0% @10.0uMB-23171.0uM60.0% @10.0uMB-231873.0% @10.0uM25.0% @10.0uMB-231975.0% @10.0uM40.0% @10.0uMB-232044.0% @10.0uM35.0% @10.0uMB-232169.0% @10.0uM27.0% @10.0uMB-232276.0% @10.0uM38.0% @10.0uMB-232369.0% @10.0uM46.0% @10.0uMB-232458.0% @10.0uM36.0% @10.0uMB-232560.0% @10.0uM51.0% @10.0uMB-232676.0% @10.0uM33.0% @10.0uMB-232776.0% @10.0uM23.0% @10.0uMB-232865.0% @10.0uM28.0% @10.0uMB-232972.0% @10.0uM53.0% @10.0uMB-233081.0% @10.0uM37.0% @10.0uMB-233174.0% @10.0uM44.0% @10.0uMB-233270.0% @10.0uM47.0% @10.0uMB-233358.0% @10.0uM36.0% @10.0uMB-233481.0% @10.0uM45.0% @10.0uMB-233582.0% @10.0uM50.0% @10.0uMB-233648.0% @10.0uM35.0% @10.0uMB-233746.0% @10.0uM59.0% @10.0uMB-233873.0% @10.0uM50.0% @10.0uMB-233984.0% @10.0uM>10.0uMB-234035.0% @10.0uM12.0% @10.0uMB-234175.0% @10.0uM50.0% @10.0uMB-234283.0% @10.0uM46.0% @10.0uMB-234343.0% @10.0uM27.0% @10.0uMB-234471.0% @10.0uM50.0% @10.0uMB-234564.0% @10.0uM38.0% @10.0uMB-234645.0% @10.0uM48.0% @10.0uMB-234749.0% @10.0uM50.0% @10.0uMB-234876.0% @10.0uM48.0% @10.0uMB-234975.0% @10.0uM27.0% @10.0uMB-235038.0% @10.0uM56.0% @10.0uMB-235177.0% @10.0uM1.0% @10.0uMB-235237.0% @10.0uM19.0% @10.0uMB-235338.0% @10.0uM33.0% @10.0uMB-235465.0% @10.0uM25.0% @10.0uMB-235584.0% @10.0uM50.0% @10.0uMB-235677.0% @10.0uM45.0% @10.0uMB-235747.0% @10.0uM41.0% @10.0uMB-235817.0% @10.0uM52.0% @10.0uMB-235976.0% @10.0uM35.0% @10.0uMB-236045.0% @10.0uM>10.0uMB-236119.0% @10.0uM46.0% @10.0uMB-236260% @100.0uM39.0% @10.0uMB-236344.0% @10.0uM1.0% @10.0uMB-236447.0% @10.0uM4.0% @10.0uMB-236582.0% @10.0uM43.0% @10.0uMB-236670.0% @10.0uM59.0% @10.0uMB-236746.0% @10.0uM40.0% @1.0uMB-236865.0% @10.0uM55.0% @10.0uMB-236932.0% @10.0uM>10.0uMB-237073% @100.0uM20.0% @10.0uMB-237154.0% @10.0uM36.0% @10.0uMB-237255.0% @100.0uM>10.0uMB-237350.0% @100.0uM6% @10.0uMB-237435.0% @10.0uM20.0% @10.0uMB-237562.0% @100.0uM>10.0uMB-237632.0% @10.0uM17.0% @10.0uMB-237734.0% @10.0uM17.0% @10.0uMB-237848.0% @10.0uM61.0% @10.0uMB-237973.0% @100.0uM45.0% @1.0uMB-238081% @100.0uM53.0% @10.0uMB-238168% @100.0uM2.0% @10.0uMB-238251.0% @10.0uM24.0% @10.0uMB-238363.0% @10.0uM35.0% @10.0uMB-238449% @100.0uM10.0% @10.0uMB-238579.0% @10.0uM19.0% @10.0uMB-238638.0% @10.0uM19.0% @10.0uMB-238750.0% @100.0uM>10.0uMB-238842.0% @10.0uM24.0% @10.0uMB-238939.0% @10.0uM29.0% @10.0uMB-239034.0% @10.0uM27.0% @1.0uMB-239140.0% @10.0uM59.0% @10.0uMB-239263.0% @10.0uM46.0% @10.0uMB-239343.0% @10.0uM>10.0uMB-239437.0% @10.0uM22.0% @10.0uMB-239532.0% @10.0uM28.0% @10.0uMB-239675.0% @10.0uM>10.0uMB-239783.0% @10.0uM22.0% @10.0uMB-239855% @100.0uM10.0% @10.0uMB-239969.0% @10.0uM18.0% @10.0uMB-240060.0% @10.0uM40.0% @10.0uMB-240178.0% @10.0uM44.0% @10.0uMB-240243.0% @10.0uM52.0% @10.0uMB-240372% @100.0uM52.0% @10.0uMB-240458% @100.0uM52.0% @10.0uMB-240547% @100.0uM>10.0uMB-240645.0% @10.0uM24.0% @10.0uMB-240747% @100.0uM27.0% @10.0uMB-240839.0% @10.0uM10.0% @10.0uMB-240978.0% @10.0uM26.0% @10.0uMB-241033.0% @10.0uM32.0% @10.0uMB-241126% @100.0uM13.0% @10.0uMB-241240.0% @10.0uM31.0% @10.0uMB-241375.0% @10.0uM37.0% @10.0uMB-241486.0% @10.0uM38.0% @10.0uMB-241594.0% @10.0uM50.0% @10.0uMB-241685.0% @10.0uM43.0% @1.0uMB-241783.0% @10.0uM18.0% @10.0uMB-241888.0% @10.0uM34.0% @10.0uMB-241986.0% @10.0uM66.0% @10.0uMB-242070.0% @10.0uM34.0% @10.0uMB-242189.0% 210.0uM38.0% @10.0uMB-242290.0% @10.0uM17.0% @10.0uMB-242385.0% @10.0uM>10.0uMB-242486.0% @10.0uM43.0% @10.0uMB-242579.0% @10.0uM42.0% @10.0uMB-242688.0% @10.0uM53.0% @10.0uMB-242787.0% @10.0uM59.0% @10.0uMB-242882.0% @10.0uM50.0% @10.0uMB-242992.0% @10.0uM32.0% @10.0uMB-243090.0% @10.0uM61.0% @10.0uMB-243185.0% 210.0uM68.0% @10.0uMB-243286.0% 210.0uM40.0% @10.0uMB-243394.0% @10.0uM84.0% @10.0uMB-243492.0% @10.0uM63.0% @10.0uMB-243584.0% @10.0uM4.0% @10.0uMB-243680.0% @10.0uM54.0% @10.0uMB-243782.0% @10.0uM41.0% @10.0uMB-243875.0% @10.0uM40.0% @10.0uMB-243981.0% @10.0uM44.0% @10.0uMB-244077.0% @10.0uM78.0% @10.0uMB-244186.0% @10.0uM46.0% @10.0uMB-244286.0% @10.0uM>10.0uMB-244384.0% @10.0uM44.0% @10.0uMB-244489.0% @10.0uM7.0% @10.0uMB-244594.0% @10.0uM15.0% @10.0uMB-244690.0% @10.0uM28.0% @10.0uMB-244794.0% @10.0uM>10.0uMB-244875.0% @10.0uM30.0% @10.0uMB-244986.0% @10.0uM42.0% @10.0uMB-245087.0% @10.0uM46.0% @1.0uMB-245187.0% @10.0uM45.0% @10.0uMB-245289.0% @10.0uM33.0% @10.0uMB-245391.0% @10.0uM>10.0uMB-245488.0% @10.0uM40.0% @10.0uMB-245587.0% @10.0uM54.0% @10.0uMB-245686.0% @10.0uM53.0% @10.0uMB-245790.0% @10.0uM18.0% @10.0uMB-245883.0% @10.0uM36.0% @10.0uMB-245982.0% @10.0uM81.0% @10.0uMB-246080.0% @10.0uM79.0% @10.0uMB-246167.0% @10.0uM59.0% @10.0uM

Biological data from a number of compounds of Examples C-74 through C-139 are shown in the following tables.

In vitro P38-alpha kinase inhibitory data are shown in the column identified as:

“P38 alpha kinase IC50, μM”

In vitro human whole blood assay data for measuring the ability of the compounds to inhibit TNF production in human whole blood stimulated with LPS are shown in the column identified as:

“Human Whole Blood IC50, μM or %Inhib@conc. (μM)”

In vivo assessment of the ability of the compounds to inhibit LPS-stimulated TNF release in the rat is shown in the column identified as:

“Rat LPS Model % Inhibition@adose@predose time”

wherein the dose is milligram per kilogram (mpk) administered by oral gavage and the predose time indicates the number of hours before LPS challenge when the compound is administered.

Rat LPS ModelP38 alphaHuman Whole Blood% Inhibition@kinaseIC50, μM ordose@predoseExample#IC50, μM% Inhib@conc. (μM)timeC-740.0370.5654% @5 mpk@-4 hC-750.0450.471% @5 mpk@-4 hC-760.073.2466% @5 mpk@-4 hC-770.0718.292% @5 mpk@-4 hC-780.06810.587% @5 mpk@-4 hC-790.0450.5283% @5 mpk@-4 hC-800.00851% @ 5 μMC-810.03740% @ 5 μMC-820.157.31C-830.241.2325% @5 mpk@-4 hC-840.0480.8822% @5 mpk@-4 hC-850.57>25C-860.0070.1966% @5 mpk@-4 hC-870.0270.34C-880.0120.359% @5 mpk@-4 hC-890.0390.1227% @5 mpk@-4 hC-900.0370.48C-910.0542.3163% @5 mpk@-4 hC-920.0240.2866% @5 mpk@-4 hC-930.0090.3850% @5 mpk@-4 hC-940.020.2773% @5 mpk@-4 hC-950.133.9132% @5 mpk@-4 hC-960.0772.138% @5 mpk@-4 hC-970.0253.8321% @5 mpk@-4 hC-980.0160.6478% @5 mpk@-4 hC-990.0620.3836% @5 mpk@-4 hC-1000.0270.2744% @5 mpk@-4 hC-1010.0833.7152% @5 mpk@-4 hC-1020.297.5672% @5 mpk@-4 hC-1050.0330.1346% @5 mpk@-4 hC-1060.0260.4423% @5 mpk@-4 hC-1070.0140.3811% @5 mpk@-4 hC-1080.020.73 0% @5 mpk@-4 hC-1110.216.0539% @5 mpk@-4 hC-1120.546.3689% @5 mpk@-4 hC-1130.0822.7277% @5 mpk@-4 hC-1140.111.7339% @5 mpk@-4 hC-1150.04210.239% @5 mpk@-4 hC-1160.4290.5053% @5 mpk@-4 hC-1173.427.2671% @5 mpk@-4 hC-1180.298>2539% @5 mpk@-4 hC-1200.718.626% @5 mpk@-4 hC-1210.1115.339% @5 mpk@-4 hC-1220.02555% @5 mpk@-4 hC-1230.67>25.0C-1240.174.5651% @20 mpk@-4 hC-1257.22>25.0C-1260.71>25.0 6% @20 mpk@-4 hC-1270.0380.2753% @5 mpk@-4 hC-1280.092.2263% @5 mpk@-4 hC-1320.08644% @ 5 μMC-1330.164.5455% @5 mpk@-4 hC-1356.0C-1360.032C-1370.05158% @5 mpk@-4 hC-1380.280.6826% @5 mpk@-4 hC-1390.23.6646% @5 mpk@-4 h

Additional compounds of interest can be prepared as set forth above and as described below in Scheme D-1, wherein the R₁and R₂substituents are as defined previously.
embedded image

The synthesis begins with the treatment of 4-methylpyrimidine 2 with a base such as LiHMDS, LDA or tBuOK in an organic solvent such as THF or ether which is cooled in an ice bath (0-10° C.). To the resulting 4-methylanion is added a solution of a suitably protected (Boc is shown) ethyl ester of isonipecotic acid 1 in THF or ether. The reaction is allowed to warm to room temperature and stirred for a period of 4 hours to 20 hours at which time the desired ketone 3 is isolated after aqueous work up. Condensation of the ketone 3 with tosylhydrazide in toluene or benzene as a solvent at refluxing temperatures for a period of 1 hour to 5 hours affords the hydrazone 4. The hydrazone 4 is reacted with a suitably substituted benzoyl chloride 5, in the presence of a base such as LiHMDS or LDA or tBuOK or triethylamine at temperatures ranging from 0° C. to 70° C. The reaction is stirred for a period of 3-6 hours. Acidic hydrolysis of the protecting groups with an aqueous acid such as HCl or H₂SO₄and subsequent neutralization with an aqueous base such as NaOH or KOH affords the desired pyrazole 6. Treatment of the pyrazole 6 with an acid chloride 7 in the presence of base or with an acid 8 under standard peptide coupling conditions (EDC or DCC or PyBrOP with an additive such as HOBt or HATU and base such as N-methylmorpholine or diisopropylethylamine or triethylamine) affords the desired pyrazole amide 9. In most instance the desired products can be obtained pure by direct trituration with solvents such as methanol, ethyl acetate, acetonitrile or ether and/or recrystallization from suitable solvents.

The following examples contain detailed descriptions of the methods of preparation of these additional compounds that form part of the invention. These detailed descriptions are presented for illustrative purposes only and are not intended as a restriction on the scope of the invention. All compounds showed NMR spectra consistent with their assigned structures.

EXAMPLE D-1
N-(2-Hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole

embedded image

Step 1: A 5 L 4-necked round bottom flask fitted with an overhead mechanical stirrer, N₂inlet and a thermocouple was charged with 600 g (2.75 mol) of di-tert-butyl-dicarbonate and 1.5 L of CH₂Cl₂. The solution was cooled to 0° C. and 428 g (2.73 mol) of ethyl isonipecotate was added dropwise via an addition funnel. The addition took 45 minutes and the temperature rose from 0° C. to 17.4° C. The reaction mixture was stirred for an additional 2 hours at ambient temperature. The solvent was removed in vacuo to afford 725 g of a yellow oil (residual solvent remained).
embedded image

Step 2: A 3 L 3-necked round bottom flask fitted with an overhead mechanical stirrer, a N₂inlet, an addition funnel and a thermocouple was charged with 1850 mL (1.85 mol) of a 1.0 M solution of LiHMDS in THF. The flask was cooled to 5° C. and 68 mL (0.74 mol) of 4-methylpyrimidine was added (neat) to the stirred solution. To this solution was added 198 g (0.77 mol) of Ethyl-N-t-butylcarbonyl isonipecotate dissolved in 160 mL of THF. The ice bath was removed and the reaction was allowed to stir for 18 hours. The reaction was quenched with 500 mL of saturated NH₄Cl and was extracted with 500 mL of ethyl acetate. The organic phase was washed with 500 mL of brine, dried over anhydrous Na₂SO₄, filtered and concentrated in vacuo to afford 235 g of a brown oil.
embedded image

Step 3: A 2 L 3-necked round bottom flask fitted with an overhead mechanical stirrer, a Dean-Stark trap and a thermocouple was charged with 1.5 L of toluene, 226 g (0.742 mol) of N-t-butylcarbonyl-1-(4-piperidyl)-2-(4-pyrimidyl)-1-ethanone and 138.4 g (0.743 mol) of tosyl hydrazide. The mixture was warmed to reflux. The solution was allowed to reflux for 2 hours and was cooled to ambient temperature. The reaction was allowed to stand overnight. A fine precipitate formed and was removed by filtration. The filtrate was concentrated in vacuo to afford a brown solid. The solid was suspended in 500 mL of ethyl acetate and the resulting mixture was placed in a sonication bath for 5 hours. The mixture was cooled in an ice bath and was filtered to afford 310 g of a wet solid. The solid was dried in a vacuum oven (40° C., 5 mm) overnight to afford 248 g of the desired hydrazone (71%).

¹H NMR (CDCl₃) δ 9.03 (d, J=1.2 Hz, 1H), 8.72 (d, J=5.2 Hz, 2H), 7.89 (d, J=8.3 Hz, 2H), 7.32 (d, J=8.1 Hz, 2H), 7.26 (dd, J=5.2, 1.0 Hz, 1H), 4.03 (d, J=12.1 Hz, 2H), 3.76 (s, 2H), 2.71 (t, J=12.1 Hz, 2H), 2.43 (s, 3H), 2.34 (m, 1H), 1.66 (d, J=13.5 Hz, 2H), 1.47 (s, 9H), 1.38 (m, 2H); MS (M +H): 474 (base peak).

Step 4:
embedded image

Method A. A 2 L 3-necked round bottom flask fitted with an overhead mechanical stirrer, a N₂inlet, an addition funnel and a thermocouple was charged with 400 mL (400 mmol) of a 1.0 M solution of LiHMDS in THF. The solution was cooled to −21.9° C. and a solution of 62 g (131 mmol) of N-t-butylcarbonyl-1-(4-piperidyl)-2-(4-pyrimidyl)-1-ethanone p-toluenesulfonyl hydrazone in 400 mL of THF was added slowly. The temperature never exceeded −11° C. throughout the addition. The solution was re-cooled to −19.6° C. and 23.0 g (131 mmol in 250 mL of THF) of p-chlorobenzoylchloride was added slowly. The temperature never exceeded −13° C. throughout the addition. The cooling bath was removed and the reaction was allowed to warm to ambient temperature. After 3 hours the reaction was quenched with 600 mL of 3 N HCl. The reaction was warmed to reflux and was held at reflux for 2 hours. The reaction was allowed to cool to ambient temperature overnight. The reaction mixture was washed with 1.4 L of Et₂O and the aqueous phase was neutralized with 1 L of 2.5 N NaOH. The aqueous phase was extracted with ethyl acetate (2×1000 mL). The combined organic phases were washed with brine (1×500 mL), dried over anhydrous Na₂SO₄, filtered and concentrated in vacuo to afford 21 g of a yellow solid. The solid was suspended in 500 mL of 2:1 Et₂O/hexane. After sonication the solid was isolated by filtration to leave a wet solid. The solid was dried in a vacuum oven to afford 13.8 g of 5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl) pyrazole.

¹H NMR (DMSO-d₆) 9.18 (s, 1H), 8.65 (d, J=5.2, 1H), 7.44 (d, J=8.5, 2H), 7.37 (d, J=7.7 Hz, 2H), 7.15 (d, J=5.2 Hz, 1H), 3.16 (m, 1H), 3.00 (d, J=11.9 Hz, 2H), 2.52 (m, 2H), 1.69 (m, 4H); MS (M +H): 340 (base peak).
embedded image

Method B: To a solution of 200 g (423 mmol) of N-t-butylcarbonyl-1-(4-piperidyl)-2-(4-pyrimidyl)-1-ethanone p-toluenesulfonyl hydrazone in 800 mL THF was added 70 mL (500 mmol) of triethylamine in a 3 L three necked flask. The solution was cooled in an ice/salt/water bath to 0-5° C. To this cold solution was added a solution of 4-chlorobenzoyl chloride (74 g, 423 mmol) in 100 mL THF dropwise, maintaining the temperature below 10° C. After the addition was complete the ice-bath was removed and replaced with a heating mantle. 4-N,N-dimethylaminopyridine (5 g, 40 mmol) was added and the reaction mixture was heated to 50° C. for 15-30 minutes. The reaction mixture was filtered and the residue washed with THF (100 mL). The combined filtrates were evaporated under reduced pressure to a semisolid.

The semisolid residue was dissolved in 450 mL THF and 180 mL of 12 N HCl was added to this solution rapidly. The reaction mixture was heated to 65° C. for 1.5-2 hours and transferred to a separatory funnel. The organic layer was discarded and the aqueous phase was washed twice with 200 mL of THF. The aqueous phase was transferred back to a 2 L flask and cooled to 0-10° C. in an ice bath. The pH of the solution was adjusted to between 9-10 by dropwise addition of 15 N ammonium hydroxide (˜180 mL). This mixture was transferred back to a separatory funnel and extracted with warm n-butanol (3×150 mL). The combined n-butanol phases were evaporated under reduced pressure to dryness. The residue was then stirred with methanol (200 mL) filtered and dried to obtain 129 g (90%) of the desired 5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl) pyrazole as a off-white solid. This material was identical in all respects to the material prepared by Method A.
embedded image

Step 5: A 1 L round bottom flask was charged with 34.2 g (102 mmol) of 5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl) pyrazole, 500 mL of CH₂Cl₂and 26.6 mL (153 mmol) of Hunig's base. To this suspension was added 16.5 g (122 mmol) of 1-hydroxybenzotriazole and 8.1 g (106 mmol) of glycolic acid. The addition of glycolic acid was followed by the addition of 23.7 g (122 mmol) of 1-(3-dimethylaminopropyl)3-ethylcarbodiimide hydrochloride. The reaction was allowed to stir at ambient temperature overnight. The reaction was concentrated in vacuo to leave an oily residue. The residue was dissolved in 400 mL of methanol and 50 mL of 2.5 N NaOH. The reaction mixture was stirred at ambient temperature for 1 hour. The mixture was acidified to pH 5 with 2 N HCl and was extracted with CH₂Cl₂(6×200 mL). The combined organic phases were filtered through phase paper and the filtrate was concentrated in vacuo to leave a yellow residue. The residue was treated with 75 mL of acetonitrile. A precipitate formed. The solid was filtered and washed with additional acetonitrile and Et₂O to afford 31.4 g of N-(2-hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl) pyrazole. ¹H NMR (DMSO-d₆) 9.20 (s, 1H), 8.67 (d, J=4.8, 1H), 7.40 (m, 4H), 7.17 (d, J=4.0, 1H), 4.53 (m, 2H), 4.13 (s, 2H), 3.77 (m, 1H), 3.05 (t, J=12.7 Hz, 1H), 2.69 (m, 1H), 1.90 (m, 2H), 1.73 (m, 2H); MS (M+H) 398 (base peak).

EXAMPLE D-2
N-(2-Hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole hydrochloride

embedded image

A 25 mL round bottom flask was charged with 65 mg (0.164 mmol) of N-(2-hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl) pyrazole and 2.5 mL of dioxane. To this suspension was added 0.082 mL of 4 N HCl in dioxane. The mixture was stirred for 2 hours. The mixture was diluted with 5 mL of Et₂O and filtered. The solid was dried over solid CaSO₄under vacuum for 12 h to afford 68 mg of N-(2-hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl) pyrazole hydrochloride. ¹H NMR (DMSO-d₆) 9.18(s, 1H), 8.63(d, J=5.37 Hz, 1H), 7.40(d, J=8.59 Hz, 2H), 7.33(d, J=8.59 Hz, 2H), 7.15(m, 1H), 4.40(m, 1H), 4.06(m, 2H), 3.72(m, 1H), 3.33(m, 1H), 2.97(m, 1H), 2.62(m, 1H), 1.83(m, 2H), 1.64(m, 2H); MS (M+H): 398.

EXAMPLE D-3
N-(2-Methoxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole (fumarate salt)

embedded image

To a suspension of 250 mg (0.74 mmol) of 5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl) pyrazole (Example C-1, Step 3) and 180 mg (1.48 mmol) of N,N-dimethylamino pyridine in 20 mL of CH₂Cl₂was added 88 mg (0.81 mmol) of 2-methoxyacetyl chloride. The reaction was stirred for 5 hours. The reaction was quenched with 20 mL of saturated NH₄Cl. The mixture was extracted with n-butyl alcohol and the organic layer was washed with brine. The solvent was removed to afford 72 mg of an oil. This oil was dissolved in 1 mL of warm MeOH. This solution was combined with a warm solution of 1 equivalent of fumaric acid in warm MeOH. The solution was cooled to ambient temperature and the reaction was allowed to stir for 1 hour. The solvent was removed in vacuo and the residue was triturated with Et₂O. The resulting solid was isolated by filtration to yield 56 mg of an off-white powder. ¹H NMR (DMSO-d₆) 13.23 (bs, 1H), 9.19 (d, J=1.2 Hz, 1H), 8.65 (d, J=5.1 Hz, 1H), 7.41 (m, 4H), 7.16 (dd, J=5.4, 1.2 Hz, 1H), 4.45 (bd, J=11.1 Hz, 1H), 4.11 (qz, J=39.0, 13.8 Hz, 2H), 3.86 (bd, J=12.9 Hz, 1H), 3.32 (m, 4H), 3.04 (bt, J=12.3 Hz, 1H), 2.63 (bt, J=12.0 Hz, 1H), 1.77 (m, 4H); MS (M +H): 411 (base peak).

EXAMPLE D-4
N-(2-Hydroxy-2-methylpropionyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole hydrochloride

embedded image

Step 1: To a suspension of 2.05 g (6.1 mmol) of 5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl) pyrazole (Example C-1, Step 3) and 3.7 g (30.5 mmol) of N,N-dimethylamino pyridine in 30 mL of CH₂Cl₂was added 1.06 mL (7.3 mmol) of 2-acetoxy-2-methylpropionyl chloride. The reaction was allowed to stir overnight at ambient temperature. The reaction was quenched with saturated NH4Cl and water. The resulting aqueous phase was extracted with CH₂Cl₂. The combined organic layers were concentrated in vacuo to leave an oily solid. The residue was treated with CH₃CN and allowed to stand for 15 minutes. The resulting suspension was diluted with Et2O and was filtered to afford 2.2 g of a solid. Analysis by LC/MS indicated that the solid was a mixture of the hydroxy derivative and the acetoxy derivative. This solid was carried on to the next step without further purification.

Step 2: A solution of 1 g of the solid from step 1 in 10 mL of MeOH was treated with 500 mg of solid K₂CO₃. The mixture was allowed to stir overnight at ambient temperature. The suspension was treated with water and the resulting solution was extracted with ethyl acetate. The organic phase was filtered through phase separation paper (to remove the residual water) and was concentrated in vacuo to leave an oily solid. The solid was dried under vacuum and was treated with CH₃CN. The suspension was filtered to afford 825 mg of an off-white solid. This solid was suspended in 5 mL of dioxane and 0.5 mL of 4 N HCl in dioxane was added. The suspension was stirred for 1 hour and the suspension was filtered to leave a solid. The solid was washed with Et₂O and the resulting suspension was filtered to give 900 mg of the title compound. ¹H NMR (DMSO-d₆) 9.23 (s, 1H), 8.69 (s, 1H), 7.45 (m, 4H), 7.19 (s, 1H), 4.8 (br m, 4H), 3.85 (m, 2H), 3.38 (m, 1H), 1. 89 (m, 2H), 1.72 (m, 2H), 1.37 (s, 6H); MS (M+H): 426 (base peak).

EXAMPLE D-5
(S)-N-(2-Hydroxypropionyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole hydrochloride

embedded image

By following the method of Example C-1 and substituting (S)-lactic acid for glycolic acid the title compound was prepared. ¹H NMR (DMSO-d₆) 13.15 (s, br, 1H), 9.12(d, J=1.07 Hz, 1H), 8.59(d, J=5.37 Hz, 1H), 7.39(d, J=7.79 Hz, 2H), 7.31(d, J=8.33, 2H), 7.10(dd, J=1.34, 5.1 Hz, 1H), 4.76(m, 1H), 4.41(m, 2H), 3.99(m, 1H), 2.97(m, 1H), 2.45(m, 1H), 1.83(m, 2H), 1.64(m, 2H), 1.15(m, 3H); MS (M+H): 412 (base peak).

EXAMPLE D-6
(R)-N-(2-Hydroxypropionyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole hydrochloride

embedded image

By following the method of Example C-1 and substituting (R)-lactic acid for glycolic acid the title compound was prepared. ¹H NMR (CDCl₃) 9.24(s, 1H), 8.52(d, J=5.0 Hz, 1H), 7.32-7.36(m, 4H), 6.98(d, J=5.3 Hz, 1H), 4.72(d, J=10.5 Hz, 1H), 4.55(br, 1H), 3.88(d, J=13.1 Hz, 1H), 3.66(br, 1H), 3.19(br, 1H), 2.82(t, J=12.4 Hz, 1H), 2.10(br, 2H), 1.37(d, J=6.2 Hz, 3H), 1.81-1.90(m, 2H); MS (M+H): 412 (base peak).

EXAMPLE D-7
(R)-N-(2-Hydroxy-2-phenylacetyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole

embedded image

By following the method of Example C-1 and substituting (R)-phenylacetic acid for glycolic acid the title compound was prepared. ¹H NMR (DMSO-d₆) 9.15 (d, J=0.9 Hz, 1H), 8.63 (d, J=5.4 Hz, 1H), 7.40 (m, 9H), 7.13 (t, J=6.6 Hz, 1H), 5.43 (d, J=19.5 Hz, 1H), 4.51 (s, 1H), 4.04 (m, 1H), 3.33 (m, 4H), 2.8 (m, 2H), 1.68 (m, 3H); MS (M+H): 474 (base peak).

EXAMPLE D-8
N-(2-Hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-fluorophenyl)pyrazole

embedded image

By following the method of Example C-1 and substituting 4-fluorobenzoyl chloride for 4-chlorobenzoyl chloride the title compound was prepared. ¹H NMR (DMF-d₇) 13.48(s, 1H), 9.40(s, 1H), 8.86(d, J=5.1 Hz, 1H), 7.71(br, 2H), 7.42(bd, J=5.2 Hz, 3H), 4.78(br, 1H), 4.43(s, 2H), 4.04(br, 1H), 3.79(br, 1H), 3.70(s, 1H), 3.34(t, J=12.2 Hz, 1H), 3.0(br, 1H), 2.21(d, J=10.9 Hz, 2H), 2.08(br, 1H); MS (M+H): 382 (base peak).

EXAMPLE D-9
N-(2-Hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-trifluoromethylphenyl)pyrazole

embedded image

By following the method of Example C-1 and substituting 4-trifluoromethylbenzoyl chloride for 4-chlorobenzoyl chloride the title compound was prepared.

¹H NMR (DMF-d₇) 13.47(s, 1H), 9.24(s, 1H), 8.73(d, J=4.0 Hz, 1H), 7.77(bd, J=13.3 Hz, 4H), 7.34(d, J=4.3 Hz, 1H), 4.61(br, 1H), 4.26(s, 2H), 3.87(br, 1H), 3.52(s, 2H), 3.17(t, J=12.0 Hz, 1H), 2.8 (br, 1H), 2.02(br, 2H), 1.91(br, 1H); MS (M+H): 432 (base peak).

EXAMPLE D-10
N-(2-Hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-trifluoromethoxyphenyl)pyrazole

embedded image

By following the method of Example C-1 and substituting 4-trifluoromethoxybenzoyl chloride for 4-chlorobenzoyl chloride the title compound was prepared.

¹H NMR (DMF-d₇) 13.55(s, 1H), 9.40(s, 1H), 8.88(d, J=4.6 Hz, 1H), 7.81(d, J=7.7 Hz, 2H), 7.64(br, 2H), 7.47(d, J=4.4 Hz, 1H), 4.75(br, 1H), 4.42(s, 2H), 4.04(d, J=12.5 Hz, 1H), 3.69(br, 2H), 3.34(t, J=12.0 Hz, 1H), 3.0(br, 1H), 2.20(d, J=11.7 Hz, 2H), 2.05(br, 1H); MS (M+H): 448 (base peak).

EXAMPLE D-11
N-(2-Hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(3-chlorophenyl)pyrazole

embedded image

By following the method of Example C-1 and substituting 3-chlorobenzoyl chloride for 4-chlorobenzoyl chloride the title compound was prepared. ¹H NMR (DMF-d₇) 13.41(s, 1H), 9.24(s, 1H), 8.73(d, J=4.9 Hz, 1H), 7.56(s, 1H), 7.49(br, 2H), 7.41(br, 1H), 7.32(d, J.=4.2 Hz, 1H), 4.60(d, J=11.7 Hz, 1H), 4.25(s, 2H), 3.87(d, J=12.7 Hz, 1H), 3.52(bs, 2H), 3.17(t, J=12.1 Hz, 1H), 2.84(d, J=12.5 Hz, 1H), 2.03(d, J=11.9 Hz, 2H), 1.87(br, 1H); MS (M+H): 398 (base peak).

EXAMPLE D-12
N-(2-Hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(3-fluorophenyl)pyrazole

embedded image

By following the method of Example C-1 and substituting 3-fluorobenzoyl chloride for 4-chlorobenzoyl chloride the title compound was prepared. ¹H NMR (DMF-d₇) 13.38(s, 1H), 9.24(s, 1H), 8.72(d, J=5.2 Hz, 1H), 7.49(dd, J=8.0 and 6.2 Hz, 1H), 7.24-7.32(m, 4H), 4.60(d, J=13.1 Hz, 1H), 4.25 (s, 2H), 3.87(d, J=13.3 Hz, 1H), 3.55-3.60(m, 1H), 3.52(s, 1H), 3.17(t, J=12.2 Hz, 1H), 2.82(d, J=12.9 Hz, 1H), 2.03(d, J=10.9 Hz, 2H), 1.83-1.96(m, 1H); MS (M+H): 382 (base peak).

EXAMPLE D-13
N-(2-Hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(3-trifluoromethylphenyl)pyrazole

embedded image

By following the method of Example C-1 and substituting 3-trifluoromethylbenzoyl chloride for 4-chlorobenzoyl chloride the title compound was prepared.

¹H NMR (DMF-d₇) 13.76(s, 1H), 9.41(s, 1H), 8.91(d, J=5.3 Hz, 1H), 8.02(s, 1H), 7.95(t, J=6.5 Hz, 2H), 7.85(t, J=7.5 Hz, 1H), 7.53(d, J=4.6 Hz, 1H), 4.78(d, J=11.9 Hz, 1H), 4.45(d, J=16.3 Hz, 2H), 4.06(d, J=12.5 Hz, 1H), 3.69(bs, 2H), 3.34(t, J=11.3 Hz, 1H), 3.01(d, J=13.1 Hz, 1H), 2.20(d, J=11.1 Hz, 2H), 2.12(br, 1H); MS (M+H): 432 (base peak).

The following examples can be prepared in a manner similar to that described above for the synthesis of Examples C1-C13.

EXAMPLE D-14
5-[4-N-(2-hydroxy-2-(2-chlorophenyl)acetyl)piperidyl]-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE D-15
5-[4-N-(2-hydroxy-2-(3-chlorophenyl)acetyl)piperidyl]-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE D-16
5-[4-N-(1-hydroxy-1-cyclohexylacetyl)piperidyl]-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE D-17
5-[4-N-(2-hydroxy-1-cyclohexylacetyl)piperidyll-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE D-18
5-[4-N-(3-hydroxy-1-cyclohexylacetyl)piperidyl]-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE D-19
5-[4-N-(4-hydroxy-1-cyclohexylacetyl)piperidyl]-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE D-20
5-[4-N-(1-hydroxy-1-cyclopentylacetyl)piperidyl]-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE D-21
5-[4-N-(2-hydroxy-1-cyclopentylacetyl)piperidyl]-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE D-22
5-[4-N-(3-hydroxy-1-cyclopentylacetyl)piperidyl]-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE D-23
5-[4-N-(3-hydroxypropionyl)piperidyl]-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE D-24
5-[4-N-(2-hydroxy-3,3,3-trifluoropropionyl)piperidyl]-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE D-25
5-[4-N-(2-hydroxy-3-methylbutyryl)piperidyl]-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE D-26
5-[4-N-(2-hydroxyisocaproyl)piperidyl]-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE D-27
5-[4-N-(2-hydroxy-2-cyclohexylacetyl)piperidyl]-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE D-28
5-(4-N-(2-hydroxy-2-(4-methoxyphenyl)acetyl)piperidyl]-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE D-29
5-[4-N-(2-hydroxy-2-(3-methoxyphenyl)acetyl)piperidyl]-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE D-30
5-[4-N-(2-hydroxy-2-(4-trifluoromethylphenyl)acetyl)piperidyl]-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE D-31
5-[4-N-(2-hydroxy-3-phenylpropionyl)piperidyl]-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE D-32
5-[4-N-(2-hydroxy-3-(4-hydroxyphenyl)propionyl)piperidyl]-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE D-33
5-[4-N-(2-hydroxy-3-imidazolpropionyl)piperidyl]-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole

embedded image

The synthesis of 2-substituted pyrimidinyl pyrazoles is shown in Scheme 2. Reaction of 2-methylmercapto-4-methyl pyrimidine 10 with N-Boc methyl ester of isonipecotic acid (1) under basic (base selected from LiHMDS or LDA or tBuOK) conditions in an anhydrous solvent such as tetrahydrofuran or ether affords the desired ketone 11. Condensation of the ketone 11 with tosyl hydrazine under refluxing conditions in either toluene or benzene affords the hydrazone 12. The hydrazone 12 is deprotonated under basic (base selected from LiHMDS or LDA or tBuOK) conditions in an anhydrous solvent such as tetrahydrofuran or ether and the anion is reacted in situ with a suitably substituted benzoyl chloride 5 to afford, after mild aqueous work up, the desired and fully protected pyrazole 13. Oxidation of the 2-mercaptomethyl group present in 13 with oxidants selected from but not limited to Oxone®, H₂O₂or mCPBA in solvents such as dichloromethane, acetonitrile or tetrahyrofuran affords the 2-methane sulfonyl pyrazole 14. The 2-methanesulfone group in 14 is conveniently displaced with various amines, aryloxides or alkoxides in solvents such as tetrahydrofuran, dioxane, dimethylformamide or acetonitrile at temperatures ranging from 20° C. to 200° C. Under these reaction conditions the tosyl protecting group on the pyrazole is also simultaneously deprotected. Aqueous workup affords the desired tosyl deprotected, 2-alkoxy, or 2-aryloxy or 2-amino substituted pyrazoles 15. The alkoxides or aryloxides are generated from their respective alcohols or phenols with suitable bases such as LiHMDS, NaH, LDA or tBuOK in solvents such as tetrahydrofuran, dioxane or dimethylformamide. Deprotection of the remaining N-Boc group in 15 is accomplished with trifluoroacetic acid or hydrochloric acid in solvents such as dichloromethane or dioxane to afford the pyrazole 16. Treatment of the pyrazole 16 with an acid chloride 7 in the presence of base or with an acid 8 under standard peptide coupling conditions (EDC or DCC or PyBrOP with an additive such as HOBt or HATU and base such as N-methylmorpholine or diisopropyl ethylamine) affords the desired final products 17.
embedded image

The following 2-substituted pyrimidine compounds can be prepared as set forth above, particularly in a manner similar to that outlined above in Scheme D-2.

EXAMPLE D-34
5-[4-N-(2-hydroxyacetyl)piperidyl]-4-[4-(2-thiomethyl)pyrimidyl]-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE D-35
5-[4-N-(2-hydroxyacetyl)piperidyl]-4-[4-(2-methanesulfonyl)pyrimidyl]-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE D-36
5-[4-N-(2-hydroxyacetyl)piperidyl]-4-[4-(2-amino)pyrimidyl]-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE D-37
5-[4-N-(2-hydroxyacetyl)piperidyl]-4-[4-(2-methylamino)pyrimidyl]-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE D-38
5-[4-N-(2-hydroxyacetyl)piperidyl]-4-[4-(2-isopropylamino)pyrimidyl]-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE D-39
5-[4-N-(2-hydroxyacetyl)piperidyl]-4-[4-(2-S-methylbenzylamino)pyrimidyl]-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE D-40
5-[4-N-(2-hydroxyacetyl)piperidyl]-4-[4-(2-R-methylbenzylamino)pyrimidyl]-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE D-41
5-[4-N-(2-hydroxyacetyl)piperidyl]-4-[4-(2-methoxy)pyrimidyl]-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE D-42
5-[4-N-(2-hydroxyacetyl)piperidyl]-4-[4-(p-fluorophenoxy)pyrimidyl]-3-(4-chlorophenyl)pyrazole

embedded image

EXAMPLE D-43
5-[4-N-(2-hydroxyacetyl)piperidyl]-4-[4-(p-fluoroanilino)pyrimidyl]-3-(4-chlorophenyl)pyrazole

embedded image

In a manner similar to that outlined above in Scheme D-1, for the synthesis of the piperidine analogs 6, the aminocyclohexane analogs are prepared by substitution of 1 in Scheme D-1 with a suitably protected (Boc is shown) methyl or ethyl ester of cis-aminocyclohexane carboxylic acid 10 or trans-aminocyclohexane carboxylic acid 11 or trans-aminomethylcyclohexane carboxylic acid 12, which affords the cis-aminocyclohexane 13, or trans-aminocyclohexane 14 or the trans-aminomethylcyclohexane 15 respectively (Scheme 3). Suitable reductive alkylations on 13, 14 or 15 with 1-1.5 equivalents of aldehydes or ketones in the presence of a reducing agent like sodium cyanoborohydride or sodium triacetoxyborohydride in solvents such as methanol, ethanol, acetic acid, tetrahydrofuran or dichloromethane lead to the desired mono-alkylated derivatives 16, 17 or 18 respectively.
embedded image

The dimethyl derivatives 19, 20 or 21 can be prepared by heating a solution of the aminocyclohexanes 13, 14 or 15 respectively in a mixture of formaldehyde and formic acid at temperatures ranging from 40° C. to 110° C.

An additional group of compounds of interest includes the following:
embedded image

Biological data for a number of compounds are shown in the following table. In vitro p38 alpha kinase inhibitory data are shown in the column identified as “p38 alpha IC₅₀(μM)”. In vitro human whole blood assay data for measuring the ability of the compounds to inhibit TNF production in human whole blood stimulated with LPS are shown in the column identified as: “HWB IC₅₀(μM)”. In vivo assessment of the ability of the compounds to inhibit LPS-stimulated TNF-release in the rat is shown in the column identified as: “ratLPS/%Inh@dose (mg/kg)” wherein the dose is in milligram per kilogram (mg/kg) administered by oral gavage, 4 hours before LPS challenge.

ratLPS/ratLPS/% Inh% Inhp38 alphaHWB IC₅₀@1.0@5.0ratLPS/% InhExampleIC₅₀(uM)(uM)(mg/kg)(mg/kg)@20.0 (mg/kg)D-10.1783.0D-20.0841.7989.095.0D-30.0950.4669.088.091.0D-40.911.5542.383.099.0D-50.144.0965.078.583.0D-60.0831.3382.096.0100D-70.44>25.00D-80.181.36585D-91.6315.8586D-103.9514.880D-110.161.54386D-120.827.067191D-130.338.365387

	Number	Date	Country
Parent	10021780	Dec 2001	US
Child	10840734	May 2004	US
Parent	09513351	Feb 2000	US
Child	10021780	Dec 2001	US

	Number	Date	Country
Parent	09196623	Nov 1998	US
Child	09513351	Feb 2000	US

Substituted pyrazoles as p38 kinase inhibitors

Information

Publication Number

Date Filed

Date Published

Inventors

CPC

US Classifications

International Classifications

Abstract

Description

Claims

CROSS-REFERENCE TO RELATED APPLICATIONS

Divisions (2)

Continuation in Parts (1)